FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Zhang, JH
Dodson, M
Liang, QL
Benavides, G
Darley-Usmar, VM
AF Zhang, Jianhua
Dodson, Matthew
Liang, Qiuli
Benavides, Gloria
Darley-Usmar, Victor M.
TI Autophagy in neuronal bioenergetics and survival
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Zhang, Jianhua; Dodson, Matthew; Liang, Qiuli; Benavides, Gloria; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Free Radical Biol & Med, Birmingham, AL USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1086.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504007
ER
PT J
AU Zou, L
Li, Y
Feng, Y
Zhang, M
Chen, C
Chao, W
AF Zou, Lin
Li, Yan
Feng, Yan
Zhang, Ming
Chen, Chan
Chao, Wei
TI Interplay between complement factor B and Toll-like receptors and its
role in septic cardiomyopathy
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Zou, Lin; Li, Yan; Feng, Yan; Zhang, Ming; Chen, Chan; Chao, Wei] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 652.6
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504441
ER
PT J
AU Barnes, JA
Jacobsen, E
Feng, Y
Freedman, A
Hochberg, EP
LaCasce, AS
Armand, P
Joyce, R
Sohani, AR
Rodig, SJ
Neuberg, D
Fisher, DC
Abramson, JS
AF Barnes, Jeffrey A.
Jacobsen, Eric
Feng, Yang
Freedman, Arnold
Hochberg, Ephraim P.
LaCasce, Ann S.
Armand, Philippe
Joyce, Robin
Sohani, Aliyah R.
Rodig, Scott J.
Neuberg, Donna
Fisher, David C.
Abramson, Jeremy S.
TI Everolimus in combination with rituximab induces complete responses in
heavily pretreated diffuse large B-cell lymphoma
SO HAEMATOLOGICA
LA English
DT Article
ID RAPAMYCIN INHIBITION; TISSUE MICROARRAY; MAMMALIAN TARGET; PHASE-II;
TEMSIROLIMUS
AB Diffuse large B-cell lymphoma is an aggressive non-Hodgkin's lymphoma without a standard therapy for patients who relapse after or are not eligible for salvage autologous stem cell transplantation. In vitro analysis of lymphoma cell lines has shown that everolimus can inhibit cell cycle progression in vitro and inhibitors of the mammalian target of rapamycin have already demonstrated single-agent activity in relapsed non-Hodgkin's lymphomas including diffuse large B-cell lymphoma, validating mammalian target of rapamycin as a viable therapeutic target. We performed an open label phase II study of everolimus, an inhibitor of mammalian target of rapamycin, in combination with rituximab to examine efficacy and tolerability in patients with relapsed/refractory diffuse large B-cell lymphoma. Eligible patients were treated with everolimus 10 mg by mouth once daily on days 1-28 of a 28-day cycle with rituximab administered weekly during cycle one and then on day one of subsequent cycles. Patients were treated for a total of 12 cycles or until disease progression. The primary end-point was objective response rate, with secondary end-points being toxicity, progression-free survival, duration of response, and overall survival. Twenty-six patients (24 evaluable) were enrolled and had an overall response rate of 38% [90% CI (21%-56%)] with three complete responses and six partial responses among these 24 patients. The median duration of response among responders was 8.1 months. At a median follow-up of 12 months, the overall survival rate was 37% [90% CI (20%-54%)]. The most common grade 3 to 4 toxicities were neutropenia, anemia, and thrombocytopenia. In conclusion, everolimus in combination with rituximab is well tolerated and demonstrates activity in relapsed diffuse large B-cell lymphoma. Further studies of this combination are warranted.
C1 [Barnes, Jeffrey A.; Hochberg, Ephraim P.; Sohani, Aliyah R.; Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Jacobsen, Eric; Feng, Yang; Freedman, Arnold; LaCasce, Ann S.; Armand, Philippe; Neuberg, Donna; Fisher, David C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Joyce, Robin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Barnes, Jeffrey A.; Jacobsen, Eric; Freedman, Arnold; Hochberg, Ephraim P.; LaCasce, Ann S.; Armand, Philippe; Joyce, Robin; Sohani, Aliyah R.; Rodig, Scott J.; Fisher, David C.; Abramson, Jeremy S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Barnes, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
EM jabarnes@partners.org
FU Novartis, Inc.
FX This work was funded in part by Novartis, Inc.
NR 11
TC 20
Z9 24
U1 0
U2 4
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD APR
PY 2013
VL 98
IS 4
BP 615
EP 619
DI 10.3324/haematol.2012.075184
PG 5
WC Hematology
SC Hematology
GA 157LN
UT WOS:000319897700030
PM 23144193
ER
PT J
AU Chen, YH
Chauhan, SK
Lee, HS
Stevenson, W
Schaumburg, CS
Sadrai, Z
Saban, DR
Kodati, S
Stern, ME
Dana, R
AF Chen, Yihe
Chauhan, Sunil K.
Lee, Hyun Soo
Stevenson, William
Schaumburg, Chris S.
Sadrai, Zahra
Saban, Daniel R.
Kodati, Shilpa
Stern, Michael E.
Dana, Reza
TI Effect of Desiccating Environmental Stress Versus Systemic Muscarinic
AChR Blockade on Dry Eye Immunopathogenesis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE dry eye disease; controlled-environment chamber; scopolamine;
CD4+T-cells
ID REGULATORY T-CELLS; ACETYLCHOLINE-RECEPTOR; CHOLINERGIC SYSTEM;
SJOGRENS-SYNDROME; MOUSE MODEL; IN-VITRO; DISEASE; EXPRESSION; TH17;
KERATOCONJUNCTIVITIS
AB PURPOSE. A majority of experimental data on dry eye disease (DED) immunopathogenesis have been derived from a murine model of DED that combines desiccating environmental stress with systemic muscarinic acetylcholine receptor (mAChR) inhibition. However, to our knowledge the effects of pharmacologic mAChR blockade on the pathogenesis of experimental DED have not been evaluated systemically. The purpose of our study was to investigate the differential effects of desiccating environmental stress and mAChR inhibition on the pathogenesis of DED.
METHODS. DED was induced in female C57BL/6 mice by exposure to a desiccating environment in the controlled-environment chamber or to systemic scopolamine, or by performing extraorbital lacrimal gland excision. Clinical disease was assessed using corneal fluorescein staining (CFS) and the cotton thread test (CTT). Corneal CD11b(+) and conjunctival CD3(+) T-cell infiltration were evaluated by flow cytometry. T-cells from draining cervical lymph nodes (CLN) and distant inguinal lymph nodes (ILN) were analyzed for Th1, Th2, Th17, and Treg responses by flow cytometry and ELISA.
RESULTS. Desiccating environmental stress and systemic mAChR blockade induced similar clinical signs of DED. However, desiccating environmental stress imparted higher conjunctival CD3(+) T-cell infiltration, and greater Th17-cell activity and Treg dysfunction than mAChR blockade, while mAChR blockade decreased tear secretion to a greater extent than desiccating environmental stress. Systemic mAChR blockade attenuated Th17 activity and enhanced Th2 and Treg responses without affecting Th1 activity.
CONCLUSIONS. In vivo inhibition of mAChRs variably affects CD4(+) T-cell subsets, and desiccating environmental stress and systemic mAChR blockade induce DED through different primary pathogenic mechanisms.
C1 [Chen, Yihe; Chauhan, Sunil K.; Lee, Hyun Soo; Stevenson, William; Sadrai, Zahra; Saban, Daniel R.; Kodati, Shilpa; Dana, Reza] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA USA.
[Schaumburg, Chris S.; Stern, Michael E.] Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA USA.
RP Dana, R (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM reza.dana@schepens.harvard.edu
FU NIH [EY20889]; Allergan, Inc.
FX Supported by NIH Grant EY20889 and Allergan, Inc.
NR 31
TC 13
Z9 15
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2457
EP 2464
DI 10.1167/iovs.12-11121
PG 8
WC Ophthalmology
SC Ophthalmology
GA 156KV
UT WOS:000319821700007
PM 23482465
ER
PT J
AU Colby, K
AF Colby, Kathryn
TI Medical Treatment of Fuchs' Dystrophy in our Lifetime?
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Editorial Material
C1 Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
RP Colby, K (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
EM KAColby@meei.harvard.edu
NR 4
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2503
EP 2503
DI 10.1167/iovs.13-12034
PG 1
WC Ophthalmology
SC Ophthalmology
GA 156KV
UT WOS:000319821700012
ER
PT J
AU Kang, MH
Oh, DJ
Kang, JH
Rhee, DJ
AF Kang, Min Hyung
Oh, Dong-Jin
Kang, Ja-heon
Rhee, Douglas J.
TI Regulation of SPARC by Transforming Growth Factor beta 2 in Human
Trabecular Meshwork
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE SPARC; matricellular proteins; TGF-beta 2; Smad3; p38
ID PIGMENT EPITHELIAL-CELLS; OPEN-ANGLE GLAUCOMA; AQUEOUS-HUMOR;
INTRAOCULAR-PRESSURE; KINASE PATHWAY; HUMAN EYES; TGF-BETA-2;
EXPRESSION; FIBROSIS; COLLAGEN
AB PURPOSE. An increased aqueous level of TGF-beta 2 has been found in many primary open-angle glaucoma patients. Secreted Protein, Acidic, and Rich in Cysteine (SPARC)-null mice have a lower intraocular pressure. The mechanistic relationship between SPARC and TGF-beta 2 in trabecular meshwork (TM) is unknown. We hypothesized that TGF-beta 2 upregulates SPARC expression in TM.
METHODS. Cultured TM cells were incubated with selective inhibitors for p38 MAP kinase (p38), Smad3, p42, JNK, RhoA, PI3K, or TGF-beta 2 receptor for 2 hours, and then TGF-beta 2 was added for 24 hours in serum-free media. Quantitative polymerase chain reaction (qPCR)and immunoblot analysis were performed. Immunofluorescent microscopy was used to determine nuclear translocation of signaling proteins. Ad5.hSPARC and Lentiviral shRNA for p38 and Smad3 were constructed, and infected human TM cells.
RESULTS. SPARC was upregulated by TGF-beta 2 in the human TM cells (3.8 +/- 1.7-fold, n = 6, P = 0.01 for protein and 7.1 +/- 3.7-fold, n = 6, P = 0.01 for mRNA), while upregulation of SPARC had no effect on TGF-beta 2. TGF-beta 2-induced SPARC expression was suppressed by inhibitors against p38 (-40.3 +/- 20.9%, n = 10, P = 0.0001), Smad3 (-56.2 +/- 18.9%, n = 10, P = 0.0001), JNK (-49.1 +/- 24.6%, n = 10, P = 0.0001), and TGF-beta 2 receptor (-83.6 +/- 14.4%, n = 6, P = 0.003). Phosphorylation and translocation of Smad3, p38, and MAPKAPK2 were detected at 30 minutes and 1 hour, respectively, following TGF-beta 2 treatment. Phosphorylation of JNK and c-jun was detected before TGF-beta 2 treatment. SPARC was suppressed 31 +/- 13% (n = 5, P < 0.0001) by shRNA-p38 and 41 +/- 3% (n = 5, P < 0.0001) by shRNA-Smad3.
CONCLUSIONS. TGF-beta 2 upregulates SPARC expression in human TM through Smad-dependent (Smad2/3) or -independent (p38) signaling pathways. SPARC may be a downstream regulatory node of TGF-beta 2-mediated IOP elevation.
C1 [Kang, Min Hyung; Oh, Dong-Jin; Rhee, Douglas J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Kang, Ja-heon] Kyung Hee Univ Hosp Gangdong, Dept Ophthalmol, Seoul, South Korea.
RP Rhee, DJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM DougRhee@aol.com
FU American Glaucoma Society Mid-Career Award, Massachusetts Lions Eye
Research Fund, National Eye Institute [EY 019654-01, EY14104]
FX Supported by American Glaucoma Society Mid-Career Award, Massachusetts
Lions Eye Research Fund, National Eye Institute, EY 019654-01 (DJR) and
EY14104 (MEEI Vision-Core Grant).
NR 37
TC 14
Z9 14
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2523
EP 2532
DI 10.1167/iovs.12-11474
PG 10
WC Ophthalmology
SC Ophthalmology
GA 156KV
UT WOS:000319821700015
PM 23513064
ER
PT J
AU Liu, SH
Kam, WR
Ding, J
Hatton, MP
Sullivan, DA
AF Liu, Shaohui
Kam, Wendy R.
Ding, Juan
Hatton, Mark P.
Sullivan, David A.
TI Effect of Growth Factors on the Proliferation and Gene Expression of
Human Meibomian Gland Epithelial Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE meibomian gland; growth factors; gene expression
ID SERUM-FREE CULTURE; PEROXISOME-PROLIFERATOR; ACTIVATED RECEPTORS;
SEBACEOUS GLAND; CLONAL GROWTH; CYCLE REGULATION; MODEL;
DIFFERENTIATION; KERATINIZATION; PITUITARY
AB PURPOSE. We hypothesize that growth factors, including epidermal growth factor (EGF) and bovine pituitary extract (BPE), induce proliferation, but not differentiation (e.g., lipid accumulation), of human meibomian gland epithelial cells. We also hypothesize that these actions involve a significant upregulation of genes linked to cell cycle processes, and a significant downregulation of genes associated with differentiation. Our objective was to test these hypotheses.
METHODS. Immortalized human meibomian gland and conjunctival epithelial cells were cultured for varying time periods in the presence or absence of EGF, BPE, EGF + BPE, or serum, followed by cell counting, neutral lipid staining, or RNA isolation for molecular biological procedures.
RESULTS. Our studies show that growth factors stimulate a significant, time-dependent proliferation of human meibomian gland epithelial cells. These effects are associated with a significant upregulation of genes linked to cell cycle, DNA replication, ribosomes, and translation, and a significant decrease in those related to cell differentiation, tissue development, lipid metabolic processes, and peroxisome proliferator-activated receptor signaling. Serum-induced differentiation, but not growth factor-related proliferation, elicits a pronounced lipid accumulation in human meibomian gland epithelial cells. This lipogenic response is unique, and is not duplicated by human conjunctival epithelial cells.
CONCLUSIONS. Our results demonstrate that EGF and BPE stimulate human meibomian gland epithelial cells to proliferate. Further, our findings show that action is associated with an upregulation of cell cycle and translation ontologies, and a downregulation of genetic pathways linked to differentiation and lipid biosynthesis.
C1 [Liu, Shaohui; Kam, Wendy R.; Ding, Juan; Hatton, Mark P.; Sullivan, David A.] Schepens Eye Res Inst, Boston, MA 02114 USA.
[Liu, Shaohui; Kam, Wendy R.; Ding, Juan; Hatton, Mark P.; Sullivan, David A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Kam, Wendy R.; Ding, Juan; Hatton, Mark P.; Sullivan, David A.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Hatton, Mark P.] Ophthalm Consultants Boston, Boston, MA USA.
RP Sullivan, DA (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM david.sullivan@schepens.harvard.edu
RI Ding, Juan/L-5149-2013
FU NIH [EY05612]; Alcon Research, Ltd.
FX Supported by grants from NIH (EY05612) and Alcon Research, Ltd.
NR 54
TC 14
Z9 14
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2541
EP 2550
DI 10.1167/iovs.12-11221
PG 10
WC Ophthalmology
SC Ophthalmology
GA 156KV
UT WOS:000319821700017
PM 23493293
ER
PT J
AU Li, D
Jiao, J
Shatos, MA
Hodges, RR
Dartt, DA
AF Li, Dayu
Jiao, Jianwei
Shatos, Marie A.
Hodges, Robin R.
Dartt, Darlene A.
TI Effect of VIP on Intracellular [Ca2+], Extracellular Regulated Kinase
1/2, and Secretion in Cultured Rat Conjunctival Goblet Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE goblet cells; conjunctiva; ERK; intracellular Ca2+
ID VASOACTIVE INTESTINAL POLYPEPTIDE; DEPENDENT PROTEIN-KINASE; CHOLINERGIC
AGONISTS; RECEPTOR SUBTYPES; ACINAR-CELLS; CYCLIC-AMP; CAMP; CALCIUM;
PATHWAY; EGF
AB PURPOSE. To determine the intracellular signaling pathways that vasoactive intestinal peptide (VIP) uses to stimulate high molecular weight glycoconjugate secretion from cultured rat conjunctival goblet cells.
METHODS. Goblet cells from rat bulbar and forniceal conjunctiva were grown in organ culture. Presence and localization of VIP receptors (VPAC1 and 2) were determined by RT-PCR, immunofluorescence microscopy and Western blot analysis. Intracellular [Ca2+] ([Ca2+](i)) was measured using fura-2. Extracellular signal-regulated kinase (ERK)-1/2 activity was determined by Western blot analysis. High molecular weight glycoconjugate secretion was measured with an enzyme-linked lectin assay on cultured goblet cells that were serum-starved for 2 hours before stimulation with VIP, VPAC1-, or VPAC2-specific agonists. Inhibitors were added 30 minutes prior to VIP. Activation of epidermal growth factor receptor (EGFR) was measured by immunoprecipitation using an antibody against pTyr followed by Western blot analysis with an antibody against EGFR.
RESULTS. Both VIP receptors were present in rat conjunctiva and cultured goblet cells. VIP- and VPAC-specific agonists increased [Ca2+](i) and secretion in a concentration-dependent manner. VIP also increased ERK1/2 activity, VIP- stimulated increase in [Ca2+](i). Secretion, but not ERK1/2 activity, was inhibited by the protein kinase A inhibitor, H89. VIP-stimulated secretion was inhibited by siRNA for ERK2 but not by siRNA for EGFR. VIP did not increase the phosphorylation of the EGFR.
CONCLUSIONS. In conclusion, in cultured rat conjunctival goblet cells, VPAC1 and 2 receptors are functional. VIP stimulates a cAMP-dependent increase in [Ca2+](i) and glycoconjugate secretion, but not ERK1/2 activation. VIP does not activate with EGFR.
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Sch Med, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
RP Dartt, DA (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM darlene.dartt@schepens.harvard.edu
RI Jiao, Jianwei/I-1452-2013
OI Jiao, Jianwei/0000-0002-7893-0721
FU NIH [EY019470, EY09570]
FX Supported by NIH EY019470 and EY09570. The authors alone are responsible
for the content and writing of the paper.
NR 32
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2872
EP 2884
DI 10.1167/iovs.12-11264
PG 13
WC Ophthalmology
SC Ophthalmology
GA 156KV
UT WOS:000319821700056
PM 23518767
ER
PT J
AU Woodward, MJ
Patton, SC
Olsen, SA
Jones, JM
Reich, CM
Blackwell, N
Beck, JG
AF Woodward, Matthew J.
Patton, Samantha C.
Olsen, Shira A.
Jones, Judiann M.
Reich, Catherine M.
Blackwell, Nathali
Beck, J. Gayle
TI How do attachment style and social support contribute to women's
psychopathology following intimate partner violence? Examining clinician
ratings versus self-report
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Attachment style; Social support; Psychopathology; Intimate partner
violence
ID POSTTRAUMATIC-STRESS-DISORDER; GENERALIZED ANXIETY DISORDER; VEHICLE
ACCIDENT SURVIVORS; DEPRESSION-INVENTORY-II; DSM-IV ANXIETY;
PSYCHOMETRIC PROPERTIES; ADULT ATTACHMENT; MULTIDIMENSIONAL SCALE;
SEXUAL-ABUSE; PSYCHOLOGICAL DISTRESS
AB Concurrent associations between attachment style and social support in posttraumatic stress disorder, depression, and generalized anxiety disorder were explored using regression analyses in a sample of 108 victims of intimate partner violence. To examine whether assessment modality influenced findings, self-report and clinician ratings of psychopathology were compared. Both lower perceived social support and higher attachment anxiety were significantly associated with higher self-reported PTSD; however, only lower social support was significantly associated with clinician assessed PTSD. Lower social support, higher attachment anxiety, and lower attachment closeness were related with higher self-reported depression; however, only lower social support was related to clinician assessed depression. Lastly, only higher attachment anxiety was associated with self-reported GAD, whereas lower attachment dependency showed the only significant association in clinician assessed GAD. Possible explanations for discrepancies between assessment modalities are discussed, with emphasis on application to intimate partner violence and suggestions for future research. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Woodward, Matthew J.; Jones, Judiann M.; Reich, Catherine M.; Beck, J. Gayle] Univ Memphis, Dept Psychol, Memphis, TN 38152 USA.
[Patton, Samantha C.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA.
[Olsen, Shira A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Blackwell, Nathali] Univ Memphis, Dept Social Work, Memphis, TN 38152 USA.
RP Woodward, MJ (reprint author), Univ Memphis, Dept Psychol, 400 Innovation Dr, Memphis, TN 38152 USA.
EM mjwdward@memphis.edu
NR 65
TC 5
Z9 5
U1 6
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD APR
PY 2013
VL 27
IS 3
BP 312
EP 320
DI 10.1016/j.janxdis.2013.02.007
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 156AQ
UT WOS:000319792800007
PM 23602945
ER
PT J
AU Klann, JG
Murphy, SN
AF Klann, Jeffrey G.
Murphy, Shawn N.
TI Computing Health Quality Measures Using Informatics for Integrating
Biology and the Bedside
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE medical informatics; healthcare quality assessment; reimbursement;
incentive; systems integration; database management systems
ID MEANINGFUL USE
AB Background: The Health Quality Measures Format (HQMF) is a Health Level 7 (HL7) standard for expressing computable Clinical Quality Measures (CQMs). Creating tools to process HQMF queries in clinical databases will become increasingly important as the United States moves forward with its Health Information Technology Strategic Plan to Stages 2 and 3 of the Meaningful Use incentive program (MU2 and MU3). Informatics for Integrating Biology and the Bedside (i2b2) is one of the analytical databases used as part of the Office of the National Coordinator (ONC)' s Query Health platform to move toward this goal.
Objective: Our goal is to integrate i2b2 with the Query Health HQMF architecture, to prepare for other HQMF use-cases (such as MU2 and MU3), and to articulate the functional overlap between i2b2 and HQMF. Therefore, we analyze the structure of HQMF, and then we apply this understanding to HQMF computation on the i2b2 clinical analytical database platform. Specifically, we develop a translator between two query languages, HQMF and i2b2, so that the i2b2 platform can compute HQMF queries.
Methods: We use the HQMF structure of queries for aggregate reporting, which define clinical data elements and the temporal and logical relationships between them. We use the i2b2 XML format, which allows flexible querying of a complex clinical data repository in an easy-to-understand domain-specific language.
Results: The translator can represent nearly any i2b2-XML query as HQMF and execute in i2b2 nearly any HQMF query expressible in i2b2-XML. This translator is part of the freely available reference implementation of the QueryHealth initiative. We analyze limitations of the conversion and find it covers many, but not all, of the complex temporal and logical operators required by quality measures.
Conclusions: HQMF is an expressive language for defining quality measures, and it will be important to understand and implement for CQM computation, in both meaningful use and population health. However, its current form might allow complexity that is intractable for current database systems (both in terms of implementation and computation). Our translator, which supports the subset of HQMF currently expressible in i2b2-XML, may represent the beginnings of a practical compromise. It is being pilot-tested in two Query Health demonstration projects, and it can be further expanded to balance computational tractability with the advanced features needed by measure developers.
C1 [Klann, Jeffrey G.; Murphy, Shawn N.] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02129 USA.
[Klann, Jeffrey G.; Murphy, Shawn N.] Partners Healthcare Syst Inc, Research Comp, Boston, MA USA.
[Klann, Jeffrey G.; Murphy, Shawn N.] Harvard Univ, Sch Med, Boston, MA USA.
RP Klann, JG (reprint author), Massachusetts Gen Hosp, Constitut Ctr 1, Comp Sci Lab, Boston, MA 02129 USA.
EM jklann@partners.org
FU Office of the National Coordinator for Health Information Technology
[ONC 90TR001/01]
FX This work was sponsored by the Office of the National Coordinator for
Health Information Technology, Grant No. ONC 90TR001/01.
NR 23
TC 5
Z9 5
U1 0
U2 13
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD APR
PY 2013
VL 15
IS 4
AR UNSP e75
DI 10.2196/jmir.2493
PG 12
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 151EP
UT WOS:000319443800013
PM 23603227
ER
PT J
AU Dranoff, G
Fearon, D
AF Dranoff, Glenn
Fearon, Douglas
TI Tumour immunology
SO CURRENT OPINION IN IMMUNOLOGY
LA English
DT Editorial Material
C1 [Dranoff, Glenn] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA USA.
[Dranoff, Glenn] Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
[Dranoff, Glenn] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Fearon, Douglas] Li Ka Shing Ctr, CRUK Cambridge Res Inst, Cambridge CB2 0RE, England.
RP Dranoff, G (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM glenn_dranoff@dfci.harvard.edu; dtf1000@cam.ac.uk
FU NCI NIH HHS [P01 CA078378, P50 CA100707, P01 CA155258, R01 CA143083];
NIBIB NIH HHS [R01 EB015498]
NR 0
TC 4
Z9 4
U1 0
U2 7
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0952-7915
J9 CURR OPIN IMMUNOL
JI Curr. Opin. Immunol.
PD APR
PY 2013
VL 25
IS 2
BP 189
EP 191
DI 10.1016/j.coi.2013.02.012
PG 3
WC Immunology
SC Immunology
GA 150CZ
UT WOS:000319369100010
PM 23510648
ER
PT J
AU Ter-Minassian, M
Chan, JA
Hooshmand, SM
Brais, LK
Daskalova, A
Heafield, R
Buchanan, L
Qian, ZR
Fuchs, CS
Lin, XH
Christiani, DC
Kulke, MH
AF Ter-Minassian, Monica
Chan, Jennifer A.
Hooshmand, Susanne M.
Brais, Lauren K.
Daskalova, Anastassia
Heafield, Rachel
Buchanan, Laurie
Qian, Zhi Rong
Fuchs, Charles S.
Lin, Xihong
Christiani, David C.
Kulke, Matthew H.
TI Clinical presentation, recurrence, and survival in patients with
neuroendocrine tumors: results from a prospective institutional database
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
DE neuroendocrine tumors; disease-free survival; overall survival;
chromogranin A
ID PANCREATIC ENDOCRINE TUMORS; CHROMOGRANIN-A; PROGNOSTIC-FACTORS; SINGLE
INSTITUTION; CARCINOID-TUMORS; FOLLOW-UP; MANAGEMENT; DIAGNOSIS;
CLASSIFICATION; EPIDEMIOLOGY
AB The rarity of neuroendocrine tumors (NET) has contributed to a paucity of large epidemiologic studies of patients with this condition. We characterized presenting symptoms and clinical outcomes in a prospective database of over 900 patients with NET. We used data from patient questionnaires and the medical record to characterize presenting symptoms, disease-free survival (DFS), and overall survival (OS). The majority of patients in this database had gastroenteropancreatic NET. The median duration of patient-reported symptoms before diagnosis was 3.4 months; 19.5% reported durations from 1 to 5 years, 2.5% from 5 to 10 years, and 2% >10 years. The median DFS among patients with resected small bowel NET or pancreatic NET (panNET) was 5.8 and 4.1 years respectively. After correcting for left truncation bias, the median OS was 7.9 years for advanced small bowel NET and 3.9 years for advanced panNET. Chromogranin A (CGA) above twice the upper limit of normal was associated with shorter survival times (hazard ratios 2.8 (1.9, 4.0) P<0.001) in patients with metastatic disease, regardless of tumor subtype. Our data suggest that while most NET patients are diagnosed soon after symptom onset, prolonged symptom duration before diagnosis is a prominent feature of this disease. Though limited to observations from a large referral center, our observations confirm the prognostic value of CGA and suggest that median survival durations may be shorter than that reported in other institutional databases.
C1 [Ter-Minassian, Monica; Chan, Jennifer A.; Hooshmand, Susanne M.; Brais, Lauren K.; Daskalova, Anastassia; Heafield, Rachel; Buchanan, Laurie; Qian, Zhi Rong; Fuchs, Charles S.; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Ter-Minassian, Monica; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Lin, Xihong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Ter-Minassian, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Dana 1250,450 Brookline Ave, Boston, MA 02215 USA.
EM monica_ter-minassian1@dfci.harvard.edu
OI Qian, Zhi rong/0000-0003-1633-4120
FU Raymond and Beverly Sackler American Association of Cancer Research
Fellowship for Ileal Carcinoid Research; NIH [R01 CA151532-01A1,
5P50CA127003-05]; Novartis Pharmaceuticals
FX Dr M Ter-Minassian is supported by the Raymond and Beverly Sackler
American Association of Cancer Research Fellowship for Ileal Carcinoid
Research. M H Kulke is supported in part by NIH grants R01 CA151532-01A1
and 5P50CA127003-05 (Gastrointestinal Cancer SPORE). Additional funding
for this project was provided by a grant from Novartis Pharmaceuticals.
NR 43
TC 23
Z9 24
U1 0
U2 7
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD APR
PY 2013
VL 20
IS 2
BP 187
EP 196
DI 10.1530/ERC-12-0340
PG 10
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 152TS
UT WOS:000319554600008
PM 23319495
ER
PT J
AU Stone, RM
AF Stone, Richard M.
TI Highlights in acute myeloid leukemia from the 2012 meeting of the
American Society of Hematology
SO EXPERT REVIEW OF HEMATOLOGY
LA English
DT Review
ID ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ARSENIC TRIOXIDE;
THERAPY; MULTICENTER; ADULTS
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Stone, RM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,M1B-17, Boston, MA 02215 USA.
EM rstone@partners.org
FU Novartis, Ltd.
FX Rill Stone serves as an ad hoc consultant for Teva, Ltd, Celgene, Ltd,
Amgen, Inc. and Sunesis Pharmaceuticals, Inc. and has received research
support from Novartis, Ltd. The author has no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
NR 25
TC 0
Z9 0
U1 0
U2 4
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1747-4086
J9 EXPERT REV HEMATOL
JI Expert Rev. Hematol.
PD APR
PY 2013
VL 6
IS 2
BP 127
EP 129
DI 10.1586/EHM.13.14
PG 3
WC Hematology
SC Hematology
GA 149HC
UT WOS:000319308600009
PM 23547861
ER
PT J
AU Alexander, BM
Lee, EQ
Reardon, DA
Wen, PY
AF Alexander, Brian M.
Lee, Eudocia Q.
Reardon, David A.
Wen, Patrick Y.
TI Current and future directions for Phase II trials in high-grade glioma
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
DE angiogenesis; clinical trials; malignant glioma; multitargeted therapy;
targeted therapy
ID RECURRENT MALIGNANT GLIOMA; NEWLY-DIAGNOSED GLIOBLASTOMA; BEVACIZUMAB
PLUS IRINOTECAN; ENDOTHELIAL GROWTH-FACTOR; ADVANCED SOLID TUMORS;
DENDRITIC CELL VACCINATION; TRANS-SODIUM CROCETINATE; STRAND BREAK
REPAIR; CANCER STEM-CELLS; T-CELLS
AB Despite surgery, radiation and chemotherapy, the prognosis for high-grade glioma (HGG) is poor. Our understanding of the molecular pathways involved in gliomagenesis and progression has increased in recent years, leading to the development of novel agents that specifically target these pathways. Results from most single-agent trials have been modest at best, however. Despite the initial success of antiangiogenesis agents in HGG, the clinical benefit is short-lived and most patients eventually progress. Several novel agents, multi-targeted agents and combination therapies are now in clinical trials for HGG and several more strategies are being pursued.
C1 [Alexander, Brian M.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
[Lee, Eudocia Q.; Reardon, David A.; Wen, Patrick Y.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Div Canc Neurol,Ctr Neurooncol, Boston, MA 02215 USA.
RP Wen, PY (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Div Canc Neurol,Ctr Neurooncol, 450 Brookline Ave,SW 430, Boston, MA 02215 USA.
EM pwen@partners.org
FU Parker Adams Small III and Katherine Currier Small Fund For Brain Tumor
Research; Amgen; AstraZeneca; Boehringer Ingelheim; Genentech/Roche;
Geron; Medimmune; Merck; Novartis; Sanofi-Aventis; Vascular Biogenics
FX The authors gratefully acknowledge the support of the Parker Adams Small
III and Katherine Currier Small Fund For Brain Tumor Research. EQ Lee is
on the advisory boards for Genentech and Novartis. DA Reardon is a
consultant/on the advisory board (receives honoraria) for
Roche/Genentech, EMD Serono, Novartis and Abgenix. P Wen receives
research support from Amgen, AstraZeneca, Boehringer Ingelheim,
Genentech/Roche, Geron, Medimmune, Merck, Novartis, Sanofi-Aventis and
Vascular Biogenics; is on the advisory boards for Novartis, NeOnc
Technologies, Vascular Biogenics; and is a speaker for Merck,
Genentech/Roche and GlaxoSmithKline. BM Alexander has no conflicts to
disclose. The authors have no other relevant affiliations or financial
involvement with any organization or entity with a financial interest in
or financial conflict with the subject matter or materials discussed in
the manuscript apart from those disclosed.
NR 177
TC 2
Z9 3
U1 0
U2 8
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7175
EI 1744-8360
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD APR
PY 2013
VL 13
IS 4
BP 369
EP 387
DI 10.1586/ERN.12.158
PG 19
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 153ZZ
UT WOS:000319642600010
PM 23545053
ER
PT J
AU Song, FJ
Qureshi, AA
Giovannucci, EL
Fuchs, CS
Chen, WY
Stampfer, MJ
Han, JL
AF Song, Fengju
Qureshi, Abrar A.
Giovannucci, Edward L.
Fuchs, Charlie S.
Chen, Wendy Y.
Stampfer, Meir J.
Han, Jiali
TI Risk of a Second Primary Cancer after Non-melanoma Skin Cancer in White
Men and Women: A Prospective Cohort Study
SO PLOS MEDICINE
LA English
DT Article
ID BASAL-CELL CARCINOMA; NUCLEOTIDE EXCISION-REPAIR; ULTRAVIOLET-RADIATION;
DNA-REPAIR; INDUCED IMMUNOSUPPRESSION; UNITED-STATES; VITAMIN-D;
SUBSEQUENT MALIGNANCY; SUSCEPTIBILITY; MORTALITY
AB Background: Previous studies suggest a positive association between history of non-melanoma skin cancer (NMSC) and risk of subsequent cancer at other sites. The purpose of this study is to prospectively examine the risk of primary cancer according to personal history of NMSC.
Methods and Findings: In two large US cohorts, the Health Professionals Follow-up Study (HPFS) and the Nurses' Health Study (NHS), we prospectively investigated this association in self-identified white men and women. In the HPFS, we followed 46,237 men from June 1986 to June 2008 (833,496 person-years). In the NHS, we followed 107,339 women from June 1984 to June 2008 (2,116,178 person-years). We documented 29,447 incident cancer cases other than NMSC. Cox proportional hazard models were used to calculate relative risks (RRs) and 95% confidence intervals (CIs). A personal history of NMSC was significantly associated with a higher risk of other primary cancers excluding melanoma in men (RR = 1.11; 95% CI 1.05-1.18), and in women (RR = 1.20; 95% CI 1.15-1.25). Age-standardized absolute risk (AR) was 176 in men and 182 in women per 100,000 person-years. For individual cancer sites, after the Bonferroni correction for multiple comparisons (n = 28), in men, a personal history of NMSC was significantly associated with an increased risk of melanoma (RR = 1.99, AR = 116 per 100,000 person-years). In women, a personal history of NMSC was significantly associated with an increased risk of breast (RR = 1.19, AR = 87 per 100,000 person-years), lung (RR = 1.32, AR = 22 per 100,000 person-years), and melanoma (RR = 2.58, AR = 79 per 100,000 person-years).
Conclusion: This prospective study found a modestly increased risk of subsequent malignancies among individuals with a history of NMSC, specifically breast and lung cancer in women and melanoma in both men and women.
C1 [Song, Fengju; Han, Jiali] Tianjin Med Univ, Canc Inst & Hosp, Dept Epidemiol, Tianjin, Peoples R China.
[Song, Fengju; Qureshi, Abrar A.; Han, Jiali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Qureshi, Abrar A.; Giovannucci, Edward L.; Fuchs, Charlie S.; Chen, Wendy Y.; Stampfer, Meir J.; Han, Jiali] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Qureshi, Abrar A.; Giovannucci, Edward L.; Fuchs, Charlie S.; Chen, Wendy Y.; Stampfer, Meir J.; Han, Jiali] Harvard Univ, Sch Med, Boston, MA USA.
[Giovannucci, Edward L.; Stampfer, Meir J.; Han, Jiali] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Fuchs, Charlie S.; Chen, Wendy Y.; Stampfer, Meir J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Song, FJ (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Dept Epidemiol, Tianjin, Peoples R China.
EM jiali.han@channing.harvard.edu
FU US NIH [CA87969, CA055075]
FX This work was supported by US NIH CA87969 and CA055075. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 50
TC 22
Z9 22
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD APR
PY 2013
VL 10
IS 4
AR e1001433
DI 10.1371/journal.pmed.1001433
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154JA
UT WOS:000319669600015
PM 23630459
ER
PT J
AU Werring, DJ
Sperling, R
AF Werring, David J.
Sperling, Reisa
TI Inflammatory cerebral amyloid angiopathy and amyloid-modifying
therapies: Variations on the Same ARIA?
SO ANNALS OF NEUROLOGY
LA English
DT Editorial Material
ID ALZHEIMERS-DISEASE; IMAGING ABNORMALITIES; IMMUNOTHERAPY; BAPINEUZUMAB;
SPECTRUM; TRIALS
C1 [Werring, David J.] UCL, Inst Neurol, Stroke Res Grp, Dept Brain Repair & Rehabil, London, England.
[Werring, David J.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
[Sperling, Reisa] Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp, Ctr Alzheimer Res & Treatment,Med Sch, Boston, MA 02115 USA.
RP Werring, DJ (reprint author), UCL, Inst Neurol, Stroke Res Grp, Dept Brain Repair & Rehabil, London, England.
FU British Heart Foundation
NR 16
TC 12
Z9 12
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD APR
PY 2013
VL 73
IS 4
BP 439
EP 441
DI 10.1002/ana.23891
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 152HY
UT WOS:000319523800004
PM 23526685
ER
PT J
AU Piazza, F
Greenberg, SM
Savoiardo, M
Gardinetti, M
Chiapparini, L
Raicher, I
Nitrini, R
Sakaguchi, H
Brioschi, M
Billo, G
Colombo, A
Lanzani, F
Piscosquito, G
Carriero, MR
Giaccone, G
Tagliavini, F
Ferrarese, C
DiFrancesco, JC
AF Piazza, Fabrizio
Greenberg, Steven M.
Savoiardo, Mario
Gardinetti, Margherita
Chiapparini, Luisa
Raicher, Irina
Nitrini, Ricardo
Sakaguchi, Hideya
Brioschi, Monica
Billo, Giuseppe
Colombo, Antonio
Lanzani, Francesca
Piscosquito, Giuseppe
Carriero, Maria Rita
Giaccone, Giorgio
Tagliavini, Fabrizio
Ferrarese, Carlo
DiFrancesco, Jacopo C.
TI Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related
inflammation: Implications for amyloid-modifying therapies
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE PATIENTS; ABETA 1-42 ANTIBODIES; A-BETA; IMAGING
ABNORMALITIES; CEREBROSPINAL-FLUID; BOSTON CRITERIA; IMMUNOTHERAPY;
HEMORRHAGE; A-BETA-42; ANGIITIS
AB Objective Cerebral amyloid angiopathy-related inflammation (CAA-ri) is characterized by vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects with the recently defined amyloid-related imaging abnormalities (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies. Herein, we investigated the role of anti-amyloid (A) autoantibodies in the acute and remission phases of CAA-ri. Methods We used a novel ultrasensitive technique on patients from a retrospective multicenter case-control study, and evaluated the anti-A autoantibody concentration in the cerebrospinal fluid (CSF) of 10 CAA-ri, 8 CAA, 14 multiple sclerosis, and 25 control subjects. Levels of soluble A40, A42, tau, P-181 tau, and APOE genotype were also investigated. Results During the acute phase of CAA-ri, anti-A autoantibodies were specifically increased and directly correlated with A mobilization, together with augmented tau and P-181 tau. Following clinical and radiological remission, autoantibodies progressively returned to control levels, and both soluble A and axonal degeneration markers decreased in parallel. Interpretation Our data support the hypothesis that the pathogenesis of CAA-ri may be mediated by a selective autoimmune reaction against cerebrovascular A, directly related to autoantibody concentration and soluble A. The CSF dosage of anti-A autoantibodies with the technique here described can thus be proposed as a valid alternative tool for the diagnosis of CAA-ri. Moreover, given the similarities between ARIA developing spontaneously and those observed during immunization trials, anti-A autoantibodies can be considered as novel potential biomarkers in future amyloid-modifying therapies for the treatment of AD and CAA. Ann Neurol 2013;73:449-458
C1 [Piazza, Fabrizio; Gardinetti, Margherita; Ferrarese, Carlo; DiFrancesco, Jacopo C.] Univ Milan, Dept Neurosci & Biomed Technol, I-20052 Monza, MI, Italy.
[Greenberg, Steven M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hemorrhag Stroke Res Program,Dept Neurol, Boston, MA USA.
[Savoiardo, Mario; Chiapparini, Luisa] IRCCS, Fdn Neurol Inst Carlo Besta, Dept Neuroradiol, Milan, Italy.
[Raicher, Irina; Nitrini, Ricardo] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil.
[Sakaguchi, Hideya] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan.
[Brioschi, Monica] Osped Niguarda Ca Granda, Dept Neurosci, Milan, Italy.
[Billo, Giuseppe] St Bortolo Hosp, Dept Neurol, Vicenza, Italy.
[Colombo, Antonio; Lanzani, Francesca] Desio Hosp, Dept Neurol, Desio, Italy.
[Piscosquito, Giuseppe; Carriero, Maria Rita] IRCCS, Fdn Neurol Inst Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy.
[Giaccone, Giorgio; Tagliavini, Fabrizio] IRCCS, Fdn Neurol Inst Carlo Besta, Dept Neurodegenerat Dis, Milan, Italy.
[Giaccone, Giorgio; Tagliavini, Fabrizio] IRCCS, Fdn Neurol Inst Carlo Besta, Div Neuropathol Neurol, Milan, Italy.
RP Piazza, F (reprint author), Univ Milan, Dept Neurosci & Biomed Technol, Via Cadore 48, I-20052 Monza, MI, Italy.
EM fabrizio.piazza@unimib.it
RI Piazza, Fabrizio/L-2094-2016
OI Piazza, Fabrizio/0000-0002-3385-3224
FU Regione Lombardia and Social European Fund; Human Capital Development
Agreement [17AR]
FX This work was partially supported by the Regione Lombardia and Social
European Fund 2007-2013, Human Capital Development Agreement, grant ID
17AR.
NR 38
TC 46
Z9 48
U1 5
U2 27
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD APR
PY 2013
VL 73
IS 4
BP 449
EP 458
DI 10.1002/ana.23857
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 152HY
UT WOS:000319523800006
PM 23625526
ER
PT J
AU Gurol, ME
Viswanathan, A
Gidicsin, C
Hedden, T
Martinez-Ramirez, S
Dumas, A
Vashkevich, A
Ayres, AM
Auriel, E
van Etten, E
Becker, A
Carmasin, J
Schwab, K
Rosand, J
Johnson, KA
Greenberg, SM
AF Gurol, M. Edip
Viswanathan, Anand
Gidicsin, Christopher
Hedden, Trey
Martinez-Ramirez, Sergi
Dumas, Andrew
Vashkevich, Anastasia
Ayres, Alison M.
Auriel, Eitan
van Etten, Ellis
Becker, Alex
Carmasin, Jeremy
Schwab, Kristin
Rosand, Jonathan
Johnson, Keith A.
Greenberg, Steven M.
TI Cerebral amyloid angiopathy burden associated with leukoaraiosis: A
positron emission tomography/magnetic resonance imaging study
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID WHITE-MATTER LESIONS; PITTSBURGH COMPOUND-B; LOBAR INTRACEREBRAL
HEMORRHAGE; SMALL VESSEL DISEASE; ALZHEIMERS-DISEASE; HYPERINTENSITY
VOLUME; COGNITIVE IMPAIRMENT; CLINICAL-DIAGNOSIS; ELDERLY-PEOPLE;
ROTTERDAM SCAN
AB Objective We hypothesized that vascular amyloid contributes to chronic brain ischemia, therefore amyloid burden measured by Pittsburgh compound B retention on positron emission tomography (PiB PET) would correlate with the extent of magnetic resonance imaging (MRI) white matter hyperintensities (WMH; or leukoaraiosis) in patients with high vascular amyloid deposition (cerebral amyloid angiopathy [CAA]) but not in patients with high parenchymal amyloid deposition (Alzheimer disease [AD]; mild cognitive impairment [MCI]) or in healthy elderly (HE) subjects. Methods Forty-two nondemented CAA patients, 50 HE subjects, and 43 AD/MCI patients had brain MRI and PiB PET. Multivariate linear regression was used to assess the independent association between PiB retention and white matter disease volume, controlling for age, gender, apolipoprotein E genotype, and vascular risk factors within each group. Results CAA patients were younger than HE and AD subjects (68 +/- 10 vs 73.3 +/- 7 and 74 +/- 7.4, p < 0.01) but had higher amounts of WMH (median = 21 vs 3.2 and 10.8 ml, respectively, p < 0.05 for both comparisons). Global PiB retention and WMH showed strong correlation (rho = 0.52, p < 0.001) in the CAA group but not in HE or AD. These associations did not change in the multivariate models. Lobar microbleed count, another marker of CAA severity, also remained as an independent predictor of WMH volume. Interpretation Our results indicate that amyloid burden in CAA subjects (with primarily vascular amyloid) but not AD subjects (with primarily parenchymal amyloid) independently correlates with WMH volume. These findings support the idea that vascular amyloid burden directly contributes to chronic cerebral ischemia and highlights the possible utility of amyloid imaging as a marker of CAA severity. Ann Neurol 2013;73:529-536
C1 [Gurol, M. Edip; Viswanathan, Anand; Martinez-Ramirez, Sergi; Dumas, Andrew; Vashkevich, Anastasia; Ayres, Alison M.; Auriel, Eitan; van Etten, Ellis; Schwab, Kristin; Rosand, Jonathan; Greenberg, Steven M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Hemorrhag Stroke Res Ctr, Boston, MA 02114 USA.
[Gurol, M. Edip] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Gidicsin, Christopher; Hedden, Trey; Becker, Alex; Carmasin, Jeremy; Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Hedden, Trey] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA.
[Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, Boston, MA USA.
RP Gurol, ME (reprint author), MGH Stroke Res Ctr, 55 Fruit St CPZ 175 Suite 300, Boston, MA 02114 USA.
EM megurol@partners.org
RI Gurol, Edip/J-2279-2014;
OI Gurol, Edip/0000-0002-2169-4457; Ayres, Alison/0000-0002-5492-1695
FU NIH [NINDS-T32NS048005, NIA R01 AG026484]; Fundacion Alfonso Martin
Escudero; NIH
FX This work was supported by grants from the NIH (NINDS-T32NS048005, NIA
R01 AG026484).; A.Vi.: consultancy, Athena Diagnostics. S. R. M.:
grants/grants pending, Fundacion Alfonso Martin Escudero. A.Va., A.M.A.,
J.R., K.A.J.: grants/grants pending, NIH.
NR 44
TC 49
Z9 53
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD APR
PY 2013
VL 73
IS 4
BP 529
EP 536
DI 10.1002/ana.23830
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 152HY
UT WOS:000319523800014
PM 23424091
ER
PT J
AU Pasquini, M
Le-Rademacher, J
Kato, K
Zhu, X
McCarthy, P
Ho, V
Cooke, K
Armstrong, B
Smith, A
Rizzo, J
Burkart, J
Brededson, C
AF Pasquini, M.
Le-Rademacher, J.
Kato, K.
Zhu, X.
McCarthy, P.
Ho, V.
Cooke, K.
Armstrong, B.
Smith, A.
Rizzo, J.
Burkart, J.
Brededson, C.
TI Comparison of myeloablative intravenous busulfan with cyclophosphamide
(BuCy) or fludarabine (BuFlu) prior to haematopoietic cell
transplantation (HCT) for myeloid malignancies
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 39th Annual Meeting of the
European-Group-for-Blood-and-Marrow-Transplantation (EBMT)
CY APR 07-10, 2013
CL London, ENGLAND
SP European Grp Blood & Marrow Transplantat (EBMT)
C1 [Pasquini, M.; Zhu, X.; Rizzo, J.; Burkart, J.] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA.
[Le-Rademacher, J.] Med Coll Wisconsin, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
[Kato, K.; Armstrong, B.; Smith, A.] Otsuka Pharmaceut Dev & Commercializat, Princeton, NJ USA.
[McCarthy, P.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Ho, V.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cooke, K.] Univ Hosp Case Med Ctr, Ireland Canc Ctr, Cleveland, OH USA.
[Brededson, C.] Univ Ottawa, Ottawa, ON, Canada.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2013
VL 48
SU 2
BP S61
EP S62
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 145OB
UT WOS:000319025200135
ER
PT J
AU Ringden, O
Brazauskas, R
Wang, Z
Duncan, C
Jacobsohn, D
Mattsson, J
Sorror, M
Majhail, N
AF Ringden, O.
Brazauskas, R.
Wang, Z.
Duncan, C.
Jacobsohn, D.
Mattsson, J.
Sorror, M.
Majhail, N.
TI Second solid cancers in patients treated with allogeneic haematopoietic
cell transplantation using reduced intensity/non-myeloablative
conditioning regimens: a Center for International Blood and Marrow
Transplant Research study
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 39th Annual Meeting of the
European-Group-for-Blood-and-Marrow-Transplantation (EBMT)
CY APR 07-10, 2013
CL London, ENGLAND
SP European Grp Blood & Marrow Transplantat (EBMT)
C1 [Ringden, O.; Mattsson, J.] Karolinska Univ Hosp, Stockholm, Sweden.
[Brazauskas, R.; Wang, Z.] Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA.
[Duncan, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jacobsohn, D.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Sorror, M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Majhail, N.] Natl Marrow Donor Program, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2013
VL 48
SU 2
BP S60
EP S60
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 145OB
UT WOS:000319025200131
ER
PT J
AU D'Andrea, AD
AF D'Andrea, Alan D.
TI BRCA1: A Missing Link in the Fanconi Anemia/BRCA Pathway
SO CANCER DISCOVERY
LA English
DT Editorial Material
ID TUMOR SUPPRESSION; BREAST; DNA
AB Domchek and colleagues provide a case report of a 28-year-old woman with congenital abnormalities, inherited ovarian cancer, and carboplatin hypersensitivity. Interestingly, the woman had validated germline mutations in both BRCA1 alleles. These findings further implicate BRCA1 in the Fanconi anemia/BRCA pathway and have important implications for BRCA1 genetic testing. (C) 2013 AACR.
C1 [D'Andrea, Alan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[D'Andrea, Alan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA.
RP D'Andrea, AD (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM alan_dandrea@dfci.harvard.edu
FU NHLBI NIH HHS [R37 HL052725]; NIDDK NIH HHS [R01 DK043889]
NR 12
TC 6
Z9 6
U1 2
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD APR
PY 2013
VL 3
IS 4
BP 376
EP 378
DI 10.1158/2159-8290.CD-13-0044
PG 3
WC Oncology
SC Oncology
GA 147YU
UT WOS:000319208900017
PM 23580280
ER
PT J
AU Ciarlo, CA
Zon, LI
AF Ciarlo, Christie A.
Zon, Leonard I.
TI A Model for Primary Melanoma of the CNS Implicates NRAS
SO CANCER DISCOVERY
LA English
DT Editorial Material
ID EXPRESSION
AB In this issue of Cancer Discovery, Pedersen and colleagues present the first mouse model of primary CNS melanoma, which arises when oncogenic NRAS is expressed from the endogenous Nras promoter in melanocytes during embryogenesis. In support of this model, two pediatric cases of NRAS-mutant primary melanoma of the CNS are identified. (C) 2013 AACR.
C1 Harvard Univ, Sch Med, Childrens Hosp, Stem Cell Program, Boston, MA USA.
Harvard Univ, Sch Med, Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
Harvard Univ, Sch Med, Harvard Stem Cell Inst, Dana Farber Canc Inst,Howard Hughes Med Inst, Boston, MA USA.
RP Zon, LI (reprint author), Boston Childrens Hosp, 300 Longwood Ave,Karp 7, Boston, MA 02115 USA.
EM zon@enders.tch.harvard.edu
FU NIH [5 R01 CA103846-10]
FX This work was supported by NIH grant 5 R01 CA103846-10.
NR 10
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD APR
PY 2013
VL 3
IS 4
BP 382
EP 383
DI 10.1158/2159-8290.CD-13-0076
PG 2
WC Oncology
SC Oncology
GA 147YU
UT WOS:000319208900019
PM 23580282
ER
PT J
AU Tabernero, J
Shapiro, GI
LoRusso, PM
Cervantes, A
Schwartz, GK
Weiss, GJ
Paz-Ares, L
Cho, DC
Infante, JR
Alsina, M
Gounder, MM
Falzone, R
Harrop, J
White, ACS
Toudjarska, I
Bumcrot, D
Meyers, RE
Hinkle, G
Svrzikapa, N
Hutabarat, RM
Clausen, VA
Cehelsky, J
Nochur, SV
Gamba-Vitalo, C
Vaishnaw, AK
Sah, DWY
Gollob, JA
Burris, HA
AF Tabernero, Josep
Shapiro, Geoffrey I.
LoRusso, Patricia M.
Cervantes, Andres
Schwartz, Gary K.
Weiss, Glen J.
Paz-Ares, Luis
Cho, Daniel C.
Infante, Jeffrey R.
Alsina, Maria
Gounder, Mrinal M.
Falzone, Rick
Harrop, Jamie
White, Amy C. Seila
Toudjarska, Iva
Bumcrot, David
Meyers, Rachel E.
Hinkle, Gregory
Svrzikapa, Nenad
Hutabarat, Renta M.
Clausen, Valerie A.
Cehelsky, Jeffrey
Nochur, Saraswathy V.
Gamba-Vitalo, Christina
Vaishnaw, Akshay K.
Sah, Dinah W. Y.
Gollob, Jared A.
Burris, Howard A., III
TI First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF
and KSP in Cancer Patients with Liver Involvement
SO CANCER DISCOVERY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; IN-VIVO DELIVERY; SOLID
TUMORS; NEUROENDOCRINE TUMORS; ENDOMETRIAL CANCER; NONHUMAN-PRIMATES;
ANTICANCER AGENTS; PHASE-II; SIRNA
AB RNA interference (RNAi) is a potent and specific mechanism for regulating gene expression. Harnessing RNAi to silence genes involved in disease holds promise for the development of a new class of therapeutics. Delivery is key to realizing the potential of RNAi, and lipid nanoparticles (LNP) have proved effective in delivery of siRNAs to the liver and to tumors in animals. To examine the activity and safety of LNP-formulated siRNAs in humans, we initiated a trial of ALN-VSP, an LNP formulation of siRNAs targeting VEGF and kinesin spindle protein (KSP), in patients with cancer. Here, we show detection of drug in tumor biopsies, siRNA-mediated mRNA cleavage in the liver, pharmacodynamics suggestive of target downregulation, and antitumor activity, including complete regression of liver metastases in endometrial cancer. In addition, we show that biweekly intravenous administration of ALN-VSP was safe and well tolerated. These data provide proof-of-concept for RNAi therapeutics in humans and form the basis for further development in cancer.
SIGNIFICANCE: The findings in this report show safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel first-in-class LNP-formulated RNAi therapeutic in patients with cancer. The ability to harness RNAi to facilitate specific multitargeting, as well as increase the number of druggable targets, has important implications for future drug development in oncology. (C) 2012 AACR.
C1 [Tabernero, Josep; Alsina, Maria] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Med Oncol, P Vall dHebron 119-129, Barcelona 08035, Spain.
[Cervantes, Andres] Univ Valencia, Inst Hlth Res INCLIVA, Valencia, Spain.
[Paz-Ares, Luis] Univ Seville, Hosp Virgen del Rocio, Seville, Spain.
[Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cho, Daniel C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Falzone, Rick; Harrop, Jamie; White, Amy C. Seila; Toudjarska, Iva; Bumcrot, David; Meyers, Rachel E.; Hinkle, Gregory; Svrzikapa, Nenad; Hutabarat, Renta M.; Clausen, Valerie A.; Cehelsky, Jeffrey; Nochur, Saraswathy V.; Gamba-Vitalo, Christina; Vaishnaw, Akshay K.; Sah, Dinah W. Y.; Gollob, Jared A.] Alnylam Pharmaceut Inc, Cambridge, MA USA.
[LoRusso, Patricia M.] Karmanos Canc Inst, Detroit, MI USA.
[Schwartz, Gary K.; Gounder, Mrinal M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Weiss, Glen J.] Scottsdale Healthcare, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA.
[Infante, Jeffrey R.; Burris, Howard A., III] Sarah Cannon Res Inst, Nashville, TN USA.
RP Tabernero, J (reprint author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Med Oncol, P Vall dHebron 119-129, Barcelona 08035, Spain.
EM jtabernero@vhio.net
RI Han, ziyi/O-2512-2013; IBIS, NUEVAS TERAPIA/P-3415-2015
FU Alnylam Pharmaceuticals, Inc.
FX This study was funded by Alnylam Pharmaceuticals, Inc.
NR 44
TC 227
Z9 231
U1 17
U2 85
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD APR
PY 2013
VL 3
IS 4
BP 406
EP 417
DI 10.1158/2159-8290.CD-12-0429
PG 12
WC Oncology
SC Oncology
GA 147YU
UT WOS:000319208900023
PM 23358650
ER
PT J
AU Sang, J
Acquaviva, J
Friedland, JC
Smith, DL
Sequeira, M
Zhang, CH
Jiang, Q
Xue, LQ
Lovly, CM
Jimenez, JP
Shaw, AT
Doebele, RC
He, SQ
Bates, RC
Camidge, DR
Morris, SW
El-Hariry, I
Proia, DA
AF Sang, Jim
Acquaviva, Jaime
Friedland, Julie C.
Smith, Donald L.
Sequeira, Manuel
Zhang, Chaohua
Jiang, Qin
Xue, Liquan
Lovly, Christine M.
Jimenez, John-Paul
Shaw, Alice T.
Doebele, Robert C.
He, Suqin
Bates, Richard C.
Camidge, D. Ross
Morris, Stephan W.
El-Hariry, Iman
Proia, David A.
TI Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK
Inhibitor Resistance in Non-Small Cell Lung Cancer
SO CANCER DISCOVERY
LA English
DT Article
ID RECEPTOR TYROSINE KINASE; ROS1 REARRANGEMENTS; ACQUIRED-RESISTANCE;
DOMAIN MUTATIONS; FUSION ONCOGENE; EML4-ALK; GENE; IDENTIFICATION;
CRIZOTINIB; PROTEIN
AB EML4-ALK gene rearrangements define a unique subset of patients with non-small cell lung carcinoma (NSCLC), and the clinical success of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib in this population has become a paradigm for molecularly targeted therapy. Here, we show that the Hsp90 inhibitor ganetespib induced loss of EML4-ALK expression and depletion of multiple oncogenic signaling proteins in ALK-driven NSCLC cells, leading to greater in vitro potency, superior antitumor efficacy, and prolonged animal survival compared with results obtained with crizotinib. In addition, combinatorial benefit was seen when ganetespib was used with other targeted ALK agents both in vitro and in vivo. Importantly, ganetespib overcame multiple forms of crizotinib resistance, including secondary ALK mutations, consistent with activity seen in a patient with crizotinib-resistant NSCLC. Cancer cells driven by ALK amplification and oncogenic rearrangements of ROS1 and RET kinase genes were also sensitive to ganetespib exposure. Taken together, these results highlight the therapeutic potential of ganetespib for ALK-driven NSCLC.
SIGNIFICANCE: In addition to direct kinase inhibition, pharmacologic blockade of the molecular chaperone Hsp90 is emerging as a promising approach for treating tumors driven by oncogenic rearrangements of ALK. The bioactivity profile of ganetespib presented here underscores a new therapeutic opportunity to target ALK and overcome multiple mechanisms of resistance in patients with ALK-positive NSCLC. (C) 2013 AACR.
C1 [Sang, Jim; Acquaviva, Jaime; Friedland, Julie C.; Smith, Donald L.; Sequeira, Manuel; Zhang, Chaohua; Jimenez, John-Paul; He, Suqin; Bates, Richard C.; El-Hariry, Iman; Proia, David A.] Synta Pharmaceut Corp, Lexington, MA 02421 USA.
[Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Jiang, Qin; Xue, Liquan] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA.
[Jiang, Qin; Xue, Liquan] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
[Lovly, Christine M.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37212 USA.
[Morris, Stephan W.] Insight Genet, Nashville, TN USA.
[Morris, Stephan W.] HealthChart LLC, Morris Labs, Memphis, TN USA.
[Doebele, Robert C.; Camidge, D. Ross] Univ Colorado, Ctr Canc, Div Med Oncol, Aurora, CO USA.
RP Proia, DA (reprint author), Synta Pharmaceut Corp, 125 Hartwell Ave, Lexington, MA 02421 USA.
EM dproia@syntapharma.com
RI sebastianovitsch, stepan/G-8507-2013
FU Pfizer; Eli Lilly; ImClone; Synta Pharmaceuticals Corp.
FX J. Sang and J. Acquaviva are employed as Scientist II by Synta
Pharmaceuticals Corp. C. Zhang is employed as Research Assistant II by
Synta Pharmaceuticals Corp. C. M. Lovly is a consultant/advisory board
member of Abbott. J.-P. Jimenez is employed as Assoc. Scientist by, and
has ownership interest (including patents) in, Synta Pharmaceuticals
Corp. A. T. Shaw is a consultant/advisory board member of Daiichi Sankyo
and Novartis. R. C. Doebele has commercial research grants from Pfizer,
Eli Lilly, and ImClone; has honoraria from Speakers Bureau of Abbott
Molecular; and is a consultant/advisory board member of Boehringer
Ingelheim and Pfizer. S. He is employed as a Scientist by Synta
Pharmaceuticals Corp. R. C. Bates is employed as Senior Science Writer
by Synta Pharmaceuticals Corp. S. W. Morris has ownership interest
(including patents) in Insight Genetics, Inc. I. El-Hariry is Vice
President of Clinical Research and D. A. Proia is Director of Cancer
Biology at Synta Pharmaceuticals Corp. No potential conflicts of
interest were disclosed by the other authors.; All work was funded by
Synta Pharmaceuticals Corp.
NR 48
TC 100
Z9 107
U1 4
U2 22
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD APR
PY 2013
VL 3
IS 4
BP 430
EP 443
DI 10.1158/2159-8290.CD-12-0440
PG 14
WC Oncology
SC Oncology
GA 147YU
UT WOS:000319208900025
PM 23533265
ER
PT J
AU Treon, SP
Patterson, CJ
Munshi, NC
Anderson, KC
AF Treon, Steven P.
Patterson, Christopher J.
Munshi, Nikhil C.
Anderson, Kenneth C.
TI Proceedings of the Seventh International Workshop on Waldenstrom
Macroglobulinemia
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Editorial Material
C1 [Treon, Steven P.; Patterson, Christopher J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
[Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
RP Treon, SP (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, M547, Boston, MA 02115 USA.
EM steven_treon@dfci.harvard.edu
NR 0
TC 1
Z9 2
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD APR
PY 2013
VL 13
IS 2
BP 181
EP 183
DI 10.1016/j.clml.2013.04.001
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA 148MJ
UT WOS:000319248400015
PM 23664025
ER
PT J
AU Poulain, S
Herbaux, C
Bertrand, E
Decambron, A
Fouquet, G
Boyle, E
Gay, J
Manier, S
Duthilleul, P
Roumier, C
Leleu, X
AF Poulain, Stephanie
Herbaux, Charles
Bertrand, Elisabeth
Decambron, Audrey
Fouquet, Guillemette
Boyle, Eileen
Gay, Julie
Manier, Salomon
Duthilleul, Patrick
Roumier, Christophe
Leleu, Xavier
TI Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes
in Waldenstrom Macroglobulinemia
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article; Proceedings Paper
CT 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
CY AUG 23-26, 2012
CL Newport, RI
DE Array-based genomic hybridization; MYD88 mutation; Waldenstrom
macroglobulinemia
ID MARGINAL ZONE; MICRORNA EXPRESSION; SOMATIC MUTATION; KAPPA-B; LYMPHOMA;
CELLS; ABNORMALITIES; DELETIONS; PATHWAYS
AB The pathophysiology of Waldenstrom macroglobulinemia (WM), a lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration associated with serum IgM paraprotein, is rather unclear; however, progress has been made in recent years to better determine the genetic profile of WM tumor cells. Studies based on high-throughput genomic analyses-including single-nucleotide polymorphism array (SNPa), array-based comparative genomic hybridization, and, recently, whole-genome sequencing-have improved deciphering some of the key molecular pathways associated with WM. Beyond the discovery of the myeloid differentiation primary response gene 88 (MYD88) L265P mutation, which will help greatly in the differential characterization of WM from other B-cell low-grade lymphomas, several other mechanisms of gene deregulation were identified and mapped that recurrently pointed out nuclear factor-kappa B (NF-kappa B), breakpoint cluster region (BCR), and Toll-like receptor (TLR) signaling pathways as potential targets for a better understanding of the physiopathology of WM and for future drug development. Herein, we summarize the current knowledge of the genomic patterns of WM to highlight its complexity.
The clinical and biological presentation of Waldenstrom macroglobulinemia (WM), a rare lymphoproliferative disorder characterized by bone marrow infiltration of lymphoplasmacytic cells associated with serum IgM paraprotein,(1,2) is highly heterogeneous. Although the underlying genetic basis remains to be identified in WM, high-throughput whole-genome techniques such as array-based genomic hybridization, single-nucleotide polymorphism array (SNPa), and whole-genome sequencing have helped improve the comprehensive analysis of WM genetic patterns, including the identification of several genes involved in deregulated pathways.' We seek to summarize the various mechanisms of deregulation at the genomic level currently identified in WM.
C1 [Poulain, Stephanie; Decambron, Audrey; Duthilleul, Patrick] Serv Hematol Immunol Cytogenet, Valenciennes, France.
[Poulain, Stephanie; Roumier, Christophe] Ctr Biol Pathol, Lab Hematol, Lille, France.
[Herbaux, Charles; Bertrand, Elisabeth; Manier, Salomon; Roumier, Christophe; Leleu, Xavier] Inst Rech Canc, INSERM, U837, Lille, France.
[Herbaux, Charles; Fouquet, Guillemette; Boyle, Eileen; Gay, Julie; Manier, Salomon; Leleu, Xavier] Ctr Hosp Reg & Univ Lille, Hop Huriez, Serv Malad Sang, F-59037 Lille, France.
[Manier, Salomon] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Leleu, X (reprint author), CHRU, Hop Huriez, Serv Malad Sang, Lille, France.
EM xavier.leleu@chru-lille.fr
NR 25
TC 2
Z9 2
U1 0
U2 1
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
EI 2152-2669
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD APR
PY 2013
VL 13
IS 2
BP 202
EP 204
DI 10.1016/j.clml.2013.02.008
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA 148MJ
UT WOS:000319248400021
PM 23473949
ER
PT J
AU Sacco, A
Zhang, Y
Maiso, P
Manier, S
Rossi, G
Treon, SP
Ghobrial, IM
Roccaro, AM
AF Sacco, Antonio
Zhang, Yong
Maiso, Patricia
Manier, Salomon
Rossi, Giuseppe
Treon, Steven P.
Ghobrial, Irene M.
Roccaro, Aldo M.
TI microRNA Aberrations in Waldenstrom Macroglobulinemia
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article; Proceedings Paper
CT 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
CY AUG 23-26, 2012
CL Newport, RI
DE Locked nucleic acid; micro-RNA; miRNA-155; Waldenstrom macroglobulinemia
ID B-CELL LYMPHOMAS; MULTIPLE-MYELOMA; EXPRESSION; PROLIFERATION
AB Waldenstrom macroglobulinemia (WM) is a low-grade B-cell lymphoma characterized by the presence of lymphoplasmacytic cells in the BM (BM) and monoclonal immunoglobulin M in the circulation. Although WM cells showed minimal changes in cytogenetic studies and gene expression analysis, primary WM tumor cells present with a micro-RNA (miRNA) signature that differentiates them from their normal counterparts. This may suggest the importance of miRNAs in supporting WM pathogenesis. Among deregulated miRNAs, miRNA-155 has been shown to play a pivotal role in the biological characteristics of this disease both in vitro and in vivo, thus providing the rationale for testing miRNA-based therapeutic approaches for the treatment of WM.
C1 [Sacco, Antonio; Zhang, Yong; Maiso, Patricia; Manier, Salomon; Treon, Steven P.; Ghobrial, Irene M.; Roccaro, Aldo M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rossi, Giuseppe] Spedali Civil Brescia, Dept Hematol, I-25125 Brescia, Italy.
RP Roccaro, AM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM aldo_roccaro@dfci.harvard.edu
RI Sacco, Antonio/K-4681-2016; Rossi, Giuseppe/K-3376-2016;
OI Sacco, Antonio/0000-0003-2945-9416; Rossi, Giuseppe/0000-0001-8377-2898;
Roccaro, Aldo/0000-0002-1872-5128; Maiso, Patricia/0000-0003-3745-1924
NR 16
TC 3
Z9 3
U1 0
U2 1
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD APR
PY 2013
VL 13
IS 2
BP 205
EP 207
DI 10.1016/j.clml.2013.02.007
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA 148MJ
UT WOS:000319248400022
PM 23474146
ER
PT J
AU Agarwal, A
Ghobrial, IM
AF Agarwal, Amit
Ghobrial, Irene M.
TI The Bone Marrow Microenvironment in Waldenstrom Macroglobulinemia
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article; Proceedings Paper
CT 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
CY AUG 23-26, 2012
CL Newport, RI
ID TUMOR MICROENVIRONMENT; SOMATIC MUTATION; CELL-GROWTH; ABNORMALITY;
CYTOKINES; SUGGESTS; THERAPY; MYELOMA
AB Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by widespread involvement of the bone marrow (BM). The BM microenvironment serves as not only a site for disease involvement, but it also appears that the interaction of WM cells with the BM is essential for the pathogenesis of WM. The BM microenvironment consists of the cellular and noncellular compartments. The BM has been shown to regulate cell proliferation, cell cycle, and drug resistance as well as cell dissemination and cell trafficking of WM cells. A better understanding of the role of the BM microenvironment in the pathogenesis of WM can help guide better therapeutic strategies that can target the tumor clone and also regulate the BM microenvironment.
C1 [Agarwal, Amit] Univ Arizona, Div Hematol Oncol, Tucson, AZ USA.
[Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Ghobrial, IM (reprint author), Med Oncol Dana Farber Canc Inst, Boston, MA 02215 USA.
EM irene_ghobrial@dfci.harvard.edu
FU NCI NIH HHS [R01CA154648, R01CA133799, R01 CA154648, R01 CA133799, R01
CA125690, R01CA125690, R21 CA126119]
NR 26
TC 3
Z9 3
U1 0
U2 1
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD APR
PY 2013
VL 13
IS 2
BP 218
EP 221
DI 10.1016/j.clml.2013.02.006
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA 148MJ
UT WOS:000319248400026
PM 23490994
ER
PT J
AU Treon, SP
Tripsas, CK
Ciccarelli, BT
Manning, RJ
Patterson, CJ
Sheehy, P
Hunter, ZR
AF Treon, Steven P.
Tripsas, Christina K.
Ciccarelli, Bryan T.
Manning, Robert J.
Patterson, Christopher J.
Sheehy, Patricia
Hunter, Zachary R.
TI Patients With Waldenstrom Macroglobulinemia Commonly Present With Iron
Deficiency and Those With Severely Depressed Transferrin Saturation
Levels Show Response to Parenteral Iron Administration
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article; Proceedings Paper
CT 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
CY AUG 23-26, 2012
CL Newport, RI
ID CONSENSUS PANEL RECOMMENDATIONS; 2ND INTERNATIONAL WORKSHOP;
MULTIPLE-MYELOMA; INTRAVENOUS IRON; ANEMIC PATIENTS; HEPCIDIN;
FERROPORTIN; INTERNALIZATION; CHEMOTHERAPY; MULTICENTER
AB Anemia often prompts therapy in Waldenstrom macroglobulinemia (WM), although is not fully explained by bone marrow disease involvement in many patients. Hepcidin regulates gut absorption and distribution of iron and is elevated and associated with anemia in WM. Since hepcidin evaluation remains experimental, we initiated an American Board of Internal Medicine (ABIM) practice improvement project to determine baseline transferrin saturation (TSAT) levels in untreated anemic patients with WM. Among 108 patients with WM evaluated, 56 (52%) had a TSAT level <= 20%, which included 25 (23%) patients with severely depressed TSAT levels (<= 10%). Sixteen patients with TSAT levels <= 10% received parenteral iron, and 14 of these patients showed improved hematocrit values (28.75% to 32.75%; P < .0001), mean corpuscular volume (MCV) (84.7 to 89.9; P = .006), and TSAT levels (8.1% to 21.2%; P < .0001). Anemia in 8 of these patients was previously refractory to oral iron therapy. Routine screening of iron saturation levels may therefore identify patients with WM and severe iron deficiency who may be candidates for parenteral iron therapy.
C1 [Treon, Steven P.; Tripsas, Christina K.; Ciccarelli, Bryan T.; Manning, Robert J.; Patterson, Christopher J.; Sheehy, Patricia; Hunter, Zachary R.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
[Treon, Steven P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Treon, SP (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, M547, Boston, MA 02115 USA.
EM steven_treon@dfci.harvard.edu
RI Hunter, Zachary/H-3018-2013
OI Hunter, Zachary/0000-0002-1689-1691
NR 19
TC 3
Z9 3
U1 0
U2 1
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD APR
PY 2013
VL 13
IS 2
BP 241
EP 243
DI 10.1016/j.clml.2013.02.016
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA 148MJ
UT WOS:000319248400032
PM 23523274
ER
PT J
AU Uljon, SN
Treon, SP
Tripsas, CK
Lindeman, NI
AF Uljon, Sacha N.
Treon, Steven P.
Tripsas, Christina K.
Lindeman, Neal I.
TI Challenges With Serum Protein Electrophoresis in Assessing Progression
and Clinical Response in Patients With Waldenstrom Macroglobulinemia
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article; Proceedings Paper
CT 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
CY AUG 23-26, 2012
CL Newport, RI
ID FREE LIGHT-CHAINS; MYELOMA
AB Accurate determination of the immunoglobulin (Ig) M paraprotein concentration is crucial to evaluating response in patients with Waldenstrom macroglobulinemia (WM). In most clinical laboratories, M-spike quantitation is performed by serum protein electrophoresis, which is the same method used to quantitate IgG and IgA paraproteins in patients with multiple myeloma (MM). However, the migration pattern and propensity of IgM paraproteins to form higher-order complexes in serum makes laboratory evaluation of samples from patients with WM especially challenging. We review examples of patients whose IgM paraprotein is particularly ill-suited to M-spike quantitation by serum protein electrophoresis: a case of "sticky M," a case of IgM multimers that cannot be resolved, and a case of an IgM in the beta region. In these and similar cases, a method other than M-spike quantitation, such as IgM heavy chain nephelometry, should be considered in laboratory evaluation of paraprotein concentration.
C1 [Uljon, Sacha N.; Lindeman, Neal I.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Uljon, Sacha N.; Treon, Steven P.; Tripsas, Christina K.; Lindeman, Neal I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Treon, Steven P.; Tripsas, Christina K.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
RP Uljon, SN (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM suljon@partners.org
NR 11
TC 2
Z9 2
U1 0
U2 3
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD APR
PY 2013
VL 13
IS 2
BP 247
EP 249
DI 10.1016/j.clml.2013.03.001
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA 148MJ
UT WOS:000319248400034
PM 23664026
ER
PT J
AU Tripsas, CK
Patterson, CJ
Uljon, SN
Lindeman, NI
Turnbull, B
Treon, SP
AF Tripsas, Christina K.
Patterson, Christopher J.
Uljon, Sacha N.
Lindeman, Neal I.
Turnbull, Barry
Treon, Steven P.
TI Comparative Response Assessment by Serum Immunoglobulin M M-Protein and
Total Serum Immunoglobulin M After Treatment of Patients With
Waldenstrom Macroglobulinemia
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article; Proceedings Paper
CT 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
CY AUG 23-26, 2012
CL Newport, RI
ID INTERNATIONAL WORKSHOP; RECOMMENDATIONS; RITUXIMAB; UPDATE
AB Serum immunoglobulin (Ig) M monoclonal protein determined by electrophoresis (sIgM-MP) and total serum IgM (sIgM) by nephelometry are widely used for response assessment in Waldenstrom macroglobulinemia (WM), although have not been compared for predicting changes in underlying disease burden. We, therefore, compared these serum markers with changes in bone marrow (BM) and extramedullary disease for 73 patients who were rituximab naive and treated with a rituximab-containing regimen. By linear regression analysis, reductions in sIgM-MP and sIgM showed moderate correlation with BM disease involvement (r = 0.4051 and r = 0.4490, respectively), and did not differ from one another as estimators of BM disease response (P = .3745). Neither sIgM-MP nor sIgM showed a strong correlation with BM disease response in patients with low (<1000 mg/dL) or high (>5000 mg/dL) IgM levels and extramedullary disease response. sIgM-MP and sIgM, therefore, are comparable response markers in WM. Development of newer, more accurate surrogate response markers are needed to better delineate treatment outcomes in patients with WM and with low or high IgM levels, and extramedullary disease.
C1 [Tripsas, Christina K.; Patterson, Christopher J.; Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02215 USA.
[Uljon, Sacha N.; Lindeman, Neal I.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Uljon, Sacha N.; Lindeman, Neal I.; Treon, Steven P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Turnbull, Barry] BioBridges Inc, Boston, MA USA.
RP Treon, SP (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02215 USA.
EM steven_treon@dfci.harvard.edu
NR 14
TC 5
Z9 5
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD APR
PY 2013
VL 13
IS 2
BP 250
EP 252
DI 10.1016/j.clml.2013.04.002
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA 148MJ
UT WOS:000319248400035
PM 23664027
ER
PT J
AU Schlett, CL
Truong, QA
Ahmed, W
Blankstein, R
Ferencik, M
Uthamalingam, S
Bamberg, F
Koenig, W
Januzzi, JL
Hoffmann, U
AF Schlett, Christopher L.
Truong, Quynh A.
Ahmed, Waleed
Blankstein, Ron
Ferencik, Maros
Uthamalingam, Shanmugam
Bamberg, Fabian
Koenig, Wolfgang
Januzzi, James L.
Hoffmann, Udo
TI High-sensitivity troponin T and C-reactive protein to identify patients
without cardiac structural and functional abnormalities as assessed by
cardiac CT and SPECT imaging: can biomarkers predict cardiac health?
SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
LA English
DT Article
DE Cardiovascular health; High-sensitivity troponin T; High-sensitivity
C-reactive protein; Cardiac computed tomography; Single-photon emission
computed tomography
ID CORONARY-HEART-DISEASE; LEFT-VENTRICULAR FUNCTION; ACUTE CHEST-PAIN;
COMPUTED-TOMOGRAPHY; MYOCARDIAL-INFARCTION; CLINICAL-SIGNIFICANCE;
CIRCULATING TROPONIN; PROGNOSTIC VALUE; RISK-ASSESSMENT; ARTERY-DISEASE
AB While high-sensitivity troponin-T (hsTnT) and C-reactive protein (hsCRP) are associated with structural heart disease, we thought to determine whether biomarkers can predict which heart is healthy based on multimodality imaging. Patients from the emergency department with acute chest pain suggestive of acute coronary syndrome undergoing contrast enhanced cardiac CT and stress single photon emission computed tomography (SPECT) myocardial perfusion imaging were included. HsTnT and hsCRP were assessed at time of CT. Imaging data were assessed for coronary atherosclerosis, left ventricular hypertrophy/dysfunction and myocardial perfusion abnormalities. Patients were stratified into those with or without any cardiac findings, who were considered as cardiac healthy. For biomarkers, low cut-off corresponding to good specificity and high cut-off corresponding to good sensitivity for cardiac health were derived. Among 117 patients (52 years, 55 % male), 42 (36 %) were cardiac healthy based on cardiac CT and SPECT imaging. These patients had significantly lower hsTnT and hsCRP levels as compared to those with functional or structural abnormalities (3.58 vs. 5.63 ng/L, p = 0.002; 0.82 vs. 1.93 mg/L, p = 0.0005; respectively). Patients with both low hsTnT (< 3.00 ng/L) and hsCRP (< 0.45 mg/L) had a probability of 85 % for being cardiac healthy. In contrast, patients with high hsTnT (> 7.00 ng/L) and hsCRP (> 2.00 mg/L) had 8 % probability for being cardiac healthy. Discriminative capacity of a dual-biomarker strategy was significantly improved as compared to hsTnT or hsCRP alone or to Framingham Risk score (AUC: 0.781 vs. 0.691; vs. 0.678; vs. 0.649; all p a parts per thousand currency sign 0.02, respectively). A dual-biomarker strategy of hsTnT and hsCRP is highly discriminative for patients with normal cardiac structure and function and provides incremental value beyond the Framingham risk score.
C1 [Schlett, Christopher L.; Truong, Quynh A.; Ahmed, Waleed; Ferencik, Maros; Uthamalingam, Shanmugam; Hoffmann, Udo] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac MR PET CT Program,Dept Radiol, Boston, MA 02114 USA.
[Truong, Quynh A.; Ferencik, Maros; Januzzi, James L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Blankstein, Ron] Brigham & Womens Hosp, Dept Cardiol, Cardiovasc Div, Boston, MA 02115 USA.
[Bamberg, Fabian] Univ Munich, Dept Clin Radiol, Munich, Germany.
[Koenig, Wolfgang] Univ Ulm, Dept Internal Med Cardiol 2, D-89069 Ulm, Germany.
RP Schlett, CL (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac MR PET CT Program,Dept Radiol, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
EM cschlett@partners.org; uhoffmann@partners.org
FU NIH [R01 HL080053, T32HL076136, K23HL098370, L30HL093896]; Roche
Diagnostics; Siemens Diagnostics; BRAHMS
FX We thank Mr. Eracleo for his kind support. This work was supported by
the NIH (R01 HL080053). Drs. Blankstein, Ahmed, and Truong received
support from NIH grant T32HL076136. Dr. Truong also received support
from NIH grants K23HL098370 and L30HL093896.; The reagents for
high-sensitivity troponin assays were provided free of charge by Roche
Diagnostics. Dr. Januzzi has received grant support from Roche
Diagnostics, Siemens Diagnostics, and BRAHMS.
NR 42
TC 4
Z9 5
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1569-5794
EI 1573-0743
J9 INT J CARDIOVAS IMAG
JI Int. J. Cardiovasc. Imaging
PD APR
PY 2013
VL 29
IS 4
BP 865
EP 873
DI 10.1007/s10554-012-0164-8
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 140YV
UT WOS:000318693300016
PM 23274882
ER
PT J
AU Gao, X
Prigerson, HG
Diamond, EL
Zhang, BH
Wright, AA
Meyer, F
Maciejewski, PK
AF Gao, Xin
Prigerson, Holly G.
Diamond, Eli L.
Zhang, Baohui
Wright, Alexi A.
Meyer, Fremonta
Maciejewski, Paul K.
TI Minor Cognitive Impairments in Cancer Patients Magnify the Effect of
Caregiver Preferences on End-of-Life Care
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Cancer; terminal illness; end of life; cognitive impairment; treatment
preferences; caregiver
ID DECISION-MAKING CAPACITY; SUSTAINING TREATMENT; NEAR-DEATH; DEMENTIA;
DELIRIUM; OUTCOMES; PEOPLE; IMPACT
AB Context. Cognitive impairment commonly affects cancer patients.
Objectives. To examine whether minor cognitive impairment in patients with advanced cancer is associated with the intensity of end-of-life (EOL) care or modifies the influence of patient and caregiver preferences on the intensity of EOL care.
Methods. Data were derived from structured interviews with 221 advanced cancer patient-caregiver dyads in the Coping with Cancer Study, a multisite, longitudinal cohort study. Deficits in patients' cognitive function were identified using the Short Portable Mental Status Questionnaire (SPMSQ). Patients and caregivers reported preferences regarding life-extending vs. symptom-directed care. Information regarding EOL care was obtained from postmortem interviews with caregivers. Logistic regression analyses modeled main and interactive effects of patients' cognitive impairment and patients' and caregivers' treatment preferences on intensive EOL care.
Results. Cognitive impairment was associated with less intensive EOL care (odds ratio [OR] = 0.56; 95% confidence interval [CI]: 0.34-0.91). Patients and caregivers had poor agreement regarding preferences for life-extending vs. symptom-directed care (Phi = 0.10; chi(2) = 2.32, df = 1, P = 0.13). Patient preference for life-extending care predicted intensive EOL care irrespective of cognitive status (adjusted odds ratio [AOR] = 2.11; 95% CI: 1.04-4.28). For patients with no errors on the SPMSQ, caregiver preference for life-extending care was unrelated to intensive EOL care (AOR = 0.40; 95% CI: 0.09-1.77). However, the association between caregiver preference for life-extending care and intensive EOL care increased by nearly a factor of seven for every error on the SPMSQ (interaction AOR 6.90; 95% CI: 1.40-34.12).
Conclusion. Cognitive impairment in patients with advanced cancer is associated with less intensive EOL care. Caregivers' influence on intensive EOL care dramatically increases with minor declines in patients' cognitive function. (C) 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Gao, Xin; Prigerson, Holly G.; Zhang, Baohui; Wright, Alexi A.; Maciejewski, Paul K.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA.
[Prigerson, Holly G.; Wright, Alexi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Gao, Xin; Prigerson, Holly G.; Wright, Alexi A.; Meyer, Fremonta; Maciejewski, Paul K.] Harvard Univ, Sch Med, Boston, MA USA.
[Prigerson, Holly G.; Meyer, Fremonta; Maciejewski, Paul K.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Diamond, Eli L.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, 1134 Dana Bldg,450 Brookline Ave, Boston, MA 02115 USA.
EM Holly_Prigerson@dfci.harvard.edu
FU National Institute of Mental Health [MH63892]; National Cancer Institute
[CA106370, CA156732]; Center for Psychosocial Epidemiology and Outcomes
Research, Dana-Farber Cancer Institute
FX This research was supported in part by the following grants to Dr.
Prigerson: MH63892 from the National Institute of Mental Health and
CA106370 and CA156732 from the National Cancer Institute; and the Center
for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer
Institute. The authors declare no potential conflicts of interest or
financial disclosures. All authors have read and approved the article.
NR 35
TC 4
Z9 4
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD APR
PY 2013
VL 45
IS 4
BP 650
EP 659
DI 10.1016/j.jpainsymman.2012.03.003
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 145YP
UT WOS:000319056300005
PM 22846621
ER
PT J
AU Walker, RH
AF Walker, Ruth H.
TI Commentary for "Delayed onset of progressive chorea after acute basal
ganglia injury"
SO MOVEMENT DISORDERS
LA English
DT Editorial Material
ID DISORDERS
C1 [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA.
RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, 130 W Kingbridge Rd, Bronx, NY 10468 USA.
EM ruth.walker@mssm.edu
NR 3
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR
PY 2013
VL 28
IS 5
BP 587
EP 588
DI 10.1002/mds.25481
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 144QG
UT WOS:000318953900010
PM 23629806
ER
PT J
AU Liong, M
Hoang, AN
Chung, J
Gural, N
Ford, CB
Min, C
Shah, RR
Ahmad, R
Fernandez-Suarez, M
Fortune, SM
Toner, M
Lee, H
Weissleder, R
AF Liong, Monty
Hoang, Anh N.
Chung, Jaehoon
Gural, Nil
Ford, Christopher B.
Min, Changwook
Shah, Rupal R.
Ahmad, Rushdy
Fernandez-Suarez, Marta
Fortune, Sarah M.
Toner, Mehmet
Lee, Hakho
Weissleder, Ralph
TI Magnetic barcode assay for genetic detection of pathogens
SO NATURE COMMUNICATIONS
LA English
DT Article
ID REAL-TIME PCR; MYCOBACTERIUM-TUBERCULOSIS; MICROFLUIDIC CHIP;
DRUG-RESISTANCE; NANOPARTICLES; DNA; INFECTION; DIAGNOSIS; SYSTEM;
HYBRIDIZATION
AB The task of rapidly identifying patients infected with Mycobacterium tuberculosis in resource-constrained environments remains a challenge. A sensitive and robust platform that does not require bacterial isolation or culture is critical in making informed diagnostic and therapeutic decisions. Here we introduce a platform for the detection of nucleic acids based on a magnetic barcoding strategy. PCR-amplified mycobacterial genes are sequence-specifically captured on microspheres, labelled by magnetic nanoprobes and detected by nuclear magnetic resonance. All components are integrated into a single, small fluidic cartridge for streamlined on-chip operation. We use this platform to detect M. tuberculosis and identify drug-resistance strains from mechanically processed sputum samples within 2.5 h. The specificity of the assay is confirmed by detecting a panel of clinically relevant non-M. tuberculosis bacteria, and the clinical utility is demonstrated by the measurements in M. tuberculosis-positive patient specimens. Combined with portable systems, the magnetic barcode assay holds promise to become a sensitive, high-throughput and low-cost platform for point-of-care diagnostics.
C1 [Liong, Monty; Chung, Jaehoon; Min, Changwook; Lee, Hakho; Weissleder, Ralph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA.
[Hoang, Anh N.; Gural, Nil; Fernandez-Suarez, Marta; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, BioMEMS Resource Ctr,Surg Serv, Boston, MA 02114 USA.
[Ford, Christopher B.; Shah, Rupal R.; Fernandez-Suarez, Marta; Fortune, Sarah M.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Ahmad, Rushdy] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02114 USA.
RP Lee, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA.
EM hlee@mgh.harvard.edu; rweissleder@mgh.harvard.edu
FU NIBIB [R01-EB010011, R01-EB00462605A1, R01-HL113156, P41 EB002503];
NHLBI [HHSN268201000044C]; NIH [T32CA79443, DP2 0D001378]; United States
Army Medical Research Acquisition Activity Grant [W81XWH-10-2-0161];
NIAID [U19 AI076217]; Massachusetts General Hospital Executive Committee
on Research Fellowship
FX We thank I. Bagayev, J. C. Carlson, H. J. Chung, H. Im, M. McKee, N.
Sergeyev, H. Shao and J. Song for their assistance with experiments, and
W. R. Rodriguez for helpful discussions on point-of-care diagnostic. The
patient sputum samples were collected in Dar Es Salaam, Tanzania, under
a grant from the Bill and Melinda Gates Foundation as part of Grand
Challenge 13. This work was supported in part by NIBIB grants
R01-EB010011 (R.W.), R01-EB00462605A1 (R.W.), R01-HL113156 (H.L.), P41
EB002503 (M.T.), NHLBI contract HHSN268201000044C (R.W.), NIH grant
T32CA79443 (R.W.), United States Army Medical Research Acquisition
Activity Grant W81XWH-10-2-0161 (S.M.F.), NIH grant DP2 0D001378
(S.M.F), NIAID contract U19 AI076217 (S.M.F) and the Massachusetts
General Hospital Executive Committee on Research Fellowship (A.N.H and
M.F.-S.).
NR 41
TC 44
Z9 44
U1 4
U2 100
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2013
VL 4
AR 1752
DI 10.1038/ncomms2745
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 143MR
UT WOS:000318872100109
PM 23612293
ER
PT J
AU Yang, SY
O'Cearbhaill, ED
Sisk, GC
Park, KM
Cho, WK
Villiger, M
Bouma, BE
Pomahac, B
Karp, JM
AF Yang, Seung Yun
O'Cearbhaill, Eoin D.
Sisk, Geoffroy C.
Park, Kyeng Min
Cho, Woo Kyung
Villiger, Martin
Bouma, Brett E.
Pomahac, Bohdan
Karp, Jeffrey M.
TI A bio-inspired swellable microneedle adhesive for mechanical
interlocking with tissue
SO NATURE COMMUNICATIONS
LA English
DT Article
ID AMPHIPHILIC BLOCK-COPOLYMERS; FIBRIN GLUE; SKIN-GRAFTS;
BIOCOMPATIBILITY; THICKNESS; SURGERY; CLOSURE; WOUNDS; REPAIR; SITES
AB Achieving significant adhesion to soft tissues while minimizing tissue damage poses a considerable clinical challenge. Chemical-based adhesives require tissue-specific reactive chemistry, typically inducing a significant inflammatory response. Staples are fraught with limitations including high-localized tissue stress and increased risk of infection, and nerve and blood vessel damage. Here inspired by the endoparasite Pomphorhynchus laevis, which swells its proboscis to attach to its host's intestinal wall, we have developed a biphasic microneedle array that mechanically interlocks with tissue through swellable microneedle tips, achieving similar to 3.5-fold increase in adhesion strength compared with staples in skin graft fixation, and removal force of similar to 4.5 N cm(-2) from intestinal mucosal tissue. Comprising a poly(styrene)-block-poly(acrylic acid) swellable tip and non-swellable polystyrene core, conical microneedles penetrate tissue with minimal insertion force and depth, yet high adhesion strength in their swollen state. Uniquely, this design provides universal soft tissue adhesion with minimal damage, less traumatic removal, reduced risk of infection and delivery of bioactive therapeutics.
C1 [Yang, Seung Yun; O'Cearbhaill, Eoin D.; Cho, Woo Kyung; Karp, Jeffrey M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Biomed Engn, Boston, MA 02115 USA.
[Yang, Seung Yun; O'Cearbhaill, Eoin D.; Karp, Jeffrey M.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Yang, Seung Yun; O'Cearbhaill, Eoin D.; Cho, Woo Kyung; Bouma, Brett E.; Karp, Jeffrey M.] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Sisk, Geoffroy C.; Pomahac, Bohdan] Brigham & Womens Hosp, Div Plast Surg, Dept Surg, Boston, MA 02115 USA.
[Park, Kyeng Min] Harvard Univ, Dept Chem, Cambridge, MA 02138 USA.
[Villiger, Martin; Bouma, Brett E.] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Villiger, Martin; Bouma, Brett E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Karp, JM (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Biomed Engn, Boston, MA 02115 USA.
EM jkarp@rics.bwh.harvard.edu
RI Yang, Seung Yun/B-5974-2016;
OI Park, Kyeng Min/0000-0001-6089-6169; Yang, Seung
Yun/0000-0002-1233-8960; O'Cearbhaill, Eoin/0000-0002-4666-5863
FU National Institutes of Health (NIH) [GM086433]; NIH [P41EB015903]; Basic
Science Research Program through the National Research Foundation of
Korea (NRF); Ministry of Education, Science and Technology
[2012R1A6A3A03039055]
FX We would like to thank ADMET for providing an eXpert 760 mechanical
tester that was instrumental for this work. Funding for this research
was provided by the National Institutes of Health (NIH) grant GM086433
to J.M.K., NIH grant P41EB015903 to B.E.B. and the Basic Science
Research Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology
(2012R1A6A3A03039055). This work was performed in part through the use
of MIT's Microsystems Technology Laboratories and Harvard's Center for
Nanoscale Systems. We would like to thank Albert Kwon for providing E.
coli and Dr. Bryan Laulicht for helpful discussions.
NR 37
TC 51
Z9 51
U1 13
U2 130
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2013
VL 4
AR 1702
DI 10.1038/ncomms2715
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 143MR
UT WOS:000318872100059
PM 23591869
ER
PT J
AU Surawicz, CM
Brandt, LJ
Binion, DG
Ananthakrishnan, AN
Curry, SR
Gilligan, PH
McFarland, LV
Mellow, M
Zuckerbraun, BS
AF Surawicz, Christina M.
Brandt, Lawrence J.
Binion, David G.
Ananthakrishnan, Ashwin N.
Curry, Scott R.
Gilligan, Peter H.
McFarland, Lynne V.
Mellow, Mark
Zuckerbraun, Brian S.
TI Guidelines for Diagnosis, Treatment, and Prevention of Clostridium
difficile Infections
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
ID INFLAMMATORY-BOWEL-DISEASE; PLACEBO-CONTROLLED TRIAL;
POLYMERASE-CHAIN-REACTION; FULMINANT PSEUDOMEMBRANOUS COLITIS; FECAL
MICROBIOTA TRANSPLANTATION; LACTOBACILLUS-RHAMNOSUS GG; HEALTH-CARE
EPIDEMIOLOGY; SERUM ANTIBODY-RESPONSE; PUMP INHIBITOR THERAPY; REAL-TIME
PCR
AB Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks of disease. This guideline provides recommendations for the diagnosis and management of patients with CDI as well as for the prevention and control of outbreaks while supplementing previously published guidelines. New molecular diagnostic stool tests will likely replace current enzyme immunoassay tests. We suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease. Therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease. We propose a classification of disease severity to guide therapy that is useful for clinicians. We review current treatment options for patients with recurrent CDI and recommendations for the control and prevention of outbreaks of CDI.
C1 [Surawicz, Christina M.] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98104 USA.
[Brandt, Lawrence J.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Brandt, Lawrence J.] Montefiore Med Ctr, Div Gastroenterol, Bronx, NY 10467 USA.
[Binion, David G.] Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
[Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA.
[Ananthakrishnan, Ashwin N.] Harvard Univ, Sch Med, Boston, MA USA.
[Curry, Scott R.] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA.
[Gilligan, Peter H.] Univ North Carolina Hosp, Clin Microbiol Immunol Labs, Chapel Hill, NC USA.
[McFarland, Lynne V.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA.
[McFarland, Lynne V.] Univ Washington, Sch Publ Hlth, Dept Med Chem, Seattle, WA 98104 USA.
[Mellow, Mark] INTEGRIS Baptist Med Ctr, Digest Hlth Ctr, Oklahoma City, OK USA.
[Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Surawicz, CM (reprint author), Univ Washington, Sch Med, Dept Med, Div Gastroenterol, 325 9th Ave, Seattle, WA 98104 USA.
EM surawicz@u.washington.edu
FU Optimer; Remel Lenexa, KS; Cepheid, Sunnyvale, CA; TechLab, Blacksburg,
VA; Meridian Bioscience, Cincinnati, OH
FX Dr Ananthakrishnan is on the scientific advisory boards for Prometheus
Laboratory and Janssen. Dr Binion has received honoraria and is a
consultant for Optimer, Janssen, Abbott, Salix, UCB Pharma, and Given
Imaging; Dr Brandt is on the speaker's bureau has received grant funding
from Optimer; Dr Gilligan's research was funded by Remel Lenexa, KS,
Meridian Bioscience, Cincinnati, OH; Cepheid, Sunnyvale, CA, and
TechLab, Blacksburg, VA, and has received honorarium from Alere
Scarborough, ME; Dr Mellow is on the speaker's bureau of Optimer; Dr
Zuckerbraun is on the speaker's bureau of Pfizer; Dr McFarland is on the
advisory board of BioK Canada. Dr McFarland is a Government employee.
The remaining authors declare no conflict of interest.
NR 254
TC 341
Z9 387
U1 21
U2 118
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD APR
PY 2013
VL 108
IS 4
BP 478
EP 498
DI 10.1038/ajg.2013.4
PG 21
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 141CN
UT WOS:000318703300004
PM 23439232
ER
PT J
AU Ananthakrishnan, AN
Gainer, VS
Cai, TX
Perez, RG
Cheng, SC
Savova, G
Chen, P
Szolovits, P
Xia, ZQ
De Jager, PL
Shaw, S
Churchill, S
Karlson, EW
Kohane, I
Perlis, RH
Plenge, RM
Murphy, SN
Liao, KP
AF Ananthakrishnan, Ashwin N.
Gainer, Vivian S.
Cai, Tianxi
Perez, Raul Guzman
Cheng, Su-Chun
Savova, Guergana
Chen, Pei
Szolovits, Peter
Xia, Zongqi
De Jager, Philip L.
Shaw, Stanley
Churchill, Susanne
Karlson, Elizabeth W.
Kohane, Isaac
Perlis, Roy H.
Plenge, Robert M.
Murphy, Shawn N.
Liao, Katherine P.
TI Similar Risk of Depression and Anxiety Following Surgery or
Hospitalization for Crohn's Disease and Ulcerative Colitis
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; QUALITY-OF-LIFE; POUCH-ANAL ANASTOMOSIS;
POPULATION; COHORT; EPIDEMIOLOGY; COLECTOMY; DISORDER; HISTORY; STRESS
AB OBJECTIVES: Psychiatric comorbidity is common in Crohn's disease (CD) and ulcerative colitis (UC). Inflammatory bowel disease (IBD)-related surgery or hospitalizations represent major events in the natural history of the disease. The objective of this study is to examine whether there is a difference in the risk of psychiatric comorbidity following surgery in CD and UC.
METHODS: We used a multi-institution cohort of IBD patients without a diagnosis code for anxiety or depression preceding their IBD-related surgery or hospitalization. Demographic-, disease-, and treatment-related variables were retrieved. Multivariate logistic regression analysis was performed to individually identify risk factors for depression and anxiety.
RESULTS: Our study included a total of 707 CD and 530 UC patients who underwent bowel resection surgery and did not have depression before surgery. The risk of depression 5 years after surgery was 16% and 11% in CD and UC patients, respectively. We found no difference in the risk of depression following surgery in the CD and UC patients (adjusted odds ratio, 1.11; 95% confidence interval, 0.84-1.47). Female gender, comorbidity, immunosuppressant use, perianal disease, stoma surgery, and early surgery within 3 years of care predicted depression after CD surgery; only the female gender and comorbidity predicted depression in UC patients. Only 12% of the CD cohort had >= 4 risk factors for depression, but among them nearly 44% subsequently received a diagnosis code for depression.
CONCLUSIONS: IBD-related surgery or hospitalization is associated with a significant risk for depression and anxiety, with a similar magnitude of risk in both diseases.
C1 [Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Crohns & Colitis Ctr, Boston, MA 02114 USA.
[Ananthakrishnan, Ashwin N.; Xia, Zongqi; De Jager, Philip L.; Shaw, Stanley; Karlson, Elizabeth W.; Kohane, Isaac; Perlis, Roy H.; Plenge, Robert M.; Murphy, Shawn N.; Liao, Katherine P.] Harvard Univ, Sch Med, Boston, MA USA.
[Gainer, Vivian S.; Perez, Raul Guzman; Murphy, Shawn N.] Partners HealthCare, Res Comp, Charlestown, MA USA.
[Cai, Tianxi; Cheng, Su-Chun] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Savova, Guergana; Chen, Pei; Kohane, Isaac] Childrens Hosp, Boston, MA 02115 USA.
[Szolovits, Peter] MIT, Cambridge, MA 02139 USA.
[Xia, Zongqi; De Jager, Philip L.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Shaw, Stanley] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Churchill, Susanne; Kohane, Isaac] Brigham & Womens Hosp, I2b2 Natl Ctr Biomed Comp, Boston, MA 02115 USA.
[Karlson, Elizabeth W.; Plenge, Robert M.; Liao, Katherine P.] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Psychiat Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA.
[Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA.
EM aananthakrishnan@partners.org
OI Szolovits, Peter/0000-0001-8411-6403
FU NIH [U54-LM008748, K08 AR060257, K24 AR052403, P60 AR047782, R01
AR049880]; American Gastroenterological Association; US National
Institutes of Health [K23 DK097142]; Katherine Swan Ginsburg Fund; US
National Institutes of Health (NIH) [R01-AR056768, U01-GM092691,
R01-AR059648]; Burroughs Wellcome Fund
FX This study was supported by NIH U54-LM008748. A.N.A is supported by
funding from the American Gastroenterological Association and from the
US National Institutes of Health (K23 DK097142). K.P.L. is supported by
the NIH K08 AR060257 and the Katherine Swan Ginsburg Fund. R.M.P. is
supported by grants from the US National Institutes of Health (NIH;
R01-AR056768, U01-GM092691, and R01-AR059648) and holds a Career Award
for Medical Scientists from the Burroughs Wellcome Fund. E.W.K is
supported by grants from the NIH (K24 AR052403, P60 AR047782, and R01
AR049880).
NR 44
TC 24
Z9 24
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD APR
PY 2013
VL 108
IS 4
BP 594
EP 601
DI 10.1038/ajg.2012.471
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 141CN
UT WOS:000318703300016
PM 23337479
ER
PT J
AU Shah, D
Sah, S
Wanchu, A
Wu, MX
Bhatnagar, A
AF Shah, Dilip
Sah, Sangita
Wanchu, Ajay
Wu, Mei X.
Bhatnagar, Archana
TI Altered redox state and apoptosis in the pathogenesis of systemic lupus
erythematosus
SO IMMUNOBIOLOGY
LA English
DT Article
DE Glutathione; Altered redox state; Apoptosis; Systemic lupus
erythematosus (SLE)
ID OXIDATIVE STRESS; DISEASE-ACTIVITY; MITOCHONDRIAL HYPERPOLARIZATION;
RHEUMATOID-ARTHRITIS; GLUTATHIONE; BLOOD; ANTIOXIDANT; DAMAGE; CELLS;
DEPLETION
AB An altered redox status and increased lymphocyte apoptosis have been implicated in the development of systemic lupus erythematosus (SLE). In this study, we evaluated the relationship between glutathione (GSH) depletion, reactive oxygen species (ROS) and, the progression of apoptosis and their association with SLE severity. Significant low levels of intracellular glutathione, total thiol and altered redox state (GSH/GSSG) were found in SLE patients, in which lymphocyte apoptosis and activated caspase-3 expression in the lymphocytes were remarkably increased. The severity of disease was positively allied with the increased levels of lymphocyte apoptosis and caspase-3, but negatively with the decreased levels of total thiol, depleted intracellular glutathione and altered redox state (GSH/GSSG). The lymphocyte apoptosis and activated caspase-3 expression were negatively associated with intracellular levels of GSH and redox state and positively associated with the elevated levels of multiple oxidative stress markers: ROS and lipid peroxidation measured as malondialdehyde (MDA). These results suggest that GSH depletion and elevated oxidative stress trigger apoptosis and may be coupled with the severity of the disease. (C) 2012 Elsevier GmbH. All rights reserved.
C1 [Shah, Dilip; Wu, Mei X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA.
[Shah, Dilip; Bhatnagar, Archana] Panjab Univ, Dept Biochem, Chandigarh 160014, India.
[Sah, Sangita] KIE Univ, Jawaharlal Nehru Med Coll, Dept Biochem, Belgaum, India.
[Wanchu, Ajay] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis OP09, Portland, OR 97239 USA.
[Wu, Mei X.] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA.
RP Bhatnagar, A (reprint author), Panjab Univ, Dept Biochem, Basic Med Sci Bldg, Chandigarh 160014, India.
EM bhatnagar.archana@gmail.com
FU Council of Scientific and Industrial Research, New Delhi, India
FX This work was supported by grant received from Council of Scientific and
Industrial Research, New Delhi, India. The authors would like to
acknowledge Dr. Aman Sharma for analyzing the clinical data, Dr.
Narendra Kumar for cutesy help in statistics analysis, Mrs Bhupinder and
Mrs Sandhya for flow cytometry analysis of the samples.
NR 46
TC 11
Z9 11
U1 0
U2 3
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD APR
PY 2013
VL 218
IS 4
BP 620
EP 627
DI 10.1016/j.imbio.2012.07.030
PG 8
WC Immunology
SC Immunology
GA 145NQ
UT WOS:000319024100022
PM 22940256
ER
PT J
AU Maughan-Brown, B
Venkataramani, AS
AF Maughan-Brown, Brendan
Venkataramani, Atheendar S.
TI Incorrect Beliefs About Male Circumcision and Male-to-Female HIV
Transmission Risk in South Africa: Implications for Prevention
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
C1 [Maughan-Brown, Brendan] Univ Cape Town, Southern Africa Labour & Dev Res Unit, ZA-7925 Cape Town, South Africa.
[Venkataramani, Atheendar S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
RP Venkataramani, AS (reprint author), Massachusetts Gen Hosp, Dept Med, Charlestown HealthCare Ctr, 73 High St, Charlestown, MA 02129 USA.
EM avenkataramani@partners.org
NR 8
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 1
PY 2013
VL 62
IS 4
BP E121
EP E123
DI 10.1097/QAI.0b013e3182826343
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 145SM
UT WOS:000319037700005
PM 24135737
ER
PT J
AU Ebert, MH
Findling, RL
Gelenberg, AJ
Kane, JM
Nierenberg, AA
Tariot, PN
AF Ebert, Michael H.
Findling, Robert L.
Gelenberg, Alan J.
Kane, John M.
Nierenberg, Andrew A.
Tariot, Pierre N.
TI The Effects of the Affordable Care Act on the Practice of Psychiatry
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Editorial Material
C1 [Ebert, Michael H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA.
[Ebert, Michael H.] VA Connecticut Healthcare Syst, New Haven, CT USA.
[Findling, Robert L.] Johns Hopkins Med, Dept Psychiat & Behav Sci, Baltimore, MD USA.
[Findling, Robert L.] Kennedy Krieger Inst, Baltimore, MD USA.
[Gelenberg, Alan J.] Penn State Hershey Milton S Hershey Med Ctr, Dept Psychiat, Hershey, PA USA.
[Kane, John M.] Zucker Hillside Hosp, Dept Psychiat, Glen Oaks, NY USA.
[Kane, John M.] Hofstra North Shore Long Isl Jewish Sch Med, Dept Psychiat, Uniondale, NY USA.
[Kane, John M.] North Shore Long Isl Jewish Hlth Syst, Behav Hlth Serv, New Hyde Pk, NY USA.
[Nierenberg, Andrew A.] Harvard Univ, Sch Med, Bipolar Clin, Boston, MA USA.
[Nierenberg, Andrew A.] Harvard Univ, Sch Med, Res Program, Depress Clin & Res Program, Boston, MA USA.
[Nierenberg, Andrew A.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Nierenberg, Andrew A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tariot, Pierre N.] Univ Arizona, Coll Med, Alzheimers Prevent Initiat, Banner Alzheimers Inst, Phoenix, AZ USA.
[Tariot, Pierre N.] Univ Arizona, Coll Med, Dept Psychiat, Phoenix, AZ USA.
RP Ebert, MH (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA.
NR 15
TC 4
Z9 4
U1 0
U2 2
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD APR
PY 2013
VL 74
IS 4
BP 357
EP 361
DI 10.4088/JCP.12128co1c
PG 5
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 146KS
UT WOS:000319090600003
PM 23656840
ER
PT J
AU Goss, PE
Lee, BL
Badovinac-Crnjevic, T
Strasser-Weippl, K
Chavarri-Guerra, Y
St Louis, J
Villarreal-Garza, C
Unger-Saldana, K
Ferreyra, M
Debiasi, M
Liedke, PER
Touya, D
Werutsky, G
Higgins, M
Fan, L
Vasconcelos, C
Cazap, E
Vallejos, C
Mohar, A
Knaul, F
Arreola, H
Batura, R
Luciani, S
Sullivan, R
Finkelstein, D
Simon, S
Barrios, C
Kightlinger, R
Gelrud, A
Bychkovsky, V
Lopes, G
Stefani, S
Blaya, M
Souza, FH
Santos, FS
Kaemmerer, A
de Azambuja, E
Zorilla, AFC
Murillo, R
Jeronimo, J
Tsu, V
Carvalho, A
Gil, CF
Sternberg, C
Duenas-Gonzalez, A
Sgroi, D
Cuello, M
Fresco, R
Reis, RM
Masera, G
Gabus, R
Ribeiro, R
Knust, R
Ismael, G
Rosenblatt, E
Roth, B
Villa, L
Solares, AL
Leon, MX
Torres-Vigil, I
Covarrubias-Gomez, A
Hernandez, A
Bertolino, M
Schwartsmann, G
Santillana, S
Esteva, F
Fein, L
Mano, M
Gomez, H
Hurlbert, M
Durstine, A
Azenha, G
AF Goss, Paul E.
Lee, Brittany L.
Badovinac-Crnjevic, Tanja
Strasser-Weippl, Kathrin
Chavarri-Guerra, Yanin
St Louis, Jessica
Villarreal-Garza, Cynthia
Unger-Saldana, Karla
Ferreyra, Mayra
Debiasi, Marcio
Liedke, Pedro E. R.
Touya, Diego
Werutsky, Gustavo
Higgins, Michaela
Fan, Lei
Vasconcelos, Claudia
Cazap, Eduardo
Vallejos, Carlos
Mohar, Alejandro
Knaul, Felicia
Arreola, Hector
Batura, Rekha
Luciani, Silvana
Sullivan, Richard
Finkelstein, Dianne
Simon, Sergio
Barrios, Carlos
Kightlinger, Rebecca
Gelrud, Andres
Bychkovsky, Vladimir
Lopes, Gilberto
Stefani, Stephen
Blaya, Marcelo
Souza, Fabiano Hahn
Santos, Franklin Santana
Kaemmerer, Alberto
de Azambuja, Evandro
Cardona Zorilla, Andres Felipe
Murillo, Raul
Jeronimo, Jose
Tsu, Vivien
Carvalho, Andre
Gil, Carlos Ferreira
Sternberg, Cinthya
Duenas-Gonzalez, Alfonso
Sgroi, Dennis
Cuello, Mauricio
Fresco, Rodrigo
Reis, Rui Manuel
Masera, Guiseppe
Gabus, Raul
Ribeiro, Raul
Knust, Renata
Ismael, Gustavo
Rosenblatt, Eduardo
Roth, Berta
Villa, Luisa
Lara Solares, Argelia
Ximena Leon, Marta
Torres-Vigil, Isabel
Covarrubias-Gomez, Alfredo
Hernandez, Andres
Bertolino, Mariela
Schwartsmann, Gilberto
Santillana, Sergio
Esteva, Francisco
Fein, Luis
Mano, Max
Gomez, Henry
Hurlbert, Marc
Durstine, Alessandra
Azenha, Gustavo
TI Planning cancer control in Latin America and the Caribbean
SO LANCET ONCOLOGY
LA English
DT Article
ID CELL LUNG-CANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; UNIVERSAL HEALTH
COVERAGE; WOOD-SMOKE EXPOSURE; NEPHRECTOMY INITIAL-EXPERIENCE;
HER2-POSITIVE BREAST-CANCER; FACTOR RECEPTOR MUTATIONS; MIDDLE-INCOME
COUNTRIES; LONG-TERM SURVIVAL; OF-THE-LITERATURE
AB Non-communicable diseases, including cancer, are overtaking infectious disease as the leading health-care threat in middle-income and low-income countries. Latin American and Caribbean countries are struggling to respond to increasing morbidity and death from advanced disease. Health ministries and health-care systems in these countries face many challenges caring for patients with advanced cancer: inadequate funding; inequitable distribution of resources and services; inadequate numbers, training, and distribution of health-care personnel and equipment; lack of adequate care for many populations based on socioeconomic, geographic, ethnic, and other factors; and current systems geared toward the needs of wealthy, urban minorities at a cost to the entire population. This burgeoning cancer problem threatens to cause widespread suffering and economic peril to the countries of Latin America. Prompt and deliberate actions must be taken to avoid this scenario. Increasing efforts towards prevention of cancer and avoidance of advanced, stage IV disease will reduce suffering and mortality and will make overall cancer care more affordable. We hope the findings of our Commission and our recommendations will inspire Latin American stakeholders to redouble their efforts to address this increasing cancer burden and to prevent it from worsening and threatening their societies.
C1 [Goss, Paul E.; Lee, Brittany L.; Badovinac-Crnjevic, Tanja; St Louis, Jessica; Higgins, Michaela; Fan, Lei; Finkelstein, Dianne] Massachusetts Gen Hosp, Avon Int Breast Canc Res Program, Boston, MA 02114 USA.
[Lee, Brittany L.; Knaul, Felicia; Sgroi, Dennis] Harvard Univ, Sch Med, Boston, MA USA.
[Lee, Brittany L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Strasser-Weippl, Kathrin] Wilhelminen Hosp, Ctr Oncol & Hematol, Vienna, Austria.
[Chavarri-Guerra, Yanin] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Hematol Oncol, Salvador Zubiran, Mexico.
[Villarreal-Garza, Cynthia] Inst Nacl Cancerol, Med Oncol & Breast Canc Dept, Mexico City, DF, Mexico.
[Ferreyra, Mayra] Maria Curie Hosp, Dept Oncol, Buenos Aires, DF, Argentina.
[Debiasi, Marcio; Liedke, Pedro E. R.; Kaemmerer, Alberto] Hosp Mae Deus, Inst Canc, Hosp Clin Porto Alegre, Serv Oncol, Porto Alegre, RS, Brazil.
[Debiasi, Marcio] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Dept Med Oncol, Porto Alegre, RS, Brazil.
[Liedke, Pedro E. R.; Schwartsmann, Gilberto] Univ Fed Rio Grande do Sul, Dept Med Oncol, Hosp Clin, Porto Alegre, RS, Brazil.
[Touya, Diego; Cuello, Mauricio; Fresco, Rodrigo] Univ Republica, Hosp Clin, Dept Oncol, Montevideo, Uruguay.
[Werutsky, Gustavo] Hosp Sao Lucas PUCRS, Latin Amer Cooperat Oncol Grp, Porto Alegre, RS, Brazil.
[Werutsky, Gustavo] Hosp Sao Lucas PUCRS, Dept Med Oncol, Porto Alegre, RS, Brazil.
[Vasconcelos, Claudia] Grp Brasileiro Estudios Canc Mama, Sao Paulo, Brazil.
[Cazap, Eduardo] UICC, Geneva, Switzerland.
[Cazap, Eduardo] Minist Hlth, Natl Canc Inst, Buenos Aires, DF, Argentina.
[Vallejos, Carlos] Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima, Peru.
[Mohar, Alejandro] Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico.
[Mohar, Alejandro; Duenas-Gonzalez, Alfonso] Inst Nacl Cancerol, Mexico City, DF, Mexico.
[Knaul, Felicia] Harvard Global Equity Initiat, Boston, MA USA.
[Knaul, Felicia] Mexican Hlth Fdn, Mexico City, DF, Mexico.
[Knaul, Felicia] Tomatelo Pecho, Mexico City, DF, Mexico.
[Arreola, Hector] Fdn Mexicana Salud, Tlalpan, Mexico.
[Batura, Rekha] Kings Coll London, Kings Hlth Partners, Inst Oncopolicy, London WC2R 2LS, England.
[Sullivan, Richard] Kings Coll London, Kings Hlth Partners, Guys Hosp, Integrated Canc Ctr, London WC2R 2LS, England.
[Luciani, Silvana] Pan Amer Hlth Org, Area Hlth Surveillance Dis Prevent & Control, Washington, DC USA.
[Finkelstein, Dianne] Massachusetts Gen Hosp, Dept Biostat, Ctr Biostat, Boston, MA 02114 USA.
[Unger-Saldana, Karla] CIDE, Mexico City, DF, Mexico.
[Simon, Sergio] Fed Univ Sao Paulo UNIFESP, Dept Clin Oncol, Sao Paulo, Brazil.
[Simon, Sergio] Brazilian Breast Canc Study Grp GBECAM, Sao Paulo, Brazil.
[Barrios, Carlos] Hosp Mae Deus, Inst Canc, PUCRS Sch Med, Dept Med, Porto Alegre, RS, Brazil.
[Barrios, Carlos] LACOG, Porto Alegre, RS, Brazil.
[Kightlinger, Rebecca] Univ Virginia, Dept Obstet & Gynecol, Charlottesville, VA USA.
[Gelrud, Andres] Univ Chicago, Med Ctr, Ctr Pancreat Dis, Chicago, IL 60637 USA.
[Bychkovsky, Vladimir] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Lopes, Gilberto] Johns Hopkins Singapore Int Med Ctr, Dept Med Oncol, Singapore, Singapore.
[Lopes, Gilberto] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Stefani, Stephen] ICMD, Porto Alegre, RS, Brazil.
[Stefani, Stephen] Fundacao Unimed, Porto Alegre, RS, Brazil.
[Blaya, Marcelo] East Jefferson Gen Hosp, Dept Med, Metairie, LA USA.
[Souza, Fabiano Hahn] Roche Diagnost Latin Amer, Med & Sci Affairs, Sao Paulo, Brazil.
[Santos, Franklin Santana] Arnaldo Vieira de Carvalho Inst Canc, Palliat Care Unit, Sao Paulo, Brazil.
[de Azambuja, Evandro] Inst Jules Bordet, Breast European Adjuvant Studies Team BREAST, Ctr Data, B-1000 Brussels, Belgium.
[Cardona Zorilla, Andres Felipe] Fdn Santa Fe, Inst Oncol, Clin & Translat Oncol Grp, Bogota, Colombia.
[Murillo, Raul] Inst Nacl Cancerol, Bogota, Colombia.
[Jeronimo, Jose; Tsu, Vivien] PATH, Seattle, WA USA.
[Carvalho, Andre; Reis, Rui Manuel] Barretos Canc Hosp, Teaching & Res Inst, Mol Oncol Res Ctr, Barretos, Brazil.
[Gil, Carlos Ferreira] Inst Nacl Canc Jose Alencar Gomes da Silva, Dept Clin Res, Rio De Janeiro, Brazil.
[Sternberg, Cinthya] Insitituto Nacl Canc INCA, Chief Translat Program, Rio De Janeiro, Brazil.
[Knust, Renata] Insitituto Nacl Canc INCA, Coordenacao Pesquisa Clin & Inc Tecnol, Rio De Janeiro, Brazil.
[Duenas-Gonzalez, Alfonso] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Unit Biomed Res Canc, Mexico City, DF, Mexico.
[Sgroi, Dennis] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
[Masera, Guiseppe] Univ Milano Bicocca, Fdn MBBM AOS Gerardo, Dept Pediat, Monza, Italy.
[Gabus, Raul] Hosp Maciel, Serv Hematol & Bone Marrow Transplantat, Montevideo, Uruguay.
[Ribeiro, Raul] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
[Ribeiro, Raul] St Jude Childrens Res Hosp, Int Outreach Program, Memphis, TN 38105 USA.
[Ribeiro, Raul] Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pediat, Memphis, TN 38163 USA.
[Ismael, Gustavo] Hosp Amaral Carvalho, Clin Oncol & Hematol Dept, Jau, Brazil.
[Rosenblatt, Eduardo] IAEA, Div Human Hlth, Appl Radiat Biol & Radiotherapy Sect, A-1400 Vienna, Austria.
[Roth, Berta] Univ Buenos Aires, Inst Oncol Angel H Roffo, Area Terapia Radiante & Diagnost Imagenes, Buenos Aires, DF, Argentina.
[Villa, Luisa] Santa Casa, Sch Med, Sao Paulo, Brazil.
[Villa, Luisa] Univ Sao Paulo, Sao Paulo, Brazil.
[Lara Solares, Argelia; Covarrubias-Gomez, Alfredo; Hernandez, Andres] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Pain & Palliat Med, Mexico City, DF, Mexico.
[Ximena Leon, Marta] Univ La Sabana, Bogota, Colombia.
[Torres-Vigil, Isabel] Univ Houston, Dorothy I Height Ctr Hlth Equ & Evaluat Res, Houston, TX USA.
[Torres-Vigil, Isabel] Univ Texas MD Anderson Canc Ctr, Dept Palliat Canc Med, Houston, TX 77030 USA.
[Bertolino, Mariela] Hosp Tornu FEMEBA Fdn, Palliat Care Unit, Buenos Aires, DF, Argentina.
[Bertolino, Mariela] Icalma Fdn, Buenos Aires, DF, Argentina.
[Santillana, Sergio] GlaxoSmithKline Oncol, Clin Dev Oncol, Collegeville, PA USA.
[Esteva, Francisco] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Smithville, TX USA.
[Fein, Luis] IOR, Rosario, Argentina.
[Mano, Max] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil.
[Gomez, Henry] Inst Nacl Enfermedades Neoplas, Lima, Peru.
[Hurlbert, Marc] Avon Fdn Breast Canc Crusade, New York, NY USA.
[Durstine, Alessandra; Azenha, Gustavo] Amer Canc Soc, New York, NY USA.
RP Goss, PE (reprint author), Massachusetts Gen Hosp, Ctr Canc, Avon Breast Canc Ctr Excellence, 55 Fruit St,Lawrence House,LRH-302, Boston, MA 02114 USA.
EM pgoss@partners.org
RI Sternberg, Cinthya/K-4038-2012; Reis, Rui/C-2859-2009; Debiasi,
Marcio/G-7780-2014; Ferreira, Carlos Gil/G-4957-2013; Barrios,
Carlos/G-8525-2015; Schwartsmann, Gilberto/G-4256-2016; Stefani,
Stefania/K-8075-2016;
OI Sternberg, Cinthya/0000-0002-4760-6339; Reis, Rui/0000-0002-9639-7940;
Schwartsmann, Gilberto/0000-0002-7850-1644; Stefani,
Stefania/0000-0003-1594-7427; Fresco, Rodrigo/0000-0001-5342-3486;
Gomez, Henry/0000-0003-2660-1843; Hurlbert, Marc/0000-0003-3301-3572;
Sullivan, Richard/0000-0002-6435-1825
FU Avon Foundation, New York
FX PEG thanks Julio Frenk for his support in the preparation of part 2.
PEG, JS, TBC, and LF are supported by the Avon Foundation, New York.
NR 371
TC 102
Z9 118
U1 9
U2 59
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD APR
PY 2013
VL 14
IS 5
BP 391
EP 436
PG 46
WC Oncology
SC Oncology
GA 140TY
UT WOS:000318679700008
PM 23628188
ER
PT J
AU Rhee, SJ
Cantelmo, NL
Conrad, MF
Stoughton, J
AF Rhee, Soo J.
Cantelmo, Nancy L.
Conrad, Mark F.
Stoughton, Julianne
TI Factors Influencing the Incidence of Endovenous Heat-Induced Thrombosis
(EHIT)
SO VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Article
DE varicose veins; venous thrombosis; venous insuffiency; endothermal
ablation
ID GREATER SAPHENOUS-VEIN; RADIOFREQUENCY ABLATION; VENOUS THROMBOEMBOLISM;
RISK-ASSESSMENT; LASER THERAPY; SINGLE-CENTER; COMPLICATIONS;
EXPERIENCE; EFFICACY; REFLUX
AB Introduction: Extension of thrombus from the great saphenous vein into the common femoral vein can be an early post-procedural complication of endothermal ablation (ETA). Methods: A retrospective review was performed over a 3-year period. Intraprocedural ultrasound images demonstrating the distance of the catheter tip to the saphenofemoral junction (SFJ) were available for 519 procedures, and this distance was measured. Results: Twenty-one (4.0%) cases of endovenous heat-induced thrombus (EHIT) were diagnosed. In all, 15 (6.4%) EHITs occurred following endovenous laser ablation and 6 (2.1%) after radio-frequency (P=.02). Distance from catheter tip to SFJ, vein diameter, concomitant treatments, and perioperative anticoagulation were not significant risk factors for EHIT. Of the clinical factors assessed, gender (P=.002), Clinical, Etiologic, Anatomic and Pathophysiologic classification 3 to 6 (P=.003), history of prior thrombosis (P=.04), and Caprini thrombosis risk factor assessment score (P=.004) were significant. On multivariate analysis, Caprini score (P=.0002) and male gender (P=.0003) remained significant. Conclusions: Male gender and increased Caprini score are predictive factors for EHIT following ETA.
C1 [Rhee, Soo J.; Cantelmo, Nancy L.; Stoughton, Julianne] VeinSolut North Suburban Boston, Stoneham, MA USA.
[Cantelmo, Nancy L.; Conrad, Mark F.; Stoughton, Julianne] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
[Cantelmo, Nancy L.; Conrad, Mark F.; Stoughton, Julianne] Harvard Univ, Sch Med, Boston, MA USA.
RP Stoughton, J (reprint author), Massachusetts Gen Hosp, 15 Parkman St WAC 440, Boston, MA 02114 USA.
EM jstoughton@partners.org
NR 19
TC 11
Z9 13
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1538-5744
J9 VASC ENDOVASC SURG
JI Vasc. Endovasc. Surg.
PD APR
PY 2013
VL 47
IS 3
BP 207
EP 212
DI 10.1177/1538574413478494
PG 6
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 145GY
UT WOS:000319004400006
PM 23427285
ER
PT J
AU Karia, P
Azzi, J
Heher, E
Schmults, C
AF Karia, P.
Azzi, J.
Heher, E.
Schmults, C.
TI A Cohort Study of Solid Organ Transplant Recipients Who Develop
Malignancy: Risk of Subsequent Malignancy on mTOR vs. Non-mTOR Regimens.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Karia, P.; Azzi, J.; Schmults, C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Heher, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 97
EP 97
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300219
ER
PT J
AU Yamada, Y
Boskovic, S
Lee, S
Nadazdin, O
Smith, R
Colvin, R
Madsen, J
Sachs, D
Cosimi, A
Kawai, T
Benichou, G
AF Yamada, Y.
Boskovic, S.
Lee, S.
Nadazdin, O.
Smith, R.
Colvin, R.
Madsen, J.
Sachs, D.
Cosimi, A.
Kawai, T.
Benichou, G.
TI In Vivo IL-2 Administration Can Abrogate Tolerance to Kidney Allografts
Induced Via Mixed Chimerism in Non-Human Primates
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Yamada, Y.; Boskovic, S.; Lee, S.; Nadazdin, O.; Smith, R.; Colvin, R.; Madsen, J.; Sachs, D.; Cosimi, A.; Kawai, T.; Benichou, G.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 103
EP 103
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300241
ER
PT J
AU Yamada, Y
Lee, S
Boskovic, S
Nadazdin, O
Smith, R
Colvin, R
Madsen, J
Sachs, D
Benichou, G
Cosimi, B
Kawai, T
AF Yamada, Y.
Lee, S.
Boskovic, S.
Nadazdin, O.
Smith, R.
Colvin, R.
Madsen, J.
Sachs, D.
Benichou, G.
Cosimi, B.
Kawai, T.
TI Development of a Clinically Relevant Conditioning Regimen Using
Available Costimulatory Blockade Reagents for Induction of Renal
Allograft Tolerance Via Mixed Hematopoietic Chimerism
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Yamada, Y.; Lee, S.; Boskovic, S.; Nadazdin, O.; Smith, R.; Colvin, R.; Madsen, J.; Sachs, D.; Benichou, G.; Cosimi, B.; Kawai, T.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 104
EP 104
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300242
ER
PT J
AU Gilstrap, L
Niehaus, E
Maurer, M
Feltrin, G
Estep, J
Witteles, R
Zucker, M
Baran, D
Kushwaha, S
Seldin, D
Semigran, M
AF Gilstrap, L.
Niehaus, E.
Maurer, M.
Feltrin, G.
Estep, J.
Witteles, R.
Zucker, M.
Baran, D.
Kushwaha, S.
Seldin, D.
Semigran, M.
TI A Multi-Center, International Registry of Cardiac Transplantation for
Light Chain (AL) and Transthyreitin (TTR) Amyloidosis.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Gilstrap, L.; Niehaus, E.; Semigran, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Maurer, M.] Columbia Univ, Med Ctr, New York, NY USA.
[Feltrin, G.] Univ Padua, Padua, Italy.
[Estep, J.] Methodist Hosp, Houston, TX 77030 USA.
[Zucker, M.; Baran, D.] Newark Beth Israel, Newark, NJ USA.
[Kushwaha, S.] Mayo Clin, Rochester, MN USA.
[Seldin, D.] Boston Univ, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 130
EP 130
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300321
ER
PT J
AU Bergstrom, B
Louis, S
Peterson, F
Aguiar, H
Friedman, M
Malinoski, D
AF Bergstrom, B.
Louis, S.
Peterson, F.
Aguiar, H.
Friedman, M.
Malinoski, D.
TI The Use of the Flotrac System To Guide Donor Management Is Associated
with Increased Organs Transplanted Per Donor.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Bergstrom, B.] Donor Network Arizona, Phoenix, AZ USA.
[Louis, S.; Malinoski, D.] Portland VA Med Ctr, Portland, OR USA.
[Peterson, F.; Aguiar, H.; Friedman, M.] OneLegacy, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 138
EP 138
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300346
ER
PT J
AU Lee, S
Yamada, Y
Boskovic, S
Atif, M
Tonsho, M
Nadazdin, O
Smith, R
Colvin, R
Allan, J
Madsen, J
Cosimi, A
Benichou, G
Kawai, T
AF Lee, S.
Yamada, Y.
Boskovic, S.
Atif, M.
Tonsho, M.
Nadazdin, O.
Smith, R.
Colvin, R.
Allan, J.
Madsen, J.
Cosimi, A.
Benichou, G.
Kawai, T.
TI Renal Allograft Tolerance Can Be Achieved in Non-Human Primates Via
Delayed Mixed-Hematopoietic Chimerism and Alefacept Treatment.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Lee, S.; Yamada, Y.; Boskovic, S.; Atif, M.; Tonsho, M.; Nadazdin, O.; Smith, R.; Colvin, R.; Allan, J.; Madsen, J.; Cosimi, A.; Benichou, G.; Kawai, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 149
EP 149
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300381
ER
PT J
AU Lee, S
Aoyama, A
Tonsho, M
Boskovic, S
Yamada, Y
Nadazdin, O
Smith, R
Colvin, R
Cosimi, A
Madsen, J
Kawai, T
Benichou, G
Allan, J
AF Lee, S.
Aoyama, A.
Tonsho, M.
Boskovic, S.
Yamada, Y.
Nadazdin, O.
Smith, R.
Colvin, R.
Cosimi, A.
Madsen, J.
Kawai, T.
Benichou, G.
Allan, J.
TI Lung Allograft Tolerance in Non-Human Primates Via Establishment of
Stable Mixed Hematopoietic Chimerism.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Lee, S.; Aoyama, A.; Tonsho, M.; Boskovic, S.; Yamada, Y.; Nadazdin, O.; Smith, R.; Colvin, R.; Cosimi, A.; Madsen, J.; Kawai, T.; Benichou, G.; Allan, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 150
EP 150
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300382
ER
PT J
AU Ferdman, J
Porcheray, F
Moore, C
Gao, B
DeVito, J
Tullius, S
Kawai, T
Wong, W
Zorn, E
AF Ferdman, J.
Porcheray, F.
Moore, C.
Gao, B.
DeVito, J.
Tullius, S.
Kawai, T.
Wong, W.
Zorn, E.
TI Expansion and Differentiation of B Cell Clones in Rejected Kidney
Grafts.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Ferdman, J.; Porcheray, F.; Moore, C.; Gao, B.; DeVito, J.; Kawai, T.; Wong, W.; Zorn, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tullius, S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 178
EP 178
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300477
ER
PT J
AU Tonsho, M
Benichou, G
Boskovic, S
Nadazdin, O
Smith, N
Colvin, R
Sachs, D
Cosimi, A
Kawai, T
Madsen, J
AF Tonsho, M.
Benichou, G.
Boskovic, S.
Nadazdin, O.
Smith, N.
Colvin, R.
Sachs, D.
Cosimi, A.
Kawai, T.
Madsen, J.
TI Successful Tolerance Induction of Cardiac Allografts in Nonhuman
Primates through Donor Kidney Co-Transplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Tonsho, M.; Benichou, G.; Boskovic, S.; Nadazdin, O.; Smith, N.; Colvin, R.; Cosimi, A.; Kawai, T.; Madsen, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sachs, D.; Madsen, J.] Massachusetts Gen Hosp, Transplant Biol Res Ctr, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 181
EP 182
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300491
ER
PT J
AU Fan, Z
Jung, K
Yun, S
Strom, T
Koulmanda, M
AF Fan, Z.
Jung, K.
Yun, S.
Strom, T.
Koulmanda, M.
TI Critical Role of Allograft Infiltrating ROR Gamma t Positive Innate
Immune Cells and Hematopoietic Progenitor Cells
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Fan, Z.; Strom, T.; Koulmanda, M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Transplant Inst, Boston, MA 02215 USA.
[Jung, K.; Yun, S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 189
EP 189
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300516
ER
PT J
AU Porcheray, F
Fraser, J
Gao, B
McColl, A
DeVito, J
Dargon, I
Helou, Y
Wong, W
Girouard, T
Saidman, S
Colvin, R
Palmisano, A
Maggiore, U
Vaglio, A
Smith, R
Zorn, E
AF Porcheray, F.
Fraser, J.
Gao, B.
McColl, A.
DeVito, J.
Dargon, I.
Helou, Y.
Wong, W.
Girouard, T.
Saidman, S.
Colvin, R.
Palmisano, A.
Maggiore, U.
Vaglio, A.
Smith, R.
Zorn, E.
TI Humoral Rejection of Human Kidney Grafts Associates with Polyreactive
Antibodies That Bind Apoptotic Cells and Activate Complement
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Porcheray, F.; Fraser, J.; Gao, B.; McColl, A.; DeVito, J.; Dargon, I.; Helou, Y.; Wong, W.; Girouard, T.; Saidman, S.; Colvin, R.; Smith, R.; Zorn, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Palmisano, A.; Maggiore, U.; Vaglio, A.] Univ Hosp Parma, Parma, Italy.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 232
EP 233
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300659
ER
PT J
AU Zhao, G
Yang, M
Wei, L
Huang, X
Lei, J
Markmann, J
Deng, S
AF Zhao, G.
Yang, M.
Wei, L.
Huang, X.
Lei, J.
Markmann, J.
Deng, S.
TI A Prevascularized Tissue-Engineered Construct Serves as an Alternative
Site for Pancreatic Islet Transplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Zhao, G.; Yang, M.; Wei, L.; Huang, X.; Deng, S.] Sichuan Prov Peoples Hosp, Dept Surg, Chengdu, Sichuan Provinc, Peoples R China.
[Zhao, G.; Yang, M.; Wei, L.; Lei, J.; Markmann, J.; Deng, S.] Massachusetts Gen Hosp, Transplant Unit, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 238
EP 238
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300676
ER
PT J
AU Grijalva, J
Camargo, F
Sadri-Vakili, G
Vakili, K
AF Grijalva, J.
Camargo, F.
Sadri-Vakili, G.
Vakili, K.
TI YAP Phosphorylation Is Altered during Liver Regeneration in a Rat
Hepatectomy Model.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Grijalva, J.; Vakili, K.] Boston Childrens Hosp, Dept Surg, Boston, MA USA.
[Camargo, F.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Boston, MA 02115 USA.
[Sadri-Vakili, G.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 256
EP 257
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300746
ER
PT J
AU Heaphy, E
Mandelbrot, D
Rodriquez, J
Schold, J
Poggio, E
AF Heaphy, E.
Mandelbrot, D.
Rodriquez, J.
Schold, J.
Poggio, E.
TI First-Year Renal Function Changes among Living Kidney Donors (LKD) in
the United States
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Poggio, E.] Cleveland Clin, Nephrol & HTN, Cleveland, OH 44106 USA.
[Heaphy, E.; Schold, J.] Cleveland Clin, Cleveland, OH 44106 USA.
[Mandelbrot, D.; Rodriquez, J.] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 305
EP 305
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301127
ER
PT J
AU Faustman, D
AF Faustman, D.
TI Modification of Donor Tissue Antigens with Papain To Inhibit Transplant
Rejection.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 Massachusetts Gen Hosp, Immunobiol Lab, Charlestown, MA USA.
Harvard Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 318
EP 318
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301169
ER
PT J
AU Baddley, J
Klausing, B
Brizendine, K
Kumar, V
Julian, B
Eckhoff, D
Tallaj, J
Wille, K
Moser, S
Pappas, P
AF Baddley, J.
Klausing, B.
Brizendine, K.
Kumar, V.
Julian, B.
Eckhoff, D.
Tallaj, J.
Wille, K.
Moser, S.
Pappas, P.
TI Treatment of Cryptococcosis in Solid-OrganTransplant Recipients: Relapse
Is Rare after Discontinuation of Therapy.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Baddley, J.; Klausing, B.; Kumar, V.; Julian, B.; Eckhoff, D.; Tallaj, J.; Wille, K.; Moser, S.; Pappas, P.] Univ Alabama Birmingham, Birmingham, AL USA.
[Baddley, J.] Birmingham VAMC, Birmingham, AL USA.
[Brizendine, K.] Cleveland Clin, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 344
EP 344
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301266
ER
PT J
AU Martins, P
Almusa, A
Markmann, J
Hertl, M
Elias, N
AF Martins, P.
Almusa, A.
Markmann, J.
Hertl, M.
Elias, N.
TI Acute Diverticulitis Incidence, Management, and Outcomes in Solid Organ
Transplant Patients.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Martins, P.; Almusa, A.; Markmann, J.; Hertl, M.; Elias, N.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Transplant Div, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 346
EP 346
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301271
ER
PT J
AU Lee, K
Lian, M
Stott, R
Yeh, H
Deng, S
Kim, J
Markmann, J
AF Lee, K.
Lian, M.
Stott, R.
Yeh, H.
Deng, S.
Kim, J.
Markmann, J.
TI Spontaneous Acceptance of Mouse Islet Allografts in B Cell-Deficient
Donor and Recipient Is Associated with Donor-Derived Plasmacytoid
Dendritic Cells.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Lee, K.; Lian, M.; Stott, R.; Yeh, H.; Deng, S.; Kim, J.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 360
EP 361
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301319
ER
PT J
AU Kim, J
Lee, K
Zhao, G
Stott, R
Soohoo, J
Lian, M
Fitzgerald, L
Yeh, H
Deng, S
Markmann, J
AF Kim, J.
Lee, K.
Zhao, G.
Stott, R.
Soohoo, J.
Lian, M.
Fitzgerald, L.
Yeh, H.
Deng, S.
Markmann, J.
TI Transplantation Tolerance That Depends on Regulatory T Cells Induced by
TGF-beta-Producing Regulatory B Cells.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Kim, J.; Lee, K.; Zhao, G.; Stott, R.; Soohoo, J.; Lian, M.; Fitzgerald, L.; Yeh, H.; Deng, S.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Zhao, G.; Markmann, J.] Sichual Prov Peoples Hosp, Chengdu, Sichuan Provinc, Peoples R China.
[Fitzgerald, L.] Tufts Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 361
EP 361
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301321
ER
PT J
AU Shinoda, K
Akiyoshi, T
Chase, C
Farkash, E
Russell, P
Madsen, J
Colvin, R
AF Shinoda, K.
Akiyoshi, T.
Chase, C.
Farkash, E.
Russell, P.
Madsen, J.
Colvin, R.
TI Depletion of Both Recipient and Donor Foxp3+Cells Can Break Tolerance of
Skin or Heart Allografts Induced by Mixed Chimerism in Mice.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Shinoda, K.; Akiyoshi, T.; Chase, C.; Farkash, E.; Russell, P.; Madsen, J.; Colvin, R.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
[Akiyoshi, T.; Farkash, E.; Colvin, R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 362
EP 362
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301325
ER
PT J
AU Madariaga, M
Michel, S
Tasaki, M
Villani, V
Farkash, E
La Muraglia, G
Allan, J
Sachs, D
Yamada, K
Madsen, J
AF Madariaga, M.
Michel, S.
Tasaki, M.
Villani, V.
Farkash, E.
La Muraglia, G., II
Allan, J.
Sachs, D.
Yamada, K.
Madsen, J.
TI Kidney-Induced Cardiac Allograft Tolerance across a Full MHC-Barrier in
Miniature Swine.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Madariaga, M.; Michel, S.; Tasaki, M.; Villani, V.; La Muraglia, G., II; Allan, J.; Sachs, D.; Yamada, K.; Madsen, J.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Cardiothorac Transplantat Lab, Boston, MA 02114 USA.
[Madariaga, M.; Michel, S.; Tasaki, M.; Villani, V.; Farkash, E.; La Muraglia, G., II; Allan, J.; Sachs, D.; Yamada, K.; Madsen, J.] Harvard Univ, Sch Med, Boston, MA USA.
[Farkash, E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 365
EP 365
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301337
ER
PT J
AU Gao, B
Porcheray, F
Moore, C
McColl, A
Ferdman, J
Abidoglu, C
Girouard, T
DeVito, J
Paine, R
Saidman, S
Wong, W
Zorn, E
AF Gao, B.
Porcheray, F.
Moore, C.
McColl, A.
Ferdman, J.
Abidoglu, C.
Girouard, T.
DeVito, J.
Paine, R.
Saidman, S.
Wong, W.
Zorn, E.
TI Pre-Transplant Serum IgG Reactivity to Apoptotic Cells Correlates with
HLA Reactivity and Kidney Graft Loss.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Gao, B.; Porcheray, F.; Moore, C.; McColl, A.; Ferdman, J.; Abidoglu, C.; Girouard, T.; DeVito, J.; Paine, R.; Saidman, S.; Wong, W.; Zorn, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gao, B.] Jilin Univ, Hosp 1, Changchun 130023, Jilin, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 366
EP 367
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301343
ER
PT J
AU Tena, A
Leonard, D
Tasaki, M
Mallard, C
Germana, S
Terlouw, S
Dobrinsky, J
Mtango, N
Verstegen, J
Sachs, D
Hawley, R
AF Tena, A.
Leonard, D.
Tasaki, M.
Mallard, C.
Germana, S.
Terlouw, S.
Dobrinsky, J.
Mtango, N.
Verstegen, J.
Sachs, D.
Hawley, R.
TI GalKO-hCD47 Transgenic Hematopoietic Stem and Progenitor Cells for
Induction of Mixed Xenogeneic Chimerism in Primates: Initial Results.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Tena, A.; Leonard, D.; Tasaki, M.; Mallard, C.; Germana, S.; Sachs, D.; Hawley, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Terlouw, S.; Dobrinsky, J.; Mtango, N.; Verstegen, J.] Minitube Amer, Verona, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 371
EP 371
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301361
ER
PT J
AU Ueno, T
Yeung, M
Jun, K
McGrath, M
Da Silva, N
Ikeda, T
Najafian, N
Sylvie, B
Brown, D
Yun, A
Weissleder, R
Sayegh, M
AF Ueno, T.
Yeung, M.
Jun, K.
McGrath, M.
Da Silva, N.
Ikeda, T.
Najafian, N.
Sylvie, B.
Brown, D.
Yun, A.
Weissleder, R.
Sayegh, M.
TI Potential Contributions to the Direct Pathway by Donor Dendritic Cells
at Vascularized Graft.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Ueno, T.; Da Silva, N.; Sylvie, B.; Brown, D.; Weissleder, R.] Massachusetts Gen Hosp, CSB, Boston, MA 02114 USA.
[Ueno, T.; Yeung, M.; McGrath, M.; Najafian, N.; Sayegh, M.] Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA.
[Jun, K.; Yun, A.] Massachusetts Gen Hosp, Wellman Ctr, Boston, MA 02114 USA.
[Ueno, T.; Ikeda, T.] Tokyo Med Univ Hosp, Tokyo, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 376
EP 376
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301378
ER
PT J
AU Madariaga, M
Sihag, S
Gottschall, J
Farkash, E
Haas, M
Carroll, M
Allan, J
AF Madariaga, M.
Sihag, S.
Gottschall, J.
Farkash, E.
Haas, M.
Carroll, M.
Allan, J.
TI Mitigating Lung Ischemia-Reperfusion Injury in Miniature Swine.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Madariaga, M.; Sihag, S.; Gottschall, J.; Haas, M.; Allan, J.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Cardiothorac Transplantat Lab, Boston, MA 02114 USA.
[Farkash, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Carroll, M.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 410
EP 410
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301499
ER
PT J
AU Jain, N
Wong, I
Wong, E
Boneschansker, L
Aranyosi, A
Briscoe, D
Irimia, D
AF Jain, N.
Wong, I.
Wong, E.
Boneschansker, L.
Aranyosi, A.
Briscoe, D.
Irimia, D.
TI Live-Time Imaging of Chemotactic Responses in Activated T Cells
Demonstrate Novel Exploratory Patterns of Migration towards Chemokines.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Jain, N.; Boneschansker, L.; Briscoe, D.] Boston Childrens Hosp, Div Nephrol, Boston, MA USA.
[Jain, N.; Wong, I.; Wong, E.; Aranyosi, A.; Irimia, D.] Massachusetts Gen Hosp, Dept Surg, BioMEMS Resource Ctr, Boston, MA 02114 USA.
[Jain, N.; Wong, I.; Wong, E.; Boneschansker, L.; Aranyosi, A.; Briscoe, D.; Irimia, D.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 412
EP 412
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301506
ER
PT J
AU Farris, A
Chan, S
Climenhaga, J
Colvin, R
Mengel, M
AF Farris, A.
Chan, S.
Climenhaga, J.
Colvin, R.
Mengel, M.
TI The Multicenter Banff Fibrosis Trial: Comparing Visual Assessment of
Interstitial Fibrosis in Kidney Biopsies to Computer-Based Image
Analysis and Organ Function.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Farris, A.] Emory Univ, Atlanta, GA 30322 USA.
[Chan, S.; Climenhaga, J.; Mengel, M.] Univ Alberta, Edmonton, AB, Canada.
[Colvin, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 420
EP 420
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301530
ER
PT J
AU Chen, G
Ko, D
Wang, C
Qiu, J
Han, M
He, X
Chen, L
AF Chen, G.
Ko, D.
Wang, C.
Qiu, J.
Han, M.
He, X.
Chen, L.
TI Utilization of Kidneys from Donors after Circulatory Death in China: An
Initial Report from a Single Center.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Chen, G.; Wang, C.; Qiu, J.; Han, M.; He, X.; Chen, L.] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510275, Guangdong, Peoples R China.
[Ko, D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA USA.
[Ko, D.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 481
EP 482
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301741
ER
PT J
AU Martins, P
Berendsen, T
Yeh, H
Bruinsma, B
Izamis, M
Uygun, K
McDaid, J
Yarmush, M
Markmann, J
AF Martins, P.
Berendsen, T.
Yeh, H.
Bruinsma, B.
Izamis, M.
Uygun, K.
McDaid, J.
Yarmush, M.
Markmann, J.
TI Perfluorocarbon Added to the University of Winsconsin Solution Reduces
Ischemia Reperfusion Injury and Prolongs Survival of DCD Liver Grafts.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Martins, P.; Yeh, H.; McDaid, J.; Markmann, J.] Massachusetts Gen Hosp, Dept Surg, Div Transplantat, Boston, MA 02114 USA.
[Berendsen, T.; Bruinsma, B.; Izamis, M.; Uygun, K.; Yarmush, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA USA.
[Berendsen, T.; Bruinsma, B.; Izamis, M.; Uygun, K.; Yarmush, M.] Shriners Hosp Children, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 490
EP 490
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301770
ER
PT J
AU Da Silva, C
Studer, P
Csizmadia, E
Minussi, D
Daniels, K
Ferran, C
AF Da Silva, C.
Studer, P.
Csizmadia, E.
Minussi, D.
Daniels, K.
Ferran, C.
TI Fish Oil Diet Overcomes Genetic Predisposition Restoring Hepatocyte
Proliferation in Livers of A20 Heterozygous Mice Following Partial
Hepatectomy
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Da Silva, C.; Studer, P.; Csizmadia, E.; Minussi, D.; Daniels, K.; Ferran, C.] Beth Israel Deaconess Med Ctr HMS, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 492
EP 492
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301778
ER
PT J
AU Irwin, L
Cetrulo, C
Winograd, J
Marquez, A
Noska, S
Israelian, A
Parker, H
Norman, A
Fishman, J
AF Irwin, L.
Cetrulo, C.
Winograd, J.
Marquez, A.
Noska, S.
Israelian, A.
Parker, H.
Norman, A.
Fishman, J.
TI Incorporating a Vascularized Composite Allograft Transplant Program into
a Transplant Center.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Irwin, L.; Cetrulo, C.; Winograd, J.; Marquez, A.; Noska, S.; Israelian, A.; Parker, H.; Norman, A.; Fishman, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 538
EP 539
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301932
ER
PT J
AU Myaskovsky, L
Pleis, J
Ramkumar, M
Mittalhenkle, A
Langone, A
Thomas, C
AF Myaskovsky, L.
Pleis, J.
Ramkumar, M.
Mittalhenkle, A.
Langone, A.
Thomas, C.
TI Has the VA Found a Way To Reduce Racial Disparities in Kidney Transplant
Evaluation? Preliminary Results from the National VA Kidney Transplant
Study.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Myaskovsky, L.; Pleis, J.; Ramkumar, M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Myaskovsky, L.; Pleis, J.; Ramkumar, M.] U Pittsburgh, Pittsburgh, PA USA.
[Mittalhenkle, A.] Portland VA Med Ctr, Portland, Dorset, England.
[Langone, A.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA.
[Thomas, C.] Iowa City VA Healthcare, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 541
EP 541
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301941
ER
PT J
AU Lowalekar, S
Cao, H
Lu, X
Treanor, P
Thatte, H
AF Lowalekar, S.
Cao, H.
Lu, X.
Treanor, P.
Thatte, H.
TI Somah - A Novel Modality for Subnormothermic Preservation of Donor
Hearts.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Lowalekar, S.; Cao, H.; Lu, X.; Treanor, P.; Thatte, H.] VA Boston Healthcare Syst, Cardiac Surg Div, Boston, MA USA.
[Lowalekar, S.; Cao, H.; Lu, X.; Thatte, H.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Lowalekar, S.; Cao, H.; Lu, X.; Thatte, H.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 550
EP 550
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301972
ER
PT J
AU Morris, H
Shen, Y
Kawai, T
Robins, H
Sykes, M
AF Morris, H.
Shen, Y.
Kawai, T.
Robins, H.
Sykes, M.
TI Role of Deletion of Donor-Reactive T Cells in Maintaining Human
Allograft Tolerance Achieved via Combined Kidney and Bone Marrow
Transplantation (CKBMT).
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Morris, H.; Shen, Y.; Sykes, M.] Columbia Univ, Med Ctr, New York, NY USA.
[Robins, H.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Kawai, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 550
EP 550
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301973
ER
PT J
AU Ndishabandi, D
Shinoda, K
Colvin, R
Alessandrini, A
AF Ndishabandi, D.
Shinoda, K.
Colvin, R.
Alessandrini, A.
TI Strain Specific Induction of Regulatory T Cells by Plasmacytoid
Dendritic Cells.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Ndishabandi, D.; Shinoda, K.; Colvin, R.; Alessandrini, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 550
EP 551
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301975
ER
PT J
AU Zhang, LT
Zhang, LJ
Zhang, JJ
Ye, XX
Xie, AM
Chen, LY
Kang, JX
Cai, C
AF Zhang, Liang-Tao
Zhang, Li-Jian
Zhang, Jun-Jie
Ye, Xiao-Xia
Xie, Ai-Mei
Chen, Li-Yu
Kang, Jing X.
Cai, Chun
TI Quantification of the sixth DNA base 5-hydroxymethylcytosine in
colorectal cancer tissue and C-26 cell line
SO BIOANALYSIS
LA English
DT Article
ID ONCOMETABOLITE 2-HYDROXYGLUTARATE; GENOMIC DNA; 5-METHYLCYTOSINE;
SPECTROMETRY; METHYLATION; EPIGENETICS; TET1
AB Background: DNA methylation at the five position of cytosine is well recognized as an important epigenetic modification in human health and disease. Recent evidences demonstrated that 5-methylcytosine (5-mC) by the TET family of enzymes can be converted to 5-hydroxymethylcytosine (5-hmC). Here, we use an ultrasensitive and accurate isotope-based LC-MS/MS method to precisely determine the levels of 5-hmC and 5-mC in colorectal cancer and the C-26 colon adenocarcinoma cell line. Results: Our data showed that 5-hmC content is significantly reduced (approximately sixfold) in colorectal cancer as compared with adjacent normal tissue. Similarly, the ratio of 5-hmC to 5-mC dropped from 0.054 +/- 0.005 in normal tissues, to 0.011 +/- 0.002 in cancer. Conclusion: The analysis of 5-hmC levels and the ratio of 5-hmC:5-mC during tumor progression might provide insight into the role of this modification in cellular immortalization and transformation.
C1 [Zhang, Liang-Tao; Zhang, Li-Jian; Zhang, Jun-Jie; Ye, Xiao-Xia; Xie, Ai-Mei; Chen, Li-Yu; Cai, Chun] Guangdong Med Coll, Zhanjiang 524023, Guangdong, Peoples R China.
[Kang, Jing X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
RP Cai, C (reprint author), Guangdong Med Coll, Zhanjiang 524023, Guangdong, Peoples R China.
EM caichun2006@tom.com
FU Science & Technology Innovation Fun of Guangdong Medical College
[STIF201125]
FX This work was supported by Science & Technology Innovation Fun of
Guangdong Medical College, STIF201125. The authors have no other
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript apart from those
disclosed.
NR 25
TC 11
Z9 12
U1 0
U2 25
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1757-6180
J9 BIOANALYSIS
JI Bioanalysis
PD APR
PY 2013
VL 5
IS 7
BP 839
EP 845
DI 10.4155/BIO.13.28
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 139LW
UT WOS:000318585200014
PM 23534428
ER
PT J
AU Kassab, GS
Bhatt, DL
Lefevre, T
Louvard, Y
AF Kassab, Ghassan S.
Bhatt, Deepak L.
Lefevre, Thierry
Louvard, Yves
TI Relation of angiographic side branch calibre to myocardial mass: a proof
of concept myocardial infarct index
SO EUROINTERVENTION
LA English
DT Editorial Material
DE allometric scaling; biomarkers; design; ischaemia; scaling laws
ID PERCUTANEOUS CORONARY INTERVENTION; SCALING LAWS; DESIGN; ARTERIES;
VOLUME; TREES
AB Elevation of biomarkers and ischaemia after coronary stenting of a bifurcation is not uncommon due to side branch (SB) occlusion. Hence, it is important to understand the relation between the lumen calibre of the SB and the myocardial mass affected. The objective of this proof of concept perspective is to provide a formulation for the relation between the SB calibre and perfused myocardial mass based on experimentally-validated scaling laws. A lumen calibre-mass scaling law provides a nearly linear relation between cross-sectional area of SB and the myocardial mass at risk. It is clinically known that the larger the diameter of the SB the more myocardial mass is at risk. The present analysis formulates this notion quantitatively and provides a simple relation where the %infarct can be determined directly from the angiographic cross-sectional area of SB. This relation can help guide the decision for bifurcation stenting where the SB may be at risk for occlusion. This brief proof of concept perspective provides a basis for future human studies that may demarcate the calibre (and hence myocardial mass) in relation to cardiac biomarkers as a cut-off for treatment of SB.
C1 [Kassab, Ghassan S.] Indiana Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
[Kassab, Ghassan S.] Indiana Purdue Univ, Dept Surg, Indianapolis, IN 46202 USA.
[Kassab, Ghassan S.] Indiana Purdue Univ, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Lefevre, Thierry; Louvard, Yves] Inst Cardiovasc Paris Sud, Massy, France.
RP Kassab, GS (reprint author), Indiana Purdue Univ, 635 Barnhill Dr,MS 2069, Indianapolis, IN 46202 USA.
EM gkassab@iupui.edu
FU NHLBI NIH HHS [HL092048-5]
NR 14
TC 4
Z9 4
U1 0
U2 1
PU EUROPA EDITION
PI TOULOUSE CEDEX 6
PA 5, RUE SAINT-PANTALEON, BP 61508, TOULOUSE CEDEX 6, 31015, FRANCE
SN 1774-024X
J9 EUROINTERVENTION
JI EuroIntervention
PD APR
PY 2013
VL 8
IS 12
BP 1461
EP 1463
DI 10.4244/EIJV8I12A220
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 141UJ
UT WOS:000318751700017
PM 23680961
ER
PT J
AU Kumbhani, DJ
Steg, PG
Cannon, CP
Eagle, KA
Smith, SC
Crowley, K
Goto, S
Ohman, EM
Bakris, GL
Perlstein, TS
Kinlay, S
Bhatt, DL
AF Kumbhani, Dharam J.
Steg, P. Gabriel
Cannon, Christopher P.
Eagle, Kim A.
Smith, Sidney C., Jr.
Crowley, Kevin
Goto, Shinya
Ohman, E. Magnus
Bakris, George L.
Perlstein, Todd S.
Kinlay, Scott
Bhatt, Deepak L.
CA REACH Registry Investigators
TI Resistant hypertension: a frequent and ominous finding among
hypertensive patients with atherothrombosis
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Resistant hypertension; Atherosclerosis; Mortality; Stroke; Heart
failure
ID AMBULATORY BLOOD-PRESSURE; PRESERVED EJECTION FRACTION; CARDIOVASCULAR
EVENT RATES; UNITED-STATES; EUROPEAN-SOCIETY; HEART-FAILURE;
RISK-FACTORS; DOUBLE-BLIND; TASK-FORCE; OUTPATIENTS
AB The effect of resistant hypertension on outcomes in patients with atherothrombotic disease is currently unknown. Accordingly, we sought to determine the prevalence and outcomes of resistant hypertension in stable hypertensive outpatients with subclinical or established atherothombotic disease enrolled in the international Reduction of Atherothrombosis for Continued Health (REACH) registry.
Resistant hypertension was defined as a blood pressure 140/90 mmHg at baseline (130/80 mmHg if diabetes/renal insufficiency) with the use of 3 antihypertensive medications, including a diuretic. The primary outcome was a composite of cardiovascular death, myocardial infarction, or stroke at 4 years. A total of 53 530 hypertensive patients were included. The prevalence of resistant hypertension was 12.7; 6.2 on 3 antihypertensive agents, 4.6 on 4 agents, and 1.9 on 5 agents (mean: 4.7 0.8). In addition to a diuretic, these patients were being treated mostly with ACE-inhibitors/angiotensin receptor blockers (90.1), beta-blockers (67.0), and calcium channel blockers (50.8). Patients with resistant hypertension had a higher risk of the primary endpoint on multivariable analysis [hazard ratio (HR) 1.11, 95 confidence interval (CI) 1.021.20; P 0.017], including an increased non-fatal stroke risk (HR: 1.26; 95 CI: 1.101.45; P 0.0008). Hospitalizations due to congestive heart failure were higher (P 0.0001). Patients on 5 agents had a higher adjusted risk for the primary endpoint when compared with those on 3 agents (P 0.03).
The presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.
C1 [Kumbhani, Dharam J.; Cannon, Christopher P.; Perlstein, Todd S.; Kinlay, Scott; Bhatt, Deepak L.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Kumbhani, Dharam J.; Cannon, Christopher P.; Perlstein, Todd S.; Kinlay, Scott; Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Steg, P. Gabriel] INSERM, U698, Paris, France.
[Steg, P. Gabriel] Univ Paris Diderot, Paris, France.
[Steg, P. Gabriel] AP HP, Paris, France.
[Cannon, Christopher P.; Crowley, Kevin] TIMI Study Grp, Boston, MA USA.
[Eagle, Kim A.] Univ Michigan, Ctr Cardiovasc, Ann Arbor, MI 48109 USA.
[Smith, Sidney C., Jr.] Univ N Carolina, Ctr Cardiovasc Sci & Med, Chapel Hill, NC USA.
[Goto, Shinya] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan.
[Ohman, E. Magnus] Duke Univ, Div Cardiol, Durham, NC USA.
Univ Chicago Med, Chicago, IL USA.
[Kinlay, Scott; Bhatt, Deepak L.] VA Boston Healthcare Syst, Div Cardiol, Boston, MA 02132 USA.
RP Bhatt, DL (reprint author), Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
EM dlbhattmd@post.harvard.edu
RI sebastianovitsch, stepan/G-8507-2013
FU Sanofi-Aventis; Bristol-Myers Squibb; Waksman Foundation (Tokyo, Japan);
Servier; Intekrin Therapeutics; Accumetrics; AstraZeneca;
GlaxoSmithKline; Merck; Takeda; Blue Cross Blue Shield of Michigan;
National Institutes of Health (NIH); Mardigian Foundation Varbedian
Fund; GORE; Hewlett Foundation; Eisai; Berlinger-Ingelheim; CV
Therapeutics; Daiichi-Sankyo; Datascope; Eli Lilly; Marquet;
Schering-Plough; Medicines Company; Forest Labs; Relapsya; WebMD;
Amarin; Ethicon; Medtronic (co-PI of SYMPLICITY HTN-3)
FX The REACH Registry is sponsored by Sanofi-Aventis, Bristol-Myers Squibb,
and the Waksman Foundation (Tokyo, Japan). The REACH Registry is
endorsed by the World Heart Federation. No funding was received for this
manuscript. No sponsors reviewed this manuscript.; D.J.K.: Honoraria:
American College of Cardiology, SomahLutions. Ph.G.S.: Research grant
from Servier; participated in consultancy or advisory board for Eisai,
Amgen, Astellas, Bayer, Boehringer Ingelheim, BMS, Daiichi-Sankyo-Lilly,
GSK, Merck, Pfizer, Roche, The Medicines Company, AstraZeneca,
Sanofi-Aventis, Servier; and being a stockholder in Aterovax. C. P. C.:
Research grants from Intekrin Therapeutics, Accumetrics, AstraZeneca,
GlaxoSmithKline, Merck, Takeda; honoraria from Pfizer, AstraZeneca;
participated in consultancy or advisory board for Bristol-Myers
Squibb/Sanofi, Novartis, Alnylam; and having ownership interest in
Automedics Medical Systems. K. A. E.: Grant/research support from
Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, the National
Institutes of Health (NIH), Sanofi-Aventis, the Mardigian Foundation
Varbedian Fund, GORE, and the Hewlett Foundation and being a consultant
for the NIH National Heart, Lung, and Blood Institute, Sanofi-Aventis,
and the Robert Wood Johnson. Foundation: S. C. S.: None. K. C.: None. S.
G.: Research grants from Sanofi-Aventis, Eisai, Berlinger-Ingelheim;
participated in consultancy or advisory board for Eisai, Sanofi-Aventis,
Otsuka. E.M.O.: Research grants from Bristol-Myers Squibb, CV
Therapeutics, Daiichi-Sankyo, Datascope, Eli Lilly, Marquet,
Sanofi-Aventis, Schering-Plough, and The Medicines Company, and
providing consulting or other services for Abiomed, AstraZeneca, CV
Therapeutics, Datascope, Gilead Sciences, Liposcience, Marquet,
Northpoint Domain, Pozen, Response Biomedical, Sanofi-Aventis, The
Medicines Company, and WebMD (theheart.org). G. L. B.: Research Grants
from Forest Labs, Relapsya, WebMD and Consultant to: Abbott, Takeda,
Johnson & Johnson, Daichi-Sankyo, Medtronic. T. S. P.: None. S. K.:
None. D. L. B.: Advisory Board: Medscape Cardiology; Board of Directors:
Boston VA Research Institute, Society of Chest Pain Centers; Chair:
American Heart Association Get With The Guidelines Science Subcommittee;
Honoraria: American College of Cardiology (Editor, Clinical Trials,
Cardiosource), Duke Clinical Research Institute (clinical trial steering
committees), Slack Publications (Chief Medical Editor, Cardiology Today
Intervention), WebMD (CME steering committees); Other: Senior Associate
Editor, Journal of Invasive Cardiology; Research Grants: Amarin,
AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic (co-PI of
SYMPLICITY HTN-3), Sanofi-Aventis, The Medicines Company; Unfunded
Research: FlowCo, PLx Pharma, Takeda.
NR 37
TC 67
Z9 69
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD APR
PY 2013
VL 34
IS 16
BP 1204
EP 1214
DI 10.1093/eurheartj/ehs368
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 139AN
UT WOS:000318553800010
PM 23144048
ER
PT J
AU Massimini, DF
Singh, A
Wells, JH
Li, GA
Warner, JJP
AF Massimini, Daniel F.
Singh, Anshu
Wells, Jessica H.
Li, Guoan
Warner, Jon J. P.
TI Suprascapular nerve anatomy during shoulder motion: a cadaveric proof of
concept study with implications for neurogenic shoulder pain
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE In-vivo biomechanics; neuropathy; rotator cuff tear; nerve tracking
ID ROTATOR-CUFF TEARS; GEOMETRIC IMAGE DISTORTION; ARTHROSCOPIC RELEASE;
VOLLEYBALL PLAYERS; GANGLION CYSTS; NEUROPATHY; SUPRASPINATUS;
ENTRAPMENT; MUSCLE; NOTCH
AB Background: The suprascapular nerve (SSN) carries sensory fibers which may contribute to shoulder pain. Prior anatomic study demonstrated that alteration in SSN course with simulated rotator cuff tendon (RCT) tears cause tethering and potential traction injury to the nerve at the suprascapular notch. Because the SSN has been implicated as a major source of pain with RCT tearing, it is critical to understand nerve anatomy during shoulder motion. We hypothesized that we could evaluate the SSN course with a novel technique to evaluate effects of simulated RCT tears, repair, and/or release of the nerve.
Methods: The course of the SSN was tracked with a dual fluoroscopic imaging system in a cadaveric model with simulated rotator cuff muscle forces during dynamic shoulder motion.
Results: After a simulated full-thickness supraspinatus/infraspinatus tendon tear, the SSN translated medially 3.5 mm at the spinoglenoid notch compared to the anatomic SSN course. Anatomic footprint repair of these tendons restored the SSN course to normal. Open release of the transverse scapular ligament caused the SSN to move 2.5 mm superior-posterior out of the suprascapular notch.
Conclusion: This pilot study demonstrated that the dynamic SSN course can be evaluated and may be altered by a RCT tear. Preliminary results suggest release of the transverse scapular ligament allowed the SSN to move upward out of the notch. This provides a biomechanical proof of concept that SSN traction neuropathy may occur with RCT tears and that release of the transverse scapular ligament may alleviate this by altering the course of the nerve. (C) 2013 Journal of Shoulder and Elbow Surgery Board of Trustees.
C1 [Massimini, Daniel F.; Singh, Anshu; Wells, Jessica H.; Li, Guoan; Warner, Jon J. P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab, Boston, MA USA.
[Massimini, Daniel F.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
RP Warner, JJP (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 3200, Boston, MA 02114 USA.
EM jwarner@partners.org
FU Harvard Shoulder Service
FX This work was supported by unrestricted funds of the Harvard Shoulder
Service.
NR 30
TC 10
Z9 10
U1 1
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD APR
PY 2013
VL 22
IS 4
BP 463
EP 470
DI 10.1016/j.jse.2012.04.018
PG 8
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 140UB
UT WOS:000318680100010
PM 22819576
ER
PT J
AU Neuhaus, V
Ring, D
AF Neuhaus, Valentin
Ring, David
TI Effect of different statistical methods on union or time to union in a
published study about clavicular fractures
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Clavicle; fracture; intention-to-treat; time to union; union
ID CLINICAL-TRIALS; TREAT
AB Background: Time to union is a suspect measure for comparing treatments given the absence of a consensus definition of union, the limited reliability of diagnostic tests, and inconsistency in evaluation times. The purpose of this study was to quantify the variations in union and time to union according to different statistical methods and different approaches to missing data.
Materials and methods: Data from a published multicenter, randomized trial comparing operative and nonoperative treatment of clavicular fractures were reanalyzed. Two main types of missing data were encountered: (1) lost to follow-up or died before union and (2) missed appointment. We studied the effect of four statistical methods-comparison of means, comparison of medians, x(2), and Kaplan-Meier curves-for comparing union or time to union between cohorts for the following scenarios: strict intention-to-treat, intention-to-treat with exclusion of patients with less than 12 months of follow-up, as-treated analysis, and four different imputation methods for missing data.
Results: Mean and median time to union varied up to 17%, but comparative statistics consistently demonstrated shorter time to union among operatively treated patients. There were significant differences in the odds ratio, x(2) values, and the number needed to treat (8%-62%) of union vs nonunion for the three principal analyses.
Conclusion: Different strategies for handling missed evaluations seem to influence categoric results (eg, union or nonunion) more than continuous measures such as time to union.
C1 [Neuhaus, Valentin; Ring, David] Massachusetts Gen Hosp, Orthopaed Hand Serv, Boston, MA 02114 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, Ste 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 9
TC 1
Z9 1
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD APR
PY 2013
VL 22
IS 4
BP 471
EP 477
DI 10.1016/j.jse.2012.03.015
PG 7
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 140UB
UT WOS:000318680100011
PM 22525939
ER
PT J
AU Ravicz, ME
Rosowski, JJ
AF Ravicz, Michael E.
Rosowski, John J.
TI Inner-ear sound pressures near the base of the cochlea in chinchilla:
Further investigation
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID FREQUENCY-POSITION MAP; MIDDLE-EAR; INPUT IMPEDANCE; INTRACOCHLEAR
PRESSURE; GERBIL; CAT; ADMITTANCE; TRANSMISSION; MECHANICS; VELOCITY
AB The middle-ear pressure gain G(MEP), the ratio of sound pressure in the cochlear vestibule P-V to sound pressure at the tympanic membrane P-TM, is a descriptor of middle-ear sound transfer and the cochlear input for a given stimulus in the ear canal. G(MEP) and the cochlear partition differential pressure near the cochlear base Delta P-CP, which determines the stimulus for cochlear partition motion and has been linked to hearing ability, were computed from simultaneous measurements of P-V, P-TM, and the sound pressure in scala tympani near the round window P-ST in chinchilla. G(MEP) magnitude was approximately 30 dB between 0.1 and 10 kHz and decreased sharply above 20 kHz, which is not consistent with an ideal transformer or a lossless transmission line. The G(MEP) phase was consistent with a roughly 50-mu s delay between P-V and P-TM. G(MEP) was little affected by the inner-ear modifications necessary to measure P-ST. G(MEP) is a good predictor of Delta P-CP at low and moderate frequencies where P-V >> P-ST but overestimates Delta P-CP above a few kilohertz where P-V approximate to P-ST. The ratio of P-ST to P-V provides insight into the distribution of sound pressure within the cochlear scalae. (C) 2013 Acoustical Society of America.
C1 [Ravicz, Michael E.; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol & Hlth Sci & Technol, Boston, MA 02115 USA.
RP Ravicz, ME (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM mike_ravicz@meei.harvard.edu
FU National Science Foundation under NSF Award [ECS-0335765]; NIDCD
FX We thank Elizabeth Olson and Wei Dong for much help in learning to
fabricate and use the pressure sensors, Elizabeth Olson for many helpful
discussions, Melissa McKinnon for animal surgery and assistance with
experiments, and the staff of the Eaton-Peabody Laboratory for technical
support. The reviewers offered helpful comments. This work was carried
out in part through the use of MIT's Microsystems Technology
Laboratories and the help of Kurt Broderick and in part at the Center
for Nanoscale Systems (CNS) with the help of Ed Macomber. CNS is a
member of the National Nanotechnology Infrastructure Network (NNIN),
which is supported by the National Science Foundation under NSF Award
No. ECS-0335765, and a part of the Faculty of Arts and Sciences at
Harvard University. Supported by NIDCD.
NR 51
TC 8
Z9 8
U1 0
U2 6
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD APR
PY 2013
VL 133
IS 4
BP 2208
EP 2223
DI 10.1121/1.4792139
PG 16
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA 139BB
UT WOS:000318555300055
PM 23556590
ER
PT J
AU Shera, CA
Cooper, NP
AF Shera, Christopher A.
Cooper, Nigel P.
TI Basilar-membrane interference patterns from multiple internal reflection
of cochlear traveling waves
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID EVOKED OTOACOUSTIC EMISSIONS; AUDITORY-NERVE-FIBER; COHERENT REFLECTION;
MIDDLE-EAR; DISTORTION PRODUCTS; ACOUSTIC EMISSIONS; CHINCHILLA COCHLEA;
CLICK RESPONSES; GROUP DELAY; MECHANICS
AB At low stimulus levels, basilar-membrane (BM) mechanical transfer functions in sensitive cochleae manifest a quasiperiodic rippling pattern in both amplitude and phase. Analysis of the responses of active cochlear models suggests that the rippling is a mechanical interference pattern created by multiple internal reflection within the cochlea. In models, the interference arises when reverse-traveling waves responsible for stimulus-frequency otoacoustic emissions (SFOAEs) reflect off the stapes on their way to the ear canal, launching a secondary forward-traveling wave that combines with the primary wave produced by the stimulus. Frequency-dependent phase differences between the two waves then create the rippling pattern measurable on the BM. Measurements of BM ripples and SFOAEs in individual chinchilla ears demonstrate that the ripples are strongly correlated with the acoustic interference pattern measured in ear-canal pressure, consistent with a common origin involving the generation of SFOAEs. In BM responses to clicks, the ripples appear as temporal fine structure in the response envelope (multiple lobes, waxing and waning). Analysis of the ripple spacing and response phase gradients provides a test for the role of fast-and slow-wave modes of reverse energy propagation within the cochlea. The data indicate that SFOAE delays are consistent with reverse slow-wave propagation but much too long to be explained by fast waves. (C) 2013 Acoustical Society of America.
C1 [Shera, Christopher A.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Cooper, Nigel P.] Keele Univ, Sch Life Sci, Keele ST5 5BG, Staffs, England.
RP Shera, CA (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM christopher.shera@gmail.com
FU NIDCD, National Institutes of Health [R01 DC003687]; Royal Society; MRC
(UK)
FX We thank Bill Rhode for generously sharing his data and Christopher
Bergevin, John Guinan, and the anonymous reviewers for helpful comments
on the manuscript. Supported by the NIDCD, National Institutes of Health
(Grant No. R01 DC003687), the Royal Society, and the MRC (UK).
NR 52
TC 10
Z9 10
U1 0
U2 7
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD APR
PY 2013
VL 133
IS 4
BP 2224
EP 2239
DI 10.1121/1.4792129
PG 16
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA 139BB
UT WOS:000318555300056
PM 23556591
ER
PT J
AU Noel, VA
Eddington, DK
AF Noel, Victor A.
Eddington, Donald K.
TI Sensitivity of bilateral cochlear implant users to fine-structure and
envelope interaural time differences
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID MINIMUM AUDIBLE ANGLE; SPEECH-INTELLIGIBILITY; SOUND LOCALIZATION;
ELECTRIC HEARING; BINAURAL SENSITIVITY; INFERIOR COLLICULUS; DELAY
SENSITIVITY; LATERALIZATION; LEVEL; NOISE
AB Bilateral cochlear implant users have poor sensitivity to interaural time differences (ITDs) of high-rate pulse trains, which precludes use of these stimuli to convey fine-structure ITD cues. However, previous reports of single-neuron recordings in cats demonstrated good ITD sensitivity to 1000 pulses-per-second (pps) pulses when the pulses were sinusoidally amplitude modulated. The ability of modulation to restore ITD sensitivity to high-rate pulses in humans was tested by measuring ITD thresholds for three conditions: ITD encoded in the modulated carrier pulses alone, in the envelope alone, and in the whole waveform. Five of six subjects were not sensitive to ITD in the 1000-pps carrier, even with modulation. One subject's 1000-pps carrier ITD sensitivity did significantly improve due to modulation. Sensitivity to ITD encoded in the envelope was also measured as a function of modulation frequency, including at frequencies from 4 to 16 Hz where much of the speech envelope's energy and information resides. Sensitivity was best at the modulation frequency of 100 Hz and degraded rapidly outside of a narrow range. These results provide little evidence to support encoding ITD in the carrier of current bilateral processors, and suggest envelope ITD sensitivity is poor for an important segment of the speech modulation spectrum. (C) 2013 Acoustical Society of America.
C1 [Noel, Victor A.; Eddington, Donald K.] Massachusetts Eye & Ear Infirm, Cochlear Implant Res Lab, Boston, MA 02114 USA.
[Eddington, Donald K.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
RP Noel, VA (reprint author), Massachusetts Eye & Ear Infirm, Cochlear Implant Res Lab, 243 Charles St, Boston, MA 02114 USA.
EM victor_noel@meei.harvard.edu
FU NIH [R01-DC005775, R01-DC007528]
FX This work was supported by NIH Grant Nos. R01-DC005775 and R01-DC007528.
Advanced Bionics provided the binaural-research-interface hardware.
NR 50
TC 3
Z9 3
U1 0
U2 9
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD APR
PY 2013
VL 133
IS 4
BP 2314
EP 2328
DI 10.1121/1.4794372
PG 15
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA 139BB
UT WOS:000318555300063
PM 23556598
ER
PT J
AU Singer, SJ
Friedberg, MW
Kiang, MV
Dunn, T
Kuhn, DM
AF Singer, Sara J.
Friedberg, Mark W.
Kiang, Mathew V.
Dunn, Toby
Kuhn, Diane M.
TI Development and Preliminary Validation of the Patient Perceptions of
Integrated Care Survey
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE integration; coordination; patient-centeredness; survey; psychometric
analysis
ID CLINICIAN
AB Valid measures of the integration of patient care could provide rapid and accurate feedback on the successfulness of current efforts to improve health care delivery systems. This article describes the development and pilot testing of a new survey, based on a novel conceptual model, which measures the integration of patient care as experienced by patients. We administered the survey to 1,289 patients with multiple chronic conditions from one health system and received responses from 527 patients (43%). Psychometric analysis of responses supported a six-dimension model of integration with satisfactory internal consistency, discriminant validity, and goodness of fit. The Patient Perceptions of Integrated Care survey can be used to measure the integration of care received by chronically ill patients for two main purposes: as a research tool to compare interventions intended to improve the integration of care and as a quality improvement tool intended to guide the refinement of delivery system innovations.
C1 [Singer, Sara J.; Kiang, Mathew V.] Harvard Univ, Boston, MA 02115 USA.
[Singer, Sara J.; Friedberg, Mark W.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Singer, Sara J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Friedberg, Mark W.] RAND Corp, Boston, MA USA.
[Friedberg, Mark W.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kuhn, Diane M.] Harvard Univ, Cambridge, MA 02138 USA.
RP Singer, SJ (reprint author), Harvard Univ, Sch Publ Hlth, Sch Med, Mongan Inst Hlth Policy,Massachusetts Gen Hosp, 677 Huntington Ave,Kresge Bldg 3,Room 317, Boston, MA 02115 USA.
EM ssinger@hsph.harvard.edu
FU Kaiser Permanente Institute for Health Policy for the Integrated Patient
Care Roundtable
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: Financial
support was provided by Kaiser Permanente Institute for Health Policy
for the Integrated Patient Care Roundtable, the Lucian Leape Institute
for cognitive testing, and the Harvard School of Public Health for the
pilot survey and research.
NR 20
TC 6
Z9 6
U1 0
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD APR
PY 2013
VL 70
IS 2
BP 143
EP 164
DI 10.1177/1077558712465654
PG 22
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 138QK
UT WOS:000318523300002
PM 23161612
ER
PT J
AU Penuelas, O
Frutos-Vivar, F
Gordo, F
Apezteguia, C
Restrepo, MI
Gonzalez, M
Arabi, Y
Santos, C
Alhashemi, JA
Perez, F
Esteban, A
Anzueto, A
AF Penuelas, O.
Frutos-Vivar, F.
Gordo, F.
Apezteguia, C.
Restrepo, M. I.
Gonzalez, M.
Arabi, Y.
Santos, C.
Alhashemi, J. A.
Perez, F.
Esteban, A.
Anzueto, A.
TI Outcome of tracheotomized patients following reintubation
SO MEDICINA INTENSIVA
LA Spanish
DT Article
DE Reintubation; Tracheotomy; Mechanical ventilation; Mortality
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION;
ICU PATIENTS; TRACHEOSTOMY; DURATION
AB Objective: To evaluate the outcome of tracheotomized patients after reintubation.
Method: Secondary analysis from a prospective, multicenter and observational study including 36 Intensive Care Units (ICUs) from 8 countries.
Patients: A total of 180 patients under mechanical ventilation for more than 48 hours, extubated and reintubated within 48 hours.
Interventions: None.
Outcomes: ICU mortality, length of ICU stay, organ failure.
Results: Fifty-two patients (29%) underwent tracheotomy after reintubation. The median time from reintubation to tracheotomy was 2.5 days (interquartile range (IQR) 1-8 days). The length of ICU stay was significantly longer in the tracheotomy group compared with the group without tracheotomy (median time 25 days, IQR 17-43 versus 16.5 days (IQR 11-25); p < 0.001). ICU mortality in the tracheotomy group was not significantly different (31% versus 27%; p 0.57).
Conclusions: In our cohort of reintubated patients, tracheotomy is a common procedure in the ICU. Patients with tracheotomy had an outcome similar to those without tracheotomy. (C) 2012 Elsevier Espana, S.L. and SEMICYUC. All rights reserved.
C1 [Penuelas, O.; Frutos-Vivar, F.; Esteban, A.] Hosp Univ Getafe, Madrid, Spain.
[Penuelas, O.; Frutos-Vivar, F.; Esteban, A.] CIBER Enfermedades Resp, Madrid, Spain.
[Gordo, F.] Hosp Henares, Madrid, Spain.
[Apezteguia, C.] Hosp Prof A Posadas, Buenos Aires, DF, Argentina.
[Restrepo, M. I.; Anzueto, A.] South Texas Vet Hlth Care Syst, VERDICT, Audie L Murphy Div, San Antonio, TX USA.
[Restrepo, M. I.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Gonzalez, M.] Clin Medellin, Medellin, Colombia.
[Gonzalez, M.] Univ Pontificia Bolivariana, Medellin, Colombia.
[Arabi, Y.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
[Santos, C.] Hosp Clin Montevideo, Montevideo, Uruguay.
[Alhashemi, J. A.] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia.
[Perez, F.] Hosp Clin Caracas, Caracas, Venezuela.
RP Penuelas, O (reprint author), Hosp Univ Getafe, Madrid, Spain.
EM openuelas@gmail.com
RI Restrepo, Marcos/H-4442-2014;
OI Frutos-Vivar, Fernando/0000-0002-4648-9636
FU NHLBI NIH HHS [K23 HL096054]
NR 19
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0210-5691
J9 MED INTENSIVA
JI Med. Intensiv.
PD APR
PY 2013
VL 37
IS 3
BP 142
EP 148
DI 10.1016/j.medin.2012.03.013
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 139LE
UT WOS:000318583400003
PM 22608302
ER
PT J
AU Sacanell, J
Rey, T
Lopez, E
Vicente, R
Ballesteros, MA
Iranzo, R
Robles, JC
Restrepo, MI
Rello, J
AF Sacanell, J.
Rey, T.
Lopez, E.
Vicente, R.
Ballesteros, M. A.
Iranzo, R.
Robles, J. C.
Restrepo, M. I.
Rello, J.
CA Network PLUTO Postoperative Lung
TI Antifungal prophylaxis in the postoperative period of lung transplant
surgery in Spain
SO MEDICINA INTENSIVA
LA Spanish
DT Article
DE Prophylaxis; Postoperative period; Lung transplant
ID LIPOSOMAL AMPHOTERICIN-B; ASPERGILLUS INFECTION; PHARMACOKINETICS;
PREVENTION; RECIPIENTS; SAFETY
AB Objectives: To examine the type and duration of antifungal prophylaxis provided during the postoperative period of lung transplant recipients, together with the most frequent complications during admission to Intensive Care Units in Spain.
Patients and methods: A questionnaire was developed including demographic data on each transplant center, the type of antifungal prophylaxis used, its duration, and the most frequent complications. The questionnaire was distributed among the 7 Spanish national lung transplant centers, followed by analysis of the results obtained.
Results: All 7 centers completed the questionnaire. All of them provided universal prophylaxis in lung transplant patients. Monotherapy was the most widely used protocol (5/7; 71.4%), with ambhotericin B in liposomal or conventional form being the most frequent drug, administered via the inhalatory route. In the case of combination therapy, a great diversity of drugs was observed. The most frequently administered second choice drug was anidulafungin (3/7; 43%), followed by voriconazole (2/7; 28.5%). Antifungal therapy was maintained on an indefinite basis by 43% of the centers.
Invasive fungal infection (IFI) in the postoperative period of transplantation during admission to the Intensive Care Unit was suspected in 5-10% of the cases but was confirmed in less than 5%.
Among other complications registered in these patients in the Intensive Care Unit, the most frequent problems were respiratory infections (5/7; 71.5%). Conclusions: Antifungal prophylaxis during the postoperative period of lung transplantation is provided on a universal basis, though consensus is lacking as to the drug of choice, the administration route and the duration of such treatment. (C) 2012 Elsevier Espana, S.L. and SEMICYUC. All rights reserved.
C1 [Sacanell, J.; Rello, J.] Hosp Univ Vall dHebron, Serv Med Intens, Barcelona, Spain.
[Rey, T.] Hosp Univ A Coruna, Serv Anestesiol & Reanimac, La Coruna, Spain.
[Lopez, E.] Hosp Univ Doce Octubre, Serv Anestesiol & Reanimac, Madrid, Spain.
[Vicente, R.] Hosp Univ La Fe, Serv Anestesiol & Reanimac, Valencia, Spain.
[Ballesteros, M. A.] Hosp Univ Marques de Valdecilla, Serv Med Intens, Santander, Spain.
[Iranzo, R.] Hosp Univ Puerta de Hierro, Serv Anestesiol & Reanimac, Madrid, Spain.
[Robles, J. C.] Hosp Univ Reina Sofia, Serv Med Intens, Cordoba, Spain.
[Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Audie L Murphy Div, Vet Evidence Res Implementat & Disseminat Ctr, San Antonio, TX 78229 USA.
[Rello, J.] Univ Automona Barcelona, Serv Med Intens, Hosp Univ Vall dHebron, Ctr Invest Biomed Red Enfermedades Resp, Barcelona, Spain.
RP Sacanell, J (reprint author), Hosp Univ Vall dHebron, Serv Med Intens, Barcelona, Spain.
EM jsacanell@vhebron.net
RI Restrepo, Marcos/H-4442-2014;
OI Masclans, Joan R/0000-0002-0809-6823; Rello, Jordi/0000-0003-0676-6210
FU NHLBI NIH HHS [K23 HL096054]
NR 20
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0210-5691
J9 MED INTENSIVA
JI Med. Intensiv.
PD APR
PY 2013
VL 37
IS 3
BP 201
EP 205
DI 10.1016/j.medin.2012.10.003
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA 139LE
UT WOS:000318583400009
PM 23260267
ER
PT J
AU Xin, XF
Gfeller, D
Cheng, J
Tonikian, R
Sun, L
Guo, AL
Lopez, L
Pavlenco, A
Akintobi, A
Zhang, YN
Rual, JF
Currell, B
Seshagiri, S
Hao, T
Yang, XP
Shen, YA
Salehi-Ashtiani, K
Li, JJ
Cheng, AT
Bouamalay, D
Lugari, A
Hill, DE
Grimes, ML
Drubin, DG
Grant, BD
Vidal, M
Boone, C
Sidhu, SS
Bader, GD
AF Xin, Xiaofeng
Gfeller, David
Cheng, Jackie
Tonikian, Raffi
Sun, Lin
Guo, Ailan
Lopez, Lianet
Pavlenco, Alevtina
Akintobi, Adenrele
Zhang, Yingnan
Rual, Jean-Francois
Currell, Bridget
Seshagiri, Somasekar
Hao, Tong
Yang, Xinping
Shen, Yun A.
Salehi-Ashtiani, Kourosh
Li, Jingjing
Cheng, Aaron T.
Bouamalay, Dryden
Lugari, Adrien
Hill, David E.
Grimes, Mark L.
Drubin, David G.
Grant, Barth D.
Vidal, Marc
Boone, Charles
Sidhu, Sachdev S.
Bader, Gary D.
TI SH3 interactome conserves general function over specific form
SO MOLECULAR SYSTEMS BIOLOGY
LA English
DT Article
DE network evolution; phage display; protein interaction conservation; SH3
domains; yeast two-hybrid
ID PROTEIN-PROTEIN INTERACTIONS; SEMANTIC SIMILARITY MEASURES; PEPTIDE
RECOGNITION MODULES; CAENORHABDITIS-ELEGANS; C-ELEGANS; INTERACTION
NETWORKS; INTERACTION DATABASE; REGULATORY NETWORKS; EVOLUTION; DOMAINS
AB Src homology 3 (SH3) domains bind peptides to mediate protein-protein interactions that assemble and regulate dynamic biological processes. We surveyed the repertoire of SH3 binding specificity using peptide phage display in a metazoan, the worm Caenorhabditis elegans, and discovered that it structurally mirrors that of the budding yeast Saccharomyces cerevisiae. We then mapped the worm SH3 interactome using stringent yeast two-hybrid and compared it with the equivalent map for yeast. We found that the worm SH3 interactome resembles the analogous yeast network because it is significantly enriched for proteins with roles in endocytosis. Nevertheless, orthologous SH3 domain-mediated interactions are highly rewired. Our results suggest a model of network evolution where general function of the SH3 domain network is conserved over its specific form.
C1 [Xin, Xiaofeng; Gfeller, David; Tonikian, Raffi; Lopez, Lianet; Pavlenco, Alevtina; Li, Jingjing; Boone, Charles; Sidhu, Sachdev S.; Bader, Gary D.] Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada.
[Xin, Xiaofeng; Tonikian, Raffi; Li, Jingjing; Boone, Charles; Sidhu, Sachdev S.; Bader, Gary D.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 3E1, Canada.
[Cheng, Jackie; Cheng, Aaron T.; Bouamalay, Dryden; Drubin, David G.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
[Sun, Lin; Akintobi, Adenrele; Grant, Barth D.] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA.
[Guo, Ailan] Cell Signaling Technol, Danvers, MA USA.
[Zhang, Yingnan] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA.
[Rual, Jean-Francois; Hao, Tong; Yang, Xinping; Shen, Yun A.; Salehi-Ashtiani, Kourosh; Hill, David E.; Vidal, Marc] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA.
[Rual, Jean-Francois; Hao, Tong; Yang, Xinping; Shen, Yun A.; Salehi-Ashtiani, Kourosh; Hill, David E.; Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Rual, Jean-Francois; Hao, Tong; Yang, Xinping; Shen, Yun A.; Salehi-Ashtiani, Kourosh; Hill, David E.; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Currell, Bridget; Seshagiri, Somasekar] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.
[Lugari, Adrien] CNRS, IMR Lab, UPR 3243, Inst Microbiol Mediterannee, Marseille 20, France.
[Lugari, Adrien] Aix Marseille Univ, Marseille 20, France.
[Grimes, Mark L.] Univ Montana, Div Biol Sci, Ctr Struct & Funct Neurosci, Missoula, MT 59812 USA.
[Bader, Gary D.] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3E1, Canada.
RP Boone, C (reprint author), Univ Toronto, Donnelly Ctr, 160 Coll St,602, Toronto, ON M5S 3E1, Canada.
EM charlie.boone@utoronto.ca; sachdev.sidhu@utoronto.ca;
gary.bader@utoronto.ca
RI Li, Jingjing/B-5136-2016; Xin, Xiaofeng/G-7736-2016; gfeller,
david/D-3395-2009;
OI Salehi-Ashtiani, Kourosh/0000-0002-6521-5243; Li,
Jingjing/0000-0001-6025-9522; Xin, Xiaofeng/0000-0002-2439-7183;
gfeller, david/0000-0002-3952-0930; Rual,
Jean-Francois/0000-0003-4465-8819; Lugari, Adrien/0000-0001-8337-6043;
Grant, Barth/0000-0002-5943-8336
FU Canadian Institutes of Health Research [MOP-84324, MOP-93725]; US
National Institutes of Health [R01 GM067237, R01 GM65462, NHGRI R01
HG001715]; EMBO [EMBO-ALTF 241-2010]; SNSF [PBELA33-120936]
FX We thank Q Li, H Huang, J Gu, R Isserlin, H Fares, A Audhya, A Shi, S
Pant, and D Carranza for experimental and computational support. This
work was supported by the Canadian Institutes of Health Research (Grants
MOP-84324 to GDB and MOP-93725 to SSS) and the US National Institutes of
Health (Grants R01 GM067237 to BDG, R01 GM65462 to DGD and NHGRI R01
HG001715 awarded to MV and DEH). DG acknowledges the financial support
of EMBO (EMBO-ALTF 241-2010) and SNSF (PBELA33-120936). The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 88
TC 21
Z9 21
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-4292
J9 MOL SYST BIOL
JI Mol. Syst. Biol.
PD APR
PY 2013
VL 9
AR 652
DI 10.1038/msb.2013.9
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 140YS
UT WOS:000318693000013
PM 23549480
ER
PT J
AU Vitte, J
Chareyre, F
Stemmer-Rachamimov, A
Giovannini, M
AF Vitte, Jeremie
Chareyre, Fabrice
Stemmer-Rachamimov, Anat
Giovannini, Marco
TI CONDITIONAL INACTIVATION OF SMARCB1 IN P0 PERMISSIVE MOUSE CELLS
RECAPITULATES THE TUMOR SPECTRUM OF BOTH HUMAN SMARCB1-RELATED
SCHWANNOMATOSIS AND RHABDOID TUMOR PREDISPOSITION SYNDROMES
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Vitte, Jeremie; Chareyre, Fabrice; Giovannini, Marco] Univ So Calif, House Res Inst, Ctr Neural Tumor Res, Los Angeles, CA USA.
[Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Mol Neurooncol & Pathol Dept, Boston, MA 02114 USA.
[Stemmer-Rachamimov, Anat] Harvard Univ, Sch Med, Boston, MA USA.
RI Vitte, Jeremie/B-9874-2017
OI Vitte, Jeremie/0000-0002-2567-7988
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0058
BP 15
EP 15
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500055
ER
PT J
AU Bergthold, G
Rich, B
Bandopadhayay, P
Chan, J
Santaga, S
Hoshida, Y
Golub, T
Tabak, B
Ferrer-Luna, R
Grill, J
Wen, PY
Stiles, C
Kieran, M
Ligon, K
Beroukhim, R
AF Bergthold, Guillaume
Rich, Benjamin
Bandopadhayay, Pratiti
Chan, Jennifer
Santaga, Sandro
Hoshida, Yujin
Golub, Todd
Tabak, Barbara
Ferrer-Luna, Ruben
Grill, Jacques
Wen, Patrick Yung
Stiles, Charles
Kieran, Mark
Ligon, Keith
Beroukhim, Rameen
TI GENE EXPRESSION ANALYSIS OF 163 PEDIATRIC LOW-GRADE GLIOMA ACROSS
DIFFERENT AGES, LOCATIONS, HISTOLOGICAL SUBTYPES AND BRAF GENOMIC STATUS
REVEALS ASSOCIATED MOLECULAR CHARACTERISTICS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Bergthold, Guillaume; Rich, Benjamin; Bandopadhayay, Pratiti; Ferrer-Luna, Ruben; Stiles, Charles; Kieran, Mark; Ligon, Keith; Beroukhim, Rameen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chan, Jennifer; Santaga, Sandro; Wen, Patrick Yung] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hoshida, Yujin; Golub, Todd; Tabak, Barbara] Broad Inst MIT & Harvard, Boston, MA USA.
[Grill, Jacques] Inst Gustave Roussy, Villejuif, France.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0064
BP 16
EP 16
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500061
ER
PT J
AU Snuderl, M
Batista, A
Kirkpatrick, N
de Almodovar, CR
Riedemann, L
Knevels, E
Schmidt, T
Peterson, T
Roberge, S
Bais, C
Yip, S
Hasselblatt, M
Rossig, C
Ferrara, N
Klagsbrun, M
Duda, D
Fukumura, D
Xu, L
Carmeliet, P
Jain, R
AF Snuderl, Matija
Batista, Ana
Kirkpatrick, Nathaniel
de Almodovar, Carmen Ruiz
Riedemann, Lars
Knevels, Ellen
Schmidt, Thomas
Peterson, Teresa
Roberge, Sylvie
Bais, Carlos
Yip, Stephen
Hasselblatt, Martin
Rossig, Claudia
Ferrara, Napoleone
Klagsbrun, Michael
Duda, Dan
Fukumura, Dai
Xu, Lei
Carmeliet, Peter
Jain, Rakesh
TI PLACENTAL GROWTH FACTOR/NEUROPILIN 1 SIGNALING IS A THERAPEUTIC TARGET
IN PEDIATRIC MEDULLOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Snuderl, Matija] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Batista, Ana; Kirkpatrick, Nathaniel; Riedemann, Lars; Peterson, Teresa; Roberge, Sylvie; Duda, Dan; Fukumura, Dai; Xu, Lei; Jain, Rakesh] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
[de Almodovar, Carmen Ruiz; Knevels, Ellen; Schmidt, Thomas; Carmeliet, Peter] Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, Louvain, Belgium.
[Bais, Carlos; Ferrara, Napoleone] Genentech Inc, San Francisco, CA USA.
[Yip, Stephen] Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada.
[Hasselblatt, Martin; Rossig, Claudia] Univ Hosp Munster, Inst Neuropathol, Munster, Germany.
[Hasselblatt, Martin; Rossig, Claudia] Univ Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany.
[Klagsbrun, Michael] Childrens Hosp Boston, Dept Surg, Vasc Biol Program, Boston, MA USA.
RI Riedemann, Lars/J-5725-2014
OI Riedemann, Lars/0000-0002-9510-1845
NR 0
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0074
BP 19
EP 20
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500071
ER
PT J
AU Pak, E
Zhao, XS
Ponomaryov, T
Segal, R
AF Pak, Ekaterina
Zhao, Xuesong
Ponomaryov, Tatyana
Segal, Rosalind
TI IDENTIFICATION OF RESISTANCE MECHANISMS TO SMO INHIBITION IN
MEDULLOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Pak, Ekaterina; Zhao, Xuesong; Ponomaryov, Tatyana; Segal, Rosalind] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Pak, Ekaterina; Zhao, Xuesong; Ponomaryov, Tatyana; Segal, Rosalind] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Pak, Ekaterina; Zhao, Xuesong; Ponomaryov, Tatyana; Segal, Rosalind] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
[Pak, Ekaterina; Zhao, Xuesong; Ponomaryov, Tatyana; Segal, Rosalind] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0131
BP 35
EP 35
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500126
ER
PT J
AU Bandopadhayay, P
Nguyen, B
Masoud, S
Vue, N
Gholamin, S
Yu, FR
Schubert, S
Bergthold, G
Mitra, S
Qi, J
Bradner, J
Kieran, M
Beroukhim, R
Cho, YJ
AF Bandopadhayay, Pratiti
Nguyen, Brian
Masoud, Sabran
Vue, Nujsaubnusi
Gholamin, Sharareh
Yu, Furong
Schubert, Simone
Bergthold, Guillaume
Mitra, Siddhartha
Qi, Jun
Bradner, James
Kieran, Mark
Beroukhim, Rameen
Cho, Yoon-Jae
TI BET BROMODOMAIN INHIBITION OF MYC-AMPLIFIED MEDULLOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Bandopadhayay, Pratiti; Bergthold, Guillaume; Qi, Jun; Bradner, James; Kieran, Mark; Beroukhim, Rameen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bandopadhayay, Pratiti; Bergthold, Guillaume; Qi, Jun; Bradner, James; Kieran, Mark; Beroukhim, Rameen] Harvard Univ, Sch Med, Boston, MA USA.
[Nguyen, Brian; Masoud, Sabran; Vue, Nujsaubnusi; Gholamin, Sharareh; Yu, Furong; Schubert, Simone; Mitra, Siddhartha; Cho, Yoon-Jae] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Nguyen, Brian; Masoud, Sabran; Vue, Nujsaubnusi; Gholamin, Sharareh; Yu, Furong; Schubert, Simone; Mitra, Siddhartha; Cho, Yoon-Jae] Lucile Packard Childrens Hosp, Stanford, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0135
BP 36
EP 36
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500130
ER
PT J
AU Chi, SS
Cohen, K
Fisher, M
Biegel, J
Bowers, D
Fangusaro, J
Manley, P
Janss, A
Zimmerman, MA
Kieran, M
AF Chi, Susan
Cohen, Kenneth
Fisher, Michael
Biegel, Jaclyn
Bowers, Daniel
Fangusaro, Jason
Manley, Peter
Janss, Anna
Zimmerman, Mary Ann
Kieran, Mark
TI LONG-TERM OUTCOMES FROM A PROSPECTIVE PHASE II STUDY OF MULTI-AGENT
SYSTEMIC AND INTRATHECAL CHEMOTHERAPY WITH AGE- AND RISK-ADAPTED
RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED CNS ATYPICAL
TERATOID/RHABDOID TUMOR (DFCI #02-294)
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Chi, Susan; Manley, Peter; Zimmerman, Mary Ann; Kieran, Mark] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cohen, Kenneth] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA.
[Fisher, Michael; Biegel, Jaclyn] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Bowers, Daniel] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Fangusaro, Jason] Lurie Childrens Hosp Chicago, Chicago, IL USA.
[Janss, Anna] Childrens Healthcare Atlanta Egleston, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0133
BP 36
EP 36
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500128
ER
PT J
AU Calligaris, D
Liu, XH
Feldman, D
Thompson, C
Ide, J
Buhrlage, S
Gray, N
Kieran, M
Stiles, C
Agar, N
AF Calligaris, David
Liu, Xiaohui
Feldman, Daniel
Thompson, Christopher
Ide, Jennifer
Buhrlage, Sara
Gray, Nathanael
Kieran, Mark
Stiles, Charles
Agar, Nathalie
TI DEVELOPMENT OF COMBINED PK/PD STUDIES OF RAF/MEK/mTOR INHIBITORS FOR THE
TREATMENT OF PEDIATRIC LOW-GRADE ASTROCYTOMAS BY MALDI MASS SPECTROMETRY
IMAGING
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Calligaris, David; Liu, Xiaohui; Feldman, Daniel; Ide, Jennifer; Agar, Nathalie] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Kieran, Mark] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
[Buhrlage, Sara; Gray, Nathanael; Stiles, Charles] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Thompson, Christopher] Bruker Daltonics Inc, Billerica, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0139
BP 37
EP 37
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500134
ER
PT J
AU Liu, XH
Ebling, M
Ide, J
Wang, L
Davis, E
Marchionni, M
Stuart, D
Alberta, J
Kieran, M
Stiles, C
Agar, N
AF Liu, Xiaohui
Ebling, Maritza
Ide, Jennifer
Wang, Lan
Davis, Erin
Marchionni, Mark
Stuart, Darrin
Alberta, John
Kieran, Mark
Stiles, Charles
Agar, Nathalie
TI VALIDATION OF HEME AS A MARKER OF THE VASCULATURE FOR MALDI IMAGING OF
THE BLOOD-BRAIN BARRIERS IN DRUG DEVELOPMENT
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Liu, Xiaohui; Ide, Jennifer; Agar, Nathalie] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Ebling, Maritza; Wang, Lan; Davis, Erin; Marchionni, Mark; Alberta, John; Stiles, Charles] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kieran, Mark] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
[Stuart, Darrin] Novartis Inst Biomed Res, Emeryville, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0143
BP 38
EP 39
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500138
ER
PT J
AU Ramkissoon, L
Horowitz, P
Craig, J
Ramkissoon, S
Rich, B
Bergthold, G
Tabori, U
Taha, H
Bowers, D
Hawkins, C
Packer, R
Eberhart, C
Goumnerova, L
Chan, J
Santagata, S
Pomcroy, S
Ligon, A
Kieran, M
Beroukhim, R
Ligon, K
AF Ramkissoon, Lori
Horowitz, Peleg
Craig, Justin
Ramkissoon, Shakti
Rich, Benjamin
Bergthold, Guillaume
Tabori, Uri
Taha, Hala
Bowers, Daniel
Hawkins, Cynthia
Packer, Roger
Eberhart, Charles
Goumnerova, Liliana
Chan, Jennifer
Santagata, Sandro
Pomcroy, Scott
Ligon, Azra
Kieran, Mark
Beroukhim, Rameen
Ligon, Keith
TI GENOMIC ANALYSIS OF DIFFUSE PEDIATRIC LOW-GRADE GLIOMAS IDENTIFIES
RECURRENT, ONCOGENIC MYBL1-TRUNCATING REARRANGEMENTS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 [Ramkissoon, Lori; Craig, Justin; Rich, Benjamin; Bergthold, Guillaume; Ligon, Keith] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Horowitz, Peleg; Ramkissoon, Shakti; Santagata, Sandro; Ligon, Azra] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Beroukhim, Rameen] Broad Inst, Cambridge, MA USA.
[Goumnerova, Liliana; Pomcroy, Scott; Kieran, Mark] Boston Childrens Hosp, Boston, MA USA.
[Eberhart, Charles] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Taha, Hala] Childrens Canc Hosp, Cairo, Egypt.
[Tabori, Uri; Hawkins, Cynthia] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Bowers, Daniel] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Chan, Jennifer] Univ Calgary, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0146
BP 39
EP 39
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500141
ER
PT J
AU Sun, YG
Stiles, C
AF Sun, Yu Grace
Stiles, Charles
TI GENETIC ABLATION OF THE bHLH TRANSCRIPTION FACTOR OLIG2 IS SYNTHETIC
LETHAL TO BRAF ONCOGENES IN A MURINE MODEL OF PEDIATRIC LOW-GRADE
ASTROCYTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research
Conference
CY MAY 16-17, 2013
CL Fort Lauderdale, FL
C1 Harvard Univ, Sch Med, Boston, MA USA.
Dana Farber Harvard Canc Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
SU 1
MA 0172
BP 46
EP 46
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 139GR
UT WOS:000318570500166
ER
PT J
AU Westover, MB
Bianchi, MT
Yang, CH
Schneider, JA
Greenberg, SM
AF Westover, M. Brandon
Bianchi, Matt T.
Yang, Chunhui
Schneider, Julie A.
Greenberg, Steven M.
TI Estimating cerebral microinfarct burden from autopsy samples
SO NEUROLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; OLDER PERSONS; RELIGIOUS ORDERS; AGING
PROJECT; RUSH MEMORY; INFARCTS; DEMENTIA; LESIONS
AB Objective: To estimate whole-brain microinfarct burden from microinfarct counts in routine postmortem examination.
Methods: We developed a simple mathematical method to estimate the total number of cerebral microinfarcts from counts obtained in the small amount of tissue routinely examined in brain autopsies. We derived estimates of total microinfarct burden from autopsy brain specimens from 648 older participants in 2 community-based clinical-pathologic cohort studies of aging and dementia.
Results: Our results indicate that observing 1 or 2 microinfarcts in 9 routine neuropathologic specimens implies a maximum-likelihood estimate of 552 or 1,104 microinfarcts throughout the brain. Similar estimates were obtained when validating in larger sampled brain volumes.
Conclusions: The substantial whole-brain burden of cerebral microinfarcts suggested by even a few microinfarcts on routine pathologic sampling suggests a potential mechanism by which these lesions could cause neurologic dysfunction in individuals with small-vessel disease. The estimation framework developed here may generalize to clinicopathologic correlations of other imaging-negative micropathologies.
C1 [Westover, M. Brandon; Bianchi, Matt T.; Greenberg, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Hemorrhag Stroke Res Program, Boston, MA 02114 USA.
[Westover, M. Brandon; Bianchi, Matt T.; Greenberg, Steven M.] Harvard Univ, Sch Med, Boston, MA USA.
[Yang, Chunhui; Schneider, Julie A.] Rush Univ, Rush Alzheimers Dis Ctr, Dept Pathol, Med Ctr, Chicago, IL 60612 USA.
RP Greenberg, SM (reprint author), Massachusetts Gen Hosp, Dept Neurol, Hemorrhag Stroke Res Program, Boston, MA 02114 USA.
EM sgreenberg@partners.org
FU NIH [R01 AG026484]; National Institute on Aging [R01 AG15819, R01
AG17917, P30 AG10161, K08 AG00849]
FX M.B. Westover, M.T. Bianchi, and C. Yang report no disclosures. J.A.
Schneider contributed data used in this work from the Funding for the
Religious Orders Study and the Rush Memory and Aging Project, which were
supported by grants from the National Institute on Aging (R01 AG15819,
R01 AG17917, P30 AG10161, and K08 AG00849). S.M. Greenberg is funded by
R01AG026484 from the NIH. Go to Neurology.org for full disclosures.
NR 24
TC 38
Z9 38
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD APR
PY 2013
VL 80
IS 15
BP 1365
EP 1369
DI 10.1212/WNL.0b013e31828c2f52
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 139RM
UT WOS:000318601600008
PM 23486880
ER
PT J
AU Sharma, N
AF Sharma, Nutan
TI Lysosomal enzyme defects and Parkinson disease
SO NEUROLOGY
LA English
DT Editorial Material
ID MUTATIONS
C1 Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Sharma, N (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM nsharma@partners.org
NR 6
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD APR
PY 2013
VL 80
IS 17
BP 1544
EP 1545
DI 10.1212/WNL.0b013e31828f1958
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 140ZC
UT WOS:000318694000005
PM 23535496
ER
PT J
AU Martinez-Ramirez, S
Pontes-Neto, OM
Dumas, AP
Auriel, E
Halpin, A
Quimby, M
Gurol, ME
Greenberg, SM
Viswanathan, A
AF Martinez-Ramirez, Sergi
Pontes-Neto, Octavio Marques
Dumas, Andrew P.
Auriel, Eitan
Halpin, Amy
Quimby, Megan
Gurol, Mahmut Edip
Greenberg, Steven M.
Viswanathan, Anand
TI Topography of dilated perivascular spaces in subjects from a memory
clinic cohort
SO NEUROLOGY
LA English
DT Article
ID CEREBRAL AMYLOID ANGIOPATHY; VIRCHOW-ROBIN SPACES; SMALL VESSEL DISEASE;
ALZHEIMERS-DISEASE; WHITE-MATTER; ROTTERDAM-SCAN; BLOOD-PRESSURE;
MICROBLEEDS; MRI; DEMENTIA
AB Objective: To investigate whether the topography of dilated perivascular spaces (DPVS) corresponds with markers of particular small-vessel diseases such as cerebral amyloid angiopathy and hypertensive vasculopathy.
Methods: Patients were recruited from an ongoing single-center prospective longitudinal cohort study of patients evaluated in a memory clinic. All patients underwent structural, high-resolution MRI, and had a clinical assessment performed within 1 year of scan. DPVS were rated in basal ganglia (BG-DPVS) and white matter (WM-DPVS) on T1 sequences, using an established 4-point semiquantitative score. DPVS degree was classified as high (score > 2) or low (score <= 2). Independent risk factors for high degree of BG-DPVS and WM-DPVS were investigated.
Results: Eighty-nine patients were included (mean age 72.7 +/- 9.9 years, 57% female). High degree of WM-DPVS was more frequent than low degree in patients with presence of strictly lobar microbleeds (45.5% vs 28.4% of subjects). High BG-DPVS degree was associated with older age, hypertension, and higher white matter hyperintensity volumes. In multivariate analysis, increased lobar microbleed count was an independent predictor of high degree of WM-DPVS (odds ratio [OR] 1.53 [95% confidence interval (CI) 1.06-2.21], p = 0.02). By contrast, hypertension was an independent predictor of high degree of BG-DPVS (OR 9.4 [95% CI 1-85.2], p = 0.04).
Conclusions: The associations of WM-DPVS with lobar microbleeds and BG-DPVS with hypertension raise the possibility that the distribution of DPVS may indicate the presence of underlying small-vessel diseases such as cerebral amyloid angiopathy and hypertensive vasculopathy in patients with cognitive impairment.
C1 [Martinez-Ramirez, Sergi; Pontes-Neto, Octavio Marques; Dumas, Andrew P.; Auriel, Eitan; Halpin, Amy; Quimby, Megan; Gurol, Mahmut Edip; Greenberg, Steven M.; Viswanathan, Anand] Massachusetts Gen Hosp, Ctr Stroke Res, Boston, MA 02114 USA.
[Martinez-Ramirez, Sergi] Univ Autonoma Barcelona, Escola Postgrau, Bellaterra, Cerdanyola Del, Spain.
RP Martinez-Ramirez, S (reprint author), Massachusetts Gen Hosp, Ctr Stroke Res, Boston, MA 02114 USA.
EM srmartinez@partners.org
RI Pontes-Neto, Octavio/G-4294-2012; Gurol, Edip/J-2279-2014
OI Pontes-Neto, Octavio/0000-0003-0317-843X; Gurol,
Edip/0000-0002-2169-4457
FU National Institute on Aging [5P50AG005134-28]; Fundacion Alfonso Martin
Escudero, Madrid (Spain)
FX Supported by grant 5P50AG005134-28 from the National Institute on Aging.
Dr. Martinez-Ramirez is a recipient of the research grant "Becas de
Investigacion en Universidades y Centros del Extranjero" from Fundacion
Alfonso Martin Escudero, Madrid (Spain). Funding entities had no
involvement in study design, data collection, analysis and
interpretation, writing of the manuscript, or the decision to submit for
publication.
NR 30
TC 42
Z9 45
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD APR
PY 2013
VL 80
IS 17
BP 1551
EP 1556
DI 10.1212/WNL.0b013e31828f1876
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 140ZC
UT WOS:000318694000007
PM 23553482
ER
PT J
AU Suzuki, R
Ferris, HA
Chee, MJ
Maratos-Flier, E
Kahn, CR
AF Suzuki, Ryo
Ferris, Heather A.
Chee, Melissa J.
Maratos-Flier, Eleftheria
Kahn, C. Ronald
TI Reduction of the Cholesterol Sensor SCAP in the Brains of Mice Causes
Impaired Synaptic Transmission and Altered Cognitive Function
SO PLOS BIOLOGY
LA English
DT Article
ID DIABETIC-RATS; NERVOUS-SYSTEM; RECEPTOR; INSULIN; DISEASE; HIPPOCAMPUS;
METABOLISM; DYSFUNCTION; PHENOTYPE; DEMENTIA
AB The sterol sensor SCAP is a key regulator of SREBP-2, the major transcription factor controlling cholesterol synthesis. Recently, we showed that there is a global down-regulation of cholesterol synthetic genes, as well as SREBP-2, in the brains of diabetic mice, leading to a reduction of cholesterol synthesis. We now show that in mouse models of type 1 and type 2 diabetes, this is, in part, the result of a decrease of SCAP. Homozygous disruption of the Scap gene in the brains of mice causes perinatal lethality associated with microcephaly and gliosis. Mice with haploinsufficiency of Scap in the brain show a 60% reduction of SCAP protein and similar to 30% reduction in brain cholesterol synthesis, similar to what is observed in diabetic mice. This results in impaired synaptic transmission, as measured by decreased paired pulse facilitation and long-term potentiation, and is associated with behavioral and cognitive changes. Thus, reduction of SCAP and the consequent suppression of cholesterol synthesis in the brain may play an important role in the increased rates of cognitive decline and Alzheimer disease observed in diabetic states.
C1 [Suzuki, Ryo; Ferris, Heather A.; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Chee, Melissa J.; Maratos-Flier, Eleftheria] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
RP Suzuki, R (reprint author), Univ Tokyo, Tokyo, Japan.
EM c.ronald.kahn@joslin.harvard.edu
FU Mary K. Iacocca Professorship [P30 DK036836, 5 T32 DK007260-34]; [R01
DK31036]
FX This work was supported by R01 DK31036 and the Mary K. Iacocca
Professorship (to CRK), P30 DK036836 (Joslin DERC Core Facilities), and
5 T32 DK007260-34 (to HAF). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 40
TC 13
Z9 13
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD APR
PY 2013
VL 11
IS 4
AR e1001532
DI 10.1371/journal.pbio.1001532
PG 14
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics
GA 140WT
UT WOS:000318687800010
PM 23585733
ER
PT J
AU Momand, JR
Xu, GG
Walter, CA
AF Momand, Jamila R.
Xu, Guogang
Walter, Christi A.
TI The Paternal Age Effect: A Multifaceted Phenomenon
SO BIOLOGY OF REPRODUCTION
LA English
DT Review
DE DNA repair; mutagenesis; paternal age; spermatogenic cells;
spermatogonial stem cells
ID DE-NOVO MUTATIONS; MALE GERM-CELLS; SPERMATOGONIAL STEM-CELLS;
NUCLEOTIDE EXCISION-REPAIR; APERT-SYNDROME; OSTEOGENESIS IMPERFECTA;
HETEROZYGOUS MICE; COSTELLO-SYNDROME; CROUZON-SYNDROME; FGFR2 MUTATIONS
AB Birth rates for older fathers have increased 30% since 1980. When combined with the increased risk for genetic and multifactorial disorders in children conceived by older fathers, paternal age has become an important health issue for modern society. Laboratory research in this area has been minimal, perhaps because of significant experimental barriers, not the least of which is inadequate access to fresh, disease-free human testicular tissue. Regardless, progress has been made and intriguing models supported by experimental evidence have been proposed. The putative mechanisms range from reduced DNA repair activity, leading to increased mutagenesis, to positive selection of germ cells harboring specific disease-causing mutations. There remain many important venues for research in this increasingly relevant phenomenon that impacts future generations.
C1 [Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Momand, Jamila R.; Xu, Guogang; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM walter@uthscsa.edu
NR 101
TC 9
Z9 9
U1 1
U2 16
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA
SN 0006-3363
J9 BIOL REPROD
JI Biol. Reprod.
PD APR
PY 2013
VL 88
IS 4
AR 108
DI 10.1095/biolreprod.112.103440
PG 9
WC Reproductive Biology
SC Reproductive Biology
GA 138EF
UT WOS:000318490800014
PM 23515674
ER
PT J
AU Velligan, DI
Castillo, D
Lopez, L
Manaugh, B
Davis, C
Rodriguez, J
Milam, AC
Dassori, A
Miller, AL
AF Velligan, Dawn I.
Castillo, Desiree
Lopez, Linda
Manaugh, Bren
Davis, Charlotte
Rodriguez, Juanita
Milam, A. Camis
Dassori, Albana
Miller, Alexander L.
TI A Case Control Study of the Implementation of Change Model Versus
Passive Dissemination of Practice Guidelines for Compliance in
Monitoring for Metabolic Syndrome
SO COMMUNITY MENTAL HEALTH JOURNAL
LA English
DT Article
DE Metabolic syndrome monitoring; Practice guidelines; Community mental
health; Atypical antipsychotics; Implementation of change model; Serious
mental illness
ID ANTIPSYCHOTIC MEDICATIONS; VENOUS THROMBOEMBOLISM; HEALTH-CARE;
SCHIZOPHRENIA; STATEMENT; CATIE; RISK
AB We developed an intervention to improve compliance with guidelines for monitoring metabolic syndrome and compared compliance prior to intervention and three times post-intervention at three community mental health clinics in Texas. One test clinic received intervention and two other clinics served as controls. Fifty random charts were reviewed from each clinic for three specific, 1-2 weeks periods over the course of 18 months. There were significant improvements in the ordering of labs, the presence of lab results in the chart, and documentation of blood pressure, body mass index and waist circumference in the intervention clinic over time in comparison to the control clinics. Documented evidence of physician action with respect to out of range values remained low. Metabolic monitoring is a multi-step process. Removing barriers, creating specific procedures, and dedicating staff resources can improve compliance with monitoring.
C1 [Velligan, Dawn I.; Castillo, Desiree; Milam, A. Camis; Miller, Alexander L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Lopez, Linda; Manaugh, Bren; Davis, Charlotte; Rodriguez, Juanita; Milam, A. Camis] Ctr Hlth Care Serv, Bexar Cty, TX USA.
[Dassori, Albana] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
RP Velligan, DI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Mail Stop 7797,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM velligand@uthscsa.edu; castillod@uthscsa.edu; LLopez@chcsbc.org;
BManaugh@chcsbc.org; Cdavis@chscbc.org; jlrodriguez@chcsbc.org;
milama@uthscsa.edu; millera@uthscsa.edu
FU NIMH NIH HHS [R24 MH072830]
NR 18
TC 2
Z9 2
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0010-3853
J9 COMMUNITY MENT HLT J
JI Community Ment. Health J.
PD APR
PY 2013
VL 49
IS 2
BP 141
EP 149
DI 10.1007/s10597-011-9472-z
PG 9
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 136MS
UT WOS:000318366600001
PM 22350562
ER
PT J
AU Sylvia, L
Kopeski, L
Brown, C
Bolton, P
Laudate, C
DiGangi, G
Martin, P
Reid, JA
Martowski, JC
Meade, A
Sarmiento, IA
Wang, JP
Utschig, AC
Siegel, A
Neuhaus, EC
AF Sylvia, Louisa G.
Kopeski, Lynne
Brown, Carrie
Bolton, Paula
Laudate, Corina
DiGangi, Gina
Martin, Paula
Reid, James A.
Martowski, Jules C.
Meade, Amy
Sarmiento, Ingrid A.
Wang, Jianping
Utschig, Angela C.
Siegel, Arthur
Neuhaus, Edmund C.
TI An Adjunct Exercise Program for Serious Mental Illness: Who Chooses to
Participate and is it Feasible?
SO COMMUNITY MENTAL HEALTH JOURNAL
LA English
DT Article
DE Serious mental illness; Exercise; Self-selection; Feasibility
ID AUTOMATIC THOUGHTS QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIALS; BIPOLAR
DISORDER; MEDICAL BURDEN; DEPRESSION; INTERVENTION; HOPELESSNESS;
DISEASE; RISK
AB Despite evidence that exercise is beneficial for serious mental illness, it continues to be an under utilized adjunct treatment strategy. Thus, the aims of this study were to examine if self-selected or volunteer exercise programs are feasible in a structured outpatient program and who might choose to participate in such a program. Individuals with serious mental illness admitted to a partial hospital program were offered an adjunct exercise group or a control, psychoeducation group. The exercise group (N = 38) met three times a week for 50 min. Individuals who chose not to exercise (N = 28), attended a psychoeducational control group. Those who self-selected the exercise group tended to have a higher level of education, employment rate and to be Caucasian. The control group had more medical problems, a higher body mass index and alcohol intake. The groups did not differ on age, sex, or use of cigarettes and caffeine. The exercise group was regularly attended. Both groups improved equally on all outcomes symptom and psychological well-being outcomes. These data highlight that certain individuals with serious mental illness may be more likely to exercise based on demographic opposed to clinical features, or illness characteristics. Thus, adjunct exercise programs for individuals with serious mental illness seem to be feasible, but certain groups of individuals (i.e., ethnic minorities, unemployed) should be targeted for recruitment as they are less likely to volunteer for such adjunct exercise programs.
C1 [Sylvia, Louisa G.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA.
[Sylvia, Louisa G.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA.
[Sylvia, Louisa G.; Siegel, Arthur; Neuhaus, Edmund C.] Harvard Univ, Sch Med, Boston, MA USA.
[Kopeski, Lynne; Brown, Carrie; Laudate, Corina; DiGangi, Gina; Martin, Paula; Martowski, Jules C.; Meade, Amy; Sarmiento, Ingrid A.; Siegel, Arthur] McLean Hosp, Belmont, MA 02478 USA.
[Bolton, Paula] McLean Hosp, Psychiat Neurotherapeut Program, Belmont, MA 02478 USA.
[Reid, James A.] MCAS Beaufort, Mental Hlth Unit, Beaufort, SC 29902 USA.
[Wang, Jianping] Beijing Normal Univ, Beijing 100875, Peoples R China.
[Utschig, Angela C.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA.
RP Sylvia, L (reprint author), Massachusetts Gen Hosp, Bipolar Clin, 50 Staniford St,Suite 580, Boston, MA 02114 USA.
EM lsylvia2@partners.org
NR 34
TC 2
Z9 2
U1 2
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0010-3853
J9 COMMUNITY MENT HLT J
JI Community Ment. Health J.
PD APR
PY 2013
VL 49
IS 2
BP 213
EP 219
DI 10.1007/s10597-012-9555-5
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 136MS
UT WOS:000318366600011
PM 23064968
ER
PT J
AU Brown, JR
AF Brown, Jennifer R.
TI Preface
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Brown, JR (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM Jennifer_Brown@dfci.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD APR
PY 2013
VL 27
IS 2
BP XIII
EP XIV
DI 10.1016/j.hoc.2013.01.009
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA 138SK
UT WOS:000318530100001
PM 23561479
ER
PT J
AU Improgo, MR
Brown, JR
AF Improgo, Ma. Reina
Brown, Jennifer R.
TI Genomic Approaches to Chronic Lymphocytic Leukemia
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Chronic lymphocytic leukemia; Genomics; Comparative genomic
hybridization; Single-nucleotide polymorphism arrays; Linkage mapping;
Genome-wide association studies; Whole-exome sequencing; Whole-genome
sequencing
ID SUSCEPTIBILITY LOCI; COMMON VARIATION; ATM MUTATIONS; P53 MUTATIONS;
FOLLOW-UP; HYBRIDIZATION; FAMILIES; RISK; IMBALANCES; SURVIVAL
AB This article discusses recent advances in genomic approaches used to understand chronic lymphocytic leukemia. Tools for analyzing DNA-level lesions are described, data obtained from these various platforms summarized, and the clinical relevance of these findings discussed.
C1 [Improgo, Ma. Reina; Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,CLL Ctr, Boston, MA 02215 USA.
RP Brown, JR (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,CLL Ctr, 450 Brookline Ave, Boston, MA 02215 USA.
EM Jennifer_Brown@dfci.harvard.edu
FU NIH [K23 CA115682]
FX Funded by: NIH, Grant numbers: K23 CA115682.
NR 57
TC 1
Z9 1
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD APR
PY 2013
VL 27
IS 2
BP 157
EP +
DI 10.1016/j.hoc.2013.01.001
PG 16
WC Oncology; Hematology
SC Oncology; Hematology
GA 138SK
UT WOS:000318530100002
PM 23561468
ER
PT J
AU Davids, MS
Brown, JR
AF Davids, Matthew S.
Brown, Jennifer R.
TI Phosphoinositide 3 '-Kinase Inhibition in Chronic Lymphocytic Leukemia
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Lymphoid leukemia; Signaling therapies; Phosphoinositide 3 '-kinase;
B-cell receptor
ID B-CELL RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ZAP-70 EXPRESSION;
SURVIVAL SIGNALS; GENE-EXPRESSION; T-LYMPHOCYTES; P110 DELTA; CLL CELLS;
PI3K; BCR
AB Phosphoinositide 3'-kinase (PI3K) is a key node in the B-cell receptor pathway, which plays a crucial role in the trafficking, survival, and proliferation of chronic lymphocytic leukemia (CLL) cells. This article reviews the biology of PI3K, focusing on its relationship to the CLL microenvironment, and discusses the biological rationale for PI3K inhibition in CLL. Preliminary safety and efficacy data from early phase clinical trials is also discussed. Potential biomarkers for clinical response to PI3K inhibitors such as ZAP-70, IGHV status, and CCL3 are examined. Where PI3K inhibition may fit in the evolving landscape of CLL therapy is also explored.
C1 [Davids, Matthew S.; Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,CLL Ctr, Boston, MA 02215 USA.
RP Brown, JR (reprint author), Harvard Univ, Sch Med, CLL Ctr, Dana Farber Canc Inst, 450 Brookline Ave,M232, Boston, MA 02215 USA.
EM Jennifer_Brown@dfci.harvard.edu
FU NCI NIH HHS [K23 CA115682, T32 CA009172]
NR 48
TC 3
Z9 3
U1 0
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD APR
PY 2013
VL 27
IS 2
BP 329
EP +
DI 10.1016/j.hoc.2012.12.002
PG 12
WC Oncology; Hematology
SC Oncology; Hematology
GA 138SK
UT WOS:000318530100010
PM 23561476
ER
PT J
AU Edlow, JA
Caplan, LR
O'Brien, K
Tibbles, C
AF Edlow, Jonathan A.
Caplan, Louis R.
O'Brien, Karen
Tibbles, Carrie
TI Neurological emergencies in pregnant and post-partum women in
resource-poor settings Reply
SO LANCET NEUROLOGY
LA English
DT Letter
ID VENOUS THROMBOSIS
C1 [Edlow, Jonathan A.] Harvard Univ, Sch Med, Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
[Caplan, Louis R.] Harvard Univ, Sch Med, Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
[O'Brien, Karen] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Maternal & Fetal Med,Dept Obstet & Gynecol, Boston, MA 02215 USA.
RP Edlow, JA (reprint author), Harvard Univ, Sch Med, Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
EM jedlow@bidmc.harvard.edu
NR 4
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
J9 LANCET NEUROL
JI Lancet Neurol.
PD APR
PY 2013
VL 12
IS 4
BP 330
EP 330
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 138SZ
UT WOS:000318531600008
PM 23518326
ER
PT J
AU Lauer, A
Pfeilschifter, W
Schaffer, CB
Lo, EH
Foerch, C
AF Lauer, Arne
Pfeilschifter, Waltraud
Schaffer, Chris B.
Lo, Eng H.
Foerch, Christian
TI Intracerebral haemorrhage associated with antithrombotic treatment:
translational insights from experimental studies
SO LANCET NEUROLOGY
LA English
DT Review
ID DIRECT THROMBIN INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATE; ACTIVATED
FACTOR-VII; RECOMBINANT FACTOR VIIA; FRESH-FROZEN PLASMA; PRIOR
ANTIPLATELET THERAPY; REDUCED PLATELET ACTIVITY; BLOOD-CLOT FORMATION;
ATRIAL-FIBRILLATION; INTRACRANIAL HEMORRHAGE
AB Little is known about the pathophysiology of intracerebral haemorrhage that occurs during anticoagulant treatment. In observational studies, investigators have reported larger haematoma volumes and worse functional outcome in these patients than in those with intracerebral haemorrhage and a normal coagulation status. The need to prevent extensive haematoma enlargement by rapid reversal of the anticoagulation seems intuitive, although no evidence is available from randomised clinical trials. New oral anticoagulants, such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban, have been approved recently; however, intracerebral haemorrhage during dabigatran or rivaroxaban anticoagulation has not been characterised, and whether anticoagulation reversal can be beneficial in this scenario is unknown. In a translational approach, new experimental models have been developed to study anticoagulation-associated intracerebral haemorrhage in more detail and to test treatment strategies. Vitamin k antagonists enlarge haematoma volumes and worsen functional outcome in animal models. Rapid reversal of anticoagulation in the experimental setting prevents prolonged haematoma expansion and improves outcome. The new oral anticoagulants increase intracerbral haemorrhage volumes less than does warfarin. Haemostatic approaches that have been used for vitamin k-associated intracerebral haemorrhage also seem to be effective in intracerebral haemorrhage associated with the new anticoagulants. These experimental studies are valuable for filling gaps in knowledge, but the results need careful translation into routine clinical practice.
C1 [Lauer, Arne; Pfeilschifter, Waltraud; Foerch, Christian] Goethe Univ Frankfurt, Dept Neurol, D-60526 Frankfurt, Germany.
[Lauer, Arne; Lo, Eng H.; Foerch, Christian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab, Boston, MA USA.
[Schaffer, Chris B.] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA.
RP Foerch, C (reprint author), Goethe Univ Frankfurt, Dept Neurol, Schleusenweg 2-16, D-60526 Frankfurt, Germany.
EM foerch@em.uni-frankfurt.de
RI Schaffer, Chris/A-7409-2008
OI Schaffer, Chris/0000-0002-7800-9596
FU NINDS NIH HHS [R01 NS076694, P01 NS055104, R37 NS037074]
NR 99
TC 17
Z9 18
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
J9 LANCET NEUROL
JI Lancet Neurol.
PD APR
PY 2013
VL 12
IS 4
BP 394
EP 405
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA 138SZ
UT WOS:000318531600015
PM 23518332
ER
PT J
AU Kumar, P
Moy, B
AF Kumar, Pallavi
Moy, Beverly
TI The Cost of Cancer Care-Balancing Our Duties to Patients Versus Society:
Are They Mutually Exclusive?
SO ONCOLOGIST
LA English
DT Editorial Material
DE Health care costs; Ethical issues; Cancer care; Resource allocation;
Decision-making
ID QUALITY-OF-LIFE; BREAST-CANCER; DECISION-MAKING; FOLLOW-UP; CENTERED
CARE; TRASTUZUMAB; TRIAL; PARTICIPATION; MULTICENTER; PREFERENCES
C1 [Kumar, Pallavi; Moy, Beverly] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Moy, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gillette Ctr Womens Canc, 55 Fruit St,Yawkey 9A, Boston, MA 02114 USA.
EM bmoy@partners.org
NR 33
TC 3
Z9 3
U1 0
U2 3
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD APR
PY 2013
VL 18
IS 4
BP 347
EP 349
DI 10.1634/theoncologist.2013-0078
PG 3
WC Oncology
SC Oncology
GA 136CB
UT WOS:000318336200006
PM 23568002
ER
PT J
AU O'Toole, J
Jammallo, LS
Miller, CL
Skolny, MN
Specht, MC
Taghian, AG
AF O'Toole, Jean
Jammallo, Lauren S.
Miller, Cynthia L.
Skolny, Melissa N.
Specht, Michelle C.
Taghian, Alphonse G.
TI Screening for Breast Cancer-Related Lymphedema: The Need for
Standardization
SO ONCOLOGIST
LA English
DT Editorial Material
ID ARM LYMPHEDEMA; LIMB VOLUME; SURVIVORS; DIAGNOSIS; SPECTROSCOPY;
PREVALENCE; SECONDARY; IMPACT; COSTS; RISK
C1 [O'Toole, Jean] Massachusetts Gen Hosp, Dept Phys Therapy, Boston, MA 02114 USA.
[Jammallo, Lauren S.; Miller, Cynthia L.; Skolny, Melissa N.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Specht, Michelle C.] Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA.
RP Taghian, AG (reprint author), Massachusetts Gen Hosp, 100 Blossom St, Boston, MA 02114 USA.
EM ataghian@partners.org
NR 18
TC 4
Z9 4
U1 1
U2 6
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD APR
PY 2013
VL 18
IS 4
BP 350
EP 352
DI 10.1634/theoncologist.2012-0387
PG 3
WC Oncology
SC Oncology
GA 136CB
UT WOS:000318336200007
PM 23576481
ER
PT J
AU Ruddy, KJ
Meyer, ME
Giobbie-Hurder, A
Emmons, KM
Weeks, JC
Winer, EP
Partridge, AH
AF Ruddy, Kathryn J.
Meyer, Meghan E.
Giobbie-Hurder, Anita
Emmons, Karen M.
Weeks, Jane C.
Winer, Eric P.
Partridge, Ann H.
TI Long-Term Risk Perceptions of Women With Ductal Carcinoma In Situ
SO ONCOLOGIST
LA English
DT Article
DE Carcinoma; Intraductal; Noninfiltrating; Survivors; Anticipation;
Psychological; Anxiety
ID INTRADUCTAL BREAST-CANCER; SURGICAL ADJUVANT BREAST; TRIAL; TAMOXIFEN;
DIAGNOSIS; THERAPY; DCIS
AB Introduction. Previous research has demonstrated that many women with ductal carcinoma in situ (DCIS) overestimate their risk for future breast cancer at the time of diagnosis and soon thereafter. This study aims to evaluate risk perceptions after 5 years.
Patients and Methods. In a longitudinal cohort study, we mailed long-term follow-up surveys to 315 women who had previously responded to a survey 18 months after they were diagnosed with DCIS, excluding those who had experienced recurrence and those not treated at our institution. We evaluated risk perceptions with items used previously in the cohort.
Results. One hundred ninety-three women (61%) responded. The median time since diagnosis was 5.9 years. We excluded 12 because of recurrence. Of the 181 remaining, 32% perceived at least a moderate 5-year risk for developing DCIS again, 43% perceived at least a moderate lifetime risk for developing DCIS again, 27% perceived at least a moderate 5-year risk for invasive breast cancer, 38% perceived at least a moderate lifetime risk for invasive breast cancer, and 24% perceived at least a moderate risk for DCIS spreading to other body parts. In a multivariate model, worse financial status and higher perceived risk in the previous survey were the only predictors of at least a moderate perception of risk for DCIS spreading.
Conclusion. Women with a history of DCIS continue to harbor in accurate perceptions of their risk for future breast cancer events even 5 years after diagnosis. The Oncologist 2013;18:362-368
C1 [Ruddy, Kathryn J.; Meyer, Meghan E.; Weeks, Jane C.; Winer, Eric P.; Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Giobbie-Hurder, Anita] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Emmons, Karen M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
RP Ruddy, KJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM kruddy@partners.org
FU Dana-Farber/Harvard Cancer Center Specialized Program of Research
Excellence in Breast Cancer [5P50CA89393-03]
FX Funding was provided by the Dana-Farber/Harvard Cancer Center
Specialized Program of Research Excellence in Breast Cancer
(5P50CA89393-03). The principal investigator for this grant was James D.
Iglehart, M.D. However, the National Cancer Institute was not involved
in the study design; collection, analysis, or interpretation of the
data; manuscript preparation; or the decision to submit the manuscript
for publication. No one other than the authors of the study contributed
to the writing of this manuscript.
NR 19
TC 3
Z9 3
U1 0
U2 3
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD APR
PY 2013
VL 18
IS 4
BP 362
EP 368
DI 10.1634/theoncologist.2012-0376
PG 7
WC Oncology
SC Oncology
GA 136CB
UT WOS:000318336200009
PM 23568001
ER
PT J
AU Wolpin, BM
Ng, K
Zhu, AX
Abrams, T
Enzinger, PC
McCleary, NJ
Schrag, D
Kwak, EL
Allen, JN
Bhargava, P
Chan, JA
Goessling, W
Blaszkowsky, LS
Supko, JG
Elliot, M
Sato, K
Regan, E
Meyerhardt, JA
Fuchs, CS
AF Wolpin, Brian M.
Ng, Kimmie
Zhu, Andrew X.
Abrams, Thomas
Enzinger, Peter C.
McCleary, Nadine J.
Schrag, Deborah
Kwak, Eunice L.
Allen, Jill N.
Bhargava, Pankaj
Chan, Jennifer A.
Goessling, Wolfram
Blaszkowsky, Lawrence S.
Supko, Jeffrey G.
Elliot, Meaghan
Sato, Kaori
Regan, Eileen
Meyerhardt, Jeffrey A.
Fuchs, Charles S.
TI Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001)
for Patients With Refractory, Metastatic Colorectal Cancer
SO ONCOLOGIST
LA English
DT Editorial Material
AB Background. Treatments that target the vascular endothelial growth factor (VEGF) pathway have efficacy in colorectal cancer. We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor).
Methods. The phase Ib study followed a 3 + 3 dose-escalation design with three dose levels. The primary objective in the follow-on phase II study was improvement in 2-month progression-free survival (PFS) from 30% (historical benchmark) to 50% in patients with refractory, metastatic colorectal cancer.
Results. Dose-limiting toxicities in the phase Ib study were grade 3 fatigue and dehydration. Oral tivozanib (1 mg daily for 3 of 4 weeks) and oral everolimus (10 mg daily continuously) were advanced to a 40-patient phase II study. The most common grade 3-4 adverse events were thrombocytopenia and hypophosphatemia. The 2-month PFS rate was 50%, with 20 of 40 patients having stable disease (SD). Seven (18%) patients were treated for >= 6 months. Median PFS and overall survival (OS) times were 3.0 months (95% confidence interval [CI]: 1.9-3.6 months) and 5.6 months (95% CI: 4.4-10.6 months), respectively. Patients who developed grade 1+ hypertension had increased SD rates (65.2% vs. 29.4%) and longer OS times (10.6 vs. 3.7 months).
Conclusions. The oral combination of tivozanib and everolimus was well tolerated, with stable disease achieved in 50% of patients with refractory, metastatic colorectal cancer. The Oncologist 2013;18:377-378
C1 [Wolpin, Brian M.; Ng, Kimmie; Abrams, Thomas; Enzinger, Peter C.; McCleary, Nadine J.; Schrag, Deborah; Bhargava, Pankaj; Chan, Jennifer A.; Goessling, Wolfram; Elliot, Meaghan; Sato, Kaori; Regan, Eileen; Meyerhardt, Jeffrey A.; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Zhu, Andrew X.; Kwak, Eunice L.; Allen, Jill N.; Blaszkowsky, Lawrence S.; Supko, Jeffrey G.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.
[Bhargava, Pankaj] AVEO Pharmaceut, Cambridge, MA USA.
RP Wolpin, BM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM bwolpin@partners.org
OI Goessling, Wolfram/0000-0001-9972-1569
FU NCI NIH HHS [K07 CA140790, K07 CA148894]
NR 0
TC 17
Z9 19
U1 0
U2 2
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD APR
PY 2013
VL 18
IS 4
BP 377
EP 378
DI 10.1634/theoncologist.2012-0378
PG 2
WC Oncology
SC Oncology
GA 136CB
UT WOS:000318336200011
PM 23580238
ER
PT J
AU Zafar, SY
Peppercorn, JM
Schrag, D
Taylor, DH
Goetzinger, AM
Zhong, XY
Abernethy, AP
AF Zafar, S. Yousuf
Peppercorn, Jeffrey M.
Schrag, Deborah
Taylor, Donald H.
Goetzinger, Amy M.
Zhong, Xiaoyin
Abernethy, Amy P.
TI The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing
Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
SO ONCOLOGIST
LA English
DT Article
DE Neoplasms; Cost; Chemotherapy; Indigency; Medical; Quality of health
care; Financial support
ID BREAST-CANCER; CARE; HEALTH; COSTS; ADULTS; WOMEN
AB Purpose. Cancer patients carry rising burdens of health care-related out-of-pocket expenses, and a growing number of patients are considered "underinsured." Our objective was to describe experiences of insured cancer patients requesting copayment assistance and to describe the impact of health care expenses on well-being and treatment.
Methods. We conducted baseline and follow-up surveys regarding the impact of health care costs on well-being and treatment among cancer patients who contacted a national copayment assistance foundation along with a comparison sample of patients treated at an academic medical center.
Results. Among 254 participants, 75% applied for drug copayment assistance. Forty-two percent of participants reported a significant or catastrophic subjective financial burden; 68% cut back on leisure activities, 46% reduced spending on food and clothing, and 46% used savings to defray out-of-pocket expenses. To save money, 20% took less than the prescribed amount of medication, 19% partially filled prescriptions, and 24% avoided filling prescriptions altogether. Copayment assistance applicants were more likely than nonapplicants to employ at least one of these strategies to defray costs (98% vs. 78%). In an adjusted analysis, younger age, larger household size, applying for copayment assistance, and communicating with physicians about costs were associated with greater subjective financial burden.
Conclusion. Insured patients undergoing cancer treatment and seeking copayment assistance experience considerable subjective financial burden, and they may alter their care to defray out-of-pocket expenses. Health insurance does not eliminate financial distress or health disparities among cancer patients. Future research should investigate coverage thresholds that minimize adverse financial outcomes and identify cancer patients at greatest risk for financial toxicity. The Oncologist 2013;18:381-390
C1 [Zafar, S. Yousuf; Peppercorn, Jeffrey M.; Zhong, Xiaoyin; Abernethy, Amy P.] Ctr Learning Hlth Care, Duke Clin Res Inst, Div Med Oncol, Durham, NC USA.
[Zafar, S. Yousuf; Peppercorn, Jeffrey M.; Zhong, Xiaoyin; Abernethy, Amy P.] Duke Canc Inst, Dept Med, Durham, NC 27710 USA.
[Schrag, Deborah] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Taylor, Donald H.] Duke Univ, Sanford Sch Publ Policy, Durham, NC USA.
[Goetzinger, Amy M.] Univ N Carolina, Chapel Hill, NC USA.
RP Zafar, SY (reprint author), Duke Canc Inst, Dept Med, Div Med Oncol, DUMC 3505,10 Byran Searle Dr,Seeley Mudd Bld,Room, Durham, NC 27710 USA.
EM yousuf.zafar@duke.edu
FU HealthWell Foundation
FX This study was funded by the HealthWell Foundation.
NR 23
TC 138
Z9 139
U1 5
U2 20
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD APR
PY 2013
VL 18
IS 4
BP 381
EP 390
DI 10.1634/theoncologist.2012-0279
PG 10
WC Oncology
SC Oncology
GA 136CB
UT WOS:000318336200013
PM 23442307
ER
PT J
AU Rosenberg, TL
Kelley, K
Dowdall, JR
Replogle, WH
Liu, JC
Raol, NP
Zafereo, ME
AF Rosenberg, Tara L.
Kelley, Kanwar
Dowdall, Jayme R.
Replogle, William H.
Liu, Jeffrey C.
Raol, Nikhila P.
Zafereo, Mark E.
TI Section for Residents and Fellows-in-Training Survey Results
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article; Proceedings Paper
CT AAO-HNSF Annual Meeting and OTO EXPO
CY SEP 09-12, 2012
CL Washington, DC
SP AAO, HNSF, Off Res & Dev, Vet Hlth Adm, Dept Vet Affairs, MED-EL, Agcy Healthcare Res & Qual, Sect Residents & Fellows Training
DE otolaryngology residents; section for residents and fellows; survey
ID OTOLARYNGOLOGY-HEAD; NECK-SURGERY; WORKFORCE; ISSUES
AB Objectives. (1) To present data from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Section for Residents and Fellows-in-Training (SRF) annual survey from 2002 to 2011. (2) To compare and analyze trends in resident demographics, residency experiences, and post-training career choices.
Study Design. Review of cross-sectional survey data.
Setting. Residents and Fellows registered as Members-in-Training through AAO-HNS.
Methods. A review of data from surveys distributed between 2002 and 2011 was conducted. Respondent demographic data including age, postgraduate year, gender, and geographic distribution were analyzed. Responses about training experiences, fellowship selection, debt burden, and post-training practice choice were studied in order to elicit trends.
Results. Respondents have consistently rated otolaryngology, anesthesia, and trauma/critical care as the most important intern rotations for otolaryngology residents. Each year, approximately 70% of respondents have reported interest in pursuing a fellowship. Pediatric otolaryngology fellowship is now the most popular fellowship among respondents. There has been a recent increase in the percentage of respondents who are interested in pursuing a career in academics. Location, family, and lifestyle have consistently been the most important factors in determining choice of practice. Respondents have reported increasing levels of educational debt.
Conclusion. The AAO-HNS SRF survey collects important data regarding resident/fellow training. Several factors limit the generalizability of these results. Despite its limitations, these unique data provide valuable information for continual evaluation and improvement of physician training in the specialty.
C1 [Rosenberg, Tara L.] Univ Mississippi, Med Ctr, Dept Otolaryngol & Communicat Sci, Jackson, MS 39216 USA.
[Kelley, Kanwar] Univ Calif Irvine, Dept Otolaryngol Head & Neck Surg, Irvine, CA USA.
[Dowdall, Jayme R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
[Replogle, William H.] Univ Mississippi, Med Ctr, Dept Family Med, Jackson, MS 39216 USA.
[Liu, Jeffrey C.] Temple Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19122 USA.
[Raol, Nikhila P.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.
[Zafereo, Mark E.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
RP Rosenberg, TL (reprint author), Univ Mississippi, Med Ctr, Dept Otolaryngol & Communicat Sci, 2500 North State St, Jackson, MS 39216 USA.
EM trosenberg@umc.edu
NR 10
TC 6
Z9 6
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD APR
PY 2013
VL 148
IS 4
BP 582
EP 588
DI 10.1177/0194599813477353
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 136LG
UT WOS:000318362800010
PM 23396591
ER
PT J
AU Hill, CA
Ojha, S
Maturo, S
Maurer, R
Bunting, G
Hartnick, CJ
AF Hill, Courtney A.
Ojha, Shilpa
Maturo, Stephen
Maurer, Rie
Bunting, Glenn
Hartnick, Christopher J.
TI Consistency of Voice Frequency and Perturbation Measures in Children
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE pediatric; voice
ID SPEECH
AB Objective. Evaluate normal pediatric voice frequency and perturbation measures with Voice Evaluation Suite (VES) and Multi Dimensional Voice Program (MDVP), determine the consistency of these measures over time, and understand which measures might be most useful for evaluating children with voice disorders.
Study Design. Prospective, longitudinal study of normal voices of 50 children aged 4 to 17 years.
Setting. Pediatric otolaryngology clinic within tertiary hospital.
Subjects and Methods. Two tests of sustained utterances from each child were evaluated by 2 computerized voice analysis programs for frequency and perturbation. Intraclass correlation coefficient (ICC) was used to assess the reliability between the samples.
Results. Children (male/female, 1.08:1) with a mean age of 8.34 years were tested on an average of 54.2 minutes apart. Each test included 4 utterances; 1 was analyzed by MDVP, and 3 grouped utterances were averaged and evaluated by VES. Fundamental frequency had excellent reliability (ICC = 0.95) in both VES and MDVP. Jitter, shimmer, and noise to harmonic ratio were poorly reliable (ICC <= 0.4) in MDVP but had good to excellent reliability (ICC 0.66-0.8) in VES.
Conclusion. Single, sustained utterances in children provide consistent measures of frequency. Perturbation is not reliably measured by such testing, but averaging multiple samples yields improved consistency. Evaluating acoustic measure stability in spontaneous speech and in sustained utterances cued by a tuning frequency can provide further insight on pediatric voice consistency.
C1 [Hill, Courtney A.] Dartmouth Hitchcock Med Ctr, Otolaryngol Sect, Lebanon, NH 03766 USA.
[Ojha, Shilpa; Hartnick, Christopher J.] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Maturo, Stephen] San Antonio Mil Med Ctr, Dept Otolaryngol, Ft Sam Houston, TX USA.
[Maurer, Rie] Brigham & Womens Hosp, Ctr Clin Invest, Boston, MA 02115 USA.
[Maurer, Rie] Harvard Clin & Translat Sci Ctr, Harvard Catalyst, Boston, MA USA.
[Bunting, Glenn] Massachusetts Eye & Ear Infirm, Voice & Speech Lab, Boston, MA 02114 USA.
RP Hartnick, CJ (reprint author), Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM Christopher_Hartnick@meei.harvard.edu
NR 14
TC 6
Z9 7
U1 2
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD APR
PY 2013
VL 148
IS 4
BP 637
EP 641
DI 10.1177/0194599813477829
PG 5
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 136LG
UT WOS:000318362800018
PM 23396592
ER
PT J
AU Slater, LH
Hett, EC
Mark, K
Chumbler, NM
Patel, D
Lacy, DB
Collier, RJ
Hung, DT
AF Slater, Louise H.
Hett, Erik C.
Mark, Kevin
Chumbler, Nicole M.
Patel, Deepa
Lacy, D. Borden
Collier, R. John
Hung, Deborah T.
TI Identification of Novel Host-Targeted Compounds That Protect from
Anthrax Lethal Toxin-Induced Cell Death
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID IN-VIVO; BACILLUS-ANTHRACIS; DEPENDENT PROCESS; BCL-2 INHIBITORS;
MAMMALIAN-CELLS; TYROSINE KINASE; SMALL MOLECULES; CANCER-CELLS; EDEMA
FACTOR; N-TERMINUS
AB Studying how pathogens subvert the host to cause disease has contributed to the understanding of fundamental cell biology. Bacillus anthracis, the causative agent of anthrax, produces the virulence factor lethal toxin to disarm host immunity and cause pathology. We conducted a phenotypic small molecule screen to identify inhibitors of lethal toxin-induced macrophage cell death and used an ordered series of secondary assays to characterize the hits and determine their effects on cellular function. We identified a structurally diverse set of small molecules that act at various points along the lethal toxin pathway, including inhibitors of endocytosis, natural product inhibitors of organelle acidification (e.g., the botulinum neurotoxin inhibitor, toosendanin), and a novel proteasome inhibitor, 4MNB (4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene). Many of the compounds, including three drugs approved for use in humans, also protected against the related Clostridium difficile toxin TcdB, further demonstrating their value as novel tools for perturbation and study of toxin biology and host cellular processes and highlighting potential new strategies for intervening on toxin-mediated diseases.
C1 [Slater, Louise H.; Hett, Erik C.; Mark, Kevin; Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Slater, Louise H.; Hett, Erik C.; Mark, Kevin; Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Slater, Louise H.; Hett, Erik C.; Mark, Kevin; Hung, Deborah T.] Broad Inst, Infect Dis Initiat, Cambridge, MA 02142 USA.
[Slater, Louise H.; Hett, Erik C.; Mark, Kevin; Patel, Deepa; Collier, R. John; Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
[Chumbler, Nicole M.; Lacy, D. Borden] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
RP Hung, DT (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM hung@molbio.mgh.harvard.edu
OI Collier, R John/0000-0002-2427-4239
FU NIH National Research Service Award fellowship [F32AI084323]; NIH [U54
AI057159]
FX The authors would like to thank A. Barker for help with production and
purification of PA and LF, A. Clatworthy and S. Chiang for helpful
discussions, and the Broad Institute chemical screening platform for
technical help. E.C.H. was funded by an NIH National Research Service
Award fellowship F32AI084323. This work was supported in part by NIH U54
AI057159 to the New England Center of Excellence/Biodefense and Emerging
Infectious Diseases (D.T.H.).
NR 77
TC 8
Z9 8
U1 1
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD APR
PY 2013
VL 8
IS 4
BP 812
EP 822
DI 10.1021/cb300555n
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 131NY
UT WOS:000318001600020
PM 23343607
ER
PT J
AU Sengupta, S
Kulkarni, A
AF Sengupta, Shiladitya
Kulkarni, Ashish
TI Design Principles for Clinical Efficacy of Cancer Nanomedicine: A Look
into the Basics
SO ACS NANO
LA English
DT Editorial Material
ID NANOPARTICLES; CHALLENGES; DELIVERY; DENSITY; DRUGS; PEG
AB With recent advances in cancer nanomedicine, there is an increasing expectation for clinical translation. However, what are the parameters of a nanomedicine that will define clinical success, which will be measured by increased efficacy and not just ease of delivery or reduction in toxicity? In this Perspective, we build on a fundamental study by Stefanick et al. on the significance of the design principles in the engineering of a nanomedicine, such as peptide-PEG-linker length and ligand density in cellular uptake of liposomal nanoparticles. We address additional design parameters that can potentially facilitate clinical translation as well as how emerging insights into tumor biology will inspire next-generation cancer nanomedicines.
C1 [Sengupta, Shiladitya; Kulkarni, Ashish] Harvard Univ, Sch Med,Lab Nanomed, Dana Farber Canc Ctr,Dept Med,Brigham & Womens Ho, Harvard MIT Div Hlth Sci Technol,Div Biomed Engn, Boston, MA 02139 USA.
RP Sengupta, S (reprint author), Harvard Univ, Sch Med,Lab Nanomed, Dana Farber Canc Ctr,Dept Med,Brigham & Womens Ho, Harvard MIT Div Hlth Sci Technol,Div Biomed Engn, 65 Landsdowne St,Room 317, Boston, MA 02139 USA.
EM shiladit@mit.edu
FU NCI NIH HHS [1R01CA135242-01A2, R01 CA135242]
NR 20
TC 29
Z9 30
U1 0
U2 59
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD APR
PY 2013
VL 7
IS 4
BP 2878
EP 2882
DI 10.1021/nn4015399
PG 5
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 133MU
UT WOS:000318143300002
PM 23607425
ER
PT J
AU Coopey, S
Tang, R
Lei, L
Kansal, K
Colwell, A
Gadd, M
Specht, M
Austen, W
Smith, B
AF Coopey, Suzanne
Tang, Rong
Lei, Lan
Kansal, Kari
Colwell, Amy
Gadd, Michele
Specht, Michelle
Austen, William
Smith, Barbara
TI Eligibility for Nipple-Sparing Mastectomy May Be Safely Expanded
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 01-05, 2013
CL Chicago, IL
SP Amer Soc Breast Surg
C1 [Coopey, Suzanne; Tang, Rong; Lei, Lan; Kansal, Kari; Colwell, Amy; Gadd, Michele; Specht, Michelle; Austen, William; Smith, Barbara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
SU 2
BP 5
EP 6
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XS
UT WOS:000318174800006
ER
PT J
AU Dominici, L
Shulman, L
Ahn, SH
Camp, M
Cho, JY
Coopey, S
Kim, SB
Caragacianu, D
Valero, M
Barkley, C
Wang, JP
Gong, GY
Hevelone, N
Baek, S
Son, BH
Golshan, M
AF Dominici, Laura
Shulman, Lawrence
Ahn, Sei Hyun
Camp, Melissa
Cho, Ja Young
Coopey, Suzanne
Kim, Sung Bae
Caragacianu, Diana
Valero, Monica
Barkley, Christina
Wang, Jiping
Gong, Gyung-yub
Hevelone, Nathanael
Baek, Seunghee
Son, Byung Ho
Golshan, Mehra
TI Young Women With Breast Cancer in Boston and Seoul: Comparison of
Demographics, Pathology, and Management
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 01-05, 2013
CL Chicago, IL
SP Amer Soc Breast Surg
C1 [Dominici, Laura; Shulman, Lawrence; Caragacianu, Diana; Valero, Monica; Barkley, Christina; Wang, Jiping; Hevelone, Nathanael; Golshan, Mehra] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Camp, Melissa; Coopey, Suzanne] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ahn, Sei Hyun; Cho, Ja Young; Kim, Sung Bae; Gong, Gyung-yub; Baek, Seunghee; Son, Byung Ho] Asan Med Ctr, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
SU 2
BP 37
EP 37
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XS
UT WOS:000318174800047
ER
PT J
AU Kansal, KJ
Tang, R
Lei, L
Coopey, SB
Colwell, AS
Specht, MC
Gadd, MA
Taghian, A
Austen, WG
Smith, BL
AF Kansal, Kari J.
Tang, Rong
Lei, Lan
Coopey, Suzanne B.
Colwell, Amy S.
Specht, Michelle C.
Gadd, Michele A.
Taghian, Alphonse
Austen, William G., Jr.
Smith, Barbara L.
TI Impact of Postmastectomy Radiation Therapy after Nipple-Sparing
Mastectomy With Immediate Reconstruction
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 01-05, 2013
CL Chicago, IL
SP Amer Soc Breast Surg
C1 [Kansal, Kari J.; Tang, Rong; Lei, Lan; Coopey, Suzanne B.; Colwell, Amy S.; Specht, Michelle C.; Gadd, Michele A.; Taghian, Alphonse; Austen, William G., Jr.; Smith, Barbara L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
SU 2
BP 62
EP 62
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XS
UT WOS:000318174800083
ER
PT J
AU Schubart, J
Dominici, L
Farnan, M
Kelly, T
Manahan, E
Rahman, R
Smith, JS
Kass, R
AF Schubart, Jane
Dominici, Laura
Farnan, Michelle
Kelly, Tricia
Manahan, Eric
Rahman, Rakhshanda
Smith, J. Stanley
Kass, Rena
TI Shared Decision Making in Breast Cancer: National Practice Patterns of
Surgeons
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 01-05, 2013
CL Chicago, IL
SP Amer Soc Breast Surg
C1 [Schubart, Jane; Farnan, Michelle; Smith, J. Stanley; Kass, Rena] Penn State Coll Med, Hershey, PA USA.
[Dominici, Laura] Brigham & Womens Canc Ctr, Dana Farber, Boston, MA USA.
[Kelly, Tricia] St Lukes Univ Hlth Network, Allentown, PA USA.
[Manahan, Eric] Dalton Surg Grp, Dalton, GA USA.
[Rahman, Rakhshanda] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
SU 2
BP 64
EP 65
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XS
UT WOS:000318174800085
ER
PT J
AU Miller, C
Koerner, F
West, J
Freer, P
Gudewicz, T
Coopey, S
Gadd, M
Hughes, K
Smith, B
Rafferty, E
Specht, M
AF Miller, Cynthia
Koerner, Frederick
West, Jane
Freer, Phoebe
Gudewicz, Thomas
Coopey, Suzanne
Gadd, Michele
Hughes, Kevin
Smith, Barbara
Rafferty, Elizabeth
Specht, Michelle
TI Upgrade Rate of Radial Scars Without Atypia Diagnosed by Core Biopsy
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 01-05, 2013
CL Chicago, IL
SP Amer Soc Breast Surg
C1 [Miller, Cynthia; Koerner, Frederick; West, Jane; Freer, Phoebe; Gudewicz, Thomas; Coopey, Suzanne; Gadd, Michele; Hughes, Kevin; Smith, Barbara; Rafferty, Elizabeth; Specht, Michelle] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
SU 2
BP 82
EP 83
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XS
UT WOS:000318174800108
ER
PT J
AU Tang, R
Saksena, M
Coopey, S
Fernandez, L
Buckley, J
Lei, L
Aftreth, O
Koerner, F
Michaelson, J
Brachtel, E
Smith, B
AF Tang, Rong
Saksena, Mansi
Coopey, Suzanne
Fernandez, Leopoldo
Buckley, Julliette
Lei, Lan
Aftreth, Owen
Koerner, Frederick
Michaelson, James
Brachtel, Elena
Smith, Barbara
TI Microcomputed Tomography vs Mammography and Ultrasonography for
Assessment of Breast Cancer Tumor Size
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the American-Society-of-Breast-Surgeons
CY MAY 01-05, 2013
CL Chicago, IL
SP Amer Soc Breast Surg
C1 [Tang, Rong; Saksena, Mansi; Coopey, Suzanne; Fernandez, Leopoldo; Buckley, Julliette; Lei, Lan; Aftreth, Owen; Koerner, Frederick; Michaelson, James; Brachtel, Elena; Smith, Barbara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tang, Rong] Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
SU 2
BP 111
EP 112
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XS
UT WOS:000318174800143
ER
PT J
AU Jackevicius, CA
Tu, JV
Krumholz, HM
AF Jackevicius, Cynthia A.
Tu, Jack V.
Krumholz, Harlan M.
TI Statins: Is It Safe and Effective to Use Generic "Equivalents"?
SO CANADIAN JOURNAL OF CARDIOLOGY
LA English
DT Editorial Material
ID CARDIOVASCULAR-DISEASE; DRUGS; ATORVASTATIN; METAANALYSIS; PERCEPTIONS;
EFFICACY; ADULTS; RISK
C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA.
[Jackevicius, Cynthia A.; Tu, Jack V.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Jackevicius, Cynthia A.; Tu, Jack V.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada.
[Tu, Jack V.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Cardiol, Schulich Heart Ctr, Toronto, ON, Canada.
[Krumholz, Harlan M.] Sect Cardiovasc Med, Dept Med, New Haven, CT USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
[Krumholz, Harlan M.] Sect Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, New Haven, CT USA.
[Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA.
RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA.
EM cjackevicius@westernu.edu
OI Tu, Jack/0000-0003-0111-722X
NR 17
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0828-282X
J9 CAN J CARDIOL
JI Can. J. Cardiol.
PD APR
PY 2013
VL 29
IS 4
BP 408
EP 410
DI 10.1016/j.cjca.2012.08.012
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 133UQ
UT WOS:000318166500002
PM 23062664
ER
PT J
AU Camp, ER
Wang, C
Little, EC
Watson, PM
Pirollo, KF
Rait, A
Cole, DJ
Chang, EH
Watson, DK
AF Camp, E. R.
Wang, C.
Little, E. C.
Watson, P. M.
Pirollo, K. F.
Rait, A.
Cole, D. J.
Chang, E. H.
Watson, D. K.
TI Transferrin receptor targeting nanomedicine delivering wild-type p53
gene sensitizes pancreatic cancer to gemcitabine therapy
SO CANCER GENE THERAPY
LA English
DT Article
DE pancreatic cancer; transferrin; p53; nanoparticle
ID SINGLE-INSTITUTION EXPERIENCE; CELLS IN-VITRO; 1423
PANCREATICODUODENECTOMIES; NANODELIVERY SYSTEM; INTERFERING RNA;
CARCINOMA; IMMUNOLIPOPLEX; RESTORATION; XENOGRAFTS; EFFICACY
AB To overcome gene therapy barriers such as low transfection efficiency and nonspecific delivery, liposomal nanoparticles targeted by a single-chain antibody fragment to the transferrin receptor (TfRscFv) delivering wild-type (wt) human p53 (SGT-53) were developed for tumor-specific targeting. We hypothesize that SGT-53 in combination with gemcitabine will demonstrate enhanced therapeutic benefit in an in vivo metastatic pancreatic cancer model. Intrasplenic injection of 1 x 10(6) Panc02 murine pancreatic cancer cells was used to generate in vivo hepatic metastatic tumors. Nanoparticle localization was assessed by tail vein injection of TfRscFv with fluorescently labeled oligonucleotides (6-carboxyfluorescein phosphoramidite (6FAM) ODN) imaged by Xenogen IVIS 200 scan. SGT-53 (equivalent to 30 mu g of p53 intravenously) and gemcitabine (20 mg/kg intraperitoneally) alone and in combination were administered biweekly and compared with untreated mice. Survival was determined by blinded daily assessment of morbidity. Human wtp53 expression and transferrin levels in the tumors were assessed by western blot analysis. Tumor burden was quantified by liver weight. Xenogen imaging demonstrated tumor-specific uptake of TfRscFv-6FAM ODN. Exogenous human wtp53 protein was detected in the SGT-53-treated tumors compared with control. Compared with untreated mice with metastatic tumors demonstrating median survival of 20 days, SGT-53, gemcitabine and the combination demonstrated improved median survival of 29, 30 and 37 days, respectively. The combination treatment prolonged median survival when compared with single drug treatment and decreased tumor burden. The tumor targeting liposomal-based SGT-53 nanoparticle is capable of sensitizing pancreatic cancer to conventional chemotherapy in pancreatic cancer models. This approach has the potential to be translated into a new, more effective therapy for pancreatic cancer. Further optimization is ongoing, moving towards a Phase 1B/2 clinical trial. Cancer Gene Therapy (2013) 20, 222-228; doi:10.1038/cgt.2013.9; published online 8 March 2013
C1 [Camp, E. R.; Wang, C.; Cole, D. J.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Camp, E. R.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Little, E. C.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Watson, P. M.; Watson, D. K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Pirollo, K. F.; Rait, A.; Chang, E. H.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA.
[Watson, D. K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, 25 Courtenay Dr,Room 7018,MSC795, Charleston, SC 29425 USA.
EM campe@musc.edu
FU Hollings Cancer Center, Medical University of South Carolina [P30
CA138313]; National Institutes of Health [5R01CA123159-05, 1K08CA142904]
FX This work was supported in part by the Flow Cytometry and Cell Sorting
and Molecular imaging Shared Resource, Hollings Cancer Center, Medical
University of South Carolina (P30 CA138313) and National Institutes of
Health, 5R01CA123159-05 (DJC, DKW) and 1K08CA142904 (ERC).
NR 30
TC 39
Z9 39
U1 2
U2 34
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD APR
PY 2013
VL 20
IS 4
BP 222
EP 228
DI 10.1038/cgt.2013.9
PG 7
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
Research & Experimental Medicine
GA 131OT
UT WOS:000318003700002
PM 23470564
ER
PT J
AU Brennan-Minnella, AM
Shen, Y
Swanson, RA
AF Brennan-Minnella, A. M.
Shen, Y.
Swanson, R. A.
TI Phosphoinositide 3-kinase couples NMDA receptors to superoxide release
in excitotoxic neuronal death
SO CELL DEATH & DISEASE
LA English
DT Article
DE Calcium; glutamate; NADPH oxidase; protein kinase C zeta; protein kinase
M
ID PROTEIN-KINASE-C; D-ASPARTATE RECEPTOR; CEREBELLAR GRANULE CELLS; RAT
HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; NITRIC-OXIDE; GLUTAMATE
NEUROTOXICITY; NADPH-OXIDASE; OXIDATIVE STRESS; NR2B SUBUNIT
AB Sustained activation of neuronal N-methly D-aspartate (NMDA)-type glutamate receptors leads to excitotoxic cell death in stroke, trauma, and neurodegenerative disorders. Excitotoxic neuronal death results in part from superoxide produced by neuronal NADPH oxidase (NOX2), but how NMDA receptors are coupled to neuronal NOX2 activation is not well understood. Here, we identify a signaling pathway coupling NMDA receptor activation to NOX2 activation in primary neuron cultures. Calcium influx through the NR2B subunit of NMDA receptors leads to the activation of phosphoinositide 3-kinase (PI3K). Formation of phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3) by PI3K activates the atypical protein kinase C, PKC zeta (PKC xi), which in turn phosphorylates the p47(phox) organizing subunit of neuronal NOX2. Calcium influx through NR2B-containing NMDA receptors triggered mitochondrial depolarization, NOX2 activation, superoxide formation, and cell death. However, equivalent magnitude calcium elevations induced by ionomycin did not induce NOX2 activation or neuronal death, despite causing mitochondrial depolarization. The PI3K inhibitor wortmannin prevented NMDA-induced NOX2 activation and cell death, without preventing cell swelling, calcium elevation, or mitochondrial depolarization. The effects of wortmannin were circumvented by exogenous supply of the PI3K product, PI(3,4,5)P3, and by transfection with protein kinase M, a constitutively active form of PKC xi. These findings demonstrate that superoxide formation and excitotoxic neuronal death can be dissociated from mitochondrial depolarization, and identify a novel role for PI3K in this cell death pathway. Perturbations in this pathway may either increase or decrease superoxide production in response to NMDA receptor activation, and may thereby impact neurological disorders, in which excitotoxicity is a contributing factor. Cell Death and Disease (2013) 4, e580; doi:10.1038/cddis.2013.111; published online 4 April 2013
C1 [Brennan-Minnella, A. M.; Shen, Y.; Swanson, R. A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA.
RP Brennan-Minnella, AM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.
EM angela.brennan@ucsf.edu
FU US National Institutes of Health [NS041421]; US Department of Veterans
Affairs
FX We thank J-Y Ahn, SM Massa, and S Finkbeiner for helpful discussions and
C Hefner for technical assistance. This work was supported by funding
from the US National Institutes of Health (NS041421) and by the US
Department of Veterans Affairs. AMB-M designed and performed most of the
experiments and prepared the initial manuscript. RAS conceived the
project and prepared the final manuscript. The authors declare no
competing financial interests.
NR 60
TC 22
Z9 22
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR
PY 2013
VL 4
AR e580
DI 10.1038/cddis.2013.111
PG 10
WC Cell Biology
SC Cell Biology
GA 132NL
UT WOS:000318075500014
PM 23559014
ER
PT J
AU Brim, RL
Pearson, SD
AF Brim, Remy L.
Pearson, Steven D.
TI The use and reporting of patient-reported outcomes in phase III breast
cancer trials
SO CLINICAL TRIALS
LA English
DT Article
ID QUALITY-OF-LIFE; RANDOMIZED CLINICAL-TRIALS; CLINICALTRIALS.GOV;
REGISTRATION; ONCOLOGY; ISSUES; STOCK
AB Background Public and government attention to patient-centered research outcomes has been increasing, evidenced by the recent formation of the Patient Centered Outcomes Research Institute. Drug development clinical trials can be made more patient-centered by collecting patient-reported outcome measures that can inform decision making by patients and their health-care providers. Patient-reported outcomes are important to collect in trials of breast cancer therapeutics, which encompass a wide range of treatment regimens and side effects.
Purpose We sought to determine recent trends in the use of patient-reported outcomes in drug trials for the treatment of breast cancer and evaluate the reporting of these data in study publications.
Methods We searched ClinicalTrials.gov for phase Ill breast cancer drug trials, recording information on start date, primary completion date, primary outcome measure, primary sponsor, stage of cancer, and patient-reported outcome use. To assess the reporting of patient-reported outcome data, Google.com and PubMed. gov were searched for all publications resulting from included trials.
Results We found 236 eligible trials, starting between May 1989 and December 2011. Of these trials, 83 (35%) stipulated patient-reported outcome use. The rate of patient-reported outcome use in recent years has shown no increase over earlier time periods: 37% (1989-2000) versus 36% (2004-2007) versus 30% (2008-2011) (p = 0.8). Trials with sponsorship led by the pharmaceutical industry and trials including patients with locally advanced or metastatic disease had the highest rates of patient-reported outcome use (40/87 (46%) and 44/102 (43%), respectively). Among the 83 trials that collected patient-reported outcome measures, 36 were completed a minimum of 2 years before our analysis; of these 36 studies, 19 (53%) had published patient-reported outcome data.
Limitations Data were limited to self-reported descriptions of trials listed on the ClinicalTrial.gov database, which is the best compendium of trial information available, but it is neither a complete nor a fully accurate record of all trials.
Conclusions Patient-reported outcome use and reporting in breast cancer drug trials has remained relatively low despite calls for more patient-centered research. Increasing the collection and availability of patient-reported outcome data to guide clinical decisions will require aligned support from trial sponsors, researchers, journal editors, regulators and patient advocacy groups, who can all play important roles in implementing change. Clinical Trials 2013; 10: 243-249. http://ctj.sagepub.com
C1 [Brim, Remy L.; Pearson, Steven D.] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA.
[Pearson, Steven D.] Massachusetts Gen Hosp, Inst Technol Assessment, Inst Clin & Econ Review, Boston, MA 02114 USA.
RP Brim, RL (reprint author), NIH, Dept Bioeth, 10 Ctr Dr,Bldg 10,Rm 1C118, Bethesda, MD 20892 USA.
EM remy.brim@nih.gov
FU Intramural Research Program of the National Institutes of Health
Clinical Center
FX This research was supported by the Intramural Research Program of the
National Institutes of Health Clinical Center.
NR 32
TC 6
Z9 6
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
J9 CLIN TRIALS
JI Clin. Trials
PD APR
PY 2013
VL 10
IS 2
BP 243
EP 249
DI 10.1177/1740774513475529
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 135CJ
UT WOS:000318263300006
PM 23539108
ER
PT J
AU Gmyrek, GB
Graham, DB
Sandoval, GJ
Blaufuss, GS
Akilesh, HM
Fujikawa, K
Xavier, RJ
Swat, W
AF Gmyrek, Grzegorz B.
Graham, Daniel B.
Sandoval, Gabriel J.
Blaufuss, Gregory S.
Akilesh, Holly M.
Fujikawa, Keiko
Xavier, Ramnik J.
Swat, Wojciech
TI Polarity gene discs large homolog 1 regulates the generation of memory T
cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Cell polarity; Discs large protein; Memory T cell; Ovalbumin; Transgenic
T cells
ID PDZ-CONTAINING PROTEINS; TRANSGENIC MICE; IMMUNOLOGICAL SYNAPSE;
POSITIVE SELECTION; POTASSIUM CHANNEL; CUTTING EDGE; IN-VIVO; RECEPTOR;
ACTIVATION; EFFECTOR
AB Mammalian ortholog of Drosophila cell polarity protein, Dlg1, plays a critical role in neural synapse formation, epithelial cell homeostasis, and urogenital development. More recently, it has been proposed that Dlg1 may also be involved in the regulation of T-cell proliferation, migration, and Ag-receptor signaling. However, a requirement for Dlg1 in development and function of T lineage cells remains to be established. In this study, we investigated a role for Dlg1 during T-cell development and function using a combination of conditional Dlg1 KO and two different Cre expression systems where Dlg1 deficiency is restricted to the T-cell lineage only, or all hematopoietic cells. Here, using three different TCR models, we show that Dlg1 is not required during development and selection of thymocytes bearing functionally rearranged TCR transgenes. Moreover, Dlg1 is dispensable in the activation and proliferative expansion of Ag-specific TCR-transgenic CD4+ and CD8+ T cells in vitro and in vivo. Surprisingly, however, we show that Dlg1 is required for normal generation of memory T cells during endogenous response to cognate Ag. Thus, Dlg1 is not required for the thymocyte selection or the activation of primary T cells, however it is involved in the generation of memory T cells.
C1 [Gmyrek, Grzegorz B.; Graham, Daniel B.; Sandoval, Gabriel J.; Blaufuss, Gregory S.; Akilesh, Holly M.; Swat, Wojciech] Washington Univ, Sch Med, Div Immunobiol, St Louis, MO 63110 USA.
[Fujikawa, Keiko] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan.
[Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Swat, Wojciech] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
RP Swat, W (reprint author), Washington Univ, Sch Med, Div Immunobiol Lab & Genom Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.
EM swat@wustl.edu
RI Gmyrek, Grzegorz/C-3175-2011
FU National Institutes of Health [R01AI061077, R01AI073718]; Leukemia &
Lymphoma Society Scholar; Special Fellow (D.B.G.) awards; NIH [DK043351,
HL088297]
FX This work was supported by National Institutes of Health grant nos.
R01AI061077 (to W.S.), R01AI073718 (to W.S.), and Leukemia & Lymphoma
Society Scholar (W.S.) and Special Fellow (D.B.G.) awards. R.J.X was
supported by NIH grants DK043351 and HL088297.
NR 46
TC 10
Z9 10
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD APR
PY 2013
VL 43
IS 5
BP 1185
EP 1194
DI 10.1002/eji.201142362
PG 10
WC Immunology
SC Immunology
GA 135GM
UT WOS:000318276500007
PM 23436244
ER
PT J
AU Cohen, J
Malins, A
Shahpurwala, Z
AF Cohen, Joshua
Malins, Ashley
Shahpurwala, Zainab
TI Compared To US Practice, Evidence-Based Reviews In Europe Appear To Lead
To Lower Prices For Some Drugs
SO HEALTH AFFAIRS
LA English
DT Article
ID UNITED-STATES; CANCER DRUGS; REIMBURSEMENT; ONCOLOGISTS; DECISIONS;
COUNTRIES; COVERAGE; KINGDOM; IMPACT; WORTH
AB In Europe drug reimbursement decisions often weigh how new drugs perform relative to those already on the market and how cost-effective they are relative to certain metrics. In the United States such comparative-effectiveness and cost-effectiveness evidence is rarely considered. Which approach allows patients greater access to drugs? In 2000-11 forty-one oncology drugs were approved for use in the United States and thirty-one were approved in Europe. We compared patients' access to the twenty-nine cancer drugs introduced into the health care systems of the United States and four European countries. Relative to the approach used in the US Medicare program in particular, the European evidence-based approach appears to have led to reduced prices for those drugs deemed worthy of approval and reimbursement. The result is improved affordability for payers and increased access for patients to those drugs that were available. The United States lacks a systematic approach to assessing such evidence in the coverage decision-making process, which may prove inadequate for controlling costs, improving outcomes, and reducing inequities in access to care.
C1 [Cohen, Joshua] Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USA.
[Malins, Ashley] Dana Farber Canc Inst, Dis Ctr Operat, Boston, MA 02115 USA.
[Shahpurwala, Zainab] Univ Mississippi, Dept Pharm Adm, University, MS 38677 USA.
RP Cohen, J (reprint author), Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USA.
EM Joshua.cohen@tufts.edu
FU Commonwealth Fund
FX The authors thank the Commonwealth Fund for its financial support of
this study. The views presented here are those of the authors and not
necessarily those of the Commonwealth Fund, its directors, officers, or
staff.
NR 42
TC 5
Z9 5
U1 1
U2 8
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD APR
PY 2013
VL 32
IS 4
BP 762
EP 770
DI 10.1377/hlthaff.2012.0707
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 131UU
UT WOS:000318023100017
PM 23569057
ER
PT J
AU Sepucha, KR
AF Sepucha, Karen R.
TI To Err Is Health Care? Breaking The Silence
SO HEALTH AFFAIRS
LA English
DT Book Review
C1 [Sepucha, Karen R.] Massachusetts Gen Hosp, Hlth Decis Sci Ctr, Div Gen Med, Boston, MA 02114 USA.
[Sepucha, Karen R.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sepucha, KR (reprint author), Massachusetts Gen Hosp, Hlth Decis Sci Ctr, Div Gen Med, Boston, MA 02114 USA.
EM ksepucha@partners.org
NR 1
TC 0
Z9 0
U1 1
U2 1
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD APR
PY 2013
VL 32
IS 4
BP 820
EP 821
DI 10.1377/hlthaff.2012.1343
PG 2
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 131UU
UT WOS:000318023100024
ER
PT J
AU Garg, A
Burrell, L
Tripodis, Y
Goodman, E
Brooks-Gunn, J
Duggan, AK
AF Garg, Arvin
Burrell, Lori
Tripodis, Yorghos
Goodman, Elizabeth
Brooks-Gunn, Jeanne
Duggan, Anne K.
TI Maternal Mental Health during Children's First Year of Life: Association
with Receipt of Section 8 Rental Assistance
SO HOUSING POLICY DEBATE
LA English
DT Article
DE vouchers; underserved; low-income housing
ID HOME VISITING PROGRAM; MEDICAL HOME; CAGE QUESTIONNAIRE;
RANDOMIZED-TRIAL; FAMILY PROCESS; START PROGRAM; DEPRESSION;
NEIGHBORHOOD; POVERTY; WOMEN
AB Prior studies evaluating housing programs have found varied results for the impact of improved housing on maternal mental health. This study evaluated data from 169 families who participated in Hawaii's Healthy Start Program. The study's objective was to determine whether receipt of Section 8 rental assistance in the first year of a child's life decreased the risk of poor maternal mental health. Multivariable logistic regression was used to measure the association of Section 8 housing receipt with poor mental health. Overall, 50% of mothers had poor mental health at baseline, and 32% reported receipt of Section 8 housing at follow-up. Mothers who received Section 8 housing were significantly less likely to have poor maternal mental health at follow-up (adjusted odds ratio=.40; 95% confidence interval, .16.97; p < .05). Receipt of Section 8 rental assistance in the first year of a child's life may reduce the risk of poor mental health for mothers in housing need.
C1 [Garg, Arvin] Boston Univ, Sch Med, Dept Pediat, Boston Med Ctr, Boston, MA 02118 USA.
[Burrell, Lori; Duggan, Anne K.] Johns Hopkins Univ, Sch Med, Div Gen Pediat & Adolescent Med, Baltimore, MD USA.
[Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Goodman, Elizabeth] MassGen Hosp Children, MGH Ctr Child & Adolescent Hlth Policy, Boston, MA USA.
[Brooks-Gunn, Jeanne] Columbia Univ, Teachers Coll, New York, NY 10027 USA.
[Brooks-Gunn, Jeanne] Columbia Univ, Coll Phys & Surg, New York, NY USA.
RP Garg, A (reprint author), Boston Univ, Sch Med, Dept Pediat, Boston Med Ctr, Boston, MA 02118 USA.
EM arvin.garg@bmc.org
NR 77
TC 1
Z9 1
U1 6
U2 15
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1051-1482
J9 HOUS POLICY DEBATE
JI Hous. Policy Debate
PD APR 1
PY 2013
VL 23
IS 2
BP 281
EP 297
DI 10.1080/10511482.2012.762033
PG 17
WC Planning & Development; Urban Studies
SC Public Administration; Urban Studies
GA 130WZ
UT WOS:000317952100002
ER
PT J
AU Mazzoni, M
De Giorgio, R
Latorre, R
Vallorani, C
Bosi, P
Trevisi, P
Barbara, G
Stanghellini, V
Corinaldesi, R
Forni, M
Faussone-Pellegrini, MS
Sternini, C
Clavenzani, P
AF Mazzoni, Maurizio
De Giorgio, Roberto
Latorre, Rocco
Vallorani, Claudia
Bosi, Paolo
Trevisi, Paolo
Barbara, Giovanni
Stanghellini, Vincenzo
Corinaldesi, Roberto
Forni, Monica
Faussone-Pellegrini, Maria S.
Sternini, Catia
Clavenzani, Paolo
TI Expression and regulation of alpha-transducin in the pig
gastrointestinal tract
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE alpha-gustducin; taste receptors; enteroendocrine cells; chemosensing
ID BITTER TASTE RECEPTORS; ENTEROENDOCRINE STC-1 CELLS; FOOD-INTAKE;
ENDOCRINE RESPONSES; WEANLING PIGS; GUSTDUCIN; GHRELIN; SOMATOSTATIN;
SECRETION; DEPRIVATION
AB Taste signalling molecules are found in the gastrointestinal (GI) tract suggesting that they participate to chemosensing. We tested whether fasting and refeeding affect the expression of the taste signalling molecule, -transducin (Gtran), throughout the pig GI tract and the peptide content of Gtran cells. The highest density of Gtran-immunoreactive (IR) cells was in the pylorus, followed by the cardiac mucosa, duodenum, rectum, descending colon, jejunum, caecum, ascending colon and ileum. Most Gtran-IR cells contained chromogranin A. In the stomach, many Gtran-IR cells contained ghrelin, whereas in the upper small intestine many were gastrin/cholecystokinin-IR and a few somatostatin-IR. Gtran-IR and Ggust-IR colocalized in some cells. Fasting (24h) resulted in a significant decrease in Gtran-IR cells in the cardiac mucosa (29.3 +/- 0.8 versus 64.8 +/- 1.3, P<0.05), pylorus (98.8 +/- 1.7 versus 190.8 +/- 1.9, P<0.0l), caecum (8 +/- 0.01 versus 15.5 +/- 0.5, P<0.01), descending colon (17.8 +/- 0.3 versus 23 +/- 0.6, P<0.05) and rectum (15.3 +/- 0.3 versus 27.5 +/- 0.7, P<0.05). Refeeding restored the control level of Gtran-IR cells in the cardiac mucosa. In contrast, in the duodenum and jejunum, Gtran-IR cells were significantly reduced after refeeding, whereas Gtran-IR cells density in the ileum was not changed by fasting/refeeding. These findings provide further support to the concept that taste receptors contribute to luminal chemosensing in the GI tract and suggest they are involved in modulation of food intake and GI function induced by feeding and fasting.
C1 [Mazzoni, Maurizio; Latorre, Rocco; Vallorani, Claudia; Forni, Monica; Clavenzani, Paolo] Univ Bologna, Dept Vet Med Sci, I-40126 Bologna, Italy.
[De Giorgio, Roberto; Barbara, Giovanni; Stanghellini, Vincenzo; Corinaldesi, Roberto] Univ Bologna, Dept Med & Surg Sci, I-40126 Bologna, Italy.
[Bosi, Paolo; Trevisi, Paolo] Univ Bologna, Dept Agri Food Protect & Improvement, I-40126 Bologna, Italy.
[Faussone-Pellegrini, Maria S.] Univ Florence, Dept Anat Histol & Forens Med, Florence, Italy.
[Sternini, Catia] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE DDRC,Dept Med, Los Angeles, CA 90095 USA.
[Sternini, Catia] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE DDRC,Dept Neurobiol, Los Angeles, CA 90095 USA.
[Sternini, Catia] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA.
[De Giorgio, Roberto; Clavenzani, Paolo] Univ Bologna, CIRAU, I-40126 Bologna, Italy.
RP Sternini, C (reprint author), Vet Adm Greater Los Angeles Hlth Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM csternin@ucla.edu
RI Mazzoni, Maurizio/J-1918-2016;
OI Mazzoni, Maurizio/0000-0002-7384-5990; TREVISI,
PAOLO/0000-0001-7019-6828; Forni, Monica/0000-0003-1310-6202
FU NIH [DK79155, 41301]; Italian Ministry of Education, University and
Research (MIUR); 'Fondazione Del Monte di Bologna e Ravenna', Italy;
University of Bologna
FX Grant support: The present work was supported by NIH grants DK79155 and
41301 (C. S.), and grants from the Italian Ministry of Education,
University and Research (MIUR) (PRIN2009) (R. De G.), from 'Fondazione
Del Monte di Bologna e Ravenna', Italy and funds from the University of
Bologna (R. De G. and P. C.). We are grateful to Dr. Chiara Bernardini,
Department of Medical Veterinary Sciences, University of Bologna, for
her valuable technical assistance with Western blot experiments.
NR 33
TC 10
Z9 10
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD APR
PY 2013
VL 17
IS 4
BP 466
EP 474
DI 10.1111/jcmm.12026
PG 9
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 135KZ
UT WOS:000318288300004
PM 23414137
ER
PT J
AU Tonetti, MS
Van Dyke, TE
AF Tonetti, Maurizio S.
Van Dyke, Thomas E.
CA Working Grp 1 Joint EFP AAP
TI Periodontitis and atherosclerotic cardiovascular disease: consensus
report of the Joint EFP/AAP Workshop on Periodontitis and Systemic
Diseases
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE atherosclerosis; bacteremia; cardiovascular diseases; clinical trials;
C-reactive protein; epidemiology; inflammation; myocardial infarction;
periodontal diseases; periodontitis; stroke
ID OF-CARDIOLOGY; INTERVENTIONS; PROGRESSION; GUIDELINES; MANAGEMENT;
HEALTH; ADULTS
AB Background This consensus report is concerned with the association between periodontitis and atherosclerotic cardiovascular disease (ACVD). Periodontitis is a chronic multifactorial inflammatory disease caused by microorganisms and characterized by progressive destruction of the tooth supporting apparatus leading to tooth loss; as such, it is a major public health issue. Aims This report examined biological plausibility, epidemiology and early results from intervention trials. Plausibility Periodontitis leads to entry of bacteria in the blood stream. The bacteria activate the host inflammatory response by multiple mechanisms. The host immune response favors atheroma formation, maturation and exacerbation. Epidemiology In longitudinal studies assessing incident cardiovascular events, statistically significant excess risk for ACVD was reported in individuals with periodontitis. This was independent of established cardiovascular risk factors. The amount of the adjusted excess risk varies by type of cardiovascular outcome and across populations by age and gender. Given the high prevalence of periodontitis, even low to moderate excess risk is important from a public health perspective. Intervention There is moderate evidence that periodontal treatment: (i) reduces systemic inflammation as evidenced by reduction in C-reactive protein (CRP) and improvement of both clinical and surrogate measures of endothelial function; but (ii) there is no effect on lipid profiles supporting specificity. Limited evidence shows improvements in coagulation, biomarkers of endothelial cell activation, arterial blood pressure and subclinical atherosclerosis after periodontal therapy. The available evidence is consistent and speaks for a contributory role of periodontitis to ACVD. There are no periodontal intervention studies on primary ACVD prevention and there is only one feasibility study on secondary ACVD prevention. Conclusions It was concluded that: (i) there is consistent and strong epidemiologic evidence that periodontitis imparts increased risk for future cardiovascular disease; and (ii) while in vitro, animal and clinical studies do support the interaction and biological mechanism, intervention trials to date are not adequate to draw further conclusions. Well-designed intervention trials on the impact of periodontal treatment on prevention of ACVD hard clinical outcomes are needed.
C1 [Tonetti, Maurizio S.] European Res Grp Periodontol, I-16149 Genoa, Italy.
[Van Dyke, Thomas E.] Forsyth Inst, Cambridge, MA USA.
RP Tonetti, MS (reprint author), European Res Grp Periodontol, WTC Tower Genoa,Via De Marini 1, I-16149 Genoa, Italy.
EM maurizio.tonetti@ergoperio.eu
OI Graziani, Filippo/0000-0001-8780-7306
FU Colgate-Palmolive; American Academy of Periodontology
FX Group participants declare no conflict of interest. The workshop was
funded by an unrestricted educational grant from Colgate-Palmolive to
the European Federation of Periodontology and the American Academy of
Periodontology.
NR 14
TC 98
Z9 106
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-6979
EI 1600-051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD APR
PY 2013
VL 40
SU 14
SI SI
BP S24
EP S29
DI 10.1111/jcpe.12089
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 135LX
UT WOS:000318290700004
PM 23627332
ER
PT J
AU Van Dyke, TE
van Winkelhoff, AJ
AF Van Dyke, Thomas E.
van Winkelhoff, Arie Jan
TI Infection and inflammatory mechanisms
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE cardiovascular disease; infection; inflammation; pathogenesis;
periodontitis; systemic diseases
ID HUMAN PERIODONTAL-LIGAMENT; CORONARY-HEART-DISEASE;
TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; ATHEROSCLEROTIC
CARDIOVASCULAR-DISEASE; ANTIINFLAMMATORY LIPID MEDIATORS; EDITORS
CONSENSUS PERIODONTITIS; JOURNAL-OF-CARDIOLOGY;
ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PORPHYROMONAS-GINGIVALIS
AB This introductory article examines the potential mechanisms that may play a role in the associations between periodontitis and the systemic conditions being considered in the EFP/AAP Workshop in Segovia, Spain. Three basic mechanisms have been postulated to play a role in these interactions; metastatic infections, inflammation and inflammatory injury, and adaptive immunity. The potential role of each alone and together is considered in in vitro and animal studies and in human studies when available. This is not a systematic or critical review, but rather an overview of the field to set the stage for the critical reviews in each of the working groups.
C1 [Van Dyke, Thomas E.] Forsyth Inst, Cambridge, MA 02142 USA.
[van Winkelhoff, Arie Jan] Univ Groningen, Univ Med Ctr Groningen, Dept Dent & Oral Hyg, Groningen, Netherlands.
RP Van Dyke, TE (reprint author), Forsyth Inst, 245 1st St, Cambridge, MA 02142 USA.
EM tvandyke@forsyth.org
OI Van Dyke, Thomas/0000-0003-0568-124X
FU Colgate-Palmolive; American Academy of Periodontology
FX The authors declare no conflict of interest. The workshop was funded by
an unrestricted educational grant from Colgate-Palmolive to the European
Federation of Periodontology and the American Academy of Periodontology.
NR 92
TC 34
Z9 35
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-6979
EI 1600-051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD APR
PY 2013
VL 40
SU 14
SI SI
BP S1
EP S7
DI 10.1111/jcpe.12088
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 135LX
UT WOS:000318290700001
PM 23627321
ER
PT J
AU Grant, KW
Walden, BE
Summers, V
Leek, MR
AF Grant, Ken W.
Walden, Brian E.
Summers, Van
Leek, Marjorie R.
TI Auditory Models of Suprathreshold Distortion in Persons with Impaired
Hearing Introduction
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Editorial Material
ID SPEECH-RECEPTION THRESHOLD; NOISE; AID; LISTENERS; COGNITION; BENEFIT
C1 [Grant, Ken W.; Summers, Van] Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD USA.
[Walden, Brian E.] Walter Reed Army Med Ctr, Washington, DC 20307 USA.
[Leek, Marjorie R.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR USA.
RP Grant, KW (reprint author), Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD USA.
NR 24
TC 4
Z9 4
U1 0
U2 2
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD APR
PY 2013
VL 24
IS 4
BP 254
EP 257
DI 10.3766/jaaa.24.4.2
PG 4
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 134JK
UT WOS:000318206300002
PM 23636207
ER
PT J
AU Summers, V
Makashay, MJ
Theodoroff, SM
Leek, MR
AF Summers, Van
Makashay, Matthew J.
Theodoroff, Sarah M.
Leek, Marjorie R.
TI Suprathreshold Auditory Processing and Speech Perception in Noise:
Hearing-Impaired and Normal-Hearing Listeners
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Compression; frequency selectivity; hearing impaired; hearing science;
sensorineural hearing loss; speech perception; temporal fine structure
sensitivity
ID TEMPORAL FINE-STRUCTURE; FILTER SHAPES; FREQUENCY-SELECTIVITY;
FLUCTUATING MASKERS; RECEPTION THRESHOLD; INTERFERING SPEECH;
PHASE-LOCKING; INTELLIGIBILITY; NONLINEARITY; MODULATION
AB Background: It is widely believed that suprathreshold distortions in auditory processing contribute to the speech recognition deficits experienced by hearing-impaired (HI). listeners in noise. Damage to outer hair cells and attendant reductions in peripheral compression and frequency selectivity may contribute to these deficits. In addition, reduced access to temporal fine structure (TFS) information in the speech waveform may play a role.
Purpose: To examine how measures of peripheral compression, frequency selectivity, and TFS sensitivity relate to speech recognition performance by HI listeners. To determine whether distortions in processing reflected by these psychoacoustic measures are more closely associated with speech deficits in steady-state or modulated noise.
Research Design: Normal-hearing (NH) and HI listeners were tested on tasks examining frequency selectivity (notched-noise task), peripheral compression (temporal masking curve task), and sensitivity to TFS information (frequency modulation [FM] detection task) in the presence of random amplitude modulation. Performance was tested at 500, 1000, 2000, and 4000 Hz at several presentation levels. The same listeners were tested on sentence recognition in steady-state and modulated noise at several signal-to-noise ratios.
Study Sample: Ten NH and 18 HI listeners were tested. NH listeners ranged in age from 36 to 80 yr (M = 57.6). For HI listeners, ages ranged from 58 to 87 yr (M = 71.8).
Results: Scores on the FM detection task at 1 and 2 kHz were significantly correlated with speech scores in both noise conditions. Frequency selectivity and compression measures were not as clearly associated with speech performance. Speech Intelligibility Index (SII) analyses indicated only small differences in speech audibility across subjects for each signal-to-noise ratio (SNR) condition that would predict differences in speech scores no greater than 10% at a given SNR. Actual speech scores varied by as much as 80% across subjects.
Conclusions: The results suggest that distorted processing of audible speech cues was a primary factor accounting for differences in speech scores across subjects and that reduced ability to use TFS cues may be an important component of this distortion. The influence of TFS cues on speech scores was comparable in steady-state and modulated noise. Speech recognition was not related to audibility, represented by the SII, once high-frequency sensitivity differences across subjects (beginning at 5 kHz) were removed statistically. This might indicate that high-frequency hearing loss is associated with distortions in processing in lower-frequency regions.
C1 [Summers, Van; Makashay, Matthew J.] Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD 20889 USA.
[Theodoroff, Sarah M.; Leek, Marjorie R.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR USA.
RP Summers, V (reprint author), Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.
EM vsummers6@gmail.com
FU Oticon Foundation, Smorum, Denmark; Department of Veterans Affairs,
Veterans Health Administration, Rehabilitation Research and Development
Service
FX Supported by a grant from the Oticon Foundation, Smorum, Denmark.
Additional support was provided by the Department of Veterans Affairs,
Veterans Health Administration, Rehabilitation Research and Development
Service (Senior Research Career Scientist award [MRL]). The work was
supported with resources and the use of facilities at the Portland VA
Medical Center.
NR 51
TC 14
Z9 16
U1 0
U2 24
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD APR
PY 2013
VL 24
IS 4
BP 274
EP 292
DI 10.3766/jaaa.24.4.4
PG 19
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 134JK
UT WOS:000318206300004
PM 23636209
ER
PT J
AU Bernstein, JGW
Mehraei, G
Shamma, S
Gallun, FJ
Theodoroff, SM
Leek, MR
AF Bernstein, Joshua G. W.
Mehraei, Golbarg
Shamma, Shihab
Gallun, Frederick J.
Theodoroff, Sarah M.
Leek, Marjorie R.
TI Spectrotemporal Modulation Sensitivity as a Predictor of Speech
Intelligibility for Hearing-Impaired Listeners
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Fine structure; frequency selectivity; hearing loss; model; modulation;
sensorineural; spectral; speech intelligibility; temporal
ID TEMPORAL FINE-STRUCTURE; AUDITORY FILTER SHAPES; FREQUENCY-SELECTIVITY;
STRUCTURE INFORMATION; CARRIER FREQUENCY; PHASE-LOCKING; NERVE FIBERS;
NOISE; RECEPTION; RECOGNITION
AB Background: A model that can accurately predict speech intelligibility for a given hearing-impaired (HI) listener would be an important tool for hearing-aid fitting or hearing-aid algorithm development. Existing speech-intelligibility models do not incorporate variability in suprathreshold deficits that are not well predicted by classical audiometric measures. One possible approach to the incorporation of such deficits is to base intelligibility predictions on sensitivity to simultaneously spectrally and temporally modulated signals.
Purpose: The likelihood of success of this approach was evaluated by comparing estimates of spectrotemporal modulation (STM) sensitivity to speech intelligibility and to psychoacoustic estimates of frequency selectivity and temporal fine-structure (TFS) sensitivity across a group of HI listeners.
Research Design: The minimum modulation depth required to detect STM applied to an 86 dB SPL four-octave noise carrier was measured for combinations of temporal modulation rate (4, 12, or 32 Hz) and spectral modulation density (0.5, 1, 2, or 4 cycles/octave). STM sensitivity estimates for individual HI listeners were compared to estimates of frequency selectivity (measured using the notched-noise method at 500, 1000, 2000, and 4000 Hz), TFS processing ability (2 Hz frequency-modulation detection thresholds for 500, 1000, 2000, and 4000 Hz carriers) and sentence intelligibility in noise (at a 0 dB signal-to-noise ratio) that were measured for the same listeners in a separate study.
Study Sample: Eight normal-hearing (NH) listeners and 12 listeners with a diagnosis of bilateral sensorineural hearing loss participated.
Data Collection and Analysis: STM sensitivity was compared between NH and HI listener groups using a repeated-measures analysis of variance. A stepwise regression analysis compared STM sensitivity for individual HI listeners to audiometric thresholds, age, and measures of frequency selectivity and TFS processing ability. A second stepwise regression analysis compared speech intelligibility to STM sensitivity and the audiogrann-based Speech Intelligibility Index.
Results: STM detection thresholds were elevated for the HI listeners, but only for low rates and high densities. STM sensitivity for individual HI listeners was well predicted by a combination of estimates of frequency selectivity at 4000 Hz and TFS sensitivity at 500 Hz but was unrelated to audiometric thresholds. STM sensitivity accounted for an additional 40% of the variance in speech intelligibility beyond the 40% accounted for by the audibility-based Speech Intelligibility Index.
Conclusions: Impaired STM sensitivity likely results from a combination of a reduced ability to resolve spectral peaks and a reduced ability to use TFS information to follow spectral-peak movements. Combining STM sensitivity estimates with audiometric threshold measures for individual HI listeners provided a more accurate prediction of speech intelligibility than audiometric measures alone. These results suggest a significant likelihood of success for an STM-based model of speech intelligibility for HI listeners.
C1 [Bernstein, Joshua G. W.] Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD 20889 USA.
[Mehraei, Golbarg] Harvard MIT Speech & Hearing Biosci & Technol Pro, Cambridge, MA USA.
[Shamma, Shihab] Univ Maryland, Syst Res Inst, College Pk, MD 20742 USA.
[Gallun, Frederick J.; Theodoroff, Sarah M.; Leek, Marjorie R.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR USA.
RP Bernstein, JGW (reprint author), Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.
EM joshua.g.bernstein.civ@health.mil
FU Oticon Foundation, Swum, Denmark; VA Rehabilitation Research &
Development Service
FX Supported by a grant from the Oticon Foundation, Swum, Denmark (J.G.W.B.
and M.R.L.). Additional support was provided by the VA Rehabilitation
Research & Development Service (Career Development grant [F.J.G.],
Senior Research Career Scientist award [M.R.L.]), and some resources and
facilities were provided by the Portland VA Medical Center and Walter
Reed Army Medical Center.
NR 63
TC 18
Z9 18
U1 3
U2 26
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD APR
PY 2013
VL 24
IS 4
BP 293
EP 306
DI 10.3766/jaaa.24.4.5
PG 14
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 134JK
UT WOS:000318206300005
PM 23636210
ER
PT J
AU Rehani, B
Basu, P
Ellenbogen, PH
Sherin, C
Cooper, JJ
AF Rehani, Bhavya
Basu, Pat
Ellenbogen, Paul H.
Sherin, Christopher
Cooper, Joshua J.
TI The Threat to Radiologists From the Multiple-Procedure Payment Reduction
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Rehani, Bhavya] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neuroradiol, Boston, MA USA.
[Basu, Pat] Virtual Radiol Corp, Eden Prairie, MN USA.
[Ellenbogen, Paul H.] Amer Coll Radiol, Dallas, TX USA.
[Ellenbogen, Paul H.] Texas Hlth Presbyterian Hosp Dallas, Dept Radiol, Radiol Associates North Texas, Dallas, TX USA.
[Sherin, Christopher; Cooper, Joshua J.] Amer Coll Radiol, Washington, DC USA.
RP Rehani, B (reprint author), Massachusetts Gen Hosp, Dept Neuroradiol, 55 Fruit St, Boston, MA 02114 USA.
EM brehani@partners.org
NR 0
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD APR
PY 2013
VL 10
IS 4
BP 237
EP 238
DI 10.1016/j.jacr.2012.12.017
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 130UD
UT WOS:000317944700005
PM 23545081
ER
PT J
AU Hempel, S
Newberry, S
Wang, Z
Booth, M
Shanman, R
Johnsen, B
Shier, V
Saliba, D
Spector, WD
Ganz, DA
AF Hempel, Susanne
Newberry, Sydne
Wang, Zhen
Booth, Marika
Shanman, Roberta
Johnsen, Breanne
Shier, Victoria
Saliba, Debra
Spector, William D.
Ganz, David A.
TI Hospital Fall Prevention: A Systematic Review of Implementation,
Components, Adherence, and Effectiveness
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE fall prevention; implementation; hospital; systematic review
ID QUALITY IMPROVEMENT; PATIENT SAFETY; CARE HOSPITALS; INTERVENTIONS;
METAANALYSIS; INPATIENTS; WORK
AB Objectives To systematically document the implementation, components, comparators, adherence, and effectiveness of published fall prevention approaches in U.S. acute care hospitals. Design Systematic review. Studies were identified through existing reviews, searching five electronic databases, screening reference lists, and contacting topic experts for studies published through August 2011. Setting U.S. acute care hospitals. Participants Studies reporting in-hospital falls for intervention groups and concurrent (e.g., controlled trials) or historic comparators (e.g., beforeafter studies). Intervention Fall prevention interventions. Measurements Incidence rate ratios (IRR, ratio of fall rate postintervention or treatment group to the fall rate preintervention or control group) and ratings of study details. Results Fifty-nine studies met inclusion criteria. Implementation strategies were sparsely documented (17% not at all) and included staff education, establishing committees, seeking leadership support, and occasionally continuous quality improvement techniques. Most interventions (81%) included multiple components (e.g., risk assessments (often not validated), visual risk alerts, patient education, care rounds, bed-exit alarms, and postfall evaluations). Fifty-four percent did not report on fall prevention measures applied in the comparison group, and 39% neither reported fidelity data nor described adherence strategies such as regular audits and feedback to ensure completion of care processes. Only 45% of concurrent and 15% of historic control studies reported sufficient data to compare fall rates. The pooled postintervention incidence rate ratio (IRR) was 0.77 (95% confidence interval=0.521.12, P=.17; eight studies; I2: 94%). Meta-regressions showed no systematic association between implementation intensity, intervention complexity, comparator information, or adherence levels and IRR. Conclusion Promising approaches exist, but better reporting of outcomes, implementation, adherence, intervention components, and comparison group information is necessary to establish evidence on how hospitals can successfully prevent falls.
C1 [Hempel, Susanne; Newberry, Sydne; Wang, Zhen; Booth, Marika; Shanman, Roberta; Johnsen, Breanne; Shier, Victoria; Saliba, Debra; Ganz, David A.] RAND Corp, Santa Monica, CA 90407 USA.
[Saliba, Debra; Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Saliba, Debra] Univ Calif Los Angeles, JH Borun Ctr, Los Angeles, CA USA.
[Spector, William D.] Agcy Healthcare Res & Qual, Rockville, MD USA.
[Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Hempel, S (reprint author), RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90407 USA.
EM susanne_hempel@rand.org
RI Wang, Zhen/D-5991-2013
OI Wang, Zhen/0000-0002-9368-6149
FU AHRQ [HHSA290201000017I]; U.S. Department of Veterans Affairs, Veterans
Health Administration, Veterans Affairs Health Services Research and
Development (HSR&D) Service through the VA Greater Los Angeles HSR&D
Center of Excellence [VA CD2 08-012-1]
FX The editor in chief has reviewed the conflict of interest checklist
provided by the authors and has determined that the authors have no
financial or any other kind of personal conflicts with this paper. This
project was funded under Contract HHSA290201000017I TO #1 from the AHRQ.
Additional support was provided through the U.S. Department of Veterans
Affairs, Veterans Health Administration, Veterans Affairs Health
Services Research and Development (HSR&D) Service through the VA Greater
Los Angeles HSR&D Center of Excellence (Project VA CD2 08-012-1 and a
locally initiated project).
NR 29
TC 30
Z9 30
U1 2
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
IS 4
BP 483
EP 494
DI 10.1111/jgs.12169
PG 12
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 130IN
UT WOS:000317907600001
PM 23527904
ER
PT J
AU Munshi, MN
Pandya, N
Umpierrez, GE
DiGenio, A
Zhou, R
Riddle, MC
AF Munshi, Medha N.
Pandya, Naushira
Umpierrez, Guillermo E.
DiGenio, Andres
Zhou, Rong
Riddle, Matthew C.
TI Contributions of Basal and Prandial Hyperglycemia to Total Hyperglycemia
in Older and Younger Adults with Type 2 Diabetes Mellitus
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE basal hyperglycemia; insulin glargine; postprandial hyperglycemia; type
2 diabetes mellitus; older adults
ID INSULIN GLARGINE; GLYCEMIC CONTROL; THERAPY; AGENTS; TRIAL; METFORMIN;
PEOPLE
AB Objectives To evaluate the relative contributions of basal and prandial components to total hyperglycemia in older and younger adults with type 2 diabetes mellitus. Design Participant-level data were pooled from six randomized studies of 24weeks or longer treatment with insulin glargine or an active comparator. Setting Prospective, randomized Phase 3 or 4 controlled trials. Participants One thousand six hundred ninety-nine individuals: 509 (30%) aged 65 and older and 1,190 (70%) younger than 65. Measurements Contributions of basal hyperglycemia (BHG) and postprandial hyperglycemia (PPHG) to total hyperglycemia, defined as the incremental area under the curve of daytime blood glucose (BG) from the overall glucose profile calculated from 7-point self-measured BG profiles, of participants aged 65 and older were compared with those of participants younger than 65. Results After 24weeks of treatment, glycosylated hemoglobin (HbA1c) decreased in the older (8.67.0%) and younger (8.77.1%) groups; the relative contribution of BHG was significantly lower in both age groups (P<.001). The relative contribution of BHG to that of PPHG was significantly smaller in older than in younger participants at baseline (75.4% vs 79.4%; P<.001) and 24weeks (37.6% vs 44.7%; P<.001). The relative contribution of BHG to total hyperglycemia was not correlated with HbA1c at baseline and after 24weeks of treatment in older participants but was positively correlated at baseline (correlation coefficient (r)=0.082; P=.005) and 24weeks (r=0.062; P=.03) in younger participants. A significantly lower proportion of older participants reported symptomatic, glucose-confirmed, and nocturnal hypoglycemia during 24weeks of treatment (P<.001). Conclusion The relative contribution of BHG was lower, and that of PPHG was greater in older than in younger participants, suggesting that different therapeutic approaches may be required to treat hyperglycemia effectively in these different age groups.
C1 [Munshi, Medha N.] Joslin Diabet Ctr, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Munshi, Medha N.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Pandya, Naushira] Nova SE Univ, Coll Osteopath Med, Ft Lauderdale, FL 33314 USA.
[Umpierrez, Guillermo E.] Emory Univ, Sch Med, Atlanta, GA USA.
[DiGenio, Andres] Sanofi Aventis US Inc, Bridgewater, NJ USA.
[Zhou, Rong] Medpace, Cincinnati, OH USA.
[Riddle, Matthew C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Munshi, MN (reprint author), Joslin Diabet Ctr, Beth Israel Deaconess Med Ctr, 110 Francis St,LMOB 1B, Boston, MA 02215 USA.
EM medha.munshi@joslin.harvard.edu
FU sanofi-aventis U.S., Inc.; sanofi-aventis; Merck; Eli Lilly; Novo
Nordisk; Lilly; Amylin; GlaxoSmithKline; Oregon Health & Science
University; Hoffmann La Roche
FX The authors received writing and editorial support in the preparation of
this manuscript from Katherine Roberts, PhD, of Excerpta Medica, funded
by sanofi-aventis U.S., Inc.; Munshi: research grant support from
sanofi-aventis. Pandya: speaker for sanofi-aventis and consultation fees
for a research study sponsored by sanofi-aventis. Umpierrez: grant
support from sanofi-aventis and Merck and consultant fees from
sanofi-aventis, Eli Lilly, and Novo Nordisk. Zhou: employee at Medpace,
which is under contract with sanofi-aventis. Riddle: research grant
support from sanofi-aventis, Lilly, Amylin, and GlaxoSmithKline for
clinical studies at Oregon Health & Science University. Honoraria for
consulting for sanofi-aventis, Lilly, Amylin, and Hoffmann La Roche for
research trial design, implementation, and interpretation of data.
Presentations supported by sanofi-aventis at conferences associated with
professional society meetings.
NR 18
TC 6
Z9 8
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
IS 4
BP 535
EP 541
DI 10.1111/jgs.12167
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 130IN
UT WOS:000317907600007
PM 23581911
ER
PT J
AU Min, LL
Wenger, N
Walling, AM
Blaum, C
Cigolle, C
Ganz, DA
Reuben, D
Shekelle, P
Roth, C
Kerr, EA
AF Min, Lillian
Wenger, Neil
Walling, Anne M.
Blaum, Caroline
Cigolle, Christine
Ganz, David A.
Reuben, David
Shekelle, Paul
Roth, Carol
Kerr, Eve A.
TI When Comorbidity, Aging, and Complexity of Primary Care Meet:
Development and Validation of the Geriatric CompleXity of Care Index
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE ambulatory care; utilization; comorbidity
ID QUALITY-OF-CARE; VULNERABLE OLDER-PEOPLE; PRACTICE GUIDELINES;
FUNCTIONAL DECLINE; ELDERS SURVEY; LAST YEAR; MULTIMORBIDITY; RISK;
INTERVENTION; CONSEQUENCES
AB Objectives To develop and validate the Geriatric CompleXity of Care Index (GXI), a comorbidity index of medical, geriatric, and psychosocial conditions that addresses disease severity and intensity of ambulatory care for older adults with chronic conditions. Design Development phase: variable selection and rating by clinician panel. Validation phase: medical record review and secondary data analysis. Setting Assessing the Care of Vulnerable Elders-2 study. Participants Six hundred forty-four older (75) individuals receiving ambulatory care. Measures Development: 32 conditions categorized according to severity, resulting in 117 GXI variables. A panel of clinicians rated each GXI variable with respect to the added difficulty of providing primary care for an individual with that condition. Validation: Modified versions of previously validated comorbidity measures (simple count, Charlson, Medicare Hierarchical Condition Category), longitudinal clinical outcomes (functional decline, survival), intensity of ambulatory care (primary, specialty care visits, polypharmacy, number of eligible quality indicators (NQI)) over 1year of care. Results The most-morbid individuals (according to quintiles of GXI) had more visits (7.0 vs 3.7 primary care, 6.2 vs 2.4 specialist), polypharmacy (14.3% vs 0% had 14 medications), and greater NQI (33 vs 25) than the least-morbid individuals. Of the four comorbidity measures, the GXI was the strongest predictor of primary care visits, polypharmacy, and NQI (P<.001, controlling for age, sex, function-based vulnerability). Conclusion Older adults with complex care needs, as measured by the GXI, have healthcare needs above what previously employed comorbidity measures captured. Healthcare systems could use the GXI to identify the most complex elderly adults and appropriately reimburse primary providers caring for older adults with the most complex care needs for providing additional visits and coordination of care.
C1 [Min, Lillian; Cigolle, Christine] Univ Michigan, Dept Med, Div Geriatr, Sch Med, Ann Arbor, MI 48109 USA.
[Min, Lillian; Cigolle, Christine] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Care Ctr, Ann Arbor, MI USA.
[Wenger, Neil; Walling, Anne M.; Ganz, David A.; Shekelle, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Dept Med, Los Angeles, CA 90095 USA.
[Wenger, Neil; Walling, Anne M.; Ganz, David A.; Shekelle, Paul; Roth, Carol] RAND Hlth, Santa Monica, CA USA.
[Blaum, Caroline] NYU, Dept Med, Langone Med Ctr, New York, NY 10016 USA.
[Blaum, Caroline] NYU, Dept Populat Hlth, Langone Med Ctr, New York, NY 10016 USA.
[Ganz, David A.; Reuben, David] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA.
[Ganz, David A.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Kerr, Eve A.] Univ Michigan, Div Gen Internal Med, Dept Med, Sch Med, Ann Arbor, MI 48109 USA.
[Kerr, Eve A.] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA.
RP Min, LL (reprint author), Univ Michigan, Dept Med, Div Geriatr, 300 North Ingalls Bldg Wing E,Room 966, Ann Arbor, MI 48109 USA.
EM lmin@med.umich.edu
RI Kerr, Eve/I-3330-2013
FU Agency for Healthcare Research and Quality [Min R21 HS017621]; Claude
Pepper Older Americans Independence Centers at the University of
California at Los Angeles [NIA-K12 2006-2010]; University of Michigan;
Hartford-AFAR Geriatric Scholars Research Outcomes Award; Veterans
Affairs Greater Los Angeles Health Services Research and Development
Center [CD208-012-1]; Pfizer, Inc
FX This project was supported by the Agency for Healthcare Research and
Quality (Min R21 HS017621). Dr. Min was supported by the Claude Pepper
Older Americans Independence Centers at the University of California at
Los Angeles (NIA-K12 2006-2010) and the University of Michigan
(2010-2011) and a Hartford-AFAR Geriatric Scholars Research Outcomes
Award (2005-2006). Dr. Ganz is funded by a Veterans Affairs Greater Los
Angeles Health Services Research and Development Center of Excellence
Career Development Award (CD208-012-1). The original ACOVE-2 study was
supported by a contract from Pfizer, Inc. to RAND. These results were
presented at the American Geriatrics Society and Society for General
Internal Medicine Meetings in 2012.
NR 41
TC 10
Z9 11
U1 3
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
IS 4
BP 542
EP 550
DI 10.1111/jgs.12160
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 130IN
UT WOS:000317907600008
PM 23581912
ER
PT J
AU Andrews, JS
Cenzer, IS
Yelin, E
Covinsky, KE
AF Andrews, James S.
Cenzer, Irena Stijacic
Yelin, Edward
Covinsky, Kenneth E.
TI Pain as a Risk Factor for Disability or Death
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE pain; functional limitations; activities of daily living; disability;
quality of life
ID LIVING OLDER PERSONS; LOW-BACK-PAIN; LAST 2 YEARS; MUSCULOSKELETAL PAIN;
FUNCTIONAL DECLINE; DISABLED WOMEN; HEALTH; LIFE; DIFFICULTY; ADULTS
AB Objectives To determine whether pain predicts future activity of daily living (ADL) disability or death in individuals aged 60 and older. Design Prospective cohort study. Setting The 1998 to 2008 Health and Retirement Study (HRS), a nationally representative study of older community-living individuals. Participants Twelve thousand six hundred thirty-one participants in the 1998 HRS aged 60 and older who did not need help in any ADL. Measurements Participants reporting that they had moderate or severe pain most of the time were defined as having significant pain. The primary outcome was time to development of ADL disability or death over 10yrs, assessed at five successive 2-year intervals. ADL disability was defined as needing help performing any ADL: bathing, dressing, transferring, toileting, eating, or walking across a room. A discrete hazards survival model was used to examine the relationship between pain and incident disability over each 2-year interval using only participants who started the interval with no ADL disability. Several potential confounders were adjusted for at the start of each interval: demographic factors, seven chronic health conditions, and functional limitations (ADL difficulty and difficulty with five measures of mobility). Results At baseline, 2,283 (18%) participants had significant pain. Participants with pain were more likely (all P<.001) to be female (65% vs 54%), have ADL difficulty (e.g., transferring 12% vs 2%, toileting 11% vs 2%), have difficulty walking several blocks (60% vs 21%), and have difficulty climbing one flight of stairs (40% vs 12%). Over 10years, participants with pain were more likely to develop ADL disability or death (58% vs 43%, unadjusted hazard ratio (HR)=1.67, 95% confidence interval(CI)=1.571.79), although after adjustment for confounders, participants with pain were not at greater risk for ADL disability or death (HR=0.98, 95% CI=0.911.07). Adjustment for functional status almost entirely explained the difference between the unadjusted and adjusted results. Conclusion Although there are strong cross-sectional relationships between pain and functional limitations, individuals with pain are not at higher risk of subsequent disability or death after accounting for functional limitations. Like many geriatric syndromes, pain and disability may represent interrelated phenomena that occur simultaneously and require unified treatment paradigms.
C1 [Yelin, Edward] Univ Calif San Francisco, Div Rheumatol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Andrews, James S.] Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Cenzer, Irena Stijacic; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
RP Andrews, JS (reprint author), 400 Parnassus Ave,Floor B1, San Francisco, CA 94143 USA.
EM james.andrews@ucsf.edu
FU NIAMD; NIA [U01AG009740]; University of California at San Francisco
Multidisciplinary Clinical Research Center from the National Institute
of Arthritis and Musculoskeletal Diseases (NIAMD) [P60AR-053308];
National Institute on Aging (NIA) [K24 AG029812]
FX Dr. Yelin receives grant support from the NIAMD. Dr. Covinsky receives
grant support from the NIA. The HRS is funded by the NIA (U01AG009740).;
Supported in part by the University of California at San Francisco
Multidisciplinary Clinical Research Center from the National Institute
of Arthritis and Musculoskeletal Diseases (NIAMD) (P60AR-053308) and a
Midcareer Research and Mentoring Award from the National Institute on
Aging (NIA) (K24 AG029812).
NR 29
TC 14
Z9 15
U1 3
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
IS 4
BP 583
EP 589
DI 10.1111/jgs.12172
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 130IN
UT WOS:000317907600014
PM 23521614
ER
PT J
AU Hazzard, WR
AF Hazzard, William R.
TI As a Gerontologist Enters Old Age
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE gerontologist; old age; successful aging
C1 [Hazzard, William R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care, Seattle, WA USA.
RP Hazzard, WR (reprint author), VA Puget Sound Hlth Care Syst, Geriatr & Extended Care, 1660 S Columbian Way,S-182-GEC, Seattle, WA 98108 USA.
EM william.hazzard@med.va.gov
NR 0
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
IS 4
BP 639
EP 640
DI 10.1111/jgs.12176
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 130IN
UT WOS:000317907600020
PM 23581916
ER
PT J
AU Wells, RE
Kerr, CE
Wolkin, J
Dossett, M
Davis, RB
Walsh, J
Wall, RB
Kong, J
Kaptchuk, T
Press, D
Phillips, RS
Yeh, G
AF Wells, Rebecca Erwin
Kerr, Catherine E.
Wolkin, Jennifer
Dossett, Michelle
Davis, Roger B.
Walsh, Jacquelyn
Wall, Robert B.
Kong, Jian
Kaptchuk, Ted
Press, Daniel
Phillips, Russell S.
Yeh, Gloria
TI Meditation for Adults with Mild Cognitive Impairment: A Pilot Randomized
Trial
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
ID GRAY-MATTER; DISTRESS; DISEASE
C1 [Wells, Rebecca Erwin] Wake Forest Baptist Med Ctr, Dept Neurol, Winston Salem, NC USA.
[Wells, Rebecca Erwin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Kerr, Catherine E.] Brown Univ, Sch Med, Dept Family Med, Providence, RI 02912 USA.
[Kerr, Catherine E.] Brown Univ, Sch Med, Mindfulness Wellness Program, Providence, RI 02912 USA.
[Wolkin, Jennifer] NYU, Langone Med Ctr, New York, NY USA.
[Dossett, Michelle; Davis, Roger B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Sch Med,Dept Med, Boston, MA 02215 USA.
[Walsh, Jacquelyn] Harvard Univ, Brigham & Womens Hosp, Osher Ctr Integrat Med, Sch Med,Div Prevent Med, Boston, MA 02115 USA.
[Wall, Robert B.] Commonwealth Care Alliance, Boston, MA USA.
[Kong, Jian] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Kaptchuk, Ted] Harvard Univ, Sch Med, Dept Internal Med, Boston, MA USA.
[Press, Daniel] Harvard Univ, Sch Med, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Phillips, Russell S.; Yeh, Gloria] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Sch Med,Dept Med, Boston, MA 02215 USA.
RP Wells, RE (reprint author), Wake Forest Baptist Med Ctr, Dept Neurol, Winston Salem, NC USA.
FU NCATS NIH HHS [8UL1TR000170-05, UL1 TR000170]; NCCIH NIH HHS [K01
AT003459, K01 AT003883, K24 AT000589, K24 AT004095, K24AT000589,
KO1AT003883, R01 AT006364, R01AT006364, R03AT218317, R21 AT004497,
R21AT004497, T32 AT000051, T32AT000051]; NCRR NIH HHS [UL1 RR025758, UL1
RR02758]
NR 8
TC 15
Z9 15
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
IS 4
BP 642
EP 645
DI 10.1111/jgs.12179
PG 4
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 130IN
UT WOS:000317907600022
PM 23581918
ER
PT J
AU Yoshida, M
Dickey, MW
Sturt, P
AF Yoshida, Masaya
Dickey, Michael Walsh
Sturt, Patrick
TI Predictive processing of syntactic structure: Sluicing and ellipsis in
real-time sentence processing
SO LANGUAGE AND COGNITIVE PROCESSES
LA English
DT Article
DE Sluicing; Ellipsis; Prediction; Gender mismatch effects
ID EYE-TRACKING; LANGUAGE COMPREHENSION; BRAIN POTENTIALS; CONSTRAINTS;
INFORMATION; RECONSTRUCTION; DEPENDENCIES; PLAUSIBILITY; PARALLELISM;
ASYMMETRIES
AB This paper investigates the prediction of syntactic structure during sentence processing, using constructions that temporarily allow a sluicing interpretation in English. Making use of two well-known properties of sluicing and pronoun interpretation-connectivity effects and the local antecedent requirement on reflexives, respectively-we show that (1) the parser chooses a sluicing structure over other possible structures when sluicing is a possibility, and (2) the structure which the parser posits for sluicing involves detailed hierarchical syntactic structure. A self-paced reading experiment and three offline experiments (two acceptability rating studies and a sentence completion study) find evidence that readers immediately try to associate a reflexive pronoun embedded inside a wh-phrase with a potential antecedent in the preceding clause. However, this association is made only if a sluicing structure is a possible continuation of the sentence. This finding suggests that readers actively anticipated a sluicing structure when it was grammatically permissible, and that this structure is sufficiently detailed to license reflexive binding. This result adds to the increasing evidence that comprehenders make detailed predictions regarding upcoming linguistic structure.
C1 [Yoshida, Masaya] Northwestern Univ, Dept Linguist, Evanston, IL USA.
[Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA.
[Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Sturt, Patrick] Univ Edinburgh, Dept Psychol, Sch Philosophy Psychol & Language Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
RP Yoshida, M (reprint author), Northwestern Univ, Dept Linguist, 2016 Sheridan Rd, Eanston, IL 60208 USA.
EM m-yoshida@northwestern.edu
OI Dickey, Michael Walsh/0000-0002-9068-3313
NR 75
TC 14
Z9 14
U1 2
U2 17
PU PSYCHOLOGY PRESS
PI HOVE
PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND
SN 0169-0965
J9 LANG COGNITIVE PROC
JI Lang. Cogn. Process.
PD APR 1
PY 2013
VL 28
IS 3
SU S
SI SI
BP 272
EP 302
DI 10.1080/01690965.2011.622905
PG 31
WC Linguistics; Psychology, Experimental
SC Linguistics; Psychology
GA 113GE
UT WOS:000316653800005
ER
PT J
AU Shek, SY
Yeung, CK
Chan, JCY
Chan, HHL
AF Shek, Samantha Y.
Yeung, C. K.
Chan, Johnny C. Y.
Chan, Henry H. L.
TI SAFETY AND EFFICACY EVALUATION OF A COMBINED DEVICE USING INFRARED LIGHT
& BI-POLAR RADIOFREQUENCY AND SUBLATIVE RADIOFREQUENCY APPLICATORS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Conference of the
American-Society-for-Laser-Medicine-and-Surgery (ASLMS)
CY APR 03-07, 2013
CL Boston, MA
SP Amer Soc Laser Med & Surg (ASLMS)
C1 Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PD APR
PY 2013
VL 45
IS 4
BP 280
EP 280
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 135RT
UT WOS:000318306900045
ER
PT J
AU Ramos-Mendez, J
Perl, J
Faddegon, B
Schumann, J
Paganetti, H
AF Ramos-Mendez, Jose
Perl, Joseph
Faddegon, Bruce
Schuemann, Jan
Paganetti, Harald
TI Geometrical splitting technique to improve the computational efficiency
in Monte Carlo calculations for proton therapy
SO MEDICAL PHYSICS
LA English
DT Article
DE Monte Carlo; variance reduction; proton therapy; TOPAS; treatment head
ID DOSE-CALCULATION ALGORITHM; TRACK-REPEATING ALGORITHM; CLINICAL
IMPLEMENTATION; VARIANCE REDUCTION; BEAM THERAPY; PHOTON; SIMULATIONS;
DISTRIBUTIONS; RADIOTHERAPY; NOZZLE
AB Purpose: To present the implementation and validation of a geometrical based variance reduction technique for the calculation of phase space data for proton therapy dose calculation.
Methods: The treatment heads at the Francis H Burr Proton Therapy Center were modeled with a new Monte Carlo tool (TOPAS based on Geant4). For variance reduction purposes, two particle-splitting planes were implemented. First, the particles were split upstream of the second scatterer or at the second ionization chamber. Then, particles reaching another plane immediately upstream of the field specific aperture were split again. In each case, particles were split by a factor of 8. At the second ionization chamber and at the latter plane, the cylindrical symmetry of the proton beam was exploited to position the split particles at randomly spaced locations rotated around the beam axis. Phase space data in IAEA format were recorded at the treatment head exit and the computational efficiency was calculated. Depth-dose curves and beam profiles were analyzed. Dose distributions were compared for a voxelized water phantom for different treatment fields for both the reference and optimized simulations. In addition, dose in two patients was simulated with and without particle splitting to compare the efficiency and accuracy of the technique.
Results: A normalized computational efficiency gain of a factor of 10-20.3 was reached for phase space calculations for the different treatment head options simulated. Depth-dose curves and beam profiles were in reasonable agreement with the simulation done without splitting: within 1% for depth-dose with an average difference of (0.2 +/- 0.4)%, 1 standard deviation, and a 0.3% statistical uncertainty of the simulations in the high dose region; 1.6% for planar fluence with an average difference of (0.4 +/- 0.5)% and a statistical uncertainty of 0.3% in the high fluence region. The percentage differences between dose distributions in water for simulations done with and without particle splitting were within the accepted clinical tolerance of 2%, with a 0.4% statistical uncertainty. For the two patient geometries considered, head and prostate, the efficiency gain was 20.9 and 14.7, respectively, with the percentages of voxels with gamma indices lower than unity 98.9% and 99.7%, respectively, using 2% and 2 mm criteria.
Conclusions: The authors have implemented an efficient variance reduction technique with significant speed improvements for proton Monte Carlo simulations. The method can be transferred to other codes and other treatment heads. (C) 2013 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4795343]
C1 [Ramos-Mendez, Jose] Benemerita Univ Autonoma Puebla, Puebla 72750, Mexico.
[Perl, Joseph] SLAC Natl Accelerator Lab, Menlo Pk, CA 94025 USA.
[Faddegon, Bruce] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
[Schuemann, Jan; Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Schuemann, Jan; Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Ramos-Mendez, J (reprint author), Benemerita Univ Autonoma Puebla, 18 Sur & San Claudio Ave, Puebla 72750, Mexico.
EM joserm84@gmail.com
FU Consejo Nacional de Ciencia y Tecnologia (Mexico); Benemerita
Universidad Autonoma de Puebla; National Institutes of Health/National
Cancer Institute (NIH/NCI) [R01 CA 140735-01]
FX J.R.M. acknowledges the Consejo Nacional de Ciencia y Tecnologia
(Mexico) and H. Salazar-Ibarguen (Benemerita Universidad Autonoma de
Puebla) for financial supporting for his visit to the Massachusetts
General Hospital. J.R.M. thanks J. Shin (University of California San
Francisco) for discussions on Geant4 topics. This work was supported by
National Institutes of Health/National Cancer Institute (NIH/NCI) under
R01 CA 140735-01.
NR 41
TC 11
Z9 11
U1 0
U2 6
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD APR
PY 2013
VL 40
IS 4
AR 041718
DI 10.1118/1.4795343
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 130UP
UT WOS:000317945900024
PM 23556888
ER
PT J
AU Arroyo, JP
Kahle, KT
Gamba, G
AF Pablo Arroyo, Juan
Kahle, Kristopher T.
Gamba, Gerardo
TI The SLC12 family of electroneutral cation-coupled chloride
cotransporters
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE Diuretics; Hypertension; Epilepsy; WNK; Psoriasis; SLC12
ID NA+-CL-COTRANSPORTER; DISTAL CONVOLUTED TUBULE; SENSITIVE NA+;
BLOOD-PRESSURE; MOLECULAR PHYSIOLOGY; TERMINAL DOMAIN; ANGIOTENSIN-II;
CELL-VOLUME; WNK KINASES; HYPERTENSION
AB The SLC12 family encodes electroneutral cation-coupled chloride cotransporters that are critical for several physiological processes including cell volume regulation, modulation of intraneuronal chloride concentration, transepithelial ion movement, and blood pressure regulation. Members of this family are the targets of the most commonly used diuretic drugs, have been shown to be the causative genes for inherited disease such as Gitelman, Bartter and Andermann syndromes, and potentially play a role in polygenic complex diseases like arterial hypertension, epilepsy, osteoporosis, and cancer. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Pablo Arroyo, Juan; Gamba, Gerardo] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mol Physiol Unit, Mexico City 04510, DF, Mexico.
[Kahle, Kristopher T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Kahle, Kristopher T.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Gamba, G (reprint author), Mol Physiol Unit, Vasco de Quiroga 15, Mexico City 14000, DF, Mexico.
EM gamba@biomedicas.unam.mx
OI Arroyo, Juan Pablo/0000-0002-5992-5011
FU Swiss National Science Foundation through the National Center of
Competence in Research (NCCR) TransCure, University of Bern,
Switzerland; Wellcome Trust [091415]; Fondation Leducq; Mexican Council
of Science and Technology [165815]; Transatlantic Network on
Hypertension
FX Publication in part sponsored by the Swiss National Science Foundation
through the National Center of Competence in Research (NCCR) TransCure,
University of Bern, Switzerland: Director Matthias A. Hediger: Web:
http://www.transcure.ch.; We apologize to the authors of many studies on
SLC12 cotransporters whose work was not directly discussed owing to the
specific focus of this review. Due to limited references space, many
original articles that already are discussed in the reviews we cite,
were intentionally omitted to give space for more recent original work,
not included in aforementioned reviews. Supported in part by the
Wellcome Trust grant 091415, the Transatlantic Network on Hypertension
funded by the Fondation Leducq, and the Mexican Council of Science and
Technology grant No. 165815 to GG. JPA is a student in the Biomedical
Science Ph.D Program of the UNAM.
NR 70
TC 24
Z9 25
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0098-2997
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD APR-JUN
PY 2013
VL 34
IS 2-3
SI SI
BP 288
EP 298
DI 10.1016/j.mam.2012.05.002
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 135AK
UT WOS:000318258200013
PM 23506871
ER
PT J
AU Yoo, B
Pagel, MD
AF Yoo, Byunghee
Pagel, Mark D.
TI Lanthanide-Mediated Dephosphorylation Used for Peptide Cleavage during
Solid Phase Peptide Synthesis
SO MOLECULES
LA English
DT Article
DE lanthanide; dephosphorylation; peptide synthesis; solid phase
ID PHOSPHODIESTEROLYTIC ACTIVITY; PHOSPHATE-ESTERS; PHOSPHORIC-ACID;
DNA-LIKE; HYDROLYSIS; COMPLEXES; IONS; CHROMATOGRAPHY; EXTRACTION;
CATALYSIS
AB Lanthanide(III) ions can accelerate the hydrolysis of phosphomonoesters and phosphodiesters in neutral aqueous solution. In this paper, lanthanide-mediated dephosphorylation has been applied in aqueous media as an orthogonal cleavage condition that can be employed in conventional solid phase peptide synthesis (SPPS). A phosphorylated polymeric support for SPPS was developed using Boc chemistry. The cleavage of resin-bound phosphates was investigated with the addition of Eu(III), Yb(III), acid or base, a mixture of solvents or different temperatures. To demonstrate the utility of this approach for SPPS, a peptide sequence was synthesized on a phosphorylated polymeric support and quantitatively cleaved with lanthanide ions in neutral aqueous media. The protecting groups for side chains were retained during peptide cleavage using lanthanide ions. This new methodology provides a mild orthogonal cleavage condition of phosphoester as a linker during SPPS.
C1 [Yoo, Byunghee] Massachusetts Gen Hosp East, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Boston, MA 02129 USA.
[Pagel, Mark D.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85724 USA.
[Pagel, Mark D.] Univ Arizona, Dept Biomed Imaging, Tucson, AZ 85724 USA.
[Pagel, Mark D.] Univ Arizona, Dept Med Imaging, Tucson, AZ 85724 USA.
RP Pagel, MD (reprint author), Univ Arizona, Ctr Canc, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM byunghee@nmr.mgh.harvard.edu; mpagel@u.arizona.edu
FU National Cancer Institute of the NIH [CA133455-01]
FX We thank Josef Vagner and Lars Furenlid at the University of Arizona for
inspirational discussions. This work was supported by the National
Cancer Institute of the NIH (CA133455-01).
NR 37
TC 1
Z9 1
U1 3
U2 18
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD APR
PY 2013
VL 18
IS 4
BP 3894
EP 3905
DI 10.3390/molecules18043894
PG 12
WC Chemistry, Organic
SC Chemistry
GA 131TV
UT WOS:000318020100018
PM 23549296
ER
PT J
AU Sendler, E
Johnson, GD
Mao, SH
Goodrich, RJ
Diamond, MP
Hauser, R
Krawetz, SA
AF Sendler, Edward
Johnson, Graham D.
Mao, Shihong
Goodrich, Robert J.
Diamond, Michael P.
Hauser, Russ
Krawetz, Stephen A.
TI Stability, delivery and functions of human sperm RNAs at fertilization
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HUMAN-EJACULATED SPERMATOZOA; EARLY MOUSE EMBRYO; MESSENGER-RNA;
GENE-EXPRESSION; ALTERNATIVE POLYADENYLATION; EPIGENETIC MODIFICATIONS;
HUMAN SPERMATOGENESIS; CELL-DIFFERENTIATION; TARGET PREDICTION; HISTONE
RETENTION
AB Increasing attention has focused on the significance of RNA in sperm, in light of its contribution to the birth and long-term health of a child, role in sperm function and diagnostic potential. As the composition of sperm RNA is in flux, assigning specific roles to individual RNAs presents a significant challenge. For the first time RNA-seq was used to characterize the population of coding and non-coding transcripts in human sperm. Examining RNA representation as a function of multiple methods of library preparation revealed unique features indicative of very specific and stage-dependent maturation and regulation of sperm RNA, illuminating their various transitional roles. Correlation of sperm transcript abundance with epigenetic marks suggested roles for these elements in the pre- and post-fertilization genome. Several classes of non-coding RNAs including lncRNAs, CARs, pri-miRNAs, novel elements and mRNAs have been identified which, based on factors including relative abundance, integrity in sperm, available knockout data of embryonic effect and presence or absence in the unfertilized human oocyte, are likely to be essential male factors critical to early post-fertilization development. The diverse and unique attributes of sperm transcripts that were revealed provides the first detailed analysis of the biology and anticipated clinical significance of spermatozoal RNAs.
C1 [Sendler, Edward; Johnson, Graham D.; Mao, Shihong; Goodrich, Robert J.; Krawetz, Stephen A.] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA.
[Sendler, Edward; Mao, Shihong; Goodrich, Robert J.; Diamond, Michael P.; Krawetz, Stephen A.] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA.
[Hauser, Russ] Harvard Univ, Sch Publ Hlth, Sch Med, Massachusetts Gen Hosp,Dept Environm Hlth,Vincent, Boston, MA 02115 USA.
[Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Krawetz, SA (reprint author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA.
EM steve@compbio.med.wayne.edu
OI Diamond, Michael/0000-0001-6353-4489
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development [25PM6]; LIFE Study Working Group, Division of Epidemiology,
Statistics and Prevention Research; Harvard School of Public Health;
National Institute of Environmental Health Sciences [ES017285];
Charlotte B. Failing Professorship; State of Michigan's 21st Century
Fund Program
FX The authors are grateful to Ester Anton Martorell and Meritxell Jodar
Bifet for review and comments to the manuscript and Leah Sendler for her
visual review and identification of many transcript features. Samples
were also prepared for sequencing by Claudia Lalancette. Support by the
Intramural Research Program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, Contract 25PM6 in
collaboration with the LIFE Study Working Group, Division of
Epidemiology, Statistics and Prevention Research, which provided some of
the semen samples for analysis, is appreciated. Conceived and designed
the experiments: M. P. D., R. H., S. A. K.; Performed the experiments:
E. S., G.D.J., R.J.G.; Analyzed the data: E. S., G.D.J., S. M., S. A.
K.; Contributed reagents/materials/analysis tools: M. P. D., R. H.;
Wrote the manuscript: E. S., G.D.J., S. A. K.; Reviewed the manuscript:
E. S., G.D.J., S. M., R.J.G., M. P. D., R. H., S. A. K.; GENI pilot
grant from Harvard School of Public Health (to S. A. K. and R. H.);
National Institute of Environmental Health Sciences [ES017285 to R. H.];
Charlotte B. Failing Professorship (to S. A. K.); Michigan Core
Technology grant from the State of Michigan's 21st Century Fund Program
(to the Wayne State University Applied Genomics Technology Center).
Funding for open access charge: Charlotte B. Failing Professorship (to
S. A. K.).
NR 102
TC 69
Z9 72
U1 3
U2 29
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2013
VL 41
IS 7
BP 4104
EP 4117
DI 10.1093/nar/gkt132
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 133VD
UT WOS:000318167900029
PM 23471003
ER
PT J
AU Yigit, E
Zhang, QW
Xi, LQ
Grilley, D
Widom, J
Wang, JP
Rao, A
Pipkin, ME
AF Yigit, Erbay
Zhang, Quanwei
Xi, Liqun
Grilley, Dan
Widom, Jonathan
Wang, Ji-Ping
Rao, Anjana
Pipkin, Matthew E.
TI High-resolution nucleosome mapping of targeted regions using BAC-based
enrichment
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EUKARYOTIC GENOME; PAIR RESOLUTION; GENE-EXPRESSION; T-CELLS; DNA;
ORGANIZATION; CHROMATIN; DIFFERENTIATION; POSITIONS; PERFORIN
AB We report a target enrichment method to map nucleosomes of large genomes at unprecedented coverage and resolution by deeply sequencing locus-specific mononucleosomal DNA enriched via hybridization with bacterial artificial chromosomes. We achieved similar to 10 000-fold enrichment of specific loci, which enabled sequencing nucleosomes at up to similar to 500-fold higher coverage than has been reported in a mammalian genome. We demonstrate the advantages of generating high-sequencing coverage for mapping the center of discrete nucleosomes, and we show the use of the method by mapping nucleosomes during T cell differentiation using nuclei from effector T-cells differentiated from clonal, isogenic, naive, primary murine CD4 and CD8 T lymphocytes. The analysis reveals that discrete nucleosomes exhibit cell type-specific occupancy and positioning depending on differentiation status and transcription. This method is widely applicable to mapping many features of chromatin and discerning its landscape in large genomes at unprecedented resolution.
C1 [Yigit, Erbay; Grilley, Dan; Widom, Jonathan] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA.
[Zhang, Quanwei; Xi, Liqun; Wang, Ji-Ping] Northwestern Univ, Dept Stat, Evanston, IL 60208 USA.
[Rao, Anjana; Pipkin, Matthew E.] La Jolla Inst Allergy & Immunol, Div Signaling & Gene Express, La Jolla, CA 92037 USA.
[Rao, Anjana; Pipkin, Matthew E.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Rao, Anjana; Pipkin, Matthew E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Pipkin, ME (reprint author), Scripps Res Inst, Dept Canc Biol, 130 Scripps Way, Jupiter, FL 33458 USA.
EM jzwang@northwestern.edu; mpipkin@scripps.edu
RI Xi, Liqun/I-7689-2014
FU National Institutes of Health [R01AI95634, U54CA143869, R01CA42471,
R01AI 44432]; Cancer Research Institute
FX National Institutes of Health grants [R01AI95634 to M. E. P.,
U54CA143869 to J.P.W and J.W., R01CA42471 and R01AI 44432 to A. R.];
Fellowship from the Cancer Research Institute (to E.Y.) Funding for open
access charge: National Institutes of Health [R01AI95634 to M.E.P.].
NR 27
TC 8
Z9 8
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2013
VL 41
IS 7
AR e87
DI 10.1093/nar/gkt081
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 133VD
UT WOS:000318167900014
PM 23413004
ER
PT J
AU Liu, J
Lloyd, SG
AF Liu, Jian
Lloyd, Steven G.
TI High-fat, low-carbohydrate diet alters myocardial oxidative stress and
impairs recovery of cardiac function after ischemia and reperfusion in
obese rats
SO NUTRITION RESEARCH
LA English
DT Article
DE Diet; Rat; Myocardial ischemia; Obesity; Mitochondria; Oxidative stress
ID HIGH-PROTEIN-DIET; METABOLIC SYNDROME; MITOCHONDRIAL BIOGENESIS; NAD(P)H
OXIDASE; ADIPONECTIN; IMPACT; DYSFUNCTION; HEART; ACCUMULATION;
RECEPTORS
AB Obesity is associated with elevated risk of heart disease. A solid understanding of the safety and potential adverse effects of high-fat, low-carbohydrate diet (HFLCD) similar to that used by humans for weight loss on the heart is crucial. High fat intake is known to promote increases in reactive oxygen species and mitochondrial damage. We hypothesized that. there would be adverse effects of HFLCD on myocardial ischemia/reperfusion injury through enhancing oxidative stress injury and impairing mitochondrial biogenesis in a nongenetic, diet-induced rat model of obesity. To test the hypothesis, 250-g male Sprague-Dawley rats were fed an obesity-promoting diet for 7 weeks to induce obesity, then switched to HFLCD or a low-fat control diet for 2 weeks. Isolated hearts underwent global low flow ischemia for 60 minutes and reperfusion for 60 minutes. High-fat, low-carbohydrate diet resulted in greater weight gain and lower myocardial glycogen, plasma adiponectin, and insulin. Myocardial antioxidant gene transcript and protein expression of superoxide dismutase and catalase were reduced in HFLCD, along with increased oxidative gene NADPH oxidase-4 transcript and xanthine oxidase activity, and a 37% increase in nitrated protein (nitrotyrosine) in HFLCD hearts. The cardiac expression of key mitochondrial regulatory factors such as nuclear respiratory factor-1 and transcription factor A-mitochondrial were inhibited and myocardial mitochondrial DNA copy number decreased. The cardiac expression of adiponectin and its receptors was down-regulated in HFLCD. High-fat, low-carbohydrate diet impaired recovery of left ventricular rate-pressure product after ischemia/reperfusion and led to 3.5-fold increased injury as measured by lactate dehydrogenase release. In conclusion, HFLCD leads to increased ischemic myocardial injury and impaired recovery of function after reperfusion and was associated with attenuation of mitochondrial biogenesis and enhanced oxidative stress in obese rats. These findings may have important implications for diet selection in obese patients with ischemic heart disease. Published by Elsevier Inc.
C1 [Liu, Jian; Lloyd, Steven G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Lloyd, Steven G.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Lloyd, SG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
EM sglloyd@uab.edu
FU Scientist Development Grant from the American Heart Association
[0735212N]; NIH Grant [P30DK056336]
FX The present study was supported by Scientist Development Grant 0735212N
from the American Heart Association and, in part, by NIH Grant
P30DK056336. The authors would like to thank Qinglin Yang and C. Roger
White for assistance with the experiment.
NR 42
TC 13
Z9 14
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD APR
PY 2013
VL 33
IS 4
BP 311
EP 321
DI 10.1016/j.nutres.2013.02.005
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 134EI
UT WOS:000318192500009
PM 23602249
ER
PT J
AU Foley, OW
Rauh-Hain, JA
del Carmen, MG
AF Foley, Olivia W.
Rauh-Hain, J. Alejandro
del Carmen, Marcela G.
TI Recurrent Epithelial Ovarian Cancer: An Update on Treatment
SO ONCOLOGY-NEW YORK
LA English
DT Article
ID GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-II TRIAL; PLATINUM-BASED CHEMOTHERAPY;
PRIMARY PERITONEAL CANCER; PLATINUM/PACLITAXEL-REFRACTORY OVARIAN;
PEGYLATED LIPOSOMAL DOXORUBICIN; PACLITAXEL-RESISTANT OVARIAN;
SINGLE-AGENT PACLITAXEL; FALLOPIAN-TUBE CANCER; ANTITUMOR-ACTIVITY
AB An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
C1 [Foley, Olivia W.; Rauh-Hain, J. Alejandro; del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA USA.
RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9 E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 65
TC 35
Z9 35
U1 2
U2 4
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
J9 ONCOLOGY-NY
JI Oncology-NY
PD APR
PY 2013
VL 27
IS 4
BP 288
EP +
PG 8
WC Oncology
SC Oncology
GA 132IJ
UT WOS:000318060800007
PM 23781692
ER
PT J
AU Darden, PM
Thompson, DM
Roberts, JR
Hale, JJ
Pope, C
Naifeh, M
Jacobson, RM
AF Darden, Paul M.
Thompson, David M.
Roberts, James R.
Hale, Jessica J.
Pope, Charlene
Naifeh, Monique
Jacobson, Robert M.
TI Reasons for Not Vaccinating Adolescents: National Immunization Survey of
Teens, 2008-2010
SO PEDIATRICS
LA English
DT Article
DE adolescent; preventive health services; vaccination; immunization;
adolescent health services; preventive health services; vaccines;
meningococcal vaccines; papillomavirus vaccines; tetanus vaccine;
diphtheria-tetanus vaccine; attitude to health; patient acceptance of
health care; treatment refusal
ID HUMAN-PAPILLOMAVIRUS VACCINE; AGED 13-17 YEARS; UNITED-STATES;
ADVISORY-COMMITTEE; PRACTICES ACIP; COVERAGE; RECOMMENDATIONS; PARENT;
PERTUSSIS; COMMUNICATION
AB OBJECTIVE: To determine the reasons adolescents are not vaccinated for specific vaccines and how these reasons have changed over time.
METHODS: We analyzed the 2008-2010 National Immunization Survey of Teens examining reasons parents do not have their teens immunized. Parents whose teens were not up to date (Not-UTD) for Tdap/Td and MCV4 were asked the main reason they were not vaccinated. Parents of female teens Not-UTD for human papillomavirus vaccine (HPV) were asked their intent to give HPV, and those unlikely to get HPV were asked the main reason why not.
RESULTS: The most frequent reasons for not vaccinating were the same for Tdap/Td and MCV4, including "Not recommended" and "Not needed or not necessary." For HPV, the most frequent reasons included those for the other vaccines as well as 4 others, including "Not sexually active" and "Safety concerns/Side effects." "Safety concerns/Side effects" increased from 4.5% in 2008 to 7.7% in 2009 to 16.4% in 2010 and, in 2010, approaching the most common reason "Not Needed or Not Necessary" at 17.4% (95% CI: 15.7-19.1). Although parents report that health care professionals increasingly recommend all vaccines, including HPV, the intent to not vaccinate for HPV increased from 39.8% in 2008 to 43.9% in 2010 (OR for trend 1.08, 95% CI: 1.04-1.13).
CONCLUSIONS: Despite doctors increasingly recommending adolescent vaccines, parents increasingly intend not to vaccinate female teens with HPV. The concern about safety of HPV grew with each year. Addressing specific and growing parental concerns about HPV will require different considerations than those for the other vaccines.
C1 [Darden, Paul M.; Hale, Jessica J.; Naifeh, Monique] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pediat, Oklahoma City, OK 73190 USA.
[Thompson, David M.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Coll Publ Hlth, Oklahoma City, OK USA.
[Darden, Paul M.; Roberts, James R.] Med Univ S Carolina, Coll Med, Dept Pediat, Charleston, SC 29425 USA.
[Pope, Charlene] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA.
[Pope, Charlene] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Jacobson, Robert M.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA.
RP Darden, PM (reprint author), Suite 12400, Oklahoma City, OK 73104 USA.
EM paul-darden@ouhsc.edu
OI Jacobson, Robert/0000-0002-6355-8752
FU Pfizer; Novartis; Merck; US Department of Health and Human Services,
Health Resources and Services Administration, Maternal and Child Health
Research Program [R40 MC 21522]
FX Dr Darden has been a consultant and served on an advisory board to
Pfizer, Inc. in the past 3 years. Dr Jacobson has served in the past 3
years as a principal investigator for 2 multicenter vaccine studies
funded by Pfizer as well as 1 funded by Novartis, all conducted at Mayo
Clinic. He currently serves as a member of a safety review committee for
1 vaccine study as well as a member of a data and safety monitoring
board for 2 other vaccine studies, all funded by Merck. The other
authors have indicated they have no financial relationships relevant to
this article to disclose.; Supported by grant R40 MC 21522 through the
US Department of Health and Human Services, Health Resources and
Services Administration, Maternal and Child Health Research Program.
NR 30
TC 73
Z9 73
U1 5
U2 20
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD APR
PY 2013
VL 131
IS 4
BP 645
EP 651
DI 10.1542/peds.2012-2384
PG 7
WC Pediatrics
SC Pediatrics
GA 135EF
UT WOS:000318269500048
PM 23509163
ER
PT J
AU Balk, SJ
Fisher, DE
Geller, AC
AF Balk, Sophie J.
Fisher, David E.
Geller, Alan C.
TI Teens and Indoor Tanning: A Cancer Prevention Opportunity for
Pediatricians
SO PEDIATRICS
LA English
DT Article
DE indoor tanning; artificial tanning; teenagers; skin cancer; melanoma;
prevention; tanning addiction; tanning legislation
ID CUTANEOUS MALIGNANT-MELANOMA; BASAL-CELL CARCINOMAS;
ULTRAVIOLET-RADIATION; SKIN-CANCER; UNITED-STATES; YOUNG-ADULTS; SUN
EXPOSURE; FREQUENT TANNERS; BETA-ENDORPHIN; PLASMA-LEVELS
AB In October 2011, California became the first US state to ban indoor tanning for minors under age 18 years. Vermont followed in May 2012. Increasingly, scientific evidence shows that artificial tanning raises the risk of skin cancer, including melanoma, a common cancer in adolescents and young adults and the type most likely to result in death. The World Health Organization, the American Academy of Pediatrics, the American Academy of Dermatology, the American Medical Association, and other organizations strongly recommend legislation to ban minors under age 18 from indoor tanning. Several nations have banned teen tanning. Yet, tanning in salons is still a prevalent practice in the United States, especially among teen girls, where rates for the oldest teens approach 40%. There is no federal legislation to restrict minors from salon tanning. More than 60% of states have some kind of legislation regarding minors' use of tanning salons, but only California and Vermont have passed complete bans of indoor tanning for minors. The Indoor Tanning Association, an industry advocacy group, has vigorously opposed legislative efforts. Pediatricians can play key roles in counseling families and with legislative efforts. In this update, we review the prevalence of salon tanning, association with skin cancer risk, tanning addiction, the roles of the federal and state governments in regulation and legislation, and responses to arguments created by industry to oppose legislation. Preventing exposure to artificial tanning may save lives, including young lives, and is a key cancer prevention opportunity for pediatricians. Pediatrics 2013;131:772-785
C1 [Balk, Sophie J.] Albert Einstein Coll Med, Childrens Hosp Montefiore, Bronx, NY 10467 USA.
[Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Cutaneous Biol Res Ctr, Boston, MA USA.
[Geller, Alan C.] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Balk, SJ (reprint author), 1621 Eastchester Rd, Bronx, NY 10461 USA.
EM sbalk@montefiore.org
FU NCI NIH HHS [P01 CA163222]; NIAMS NIH HHS [R01 AR043369]
NR 79
TC 14
Z9 16
U1 0
U2 17
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD APR
PY 2013
VL 131
IS 4
BP 772
EP 785
DI 10.1542/peds.2012-2404
PG 14
WC Pediatrics
SC Pediatrics
GA 135EF
UT WOS:000318269500063
PM 23509165
ER
PT J
AU Oaklander, AL
Klein, MM
AF Oaklander, Anne Louise
Klein, Max M.
TI Evidence of Small-Fiber Polyneuropathy in Unexplained, Juvenile-Onset,
Widespread Pain Syndromes
SO PEDIATRICS
LA English
DT Article
DE peripheral nervous system disease; widespread chronic pain; dysautonomia
ID INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; SOCIETIES/PERIPHERAL
NERVE SOCIETY; PRACTICE PARAMETER EVALUATION; JOINT TASK-FORCE; SKIN
BIOPSY; SENSORY NEUROPATHY; AMERICAN-ACADEMY; INTRAVENOUS
IMMUNOGLOBULIN; ELECTRODIAGNOSTIC MEDICINE; ORTHOSTATIC HYPOTENSION
AB OBJECTIVE: We tested the hypothesis that acquired small-fiber polyneuropathy (SFPN), previously uncharacterized in children, contributes to unexplained pediatric widespread pain syndromes.
METHODS: Forty-one consecutive patients evaluated for unexplained widespread pain beginning before age 21 had medical records comprehensively analyzed regarding objective diagnostic testing for SFPN (neurodiagnostic skin biopsy, nerve biopsy, and autonomic function testing), plus histories, symptoms, signs, other tests, and treatments. Healthy, demographically matched volunteers provided normal controls for SFPN tests.
RESULTS: Age at illness onset averaged 12.3 +/- 5.7 years; 73% among this poly-ethnic sample were female (P = .001). Sixty-eight percent were chronically disabled, and 68% had hospitalizations. Objective testing diagnosed definite SFPN in 59%, probable SFPN in 17%, and possible SFPN in 22%. Only 1 of 41 had entirely normal SFPN test results. Ninety-eight percent of patients had other somatic complaints consistent with SFPN dysautonomia (90% cardiovascular, 82% gastrointestinal, and 34% urologic), 83% reported chronic fatigue, and 63% had chronic headache. Neurologic examinations identified reduced sensation in 68% and vasomotor abnormalities in 55%, including 23% with erythromelalgia. Exhaustive investigations for SFPN causality identified only history of autoimmune illnesses in 33% and serologic markers of disordered immunity in 89%. Treatment with corticosteroids and/or intravenous immune globulin objectively and subjectively benefited 80% of patients (12/15).
CONCLUSIONS: More than half among a large series of patients with childhood-onset, unexplained chronic widespread pain met rigorous, multitest, diagnostic criteria for SFPN, which extends the age range of acquired SFPN into early childhood. Some cases appeared immune-mediated and improved with immunomodulatory therapies.
C1 [Oaklander, Anne Louise; Klein, Max M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Oaklander, Anne Louise] Massachusetts Gen Hosp, Dept Pathol Neuropathol, Boston, MA 02114 USA.
RP Oaklander, AL (reprint author), Massachusetts Gen Hosp, 275 Charles St Warren 310, Boston, MA 02114 USA.
EM aoaklander@partners.org
FU Public Health Service [K24NS059892]; Department of Defense [GW093049];
Bradley and Curvey Family Foundations
FX Supported in part by the Public Health Service (K24NS059892), the
Department of Defense (GW093049), and the Bradley and Curvey Family
Foundations.
NR 65
TC 19
Z9 19
U1 1
U2 7
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD APR
PY 2013
VL 131
IS 4
BP E1091
EP E1100
DI 10.1542/peds.2012-2597
PG 10
WC Pediatrics
SC Pediatrics
GA 135EF
UT WOS:000318269500006
PM 23478869
ER
PT J
AU Andreassen, OA
Thompson, WK
Schork, AJ
Ripke, S
Mattingsdal, M
Kelsoe, JR
Kendler, KS
O'Donovan, MC
Rujescu, D
Werge, T
Sklar, P
Roddey, JC
Chen, CH
McEvoy, L
Desikan, RS
Djurovic, S
Dale, AM
AF Andreassen, Ole A.
Thompson, Wesley K.
Schork, Andrew J.
Ripke, Stephan
Mattingsdal, Morten
Kelsoe, John R.
Kendler, Kenneth S.
O'Donovan, Michael C.
Rujescu, Dan
Werge, Thomas
Sklar, Pamela
Roddey, J. Cooper
Chen, Chi-Hua
McEvoy, Linda
Desikan, Rahul S.
Djurovic, Srdjan
Dale, Anders M.
CA PGC Bipolar Disorder Grp
PGC Schizophrenia Working Grp
TI Improved Detection of Common Variants Associated with Schizophrenia and
Bipolar Disorder Using Pleiotropy-Informed Conditional False Discovery
Rate
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEX TRAITS; KRAEPELINIAN DICHOTOMY;
CONFERRING RISK; DSM-V; DISEASES; LOCI; SUSCEPTIBILITY; PSYCHOSIS;
INFERENCE
AB Several lines of evidence suggest that genome-wide association studies (GWAS) have the potential to explain more of the "missing heritability'' of common complex phenotypes. However, reliable methods to identify a larger proportion of single nucleotide polymorphisms (SNPs) that impact disease risk are currently lacking. Here, we use a genetic pleiotropy-informed conditional false discovery rate (FDR) method on GWAS summary statistics data to identify new loci associated with schizophrenia (SCZ) and bipolar disorders (BD), two highly heritable disorders with significant missing heritability. Epidemiological and clinical evidence suggest similar disease characteristics and overlapping genes between SCZ and BD. Here, we computed conditional Q-Q curves of data from the Psychiatric Genome Consortium (SCZ; n = 9,379 cases and n = 7,736 controls; BD: n = 6,990 cases and n = 4,820 controls) to show enrichment of SNPs associated with SCZ as a function of association with BD and vice versa with a corresponding reduction in FDR. Applying the conditional FDR method, we identified 58 loci associated with SCZ and 35 loci associated with BD below the conditional FDR level of 0.05. Of these, 14 loci were associated with both SCZ and BD (conjunction FDR). Together, these findings show the feasibility of genetic pleiotropy-informed methods to improve gene discovery in SCZ and BD and indicate overlapping genetic mechanisms between these two disorders.
C1 [Andreassen, Ole A.; Mattingsdal, Morten; Djurovic, Srdjan] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Psychosis Res, Oslo, Norway.
[Andreassen, Ole A.; Djurovic, Srdjan] Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway.
[Andreassen, Ole A.; Thompson, Wesley K.; Kelsoe, John R.; Chen, Chi-Hua; Dale, Anders M.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Schork, Andrew J.; Roddey, J. Cooper; Chen, Chi-Hua; McEvoy, Linda; Desikan, Rahul S.; Dale, Anders M.] Univ Calif San Diego, Multimodal Imaging Lab, La Jolla, CA 92093 USA.
[Schork, Andrew J.] Univ Calif San Diego, Cognit Sci Grad Program, La Jolla, CA 92093 USA.
[Schork, Andrew J.] Univ Calif San Diego, Ctr Human Dev, La Jolla, CA 92093 USA.
[Ripke, Stephan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kendler, Kenneth S.] Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
[O'Donovan, Michael C.] Cardiff Univ, Sch Med, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF10 3AX, S Glam, Wales.
[Rujescu, Dan] Univ Halle Wittenberg, Dept Psychiat, D-06108 Halle, Germany.
[Werge, Thomas] Univ Copenhagen, MHC, Inst Biol Psychiat, Copenhagen, Denmark.
[Sklar, Pamela] Mt Sinai Sch Med, Div Psychiat Genet & Genom, New York, NY USA.
[Roddey, J. Cooper; McEvoy, Linda; Desikan, Rahul S.; Dale, Anders M.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.
[Dale, Anders M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
RP Andreassen, OA (reprint author), Univ Oslo, Inst Clin Med, KG Jebsen Ctr Psychosis Res, Oslo, Norway.
EM o.a.andreassen@medisin.uio.no; amdale@ucsd.edu
RI Hansen, Thomas/O-5965-2014;
OI Hansen, Thomas/0000-0001-6703-7762; O'Donovan,
Michael/0000-0001-7073-2379; Andreassen, Ole A./0000-0002-4461-3568
FU Research Council of Norway; South-East Norway Health Authority; Kristian
Gerhard Jebsen Foundation; US-Norway Fulbright Foundation; National
Institutes of Health (NIH) [T32 EB005970]; NIH [R01AG031224,
R01EB000790, RC2DA29475]
FX OAA was supported by grants from the Research Council of Norway
(www.forskningsradet.no), the South-East Norway Health Authority
(www.helse-sorost.no), the Kristian Gerhard Jebsen Foundation
(http://www.stiftkgj.no), and the US-Norway Fulbright Foundation. RSD
was supported by a grant from the National Institutes of Health (NIH;
www.nih.gov T32 EB005970). AMD was supported by NIH grants R01AG031224,
R01EB000790, and RC2DA29475. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 45
TC 54
Z9 55
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2013
VL 9
IS 4
AR e1003455
DI 10.1371/journal.pgen.1003455
PG 16
WC Genetics & Heredity
SC Genetics & Heredity
GA 132MS
UT WOS:000318073300048
PM 23637625
ER
PT J
AU Becherel, OJ
Yeo, AJ
Stellati, A
Heng, EYH
Luff, J
Suraweera, AM
Woods, R
Fleming, J
Carrie, D
McKinney, K
Xu, XL
Deng, CX
Lavin, MF
AF Becherel, Olivier J.
Yeo, Abrey J.
Stellati, Alissa
Heng, Evelyn Y. H.
Luff, John
Suraweera, Amila M.
Woods, Rick
Fleming, Jean
Carrie, Dianne
McKinney, Kristine
Xu, Xiaoling
Deng, Chuxia
Lavin, Martin F.
TI Senataxin Plays an Essential Role with DNA Damage Response Proteins in
Meiotic Recombination and Gene Silencing
SO PLOS GENETICS
LA English
DT Article
ID SEX-CHROMOSOME INACTIVATION; OCULOMOTOR APRAXIA TYPE-2; DOUBLE-STRAND
BREAKS; CROSSING-OVER; GENOMIC INSTABILITY; GROWTH-RETARDATION;
MAMMALIAN MEIOSIS; MISMATCH REPAIR; DEFICIENT MICE; PROPHASE-I
AB Senataxin, mutated in the human genetic disorder ataxia with oculomotor apraxia type 2 (AOA2), plays an important role in maintaining genome integrity by coordination of transcription, DNA replication, and the DNA damage response. We demonstrate that senataxin is essential for spermatogenesis and that it functions at two stages in meiosis during crossing-over in homologous recombination and in meiotic sex chromosome inactivation (MSCI). Disruption of the Setx gene caused persistence of DNA double-strand breaks, a defect in disassembly of Rad51 filaments, accumulation of DNA:RNA hybrids (R-loops), and ultimately a failure of crossing-over. Senataxin localised to the XY body in a Brca1-dependent manner, and in its absence there was incomplete localisation of DNA damage response proteins to the XY chromosomes and ATR was retained on the axial elements of these chromosomes, failing to diffuse out into chromatin. Furthermore persistence of RNA polymerase II activity, altered ubH2A distribution, and abnormal XY-linked gene expression in Setx(-/-) revealed an essential role for senataxin in MSCI. These data support key roles for senataxin in coordinating meiotic crossing-over with transcription and in gene silencing to protect the integrity of the genome.
C1 [Becherel, Olivier J.; Yeo, Abrey J.; Stellati, Alissa; Heng, Evelyn Y. H.; Luff, John; Suraweera, Amila M.; Woods, Rick; Lavin, Martin F.] Queensland Inst Med Res, Radiat Biol & Oncol Lab, Brisbane, Qld 4006, Australia.
[Becherel, Olivier J.; Stellati, Alissa] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.
[Yeo, Abrey J.] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
[Fleming, Jean] Univ Otago, Dunedin, New Zealand.
[Carrie, Dianne] Queensland Inst Med Res, QCF Transgen Lab, Brisbane, Qld 4006, Australia.
[McKinney, Kristine] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Xu, Xiaoling; Deng, Chuxia] NIDDKD, Mammalian Genet Sect, NIH, Bethesda, MD 20892 USA.
[Lavin, Martin F.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia.
RP Becherel, OJ (reprint author), Queensland Inst Med Res, Radiat Biol & Oncol Lab, Brisbane, Qld 4006, Australia.
EM Martin.Lavin@qimr.edu.au
RI Lavin, Martin/F-5961-2014; Yeo, Abrey/D-9695-2015; deng,
chuxia/N-6713-2016
OI Lavin, Martin/0000-0002-5940-4769; Yeo, Abrey/0000-0003-4470-4854;
FU Australian National Health and Medical Research Council
FX Funding was obtained from the Australian National Health and Medical
Research Council. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 58
TC 32
Z9 33
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2013
VL 9
IS 4
AR e1003435
DI 10.1371/journal.pgen.1003435
PG 17
WC Genetics & Heredity
SC Genetics & Heredity
GA 132MS
UT WOS:000318073300029
PM 23593030
ER
PT J
AU Liu, L
Sabo, A
Neale, BM
Nagaswamy, U
Stevens, C
Lim, E
Bodea, CA
Muzny, D
Reid, JG
Banks, E
Coon, H
DePristo, M
Dinh, H
Fennel, T
Flannick, J
Gabriel, S
Garimella, K
Gross, S
Hawes, A
Lewis, L
Makarov, V
Maguire, J
Newsham, I
Poplin, R
Ripke, S
Shakir, K
Samocha, KE
Wu, YQ
Boerwinkle, E
Buxbaum, JD
Cook, EH
Devlin, B
Schellenberg, GD
Sutcliffe, JS
Daly, MJ
Gibbs, RA
Roeder, K
AF Liu, Li
Sabo, Aniko
Neale, Benjamin M.
Nagaswamy, Uma
Stevens, Christine
Lim, Elaine
Bodea, Corneliu A.
Muzny, Donna
Reid, Jeffrey G.
Banks, Eric
Coon, Hillary
DePristo, Mark
Dinh, Huyen
Fennel, Tim
Flannick, Jason
Gabriel, Stacey
Garimella, Kiran
Gross, Shannon
Hawes, Alicia
Lewis, Lora
Makarov, Vladimir
Maguire, Jared
Newsham, Irene
Poplin, Ryan
Ripke, Stephan
Shakir, Khalid
Samocha, Kaitlin E.
Wu, Yuanqing
Boerwinkle, Eric
Buxbaum, Joseph D.
Cook, Edwin H., Jr.
Devlin, Bernie
Schellenberg, Gerard D.
Sutcliffe, James S.
Daly, Mark J.
Gibbs, Richard A.
Roeder, Kathryn
TI Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum
Disorders and Population Controls
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; DE-NOVO MUTATIONS; COPY-NUMBER VARIATION;
SEQUENCING DATA; PRINCIPAL-COMPONENTS; FUNCTIONAL IMPACT; VARIANT
ANALYSIS; COMMON VARIANTS; LARGE-SCALE; GENES
AB We report on results from whole-exome sequencing (WES) of 1,039 subjects diagnosed with autism spectrum disorders (ASD) and 870 controls selected from the NIMH repository to be of similar ancestry to cases. The WES data came from two centers using different methods to produce sequence and to call variants from it. Therefore, an initial goal was to ensure the distribution of rare variation was similar for data from different centers. This proved straightforward by filtering called variants by fraction of missing data, read depth, and balance of alternative to reference reads. Results were evaluated using seven samples sequenced at both centers and by results from the association study. Next we addressed how the data and/or results from the centers should be combined. Gene-based analyses of association was an obvious choice, but should statistics for association be combined across centers (meta-analysis) or should data be combined and then analyzed (mega-analysis)? Because of the nature of many gene-based tests, we showed by theory and simulations that mega-analysis has better power than meta-analysis. Finally, before analyzing the data for association, we explored the impact of population structure on rare variant analysis in these data. Like other recent studies, we found evidence that population structure can confound case-control studies by the clustering of rare variants in ancestry space; yet, unlike some recent studies, for these data we found that principal component-based analyses were sufficient to control for ancestry and produce test statistics with appropriate distributions. After using a variety of gene-based tests and both meta- and mega-analysis, we found no new risk genes for ASD in this sample. Our results suggest that standard gene-based tests will require much larger samples of cases and controls before being effective for gene discovery, even for a disorder like ASD.
C1 [Liu, Li; Bodea, Corneliu A.; Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
[Sabo, Aniko; Nagaswamy, Uma; Muzny, Donna; Reid, Jeffrey G.; Dinh, Huyen; Gross, Shannon; Hawes, Alicia; Lewis, Lora; Boerwinkle, Eric; Gibbs, Richard A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Neale, Benjamin M.; Lim, Elaine; Ripke, Stephan; Samocha, Kaitlin E.; Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Neale, Benjamin M.; Lim, Elaine; Ripke, Stephan; Samocha, Kaitlin E.; Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA USA.
[Neale, Benjamin M.; Stevens, Christine; Lim, Elaine; Banks, Eric; DePristo, Mark; Fennel, Tim; Flannick, Jason; Gabriel, Stacey; Garimella, Kiran; Maguire, Jared; Poplin, Ryan; Ripke, Stephan; Shakir, Khalid; Samocha, Kaitlin E.; Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
[Coon, Hillary] Univ Utah, Dept Psychiat, Salt Lake City, UT USA.
[Makarov, Vladimir; Buxbaum, Joseph D.] Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, New York, NY USA.
[Makarov, Vladimir; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Newsham, Irene; Wu, Yuanqing] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA.
[Cook, Edwin H., Jr.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA.
[Devlin, Bernie] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Schellenberg, Gerard D.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Sutcliffe, James S.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Vanderbilt Brain Inst, Nashville, TN 37232 USA.
[Sutcliffe, James S.] Vanderbilt Univ, Dept Psychiat, Nashville, TN USA.
[Roeder, Kathryn] Carnegie Mellon Univ, Ray & Stephanie Lane Ctr Computat Biol, Pittsburgh, PA 15213 USA.
RP Liu, L (reprint author), Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
EM roeder@stat.cmu.edu
RI Liu, Li/G-1897-2015;
OI Sutcliffe, James/0000-0001-5200-6007; Buxbaum,
Joseph/0000-0001-8898-8313
FU NIH [R01MH089208, R01 MH089025, R01 MH089004, R01 MH089175, R01
MH089482, P50 HD055751, RO1 MH057881, R01 MH061009, UL1 RR024975, P30
HD015052, U54 HG003273, U54 HG003067]
FX This work was directly supported by NIH grants R01MH089208, R01
MH089025, R01 MH089004, R01 MH089175, R01 MH089482, P50 HD055751, RO1
MH057881, R01 MH061009, UL1 RR024975, P30 HD015052, U54 HG003273, and
U54 HG003067 (www.nih.gov). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 51
TC 43
Z9 43
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2013
VL 9
IS 4
AR e1003443
DI 10.1371/journal.pgen.1003443
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 132MS
UT WOS:000318073300037
PM 23593035
ER
PT J
AU Stone, AEL
Giugliano, S
Schnell, G
Cheng, LL
Leahy, KF
Golden-Mason, L
Gale, M
Rosen, HR
AF Stone, Amy E. L.
Giugliano, Silvia
Schnell, Gretja
Cheng, Linling
Leahy, Katelyn F.
Golden-Mason, Lucy
Gale, Michael, Jr.
Rosen, Hugo R.
TI Hepatitis C Virus Pathogen Associated Molecular Pattern (PAMP) Triggers
Production of Lambda-Interferons by Human Plasmacytoid Dendritic Cells
SO PLOS PATHOGENS
LA English
DT Article
ID ANTIVIRAL INNATE IMMUNITY; RIG-I; GENETIC-VARIATION; INFECTION;
RECOGNITION; RNA; REPLICATION; IL28B; EXPRESSION; CLEARANCE
AB Plasmacytoid Dendritic Cells (pDCs) represent a key immune cell in the defense against viruses. Through pattern recognition receptors (PRRs), these cells detect viral pathogen associated molecular patterns (PAMPs) and initiate an Interferon (IFN) response. pDCs produce the antiviral IFNs including the well-studied Type I and the more recently described Type III. Recent genome wide association studies (GWAS) have implicated Type III IFNs in HCV clearance. We examined the IFN response induced in a pDC cell line and ex vivo human pDCs by a region of the HCV genome referred to as the HCV PAMP. This RNA has been shown previously to be immunogenic in hepatocytes, whereas the conserved X-region RNA is not. We show that in response to the HCV PAMP, pDC-GEN2.2 cells upregulate and secrete Type III (in addition to Type I) IFNs and upregulate PRR genes and proteins. We also demonstrate that the recognition of this RNA is dependent on RIG-I-like Receptors (RLRs) and Toll-like Receptors (TLRs), challenging the dogma that RLRs are dispensable in pDCs. The IFNs produced by these cells in response to the HCV PAMP also control HCV replication in vitro. These data are recapitulated in ex vivo pDCs isolated from healthy donors. Together, our data shows that pDCs respond robustly to HCV RNA to make Type III Interferons that control viral replication. This may represent a novel therapeutic strategy for the treatment of HCV.
C1 [Stone, Amy E. L.; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA.
[Stone, Amy E. L.; Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hlth, Denver, CO USA.
[Stone, Amy E. L.; Giugliano, Silvia; Cheng, Linling; Leahy, Katelyn F.; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado Denver, Hepatitis C Ctr, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO USA.
[Schnell, Gretja; Gale, Michael, Jr.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA.
[Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Stone, AEL (reprint author), Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA.
EM Hugo.Rosen@UCDENVER.edu
OI Gale, Michael/0000-0002-6332-7436
FU VA Merit Review grant; NIH/NCATS Colorado CTSI [TL1 TR000155]; [U19 AI
1066328]
FX This work was supported by U19 AI 1066328 and a VA Merit Review grant.
Supported by NIH/NCATS Colorado CTSI Grant Number TL1 TR000155. Contents
are the authors' sole responsibility and do not necessarily represent
official NIH views. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 37
TC 35
Z9 35
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2013
VL 9
IS 4
AR e1003316
DI 10.1371/journal.ppat.1003316
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 132MN
UT WOS:000318072700053
PM 23637605
ER
PT J
AU Kallet, RH
Volsko, TA
Hess, DR
AF Kallet, Richard H.
Volsko, Teresa A.
Hess, Dean R.
TI Respiratory Care Year in Review 2012: Invasive Mechanical Ventilation,
Noninvasive Ventilation, and Cystic Fibrosis
SO RESPIRATORY CARE
LA English
DT Review
DE cystic fibrosis; mechanical ventilation; noninvasive ventilation;
respiratory failure
ID ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE
PULMONARY-DISEASE; POSITIVE-PRESSURE VENTILATION; LOWER TIDAL VOLUMES;
UNPLANNED EXTUBATION; DEAD-SPACE; NUTRITIONAL-STATUS; DISTRESS-SYNDROME;
PREVENTIVE USE
AB For the busy clinician, educator, or manager, it is becoming an increasing challenge to filter the literature to what is relevant to one's practice and then update one's practice based on the current evidence. The purpose of this paper is to review the recent literature related to invasive mechanical ventilation, noninvasive ventilation, and cystic fibrosis. These topics were chosen and reviewed in a manner that is most likely to have interest to the readers of RESPIRATORY CARE.
C1 [Kallet, Richard H.] Univ Calif San Francisco, Dept Anesthesia, Resp Care Serv, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
[Volsko, Teresa A.] Akron Childrens Hosp, Resp Care Dept, Akron, OH USA.
[Hess, Dean R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Resp Care Serv, Boston, MA USA.
RP Hess, DR (reprint author), Massachusetts Gen Hosp, Resp Care Serv, Ellison 401,55 Fruit St, Boston, MA 02114 USA.
EM dhess@partners.org
OI Volsko, Teresa/0000-0001-5111-898X
NR 64
TC 2
Z9 2
U1 0
U2 11
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
J9 RESP CARE
JI Respir. Care
PD APR
PY 2013
VL 58
IS 4
BP 702
EP 711
DI 10.4187/respcare.02412
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 134HO
UT WOS:000318201200018
PM 23564873
ER
PT J
AU Rogg, JG
White, BA
Biddinger, PD
Chang, YC
Brown, DFM
AF Rogg, Jonathan G.
White, Benjamin A.
Biddinger, Paul D.
Chang, Yuchiao
Brown, David F. M.
TI A Long-term Analysis of Physician Triage Screening in the Emergency
Department
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID IMPACT; THROUGHPUT; MORTALITY; FLOW
AB Objectives The problem of emergency department (ED) crowding is well recognized; however, little data exist on the sustainability of potential solutions, including physician triage and screening. The authors hypothesized that a physician triage screening program (Supplemented Triage and Rapid Treatment [START]) sustainably improves standard ED performance metrics. Methods This retrospective, observational, before-and-after study compared performance measures over 4years in a tertiary care urban academic medical center with approximately 90,000 annual ED visits. Patients seen between December 2006 and November 2010 were included. Outcome measures included length of stay (LOS) for ED patients, percentage of patients who left without completing assessment (LWCA), percentage of patients treated and dispositioned by START without using monitored beds, and door-to-room time. Descriptive statistics were used. Results Median LOS for START patients was 56minutes/patient lower when comparing 2010 to 2007 (p<0.0001) and for non-START patients 22minutes/patient lower (p<0.0001). The percentage of patients who LWCA decreased from 4.8% to 2.9% (p<0.0001) during the same time period. In START's first half-year, 18% of patients were discharged without using monitored beds. This increased to 29% by year 3. In addition, median door-to-room time decreased from 18.4 to 9.9minutes during the same 3-year interval. Conclusions Physician screening appears to provide sustainable improvements in ED performance metrics including ED LOS, percentage of patients who LWCA, door-to-room time, and percentage of patients treated without using a monitored bed, despite increasing ED volume. Physician screening delivers additional incremental benefits for severalyears after implementation and can effectively increase ED capacity by allowing emergency physicians to more efficiently use monitored beds. ACADEMIC EMERGENCY MEDICINE 2013; 20: 374-380 (C) 2013 by the Society for Academic Emergency Medicine
C1 [Rogg, Jonathan G.] Harvard Affiliated Emergency Med Residency, Boston, MA USA.
[White, Benjamin A.; Biddinger, Paul D.; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Div Gen Med, Boston, MA 02114 USA.
[Chang, Yuchiao] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[White, Benjamin A.; Biddinger, Paul D.; Brown, David F. M.] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA.
[Chang, Yuchiao] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Biddinger, Paul D.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
RP Brown, DFM (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Div Gen Med, Boston, MA 02114 USA.
EM dbrown2@partners.org
NR 25
TC 11
Z9 11
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD APR
PY 2013
VL 20
IS 4
BP 374
EP 380
DI 10.1111/acem.12113
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA 127EZ
UT WOS:000317681000010
PM 23701345
ER
PT J
AU Singh, JA
Jensen, M
Lewallen, D
AF Singh, Jasvinder A.
Jensen, Matthew
Lewallen, David
TI Predictors of periprosthetic fracture after total knee replacement An
analysis of 21,723 cases
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID SUPRACONDYLAR FRACTURE; TOTAL HIP; ARTHROPLASTY; FEMUR; OUTCOMES;
MORBIDITY; MORTALITY; INDEX; RISK; PAIN
AB Background and purpose Periprosthetic fracture is a devastating complication of total knee replacement (TKR). Most published studies have not comprehensively assessed clinical and demographic predictors. We wanted to determine the incidence and predictors of postoperative periprosthetic fracture after primary and revision TKR.
Patients and methods We used prospectively collected data in the Mayo Clinic Total Joint Registry on all patients who underwent primary or revision TKR at the Mayo Clinic, Rochester, from 1989 through 2008. We assessed incidence of postoperative periprosthetic fractures and modifiable (comorbidity, body mass index) and unmodifiable factors (age, sex, operative diagnosis, ASA class, previous cardiac disease, and previous thromboembolic disease) as predictors of postoperative periprosthetic fractures. We used multivariable-adjusted Cox regression analyses separately for primary and revision TKR.
Results 12,914 patients underwent 17,633 primary TKRs and 3,286 patients underwent 4,090 revision TKRs during the period 1989-2008. 1.1% of patients (188/17,633) after primary TKR and 2.5% of patients (104/4,090) after revision TKR sustained a postoperative periprosthetic fracture on or after postoperative day 1. Older age was associated with lower risk of periprosthetic fractures after primary TKR (p < 0.001). Compared to = 60 years, risk was lower for ages 61-70 years (hazard ratio (HR) = 0.5, 95% confidence interval (CI): 0.3-0.7)) and 71-80 years (HR = 0.6, CI: 0.4-0.8), but not for age > 80 years (HR = 0.9, CI: 0.5-1.6). In revision TKR cohort, a diagnosis of non-union (HR = 4.9, CI: 1.2-20), infection (HR = 2.9, CI: 1.3-6.4) or previous surgery with components removed (HR = 2.1, CI: 1.3-3.4) increased the risk of postoperative periprosthetic fracture, compared to a diagnosis of loosening/wear/osteolysis.
Interpretation We identified significant risk factors for periprosthetic fracture after primary and revision TKR. Patients with these risk factors can be informed by their surgeons of increased risk of this uncommon, but serious complication of TKR.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.
[Jensen, Matthew] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU National Institutes of Health (NIH) Clinical Translational Science Award
[1 KL2 RR024151-01]
FX We thank Youlonda Lochler for assistance in identifying the cohort for
analysis and Scott Harmsen for help with statistical analysis. This
published material is the result of work supported by the National
Institutes of Health (NIH) Clinical Translational Science Award 1 KL2
RR024151-01 (Mayo Clinic Center for Clinical and Translational Research)
and of the resources and use of facilities at the Birmingham VA Medical
Center, AL, USA.
NR 28
TC 5
Z9 7
U1 0
U2 4
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1745-3674
J9 ACTA ORTHOP
JI Acta Orthop.
PD APR
PY 2013
VL 84
IS 2
BP 170
EP 177
DI 10.3109/17453674.2013.788436
PG 8
WC Orthopedics
SC Orthopedics
GA 126ZF
UT WOS:000317661500009
PM 23530873
ER
PT J
AU Barbu, AM
Burns, JA
Lopez-Guerra, G
Landau-Zemer, T
Friedman, AD
Zeitels, SM
AF Barbu, Anca M.
Burns, James A.
Lopez-Guerra, Gerardo
Landau-Zemer, Tali
Friedman, Aaron D.
Zeitels, Steven M.
TI Salvage Endoscopic Angiolytic KTP Laser Treatment of Early Glottic
Cancer After Failed Radiotherapy
SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
LA English
DT Article; Proceedings Paper
CT Meeting of the
American-Laryngological-Rhinological-and-Otological-Society, Inc
CY APR 20-21, 2012
CL San Diego, CA
SP Amer Laryngolog Rhinolog & Otolog Soc, Inc
DE glottic cancer; glottis; laryngeal cancer; laser; microlaryngoscopy;
phonomicrosurgery; phonosurgery; radiation; vocal cord; vocal fold;
voice
ID CONSERVATION LARYNGEAL SURGERY; TUMOR ANGIOGENESIS; RADIATION FAILURE;
CARCINOMA; MICROSURGERY; MANAGEMENT; RECURRENCE; VOICE; T1
AB Objectives: Management of early glottic cancer subsequent to failed radiotherapy is challenging, especially in balancing oncological control and function preservation. Patients frequently have been incentivized against surgical management and thus have undergone radiotherapy as initial treatment. This history compounds the difficulty of discussions about surgical management after recurrence. Typically, endoscopic salvage has less morbidity than transcervical partial laryngectomy and is clearly desirable over total laryngectomy. However, there are appropriate concerns about the efficacy of endoscopic salvage and the overarching impact on larynx preservation and survival. Given our success with endoscopic angiolytic KTP laser treatment of previously nonirradiated T1 and T2 glottic cancers, we examined our results from treating similar-sized lesions after failed radiotherapy.
Methods: We performed a retrospective chart review of 20 patients from our cancer database who had undergone failed radiation therapy elsewhere for early glottic cancer and then underwent endoscopic angiolytic KTP laser treatment.
Results: Analysis of the geographic tumor recurrence of the 20 patients revealed T1a NO MO cancer in 4 patients, T1b N0 M0 cancer in 1 patient, T2a N0 M0 cancer in 1 patient, and T2b N0 M0 cancer in 14 patients. After KTP laser salvage treatment, 4 patients (20%) had local recurrence (all T2b) and required subsequent total laryngectomy, and 3 of these patients (15%) ultimately died of disease. The remaining 16 patients (80%) were free of disease at least 2 years after endoscopic salvage (average follow-up, 39 months).
Conclusions: Our investigation provides preliminary evidence that angiolytic KTP laser salvage treatment of early glottic cancer is an effective treatment after failed irradiation. Studies with larger cohorts and longer follow-up will be necessary to establish incontrovertible evidence of its efficacy.
C1 Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Zeitels, Steven M.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA.
RP Zeitels, SM (reprint author), Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, 1 Bowdoin Sq, Boston, MA 02114 USA.
NR 24
TC 3
Z9 3
U1 0
U2 2
PU ANNALS PUBL CO
PI ST LOUIS
PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 USA
SN 0003-4894
J9 ANN OTO RHINOL LARYN
JI Ann. Otol. Rhinol. Laryngol.
PD APR
PY 2013
VL 122
IS 4
BP 235
EP 239
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 125QD
UT WOS:000317555400004
PM 23697320
ER
PT J
AU Khoury, MJ
Lam, TK
Ioannidis, JPA
Hartge, P
Spitz, MR
Buring, JE
Chanock, SJ
Croyle, RT
Goddard, KA
Ginsburg, GS
Herceg, Z
Hiatt, RA
Hoover, RN
Hunter, DJ
Kramer, BS
Lauer, MS
Meyerhardt, JA
Olopade, OI
Palmer, JR
Sellers, TA
Seminara, D
Ransohoff, DF
Rebbeck, TR
Tourassi, G
Winn, DM
Zauber, A
Schully, SD
AF Khoury, Muin J.
Lam, Tram Kim
Ioannidis, John P. A.
Hartge, Patricia
Spitz, Margaret R.
Buring, Julie E.
Chanock, Stephen J.
Croyle, Robert T.
Goddard, Katrina A.
Ginsburg, Geoffrey S.
Herceg, Zdenko
Hiatt, Robert A.
Hoover, Robert N.
Hunter, David J.
Kramer, Barnet S.
Lauer, Michael S.
Meyerhardt, Jeffrey A.
Olopade, Olufunmilayo I.
Palmer, Julie R.
Sellers, Thomas A.
Seminara, Daniela
Ransohoff, David F.
Rebbeck, Timothy R.
Tourassi, Georgia
Winn, Deborah M.
Zauber, Ann
Schully, Sheri D.
TI Transforming Epidemiology for 21st Century Medicine and Public Health
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID CANCER-EPIDEMIOLOGY; TRANSLATIONAL RESEARCH; KNOWLEDGE INTEGRATION;
GENOMICS RESEARCH; UNITED-STATES; BIG-DATA; OPPORTUNITIES; SCIENCE;
THINKING; LESSONS
AB In 2012, the National Cancer Institute (NCI) engaged the scientific community to provide a vision for cancer epidemiology in the 21st century. Eight overarching thematic recommendations, with proposed corresponding actions for consideration by funding agencies, professional societies, and the research community emerged from the collective intellectual discourse. The themes are (i) extending the reach of epidemiology beyond discovery and etiologic research to include multilevel analysis, intervention evaluation, implementation, and outcomes research; (ii) transforming the practice of epidemiology by moving toward more access and sharing of protocols, data, metadata, and specimens to foster collaboration, to ensure reproducibility and replication, and accelerate translation; (iii) expanding cohort studies to collect exposure, clinical, and other information across the life course and examining multiple health-related endpoints; (iv) developing and validating reliable methods and technologies to quantify exposures and outcomes on a massive scale, and to assess concomitantly the role of multiple factors in complex diseases; (v) integrating "big data" science into the practice of epidemiology; (vi) expanding knowledge integration to drive research, policy, and practice; (vii) transforming training of 21st century epidemiologists to address interdisciplinary and translational research; and (viii) optimizing the use of resources and infrastructure for epidemiologic studies. These recommendations can transform cancer epidemiology and the field of epidemiology, in general, by enhancing transparency, interdisciplinary collaboration, and strategic applications of new technologies. They should lay a strong scientific foundation for accelerated translation of scientific discoveries into individual and population health benefits. Cancer Epidemiol Biomarkers Prev; 22(4); 508-16. (c) 2013 AACR.
C1 [Khoury, Muin J.; Lam, Tram Kim; Croyle, Robert T.; Seminara, Daniela; Winn, Deborah M.; Schully, Sheri D.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
[Hartge, Patricia; Chanock, Stephen J.; Hoover, Robert N.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Kramer, Barnet S.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA.
[Lauer, Michael S.] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA.
[Ioannidis, John P. A.] Stanford Univ, Dept Med, Stanford Prevent Res Ctr, Dept Hlth Res & Policy,Sch Med, Stanford, CA 94305 USA.
[Ioannidis, John P. A.] Stanford Univ, Dept Stat, Sch Humanities & Sci, Stanford, CA 94305 USA.
[Spitz, Margaret R.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Buring, Julie E.] Brigham & Womens Hosp, Div Med, Boston, MA 02115 USA.
[Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Cambridge, MA 02138 USA.
[Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Nutr, Cambridge, MA 02138 USA.
[Palmer, Julie R.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA.
[Goddard, Katrina A.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA.
[Ginsburg, Geoffrey S.] Duke Univ, Sch Med, Ctr Genom Med, Inst Genome Sci & Policy, Durham, NC USA.
[Herceg, Zdenko] Int Agcy Res Canc, F-69372 Lyon, France.
[Hiatt, Robert A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Olopade, Olufunmilayo I.] Univ Chicago Med, Dept Med, Ctr Clin Canc Genet & Global Hlth, Chicago, IL USA.
[Sellers, Thomas A.] Univ S Florida, H Lee Moffitt Canc Ctr, Off Director, Tampa, FL 33682 USA.
[Ransohoff, David F.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Ransohoff, David F.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Rebbeck, Timothy R.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Rebbeck, Timothy R.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Tourassi, Georgia] Oak Ridge Natl Lab, Computat Sci & Engn Div, Oak Ridge, TN USA.
[Zauber, Ann] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM muk1@CDC.GOV
RI Lauer, Michael/L-9656-2013;
OI Lauer, Michael/0000-0002-9217-8177; Palmer, Julie/0000-0002-6534-335X;
Tourassi, Georgia/0000-0002-9418-9638
FU Novartis
FX G.S. Ginsburg has a commercial research grant from Novartis. No
potential conflicts of interest were disclosed by the other authors.
NR 51
TC 50
Z9 52
U1 10
U2 80
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD APR
PY 2013
VL 22
IS 4
BP 508
EP 516
DI 10.1158/1055-9965.EPI-13-0146
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 130ZW
UT WOS:000317960900005
PM 23462917
ER
PT J
AU Berkey, CS
Willett, WC
Tamimi, RM
Rosner, B
Frazier, AL
Colditz, GA
AF Berkey, Catherine S.
Willett, Walter C.
Tamimi, Rulla M.
Rosner, Bernard
Frazier, A. Lindsay
Colditz, Graham A.
TI Dairy Intakes in Older Girls and Risk of Benign Breast Disease in Young
Women
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID CANCER-RISK; FOOD-CONSUMPTION; ADOLESCENT DIET; AMERICAN WOMEN; GROWTH;
QUESTIONNAIRE; VALIDATION; PATTERNS; WEIGHT; COHORT
AB Previous investigations found high dairy intakes in girls associated with rapid height growth and excess weight gain, which had opposite relationships with benign breast disease (BBD) in young women. We use data from the longitudinal Growing Up Today Study (GUTS) to investigate whether dairy intakes, in older children/adolescents, are associated with BBD risk in young women. GUTS includes 9,039 females, ages 9-15 years in 1996, who completed questionnaires annually through 2001, then in 2003, 2005, 2007, and 2010. Dietary food frequencies (1996-2001) obtained milk, yogurt, and cheese intakes. On 2005-2010 surveys, 7,011 females (18-29 years) reported whether a health care provider ever diagnosed them with BBD (n = 250) and if confirmed by breast biopsy (n 105). Logistic regression models estimated associations between prevalent biopsy-confirmed BBD and dairy intakes, adjusted for age and energy. Multivariable-adjusted models additionally included menarche age, childhood adiposity, adolescent alcohol consumption, and pregnancy. Further analyses stratified by family history. Age-energy-adjusted models of dairy (milk, yogurt, cheese, total dairy servings, dairy protein, dairy fat) intakes at 14 yr found no significant associations with BBD risk [milk: OR, 0.90/(serving/d); 95% confidence interval (CI), 0.76-1.05; dairy protein: OR, 0.98/(10 g/d); 95% CI, 0.82-1.17). Separate analyses of dairy intakes at 10 yr, intakes before the growth spurt, during the growth spurt, before menses-onset, and after menses-onset provided no significant associations with BBD. Multivariable adjustment, and family history stratification, did not alter the above findings. We conclude that dairy intakes by older girls have no strong relation with BBD risk in young women. Because of small number of cases, it is important to continue follow-up and re-examine later. Cancer Epidemiol Biomarkers Prev; 22(4); 670-4. (C) 2013 AACR.
C1 [Berkey, Catherine S.; Tamimi, Rulla M.; Rosner, Bernard] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Berkey, Catherine S.; Tamimi, Rulla M.; Rosner, Bernard] Harvard Univ, Sch Med, Boston, MA USA.
[Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Frazier, A. Lindsay] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Colditz, Graham A.] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA.
RP Berkey, CS (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.
EM Catherine.Berkey@channing.harvard.edu
RI Colditz, Graham/A-3963-2009
OI Colditz, Graham/0000-0002-7307-0291
FU Breast Cancer Research Foundation (NYC, NY); NIH (Bethesda, MD)
[DK46834]; American Institute for Cancer Research; American Cancer
Society
FX The study was supported by a grant from The Breast Cancer Research
Foundation (NYC, NY) and by DK46834 from the NIH (Bethesda, MD). A. L.
Frazier was supported by an award from the American Institute for Cancer
Research. G.A. Colditz was supported, in part, by an American Cancer
Society Clinical Research Professorship.
NR 25
TC 3
Z9 3
U1 2
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD APR
PY 2013
VL 22
IS 4
BP 670
EP 674
DI 10.1158/1055-9965.EPI-12-1133
PG 5
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 130ZW
UT WOS:000317960900024
PM 23542805
ER
PT J
AU Mondul, AM
Shui, IM
Yu, K
Travis, RC
Stevens, VL
Campa, D
Schumacher, FR
Ziegler, RG
Bueno-de-Mesquita, HB
Berndt, S
Crawford, ED
Gapstur, SM
Gaziano, JM
Giovannucci, E
Haiman, CA
Henderson, BE
Hunter, DJ
Johansson, M
Key, TJ
Le Marchand, L
Lindstrom, S
McCullough, ML
Navarro, C
Overvad, K
Palli, D
Purdue, M
Stampfer, MJ
Weinstein, SJ
Willett, WC
Yeager, M
Chanock, SJ
Trichopoulos, D
Kolonel, LN
Kraft, P
Albanes, D
AF Mondul, Alison M.
Shui, Irene M.
Yu, Kai
Travis, Ruth C.
Stevens, Victoria L.
Campa, Daniele
Schumacher, Frederick R.
Ziegler, Regina G.
Bueno-de-Mesquita, H. Bas
Berndt, Sonja
Crawford, E. D.
Gapstur, Susan M.
Gaziano, J. Michael
Giovannucci, Edward
Haiman, Christopher A.
Henderson, Brian E.
Hunter, David J.
Johansson, Mattias
Key, Timothy J.
Le Marchand, Loic
Lindstroem, Sara
McCullough, Marjorie L.
Navarro, Carmen
Overvad, Kim
Palli, Domenico
Purdue, Mark
Stampfer, Meir J.
Weinstein, Stephanie J.
Willett, Walter C.
Yeager, Meredith
Chanock, Stephen J.
Trichopoulos, Dimitrios
Kolonel, Laurence N.
Kraft, Peter
Albanes, Demetrius
TI Genetic Variation in the Vitamin D Pathway in Relation to Risk of
Prostate Cancer-Results from the Breast and Prostate Cancer Cohort
Consortium
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; D-BINDING PROTEIN; SUSCEPTIBILITY LOCI;
POLYMORPHISMS; PREVENTION; VARIANTS
AB Background: Studies suggest that vitamin D status may be associated with prostate cancer risk although the direction and strength of this association differs between experimental and observational studies. Genome-wide association studies have identified genetic variants associated with 25-hydroxyvitamin D [25(OH)D] status. We examined prostate cancer risk in relation to single-nucleotide polymorphisms (SNP) in four genes shown to predict circulating levels of 25(OH)D.
Methods: SNP markers localized to each of four genes (GC, CYP24A1, CYP2R1, and DHCR7) previously associated with 25(OH)D were genotyped in 10,018 cases and 11,052 controls from the National Cancer Institute (NCI) Breast and Prostate Cancer Cohort Consortium. Logistic regression was used to estimate the individual and cumulative association between genetic variants and risk of overall and aggressive prostate cancer.
Results: We observed a decreased risk of aggressive prostate cancer among men with the allele in rs6013897 near CYP24A1 associated with lower serum 25(OH)D [per A allele, OR, 0.86; 95% confidence interval (CI), 0.80-0.93; P-trend = 0.0002) but an increased risk for nonaggressive disease (per A allele: OR, 1.10; 95% CI, 1.04-1.17; P-trend = 0.002). Examination of a polygenic score of the four SNPs revealed statistically significantly lower risk of aggressive prostate cancer among men with a greater number of low vitamin D alleles (OR for 6-8 vs. 0-1 alleles, 0.66; 95% CI, 0.44-0.98; P-trend = 0.003).
Conclusions: In this large, pooled analysis, genetic variants related to lower 25(OH)D levels were associated with a decreased risk of aggressive prostate cancer.
Impact: Our genetic findings do not support a protective association between loci known to influence vitamin D levels and prostate cancer risk. Cancer Epidemiol Biomarkers Prev; 22(4); 688-96. (C) 2013 AACR.
C1 [Mondul, Alison M.; Yu, Kai; Ziegler, Regina G.; Berndt, Sonja; Purdue, Mark; Weinstein, Stephanie J.; Yeager, Meredith; Chanock, Stephen J.; Albanes, Demetrius] NCI, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA.
[Shui, Irene M.; Giovannucci, Edward; Hunter, David J.; Lindstroem, Sara; Stampfer, Meir J.; Willett, Walter C.; Trichopoulos, Dimitrios; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward; Hunter, David J.; Stampfer, Meir J.; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Div Cardiovasc Dis, Boston, MA 02115 USA.
[Giovannucci, Edward; Hunter, David J.; Stampfer, Meir J.; Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Gaziano, J. Michael] VA Boston Healthcare Syst, Boston, MA USA.
[Travis, Ruth C.; Key, Timothy J.] Univ Oxford, Nuffield Dept Clin Med, Canc Epidemiol Unit, Oxford, England.
[Stevens, Victoria L.; Gapstur, Susan M.; McCullough, Marjorie L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Campa, Daniele] German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany.
[Campa, Daniele] Univ Pisa, Dept Biol, Pisa, Italy.
[Palli, Domenico] Canc Res & Prevent Inst ISPO, Florence, Italy.
[Schumacher, Frederick R.; Haiman, Christopher A.; Henderson, Brian E.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Bueno-de-Mesquita, H. Bas] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
[Bueno-de-Mesquita, H. Bas] Univ Med Ctr, Dept Gastroenterol & Hepatol, Utrecht, Netherlands.
[Crawford, E. D.] Univ Colorado Hosp, Sect Urol Oncol, Aurora, CO USA.
[Johansson, Mattias] IARC, Lyon, France.
[Le Marchand, Loic; Kolonel, Laurence N.] Univ Hawaii, Epidemiol Program, Ctr Canc, Honolulu, HI 96822 USA.
[Navarro, Carmen] CIBERESP, Barcelona, Spain.
[Navarro, Carmen] Murcia Reg Hlth Council, Dept Epidemiol, Murcia, Spain.
[Overvad, Kim] Aarhus Univ, Dept Epidemiol, Sch Publ Hlth, Aarhus, Denmark.
[Overvad, Kim] Aarhus Univ Hosp, Dept Cardiol, Cardiovasc Res Ctr, Aalborg Hosp, DK-8000 Aarhus, Denmark.
RP Mondul, AM (reprint author), NCI, NIH, 6120 Execut Blvd,Suite 320, Rockville, MD 20852 USA.
EM mondulam@mail.nih.gov
RI Albanes, Demetrius/B-9749-2015; Campa, Daniele/K-1617-2016;
OI Campa, Daniele/0000-0003-3220-9944; Mondul, Alison/0000-0002-8843-1416;
PALLI, Domenico/0000-0002-5558-2437
FU U.S. NIH, NCI [U01-CA98233-07, U01-CA98710-06, U01-CA98216-06,
U01-CA98758-07]; NIH/NCI, Division of Cancer Epidemiology and Genetics;
National Research Service Award from the NCI, NIH [T32 CA09001]; U.S.
Army Department of Defense; NCI at the NIH; U.S. Public Health Service
contracts from the NCI, NIH [N01-CN-45165, N01-RC-45035, N01-RC-37004,
HHSN261201000006C, HHSN261200800001E]
FX This work was supported by the U.S. NIH, NCI cooperative agreements
U01-CA98233-07 (to D.J. Hunter), U01-CA98710-06 (to M.J. Thun),
U01-CA98216-06 to (E. Riboli and R. Kaaks), and U01-CA98758-07 (to B.E.
Henderson) and Intramural Research Program of NIH/NCI, Division of
Cancer Epidemiology and Genetics. I.M. Shui was supported by a National
Research Service Award (T32 CA09001) from the NCI, NIH and a U.S. Army
Department of Defense Prostate Cancer Post-doctoral Fellowship. The ATBC
Study was supported by the Intramural Research Program of the NCI at the
NIH. In addition, this research was supported by U.S. Public Health
Service contracts (N01-CN-45165, N01-RC-45035, N01-RC-37004,
HHSN261201000006C, and HHSN261200800001E) from the NCI, NIH.
NR 28
TC 15
Z9 15
U1 2
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD APR
PY 2013
VL 22
IS 4
BP 688
EP 696
DI 10.1158/1055-9965.EPI-13-0007-T
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 130ZW
UT WOS:000317960900027
PM 23377224
ER
PT J
AU Kinsey, CM
Channick, CL
AF Kinsey, C. Matthew
Channick, Colleen L.
TI Counterpoint: Are > 50 Supervised Procedures Required to Develop
Competency in Performing Endobronchial Ultrasound-Guided Transbronchial
Needle Aspiration for Lung Cancer Staging? No
SO CHEST
LA English
DT Editorial Material
ID CONTROLLED-TRIAL; LYMPH-NODES; MEDIASTINOSCOPY
C1 Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Channick, CL (reprint author), Massachusetts Gen Hosp, Pulm Special Procedures Unit, 55 Fruit St,Bigelow 952, Boston, MA 02114 USA.
EM cchannick@partners.org
NR 13
TC 8
Z9 8
U1 0
U2 2
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD APR
PY 2013
VL 143
IS 4
BP 891
EP 893
DI 10.1378/chest.12-2464
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 129VG
UT WOS:000317871500005
PM 23546479
ER
PT J
AU Kinsey, CM
Channick, CL
AF Kinsey, C. Matthew
Channick, Colleen L.
TI Rebuttal From Drs Kinsey and Channick
SO CHEST
LA English
DT Editorial Material
ID TRANSBRONCHIAL NEEDLE ASPIRATION; LEARNING-CURVE
C1 Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Channick, CL (reprint author), Massachusetts Gen Hosp, Pulm Special Procedures Unit, 55 Fruit St,Bigelow 952, Boston, MA 02114 USA.
EM cchannick@partners.org
NR 7
TC 0
Z9 0
U1 0
U2 2
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD APR
PY 2013
VL 143
IS 4
BP 894
EP 895
DI 10.1378/chest.12-2465
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 129VG
UT WOS:000317871500007
ER
PT J
AU Lipton, A
Cook, R
Brown, J
Body, JJ
Smith, M
Coleman, R
AF Lipton, A.
Cook, R.
Brown, J.
Body, J. J.
Smith, M.
Coleman, R.
TI Skeletal-related Events and Clinical Outcomes in Patients with Bone
Metastases and Normal Levels of Osteolysis: Exploratory Analyses
SO CLINICAL ONCOLOGY
LA English
DT Article
DE Bone marker; bone metastases; bone resorption; skeletal-related events;
survival; zoledronic acid
ID PLACEBO-CONTROLLED TRIAL; LONG-TERM EFFICACY; ZOLEDRONIC ACID;
PROSTATE-CANCER; BREAST-CANCER; SOLID TUMORS; DOUBLE-BLIND; LUNG-CANCER;
PHASE-III; MULTIPLE-MYELOMA
AB Aims: High levels of bone resorption markers (e.g. N-telopeptide of type I collagen; NTX) have been correlated with increased risks of skeletal-related events and death in patients with bone metastases from solid tumours. However, the disease course has not been well characterised in patients with bone metastases but normal NTX levels. Therefore, the aim of this study was to evaluate the patterns of skeletal morbidity in patients with normal NTX levels.
Materials and methods: Exploratory analyses were carried out on patients with bone metastases from breast cancer, castration-resistant prostate cancer, non-small cell lung cancer or other solid tumours treated with zoledronic acid (ZOL) in phase III trials. The effects of covariates on the relative risk of death were estimated using the Cox proportional hazard model. The prognostic values of covariates were compared between patients with normal (<64 nmol/mmol creatinine) versus elevated (>= 64 nmol/mmol creatinine) NTX levels.
Results: Among patients with normal baseline NTX (n = 501), less than 10% developed elevated NTX levels before a skeletal-related event or death during ZOL treatment over 12 months. The prognostic factors identified in these analyses were mostly similar across NTX groups. However, some indicators of aggressive disease (e.g. visceral/cerebral metastases from breast cancer) were associated with poor clinical outcomes only in the normal NTX group.
Conclusions: Skeletal-related events were generally not preceded or followed by transition to elevated NTX in patients treated with ZOL. Elevated baseline NTX and aggressive extraskeletal disease were independently associated with reduced survival. (C) 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Lipton, A.] Penn State Univ, Milton S Hershey Med Ctr, Penn State Canc Ctr, Div Hematol Oncol, Hershey, PA 17033 USA.
[Cook, R.] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada.
[Brown, J.] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England.
[Brown, J.; Coleman, R.] Univ Sheffield, Canc Res Ctr, Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
[Body, J. J.] Univ Hosp Brugmann ULB, Dept Med, Brussels, Belgium.
[Smith, M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Lipton, A (reprint author), Penn State Univ, Milton S Hershey Med Ctr, Penn State Canc Ctr, Div Hematol Oncol, Room C-6830,500 Univ Dr, Hershey, PA 17033 USA.
EM alipton@hmc.psu.edu
RI sebastianovitsch, stepan/G-8507-2013
FU Novartis Pharmaceuticals Corporation
FX The authors thank Ker-Ai Lee from the University of Waterloo for expert
assistance with the statistical analyses. We thank Tamalette Loh, PhD,
ProEd Communications, Inc.(R), for her medical editorial assistance with
this manuscript. The statistical analysis was funded through a
consulting contract between Novartis Pharmaceuticals Corporation and Dr
Cook; funding for medical editorial assistance was provided by Novartis
Pharmaceuticals Corporation.
NR 23
TC 11
Z9 11
U1 1
U2 9
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936-6555
J9 CLIN ONCOL-UK
JI Clin. Oncol.
PD APR
PY 2013
VL 25
IS 4
BP 217
EP 226
DI 10.1016/j.clon.2012.11.004
PG 10
WC Oncology
SC Oncology
GA 130BY
UT WOS:000317888900001
PM 23219232
ER
PT J
AU Herzlinger, S
Horton, ES
AF Herzlinger, Susan
Horton, Edward S.
TI Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic
and cardiovascular risks associated with type 2 diabetes
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Review
DE Exenatide; Liraglutide; Glucagon-like peptide-1; GLP-1 receptor
agonists; Cardiovascular comorbidities
ID GLUCAGON-LIKE PEPTIDE-1; IMPAIRED GLUCOSE-TOLERANCE; HUMAN GLP-1 ANALOG;
BETA-CELL FUNCTION; CORONARY-ARTERY-DISEASE; VEIN ENDOTHELIAL-CELLS;
ONCE-DAILY LIRAGLUTIDE; OPEN-LABEL TRIAL; GLYCEMIC CONTROL; RECEPTOR
AGONIST
AB Context: To examine whether widespread tissue expression of the glucagon-like peptide (GLP)-1 receptor supports the possibility of differential effects of GLP-1-based therapeutics on cardiac function, blood pressure, food intake, gastric emptying, and other regulatory activities. GLP-1 receptor agonists (RAs) have demonstrated pleiotropic effects on over-weight/obesity, hypertension, dyslipidemia, and cardiovascular (CV) disease. Food-regulatory effects have been demonstrated in preclinical and clinical trials, including reduced gastric motility and food intake leading to body weight reductions. Native GLP-1 and GLP-1 RAs have demonstrated cardioprotective effects in preclinical models.
Evidence acquisition: Using PubMed, we performed a search of the recent literature on GLP-1 and GLP-1 RAs.
Evidence synthesis: Preliminary clinical data indicate native GLP-1 has beneficial effects on endothelial cell function and vascular inflammation. Native GLP-1 and GLP-1 RAs have demonstrated renoprotective and antihypertensive effects, and reductions in lipid parameters. The GLP-1 RA liraglutide has also demonstrated positive effects on such markers of endothelial dysfunction as tumor necrosis factor-alpha and plasminogen activator inhibitor-1.
Conclusion: Preliminary data suggest GLP-1 RAs could benefit type 2 diabetes patients at risk for CV comorbidities. Additional studies are needed to confirm the extraglycemic and extrapancreatic effects and determine whether outcomes will translate into beneficial effects for patient care. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Herzlinger, Susan; Horton, Edward S.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Horton, ES (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM Edward.Horton@joslin.harvard.edu
FU Novo Nordisk Inc; Amylin; Eli Lilly and Company
FX Funding to support the preparation of this manuscript was provided by
Novo Nordisk Inc. This manuscript was prepared according to the
International Society for Medical Publication Professionals' "Good
Publication Practice for Communicating Company-Sponsored Medical
Research: the GPP2 Guidelines.'' The authors received no honorarium or
payment for their authorship of this review.; ESH has served as an
advisory board member and consultant to Amarin Corporation, PLC; Amylin
Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & CO. Inc.
and Gilead Sciences, Inc. In addition, ESH has served on Data Safety
Monitoring Boards for GI Dynamics, Inc.; Theracos, Inc. and Takeda
Pharmaceuticals U. S. A, Inc.; is a member of the Merck speakers bureau;
and has received research grant support from Amylin and Eli Lilly and
Company.
NR 93
TC 11
Z9 11
U1 2
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD APR
PY 2013
VL 100
IS 1
BP 1
EP 10
DI 10.1016/j.diabres.2012.11.009
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 128BY
UT WOS:000317744300010
PM 23332049
ER
PT J
AU Hou, JK
Chang, M
Nguyen, T
Kramer, JR
Richardson, P
Sansgiry, S
D'Avolio, LW
El-Serag, HB
AF Hou, Jason K.
Chang, Mimi
Thien Nguyen
Kramer, Jennifer R.
Richardson, Peter
Sansgiry, Shubhada
D'Avolio, Leonard W.
El-Serag, Hashem B.
TI Automated Identification of Surveillance Colonoscopy in Inflammatory
Bowel Disease Using Natural Language Processing
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Crohn's disease; Ulcerative colitis; Machine learning; Automated
retrieval console
ID ULCERATIVE-COLITIS; GUIDELINES; DIAGNOSIS; SYSTEM
AB Differentiating surveillance from non-surveillance colonoscopy for colorectal cancer in patients with inflammatory bowel disease (IBD) using electronic medical records (EMR) is important for practice improvement and research purposes, but diagnosis code algorithms are lacking. The automated retrieval console (ARC) is natural language processing (NLP)-based software that allows text-based document-level classification.
The purpose of this study was to test the feasibility and accuracy of ARC in identifying surveillance and non-surveillance colonoscopy in IBD using EMR.
We performed a split validation study of electronic reports of colonoscopy pathology for patients with IBD from the Michael E. DeBakey VA Medical Center. A gastroenterologist manually classified pathology reports as either derived from surveillance or non-surveillance colonoscopy. Pathology reports were randomly split into two sets: 70 % for algorithm derivation and 30 % for validation. An ARC generated classification model was applied to the validation set of pathology reports. The performance of the model was compared with manual classification for surveillance and non-surveillance colonoscopy.
A total of 575 colonoscopy pathology reports were available on 195 IBD patients, of which 400 reports were designated as training and 175 as testing sets. Within the testing set, a total of 69 pathology reports were classified as surveillance by manual review, whereas the ARC model classified 66 reports as surveillance for a recall of 0.77, precision of 0.80, and specificity of 0.88.
ARC was able to identify surveillance colonoscopy for IBD without customized software programming. NLP-based document-level classification may be used to differentiate surveillance from non-surveillance colonoscopy in IBD.
C1 [Hou, Jason K.; Chang, Mimi; Kramer, Jennifer R.; Richardson, Peter; Sansgiry, Shubhada; El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX USA.
[Hou, Jason K.; Chang, Mimi; Kramer, Jennifer R.; Richardson, Peter; Sansgiry, Shubhada; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Hou, Jason K.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Thien Nguyen; D'Avolio, Leonard W.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Cooperat Studies Coordinating Ctr, Jamaica Plain, MA USA.
[D'Avolio, Leonard W.] Harvard Univ, Sch Med, Div Aging, Boston, MA USA.
RP Hou, JK (reprint author), 1709 Dryden Rd,Suite 8-40, Houston, TX 77030 USA.
EM jkhou@bcm.edu
FU American College of Gastroenterology Junior Faculty Development Award;
Houston VA HSR&D Center of Excellence [HFP90-020]; Department of
Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service [MRP05-305]; National Institutes of
Health/National Institute of Diabetes and Digestive and Kidney Disease
Center [P30 DK56338, K24 DK078154-05]
FX The research reported here was supported by the American College of
Gastroenterology Junior Faculty Development Award to J.K. Hou, a pilot
grant from the Houston VA HSR&D Center of Excellence (HFP90-020) to J.K.
Hou, the Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development Service, grant MRP05-305 to
J.R. Kramer, and the National Institutes of Health/National Institute of
Diabetes and Digestive and Kidney Disease Center grant P30 DK56338, K24
DK078154-05.
NR 9
TC 7
Z9 7
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD APR
PY 2013
VL 58
IS 4
BP 936
EP 941
DI 10.1007/s10620-012-2433-8
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 126HX
UT WOS:000317605800007
PM 23086115
ER
PT J
AU Kostic, AD
Howitt, MR
Garrett, WS
AF Kostic, Aleksandar D.
Howitt, Michael R.
Garrett, Wendy S.
TI Exploring host-microbiota interactions in animal models and humans
SO GENES & DEVELOPMENT
LA English
DT Review
DE microbiome; microbiota; model organisms; symbiosis
ID HUMAN GUT MICROBIOME; INTESTINAL ALKALINE-PHOSPHATASE;
INFLAMMATORY-BOWEL-DISEASE; SCOLOPES LIGHT ORGAN; TOLL-LIKE RECEPTORS;
VIBRIO-FISCHERI; IMMUNE-SYSTEM; DROSOPHILA-MELANOGASTER;
EUPRYMNA-SCOLOPES; COMMENSAL MICROBIOTA
AB The animal and bacterial kingdoms have coevolved and coadapted in response to environmental selective pressures over hundreds of millions of years. The meta'omics revolution in both sequencing and its analytic pipelines is fostering an explosion of interest in how the gut microbiome impacts physiology and propensity to disease. Gut microbiome studies are inherently interdisciplinary, drawing on approaches and technical skill sets from the biomedical sciences, ecology, and computational biology. Central to unraveling the complex biology of environment, genetics, and microbiome interaction in human health and disease is a deeper understanding of the symbiosis between animals and bacteria. Experimental model systems, including mice, fish, insects, and the Hawaiian bobtail squid, continue to provide critical insight into how host-microbiota homeostasis is constructed and maintained. Here we consider how model systems are influencing current understanding of host-microbiota interactions and explore recent human microbiome studies.
C1 [Kostic, Aleksandar D.; Howitt, Michael R.; Garrett, Wendy S.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Kostic, Aleksandar D.; Howitt, Michael R.; Garrett, Wendy S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Kostic, Aleksandar D.; Howitt, Michael R.; Garrett, Wendy S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kostic, Aleksandar D.; Garrett, Wendy S.] Broad Inst Harvard & Massachusetts Inst Technol, Boston, MA 02141 USA.
RP Garrett, WS (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM wgarrett@hsph.harvard.edu
OI Kostic, Aleksandar/0000-0002-0837-4360
FU NIH [AI078942, R01CA154426, R01DK092405, GM099531, F32DK098826];
Burroughs Wellcome Fund; Searle Scholars Program; Lavietes Fund; Cancer
Research Institute
FX We thank members of the Garrett laboratory for discussion. Work from our
laboratory is supported by grants from the NIH (AI078942, R01CA154426,
R01DK092405, and GM099531 to W.S.G., and F32DK098826 to M.H.), the
Burroughs Wellcome Fund, the Searle Scholars Program, the Lavietes Fund,
and the Cancer Research Institute to W.S.G.
NR 168
TC 79
Z9 81
U1 12
U2 179
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD APR 1
PY 2013
VL 27
IS 7
BP 701
EP 718
DI 10.1101/gad.212522.112
PG 18
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 125YL
UT WOS:000317578000001
PM 23592793
ER
PT J
AU Ni, M
Chen, YW
Fei, T
Li, D
Lim, E
Liu, XS
Brown, M
AF Ni, Min
Chen, Yiwen
Fei, Teng
Li, Dan
Lim, Elgene
Liu, X. Shirley
Brown, Myles
TI Amplitude modulation of androgen signaling by c-MYC
SO GENES & DEVELOPMENT
LA English
DT Article
DE breast cancer; cistrome; AR; MYC; TCF7L2; FOXA1
ID EMBRYONIC STEM-CELLS; BREAST-CANCER; TRANSCRIPTIONAL NETWORK; PATHWAYS;
RECEPTOR; ACTIVATION; REPRESSION; FOXA1; EXPRESSION; ELEMENT
AB Androgen-stimulated growth of the molecular apocrine breast cancer subtype is mediated by an androgen receptor (AR)-regulated transcriptional program. However, the molecular details of this AR-centered regulatory network and the roles of other transcription factors that cooperate with AR in the network remain elusive. Here we report a positive feed-forward loop that enhances breast cancer growth involving AR, AR coregulators, and downstream target genes. In the absence of an androgen signal, TCF7L2 interacts with FOXA1 at AR-binding sites and represses the basal expression of AR target genes, including MYC. Direct AR regulation of MYC cooperates with AR-mediated activation of HER2/HER3 signaling. HER2/HER3 signaling increases the transcriptional activity of MYC through phosphorylation of MAD1, leading to increased levels of MYC/MAX heterodimers. MYC in turn reinforces the transcriptional activation of androgen-responsive genes. These results reveal a novel regulatory network in molecular apocrine breast cancers regulated by androgen and AR in which MYC plays a central role as both a key target and a cooperating transcription factor to drive oncogenic growth.
C1 [Ni, Min; Fei, Teng; Li, Dan; Lim, Elgene; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02215 USA.
[Ni, Min; Fei, Teng; Li, Dan; Lim, Elgene; Brown, Myles] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
[Chen, Yiwen; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Chen, Yiwen; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
RP Liu, XS (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
EM xsliu@jimmy.harvard.edu; myles_brown@dfci.harvard.edu
RI Fei, Teng/G-5324-2015;
OI Fei, Teng/0000-0001-5707-0673; Brown, Myles/0000-0002-8213-1658
FU Breast Cancer Research Foundation; National Cancer Institute
[P01CA080111]; National Human Genome Research Institute [R01HG004069];
Department of Defense [W81XWH-10-1-0037]
FX We thank members of the Brown laboratory for technical support and
helpful discussions. This work was supported by funding from the Breast
Cancer Research Foundation (to M. B.), the National Cancer Institute
(P01CA080111 to M. B.), the National Human Genome Research Institute
(R01HG004069 to X. S. L), and a Department of Defense Award
(W81XWH-10-1-0037 to M.N.).
NR 37
TC 30
Z9 32
U1 0
U2 9
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD APR 1
PY 2013
VL 27
IS 7
BP 734
EP 748
DI 10.1101/gad.209569.112
PG 15
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 125YL
UT WOS:000317578000004
PM 23530127
ER
PT J
AU Swirski, FK
Nahrendorf, M
AF Swirski, Filip K.
Nahrendorf, Matthias
TI Imaging macrophage development and fate in atherosclerosis and
myocardial infarction
SO IMMUNOLOGY AND CELL BIOLOGY
LA English
DT Review
DE atherosclerosis; imaging; macrophage; myocardial infarction
ID POSITRON-EMISSION-TOMOGRAPHY; ULTRASMALL SUPERPARAMAGNETIC PARTICLES;
MATRIX-METALLOPROTEINASE ACTIVATION; STEM-CELL PROLIFERATION; IN-VIVO;
HEMATOPOIETIC STEM; BONE-MARROW; CORONARY ATHEROSCLEROSIS; MONOCYTE
ACCUMULATION; INFLAMMATORY SITES
AB Macrophages are central regulators of disease progression in both atherosclerosis and myocardial infarction (MI). In atherosclerosis, macrophages are the dominant leukocyte population that influences lesional development. In MI, which is caused by atherosclerosis, macrophages accumulate readily and have important roles in inflammation and healing. Molecular imaging has grown considerably as a field and can reveal biological process at the molecular, cellular and tissue levels. Here, we explore how various imaging modalities, from intravital microscopy in mice to organ-level imaging in patients, are contributing to our understanding of macrophages and their progenitors in cardiovascular disease. Immunology and Cell Biology (20 1 3) 91, 297-303; doi:10.1038/icb.2012.72; published online 4 December 2012
C1 Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Swirski, FK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM mnahrendorf@mgh.harvard.edu
FU NHLBI [R01HL095612, R01HL095629, R01HL096576]
FX This work was supported in part by NHLBI grants R01HL095612, R01HL095629
and R01HL096576.
NR 74
TC 9
Z9 9
U1 3
U2 31
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0818-9641
J9 IMMUNOL CELL BIOL
JI Immunol. Cell Biol.
PD APR
PY 2013
VL 91
IS 4
BP 297
EP 303
DI 10.1038/icb.2012.72
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 131NA
UT WOS:000317999200006
PM 23207281
ER
PT J
AU Dalle, S
Poulalhon, N
Debarbieux, S
Zaharia, D
Mihm, MC
Lacouture, ME
Rosen, A
Marghoob, AA
Busam, KJ
Depaepe, L
Bringuier, PP
Richez, P
Baurain, JF
Bressac-de Paillerets, B
Balme, B
Thomas, L
AF Dalle, Stephane
Poulalhon, Nicolas
Debarbieux, Sebastien
Zaharia, Daniela
Mihm, Martin C.
Lacouture, Mario E.
Rosen, Alyx
Marghoob, Ashfaq A.
Busam, Klaus J.
Depaepe, Lauriane
Bringuier, Pierre-Paul
Richez, Pauline
Baurain, Jean-Francois
Bressac-de Paillerets, Brigitte
Balme, Brigitte
Thomas, Luc
TI Tracking of Second Primary Melanomas in Vemurafenib-Treated Patients
SO JAMA DERMATOLOGY
LA English
DT Letter
C1 [Dalle, Stephane; Poulalhon, Nicolas; Debarbieux, Sebastien; Zaharia, Daniela; Thomas, Luc] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Unit Dermatol, Lyon, France.
[Dalle, Stephane; Zaharia, Daniela; Thomas, Luc] Univ Lyon 1, F-69365 Lyon, France.
[Dalle, Stephane] Canc Res Ctr Lyon, Lyon, France.
[Mihm, Martin C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Mihm, Martin C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lacouture, Mario E.; Rosen, Alyx; Marghoob, Ashfaq A.] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY 10021 USA.
[Busam, Klaus J.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
[Depaepe, Lauriane; Bringuier, Pierre-Paul; Balme, Brigitte] Hosp Civils Lyon, Hop Edouard Herriot, Ctr Hosp Lyon Sud, Unit Pathol, Lyon, France.
[Richez, Pauline] Catholic Univ Louvain, Clin Univ St Luc, Ctr Canc, Dept Dermatol, B-1200 Brussels, Belgium.
[Baurain, Jean-Francois] Catholic Univ Louvain, Clin Univ St Luc, Ctr Canc, Dept Oncol, B-1200 Brussels, Belgium.
[Bressac-de Paillerets, Brigitte] Inst Cancerol Gustave Roussy, Dept Biopathol, Serv Genet, Villejuif, France.
[Bressac-de Paillerets, Brigitte] INSERM, U946, Genet Variat & Human Dis Unit, Paris, France.
RP Dalle, S (reprint author), Ctr Hosp Lyon Sud, Serv Dermatol, F-69495 Lyon, France.
EM stephane.dalle@chu-lyon.fr
NR 5
TC 15
Z9 15
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD APR
PY 2013
VL 149
IS 4
BP 488
EP 490
DI 10.1001/jamadermatol.2013.21
PG 4
WC Dermatology
SC Dermatology
GA 127XH
UT WOS:000317731700025
PM 23715012
ER
PT J
AU Patel, SM
Thames, AD
Arbid, N
Panos, SE
Castellon, S
Hinkin, CH
AF Patel, Sapna M.
Thames, April D.
Arbid, Natalie
Panos, Stella E.
Castellon, Steven
Hinkin, Charles H.
TI The aggregate effects of multiple comorbid risk factors on cognition
among HIV-infected individuals
SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY
LA English
DT Article
DE HIV; Neuropsychology; Comorbid risk factors; Aging; Cognition
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; INTIMA-MEDIA THICKNESS;
NEUROPSYCHOLOGICAL TEST-PERFORMANCE; ANTIRETROVIRAL THERAPY; MEDICATION
ADHERENCE; DRUG-USE; METHAMPHETAMINE DEPENDENCE; NEUROCOGNITIVE
DISORDERS; CARDIOVASCULAR-DISEASE
AB This study developed and then cross-validated a novel weighting algorithm based on multiple comorbid risk factors (stimulant use, vascular disease, hepatitis C, HIV disease severity, cognitive reserve) to predict cognitive functioning among 366 HIV+ adults. The resultant risk severity score was used to differentially weight, as a function of age, the impact and magnitude of multiple risk factors on cognition. Among older adults (50 years) the risk severity index was differentially predictive of learning/memory and verbal fluency, whereas among younger adults it was linked to working memory and executive function. Cognitive reserve was found to be the most robust predictor of neurocognition.
C1 [Patel, Sapna M.; Thames, April D.; Panos, Stella E.; Castellon, Steven; Hinkin, Charles H.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
[Patel, Sapna M.; Thames, April D.; Arbid, Natalie; Panos, Stella E.; Castellon, Steven; Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Patel, SM (reprint author), Univ Calif Los Angeles, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA.
EM smpatel@mednet.ucla.edu
RI Thames, April/K-1964-2014
OI Thames, April/0000-0001-8414-7189
FU National Institute on Drug Abuse [R01 DA 13799]; National Institute of
Mental Health [T32 MH19535]; NIMH [T32MH19535, K23MH095661]
FX This study was supported by a grant from the National Institute on Drug
Abuse (R01 DA 13799) and by the National Institute of Mental Health
Training Grant (T32 MH19535; PI: Charles Hinkin). Dr. Patel and Dr.
Panos are supported by the NIMH Institutional Training Grant (No.
T32MH19535) and Dr. Thames is supported by NIMH Grant (No. K23MH095661).
We would also like to acknowledge the help from members of our
laboratory: Sara-Beth Lawrence, Tim Arentsen, and Vanessa Streiff.
NR 89
TC 7
Z9 7
U1 3
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1380-3395
J9 J CLIN EXP NEUROPSYC
JI J. Clin. Exp. Neuropsychol.
PD APR 1
PY 2013
VL 35
IS 4
BP 421
EP 434
DI 10.1080/13803395.2013.783000
PG 14
WC Psychology, Clinical; Clinical Neurology; Psychology
SC Psychology; Neurosciences & Neurology
GA 129LR
UT WOS:000317841600008
PM 23547924
ER
PT J
AU Villamar, MF
Wivatvongvana, P
Patumanond, J
Bikson, M
Truong, DQ
Datta, A
Fregni, F
AF Villamar, Mauricio F.
Wivatvongvana, Pakorn
Patumanond, Jayanton
Bikson, Marom
Truong, Dennis Q.
Datta, Abhishek
Fregni, Felipe
TI Focal Modulation of the Primary Motor Cortex in Fibromyalgia Using
4x1-Ring High-Definition Transcranial Direct Current Stimulation
(HD-tDCS): Immediate and Delayed Analgesic Effects of Cathodal and
Anodal Stimulation
SO JOURNAL OF PAIN
LA English
DT Article
DE Fibromyalgia; chronic pain; transcranial direct current stimulation
(tDCS); high-definition transcranial direct current stimulation
(HD-tDCS); electrical brain stimulation; transcranial electrical
stimulation (tES)
ID NONINVASIVE BRAIN-STIMULATION; CHRONIC WIDESPREAD PAIN; DC STIMULATION;
MAGNETIC STIMULATION; CENTRAL SENSITIZATION; GENERAL-POPULATION; TENDER
POINTS; PERCEPTION; THRESHOLDS; PREVALENCE
AB Fibromyalgia is a prevalent chronic pain syndrome characterized by altered pain and sensory processing in the central nervous system, which is often refractory to multiple therapeutic approaches. Given previous evidence supporting analgesic properties of noninvasive brain stimulation techniques in this condition, this study examined the effects of a novel, more focal method of transcranial direct current stimulation (tDCS), using the 4x1-ring configuration of high-definition (HD)-tDCS, on overall perceived pain in fibromyalgia patients. In this patient- and assessor-blind, sham-controlled, crossover trial, 18 patients were randomized to undergo single 20-minute sessions of anodal, cathodal, and sham HD-tDCS at 2.0 mA in a counterbalanced fashion. The center electrode was positioned over the left primary motor cortex. Pain scales and sensory testing were assessed before and after each intervention. A finite element method brain model was generated to predict electric field distribution. We found that both active stimulation conditions led to significant reduction in overall perceived pain as compared to sham. This effect occurred immediately after cathodal HD-tDCS and was evident for both anodal and cathodal HD-tDCS 30 minutes after stimulation. Furthermore, active anodal stimulation induced a significant bilateral increase in mechanical detection thresholds. These interventions proved well tolerated in our patient population.
Perspective: 4x1-ring HD-tDCS, a novel noninvasive brain stimulation technique capable of more focal and targeted stimulation, provides significant reduction in overall perceived pain in fibromyalgia patients as compared to sham stimulation, irrespective of current polarity. This technique may have other applications in research and clinical settings, which should be further explored. (C) 2013 by the American Pain Society
C1 [Villamar, Mauricio F.; Wivatvongvana, Pakorn; Datta, Abhishek; Fregni, Felipe] Spaulding Rehabil Hosp, Lab Neuromodulat, Dept Phys Med & Rehabil, Boston, MA 02114 USA.
[Villamar, Mauricio F.; Wivatvongvana, Pakorn; Datta, Abhishek; Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Villamar, Mauricio F.] Pontifical Catholic Univ Ecuador, Sch Med, Quito, Ecuador.
[Wivatvongvana, Pakorn] Chiang Mai Univ, Fac Med, Dept Rehabil Med, Chiang Mai 50000, Thailand.
[Wivatvongvana, Pakorn] Chiang Mai Univ, Fac Med, Clin Epidemiol & Clin Stat Unit, Chiang Mai 50000, Thailand.
[Bikson, Marom; Truong, Dennis Q.; Datta, Abhishek] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA.
RP Fregni, F (reprint author), Spaulding Rehabil Hosp, Lab Neuromodulat, 125 Nashua St 726, Boston, MA 02114 USA.
EM ffregni@post.harvard.edu
FU Translational Research Award from the Wallace H. Coulter Foundation
FX Funded by a Translational Research Award from the Wallace H. Coulter
Foundation.
NR 55
TC 39
Z9 42
U1 0
U2 15
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2013
VL 14
IS 4
BP 371
EP 383
DI 10.1016/j.jpain.2012.12.007
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 126RP
UT WOS:000317639200012
PM 23415877
ER
PT J
AU Chen, L
Vo, T
Seefeld, L
Malarick, C
Houghton, M
Ahmed, S
Zhang, Y
Cohen, A
Retamozo, C
St Hilaire, K
Zhang, V
Mao, JR
AF Chen, Lucy
Trang Vo
Seefeld, Lindsey
Malarick, Charlene
Houghton, Mary
Ahmed, Shihab
Zhang, Yi
Cohen, Abigail
Retamozo, Cynthia
St Hilaire, Kristen
Zhang, Vivian
Mao, Jianren
TI Lack of Correlation Between Opioid Dose Adjustment and Pain Score Change
in a Group of Chronic Pain Patients
SO JOURNAL OF PAIN
LA English
DT Article
DE Opioid therapy; chronic pain; opioid dose adjustment; numeric pain score
ID CHRONIC NONCANCER PAIN; NEUROPATHIC PAIN; THERAPY; EFFICACY; ESCALATION;
MISUSE; ABUSE
AB Despite the increasing use of opioid analgesics for chronic pain management, it is unclear whether opioid dose escalation leads to better pain relief during chronic opioid therapy. In this study, we retrospectively analyzed clinical data collected from the Massachusetts General Hospital Center for Pain Medicine over a 7-year period. We examined 1) the impact of opioid dose adjustment (increase or decrease) on clinical pain score; 2) gender and age differences in response to opioid therapy; and 3) the influence of clinical pain conditions on the opioid analgesic efficacy. A total of 109 subjects met the criteria for data collection. We found that neither opioid dose increase, nor decrease, correlated with point changes in clinical pain score in a subset of chronic pain patients over a prolonged course of opioid therapy (an average of 704 days). This lack of correlation was consistent regardless of the type of chronic pain including neuropathic, nociceptive, or mixed pain conditions. Neither gender nor age differences showed a significant influence on the clinical response to opioid therapy in these subjects. These results suggest that dose adjustment during opioid therapy may not necessarily alter long-term clinical pain score in a group of chronic pain patients and that individualized opioid therapy based on the clinical effectiveness should be considered to optimize the treatment outcome.
Perspective: The study reports a relationship, or lack thereof, between opioid dose change and clinical pain score in a group of chronic pain patients. The study also calls for further investigation into the effectiveness of opioid therapy in the management of chronic nonmalignant pain conditions. (C) 2013 by the American Pain Society
C1 [Chen, Lucy; Trang Vo; Seefeld, Lindsey; Malarick, Charlene; Houghton, Mary; Ahmed, Shihab; Zhang, Yi; Cohen, Abigail; Retamozo, Cynthia; St Hilaire, Kristen; Zhang, Vivian; Mao, Jianren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA.
RP Chen, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA.
EM llchen@partners.org
FU NIH [RO1 DA022576, P20 DA026002, RO1 AT005819]
FX This work was supported by NIH grants RO1 DA022576, P20 DA026002, and
RO1 AT005819.
NR 29
TC 9
Z9 9
U1 0
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2013
VL 14
IS 4
BP 384
EP 392
DI 10.1016/j.jpain.2012.12.012
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 126RP
UT WOS:000317639200013
PM 23452826
ER
PT J
AU Psutka, SP
Cendron, M
AF Psutka, Sarah P.
Cendron, Marc
TI Bladder diverticula in children
SO JOURNAL OF PEDIATRIC UROLOGY
LA English
DT Review
DE Bladder; Diverticulum; Bladder diverticula; Children; Paraureteral
diverticulum
ID EHLERS-DANLOS-SYNDROME; WILLIAMS-BEUREN-SYNDROME; PARAURETERAL
DIVERTICULA; VESICAL DIVERTICULA; URINARY-BLADDER; VESICOURETERAL
REFLUX; SOTOS-SYNDROME; DIAGNOSIS; OBSTRUCTION; MANAGEMENT
AB This review of bladder diverticula in children includes: historical aspects of the condition, its presentation and diagnosis, as well as management options. The purpose of the review is to provide a comprehensive and in-depth understanding of a relatively infrequent but clinically challenging urologic abnormality that may affect not only the bladder but also the upper urinary tract and kidney. (C) 2012 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
C1 [Psutka, Sarah P.] Childrens Hosp Boston, Dept Urol, Boston, MA 02115 USA.
[Cendron, Marc] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
RP Cendron, M (reprint author), Massachusetts Gen Hosp, Dept Urol, 55 Fruit St, Boston, MA 02114 USA.
EM Marc.Cendron@childrens.harvard.edu
NR 50
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-5131
J9 J PEDIATR UROL
JI J. Pediatr. Urol
PD APR
PY 2013
VL 9
IS 2
BP 129
EP 138
DI 10.1016/j.jpurol.2012.02.013
PG 10
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 129KI
UT WOS:000317837600010
PM 22658330
ER
PT J
AU Coit, DG
Andtbacka, R
Anker, CJ
Bichakjian, CK
Carson, WE
Daud, A
DiMaio, D
Fleming, MD
Guilds, V
Halpern, AC
Hodi, FS
Kelley, MC
Khushalani, NI
Kudchadkar, RR
Lange, JR
Lind, A
Martini, MC
Olszanski, AJ
Pruitt, SK
Ross, MI
Swetter, SM
Tanabe, KK
Thompson, JA
Trisal, V
Urist, MM
McMillian, N
Ho, M
AF Coit, Daniel G.
Andtbacka, Robert
Anker, Christopher J.
Bichakjian, Christopher K.
Carson, William E., III
Daud, Adil
DiMaio, Dominick
Fleming, Martin D.
Guilds, Valerie
Halpern, Allan C.
Hodi, F. Stephen, Jr.
Kelley, Mark C.
Khushalani, Nikhil I.
Kudchadkar, Ragini R.
Lange, Julie R.
Lind, Anne
Martini, Mary C.
Olszanski, Anthony J.
Pruitt, Scott K.
Ross, Merrick I.
Swetter, Susan M.
Tanabe, Kenneth K.
Thompson, John A.
Trisal, Vijay
Urist, Marshall M.
McMillian, Nicole
Ho, Maria
TI Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID LYMPH-NODE BIOPSY; POSITRON-EMISSION-TOMOGRAPHY; STAGE-III MELANOMA;
COOPERATIVE-ONCOLOGY-GROUP; HIGH-RISK MELANOMA; METASTATIC MELANOMA;
COMPUTED-TOMOGRAPHY; THIN MELANOMA; OPEN-LABEL; CUTANEOUS MELANOMA
AB The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma. (JNCCN 2013;11:395-407)
C1 [Coit, Daniel G.; Halpern, Allan C.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Andtbacka, Robert; Anker, Christopher J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Bichakjian, Christopher K.] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA.
[Carson, William E., III] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Carson, William E., III] Solove Res Inst, Columbus, OH USA.
[Daud, Adil] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[DiMaio, Dominick] Univ Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Fleming, Martin D.] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Guilds, Valerie] Aim Melanoma, Plano, TX USA.
[Hodi, F. Stephen, Jr.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Kelley, Mark C.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Khushalani, Nikhil I.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Kudchadkar, Ragini R.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Lange, Julie R.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Lind, Anne] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Lind, Anne] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Martini, Mary C.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Olszanski, Anthony J.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Pruitt, Scott K.] Duke Canc Inst, Durham, NC USA.
[Ross, Merrick I.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Swetter, Susan M.] Stanford Canc Inst, Stanford, CA USA.
[Tanabe, Kenneth K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Thompson, John A.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA.
[Trisal, Vijay] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Urist, Marshall M.] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA.
[McMillian, Nicole; Ho, Maria] Natl Comprehens Canc Network, Ft Washington, PA USA.
RP Coit, DG (reprint author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
RI Carson, William/E-2846-2011
FU Eisai, Inc.; Millennium: The Takeda Oncology Company; Teva
Pharmaceuticals; Bayer Health-Care Pharmaceuticals Inc.; Celgene
Corporation; Endo Pharmaceuticals and HealthTronics; Genentech; ARIAD
Pharmaceuticals, Inc.
FX Supported by educational grants from Eisai, Inc.; Millennium: The Takeda
Oncology Company; Teva Pharmaceuticals; Bayer Health-Care
Pharmaceuticals Inc.; Celgene Corporation; Endo Pharmaceuticals and
HealthTronics; Genentech; and ARIAD Pharmaceuticals, Inc.
NR 52
TC 60
Z9 61
U1 0
U2 7
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD APR
PY 2013
VL 11
IS 4
BP 395
EP 407
PG 13
WC Oncology
SC Oncology
GA 125ML
UT WOS:000317543800007
PM 23584343
ER
PT J
AU Clark, PE
Agarwal, N
Biagio, MC
Eisenberger, MA
Greenberg, RE
Herr, HW
Inman, BA
Kuban, DA
Kuzel, TM
Lele, SM
Michalski, J
Pagliaro, LC
Pal, SK
Patterson, A
Plimack, ER
Pohar, KS
Porter, MP
Richie, JP
Sexton, WJ
Shipley, WU
Small, EJ
Spiess, PE
Trump, DL
Wile, G
Wilson, TG
Dwyer, M
Ho, M
AF Clark, Peter E.
Agarwal, Neeraj
Biagio, Matthew C.
Eisenberger, Mario A.
Greenberg, Richard E.
Herr, Harry W.
Inman, Brant A.
Kuban, Deborah A.
Kuzel, Timothy M.
Lele, Subodh M.
Michalski, Jeff
Pagliaro, Lance C.
Pal, Sumanta K.
Patterson, Anthony
Plimack, Elizabeth R.
Pohar, Kamal S.
Porter, Michael P.
Richie, Jerome P.
Sexton, Wade J.
Shipley, William U.
Small, Eric J.
Spiess, Philippe E.
Trump, Donald L.
Wile, Geoffrey
Wilson, Timothy G.
Dwyer, Mary
Ho, Maria
TI Bladder Cancer
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
ID TRANSITIONAL-CELL CARCINOMA; BACILLUS-CALMETTE-GUERIN; PHASE-II TRIAL;
RANDOMIZED CLINICAL-TRIALS; ADVANCED UROTHELIAL CANCER; INDIVIDUAL
PATIENT DATA; REPEAT TRANSURETHRAL RESECTION; GEMCITABINE PLUS
CISPLATIN; LONG-TERM OUTCOMES; NEOADJUVANT CHEMOTHERAPY
AB Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management. (JNCCN 2013;11:446-475)
C1 [Clark, Peter E.; Wile, Geoffrey] Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA.
[Agarwal, Neeraj] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Biagio, Matthew C.; Sexton, Wade J.; Spiess, Philippe E.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Eisenberger, Mario A.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Greenberg, Richard E.; Plimack, Elizabeth R.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Herr, Harry W.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Inman, Brant A.] Duke Canc Inst, Durham, NC USA.
[Kuban, Deborah A.; Pagliaro, Lance C.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Kuzel, Timothy M.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Lele, Subodh M.] Univ Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Michalski, Jeff] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Michalski, Jeff] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Pal, Sumanta K.; Wilson, Timothy G.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Patterson, Anthony] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Pohar, Kamal S.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Porter, Michael P.] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Shipley, William U.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Small, Eric J.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Trump, Donald L.] Roswell Pk Canc Inst, Buffalo, NY USA.
RP Clark, PE (reprint author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA.
RI Clark, Peter/E-1423-2011
OI Clark, Peter/0000-0002-8006-7015
FU Bristol-Myers Squibb Company; Genentech, Inc.; Agensys, Inc.;
sanofi-aventis U.S. LLC; Endo Pharmaceuticals; GlaxoSmithKline plc;
Bayer HealthCare; CureTech Ltd.; Eli Lilly and Company; Merck Co., Inc.;
Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Alton
Pharmaceuticals; Argos Therapeutics, Inc.; Biovex, Inc.
FX Clinical Research Support: Bristol-Myers Squibb Company; Genentech,
Inc.; Agensys, Inc.; and sanofi-aventis U.S. LLC; Endo Pharmaceuticals;
GlaxoSmithKline plc; Bayer HealthCare; Bristol-Myers Squibb Company;
CureTech Ltd.; Eli Lilly and Company; GlaxoSmithKline plc; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.;
Alton Pharmaceuticals; Argos Therapeutics, Inc.; and Biovex, Inc.; Endo
Pharmaceuticals
NR 101
TC 127
Z9 129
U1 0
U2 16
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD APR
PY 2013
VL 11
IS 4
BP 446
EP 475
PG 30
WC Oncology
SC Oncology
GA 125ML
UT WOS:000317543800011
PM 23584347
ER
PT J
AU King, MW
Street, AE
Gradus, JL
Vogt, DS
Resick, PA
AF King, Matthew W.
Street, Amy E.
Gradus, Jaimie L.
Vogt, Dawne S.
Resick, Patricia A.
TI Gender Differences in Posttraumatic Stress Symptoms Among OEF/OIF
Veterans: An Item Response Theory Analysis
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID SEX-DIFFERENCES; MENTAL-HEALTH; DISORDER; TRAUMA; PTSD; COMBAT; WOMEN;
RISK
AB Establishing whether men and women tend to express different symptoms of posttraumatic stress in reaction to trauma is important for both etiological research and the design of assessment instruments. Use of item response theory (IRT) can reveal how symptom reporting varies by gender and help determine if estimates of symptom severity for men and women are equally reliable. We analyzed responses to the PTSD Checklist (PCL) from 2,341 U.S. military veterans (51% female) who completed deployments in support of operations in Afghanistan and Iraq (Operation Enduring Freedom/Operation Iraqi Freedom [OEF/OIF]), and tested for differential item functioning by gender with an IRT-based approach. Among men and women with the same overall posttraumatic stress severity, women tended to report more frequent concentration difficulties and distress from reminders whereas men tended to report more frequent nightmares, emotional numbing, and hypervigilance. These item-level gender differences were small (on average d = 0.05), however, and had little impact on PCL measurement precision or expected total scores. For practical purposes, men's and women's severity estimates had similar reliability. This provides evidence that men and women veterans demonstrate largely similar profiles of posttraumatic stress symptoms following exposure to military-related stressors, and some theoretical perspectives suggest this may hold in other traumatized populations.
C1 [King, Matthew W.; Street, Amy E.; Gradus, Jaimie L.; Vogt, Dawne S.; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA.
[Street, Amy E.; Gradus, Jaimie L.; Vogt, Dawne S.; Resick, Patricia A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Gradus, Jaimie L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP King, MW (reprint author), VA Boston Healthcare Syst 116B 3, 150 S Huntington Ave, Boston, MA 02130 USA.
EM matthew.king2@va.gov
OI Gradus, Jaimie/0000-0003-1459-5327
NR 40
TC 9
Z9 9
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD APR
PY 2013
VL 26
IS 2
BP 175
EP 183
DI 10.1002/jts.21802
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 123CP
UT WOS:000317366200001
PM 23526678
ER
PT J
AU Avins, AL
Lee, JY
Meyers, CM
Barry, MJ
AF Avins, Andrew L.
Lee, Jeannette Y.
Meyers, Catherine M.
Barry, Michael J.
CA CAMUS Study Grp
TI Safety and Toxicity of Saw Palmetto in the CAMUS Trial
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostate; Serenoa; prostatic hyperplasia; lower urinary tract symptoms;
phytotherapy
ID BENIGN PROSTATIC HYPERPLASIA; SERENOA-REPENS; INDUCED PANCREATITIS;
EXTRACT; PHYTOTHERAPY; HERB
AB Purpose: Extracts of the saw palmetto berry are used by many men in the United States as self-treatment for lower urinary tract symptoms due to benign prostatic hyperplasia. While the most recent data from double-blind clinical trials do not support efficacy superior to that of placebo, there are sparse data on saw palmetto toxicity.
Materials and Methods: A total of 369 patients were randomized in the CAMUS (Complementary and Alternative Medicine for Urological Symptoms) trial, of whom 357 were included in this modified intent to treat analysis. Participants were randomized to 320, 640 and 960 mg daily of an ethanolic saw palmetto extract or to an identical-appearing placebo in an escalating manner at 6-month intervals for a total of 18 months of followup. Adverse event assessments, vital signs, and blood and urine laboratory tests were obtained at regular intervals.
Results: There were no statistically significant differences between the groups in the rates of serious or nonserious adverse events, changes in vital signs, digital prostate examination findings or study withdrawal rates. Overall, there were no significant intergroup differences in laboratory test abnormalities, while differences in individual laboratory tests were rare and small in magnitude. No evidence of significant dose-response phenomena was identified.
Conclusions: The saw palmetto extract used in the CAMUS trial showed no evidence of toxicity at doses up to 3 times the usual clinical dose during an 18-month period.
C1 [Avins, Andrew L.] No Calif Kaiser Permanente Div Res, Oakland, CA 94612 USA.
[Avins, Andrew L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Avins, Andrew L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Lee, Jeannette Y.] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA.
[Meyers, Catherine M.] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA.
[Barry, Michael J.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
RP Avins, AL (reprint author), No Calif Kaiser Permanente Div Res, 2000 Broadway,3rd Floor, Oakland, CA 94612 USA.
EM andrew.avins@ucsf.edu
FU National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases [U01 DK63795, U01 DK63797, U01 DK63825,
U01 DK63835, U01 DK63866, U01 DK63833, U01 DK63862, U01 DK63840, U01
DK63883, U01 DK63831, U01 DK63778, U01 DK63788]; National Center for
Complementary and Alternative Medicine; Office of Dietary Supplements,
National Institutes of Health
FX Supported by National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases Cooperative Agreements U01
DK63795, U01 DK63797, U01 DK63825, U01 DK63835, U01 DK63866, U01
DK63833, U01 DK63862, U01 DK63840, U01 DK63883, U01 DK63831, U01 DK63778
and U01 DK63788, the National Center for Complementary and Alternative
Medicine, and the Office of Dietary Supplements, National Institutes of
Health.
NR 27
TC 3
Z9 3
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD APR
PY 2013
VL 189
IS 4
BP 1415
EP 1420
DI 10.1016/j.juro.2012.10.002
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 127TN
UT WOS:000317721800064
PM 23063633
ER
PT J
AU Pashtan, I
Mauch, PM
Chen, YH
Dorfman, DM
Silver, B
Ng, AK
AF Pashtan, Itai
Mauch, Peter M.
Chen, Yu-Hui
Dorfman, David M.
Silver, Barbara
Ng, Andrea K.
TI Radiotherapy in the management of localized primary cutaneous B-cell
lymphoma
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE Primary cutaneous B-cell lymphoma; prognosis; radiation; dose; local
control
ID TREATMENT-OF-CANCER; WHO-EORTC CLASSIFICATION; EUROPEAN-ORGANIZATION;
UNITED-STATES; PROPOSAL; SYSTEM
AB The optimal therapy and radiation dose for patients with localized primary cutaneous B-cell lymphoma (PCBCL) are unknown. We retrospectively identified 23 patients with localized (T1-T2) PCBCL treated with definitive radiation to doses ranging from 30 to 44 Gy (median, 36 Gy). With a median follow-up of 4.8 years, the 5-year overall survival rate was 100%, the relapse-free survival rate was 71% (95% confidence interval, 46-86%) and there were no local recurrences, suggesting that radiotherapy to a dose of 30 Gy may be sufficient for cure.
C1 [Pashtan, Itai] Harvard Radiat Oncol Program, Boston, MA USA.
[Mauch, Peter M.; Silver, Barbara; Ng, Andrea K.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA.
[Mauch, Peter M.; Silver, Barbara; Ng, Andrea K.] Harvard Univ, Sch Med, Boston, MA USA.
[Chen, Yu-Hui] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Dorfman, David M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Pashtan, I (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,ASB1-L2, Boston, MA 02115 USA.
EM ipashtan@partners.org
NR 14
TC 3
Z9 3
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD APR
PY 2013
VL 54
IS 4
BP 726
EP 730
DI 10.3109/10428194.2012.723707
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA 103EP
UT WOS:000315898100012
PM 22916994
ER
PT J
AU Cheng, G
Servaes, S
Zhuang, HM
AF Cheng, Gang
Servaes, Sabah
Zhuang, Hongming
TI Value of F-18-fluoro-2-deoxy-D-glucose positron emission
tomography/computed tomography scan versus diagnostic contrast computed
tomography in initial staging of pediatric patients with lymphoma
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE FDG PET/CT; lymphoma; Hodgkin disease; staging; pediatric
ID FDG-PET; CHILDHOOD LYMPHOMA; HODGKINS-LYMPHOMA; MANAGEMENT; BONE;
ADOLESCENTS; CHILDREN; UTILITY; IMPACT; CT
AB Our objective was to evaluate the value of F-18-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) versus diagnostic contrast CT in the initial staging of pediatric Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL). Thirty patients with HD and 21 patients with NHL were included in this retrospective study. On nodal lesion analysis, PET/CT detected 94.8% (HD) and 88.3% (NHL) of total lesions, respectively, in contrast to 82.6% (HD) and 69.1% (NHL), respectively, for diagnostic contrast CT. PET/CT also detected more extranodal lesions. On the patient level, PET/CT detected additional lesions in 50% of patients with HD and in 42.9% of patients with NHL. In contrast, diagnostic contrast CT detected additional lesions in 16.7% (HD) and 23.8% (NHL) of total cases. FDG PET/CT led to upstaging in seven cases of HD and seven cases of NHL, while diagnostic contrast CT upstaged two cases of NHL. We conclude that FDG PET/CT outperforms diagnostic contrast CT in the initial staging of pediatric patients with lymphoma.
C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
[Servaes, Sabah; Zhuang, Hongming] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA.
RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM gangcheng99@yahoo.com; zhuang@email.chop.edu
NR 21
TC 13
Z9 13
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD APR
PY 2013
VL 54
IS 4
BP 737
EP 742
DI 10.3109/10428194.2012.727416
PG 6
WC Oncology; Hematology
SC Oncology; Hematology
GA 103EP
UT WOS:000315898100014
PM 22957898
ER
PT J
AU Fathi, AT
Preffer, FI
Sadrzadeh, H
Ballen, KK
Amrein, PC
Attar, EC
McAfee, SL
Dillon, L
Chen, YB
Hasserjian, RP
AF Fathi, Amir T.
Preffer, Frederic I.
Sadrzadeh, Hossein
Ballen, Karen K.
Amrein, Philip C.
Attar, Eyal C.
McAfee, Steven L.
Dillon, Laura
Chen, Yi-Bin
Hasserjian, Robert P.
TI CD30 expression in acute myeloid leukemia is associated with
FLT3-internal tandem duplication mutation and leukocytosis
SO LEUKEMIA & LYMPHOMA
LA English
DT Letter
ID VARIANT CD30; RECEPTOR; PROGRESS; FLT3; AML
C1 [Fathi, Amir T.; Preffer, Frederic I.; Sadrzadeh, Hossein; Ballen, Karen K.; Amrein, Philip C.; Attar, Eyal C.; McAfee, Steven L.; Dillon, Laura; Chen, Yi-Bin; Hasserjian, Robert P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA.
RP Fathi, AT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Zero Emerson Pl,Suite 118, Boston, MA 02114 USA.
EM afathi@partners.org
NR 15
TC 6
Z9 6
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD APR
PY 2013
VL 54
IS 4
BP 860
EP 863
DI 10.3109/10428194.2012.728596
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA 103EP
UT WOS:000315898100030
PM 22966913
ER
PT J
AU Spindler, SR
Mote, PL
Flegal, JM
Teter, B
AF Spindler, Stephen R.
Mote, Patricia L.
Flegal, James M.
Teter, Bruce
TI Influence on Longevity of Blueberry, Cinnamon, Green and Black Tea,
Pomegranate, Sesame, Curcumin, Morin, Pycnogenol, Quercetin, and
Taxifolin Fed Iso-Calorically to Long-Lived, F1 Hybrid Mice
SO REJUVENATION RESEARCH
LA English
DT Article
ID LIFE-SPAN EXTENSION; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS;
DROSOPHILA-MELANOGASTER; EXTRACT; HEALTH; ACID; EXPRESSION; CAFFEINE;
SURVIVAL
AB Phytonutrients reportedly extend the life span of Caenorhabditis elegans, Drosophila, and mice. We tested extracts of blueberry, pomegranate, green and black tea, cinnamon, sesame, and French maritime pine bark (Pycnogenol and taxifolin), as well as curcumin, morin, and quercetin for their effects on the life span of mice. While many of these phytonutrients reportedly extend the life span of model organisms, we found no significant effect on the life span of male F1 hybrid mice, even though the dosages used reportedly produce defined therapeutic end points in mice. The compounds were fed beginning at 12 months of age. The control and treatment groups were iso-caloric with respect to one another. A 40% calorically restricted and other groups not reported here did experience life span extension. Body weights were un-changed relative to controls for all but two supplemented groups, indicating most supplements did not change energy absorption or utilization. Tea extracts with morin decreased weight, whereas quercetin, taxifolin, and Pycnogenol together increased weight. These changes may be due to altered locomotion or fatty acid biosynthesis. Published reports of murine life span extension using curcumin or tea components may have resulted from induced caloric restriction. Together, our results do not support the idea that isolated phytonutrient anti-oxidants and anti-inflammatories are potential longevity therapeutics, even though consumption of whole fruits and vegetables is associated with enhanced health span and life span.
C1 [Spindler, Stephen R.; Mote, Patricia L.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.
[Flegal, James M.] Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA.
[Teter, Bruce] VA Greater Los Angeles Healthcare Syst, Dept Med, Sepulveda, CA USA.
RP Spindler, SR (reprint author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.
EM spindler@ucr.edu
OI Flegal, James/0000-0002-9960-8942
FU Alva, LLC
FX The authors thank Ms. Carol Boyd for her invaluable help feeding and
monitoring the mice. This work was funded by Alva, LLC, whose business
is funding research. The funding organization and its members had no
role in study design, data collection or analysis, decision to publish,
or preparation of the manuscript.
NR 60
TC 13
Z9 13
U1 3
U2 27
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
J9 REJUV RES
JI Rejuv. Res.
PD APR
PY 2013
VL 16
IS 2
BP 143
EP 151
DI 10.1089/rej.2012.1386
PG 9
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 129IM
UT WOS:000317832600008
PM 23432089
ER
PT J
AU Khodneva, Y
Pletcher, M
Safford, M
Schumacher, J
Tucker, J
Kertesz, S
AF Khodneva, Yulia
Pletcher, Mark
Safford, Monika
Schumacher, Joseph
Tucker, Jalie
Kertesz, Stefan
TI Conjoint Trajectories of Drug Use and Trajectories of Depressive
Symptoms in Adults: A 2-Decade Portrait of Comorbidity (the CARDIA
study)
SO SUBSTANCE ABUSE
LA English
DT Meeting Abstract
C1 [Khodneva, Yulia; Tucker, Jalie; Kertesz, Stefan] Univ Alabama Birmingham, Birmingham, AL USA.
[Pletcher, Mark; Safford, Monika; Schumacher, Joseph] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Kertesz, Stefan] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0889-7077
J9 SUBST ABUS
JI Subst. Abus.
PD APR 1
PY 2013
VL 34
IS 2
BP 215
EP 215
PG 1
WC Substance Abuse
SC Substance Abuse
GA 128BI
UT WOS:000317742700038
ER
PT J
AU Park, TW
Cheng, DM
Samet, JH
Winter, M
Saitz, R
AF Park, Tae Woo
Cheng, Debbie M.
Samet, Jeffrey H.
Winter, Michael
Saitz, Richard
TI Effectiveness of Chronic Care Management for Substance Dependence in
Primary Care Among Patients with Co-Occurring Mental Health Disorders
SO SUBSTANCE ABUSE
LA English
DT Meeting Abstract
C1 VA Boston Healthcare Syst, Boston, MA USA.
Boston Univ, Sch Med, Boston, MA 02215 USA.
Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0889-7077
J9 SUBST ABUS
JI Subst. Abus.
PD APR 1
PY 2013
VL 34
IS 2
BP 215
EP 215
PG 1
WC Substance Abuse
SC Substance Abuse
GA 128BI
UT WOS:000317742700039
ER
PT J
AU Ottum, A
Sethi, AK
Jacobs, E
Zerbel, S
Gaines, ME
Safdar, N
AF Ottum, Andrew
Sethi, Ajay K.
Jacobs, Elizabeth
Zerbel, Sara
Gaines, Martha E.
Safdar, Nasia
TI Engaging patients in the prevention of health care-associated
infections: A survey of patients' awareness, knowledge, and perceptions
regarding the risks and consequences of infection with
methicillin-resistant Staphylococcus aureus and Clostridium difficile
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE MRSA; Clostridium difficile; Awareness
ID EDUCATION MODEL; HOSPITALS
AB Background and objective: Methicillin-resistant Staphylococcus aureus (MRSA) infections and Clostridium difficile infections (CDI) are major health care-associated infections (HAIs). Little is known about patients' knowledge of these HAIs. Therefore, we surveyed patients to determine awareness, knowledge, and perceptions of MRSA infections and CDI.
Design: An interviewer-administered questionnaire.
Setting: A tertiary care academic medical center.
Participants: Adult patients who met at least one of the following criteria: at risk of CDI or MRSA infection, current CDI or colonization or current MRSA infection or colonization, or history of CDI or MRSA infection.
Methods: Two unique surveys were developed and administered to 100 patients in 2011.
Results: Overall, 76% of patients surveyed were aware of MRSA, whereas 44% were aware of C difficile. The strongest predictor of patients' awareness of these infections was having a history of HAI. Patients with a history of HAI were significantly more likely to have heard of both MRSA (odds ratio, 13.29; 95% confidence interval, 2.84-62.14; P = .001) and C difficile (odds ratio, 9.78; 95% confidence interval, 2.66-35.95; P = .001), than those patients without a history of HAI. There was also a significant positive association between having a history of HAI and greater knowledge of the risk factors, health consequences, and prevention techniques relative to CDI and MRSA infections.
Conclusions: There are additional opportunities to engage patients about the risks and consequences of MRSA and CDIs, particularly those without a history of HAI. Copyright (C) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Ottum, Andrew; Sethi, Ajay K.; Jacobs, Elizabeth] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA.
[Jacobs, Elizabeth; Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI USA.
[Zerbel, Sara; Safdar, Nasia] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Madison, WI USA.
[Gaines, Martha E.] Univ Wisconsin, Ctr Patient Partnerships, Madison, WI USA.
[Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Safdar, N (reprint author), 5221 MFCB,1685 Highland Ave, Madison, WI 53705 USA.
EM ns2@medicine.wisc.edu
NR 12
TC 6
Z9 6
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD APR
PY 2013
VL 41
IS 4
BP 322
EP 326
DI 10.1016/j.ajic.2012.04.334
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 123UG
UT WOS:000317416000008
PM 22884494
ER
PT J
AU Sips, PY
Irie, T
Zou, L
Shinozaki, S
Sakai, M
Shimizu, N
Nguyen, R
Stamler, JS
Chao, W
Kaneki, M
Ichinose, F
AF Sips, Patrick Y.
Irie, Tomoya
Zou, Lin
Shinozaki, Shohei
Sakai, Michihiro
Shimizu, Nobuyuki
Nguyen, Rebecca
Stamler, Jonathan S.
Chao, Wei
Kaneki, Masao
Ichinose, Fumito
TI Reduction of cardiomyocyte S-nitrosylation by S-nitrosoglutathione
reductase protects against sepsis-induced myocardial depression
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE S-nitrosylation; sepsis; myocardial depression; GSNOR; genetically
modified mice
ID NITRIC-OXIDE SYNTHASE; RAT CARDIAC MYOCYTES; SOLUBLE GUANYLYL CYCLASE;
SEPTIC SHOCK; SYSTEMIC INFLAMMATION; ENDOTOXIC-SHOCK; TREATED RATS;
DYSFUNCTION; MICE; CALCIUM
AB Sips PY, Irie T, Zou L, Shinozaki S, Sakai M, Shimizu N, Nguyen R, Stamler JS, Chao W, Kaneki M, Ichinose F. Reduction of cardiomyocyte S-nitrosylation by S-nitrosoglutathione reductase protects against sepsis-induced myocardial depression. Am J Physiol Heart Circ Physiol 304: H1134-H1146, 2013. First published February 15, 2013; doi: 10.1152/ajpheart.00887.2012.-Myocardial depression is an important contributor to morbidity and mortality in septic patients. Nitric oxide (NO) plays an important role in the development of septic cardiomyopathy, but also has protective effects. Recent evidence has indicated that NO exerts many of its downstream effects on the cardiovascular system via protein S-nitrosylation, which is negatively regulated by S-nitrosoglutathione reductase (GSNOR), an enzyme promoting denitrosylation. We tested the hypothesis that reducing cardiomyocyte S-nitrosylation by increasing GSNOR activity can improve myocardial dysfunction during sepsis. Therefore, we generated mice with a cardiomyocyte-specific overexpression of GSNOR (GSNOR-CMTg mice) and subjected them to endotoxic shock. Measurements of cardiac function in vivo and ex vivo showed that GSNOR-CMTg mice had a significantly improved cardiac function after lipopolysaccharide challenge (LPS, 50 mg/kg) compared with wild-type (WT) mice. Cardiomyocytes isolated from septic GSNOR-CMTg mice showed a corresponding improvement in contractility compared with WT cells. However, systolic Ca2+ release was similarly depressed in both genotypes after LPS, indicating that GSNOR-CMTg cardiomyocytes have increased Ca2+ sensitivity during sepsis. Parameters of inflammation were equally increased in LPS-treated hearts of both genotypes, and no compensatory changes in NO synthase expression levels were found in GSNOR-overexpressing hearts before or after LPS challenge. GSNOR overexpression however significantly reduced total cardiac protein S-nitrosylation during sepsis. Taken together, our results indicate that increasing the denitrosylation capacity of cardiomyocytes protects against sepsis-induced myocardial depression. Our findings suggest that specifically reducing protein S-nitrosylation during sepsis improves cardiac function by increasing cardiac myofilament sensitivity to Ca2+.
C1 [Sips, Patrick Y.; Irie, Tomoya; Zou, Lin; Shinozaki, Shohei; Sakai, Michihiro; Shimizu, Nobuyuki; Nguyen, Rebecca; Chao, Wei; Kaneki, Masao; Ichinose, Fumito] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA.
[Sips, Patrick Y.; Irie, Tomoya; Zou, Lin; Shinozaki, Shohei; Sakai, Michihiro; Shimizu, Nobuyuki; Nguyen, Rebecca; Chao, Wei; Kaneki, Masao; Ichinose, Fumito] Harvard Univ, Sch Med, Charlestown, MA USA.
[Stamler, Jonathan S.] Case Western Reserve Univ, Inst Transformat Mol Med, Cleveland, OH 44106 USA.
[Stamler, Jonathan S.] Univ Hosp, Case Med Ctr, Cleveland, OH USA.
RP Sips, PY (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, CNY 149,Rm 4312,149 13th St, Charlestown, MA 02129 USA.
EM psips@partners.org
OI Sips, Patrick/0000-0001-9241-5980
FU American Heart Association; National Institute of Health [DK-05827,
GM-079360, HL-101930]
FX This work was supported by the American Heart Association - Philips
Resuscitation Fellowship Award (P. Y. Sips) and National Institute of
Health Grants DK-05827 (M. Kaneki), GM-079360 (F. Ichinose), and
HL-101930 (F. Ichinose).
NR 60
TC 10
Z9 10
U1 2
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD APR
PY 2013
VL 304
IS 8
BP H1134
EP H1146
DI 10.1152/ajpheart.00887.2012
PG 13
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 126GP
UT WOS:000317601600010
PM 23417863
ER
PT J
AU Moye, J
Marson, DC
Edelstein, B
AF Moye, Jennifer
Marson, Daniel C.
Edelstein, Barry
TI Assessment of Capacity in an Aging Society
SO AMERICAN PSYCHOLOGIST
LA English
DT Article
DE capacity; competency; decision making; informed consent; assessment
ID MILD COGNITIVE IMPAIRMENT; DECISION-MAKING CAPACITY; DECLINING FINANCIAL
CAPACITY; DIFFERENT LEGAL STANDARDS; TRAUMATIC BRAIN-INJURY; TO-MODERATE
DEMENTIA; ALZHEIMERS-DISEASE; OLDER-ADULTS; PROTOTYPE-INSTRUMENT;
PHYSICIAN JUDGMENTS
AB Over the past 40 years, the assessment and scientific study of capacity in older adults has emerged as a distinct field of clinical and research activity for psychologists. This new field reflects the convergence of several trends: the aging of American society, the growing incidence and prevalence of dementia, and the patient rights, deinstitutionalization, and disability rights movements. Because of these forces, capacity issues now permeate the fabric of everyday life, whether in the form of guardianship petitions, questions of capacity to consent to treatment, the ability to make a new will, or participation in human research. In seeking to resolve these issues, families, clinicians, and legal professionals increasingly turn to psychologists to assess a capacity and to provide empirically supported judgments that properly balance autonomy and protection for the individual. Psychologists have taken a leading role in the development of functional assessment instruments that measure important aspects of the capacity construct. In addition, psychology has been a major contributor to the scientific study of capacity. In collaboration with colleagues from medicine and law, psychologists have articulated crucial theoretical frameworks that integrate legal, clinical, and ethical dimensions of the capacity problem. This article focuses on the evolution of theory, law, science, and practice in the evaluation of capacity in older adults and its recent culmination in a series of interdisciplinary handbooks sponsored by the American Psychological Association and the American Bar Association.
C1 [Moye, Jennifer] VA Boston Healthcare Syst, Brockton, MA 02301 USA.
[Moye, Jennifer] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA.
[Marson, Daniel C.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA.
[Marson, Daniel C.] Univ Alabama Birmingham, Alzheimers Dis Ctr, Birmingham, AL USA.
[Edelstein, Barry] W Virginia Univ, Dept Psychol, Morgantown, WV 26506 USA.
RP Moye, J (reprint author), VA Boston Healthcare Syst, Brockton Campus,940 Belmont St, Brockton, MA 02301 USA.
EM jennifer.moye@va.gov
RI Moye, Jennifer/F-2240-2017
OI Moye, Jennifer/0000-0002-3434-347X
FU Intramural VA [VA999999]; NIA NIH HHS [R56 AG021927, AG021927, R01
AG021927]; NICHD NIH HHS [HD053074, R01 HD053074]; NIMH NIH HHS [R29
MH057104]
NR 106
TC 18
Z9 18
U1 3
U2 40
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
J9 AM PSYCHOL
JI Am. Psychol.
PD APR
PY 2013
VL 68
IS 3
BP 158
EP 171
DI 10.1037/a0032159
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA 125EO
UT WOS:000317522000004
PM 23586491
ER
PT J
AU Crivellari, D
Gray, KP
Dellapasqua, S
Puglisi, F
Ribi, K
Price, KN
Lang, I
Gianni, L
Spazzapan, S
Pinotti, G
Luthi, JM
Gelber, RD
Regan, MM
Colleoni, M
Castiglione-Gertsch, M
Maibach, R
Rabaglio, M
Coates, AS
Goldhirsch, A
AF Crivellari, Diana
Gray, Kathryn P.
Dellapasqua, Silvia
Puglisi, Fabio
Ribi, Karin
Price, Karen N.
Lang, Istvan
Gianni, Lorenzo
Spazzapan, Simon
Pinotti, Graziella
Luethi, Jean-Marc
Gelber, Richard D.
Regan, Meredith M.
Colleoni, Marco
Castiglione-Gertsch, Monica
Maibach, Rudolf
Rabaglio, Manuela
Coates, Alan S.
Goldhirsch, Aron
CA Int Breast Canc Study Grp
TI Adjuvant pegylated liposomal doxorubicin for older women with endocrine
nonresponsive breast cancer who are NOT suitable for a "standard
chemotherapy regimen": The CASA randomized trial
SO BREAST
LA English
DT Article
DE Adjuvant treatment; Endocrine nonresponsive; Chemotherapy; Pegylated
liposomal doxorubicin; Elderly; Breast cancer
ID QUALITY-OF-LIFE; ELDERLY-PATIENTS PTS; INTERNATIONAL SOCIETY; GERIATRIC
ONCOLOGY; CAPECITABINE X; IBANDRONATE I; MINI-COG; GBG 32; SURVIVAL;
PHARMACOKINETICS
AB There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of "standard chemotherapy regimens" such as AC or CMF. The CASA trial studied pegylated liposomal doxorubicin (PLD) and low dose, metronomic cyclophosphamide methotrexate (CM) for older (>65), vulnerable women with operable, ER and PgR-negative breast cancer. After two years the trial closed early, due to slow and inadequate accrual, with 77 patients (38:PLD, 36:CM, 3:nil). Sixty-eight percent completed PLD; 83% completed CM (both 16 weeks). Patients on PLD reported worse quality of life, cognitive and physical functioning than non-PLD regimens (primarily CM). At a median follow-up of 42 months, 81% of randomized patients remained free of any breast cancer recurrence. Based on our limited experience, PLD and CM may be reasonable options for further study for elderly vulnerable patients with endocrine nonresponsive breast cancer. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Crivellari, Diana; Spazzapan, Simon] Ctr Riferimento Oncol, I-33081 Aviano, Italy.
[Gray, Kathryn P.; Gelber, Richard D.; Regan, Meredith M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, IBCSG, Ctr Stat, Boston, MA 02115 USA.
[Gray, Kathryn P.; Gelber, Richard D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Dellapasqua, Silvia; Colleoni, Marco] European Inst Oncol, Dept Med, Res Unit Med Senol, Milan, Italy.
[Puglisi, Fabio] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy.
[Ribi, Karin] Int Breast Canc Study Grp, Coordinating Ctr, Qual Life Off, Bern, Switzerland.
[Price, Karen N.] Int Breast Canc Study Grp, Ctr Stat, Boston, MA USA.
[Price, Karen N.; Maibach, Rudolf] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA.
[Lang, Istvan] Natl Inst Oncol, Budapest, Hungary.
[Gianni, Lorenzo] Osped Infermi Rimini, Dept Oncol, Rimini, Italy.
[Gianni, Lorenzo] Ist Sci Romagnolo Studio & Cura Tumori, Rimini, Italy.
[Pinotti, Graziella] Osped Circolo Varese, Varese, Italy.
[Pinotti, Graziella] Fdn Macchi, Varese, Italy.
[Luethi, Jean-Marc] Spital SIS AG, Thun, Switzerland.
[Gelber, Richard D.; Regan, Meredith M.] Harvard Univ, Sch Med, Boston, MA USA.
[Castiglione-Gertsch, Monica] Univ Geneva, Dept Med Hop, Unite Oncogynecol Med, Geneva, Switzerland.
[Maibach, Rudolf; Rabaglio, Manuela] Int Breast Canc Study Grp, Coordinating Ctr, Bern, Switzerland.
[Rabaglio, Manuela] Univ Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland.
[Coates, Alan S.] Int Breast Canc Study Grp, Sydney, NSW, Australia.
[Coates, Alan S.] Univ Sydney, Sydney, NSW 2006, Australia.
[Goldhirsch, Aron] European Inst Oncol, Dept Med, Milan, Italy.
RP Crivellari, D (reprint author), Ctr Riferimento Oncol, I-33081 Aviano, Italy.
EM dcrivellari@cro.it
OI Puglisi, Fabio/0000-0003-0573-4938
FU Schering-Plough Company
FX Partial support was provided by Schering-Plough Company. The CASA trial
was coordinated by the International Breast Cancer Study Group (IBCSG)
on behalf of the Breast International Group (BIG); Swedish Cancer
Society; The Cancer Council Australia; Australian New Zealand Breast
Cancer Trials Group (National Health and Medical Research Council); the
Frontier Science and Technology Research Foundation; the Swiss Group for
Clinical Cancer Research (SAKK); the Swiss Cancer League; and the United
States National Institutes of Health (CA-75362).
NR 33
TC 19
Z9 19
U1 2
U2 11
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
J9 BREAST
JI Breast
PD APR
PY 2013
VL 22
IS 2
BP 130
EP 137
DI 10.1016/j.breast.2013.01.015
PG 8
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 126QA
UT WOS:000317634900004
PM 23453899
ER
PT J
AU Ruddy, KJ
Giobbie-Hurder, A
Giordano, SH
Goldfarb, S
Kereakoglow, S
Winer, EP
Partridge, AH
AF Ruddy, Kathryn J.
Giobbie-Hurder, Anita
Giordano, Sharon H.
Goldfarb, Shari
Kereakoglow, Sandra
Winer, Eric P.
Partridge, Ann H.
TI Quality of life and symptoms in male breast cancer survivors
SO BREAST
LA English
DT Article
DE Breast neoplasms; Male; Hot flashes; Sexual dysfunction; Physiologic;
Quality of life; Survivors
ID PROSTATE-CANCER; WOMEN; TAMOXIFEN; DEPRESSION; THERAPY; ANXIETY
AB Introduction: Little is known about quality of life and symptoms of male breast cancer survivors.
Patients and methods: We recruited men with stage 0-4 breast cancer for an on-line survey through www.outoftheshadowofpink.com, www.malebreastcancer.org, and www.malebreastcancer.ca. Surveys included Expanded Prostate Cancer Index Composite (EPIC) Hormonal/Sexual Scales, Hospitalized Anxiety and Depression Scale (HADS), Functional Assessment of Cancer Therapy-Breast (FACT-B), sociodemographic/disease-related, genetic, and fertility-related items.
Results: Forty-two responded. Mean EPIC Sexual and Hormonal scores were 44.5 and 81.3, respectively, suggesting symptom burden. Mean FACT-B score was 111.1, consistent with impaired overall quality of life.
Conclusions: Male survivors experience substantial sexual and hormonal symptoms. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Ruddy, Kathryn J.; Giobbie-Hurder, Anita; Kereakoglow, Sandra; Winer, Eric P.; Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Giordano, Sharon H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Goldfarb, Shari] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Ruddy, KJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM kruddy@partners.org
FU Dana-Farber Cancer Institute
FX This study was supported by institutional funds at Dana-Farber Cancer
Institute.
NR 21
TC 3
Z9 4
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
J9 BREAST
JI Breast
PD APR
PY 2013
VL 22
IS 2
BP 197
EP 199
DI 10.1016/j.breast.2012.12.014
PG 3
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 126QA
UT WOS:000317634900017
PM 23313328
ER
PT J
AU Vasdev, N
Green, DE
Vines, DC
McLarty, K
McCormick, PN
Moran, MD
Houle, S
Wilson, AA
Reilly, RM
AF Vasdev, Neil
Green, David E.
Vines, Douglass C.
McLarty, Kristin
McCormick, Patrick N.
Moran, Matthew D.
Houle, Sylvain
Wilson, Alan A.
Reilly, Raymond M.
TI Positron-Emission Tomography Imaging of the TSPO with [F-18]FEPPA in a
Preclinical Breast Cancer Model
SO CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
LA English
DT Article
DE automation; breast cancer; [F-18]FEPPA; fluorine-18; peripheral
benzodiazepine receptor; positron-emission tomography; translocator
protein; TSPO
ID PERIPHERAL BENZODIAZEPINE-RECEPTORS; TRANSLOCATOR PROTEIN TSPO;
MICROGLIAL ACTIVATION; IN-VIVO; 18 KDA; CELL-PROLIFERATION; PET
RADIOLIGAND; BINDING-SITE; EXPRESSION; LOCALIZATION
AB The present study aims to image the 18-kDa translocator protein (TSPO; formerly known as the peripheral benzodiazepine receptor) in a preclinical human breast cancer (BC) xenograft mouse model with positron-emission tomography (PET). An automated radiosynthesis of [F-18]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([F-18]FEPPA) was validated for human use using a commercial synthesis module and resulted in a high radiochemical yield (30%+/- 8%, uncorrected; n = 54) and specific activity (6 +/- 4 Ci/ mu mol). Tumor uptake of [F-18]FEPPA in mice bearing subcutaneous MDA-MB-231 BC xenografts was evaluated by PET-computed tomography imaging and ex vivo biodistribution studies. Although the tumor was successfully visualized, ex vivo biodistribution studies revealed low tumor uptake (0.7%ID/g), with the majority of radioactivity distributed in the spleen, muscle, and heart despite high TSPO expression in this cell line. Our laboratory routinely prepares [F-18]FEPPA for human-imaging studies in the central nervous system, and we envision that radiopharmaceuticals that target the TSPO have the potential for imaging macrophages in the tumor microenvironment.
C1 [Vasdev, Neil; McCormick, Patrick N.; Moran, Matthew D.; Houle, Sylvain; Wilson, Alan A.] Ctr Addict & Mental Hlth, PET Ctr, Toronto, ON, Canada.
[Vasdev, Neil; McCormick, Patrick N.; Moran, Matthew D.; Houle, Sylvain; Wilson, Alan A.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
[Vines, Douglass C.] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.
[McLarty, Kristin; Reilly, Raymond M.] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada.
[Reilly, Raymond M.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada.
[Green, David E.; Vines, Douglass C.] Princess Margaret Hosp, Radiat Med Program, STTARR Innovat Ctr, Toronto, ON M4X 1K9, Canada.
[Reilly, Raymond M.] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada.
RP Vasdev, N (reprint author), Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, 55 Fruit St,White 427, Boston, MA 02114 USA.
EM vasdev.neil@mgh.harvard.edu
RI Wilson, Alan/A-1788-2011
FU Ontario Institute for Cancer Research; Government of Ontario
FX This research was supported by grants from the Ontario Institute for
Cancer Research (One Millimetre Cancer Challenge) with funding provided
by the Government of Ontario. The authors gratefully acknowledge Armando
Garcia and Winston Stableford for 18F production. The authors
would like to thank Lisa DiDiodato for performing the CT imaging.
NR 44
TC 4
Z9 4
U1 0
U2 8
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1084-9785
J9 CANCER BIOTHER RADIO
JI Cancer Biother. Radiopharm.
PD APR
PY 2013
VL 28
IS 3
BP 254
EP 259
DI 10.1089/cbr.2012.1196
PG 6
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy;
Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy;
Radiology, Nuclear Medicine & Medical Imaging
GA 124PU
UT WOS:000317478200011
PM 23350894
ER
PT J
AU Pusztaszeri, MP
Sadow, PM
Faquin, WC
AF Pusztaszeri, Marc P.
Sadow, Peter M.
Faquin, William C.
TI Association of CD1a-Positive Dendritic Cells With Papillary Thyroid
Carcinoma in Thyroid Fine-Needle Aspirations A Cytologic and
Immunocytochemical Evaluation
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE dendritic cells; Langerhans cells; thyroid; papillary carcinoma;
cytopathology; fine-needle aspiration; CD1a; immunohistochemistry
ID ANTIGEN-PRESENTING FUNCTION; LANGERHANS CELLS; HISTIOCYTOID CELLS;
IMMUNE-RESPONSES; EXPRESS CD83; CLASS-II; TUMOR; CANCER; CD1A;
MATURATION
AB BACKGROUND: In contrast to other primary thyroid neoplasms and benign thyroid tissue, it has been demonstrated histologically that dendritic cells (DCs) are associated with papillary thyroid carcinoma (PTC). However, the presence and potential diagnostic value of DCs in thyroid fine-needle aspirations (FNAs) have not been previously described. METHODS: The authors quantitatively assessed for the presence of DCs that were positive for cluster of differentiation 1a (CD1a) (a 43-49 kD protein expressed on DCs and cortical thymocytes) in cytologic samples of histologically confirmed PTC (n = 31) and in a control group of benign thyroid nodules (BTNs) (n = 29) using immunocytochemical staining with antibodies against CD1a. A subset of the corresponding PTCs (n = 11) and BTNs (n = 10) from surgical resection specimens also were assessed immunohistochemically for both CD1a and Langerin (a type II transmembrane cell surface receptor produced by Langerhans cells). RESULTS: CD1a-positive DCs were identified in 97% PTCs (n = 30 of 31 PTCs) in thyroid FNA specimens. DCs were largely present in 2 distinct patterns: either as isolated DCs in the background (n = 29 of 31) and/or associated with tumor cells (n = 30 of 31). Tumor-associated DCs (mean +/- standard deviation: 6.44 +/- 6.13 DCs per tumor cluster) exhibited multiple dendritic cytoplasmic processes extending over and between malignant cells within groups. The 3 PTC cases with the least DCs corresponded to the follicular variant at excision. In contrast, only 31% of BTNs (n = 9 of 29 BTNs; P = .0048) contained CD1a-positive DCs. When DCs were present in BTN, they were isolated primarily in the background (27%; n = 8 of 29), although 17% of BTNs (n = 5 of 29) contained rare DCs among thyrocytes, revealing both patterns in 4 cases. Both thyrocyte-associated DCs and background DCs were more numerous in PTC FNAs than in BTN FNAs, but only the thyrocyte-associated group of DCs was statistically significant (P < .0001 and P = .1173, respectively). Similar findings were reported in histologic samples in which all PTCs examined (n = 11 of 11) contained both CD1a-positive and Langerin-positive DCs; only 20% of BTNs (n = 2 of 10) contained rare DCs. CONCLUSIONS: CD1a-positive DCs were present in FNA specimens of PTC, typically in close association with tumor cells, whereas they were rare in BTNs. The increased presence of CD1a-positive DCs in PTC may be a useful diagnostic adjuvant. Cancer (Cancer Cytopathol) 2013;121:206213. (c) 2012 American Cancer Society.
C1 [Pusztaszeri, Marc P.] Univ Hosp Geneva, Dept Pathol, Geneva, Switzerland.
[Pusztaszeri, Marc P.; Sadow, Peter M.; Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Pusztaszeri, Marc P.; Sadow, Peter M.; Faquin, William C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Faquin, WC (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 219,55 Fruit St, Boston, MA 02114 USA.
EM wfaquin@partners.org
FU Department of Pathology, Massachusetts General Hospital; Nuovo-Soldati
Foundation
FX This study was supported by the Mini-Vickery Award grant from the
Department of Pathology, Massachusetts General Hospital. M. P. P.
received support from the Nuovo-Soldati Foundation for his visiting
fellowship to Massachusetts General Hospital.
NR 45
TC 7
Z9 8
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD APR
PY 2013
VL 121
IS 4
BP 206
EP 213
DI 10.1002/cncy.21239
PG 8
WC Oncology; Pathology
SC Oncology; Pathology
GA 129TN
UT WOS:000317865500008
PM 23042745
ER
PT J
AU Meng, SS
Zhang, XH
Giovannucci, EL
Ma, J
Fuchs, CS
Cho, EY
AF Meng, Shasha
Zhang, Xuehong
Giovannucci, Edward L.
Ma, Jing
Fuchs, Charles S.
Cho, Eunyoung
TI No association between garlic intake and risk of colorectal cancer
SO CANCER EPIDEMIOLOGY
LA English
DT Article
DE Garlic intake; Colorectal cancer; Incidence; Prospective study; Garlic
supplement; Carcinogenesis
ID COLON-CANCER; HEALTH
AB Background: Although experimental studies suggested beneficial role of garlic intake on colorectal carcinogenesis, limited prospective cohort studies have evaluated garlic intake in relation to colorectal cancer (CRC) incidence.
Methods: We followed 76,208 women in the Nurses' Health Study and 45,592 men in the Health Professionals Follow-up Study for up to 24 years and examined garlic intake and garlic supplement use in relation to CRC risk. Information on garlic intake and supplement use was assessed using a validated food frequency questionnaire and a Cox proportional hazard regression model was used to estimate the multivariable hazard ratio (MV-HR) and 95% confidence intervals (95% CIs).
Results: We documented 2368 (1339 women and 1029 men) incident CRC cases and found no association between garlic intake and CRC risk; the MV-HRs (95% CIs) associated with garlic (1 clove or 4 shakes per serving) intake >= 1/day compared with < 1/month were 1.21 (0.94-1.57; p-trend = 0.14) for women and 1.00 (0.71-1.42; p-trend = 0.89) for men. The MV-HRs (95% CIs) of CRC for garlic supplement use, which was used in 6% of the participants in each study, were 0.72 (0.48-1.07) for women and 1.22 (0.83-1.78) for men.
Conclusion: Our prospective data do not support an important role of garlic intake or garlic supplement use in colorectal carcinogenesis. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Meng, Shasha; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Zhang, Xuehong; Giovannucci, Edward L.; Ma, Jing; Cho, Eunyoung] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA.
[Zhang, Xuehong; Giovannucci, Edward L.; Ma, Jing; Cho, Eunyoung] Harvard Univ, Sch Med, Boston, MA USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA USA.
[Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Cho, EY (reprint author), Brigham & Womens Hosp, Channing Div Network Med, Dept Med, 181 Longwood Ave, Boston, MA USA.
EM eunyoung.cho@channing.harvard.edu
FU National Institutes of Health [CA136950, CA87969, CA55075]
FX This study was supported by research grant CA136950, CA87969, and
CA55075 from the National Institutes of Health. There are no financial
disclosures from any authors.
NR 10
TC 6
Z9 7
U1 2
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1877-7821
J9 CANCER EPIDEMIOL
JI Cancer Epidemiol.
PD APR
PY 2013
VL 37
IS 2
BP 152
EP 155
DI 10.1016/j.canep.2012.11.002
PG 4
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 123UD
UT WOS:000317415700008
PM 23265869
ER
PT J
AU Tanwar, PS
Kaneko-Tarui, T
Lee, HJ
Zhang, LH
Teixeira, JM
AF Tanwar, Pradeep S.
Kaneko-Tarui, Tomoko
Lee, Ho-Joon
Zhang, LiHua
Teixeira, Jose M.
TI PTEN loss and HOXA10 expression are associated with ovarian endometrioid
adenocarcinoma differentiation and progression
SO CARCINOGENESIS
LA English
DT Article
ID FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; BETA-CATENIN
GENE; REPRODUCTIVE-TRACT; SURFACE EPITHELIUM; WNT/BETA-CATENIN; CELL
TUMOR; COLI APC; CANCER; MOUSE
AB Epithelial ovarian cancer is a heterogeneous disease that is subdivided into five major histotypes but the mechanisms driving their differentiation are not clear. Mutations in adenomatous polyposis coli (APC) and -catenin are commonly observed in the human ovarian endometrioid adenocarcinoma (OEA) patients. However, the mechanisms subsequent to APC deletion in ovarian tumorigenesis have not been well characterized. We have conditionally deleted APC in the murine ovarian surface epithelium (OSE) and showed that its loss leads to development of epithelial inclusion cysts. High-grade OEAs with tightly packed villoglandular histology were observed in older APC-deleted mice. Phosphatase and tensin homolog (PTEN) expression was elevated in the early lesions but lost after progression to the more advanced tumors. Knockdown of APC or expression of a gain-of-function -catenin similarly induced human OSE cells to develop tumors with endometrioid histology in xenografts. Expression of HOXA10 was induced in both the advanced APC-deleted murine tumors and in the tumor xenografts of human OSE cells with knocked-down APC. These results show that reduced APC activity is sufficient to induce formation of epithelial inclusion cysts and support OEA development and suggest that induced HOXA10 expression and loss of PTEN are key mechanisms driving endometrioid histotype differentiation and progression.
C1 Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA.
[Teixeira, Jose M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Teixeira, JM (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol Thier 931, 55 Fruit St, Boston, MA 02114 USA.
EM teixeira@helix.mgh.harvard.edu
OI Teixeira, Jose/0000-0002-6438-5064
FU National Institutes of Health [HD052701]; Vincent Center Memorial Funds
FX National Institutes of Health (HD052701) and Vincent Center Memorial
Funds to J.M.T.
NR 56
TC 11
Z9 13
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD APR
PY 2013
VL 34
IS 4
BP 893
EP 901
DI 10.1093/carcin/bgs405
PG 9
WC Oncology
SC Oncology
GA 123PB
UT WOS:000317401200020
PM 23276799
ER
PT J
AU Holland, JP
Kang, A
Cohrs, S
Selivanova, SV
Sephton, SM
Betzel, T
Frey, D
Wieser, M
Jaussi, R
Kammerer, RA
Schibli, R
Fischer, E
AF Holland, Jason P.
Kang, Albert
Cohrs, Susan
Selivanova, Svetlana V.
Sephton, Selena Milicevic
Betzel, Thomas
Frey, Daniel
Wieser, Mara
Jaussi, Rolf
Kammerer, Richard A.
Schibli, Roger
Fischer, Eliane
TI Synthesis and Evaluation of Biphenyl Compounds as Kinesin Spindle
Protein Inhibitors
SO CHEMISTRY & BIODIVERSITY
LA English
DT Article
DE Kinesin spindle protein; Biphenyls; Inhibitors; Mitosis;
Antiproliferative activity; Confocal fluorescence microscopy;
Density-functional theory (DFT)
ID CANCER-CELLS; MECHANISM; AGENTS; KSP
AB Kinesin spindle protein (KSP), an ATP-dependent motor protein, plays an essential role in bipolar spindle formation during the mitotic phase (M phase) of the normal cell cycle. KSP has emerged as a novel target for antimitotic anticancer drug development. In this work, we synthesized a range of new biphenyl compounds and investigated their properties in vitro as potential antimitotic agents targeting KSP expression. Antiproliferation (MTT (=3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)) assays, combined with fluorescence-assisted cell sorting (FACS) and Western blot studies analyzing cell-cycle arrest confirmed the mechanism and potency of these biphenyl compounds in a range of human cancer cell lines. Structural variants revealed that functionalization of biphenyl compounds with bulky aliphatic or aromatic groups led to a loss of activity. However, replacement of the urea group with a thiourea led to an increase in antiproliferative activity in selected cell lines. Further studies using confocal fluorescence microscopy confirmed that the most potent biphenyl derivative identified thus far, compound 7, exerts its pharmacologic effect specifically in the M phase and induces monoaster formation. These studies confirm that chemical scope remains for improving the potency and treatment efficacy of antimitotic KSP inhibition in this class of biphenyl compounds.
C1 [Holland, Jason P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Holland, Jason P.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Holland, Jason P.; Kang, Albert; Selivanova, Svetlana V.; Sephton, Selena Milicevic; Betzel, Thomas; Schibli, Roger] ETH, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland.
[Cohrs, Susan; Schibli, Roger; Fischer, Eliane] Paul Scherrer Inst, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland.
[Frey, Daniel; Wieser, Mara; Jaussi, Rolf; Kammerer, Richard A.] Paul Scherrer Inst, Lab Biomol Res, CH-5232 Villigen, Switzerland.
RP Holland, JP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, 55 Fruit St,White 427, Boston, MA 02114 USA.
EM holland.jason@mgh.harvard.edu; eliane.fischer@psi.ch
RI Fischer, Eliane/M-2590-2013;
OI Fischer, Eliane/0000-0002-3399-3737; Holland, Jason/0000-0002-0066-219X;
Schibli, Roger/0000-0002-1537-3833
FU ETH Fellowship Program [FEL-01-10-1]
FX Funded in part by the ETH Fellowship Program (FEL-01-10-1; JPH). We
thank Dr. Aristeidis Chiotellis and Cindy Fischer for helpful
discussions and advice regarding chemical synthesis and chromatography.
We also thank Drs. Tobias Schwarz and Joaquim Hehl at the Light
Microscopy Centre, ETH Zurich, for technical support regarding
fluorescence microscopy studies.
NR 21
TC 2
Z9 2
U1 0
U2 8
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1612-1872
EI 1612-1880
J9 CHEM BIODIVERS
JI Chem. Biodivers.
PD APR
PY 2013
VL 10
IS 4
BP 538
EP 555
DI 10.1002/cbdv.201200400
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 126LD
UT WOS:000317616400004
PM 23576341
ER
PT J
AU Wu, JHY
Lemaitre, RN
Manichaikul, A
Guan, WH
Tanaka, T
Foy, M
Kabagambe, EK
Djousse, L
Siscovick, D
Fretts, AM
Johnson, C
King, IB
Psaty, BM
McKnight, B
Rich, SS
Chen, YDI
Nettleton, JA
Tang, WH
Bandinelli, S
Jacobs, DR
Browning, BL
Laurie, CC
Gu, XJ
Tsai, MY
Steffen, LM
Ferrucci, L
Fornage, M
Mozaffarian, D
AF Wu, Jason H. Y.
Lemaitre, Rozenn N.
Manichaikul, Ani
Guan, Weihua
Tanaka, Toshiko
Foy, Millennia
Kabagambe, Edmond K.
Djousse, Luc
Siscovick, David
Fretts, Amanda M.
Johnson, Catherine
King, Irena B.
Psaty, Bruce M.
McKnight, Barbara
Rich, Stephen S.
Chen, Yii-Der I.
Nettleton, Jennifer A.
Tang, Weihong
Bandinelli, Stefania
Jacobs, David R., Jr.
Browning, Brian L.
Laurie, Cathy C.
Gu, Xiangjun
Tsai, Michael Y.
Steffen, Lyn M.
Ferrucci, Luigi
Fornage, Myriam
Mozaffarian, Dariush
TI Genome-Wide Association Study Identifies Novel Loci Associated With
Concentrations of Four Plasma Phospholipid Fatty Acids in the De Novo
Lipogenesis Pathway Results From the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE epidemiology; fatty acids; genome-wide association study; lipogenesis
ID MIDDLE-AGED ADULTS; ENDOPLASMIC-RETICULUM; ATHEROSCLEROSIS RISK;
INTERMITTENT HYPOXIA; SYNTHASE INHIBITORS; ALCOHOL-CONSUMPTION; HEPATIC
STEATOSIS; ADIPOSE-TISSUE; PPAR-ALPHA; ER STRESS
AB Background-Palmitic acid (16:0), stearic acid (18:0), palmitoleic acid (16:1n-7), and oleic acid (18:1n-9) are major saturated and monounsaturated fatty acids that affect cellular signaling and metabolic pathways. They are synthesized via de novo lipogenesis and are the main saturated and monounsaturated fatty acids in the diet. Levels of these fatty acids have been linked to diseases including type 2 diabetes mellitus and coronary heart disease.
Methods and Results-Genome-wide association studies were conducted in 5 population-based cohorts comprising 8961 participants of European ancestry to investigate the association of common genetic variation with plasma levels of these 4 fatty acids. We identified polymorphisms in 7 novel loci associated with circulating levels of >= 1 of these fatty acids. ALG14 (asparagine-linked glycosylation 14 homolog) polymorphisms were associated with higher 16:0 (P=2.7x10(-11)) and lower 18:0 (P=2.2x10(-18)). FADS1 and FADS2 (desaturases) polymorphisms were associated with higher 16:1n-7 (P=6.6x10(-13)) and 18:1n-9 (P=2.2x10(-32)) and lower 18:0 (P=1.3x10(-20)). LPGAT1 (lysophosphatidylglycerol acyltransferase) polymorphisms were associated with lower 18:0 (P=2.8x10(-9)). GCKR (glucokinase regulator; P=9.8x10(-10)) and HIF1AN (factor inhibiting hypoxia-inducible factor-1; P=5.7x10(-9)) polymorphisms were associated with higher 16:1n-7, whereas PKD2L1 (polycystic kidney disease 2-like 1; P=5.7x10(-15)) and a locus on chromosome 2 (not near known genes) were associated with lower 16:1n-7 (P=4.1x10(-8)).
Conclusions-Our findings provide novel evidence that common variations in genes with diverse functions, including protein-glycosylation, polyunsaturated fatty acid metabolism, phospholipid modeling, and glucose-and oxygen-sensing pathways, are associated with circulating levels of 4 fatty acids in the de novo lipogenesis pathway. These results expand our knowledge of genetic factors relevant to de novo lipogenesis and fatty acid biology. (Circ Cardiovasc Genet. 2013;6:171-183.)
C1 [Wu, Jason H. Y.; Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Nutr, Boston, MA 02115 USA.
[Wu, Jason H. Y.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
[Lemaitre, Rozenn N.; Siscovick, David; Fretts, Amanda M.; Johnson, Catherine; Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Siscovick, David] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[McKnight, Barbara; Laurie, Cathy C.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Browning, Brian L.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Manichaikul, Ani] Univ Virginia, Ctr Publ Hlth Genom, Div Biostat & Epidemiol, Charlottesville, VA USA.
[Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
[Guan, Weihua] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
[Tang, Weihong; Jacobs, David R., Jr.; Steffen, Lyn M.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Tsai, Michael Y.] Univ Minnesota, Sch Publ Hlth, Lab Med & Pathol, Minneapolis, MN USA.
[Tanaka, Toshiko; Ferrucci, Luigi] NIA, Clin Res Branch, NIH, Bethesda, MD 20892 USA.
[Foy, Millennia; Gu, Xiangjun; Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX USA.
[Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA.
[Kabagambe, Edmond K.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
[Djousse, Luc] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Aging,Dept Med, Boston, MA 02115 USA.
[Mozaffarian, Dariush] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA.
[Djousse, Luc] Boston VA Healthcare Syst, Boston, MA USA.
[King, Irena B.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Chen, Yii-Der I.] Cedars Sinai Med Ctr, Med Genet Res Inst, Los Angeles, CA 90048 USA.
[Bandinelli, Stefania] Azienda Sanit Firenze, Geriatr Unit, Florence, Italy.
RP Wu, JHY (reprint author), Harvard Univ, Sch Publ Hlth, Kresge Bldg 913,677 Huntington Ave, Boston, MA 02115 USA.
EM jasonwu@hsph.harvard.edu
RI Browning, Brian/A-1178-2010; Djousse, Luc/F-5033-2017
OI Browning, Brian/0000-0001-6454-6633; Djousse, Luc/0000-0002-9902-3047
FU National Heart, Lung, and Blood Institute NHLBI [HHSN268201100005C,
HHSN268201100006C, HHSN2682011 00007C, HHSN268201100008C,
HHSN268201100009C, HHSN 268201100010C, HHSN268201100011C,
HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694]; National Human
Genome Research Institute [U01HG004402, U01-HG-004729, U01-HG-004446,
U01-HG-004424]; National Institutes of Health [HSN268200625226C]; NIH
[UL1RR025005]; NIH Roadmap for Medical Research; NHLBI [N01-HC-85239,
N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222,
N01-HC-75150, N01-HC-45133, HL080295, HL075366, HL087652, HL105756];
National Institute on Aging [AG-023629, AG-15928, AG-20098, AG-027058];
National Center for Research Resources CTSI [UL 1RR033176]; National
Institute of Diabetes and Digestive and Kidney Diseases [DK063491];
Italian Ministry of Health [ICS110.1/RF97.71]; US National Institute on
Aging [263 MD 9164, 263 MD 821336]; Intramural research program of the
National Institute on Aging, National Institutes of Health; MESA;
National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases [5K01DK082729-02]; National Heart, Lung,
and Blood Institute [N01-HC-95095, N01-HC-48047, N01-HC-48048,
N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, N01-HC-45205,
N01-HC-45204, R01-HL-084099, N01-HC-95159, N01-HC-95169, RR-024156,
N02-HL-6-4278]; [R01HL071051]; [R01HL071205]; [R01HL071250];
[R01HL071251]; [R01HL071252]; [R01HL071258]; [R01HL071259]
FX The ARIC Study is performed as a collaborative study supported by
National Heart, Lung, and Blood Institute NHLBI contracts
(HHSN268201100005C, HHSN268201100006C, HHSN2682011 00007C,
HHSN268201100008C, HHSN268201100009C, HHSN 268201100010C,
HHSN268201100011C, HHSN268201100012C), R01HL087641, R01HL59367, and
R01HL086694; National Human Genome Research Institute contract
U01HG004402; and National Institutes of Health contract
HSN268200625226C. The authors thank the staff and participants of the
ARIC Study for their important contributions. Infrastructure was partly
supported by Grant Number UL1RR025005, a component of the NIH and NIH
Roadmap for Medical Research. The CHS research reported in this article
was supported by the NHLBI contracts N01-HC-85239, N01-HC-85079 through
N01-HC-85086; N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150,
and N01-HC-45133, and grants HL080295, HL075366, HL087652, and HL105756
with additional contribution from National Institute of Neurological
Disorders and Stroke. Additional support was provided through AG-023629,
AG-15928, AG-20098, and AG-027058 from the National Institute on Aging.
See also http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping
were supported, in part, by National Center for Research Resources CTSI
grant UL 1RR033176 and National Institute of Diabetes and Digestive and
Kidney Diseases grant DK063491 to the Southern California Diabetes
Endocrinology Research Center. The Coronary Artery Risk Development in
Young Adults CARDIA study is funded by contracts N01-HC-95095,
N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-45134,
N01-HC-05187, N01-HC-45205, and N01-HC-45204 from the NHLBI to the
CARDIA investigators. Genotyping of the CARDIA participants was
supported by grants U01-HG-004729, U01-HG-004446, and U01-HG-004424 from
the National Human Genome Research Institute and R01-HL-084099 from the
NHLBI to Dr Fornage. Statistical analyses and fatty acid measures were
funded by R01-HL-084099 from the NHLBI to Dr Foy. The InCHIANTI Study
baseline (1998-2000) was supported as a targeted project
(ICS110.1/RF97.71) by the Italian Ministry of Health, in part by the US
National Institute on Aging (contracts 263 MD 9164 and 263 MD 821336),
and in part by the Intramural research program of the National Institute
on Aging, National Institutes of Health. The Multi-Ethnic Study of
Atherosclerosis (MESA) and MESA SHARe were supported by contracts
N01-HC-95159 through N01-HC-95169 and RR-024156 from the NHLBI. Funding
for MESA SHARe genotyping was provided by NHLBI contract N02-HL-6-4278.
MESA Family is conducted and supported in collaboration with MESA
investigators, and support is provided by grants and contracts
R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071252,
R01HL071258, and R01HL071259. The authors thank the other investigators,
the staff, and the participants of the MESA study for their valuable
contributions. A full list of participating MESA investigators and
institutions can be found at http://www.mesa-nhlbi.org. Dr Nettleton is
supported by a K01 from the National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases
(5K01DK082729-02).; The authors thank the other investigators, the
staff, and the participants of the ARIC study, the CARDIA study, the CHS
study, the MESA study, and the InCHIANTI study for their important
contributions. A full list of principal CHS investigators and
institutions can be found at http://www.chs-nhlbi.org/pi.htm. A full
list of principal CARDIA investigators and institutions can be found at
http://www.cardia.dopm.uab.edu/study-information/participating-instituti
ons. A full list of participating MESA investigators and institutions
can be found at http://www.mesa-nhlbi.org. The authors acknowledge the
essential role of the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium in the development and support of this
manuscript. CHARGE members include National Heart, Lung, and Blood
Institute's (NHLBI's) Atherosclerosis Risk in Communities (ARIC) Study,
National Institute of Health (NIH) and Icelandic Heart Association's
Age, Gene/Environment Susceptibility (AGES) Study, NHLBI's
Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), and
the Netherland's Rotterdam Study (RS).
NR 74
TC 21
Z9 21
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD APR
PY 2013
VL 6
IS 2
BP 171
EP +
DI 10.1161/CIRCGENETICS.112.964619
PG 37
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA 128AW
UT WOS:000317741400006
PM 23362303
ER
PT J
AU Kramer, JR
Fischbach, LA
Richardson, P
Alsarraj, A
Fitzgerald, S
Shaib, Y
Abraham, NS
Velez, M
Cole, R
Anand, B
Verstovsek, G
Rugge, M
Parente, P
Graham, DY
El-Serag, HB
AF Kramer, Jennifer R.
Fischbach, Lori A.
Richardson, Peter
Alsarraj, Abeer
Fitzgerald, Stephanie
Shaib, Yasser
Abraham, Neena S.
Velez, Maria
Cole, Rhonda
Anand, Bhupinderjit
Verstovsek, Gordana
Rugge, Massimo
Parente, Paola
Graham, David Y.
El-Serag, Hashem B.
TI Waist-to-Hip Ratio, but Not Body Mass Index, Is Associated With an
Increased Risk of Barrett's Esophagus in White Men
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Visceral Obesity; Epidemiologic Study; Veterans Affairs; Risk Factors
ID GASTROESOPHAGEAL-REFLUX DISEASE; GENERAL-POPULATION; METABOLIC SYNDROME;
CENTRAL ADIPOSITY; HIATAL-HERNIA; FLAP VALVE; OBESITY; PREVALENCE;
SYMPTOMS; ADENOCARCINOMA
AB BACKGROUND & AIMS: Abdominal obesity increases the risk of gastroesophageal reflux disease (GERD) and also might contribute to the development of Barrett's esophagus (BE), although results are inconsistent. We examined the effects of waist-to-hip ratio (WHR) and body mass index (BMI) on the risk of BE and investigated whether race, GERD symptoms, or hiatus hernia were involved.
METHODS: We conducted a case-control study using data from eligible patients who underwent elective esophagogastroduodenoscopy; 237 patients had BE and the other 1021 patients served as endoscopy controls. We also analyzed data and tissue samples from enrolled patients who were eligible for screening colonoscopies at a primary care clinic (colonoscopy controls, n = 479). All patients underwent esophagogastroduodenoscopy, completed a survey, and had anthropometric measurements taken. WHR was categorized as high if it was 0.9 or greater for men or 0.85 or greater for women. Data were analyzed with logistic regression.
RESULTS: There was no association between BMI and BE. However, more patients with BE had a high WHR (92.4%) than endoscopy controls (79.5%) or colonoscopy controls (84.6%) (P < .001 and P = .008, respectively). In adjusted analysis, patients with BE were 2-fold more likely to have a high WHR than endoscopy controls (odds ratio [OR], 1.93; 95% confidence interval [CI], 1.1-3.5), this association was stronger for patients with long-segment BE (OR, 2.81; 95% CI, 1.0-7.9). A high WHR was associated significantly with BE only in whites (OR, 2.5; 95% CI, 1.2-5.4), but not in blacks or Hispanics. GERD symptoms, hiatus hernia, or gastroesophageal valve flap grade could not account for the association.
CONCLUSIONS: High WHR, but not BMI, is associated with a significant increase in the risk of BE, especially long-segment BE and in whites. The association is not caused by GERD symptoms or hiatus hernia.
C1 [Kramer, Jennifer R.; Richardson, Peter; Alsarraj, Abeer; Fitzgerald, Stephanie; Abraham, Neena S.; El-Serag, Hashem B.] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA.
[Abraham, Neena S.; Velez, Maria; Cole, Rhonda; Anand, Bhupinderjit; Graham, David Y.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Verstovsek, Gordana] Baylor Coll Med, Dept Pathol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Kramer, Jennifer R.; Richardson, Peter; Shaib, Yasser] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Shaib, Yasser; Abraham, Neena S.; Velez, Maria; Cole, Rhonda; Anand, Bhupinderjit; Graham, David Y.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Verstovsek, Gordana] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
[Fischbach, Lori A.] Univ Arkansas Med Sci, Dept Epidemiol, Fay W Boozman Coll Publ Hlth, Little Rock, AR 72205 USA.
[Rugge, Massimo] Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med DIMED, Padua, Italy.
[Parente, Paola] Casa Sollievo Sofferenza, Dept Pathol, San Giovanni Rotondo, Italy.
RP Kramer, JR (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM jennifer.kramer@va.gov
RI Rugge, Massimo/K-7525-2016
FU National Institutes of Health grant National Cancer Institute [R01
116845]; Houston VA HSR&D Center of Excellence [HFP90-020]; Texas
Digestive Disease Center National Institutes of Health [DK58338];
National Institute of Diabetes and Digestive and Kidney Diseases
[K24-04-107]
FX Supported in part by National Institutes of Health grant National Cancer
Institute R01 116845, the Houston VA HSR&D Center of Excellence
(HFP90-020), and the Texas Digestive Disease Center National Institutes
of Health (DK58338). Also supported by the National Institute of
Diabetes and Digestive and Kidney Diseases (K24-04-107 to H.B.E.-S.).
The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government.
NR 37
TC 39
Z9 39
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD APR
PY 2013
VL 11
IS 4
BP 373
EP +
DI 10.1016/j.cgh.2012.11.028
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 123TK
UT WOS:000317413700012
PM 23220167
ER
PT J
AU Lin, JH
Zhang, SMM
Rexrode, KM
Manson, JE
Chan, AT
Wu, KN
Tworoger, SS
Hankinson, SE
Fuchs, C
Gaziano, JM
Buring, JE
Giovannucci, E
AF Lin, Jennifer H.
Zhang, Shumin M.
Rexrode, Kathryn M.
Manson, Joann E.
Chan, Andrew T.
Wu, Kana
Tworoger, Shelley S.
Hankinson, Susan E.
Fuchs, Charles
Gaziano, J. Michael
Buring, Julie E.
Giovannucci, Edward
TI Association Between Sex Hormones and Colorectal Cancer Risk in Men and
Women
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Estrogen; Incidence; Colorectal Cancer; Testosterone
ID ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; BINDING GLOBULIN;
PROSTATE-CANCER; SUBSEQUENT RISK; RECTAL-CANCER; THERAPY; METAANALYSIS;
COLON; TESTOSTERONE
AB BACKGROUND & AIMS: There is observational and clinical evidence that indicates that sex hormones affect development of colorectal cancer in men and women. However, the relationship between endogenous sex hormone levels and colorectal cancer is unclear.
METHODS: We collected data on lifestyle, medical history, and diet (through 2008), along with blood samples, from the Nurses' Health Study, the Women's Health Study, the Health Professional Follow-up Study, and the Physicians' Health Study II. We measured plasma levels of estrone, estradiol, testosterone, sex hormone binding globulin (SHBG), and C-peptide among 730 women (293 cases of colorectal cancer and 437 healthy individuals as controls) and 1158 men (439 colorectal cancer cases and 719 controls) and used unconditional logistic regression to estimate relative risks (RRs) and 95% confidence intervals. All statistical tests were 2-sided.
RESULTS: Total testosterone, SHBG, and the ratio of estradiol to testosterone were associated with colorectal cancer in men after adjustments for matching and risk factors for colorectal cancer, including body mass index and plasma levels of C-peptide. The RRs in the highest relative to the lowest quartile were 0.62 for testosterone (95% confidence interval, 0.40-0.96), 0.65 for SHBG (95% confidence interval, 0.42-0.99), and 2.63 for the ratio (95% confidence interval, 1.58-4.36) (P values for trend <= .02). However, in women, only the ratio of estradiol to testosterone was (inversely) associated with colorectal cancer after adjustments for all factors (RR, 0.43; 95% confidence interval, 0.22-0.84; P value for trend = .03).
CONCLUSIONS: On the basis of combined data from 4 population studies, there appears to be an association between levels of sex hormones and colorectal cancer risk in men. There also appears to be an inverse association between the ratio of estradiol to testosterone and colorectal cancer in postmenopausal women.
C1 [Lin, Jennifer H.; Zhang, Shumin M.; Rexrode, Kathryn M.; Manson, Joann E.; Gaziano, J. Michael; Buring, Julie E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Chan, Andrew T.; Tworoger, Shelley S.; Hankinson, Susan E.; Fuchs, Charles; Giovannucci, Edward] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Manson, Joann E.; Tworoger, Shelley S.; Hankinson, Susan E.; Buring, Julie E.; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
[Wu, Kana; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02215 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA.
[Hankinson, Susan E.] Univ Massachusetts, Div Biostat & Epidemiol, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA.
[Fuchs, Charles] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Gaziano, J. Michael] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
RP Lin, JH (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, 900 Commonwealth Ave East, Boston, MA 02215 USA.
EM jhlin@rics.bwh.harvard.edu
OI Tworoger, Shelley/0000-0002-6986-7046; Rexrode,
Kathryn/0000-0003-3387-8429
FU National Cancer Institute [CA126846, CA49449, CA47988, CA87969, CA55075,
CA34944, CA40360, CA097193, CA123089, CA137178]; National Heart, Lung,
and Blood Institute [HL043851, HL080467, HL26490, HL34595]
FX Supported by grants CA126846, CA49449, CA47988, CA87969, CA55075,
CA34944, CA40360, CA097193, CA123089, and CA137178 from the National
Cancer Institute and grants HL043851, HL080467, HL26490, and HL34595
from the National Heart, Lung, and Blood Institute.
NR 26
TC 28
Z9 30
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD APR
PY 2013
VL 11
IS 4
BP 419
EP +
DI 10.1016/j.cgh.2012.11.012
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 123TK
UT WOS:000317413700020
PM 23200979
ER
PT J
AU Fett, N
Neves, J
AF Fett, Nicole
Neves, Jennifer
TI Multiple Eruptive Milia
SO CUTIS
LA English
DT Article
ID CLASSIFICATION; BOY
AB Multiple eruptive milia (MEM) is a rare skin condition characterized by sudden onset of multiple milia occurring mainly on the head, neck, and trunk. Milia are small, benign, 1- to 4-mm, white keratinous cysts. The lesions generally are asymptomatic and may arise spontaneously or secondary to a number of processes. Multiple eruptive milia are cosmetically troublesome and difficult to treat. We report the case of a 40-year-old man with an abrupt onset of MEM on the face. Cutis. 2013; 91: 191-192.
C1 [Fett, Nicole; Neves, Jennifer] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Fett, Nicole] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Fett, N (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Ste 1-330A,3400 Civic Ctr Blvd, Philadelphia, PA 19104 USA.
EM Nicole.fett@uphs.upenn.edu
NR 7
TC 1
Z9 1
U1 0
U2 0
PU QUADRANT HEALTHCOM INC
PI PARSIPPANY
PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA
SN 0011-4162
J9 CUTIS
JI Cutis
PD APR
PY 2013
VL 91
IS 4
BP 191
EP 192
PG 2
WC Dermatology
SC Dermatology
GA 127QB
UT WOS:000317712400009
PM 23763079
ER
PT J
AU O'Donovan, A
Rush, G
Hoatam, G
Hughes, BM
McCrohan, A
Kelleher, C
O'Farrelly, C
Malone, KM
AF O'Donovan, Aoife
Rush, Gavin
Hoatam, Gerard
Hughes, Brian M.
McCrohan, AnnMaria
Kelleher, Cecily
O'Farrelly, Cliona
Malone, Kevin M.
TI SUICIDAL IDEATION IS ASSOCIATED WITH ELEVATED INFLAMMATION IN PATIENTS
WITH MAJOR DEPRESSIVE DISORDER
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE depression; biological markers; mood disorders; stress; suicide;
self-harm
ID NATIONAL COMORBIDITY SURVEY; IMMUNE ACTIVATION; CANCER-PATIENTS; DSM-IV;
INTERLEUKIN-6; STRESS; PREVALENCE; ATTEMPTERS; RESPONSES; CORTISOL
AB Background Patients with major depressive disorder (MDD) who attempt or complete suicide have elevated inflammation compared to nonsuicidal patients with MDD. However, greater severity of depression and the medical lethality of suicide attempts could account for such elevated inflammation in suicide attempters and suicide completers. Methods To clarify, we measured inflammatory markers in patients with MDD with and without high levels of suicidal ideation and in nondepressed controls (N = 124). Levels of suicidal ideation, depression severity, and recent suicide attempts were assessed by structured clinical interviews. A composite score including the inflammatory markers tumor necrosis factor- (TNF-), interleukin-6 (IL-6), interleukin-10 (IL-10), and C-reactive protein (CRP) was used as an inflammatory index. Analysis of covariance models were used to assess group differences with adjustments for age and gender. Results Patients with MDD and high suicidal ideation had significantly higher inflammatory index scores than both controls, F(1,53) = 18.08, partial 2 = .25, P < .001, and patients with MDD and lower suicidal ideation F(1,44) = 7.59, partial 2 = .15, P = .009. In contrast, patients with lower suicidal ideation were not significantly different from controls on the inflammatory index, F(1,63) = .52, partial 2 = .01, P = .47. Follow-up analyses indicated that differences between patients with MDD and high versus lower suicidal ideation were independent of depression severity and recent suicide attempts. Conclusions Suicidal ideation may be uniquely associated with inflammation in depressed patients.
C1 [O'Donovan, Aoife; Malone, Kevin M.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland.
[O'Donovan, Aoife; McCrohan, AnnMaria; Malone, Kevin M.] St Vincents Univ Hosp, Dept Psychiat Psychotherapy & Mental Hlth Res, Dublin 4, Ireland.
[O'Donovan, Aoife] San Francisco VA Med Ctr, Stress & Hlth Res Program, San Francisco, CA USA.
[O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Rush, Gavin] St Patricks Univ Hosp, Dublin, Ireland.
[Hoatam, Gerard] Creighton Univ, Sch Med, Omaha, NE USA.
[Hughes, Brian M.] Natl Univ Ireland, Dept Psychol, Galway, Ireland.
[Kelleher, Cecily] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Dublin 2, Ireland.
[O'Farrelly, Cliona] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland.
RP O'Donovan, A (reprint author), Univ Calif San Francisco, Dept Psychiat, 3333 Calif St,Suite 465, San Francisco, CA 94143 USA.
EM aoife.odonovan@ucsf.edu
OI Malone, Kevin M/0000-0001-5665-4706
FU Craig Dobbin Newman Scholarship in Mental Health Research and Society in
Science - The Branco Weiss Fellowship; Lundbeck Research Scholarship
FX This study was supported by the Craig Dobbin Newman Scholarship in
Mental Health Research and Society in Science - The Branco Weiss
Fellowship to A.O.D. and by a Lundbeck Research Scholarship to G. R. The
authors would like to thank Josh Woolley, M.D./Ph.D., Ashkan Ahmadian,
B. A., and Kristen Nishimi, B. A., for helpful feedback on this
manuscript.
NR 44
TC 38
Z9 39
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD APR
PY 2013
VL 30
IS 4
BP 307
EP 314
DI 10.1002/da.22087
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 126GJ
UT WOS:000317600800004
PM 23504697
ER
PT J
AU Bleich, S
Nanda, NC
Hage, FG
AF Bleich, Steven
Nanda, Navin C.
Hage, Fadi G.
TI The Incremental Value of Three-Dimensional Transthoracic
Echocardiography in Adult Congenital Heart Disease
SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED
TECHNIQUES
LA English
DT Article
DE three-dimensional echocardiography; congenital heart disease; atrial
septal defect; ventricular septal defect; anomalous coronary artery;
coarctation of aorta
ID VENTRICULAR SEPTAL-DEFECTS; COR-TRIATRIATUM SINISTER; BICUSPID
AORTIC-VALVE; OF-THE-ART; GREAT-ARTERIES; PULMONARY-ARTERY;
FORAMEN-OVALE; MANAGEMENT; TRANSPOSITION; COARCTATION
AB Imaging with echocardiography is useful in diagnosing congenital heart disease (CHD). Two-dimensional (2D) transthoracic echocardiography (TTE) has been the standard cardiac imaging modality, but it forces the reader to mentally create the three-dimensional (3D) cardiac anatomy to understand these complex diseases. 3D TTE, which has relatively recently emerged to address this limitation, is capable of providing clear and dynamic 3D views of these anatomic defects and offers more insight on how to manage them. This review article will address the benefit of utilizing 3D TTE for proper characterization of different types of CHD in the adult and as a guide to appropriate treatment. (Echocardiography 2013;30:483-494)
C1 [Bleich, Steven] Univ Alabama Birmingham, Dept Med, Div Internal Med, Birmingham, AL 35249 USA.
[Nanda, Navin C.; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35249 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
RP Nanda, NC (reprint author), Univ Alabama Birmingham, Heart Stn SWB S102, 619 19th St South, Birmingham, AL 35249 USA.
EM nanda@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 51
TC 3
Z9 3
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-2822
J9 ECHOCARDIOGR-J CARD
JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.
PD APR
PY 2013
VL 30
IS 4
BP 483
EP 494
DI 10.1111/echo.12130
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 123XS
UT WOS:000317425900025
PM 23551608
ER
PT J
AU Swirski, FK
AF Swirski, F. K.
TI Monocyte subsets in chronic inflammation
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Meeting Abstract
C1 [Swirski, F. K.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Swirski, F. K.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD APR
PY 2013
VL 43
SU 1
SI SI
BP 11
EP 11
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 120AE
UT WOS:000317141000031
ER
PT J
AU Copin, JC
da Silva, RF
Fraga-Silva, RA
Capettini, L
Quintao, S
Lenglet, S
Pelli, G
Galan, K
Burger, F
Braunersreuther, V
Schaller, K
Deruaz, M
Proudfoot, AE
Dallegri, F
Stergiopulos, N
Santos, RAS
Gasche, Y
Mach, F
Montecucco, F
AF Copin, J. C.
da Silva, R. F.
Fraga-Silva, R. A.
Capettini, L.
Quintao, S.
Lenglet, S.
Pelli, G.
Galan, K.
Burger, F.
Braunersreuther, V.
Schaller, K.
Deruaz, M.
Proudfoot, A. E.
Dallegri, F.
Stergiopulos, N.
Santos, R. A. S.
Gasche, Y.
Mach, F.
Montecucco, F.
TI The selective pharmacologic inhibition of CXC chemokines is associated
with an improvement of histological features of vulnerability in mouse
atherosclerotic plaques
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Meeting Abstract
C1 [Copin, J. C.] Univ Hosp Geneva, Div Neurosurg, Geneva, Switzerland.
[Copin, J. C.; Schaller, K.; Gasche, Y.] Univ Geneva, Geneva Neurosci Ctr, Geneva, Switzerland.
[da Silva, R. F.; Fraga-Silva, R. A.; Capettini, L.; Quintao, S.; Stergiopulos, N.] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland.
[da Silva, R. F.; Fraga-Silva, R. A.; Capettini, L.; Quintao, S.; Santos, R. A. S.] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil.
[Lenglet, S.; Pelli, G.; Galan, K.; Burger, F.; Braunersreuther, V.; Mach, F.; Montecucco, F.] Univ Geneva, Fdn Med Res, Div Cardiol, Geneva, Switzerland.
[Deruaz, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Proudfoot, A. E.] Merck Serono Geneva Res Ctr, Geneva, Switzerland.
[Dallegri, F.; Montecucco, F.] Univ Genoa, Dept Internal Med, Clin Internal Med 1, Sch Med, I-16126 Genoa, Italy.
[Gasche, Y.] Univ Hosp Geneva, Div Intens Care Med, Geneva, Switzerland.
RI LENGLET, Sebastien/N-8923-2013; Santos, Robson/C-9336-2011; Montecucco,
Fabrizio/K-8543-2016
OI LENGLET, Sebastien/0000-0002-4853-8163; Santos,
Robson/0000-0001-8738-5852; Montecucco, Fabrizio/0000-0003-0823-8729
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD APR
PY 2013
VL 43
SU 1
SI SI
BP 23
EP 23
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 120AE
UT WOS:000317141000069
ER
PT J
AU Polasek, M
Caravan, P
AF Polasek, Miloslav
Caravan, Peter
TI Is Macrocycle a Synonym for Kinetic Inertness in Gd(III) Complexes?
Effect of Coordinating and Noncoordinating Substituents on Inertness and
Relaxivity of Gd(III) Chelates with DO3A-like Ligands
SO INORGANIC CHEMISTRY
LA English
DT Article
ID NEPHROGENIC SYSTEMIC FIBROSIS; MRI CONTRAST AGENTS; LANTHANIDE
COMPLEXES; WATER-EXCHANGE; AQUEOUS-SOLUTION; PHYSICOCHEMICAL PROPERTIES;
LUMINESCENCE PROPERTIES; GADOLINIUM COMPLEX; STRUCTURAL ENTRY;
SERUM-ALBUMIN
AB Gadolinium chelates with octadentate ligands are widely used as contrast agents for magnetic resonance imaging (MRI), with macrocyclic ligands based on DO3A being preferred for the high kinetic inertness of their Gd chelates. A major challenge in the design of new bifunctional MM probes is the need to control the rotational motion of the chelate, which greatly affects its relaxivity. In this work we explored facile alkylation of a secondary amine in macrocyclic DO3A-like ligands to create a short, achiral linkage to limit the undesired internal motion of chelates within larger molecular constructs. The acetate moiety on the trans nitrogen was also replaced with either a bidentate (ethoxyacetate, L1 or methyl picolinate, L2) or bulky monodentate (methyl phosphonate, L3) donor arm to give octa- or heptadentate ligands, respectively. The resultant Gd(III) complexes were all monohydrated (q = 1) and exhibited water residency times that spanned 2 orders of magnitude (tau(M) = 2190 +/- 170, 3500 +/- 90, and 12.7 +/- 3.8 ns at 37 degrees C for GdL1, GdL2, and GdL3, respectively). Alkylation of the secondary amine with a noncoordinating biphenyl moiety resulted in coordinatively saturated q = 0 complexes of octadentate ligands L1 and L2. Relaxivities were limited by slow water exchange and/or lack of water coligand. All complexes showed decreased inertness compared to [Gd(DO3A)] despite higher ligand denticity, and inertness was further decreased upon N-alkylation. These results demonstrate that high kinetic inertness and in vivo safety of Gd chelates with macrocyclic ligands should not be generalized.
C1 [Polasek, Miloslav; Caravan, Peter] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Caravan, P (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St,Suite 2301, Charlestown, MA 02129 USA.
EM caravan@nmr.mgh.harvard.edu
RI Polasek, Miloslav/G-5949-2014
FU National Institute of Biomedical Imaging and Bioengineering
[R01EB009062]
FX This work was supported in part by award R01EB009062 from the National
Institute of Biomedical Imaging and Bioengineering.
NR 73
TC 17
Z9 17
U1 1
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0020-1669
J9 INORG CHEM
JI Inorg. Chem.
PD APR 1
PY 2013
VL 52
IS 7
BP 4084
EP 4096
DI 10.1021/ic400227k
PG 13
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 119JT
UT WOS:000317094300074
PM 23517079
ER
PT J
AU Karolyi, M
Seifarth, H
Liew, G
Schlett, CL
Maurovich-Horvat, P
Stolzmann, P
Dai, GP
Huang, SN
Goergen, CJ
Nakano, M
Otsuka, F
Virmani, R
Hoffmann, U
Sosnovik, DE
AF Karolyi, Mihaly
Seifarth, Harald
Liew, Gary
Schlett, Christopher L.
Maurovich-Horvat, Pal
Stolzmann, Paul
Dai, Guangping
Huang, Shuning
Goergen, Craig J.
Nakano, Masataka
Otsuka, Fumiyuki
Virmani, Renu
Hoffmann, Udo
Sosnovik, David E.
TI Classification of Coronary Atherosclerotic Plaques Ex Vivo With T1, T2,
and Ultrashort Echo Time CMR
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE atherosclerosis; CMR; coronary artery; plaque classification; ultrashort
TE
ID CARDIOVASCULAR MAGNETIC-RESONANCE; OPTICAL COHERENCE TOMOGRAPHY; SPIRAL
COMPUTED-TOMOGRAPHY; IN-VIVO; CAROTID PLAQUE; HIGH-RESOLUTION;
INTRAVASCULAR ULTRASOUND; INTRAPLAQUE HEMORRHAGE; VULNERABLE PLAQUE;
FIBROUS CAP
AB OBJECTIVES This study sought to determine whether the classification of human coronary atherosclerotic plaques with T1, T2, and ultrashort echo time (UTE) cardiac magnetic resonance (CMR) would correlate well with atherosclerotic plaque classification by histology.
BACKGROUND CMR has been extensively used to classify carotid plaque, but its ability to characterize coronary plaque remains unknown. In addition, the detection of plaque calcification by CMR remains challenging. Here, we used T1, T2, and UTE CMR to evaluate atherosclerotic plaques in fixed post-mortem human coronary arteries. We hypothesized that the combination of T1, T2, and UTE CMR would allow both calcified and lipid-rich coronary plaques to be accurately detected.
METHODS Twenty-eight plaques from human donor hearts with proven coronary artery disease were imaged at 9.4-T with a T1-weighted 3-dimensional fast low-angle shot (FLASH) sequence (250-mu m resolution), a T2-weighted rapid acquisition with refocused echoes (RARE) sequence (in-plane resolution 0.156 mm), and an UTE sequence (300-mu m resolution). Plaques showing selective hypointensity on T2-weighted CMR were classified as lipid-rich. Areas of hypointensity on the T1-weighted images, but not the UTE images, were classified as calcified. Hyperintensity on the T1-weighted and UTE images was classified as hemorrhage. Following CMR, histological characterization of the plaques was performed with a pentachrome stain and established American Heart Association criteria.
RESULTS CMR showed high sensitivity and specificity for the detection of calcification (100% and 90%, respectively) and lipid-rich necrotic cores (90% and 75%, respectively). Only 2 lipid-rich foci were missed by CMR, both of which were extremely small. Overall, CMR-based classification of plaque was in complete agreement with the histological classification in 22 of 28 cases (weighted k = 0.6945, p < 0.0001).
CONCLUSIONS The utilization of UTE CMR allows plaque calcification in the coronary arteries to be robustly detected. High-resolution CMR with T1, T2, and UTE contrast enables accurate classification of human coronary atherosclerotic plaque. (J Am Coll Cardiol Img 2013;6:466-74) (C) 2013 by the American College of Cardiology Foundation
C1 [Karolyi, Mihaly; Seifarth, Harald; Liew, Gary; Schlett, Christopher L.; Maurovich-Horvat, Pal; Stolzmann, Paul; Hoffmann, Udo; Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, Boston, MA USA.
[Dai, Guangping; Huang, Shuning; Goergen, Craig J.; Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Boston, MA USA.
[Nakano, Masataka; Otsuka, Fumiyuki; Virmani, Renu] CV Path Inst Inc, Gaithersburg, MD USA.
RP Sosnovik, DE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA.
EM sosnovik@nmr.mgh.harvard.edu
OI Maurovich-Horvat, Pal/0000-0003-0885-736X; Goergen,
Craig/0000-0001-8883-7953
FU National Institutes of Health [P41RR14075, S10RR025563]; Deutsche
Forschungsgemeinschaft [DFG Se 2029/1-1]
FX The study was partially supported by National Institutes of Health
grants P41RR14075 and S10RR025563. Dr. Seifarth was supported by a
Deutsche Forschungsgemeinschaft grant (DFG Se 2029/1-1). Dr. Sosnovik
has received research support from and is a consultant for Siemens
Medical. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose. The first two
authors, Drs. Karolyi and Seifarth, contributed equally to this work;
Drs. Hoffmann and Sosnovik are joint senior authors.
NR 37
TC 7
Z9 9
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD APR
PY 2013
VL 6
IS 4
BP 466
EP 474
DI 10.1016/j.jcmg.2012.09.015
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 129LU
UT WOS:000317842300007
PM 23498670
ER
PT J
AU Blecker, S
Bhatia, RS
You, JJ
Lee, DS
Alter, DA
Wang, JT
Wong, HJ
Tu, JV
AF Blecker, Saul
Bhatia, R. Sacha
You, John J.
Lee, Douglas S.
Alter, David A.
Wang, Julie T.
Wong, Hannah J.
Tu, Jack V.
TI Temporal Trends in the Utilization of Echocardiography in Ontario, 2001
to 2009
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE cardiovascular imaging; echocardiography; resource utilization
ID APPROPRIATENESS USE CRITERIA; TRANSTHORACIC ECHOCARDIOGRAPHY;
HEART-FAILURE; CARE; MEDICARE; RATES; CANADA
AB The purpose of this study was to examine utilization and growth in echocardiography among the general population of Ontario between 2001 and 2009. The age- and sex-adjusted rates of echocardiography grew from 39.1 per 1,000 persons in 2001 to 59.9 per 1,000 persons in 2009, for an annual rate of increase of 5.5%. Repeat echocardiograms increased at a rate of 10.6% per year and accounted for 25.3% of all procedures in 2009 as compared to 18.5% in 2002. While significant increases in echocardiography utilization were observed, opportunities may exist to improve the clinical utility of the echocardiograms performed in Ontario.
C1 [Blecker, Saul] NYU, Sch Med, Dept Populat Hlth, New York, NY USA.
[Blecker, Saul] NYU, Sch Med, Dept Med, New York, NY USA.
[Bhatia, R. Sacha] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Bhatia, R. Sacha; Wong, Hannah J.] Harvard Univ, Sch Med, Boston, MA USA.
[Bhatia, R. Sacha; You, John J.; Lee, Douglas S.; Alter, David A.; Wang, Julie T.; Tu, Jack V.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada.
[You, John J.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
[You, John J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
[Lee, Douglas S.; Alter, David A.; Tu, Jack V.] Univ Toronto, Dept Med, Toronto, ON, Canada.
[Lee, Douglas S.] Toronto Gen Hosp, Univ Hlth Network, Div Cardiol, Toronto, ON, Canada.
[Alter, David A.] Toronto Rehabil Inst, Cardiac Rehabil & Secondary Prevent Program, Toronto, ON, Canada.
[Alter, David A.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
[Wong, Hannah J.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Wong, Hannah J.] Massachusetts Gen Hosp, Dept Imaging, Boston, MA 02114 USA.
[Wong, Hannah J.] Univ Hlth Network, Ctr Innovat Complex Care, Toronto, ON, Canada.
[Tu, Jack V.] Sunnybrook Schulich Heart Ctr, Toronto, ON, Canada.
RP Tu, JV (reprint author), Inst Clin Evaluat Sci, G106-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM tu@ices.on.ca
RI Lee, Douglas/J-4315-2014;
OI Tu, Jack/0000-0003-0111-722X; Wong, Hannah/0000-0002-9740-0312
FU Ontario Ministry of Health and Long-Term Care; Canadian Institutes of
Health Research; National Heart, Lung, and Blood Institute
[5T32HL007024]; Clinician-Scientist Award from the Canadian Institutes
of Health Research; Career Investigator Award from the Heart and Stroke
Foundation of Ontario; Canada Research Chair in Health Services Research
FX The Institute for Clinical Evaluative Sciences is supported by the
Ontario Ministry of Health and Long-Term Care. The results and
conclusions are those of the authors, and should not be attributed to
any of the funding agencies. This project was supported by operating
grants from the Ontario Ministry of Health and Long-Term Care and the
Canadian Institutes of Health Research. Dr. Blecker was supported in
part by National Heart, Lung, and Blood Institute Grant 5T32HL007024.
Dr. Lee is supported by a Clinician-Scientist Award from the Canadian
Institutes of Health Research. Dr. Alter is supported by a Career
Investigator Award from the Heart and Stroke Foundation of Ontario. Dr.
Tu is supported by a Canada Research Chair in Health Services Research
and a Career Investigator Award from the Heart and Stroke Foundation of
Ontario. All other authors have reported they have no relationships
relevant to the contents of this paper to disclose.
NR 29
TC 15
Z9 15
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD APR
PY 2013
VL 6
IS 4
BP 515
EP 522
DI 10.1016/j.jcmg.2012.10.026
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 129LU
UT WOS:000317842300014
PM 23579013
ER
PT J
AU Kumar, V
Donahue, DM
Patel, N
AF Kumar, Vishesh
Donahue, Dean Michael
Patel, Neha
TI An Unexpected Complication During Cardiac Catheterization Blood Clot
Cast of the Tracheobronchial Tree: First Case During Cardiac
Catheterization
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
DE anticoagulation; bleeding; respiratory failure
ID THROMBUS
C1 [Kumar, Vishesh] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Donahue, Dean Michael] Massachusetts Gen Hosp, Dept Thorac Surg, Boston, MA 02114 USA.
[Donahue, Dean Michael] North Shore Med Ctr, Salem, MA USA.
[Patel, Neha] Signature Healthcare, Brockton Hosp, Brockton, MA USA.
RP Kumar, V (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Richard B Simches Res Plaza,185 Cambridge St,Room, Boston, MA 02114 USA.
EM kumar.vishesh@mgh.harvard.edu
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD APR
PY 2013
VL 6
IS 4
DI 10.1016/j.jcin.2012.11.007
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 124SX
UT WOS:000317487900001
ER
PT J
AU Rosner, W
Hankinson, SE
Sluss, PM
Vesper, HW
Wierman, ME
AF Rosner, William
Hankinson, Susan E.
Sluss, Patrick M.
Vesper, Hubert W.
Wierman, Margaret E.
TI Challenges to the Measurement of Estradiol: An Endocrine Society
Position Statement
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BREAST-CANCER RISK; ENDOGENOUS SEX-HORMONES; BONE-MINERAL DENSITY;
POSTMENOPAUSAL WOMEN; MASS-SPECTROMETRY; SERUM ESTRADIOL; DIRECT
RADIOIMMUNOASSAYS; CIRCULATING ESTRADIOL; ENDOMETRIAL CANCER;
ESTROGEN-RECEPTORS
AB Objective: The objective of the study was to evaluate the current state of clinical assays for estradiol in the context of their applications.
Participants: The participants were appointed by the Council of The Endocrine Society and charged with attaining the objective using published data and expert opinion.
Evidence: Data were gathered from published sources via online databases (principally PubMed, Ovid MEDLINE, Google Scholar), and the clinical and laboratory experience of the participants.
Consensus Process: The statement was an effort of the committee and was reviewed by each member. The Clinical Affairs Committee, the Council of The Endocrine Society, and JCEM reviewers reviewed the manuscript and made recommendations.
Conclusions: The measurement of estradiol in biological fluids is important in human biology from cradle to grave. In addition to its centrality in sexual development, it has significant effects on skin, blood vessels, bone, muscle, coagulation, hepatic cells, adipose tissue, the kidney, the gastrointestinal tract, brain, lung, and pancreas. Alterations in its plasma concentration have been implicated in coronary artery disease, stroke, and breast cancer. Although modern immunoassays and liquid chromatography/tandem mass spectrometry-based methods for estradiol are reasonably well suited to the diagnosis and management of infertility (nonetheless, imprecision and method-to-method differences remain problematic), the very low concentrations that appear to be crucial in nonreproductive tissues are a separate and more difficult issue. Such levels of estradiol are too low to be routinely measured accurately or precisely, and further evolution of analytical methods and the way in which estradiol is standardized is needed. (J Clin Endocrinol Metab 98: 1376-1387, 2013)
C1 [Rosner, William] Columbia Univ, Coll Phys & Surg, New York, NY 10019 USA.
[Rosner, William] St Lukes Roosevelt Hosp, New York, NY 10019 USA.
[Hankinson, Susan E.] Univ Massachusetts, Div Biostat & Epidemiol, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA.
[Hankinson, Susan E.] Brigham & Womens Hosp, Div Network Med, Boston, MA 02115 USA.
[Sluss, Patrick M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
[Vesper, Hubert W.] US Ctr Dis Control & Prevent, Div Sci Lab, Clin Chem Branch, Atlanta, GA 30341 USA.
[Wierman, Margaret E.] Univ Colorado, Sch Med, Aurora, CO 80045 USA.
[Wierman, Margaret E.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Rosner, W (reprint author), St Lukes Roosevelt Hosp, Dept Med, AJA 403,1000 10th Ave, New York, NY 10019 USA.
EM wr7@columbia.edu
FU National Institutes of Health [R01 CA49449, R01 CA6762]
FX S.E.H. is funded by National Institutes of Health Grants R01 CA49449 and
R01 CA6762. W.R., P.M.S., H.W.V., and M.E.W. have no conflicts to
declare.
NR 86
TC 80
Z9 83
U1 2
U2 20
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2013
VL 98
IS 4
BP 1376
EP 1387
DI 10.1210/jc.2012-3780
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 120TJ
UT WOS:000317195600038
PM 23463657
ER
PT J
AU Ackerman, KE
Pierce, L
Guereca, G
Slattery, M
Lee, H
Goldstein, M
Misra, M
AF Ackerman, Kathryn E.
Pierce, Lisa
Guereca, Gabriela
Slattery, Meghan
Lee, Hang
Goldstein, Mark
Misra, Madhusmita
TI Hip Structural Analysis in Adolescent and Young Adult Oligoamenorrheic
and Eumenorrheic Athletes and Nonathletes
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID DOUBLY LABELED WATER; NECK BONE STRENGTH; PHYSICAL-ACTIVITY;
FEMORAL-NECK; OSTEOPOROTIC FRACTURES; NUTRIENT DATABASE;
STRESS-FRACTURES; GEOMETRY; FEMUR; PREDICTION
AB Context: Stress fractures are common in endurance athletes. Whereas studies have described distal tibia bone structure in athletes, there are few data regarding hip geometric parameters. Hip structural analysis (HSA) using dual-energy x-ray absorptiometry is a validated technique to assess hip bone structure.
Objectives: The purpose of this study was to compare hip geometry in young oligoamenorrheic athletes (AAs), eumenorrheic athletes (EAs), and nonathletes using HSA. We hypothesized that AAs would have impaired bone structure compared with that of EAs.
Design: This was a cross-sectional study.
Setting: The setting was a clinical research center. Subjects: We enrolled 55 AAs, 24 EAs, and 23 nonathletes of normal weight who were 14 to 22 years old. Athletes ran >= 20 miles/wk or were engaged in weight-bearing sports for >= 4 hours/wk.
Main Outcome Measures: Dual-energy x-ray absorptiometry was used for HSA and hip areal bone mineral density (aBMD).
Results: Hip aBMD Z-scores were lower in AAs and in nonathletes than in EAs (P = .002). A larger proportion of AAs than EAs and nonathletes had hip Z-scores <-1 (30.9, 4.2, 17.4%, P = .01). At the narrow neck, trochanteric region, and femoral shaft, subperiosteal width, cross-sectional moment of inertia, and section modulus were higher in EAs than in nonathletes; values in AAs did not differ from those of nonathletes. Cross-sectional area was lower in AAs and in nonathletes than in EAs. Groups did not differ for cortical thickness or buckling ratio. Group differences were lost after adjustment for lean mass but not aBMD.
Conclusions: In an eugonadal state, athletic activity confers benefits for hip structure independent of aBMD. This advantage is lost in AAs, who do not differ from nonathletes for most parameters and fare worse than EAs for cross-sectional area. (J Clin Endocrinol Metab 98: 1742-1749, 2013)
C1 [Ackerman, Kathryn E.; Pierce, Lisa; Guereca, Gabriela; Slattery, Meghan; Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Lee, Hang] Massachusetts Gen Hosp, Div Biostat, Boston, MA 02114 USA.
[Goldstein, Mark] Massachusetts Gen Hosp, Dept Med, Div Adolescent & Young Adult Med, Boston, MA 02114 USA.
[Misra, Madhusmita] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Ackerman, Kathryn E.] Boston Childrens Hosp, Div Sports Med, Boston, MA 02116 USA.
Harvard Univ, Sch Med, Boston, MA 02116 USA.
RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457,55 Fruit St, Boston, MA 02114 USA.
EM mmisra@partners.org
FU National Institutes of Health [1 UL1 RR025758, 1 R01 HD060827, 1 K24
HD071843]
FX This work was supported by the National Institutes of Health (Grants 1
UL1 RR025758, 1 R01 HD060827, and 1 K24 HD071843).
NR 30
TC 8
Z9 8
U1 0
U2 10
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2013
VL 98
IS 4
BP 1742
EP 1749
DI 10.1210/jc.2013-1006
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 120TJ
UT WOS:000317195600081
PM 23476076
ER
PT J
AU Crandall, CJ
Tseng, CH
Karlamangla, AS
Finkelstein, JS
Randolph, JF
Thurston, RC
Huang, MH
Zheng, HY
Greendale, GA
AF Crandall, Carolyn J.
Tseng, Chi-Hong
Karlamangla, Arun S.
Finkelstein, Joel S.
Randolph, John F., Jr.
Thurston, Rebecca C.
Huang, Mei-Hua
Zheng, Huiyong
Greendale, Gail A.
TI Serum Sex Steroid Levels and Longitudinal Changes in Bone Density in
Relation to the Final Menstrual Period
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID HORMONE-BINDING GLOBULIN; FOLLICLE-STIMULATING-HORMONE; POSTMENOPAUSAL
WOMEN; MINERAL DENSITY; MENOPAUSAL TRANSITION; VERTEBRAL FRACTURES;
CIRCULATING ANDROGENS; PERIMENOPAUSAL WOMEN; ENDOGENOUS ESTRADIOL;
ESTROGEN DEFICIENCY
AB Context: The associations of serum sex steroid and FSH levels with change of bone mineral density (BMD) across the complete menopausal transition are incompletely understood.
Objective: The objective of the study was to examine the associations of annual serum levels of FSH, estradiol (E-2), T, and SHBG with the rates of bone loss in 3 phases: pretransmenopausal [baseline to 1 year before the final menstrual period (FMP)], transmenopausal (1 year before to 2 years after the FMP), later postmenopausal (>= 2 years after the FMP).
Design: The design of the study was a repeated-measures, mixed-effects regression.
Setting: This was a community-based observational study, with a 10-year follow-up.
Participants: A total of 720 participants of the Study of Women's Health Across the Nation Bone Study participated in the study.
Outcome Measures: Annualized lumbar spine (LS) and femoral neck (FN) BMD decline was measured.
Results: The mean annual change in BMD was slowest in pretransmenopause (0.27%/year in FN) and fastest in transmenopause (2.16%/year in LS). In the pretransmenopausal phase, for every doubling of FSH level, LS BMD change was faster by -0.32%/year (P < .0001). In the transmenopausal phase, for every doubling of FSH level, LS BMD change was -0.35%/year faster (P < .0001); for every doubling of SHBG level, LS BMD change was -0.36%/year faster (P < .0001). In the later postmenopausal phase, for each doubling of the E-2 level, the LS BMD change was slower by +0.26%/year (P = .049); for each SHBG doubling, the LS BMD change was 0.21%/year slower (P = .048). The FN associations were weaker and inconsistent.
Conclusions: Higher E-2 levels and lower FSH levels were associated with lower rates of LS bone loss in some but not all menopausal transition phases. (J Clin Endocrinol Metab 98: E654-E663, 2013)
C1 [Crandall, Carolyn J.; Tseng, Chi-Hong] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90024 USA.
[Karlamangla, Arun S.; Huang, Mei-Hua; Greendale, Gail A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90024 USA.
[Finkelstein, Joel S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Randolph, John F., Jr.] Univ Michigan Hlth Syst, Div Reprod Endocrinol & Infertil, Ann Arbor, MI 48109 USA.
[Zheng, Huiyong] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Thurston, Rebecca C.] Univ Pittsburgh, Sch Med, Dept Psychiat & Epidemiol, Pittsburgh, PA 15213 USA.
Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
RP Crandall, CJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Univ Calif Los Angeles Med GIM, 911 Broxton Ave,1st Floor, Los Angeles, CA 90024 USA.
EM ccrandall@mednet.ucla.edu
FU National Institutes of Health (NIH), DHHS, through the National
Institute on Aging (NIA); National Institute of Nursing Research (NINR);
NIH Office of Research on Women's Health (ORWH) [NR004061, AG012505,
AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495]
FX The Study of Women's Health Across the Nation (SWAN) has grant support
from the National Institutes of Health (NIH), DHHS, through the National
Institute on Aging (NIA), the National Institute of Nursing Research
(NINR) and the NIH Office of Research on Women's Health (ORWH) (Grants
NR004061; AG012505, AG012535, AG012531, AG012539, AG012546, AG012553,
AG012554, AG012495). The content of this manuscript is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIA, NINR, ORWH or the NIH.
NR 58
TC 5
Z9 5
U1 1
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2013
VL 98
IS 4
BP E654
EP E663
DI 10.1210/jc.2012-3651
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 120TJ
UT WOS:000317195600006
PM 23443812
ER
PT J
AU Tsai, CL
Lee, WY
Delclos, GL
Hanania, NA
Camargo, CA
AF Tsai, Chu-Lin
Lee, Wen-Ya
Delclos, George L.
Hanania, Nicola A.
Camargo, Carlos A., Jr.
TI Comparative Effectiveness of Noninvasive Ventilation vs Invasive
Mechanical Ventilation in Chronic Obstructive Pulmonary Disease Patients
With Acute Respiratory Failure
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; POSITIVE-PRESSURE VENTILATION; ACUTE
EXACERBATIONS; UNITED-STATES; WARD; MULTICENTER; OUTCOMES; SUCCESS; COPD
AB BACKGROUND Limited evidence exists on the comparative effectiveness of noninvasive ventilation (NIV) vs invasive mechanical ventilation (IMV) in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients with respiratory failure. OBJECTIVES To characterize the use of NIV and IMV, and to compare the effectiveness of NIV vs IMV in AECOPD. DESIGN AND PATIENTS Retrospective cohort study using data from the 20062008 Nationwide Emergency Department Sample. Emergency department visits for AECOPD with acute respiratory failure were identified with codes from the International Classification of Diseases, Ninth Revision, Clinical Modification. MEASURES The outcome measures were inpatient mortality, hospital length of stay, hospital charges, and complications. RESULTS There were an estimated 101,000 visits annually for AECOPD with acute respiratory failure; 96% were admitted to the hospital. Of these, NIV use increased from 14% in 2006 to 16% in 2008 (P=0.049). Use of NIV, however, varied widely between hospitals, ranging from 0% to 100% with a median of 11%. Noninvasive ventilation was more often used in highercase volume, Northeastern hospitals. In a propensity score analysis, NIV use, compared with IMV, was associated with lower inpatient mortality (risk ratio: 0.54, 95% confidence interval [CI]: 0.50-0.59), shortened hospital length of stay (3.2 days; 95% CI: 3.4 to 2.9 days), lower hospital charges ($35,012; 95% CI: $36,848 to $33,176), and lower risk of iatrogenic pneumothorax (0.05% vs 0.5%, P<0.001). CONCLUSIONS Although NIV use is increasing in US hospitals, its adoption remains low and varies widely between hospitals. Our observational study suggests NIV appears to be more effective and safer than IMV for AECOPD in the real-world setting. Journal of Hospital Medicine 2013;8:165172. (c) 2013 Society of Hospital Medicine
C1 [Tsai, Chu-Lin; Lee, Wen-Ya; Delclos, George L.] Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
[Hanania, Nicola A.] Baylor Coll Med, Dept Med, Sect Pulm & Crit Care Med, Houston, TX 77030 USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Tsai, CL (reprint author), Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, 1200 Herman Pressler,Suite W610, Houston, TX 77030 USA.
EM cltsai@post.harvard.edu
OI TSAI, CHU-LIN/0000-0003-4639-1513
FU Agency for Healthcare Research and Quality [R03HS020722]
FX Partial results from this study were presented at the 2012 Society for
Academic Emergency Medicine Annual Meeting, Chicago, Illinois, May 9-12,
2012. This project was supported by grant number R03HS020722 from the
Agency for Healthcare Research and Quality. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the Agency for Healthcare Research and Quality. The
authors have no conflicts of interest to disclose.
NR 44
TC 12
Z9 15
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD APR
PY 2013
VL 8
IS 4
BP 165
EP 172
DI 10.1002/jhm.2014
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122ED
UT WOS:000317298700001
PM 23401469
ER
PT J
AU Yallampalli, R
Wilde, EA
Bigler, ED
McCauley, SR
Hanten, G
Troyanskaya, M
Hunter, JV
Chu, ZL
Li, XQ
Levin, HS
AF Yallampalli, Ragini
Wilde, Elisabeth A.
Bigler, Erin D.
McCauley, Stephen R.
Hanten, Gerri
Troyanskaya, Maya
Hunter, Jill V.
Chu, Zili
Li, Xiaoqi
Levin, Harvey S.
TI Acute White Matter Differences in the Fornix Following Mild Traumatic
Brain Injury Using Diffusion Tensor Imaging
SO JOURNAL OF NEUROIMAGING
LA English
DT Article
DE Diffusion tensor imaging; mild traumatic brain injury; fornix
ID AXONAL INJURY; HIPPOCAMPAL; CONCUSSION; RESPONSES; ATROPHY; MEMORY
AB The integrity of the fornix using diffusion tensor imaging (DTI) in adolescent participants with acute mild traumatic brain injury (mTBI) compared to a demographically matched control group was examined. Fractional anisotropy (FA) in the fornix was elevated in the mild traumatic brain injured group. Performance on the Automated Neuropsychological Assessment Metrics (ANAM) was lower in the group with mTBI. A relation was found between lower performance on cognitive tasks and higher FA. The potential role of fornix injury as a basis of memory and processing speed deficits in mTBI is discussed.
C1 [Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA.
[Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA.
[Wilde, Elisabeth A.; McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
[McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
[Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA.
[Wilde, Elisabeth A.; McCauley, Stephen R.; Troyanskaya, Maya; Levin, Harvey S.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Yallampalli, Ragini] Univ Houston, Dept Psychol, Houston, TX USA.
[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.
[Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA.
[Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA.
[Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA.
RP Wilde, EA (reprint author), Baylor Coll Med, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.
EM ewilde@bcm.edu
FU National Institutes of Health [NS056202-02]
FX This research was supported by Grant NS056202-02 awarded to Harvey S.
Levin by the National Institutes of Health. We would also like to
acknowledge the generous support by Mission Connect of the TIRR
Foundation. We would also like to thank the patients and their families
for involvement in this study. The information in this manuscript and
the manuscript itself has never been published either electronically or
in print. None of the authors have any financial or other
relationship(s) that could be construed as a conflict of interest with
respect to the content of this manuscript. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.
NR 30
TC 23
Z9 23
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1051-2284
J9 J NEUROIMAGING
JI J. Neuroimaging
PD APR
PY 2013
VL 23
IS 2
BP 224
EP 227
DI 10.1111/j.1552-6569.2010.00537.x
PG 4
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 126LN
UT WOS:000317617800016
PM 21988147
ER
PT J
AU Shaikhouni, A
Donoghue, JP
Hochberg, LR
AF Shaikhouni, Ammar
Donoghue, John P.
Hochberg, Leigh R.
TI Somatosensory responses in a human motor cortex
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
DE brain machine interfaces; decoding; stroke; plasticity
ID REORGANIZATION FOLLOWING MOTOR; PYRAMIDAL TRACT NEURONS; SENSORIMOTOR
CORTEX; PRECENTRAL CORTEX; SENSORY INPUT; UNANESTHETIZED MONKEY;
SPATIAL-ORGANIZATION; DYNAMIC ORGANIZATION; CONSCIOUS MONKEYS; TARGET
MUSCLES
AB Shaikhouni A, Donoghue JP, Hochberg LR. Somatosensory responses in a human motor cortex. J Neurophysiol 109: 2192-2204, 2013. First published January 23, 2013; doi:10.1152/jn.00368.2012.-Somatic sensory signals provide a major source of feedback to motor cortex. Changes in somatosensory systems after stroke or injury could profoundly influence brain computer interfaces (BCI) being developed to create new output signals from motor cortex activity patterns. We had the unique opportunity to study the responses of hand/arm area neurons in primary motor cortex to passive joint manipulation in a person with a long-standing brain stem stroke but intact sensory pathways. Neurons responded to passive manipulation of the contralateral shoulder, elbow, or wrist as predicted from prior studies of intact primates. Thus fundamental properties and organization were preserved despite arm/hand paralysis and damage to cortical outputs. The same neurons were engaged by attempted arm actions. These results indicate that intact sensory pathways retain the potential to influence primary motor cortex firing rates years after cortical outputs are interrupted and may contribute to online decoding of motor intentions for BCI applications.
C1 [Shaikhouni, Ammar; Donoghue, John P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA.
[Shaikhouni, Ammar; Donoghue, John P.; Hochberg, Leigh R.] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA.
[Donoghue, John P.; Hochberg, Leigh R.] Ctr Neurorestorat & Neurotechnol, Dept Vet Affairs, Providence, RI USA.
[Hochberg, Leigh R.] Brown Univ, Sch Engn, Providence, RI 02912 USA.
[Hochberg, Leigh R.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.
[Hochberg, Leigh R.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA.
RP Shaikhouni, A (reprint author), Ohio State Univ, Med Ctr, Dept Neurol Surg, N1014 Doan Hall,410 West 10th Ave, Columbus, OH 43210 USA.
EM ammar.shaikhouni@osumc.edu
FU Rehabilitation Research and Development Service, Office of Research and
Development, Department of Veterans Affairs; National Institutes of
Health [N01 HD-53403, RC1 HD-063931, R01 DC-009899, R01 EB-007401,
NS-25074]; National Center for Research Resources [C06 16549-01A1];
Doris Duke Charitable Foundation; Massachusetts General Hospital-Deane
Institute of Integrated Research on Atrial Fibrillation and Stroke;
Katie Samson Foundation; Cyberkinetics Neurotechnology Systems, Inc.;
Massachusetts General and Spaulding Rehabilitation Hospitals; CKI
FX This work is supported by the Rehabilitation Research and Development
Service, Office of Research and Development, Department of Veterans
Affairs. Additional support is provided by National Institutes of Health
Grants N01 HD-53403, RC1 HD-063931, R01 DC-009899, R01 EB-007401, and
NS-25074; National Center for Research Resources Grant C06 16549-01A1;
the Doris Duke Charitable Foundation; the Massachusetts General
Hospital-Deane Institute of Integrated Research on Atrial Fibrillation
and Stroke; and the Katie Samson Foundation.; The pilot clinical trial
from which these data are derived was sponsored in part by Cyberkinetics
Neurotechnology Systems, Inc. J. P. Donoghue is a former Chief
Scientific Officer and director of Cyberkinetics Neurotechnology
Systems, Inc. (CKI); he held stocks and received compensation. L. R.
Hochberg received research support from Massachusetts General and
Spaulding Rehabilitation Hospitals, which in turn received clinical
trial support from CKI. A. Shaikhouni was a contracted consultant for
CKI and received compensation. CKI ceased operations in 2009.
NR 60
TC 6
Z9 6
U1 2
U2 15
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD APR
PY 2013
VL 109
IS 8
BP 2192
EP 2204
DI 10.1152/jn.00368.2012
PG 13
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 125XG
UT WOS:000317574700019
PM 23343902
ER
PT J
AU Maule, AL
Heaton, KJ
Rodrigues, E
Smith, KW
McClean, MD
Proctor, SP
AF Maule, Alexis L.
Heaton, Kristin J.
Rodrigues, Ema
Smith, Kristen W.
McClean, Michael D.
Proctor, Susan P.
TI Postural Sway and Exposure to Jet Propulsion Fuel 8 Among US Air Force
Personnel
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID CLINICAL BALANCE TESTS; TRUNK SWAY; INHALATION EXPOSURE; URINARY
BIOMARKERS; SOLVENT EXPOSURE; DERMAL EXPOSURE; WORKERS; JP-8; STABILITY;
GAIT
AB Objective: To determine whether short-term jet propulsion fuel 8 (JP-8) exposure is associated with balance measurements in JP-8-exposed air force personnel. Methods: As part of a larger neuroepidemiology study, balance tasks were completed by JP-8 exposed individuals (n = 37). Short-term JP-8 exposure was measured using personal breathing zone levels and urinary biomarkers. Multivariate linear regression analyses were conducted to examine the relationship between workday JP-8 exposure and postural sway. Results: Balance control decreased as the task became more challenging. Workday exposure to JP-8, measured by either personal air or urinary metabolite levels, was not significantly related to postural sway. Increases in workday postural sway were associated with demographic variables, including younger age, being a current smoker, and higher body mass index. Conclusion: Results suggest that short-term workday JP-8 exposure does not significantly contribute to diminished balance control.
C1 [Maule, Alexis L.; Heaton, Kristin J.; Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA.
[Heaton, Kristin J.; Proctor, Susan P.] USA, Environm Med Res Inst, Natick, MA 01760 USA.
[Rodrigues, Ema; Smith, Kristen W.; McClean, Michael D.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Proctor, Susan P.] VA Boston Healthcare Syst, Boston, MA USA.
RP Proctor, SP (reprint author), USA, Mil Performance Div, Environm Med Res Inst, Kansas St,Bldg 42, Natick, MA 01760 USA.
EM susan.proctor@us.army.mil
RI sebastianovitsch, stepan/G-8507-2013; Heaton, Kristin/E-3660-2013;
McClean, Michael/J-2934-2015;
OI McClean, Michael/0000-0002-3902-8823
FU US Air Force; US Army Medical Research and Materiel Command/Neurotoxin
Exposure Treatment Program [W81XWH-06-1-0105]
FX The authors thank the US Air Force personnel for their support and
generous participation in the project. They thank the additional Boston
area study team personnel (N. Longcore, E. Kryskow, K. Merchant-Borna,
H. MacDonald, and A. Graefe) and other personnel from local universities
for their assistance in data collection at the respective US Air Force
base locations. This work was supported by the US Army Medical Research
and Materiel Command/Neurotoxin Exposure Treatment Program though a
grant award (W81XWH-06-1-0105; principal investigator: S.P. Proctor) to
the Henry M. Jackson Foundation for the Advancement of Military
Medicine, Inc.
NR 34
TC 3
Z9 3
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD APR
PY 2013
VL 55
IS 4
BP 446
EP 453
DI 10.1097/JOM.0b013e31827db94b
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 124BT
UT WOS:000317439500011
PM 23532195
ER
PT J
AU Collins, E
Ebert, J
Hentzen, K
Johnson, D
Stevenson, K
AF Collins, E.
Ebert, J.
Hentzen, K.
Johnson, D.
Stevenson, K.
TI Development of a telephone clinic for the management of neuropathic pain
SO JOURNAL OF PAIN
LA English
DT Meeting Abstract
C1 [Collins, E.; Ebert, J.; Hentzen, K.; Johnson, D.; Stevenson, K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2013
VL 14
IS 4
SU 1
BP S39
EP S39
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 126RR
UT WOS:000317639400154
ER
PT J
AU Loggia, M
Renella, CB
Kim, J
Cahalan, C
Gollub, R
Wasan, A
Edwards, R
Napadow, V
AF Loggia, M.
Renella, C. Berna
Kim, J.
Cahalan, C.
Gollub, R.
Wasan, A.
Edwards, R.
Napadow, V.
TI Brain processing of pain and expectancy of relief in fibromyalgia is
modulated by catastrophizing
SO JOURNAL OF PAIN
LA English
DT Meeting Abstract
C1 [Loggia, M.; Renella, C. Berna; Kim, J.; Cahalan, C.; Gollub, R.; Wasan, A.; Edwards, R.; Napadow, V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2013
VL 14
IS 4
SU 1
BP S49
EP S49
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 126RR
UT WOS:000317639400192
ER
PT J
AU Sein, M
Chen, L
AF Sein, M.
Chen, L.
TI Opioid-induced hyperalgesia: the primary care physician's perspective
SO JOURNAL OF PAIN
LA English
DT Meeting Abstract
C1 [Sein, M.; Chen, L.] Massachusetts Gen Hosp, Ctr Translat Pain Res, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD APR
PY 2013
VL 14
IS 4
SU 1
BP S5
EP S5
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 126RR
UT WOS:000317639400021
ER
PT J
AU Hung, EW
Mayes, MD
Sharif, R
Assassi, S
Machicao, VI
Hosing, C
St Clair, EW
Furst, DE
Khanna, D
Forman, S
Mineishi, S
Phillips, K
Seibold, JR
Bredeson, C
Csuka, ME
Nash, RA
Wener, MH
Simms, R
Ballen, K
Leclercq, S
Storek, J
Goldmuntz, E
Welch, B
Keyes-Elstein, L
Castina, S
Crofford, LJ
Mcsweeney, P
Sullivan, KM
AF Hung, Emily W.
Mayes, Maureen D.
Sharif, Roozbeh
Assassi, Shervin
Machicao, Victor I.
Hosing, Chitra
St Clair, E. William
Furst, Daniel E.
Khanna, Dinesh
Forman, Stephen
Mineishi, Shin
Phillips, Kristine
Seibold, James R.
Bredeson, Christopher
Csuka, Mary Ellen
Nash, Richard A.
Wener, Mark H.
Simms, Robert
Ballen, Karen
Leclercq, Sharon
Storek, Jan
Goldmuntz, Ellen
Welch, Beverly
Keyes-Elstein, Lynette
Castina, Sharon
Crofford, Leslie J.
Mcsweeney, Peter
Sullivan, Keith M.
TI Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients
with Early Diffuse Systemic Sclerosis in the SCOT Trial
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE GASTRIC ANTRAL VASCULAR ECTASIA; GAVE; SYSTEMIC SCLEROSIS; VASCULOPATHY;
ENDOSCOPY
ID WATERMELON STOMACH; GAVE; CYCLOPHOSPHAMIDE
AB Objective. To describe the prevalence and clinical correlates of endoscopic gastric antral vascular ectasia (GAVE; "watermelon stomach") in early diffuse systemic sclerosis (SSc).
Methods. Subjects with early, diffuse SSc and evidence of specific internal organ involvement were considered for the Scleroderma: Cyclophosphamide Or Transplant (SCOT) trial. In the screening procedures, all patients underwent upper gastrointestinal endoscopy. Patients were then categorized into those with or without endoscopic evidence of GAVE. Demographic data, clinical disease characteristics, and autoantibody data were compared using Pearson chi-square or Student t tests.
Results. Twenty-three of 103 (22.3%) individuals were found to have GAVE on endoscopy. Although not statistically significant, anti-topoisomerase I (anti-Sc170) was detected less frequently among those with GAVE (18.8% vs 44.7%; p = 0.071). Similarly, anti-RNP antibodies (anti-U1 RNP) showed a trend to a negative association with GAVE (0 vs 18.4%; p = 0.066). There was no association between anti-RNA polymerase III and GAVE. Patients with GAVE had significantly more erythema or vascular ectasias in other parts of the stomach (26.1% vs 5.0%; p = 0.003).
Conclusion. Endoscopic GAVE was present on screening in almost one-fourth of these highly selected patients with early and severe diffuse SSc. While anti-Sc170 and anti-U1 RNP trended toward a negative association with GAVE, there was no correlation between anti-RNA Pol III and GAVE. Patients with GAVE had a higher frequency of other gastric vascular ectasias outside the antrum, suggesting that GAVE may represent part of the spectrum of the vasculopathy in SSc. (J Rheurnatol First Release Feb 15 2013; doi:10.3899/jrheum.121087)
C1 [Hung, Emily W.] Rheumatol Associates Houston, Houston, TX USA.
[Mayes, Maureen D.; Assassi, Shervin; Machicao, Victor I.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
[Sharif, Roozbeh] Univ Texas Med Branch, Galveston, TX 77555 USA.
[Hosing, Chitra] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[St Clair, E. William; Sullivan, Keith M.] Duke Univ, Durham, NC USA.
[Furst, Daniel E.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Khanna, Dinesh; Mineishi, Shin; Phillips, Kristine] Univ Michigan, Ann Arbor, MI 48109 USA.
[Forman, Stephen] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Seibold, James R.] Scleroderma Res Consultants LLC, Avon, CT USA.
[Bredeson, Christopher] Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
[Csuka, Mary Ellen] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Nash, Richard A.; Mcsweeney, Peter] Colorado Blood Canc Inst, Rocky Mt Blood & Marrow Transplant Program, Denver, CO USA.
[Wener, Mark H.] Univ Washington, Seattle, WA 98195 USA.
[Simms, Robert] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Ballen, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Leclercq, Sharon; Storek, Jan] Univ Calgary, Calgary, AB, Canada.
[Goldmuntz, Ellen; Welch, Beverly] NIAID, NIH, Bethesda, MD 20892 USA.
[Keyes-Elstein, Lynette; Castina, Sharon] Rho, Chapel Hill, NC USA.
[Crofford, Leslie J.] Univ Kentucky, Lexington, KY USA.
RP Mayes, MD (reprint author), Univ Texas Hlth Sci Ctr Houston, 6431 Fannin St,Med Sch Bldg 5-270, Houston, TX 77030 USA.
EM Maureen.d.mayes@uth.unc.edu
RI Crofford, Leslie/J-8010-2013;
OI Simms, Robert/0000-0002-0101-1807; Hosing, Chitra/0000-0003-0409-5556
FU National Institutes of Health, National Institute of Allergy and
Infectious Diseases (USA) [A1-05419, HHSN272201100025C]
FX Supported by awards A1-05419 and HHSN272201100025C from the National
Institutes of Health, National Institute of Allergy and Infectious
Diseases (USA).
NR 15
TC 16
Z9 16
U1 0
U2 2
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD APR
PY 2013
VL 40
IS 4
BP 455
EP 460
DI 10.3899/jrheum.121087
PG 6
WC Rheumatology
SC Rheumatology
GA 125LF
UT WOS:000317540600018
PM 23418384
ER
PT J
AU Prowse, RL
Dalbeth, N
Kavanaugh, A
Adebajo, AO
Gaffo, AL
Terkeltaub, R
Mandell, BF
Suryana, BPP
Goldenstein-Schainberg, C
Diaz-Torne, C
Khanna, D
Liote, F
Mccarthy, G
Kerr, GS
Yamanaka, H
Janssens, H
Baraf, HF
Chen, JH
Vazquez-Mellado, J
Harrold, LR
Stamp, LK
Van de Laar, MA
Janssen, M
Doherty, M
Boers, M
Edwards, NL
Gow, P
Chapman, P
Khanna, P
Helliwell, PS
Grainger, R
Schumacher, HR
Neogi, T
Jansen, TL
Louthrenoo, W
Sivera, F
Taylor, WJ
AF Prowse, Rebecca L.
Dalbeth, Nicola
Kavanaugh, Arthur
Adebajo, Adewale O.
Gaffo, Angelo L.
Terkeltaub, Robert
Mandell, Brian F.
Suryana, Bagus P. P.
Goldenstein-Schainberg, Claudia
Diaz-Torne, Cesar
Khanna, Dinesh
Liote, Frederic
Mccarthy, Geraldine
Kerr, Gail S.
Yamanaka, Hisashi
Janssens, Hein
Baraf, Herbert F.
Chen, Jiunn-Horng
Vazquez-Mellado, Janitzia
Harrold, Leslie R.
Stamp, Lisa K.
Van de Laar, Mart A.
Janssen, Matthijs
Doherty, Michael
Boers, Maarten
Edwards, N. Lawrence
Gow, Peter
Chapman, Peter
Khanna, Puja
Helliwell, Philip S.
Grainger, Rebecca
Schumacher, H. Ralph
Neogi, Tuhina
Jansen, Tim L.
Louthrenoo, Worawit
Sivera, Francisca
Taylor, William J.
TI A Delphi Exercise to Identify Characteristic Features of Gout - Opinions
from Patients and Physicians, the First Stage in Developing New
Classification Criteria
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE GOUT; CLASSIFICATION; CRITERIA; PATIENTS; PHYSICIANS
ID DIAGNOSTIC-CRITERIA; FLUID ANALYSIS; RHEUMATOLOGY; PREVALENCE;
ARTHRITIS; HEALTH
AB Objective. To identify a comprehensive list of features that might discriminate between gout and other rheumatic musculoskeletal conditions, to be used subsequently for a case-control study to develop and test new classification criteria for gout.
Methods. Two Delphi exercises were conducted using Web-based questionnaires: one with physicians from several countries who had an interest in gout and one with patients from New Zealand who had gout. Physicians rated a list of potentially discriminating features that were identified by literature review and expert opinion, and patients rated a list of features that they generated themselves. Agreement was defined by the RAND/UCLA disagreement index.
Results. Forty-four experienced physicians and 9 patients responded to all iterations. For physicians, 71 items were identified by literature review and 15 more were suggested by physicians. The physician survey showed agreement for 26 discriminatory features and 15 as not discriminatory. The patients identified 46 features of gout, for which there was agreement on 25 items as being discriminatory and 7 items as not discriminatory.
Conclusion. Patients and physicians agreed upon several key features of gout. Physicians emphasized objective findings, imaging, and patterns of symptoms, whereas patients emphasized severity, functional results, and idiographic perception of symptoms. (First Release Feb 15 2013; J Rheumatol 2013;40:498-505; doi:10.3899/jrheum.121037)
C1 Univ Otago, Dunedin, New Zealand.
[Dalbeth, Nicola] Univ Auckland, Auckland 1, New Zealand.
[Kavanaugh, Arthur] Univ Calif San Diego, Vet Affairs Healthcare Syst, San Diego, CA 92103 USA.
[Adebajo, Adewale O.] Univ Sheffield, Sheffield, S Yorkshire, England.
Vet Affairs Med Ctr, Birmingham, AL USA.
Univ Alabama Birmingham, Birmingham, AL USA.
[Mandell, Brian F.] Case Western Reserve Univ, Cleveland Clin, CCF Lerner Coll Med, Cleveland, OH 44106 USA.
Brawijaya Univ, Malang, Indonesia.
Dr Saiful Anwar Hosp, Malang, Indonesia.
Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
[Diaz-Torne, Cesar] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
[Khanna, Dinesh; Stamp, Lisa K.] Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Paris Diderot, Paris, France.
Hop Lariboisiere, F-75475 Paris, France.
[Mccarthy, Geraldine] Univ Coll Dublin, Dublin 2, Ireland.
Georgetown Univ, Vet Affairs Med Ctr, Washington, DC USA.
[Kerr, Gail S.] Howard Univ, Vet Affairs Med Ctr, Washington, DC 20059 USA.
[Yamanaka, Hisashi] Tokyo Womens Med Univ, Tokyo, Japan.
[Janssens, Hein] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands.
[Baraf, Herbert F.] Arthrit & Rheumatism Associates, Ctr Rheumatol & Bone Res, Wheaton, MA USA.
[Chen, Jiunn-Horng] China Med Univ, China Med Univ Hosp, Taichung, Taiwan.
[Vazquez-Mellado, Janitzia] Hosp Gen Mexico City, Mexico City, DF, Mexico.
[Harrold, Leslie R.] Univ Massachusetts, Sch Med, Worcester, MA USA.
Univ Otago, Christchurch, New Zealand.
[Van de Laar, Mart A.] Med Spectrum Twente, Dept Rheumatol & Clin Immunol, Enschede, Netherlands.
[Janssen, Matthijs] Rijnstate, Dept Rheumatol, Arnhem, Netherlands.
[Doherty, Michael] Univ Nottingham, Nottingham NG7 2RD, England.
[Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
[Edwards, N. Lawrence] Univ Florida, Gainesville, FL USA.
[Gow, Peter] Counties Manukau Dist Hlth Board, Auckland, New Zealand.
[Chapman, Peter] Canterbury Dist Hlth Board, Christchurch, New Zealand.
[Helliwell, Philip S.] Univ Leeds, Leeds, W Yorkshire, England.
Univ Otago, Wellington, New Zealand.
Univ Penn, Philadelphia, PA 19104 USA.
Vet Affairs Med Ctr, Philadelphia, PA USA.
[Neogi, Tuhina] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Jansen, Tim L.] Radboud Univ Nijmegen, Med Centrum, Dept Rheumatol, NL-6525 ED Nijmegen, Netherlands.
[Louthrenoo, Worawit] Chiang Mai Univ, Chiang Mai 50000, Thailand.
Hosp Gen Elda, Alicante, Spain.
Univ Miguel Hernandez, Alicante, Spain.
RP Taylor, WJ (reprint author), Univ Otago Wellington, Dept Med, POB 7343, Wellington 6242, New Zealand.
EM Will.taylor@otago.ac.nz
RI Jansen, T.L.Th.A./L-4407-2015;
OI Cesar, Diaz-Torne/0000-0001-6275-7699; Jansen, Tim/0000-0003-3026-3154;
Neogi, Tuhina/0000-0002-9515-1711
FU Arthritis New Zealand
FX R. Prowse was supported by a Summer Student Scholarship from Arthritis
New Zealand. Dr. Kerr has participated in gout trials by Savient, Nuon,
and Ardea. Dr. Doherty is a member of advisory boards for Ardea
Biosciences, Ipsen, Menarini, Novartis, and Savient.
NR 18
TC 14
Z9 16
U1 0
U2 7
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD APR
PY 2013
VL 40
IS 4
BP 498
EP 505
DI 10.3899/jrheum.121037
PG 8
WC Rheumatology
SC Rheumatology
GA 125LF
UT WOS:000317540600024
PM 23418379
ER
PT J
AU Hawryluk, EB
O'Regan, KN
Sheehy, N
Guo, Y
Dorosario, A
Sakellis, CG
Jacene, HA
Wang, LDC
AF Hawryluk, Elena B.
O'Regan, Kevin N.
Sheehy, Niall
Guo, Ye
Dorosario, Andrew
Sakellis, Christopher G.
Jacene, Heather A.
Wang, Linda C.
TI Positron emission tomography/computed tomography imaging in Merkel cell
carcinoma: A study of 270 scans in 97 patients at the
Dana-Farber/Brigham and Women's Cancer Center
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article; Proceedings Paper
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-05, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
DE computed tomography; 2-fluoro-[F-18]-deoxy-2-D-glucose; imaging; Merkel
cell carcinoma; metastasis; positron emission tomography; staging
ID F-18-FDG PET; MANAGEMENT; MELANOMA; FEATURES; IMPACT
AB Background: Merkel cell carcinoma (MCC) is a rare and lethal cutaneous neuroendocrine carcinoma. Imaging is crucial for accurate staging, which remains a strong predictor of survival, as well as earlier detection of recurrence and progression, which are common despite aggressive management. There is no consensus on the role of initial and subsequent imaging for MCC.
Objective: We sought to evaluate the use of 2-fluoro-[F-18]-deoxy-2-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in the management of MCC.
Methods: In all, 270 FDG-PET/CT studies were performed in 97 patients with pathology-proven MCC at the Dana-Farber/Brigham and Women's Cancer Center, Boston, Mass, from August 2003 to December 2010.
Results: FDG-PET/CT scans were obtained as part of the initial (61 scans in 61 patients) and subsequent (209 scans in 79 patients) treatment strategies. MCCs were FDG-avid with a mean maximum standardized uptake value of primary lesions of 6.5 (range 1.3-12.9) and a mean maximum standardized uptake value of regional and distant metastases of 7.2 (range 1.5-9.9). FDG-PET/CT upstaged 16% of patients who underwent baseline scans. FDG-PET/CT studies showed that bone and bone-marrow metastases were more common than previously reported, and were often undetected by CT.
Limitations: Our study is limited by its retrospective design, and potential referral bias associated with a tertiary care center.
Conclusions: FDG-PET/CT performed as part of the initial management strategy tended to upstage patients with more advanced disease. FDG-PET/CT performed as part of the subsequent treatment strategy identified metastatic disease, particularly in bone/bone marrow, which was not seen on CT. FDG-PET/CT imaging is a valuable staging and restaging tool in MCC management. (J Am Acad Dermatol 2013;68:592-9.)
C1 [Hawryluk, Elena B.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[O'Regan, Kevin N.; Sheehy, Niall; Sakellis, Christopher G.; Jacene, Heather A.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Imaging, Boston, MA USA.
[Guo, Ye; Wang, Linda C.] Harvard Univ, Sch Med, Dept Dermatol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Dorosario, Andrew; Wang, Linda C.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Ctr Cutaneous Oncol, Boston, MA USA.
RP Wang, LDC (reprint author), Mercy Med Ctr, Inst Canc Care, 301 St Paul Pl,McAuley POB,Suite 607, Baltimore, MD 21202 USA.
EM lwang@mdmercy.com
NR 27
TC 22
Z9 22
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD APR
PY 2013
VL 68
IS 4
BP 592
EP 599
DI 10.1016/j.jaad.2012.08.042
PG 8
WC Dermatology
SC Dermatology
GA 120VL
UT WOS:000317201100018
PM 23127473
ER
PT J
AU Liu, ZC
Li, YQ
Liu, BL
Deperalta, DK
Zhao, T
Chong, W
Duan, XZ
Zhou, P
Velmahos, GC
Alam, HB
AF Liu, Zhengcai
Li, Yongqing
Liu, Baoling
Deperalta, Danielle K.
Zhao, Ting
Chong, Wei
Duan, Xiuzhen
Zhou, Peter
Velmahos, George C.
Alam, Hasan B.
TI Synergistic effects of hypertonic saline and valproic acid in a lethal
rat two-hit model
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article; Proceedings Paper
CT 71st Annual Meeting of the
American-Association-for-the-Surgery-of-Trauma / Clinical Congress of
Acute Care Surgery
CY SEP 12-15, 2012
CL Kauai, HI
SP Amer Assoc Surg Trauma
DE Hemorrhagic shock; sepsis; valproic acid; hypertonic saline; rats
ID ACUTE LUNG INJURY; HEMORRHAGIC-SHOCK; FLUID RESUSCITATION; NEUTROPHIL
ACTIVATION; CECAL LIGATION; RODENT MODEL; SEPSIS; INFLAMMATION; TRAUMA;
PENTRAXIN-3
AB BACKGROUND: Hemorrhagic shock (HS) followed by an infection ("second hit") can lead to severe systemic inflammatory response and multiple-organ failure. Studies have shown that resuscitation with hypertonic saline (HTS) can blunt the inflammatory response. We demonstrated that large doses of valproic acid (VPA, 300 mg/kg), a histone deacetylase inhibitor, improves survival in a rodent two-hit model (HS followed by cecal ligation and puncture [CLP]). In the present study, we examined whether combination of HTS with VPA would allow us to achieve survival advantage at a lower dose of VPA (200 mg/kg).
METHODS: Male Sprague-Dawley rats were subjected to HS (50% blood loss) and randomized into five groups (n = 7-8 per group) as follows: (1) isotonic sodium chloride solution (ISCS), (2) 7.5% saline, (3) VPA, (4) ISCS + VPA, and (5) HTS + VPA. After 24 hours, they underwent CLP, followed by the same doses of ISCS, HTS, and/or VPA and were monitored for 10 days. In a parallel experiment, blood, peritoneal irrigation fluid and lung homogenate were subjected to enzyme-linked immunosorbent assay 3 hours and 24 hours after CLP to measure myeloperoxidase activity and proinflammatory cytokines tumor necrosis factor alpha and interleukin 1 beta levels. Western blotting was performed to investigate the expression of pentraxin 3 protein in the lung homogenate at 24 hours after CLP. Hematoxylin and eosin staining of lungs at the 24 hours were performed to quantify the degree of acute lung injury.
RESULTS: HTS + VPA treatment significantly improved survival (87.5%), compared with the other groups (14.3%; p < 0.05), while attenuating peritoneal myeloperoxidase levels and proinflammatory cytokine tumor necrosis factor alpha and interleukin 1 beta levels in the serum, peritoneal cavity, and lung. The degree of acute lung injury and expression of pentraxin 3 in the lung were significantly reduced in the HTS + VPA group.
CONCLUSION: This is the first study to show that VPA and HTS can work synergistically to attenuate inflammation and improve survival in a lethal two-hit model. (J Trauma Acute Care Surg. 2013;74: 991-998. Copyright (c) 2013 by Lippincott Williams & Wilkins)
C1 [Liu, Zhengcai; Li, Yongqing; Liu, Baoling; Deperalta, Danielle K.; Zhao, Ting; Chong, Wei; Zhou, Peter; Velmahos, George C.; Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, Boston, MA 02115 USA.
[Duan, Xiuzhen] Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA.
[Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
[Chong, Wei] China Med Univ, Hosp 1, Emergency Dept, Shenyang, Peoples R China.
[Liu, Zhengcai] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Peoples R China.
RP Alam, HB (reprint author), Univ Michigan Hosp, Sect Gen Surg, 2920 Taubman Center-5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM alamh@med.umich.edu
FU NIGMS NIH HHS [R01 GM084127]
NR 40
TC 7
Z9 8
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD APR
PY 2013
VL 74
IS 4
BP 991
EP 997
DI 10.1097/TA.0b013e31828583e3
PG 7
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 123SS
UT WOS:000317411700009
PM 23511136
ER
PT J
AU Gilstrap, LG
Malhotra, R
Peltier-Saxe, D
Slicas, D
Pineda, E
Culhane-Hermann, C
Cook, N
Fernandez-Golarz, C
Wood, M
AF Gilstrap, Lauren Gray
Malhotra, Rajeev
Peltier-Saxe, Donna
Slicas, Donna
Pineda, Eliana
Culhane-Hermann, Catherine
Cook, Nakela
Fernandez-Golarz, Carina
Wood, Malissa
TI Community-Based Primary Prevention Programs Decrease the Rate of
Metabolic Syndrome Among Socioeconomically Disadvantaged Women
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID AMERICAN-HEART-ASSOCIATION; CARDIOVASCULAR-DISEASE; LIFE-STYLE; RISK;
METAANALYSIS; PREVALENCE; HEALTH; TRENDS
AB Background: Metabolic Syndrome (MetSyn) is one of the strongest predictors of type 2 diabetes (DM2) and cardiovascular disease (CVD). It is associated with a 4- to 10-fold increased risk of DM2 and a 2- to 3-fold increased risk of CVD. Low income and minority women have some of the highest rates of MetSyn. This study examines the effect of a unique, community based, primary prevention program on the rates of MetSyn and health habits.
Methods: Sixty-four low income and minority women were enrolled in the HAPPY (Health Awareness and Primary Prevention in Your neighborhood) Heart Program in an eastern suburb of Boston. Over these 2 years, patients were evaluated by an interdisciplinary medical team: their primary physician, cardiologist, nutritionist, physical therapist, and health coach. The rate of MetSyn was measured at baseline, year 1, and year 2. Comparisons were made either using the paired t test for normally distributed variables or the Wilcoxon Sign test for non-normal variables.
Results: The rate of MetSyn fell from 64.7% at baseline to 34.9% at year 1 (p = 0.01) and 28.2% at year 2 (p < 0.001). This was driven by increases in high-density lipoprotein (HDL-C) (p < 0.001) and decreases in blood pressure (p = 0.05). Fasting blood glucose trended down, but the hemoglobin A1c (HbA1c) reached significance (decreasing from 6 to 5.8, p < 0.01). Nutrition and exercise habits trended toward improvement. There were significant decreases in anxiety (p < 0.001), depression (p = 0.006) and stress (p = 0.002).
Conclusion: This lifestyle intervention program is effective at decreasing MetSyn in a socioeconomically disadvantaged, largely minority, female population. This program also decreases anxiety, stress, and depression among participants.
C1 [Gilstrap, Lauren Gray; Malhotra, Rajeev; Fernandez-Golarz, Carina] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Malhotra, Rajeev; Wood, Malissa] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Peltier-Saxe, Donna; Slicas, Donna; Pineda, Eliana; Culhane-Hermann, Catherine] Massachusetts Gen Hosp, Revere Hlth Ctr, Boston, MA 02114 USA.
[Cook, Nakela] NHLBI, NIH, Bethesda, MD 20892 USA.
RP Gilstrap, LG (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA.
EM lgilstrap@partners.org
OI Malhotra, Rajeev/0000-0003-0120-4630
NR 36
TC 3
Z9 3
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD APR
PY 2013
VL 22
IS 4
BP 322
EP 329
DI 10.1089/jwh.2012.3854
PG 8
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 126FZ
UT WOS:000317599700006
PM 23540328
ER
PT J
AU Galimberti, V
Cole, BF
Zurrida, S
Viale, G
Luini, A
Veronesi, P
Baratella, P
Chifu, C
Sargenti, M
Intra, M
Gentilini, O
Mastropasqua, MG
Mazzarol, G
Massarut, S
Garbay, JR
Zgajnar, J
Galatius, H
Recalcati, A
Littlejohn, D
Bamert, M
Colleoni, M
Price, KN
Regan, MM
Goldhirsch, A
Coates, AS
Gelber, RD
Veronesi, U
AF Galimberti, Viviana
Cole, Bernard F.
Zurrida, Stefano
Viale, Giuseppe
Luini, Alberto
Veronesi, Paolo
Baratella, Paola
Chifu, Camelia
Sargenti, Manuela
Intra, Mattia
Gentilini, Oreste
Mastropasqua, Mauro G.
Mazzarol, Giovanni
Massarut, Samuele
Garbay, Jean-Remi
Zgajnar, Janez
Galatius, Hanne
Recalcati, Angelo
Littlejohn, David
Bamert, Monika
Colleoni, Marco
Price, Karen N.
Regan, Meredith M.
Goldhirsch, Aron
Coates, Alan S.
Gelber, Richard D.
Veronesi, Umberto
CA Int Breast Canc Study Grp Trial 23
TI Axillary dissection versus no axillary dissection in patients with
sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised
controlled trial
SO LANCET ONCOLOGY
LA English
DT Article
ID INTERNATIONAL EXPERT CONSENSUS; EARLY BREAST-CANCER; PRIMARY THERAPY;
AMERICAN-COLLEGE; LYMPH-NODES; BIOPSY; HIGHLIGHTS; METASTASES;
INVOLVEMENT; RECURRENCE
AB Background For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (<= 2 mm) sentinel nodes and tumour of maximum 5 cm.
Methods In this multicentre, randomised, non-inferiority, phase 3 trial, patients were eligible if they had clinically non-palpable axillary lymph node(s) and a primary tumour of 5 cm or less and who, after sentinel-node biopsy, had one or more micrometastatic (<= 2 mm) sentinel lymph nodes with no extracapsular extension. Patients were randomly assigned (in a 1:1 ratio) to either undergo axillary dissection or not to undergo axillary dissection. Randomisation was stratified by centre and menopausal status. Treatment assignment was not masked. The primary endpoint was disease-free survival. Non-inferiority was defined as a hazard ratio (HR) of less than 1.25 for no axillary dissection versus axillary dissection. The analysis was by intention to treat. Per protocol, disease and survival information continues to be collected yearly. This trial is registered with ClinicalTrials.gov, NCT00072293.
Findings Between April 1, 2001, and Feb 28, 2010, 465 patients were randomly assigned to axillary dissection and 469 to no axillary dissection. After the exclusion of three patients, 464 patients were in the axillary dissection group and 467 patients were in the no axillary dissection group. After a median follow-up of 5.0 (IQR 3.6-7.3) years, we recorded 69 disease-free survival events in the axillary dissection group and 55 events in the no axillary dissection group. Breast-cancer-related events were recorded in 48 patients in the axillary dissection group and 47 in the no axillary dissection group (ten local recurrences in the axillary dissection group and eight in the no axillary dissection group; three and nine contralateral breast cancers; one and nine regional recurrences; and 34 and 25 distant relapses). Other non-breast cancer events were recorded in 21 patients in the axillary dissection group and eight in the no axillary dissection group (20 and six second non-breast malignancies; and one and two deaths not due to a cancer event). 5-year disease-free survival was 87.8% (95% CI 84.4-91.2) in the group without axillary dissection and 84.4% (80.7-88.1) in the group with axillary dissection (log-rank p=0.16; HR for no axillary dissection vs axillary dissection was 0.78, 95% CI 0.55-1.11, non-inferiority p=0.0042). Patients with reported long-term surgical events (grade 3-4) included one sensory neuropathy (grade 3), three lymphoedema (two grade 3 and one grade 4), and three motor neuropathy (grade 3), all in the group that underwent axillary dissection, and one grade 3 motor neuropathy in the group without axillary dissection. One serious adverse event was reported, a postoperative infection in the axilla in the group with axillary dissection.
Interpretation Axillary dissection could be avoided in patients with early breast cancer and limited sentinel-node involvement, thus eliminating complications of axillary surgery with no adverse effect on survival.
C1 [Galimberti, Viviana] European Inst Oncol, Mol Senol Unit, Senol Div, I-20141 Milan, Italy.
[Zurrida, Stefano] European Inst Oncol, Breast Diag & Surg Unit, Senol Div, I-20141 Milan, Italy.
[Luini, Alberto; Baratella, Paola; Chifu, Camelia; Sargenti, Manuela; Intra, Mattia; Gentilini, Oreste] European Inst Oncol, Senol Div, I-20141 Milan, Italy.
[Veronesi, Paolo] European Inst Oncol, Senol Div, Integrated Breast Surg Unit, I-20141 Milan, Italy.
[Viale, Giuseppe; Mastropasqua, Mauro G.; Mazzarol, Giovanni] European Inst Oncol, Div Pathol & Lab Med, IBCSG Cent Pathol Off, I-20141 Milan, Italy.
[Colleoni, Marco] European Inst Oncol, Res Unit Med Senol, Dept Med, I-20141 Milan, Italy.
[Goldhirsch, Aron] European Inst Oncol, Dept Med, I-20141 Milan, Italy.
[Veronesi, Umberto] European Inst Oncol, I-20141 Milan, Italy.
[Cole, Bernard F.] Univ Vermont, Dept Math & Stat, Coll Engn & Math Sci, Burlington, VT 05405 USA.
[Cole, Bernard F.; Price, Karen N.; Regan, Meredith M.; Gelber, Richard D.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, IBCSG Stat Ctr, Boston, MA 02115 USA.
[Viale, Giuseppe; Veronesi, Paolo] Univ Milan, Milan, Italy.
[Massarut, Samuele] Ctr Riferimento Oncol, Breast Surg Div, I-33081 Aviano, Italy.
[Garbay, Jean-Remi] Inst Gustave Roussy, Dept Surg, Villejuif, France.
[Zgajnar, Janez] Inst Oncol, Dept Surg Oncol, Ljubljana, Slovenia.
[Galatius, Hanne] Herlev Hosp, Dept Breastsurg, DK-2730 Herlev, Denmark.
[Recalcati, Angelo] Osped Alessandro Manzoni, Dept Surg, Lecce, Italy.
[Littlejohn, David] Riverina Canc Care Ctr, Wagga Wagga, NSW, Australia.
[Bamert, Monika] Kantonsspital, Breast Ctr, St Gallen, Switzerland.
[Price, Karen N.; Gelber, Richard D.] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA.
[Regan, Meredith M.; Gelber, Richard D.] Harvard Univ, Sch Med, Boston, MA USA.
[Coates, Alan S.] Int Breast Canc Study Grp, Centennial Pk, NSW, Australia.
[Coates, Alan S.] Univ Sydney, Centennial Pk, NSW, Australia.
[Gelber, Richard D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Galimberti, V (reprint author), European Inst Oncol, Dept Surg, Via Ripamonti 435, I-20141 Milan, Italy.
EM viviana.galimberti@ieo.it
FU International Breast Cancer Study Group; Swiss Group for Clinical Cancer
Research; Swiss Cancer League/Cancer Research Switzerland/Oncosuisse
[ICP OCS 01688-03-2005]; Frontier Science and Technology Research
Foundation; Cancer Council Australia; Australian New Zealand Breast
Cancer Trials Group (National Health Medical Research Council); US
National Institutes of Health [CA-75362]; Swedish Cancer Society;
Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK)
FX This clinical trial was supported by the medical institutions that
enrolled women into the trial and the International Breast Cancer Study
Group, which is funded in part by: Swiss Group for Clinical Cancer
Research; Swiss Cancer League/Cancer Research Switzerland/Oncosuisse
(Grant ID: ICP OCS 01688-03-2005), Frontier Science and Technology
Research Foundation; The Cancer Council Australia; Australian New
Zealand Breast Cancer Trials Group (National Health Medical Research
Council); US National Institutes of Health (grant number CA-75362);
Swedish Cancer Society; Foundation for Clinical Cancer Research of
Eastern Switzerland (OSKK). There was no pharmaceutical company support
for this trial. We thank the patients, physicians, nurses, and data
managers who have participated in the International Breast Cancer Study
Group Trial 23-01. We thank Sandra Lippert for data management and Don
Ward for help with the English.
NR 29
TC 296
Z9 322
U1 4
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD APR
PY 2013
VL 14
IS 4
BP 297
EP 305
DI 10.1016/S1470-2045(13)70035-4
PG 9
WC Oncology
SC Oncology
GA 123LD
UT WOS:000317390300037
PM 23491275
ER
PT J
AU Adesina, A
Chumba, D
Nelson, AM
Orem, J
Roberts, DJ
Wabinga, H
Wilson, M
Rebbeck, TR
AF Adesina, Adekunle
Chumba, David
Nelson, Ann M.
Orem, Jackson
Roberts, Drucilla J.
Wabinga, Henry
Wilson, Michael
Rebbeck, Timothy R.
TI Improvement of pathology in sub-Saharan Africa
SO LANCET ONCOLOGY
LA English
DT Article
ID DEVELOPING-COUNTRIES
AB In the coming decades, cancer will be a major clinical and public health issue in sub-Saharan Africa. However, clinical and public health infrastructure and services in many countries are not positioned to deal with the growing cancer burden. Pathology is a core service required to serve many needs related to cancer in sub-Saharan Africa. Cancer diagnosis, treatment, and research all depend on adequate pathology. Pathology is also necessary for cancer registration, which is needed to accurately estimate cancer incidence and mortality. Cancer registry data directly guide policy-makers' decisions for cancer control and the allocation of clinical and public health services. Despite the centrality of pathology in many components of cancer care and control, countries in sub-Saharan Africa have at best a tenth of the pathology coverage of that in high-income countries. Equipment, processes, and services are lacking, and there is a need for quality assurance for the definition and implementation of high-quality, accurate diagnosis. Training and advocacy for pathology are also needed. We propose approaches to improve the status of pathology in sub-Saharan Africa to address the needs of patients with cancer and other diseases.
C1 [Adesina, Adekunle] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA.
[Chumba, David] Moi Univ, Sch Med, Eldoret, Kenya.
[Nelson, Ann M.] Joint Pathol Ctr, Washington, DC USA.
[Orem, Jackson] Uganda Canc Inst, Kampala, Uganda.
[Wabinga, Henry] Mulago Hosp, Kampala, Uganda.
[Wabinga, Henry] Makerere Univ, Kampala, Uganda.
[Roberts, Drucilla J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Roberts, Drucilla J.] Harvard Univ, Sch Med, Boston, MA USA.
[Wilson, Michael] Denver Hlth Med Ctr, Dept Pathol, Denver, CO USA.
[Wilson, Michael] Univ Colorado, Sch Med, Aurora, CO USA.
[Rebbeck, Timothy R.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Rebbeck, TR (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
EM rebbeck@upenn.edu
FU African Organisation for Research and Training in Cancer; American
Association for Cancer Research Landon Foundation; US Department of
State Fulbright Program
FX We thank the African Organisation for Research and Training in Cancer
for its support of the Pathology Special Interest Group in Africa.
Support for the Special Interest Group was provided by the American
Association for Cancer Research Landon Foundation and the US Department
of State Fulbright Program (both to TRR).
NR 14
TC 44
Z9 44
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD APR
PY 2013
VL 14
IS 4
BP E152
EP E157
PG 6
WC Oncology
SC Oncology
GA 123LD
UT WOS:000317390300012
PM 23561746
ER
PT J
AU de Larrea, CF
Kyle, RA
Durie, BGM
Ludwig, H
Usmani, S
Vesole, DH
Hajek, R
San Miguel, JF
Sezer, O
Sonneveld, P
Kumar, SK
Mahindra, A
Comenzo, R
Palumbo, A
Mazumber, A
Anderson, KC
Richardson, PG
Badros, AZ
Caers, J
Cavo, M
Leleu, X
Dimopoulos, MA
Chim, CS
Schots, R
Noeul, A
Fantl, D
Mellqvist, UH
Landgren, O
Chanan-Khan, A
Moreau, P
Fonseca, R
Merlini, G
Lahuerta, JJ
Blade, J
Orlowski, RZ
Shah, JJ
AF Fernandez de Larrea, C.
Kyle, R. A.
Durie, B. G. M.
Ludwig, H.
Usmani, S.
Vesole, D. H.
Hajek, R.
San Miguel, J. F.
Sezer, O.
Sonneveld, P.
Kumar, S. K.
Mahindra, A.
Comenzo, R.
Palumbo, A.
Mazumber, A.
Anderson, K. C.
Richardson, P. G.
Badros, A. Z.
Caers, J.
Cavo, M.
Leleu, X.
Dimopoulos, M. A.
Chim, C. S.
Schots, R.
Noeul, A.
Fantl, D.
Mellqvist, U-H
Landgren, O.
Chanan-Khan, A.
Moreau, P.
Fonseca, R.
Merlini, G.
Lahuerta, J. J.
Blade, J.
Orlowski, R. Z.
Shah, J. J.
CA Int Myeloma Working Grp
TI Plasma cell leukemia: consensus statement on diagnostic requirements,
response criteria and treatment recommendations by the International
Myeloma Working Group
SO LEUKEMIA
LA English
DT Review
DE plasma cell leukemia; cytogenetics; bortezomib; transplantation;
myeloma; prognosis
ID BONE-MARROW MICROENVIRONMENT; IN-SITU HYBRIDIZATION; OF-THE-LITERATURE;
C-MYC ONCOGENE; MULTIPLE-MYELOMA; UNDETERMINED SIGNIFICANCE; MONOCLONAL
GAMMOPATHY; GENETIC ABERRATIONS; CLINICAL-FEATURES; SINGLE-CENTER
AB Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage (>= 20%) and absolute number (>= 2 x 10(9)/l) of plasma cells in the peripheral blood. It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin promptly and have high clinical activity leading to rapid disease control in an effort to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem cell transplantation if feasible. Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL. Leukemia (2013) 27, 780-791; doi:10.1038/leu.2012.336
C1 [Fernandez de Larrea, C.; Blade, J.] Hosp Clin Barcelona, Dept Hematol, Amyloidosis & Myeloma Unit, IDIBAPS, E-08036 Barcelona, Spain.
[Kyle, R. A.; Kumar, S. K.] Mayo Clin, Dept Hematol, Rochester, MN USA.
[Durie, B. G. M.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Southwest Oncol Grp, Int Myeloma Fdn, Los Angeles, CA USA.
[Ludwig, H.] Wilhelminenspital Stadt Wien, Dept Med, Ctr Oncol & Hematol, Vienna, Austria.
[Usmani, S.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
[Vesole, D. H.] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Hajek, R.] Univ Hosp Ostrava, Dept Haematooncol, Ostrava, Czech Republic.
[Hajek, R.] Sch Med Univ, Ostrava, Czech Republic.
[San Miguel, J. F.] Hosp Univ Salamanca, Serv Hematol, CIC, IBMCC USAL CSIC, Salamanca, Spain.
[Sezer, O.] Univ Hamburg, Univ Med Ctr, Hamburg, Germany.
[Sonneveld, P.] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands.
[Mahindra, A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Comenzo, R.] Tufts Med Ctr, Boston, MA USA.
[Palumbo, A.] Univ Turin, Myeloma Unit, Div Hematol, Turin, Italy.
[Mazumber, A.] NYU Comprehens Canc Ctr, New York, NY USA.
[Anderson, K. C.; Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Badros, A. Z.] Univ Maryland, Dept BMT, Baltimore, MD 21201 USA.
[Caers, J.] Ctr Hosp Univ Liege, Dept Hematol, Liege, Belgium.
[Cavo, M.] S Orsolas Univ Hosp, Bologna Sch Med, Seragnoli Inst Haematol, Bologna, Italy.
[Leleu, X.] Hosp Claude Huriez, Dept Hematol, Lille, France.
[Dimopoulos, M. A.] Univ Athens, Dept Clin Therapeut, Sch Med Athens, GR-10679 Athens, Greece.
[Chim, C. S.] Queen Mary Hosp, Div Haematol & Med Oncol, Hong Kong, Hong Kong, Peoples R China.
[Schots, R.] Univ Ziekenhuis Brussels, Dept Clin Hematol, Brussels, Belgium.
[Noeul, A.] Hospital Ruiz & Paez, Bolivar, Venezuela.
[Fantl, D.] Hosp Italiano Buenos Aires, Caba, Argentina.
[Mellqvist, U-H] Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden.
[Landgren, O.] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA.
[Chanan-Khan, A.] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA.
[Moreau, P.] Univ Hosp, Dept Clin Hematol, Nantes, France.
[Fonseca, R.] Mayo Clin Scottsdale, Div Hematol Oncol, Scottsdale, AZ USA.
[Merlini, G.] Univ Pavia, Dept Biochem, I-27100 Pavia, Italy.
[Lahuerta, J. J.] Hosp Univ 12 Octubre, Dept Hematol, Madrid, Spain.
[Orlowski, R. Z.; Shah, J. J.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Div Canc Med, Houston, TX 77030 USA.
RP de Larrea, CF (reprint author), Hosp Clin Barcelona, Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain.
EM cfernan1@clinic.ub.es; jjshah@mdanderson.org
RI Kumar, Shaji/A-9853-2008; richard, chrystelle/K-8595-2015; Garcia-Sanz,
Ramon/B-7986-2017;
OI Kumar, Shaji/0000-0001-5392-9284; Garcia-Sanz,
Ramon/0000-0003-4120-2787; SAN MIGUEL, JESUS/0000-0002-9183-4857;
Fonseca, Rafael/0000-0002-5938-3769; CAVO, MICHELE/0000-0003-4514-3227;
Merlini, Giampaolo/0000-0001-7680-3254; nahi, hareth/0000-0003-4711-5094
FU Hospital Clinic de Barcelona; Instituto de Salud Carlos III, Spain
[RD12/0036/0046]
FX This work has been supported in part by 'Josep Font' Grant from Hospital
Clinic de Barcelona and RD12/0036/0046 from Instituto de Salud Carlos
III, Spain. Meeting on Plasma Cell Leukemia was supported by the
International Myeloma Foundation.
NR 92
TC 39
Z9 41
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD APR
PY 2013
VL 27
IS 4
BP 780
EP 791
DI 10.1038/leu.2012.336
PG 12
WC Oncology; Hematology
SC Oncology; Hematology
GA 124NT
UT WOS:000317472200005
ER
PT J
AU Chen, L
Deshpande, AJ
Banka, D
Bernt, KM
Dias, S
Buske, C
Olhava, EJ
Daigle, SR
Richon, VM
Pollock, RM
Armstrong, SA
AF Chen, L.
Deshpande, A. J.
Banka, D.
Bernt, K. M.
Dias, S.
Buske, C.
Olhava, E. J.
Daigle, S. R.
Richon, V. M.
Pollock, R. M.
Armstrong, S. A.
TI Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through
genetic inactivation or pharmacological inhibition of the H3K79
methyltransferase Dot1l
SO LEUKEMIA
LA English
DT Article
DE MLL-AF10; CALM-AF10; MLL fusions; leukemia; Dot1l; EPZ004777
ID ACUTE MYELOID-LEUKEMIA; MLL-MUTANT MICE; T(10-11) TRANSLOCATION;
LEUCINE-ZIPPER; UP-REGULATION; SET DOMAIN; METHYLATION; AF10; CLATHRIN;
FUSION
AB The t(10;11)(p12;q23) translocation and the t(10;11)(p12;q14) translocation, which encode the MLL (mixed lineage leukemia)-AF10 and CALM (clathrin assembly lymphoid myeloid leukemia)-AF10 fusion oncoproteins, respectively, are two recurrent chromosomal rearrangements observed in patients with acute myeloid leukemia and acute lymphoblastic leukemia. Here, we demonstrate that MLL-AF10 and CALM-AF10-mediated transformation is dependent on the H3K79 methyltransferase Dot1l using genetic and pharmacological approaches in mouse models. Targeted disruption of Dot1l using a conditional knockout mouse model abolished in vitro transformation of murine bone marrow cells and in vivo initiation and maintenance of MLL-AF10 or CALM-AF10 leukemia. The treatment of MLL-AF10 and CALM-AF10 transformed cells with EPZ004777, a specific small-molecule inhibitor of Dot1l, suppressed expression of leukemogenic genes such as Hoxa cluster genes and Meis1, and selectively impaired proliferation of MLL-AF10 and CALM-AF10 transformed cells. Pretreatment with EPZ004777 profoundly decreased the in vivo spleen-colony-forming ability of MLL-AF10 or CALM-AF10 transformed bone marrow cells. These results show that patients with leukemia-bearing chromosomal translocations that involve the AF10 gene may benefit from small-molecule therapeutics that inhibit H3K79 methylation. Leukemia (2013) 27, 813-822;doi:10.1038/leu.2012.327
C1 [Chen, L.; Deshpande, A. J.; Banka, D.; Bernt, K. M.; Dias, S.; Armstrong, S. A.] Childrens Hosp, Div Hematol Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Chen, L.; Deshpande, A. J.; Banka, D.; Bernt, K. M.; Dias, S.; Armstrong, S. A.] Harvard Univ, Sch Med, Boston, MA USA.
[Chen, L.] Harvard Univ, Dept Mol & Cellular Biol, Boston, MA 02115 USA.
[Deshpande, A. J.; Banka, D.; Bernt, K. M.; Dias, S.; Armstrong, S. A.] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA.
[Buske, C.] Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany.
[Olhava, E. J.; Daigle, S. R.; Richon, V. M.; Pollock, R. M.] Epizyme Inc, Cambridge, MA USA.
[Armstrong, S. A.] Harvard Stem Cell Inst, Boston, MA USA.
RP Armstrong, SA (reprint author), Childrens Hosp, Karp Family Res Labs, 1 Blackfan Circle, Boston, MA 02215 USA.
EM armstros@mskcc.org
RI Bernt, Kathrin/L-1826-2016
OI Bernt, Kathrin/0000-0002-5400-0482
FU National Cancer Institute [U01CA105423, R01CA140575]; American Cancer
Society; Leukemia and Lymphoma Society; NCI; NHLBI; William Lawrence and
Blanche Hughes Foundation
FX We would like to thank Ronald Mathieu and Mahnaz Pakhtinat for their
excellent technical assistance with flow cytometry. This work was
supported by grants from the National Cancer Institute (U01CA105423,
R01CA140575), the American Cancer Society and the Leukemia and Lymphoma
Society to SAA. AJD was supported by a grant to the American Cancer
Society and the NCI Howard Temin Pathway to Independence Award. KMB was
supported by NHLBI Career Development Award and funding from the William
Lawrence and Blanche Hughes Foundation.
NR 33
TC 44
Z9 45
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD APR
PY 2013
VL 27
IS 4
BP 813
EP 822
DI 10.1038/leu.2012.327
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA 124NT
UT WOS:000317472200008
PM 23138183
ER
PT J
AU Krivtsov, AV
Figueroa, ME
Sinha, AU
Stubbs, MC
Feng, Z
Valk, PJM
Delwel, R
Dohner, K
Bullinger, L
Kung, AL
Melnick, AM
Armstrong, SA
AF Krivtsov, A. V.
Figueroa, M. E.
Sinha, A. U.
Stubbs, M. C.
Feng, Z.
Valk, P. J. M.
Delwel, R.
Doehner, K.
Bullinger, L.
Kung, A. L.
Melnick, A. M.
Armstrong, S. A.
TI Cell of origin determines clinically relevant subtypes of MLL-rearranged
AML
SO LEUKEMIA
LA English
DT Article
DE MLL; cell of origin; gene expression; DNA methylation; chemotherapy;
drug resistance
ID ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELL; ACUTE MYELOGENOUS
LEUKEMIA; EXPRESSION PROFILES; DNA METHYLATION; MOUSE MODELS; GENE;
CANCER; TRANSFORMATION; PROGENITOR
AB Mixed lineage leukemia (MLL)-fusion proteins can induce acute myeloid leukemias (AMLs) from either hematopoietic stem cells (HSCs) or granulocyte-macrophage progenitors (GMPs), but it remains unclear whether the cell of origin influences the biology of the resultant leukemia. MLL-AF9-transduced single HSCs or GMPs could be continuously replated, but HSC-derived clones were more likely than GMP-derived clones to initiate AML in mice. Leukemia stem cells derived from either HSCs or GMPs had a similar immunophenotype consistent with a maturing myeloid cell (LGMP). Gene expression analyses demonstrated that LGMP inherited gene expression programs from the cell of origin including high-level Evi-1 expression in HSC-derived LGMP. The gene expression signature of LGMP derived from HSCs was enriched in poor prognosis human MLL-rearranged AML in three independent data sets. Moreover, global 5'-mC levels were elevated in HSC-derived leukemias as compared with GMP-derived leukemias. This mirrored a difference seen in 5'-mC between MLL-rearranged human leukemias that are either EVI1 positive or EVI1 negative. Finally, HSC-derived leukemias were more resistant to chemotherapy than GMP-derived leukemias. These data demonstrate that the cell of origin influences the gene expression profile, the epigenetic state and the drug response in AML, and that these differences can account for clinical heterogeneity within a molecularly defined group of leukemias. Leukemia (2013) 27, 852-860; doi:10.1038/leu.2012.363
C1 [Krivtsov, A. V.; Sinha, A. U.; Stubbs, M. C.; Feng, Z.; Armstrong, S. A.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Krivtsov, A. V.; Sinha, A. U.; Feng, Z.; Armstrong, S. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Krivtsov, A. V.; Sinha, A. U.; Armstrong, S. A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA.
[Krivtsov, A. V.; Sinha, A. U.; Armstrong, S. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Figueroa, M. E.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA.
[Figueroa, M. E.; Melnick, A. M.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
[Valk, P. J. M.; Delwel, R.] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands.
[Doehner, K.; Bullinger, L.] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany.
[Kung, A. L.] Columbia Univ, Div Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA.
RP Armstrong, SA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pediat, HOPP Z-561,417 E 68th St, New York, NY 10065 USA.
EM armstros@mskcc.org
OI Kung, Andrew/0000-0002-9091-488X
FU National Cancer Institute [5P01CA66996]; Leukemia and Lymphoma Society;
American Cancer Society; Harvard Stem Cell Institute; German Research
Foundation (DFG Heisenberg-Stipendium) [BU 1339/3-1]
FX We thank Renee Wright for technical help and Megan Smith for
administrative assistance. This work was supported in part by the
National Cancer Institute (5P01CA66996), the Leukemia and Lymphoma
Society, the American Cancer Society and the Harvard Stem Cell
Institute, and the German Research Foundation (DFG Heisenberg-Stipendium
BU 1339/3-1).
NR 51
TC 53
Z9 54
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD APR
PY 2013
VL 27
IS 4
BP 852
EP 860
DI 10.1038/leu.2012.363
PG 9
WC Oncology; Hematology
SC Oncology; Hematology
GA 124NT
UT WOS:000317472200013
PM 23235717
ER
PT J
AU Azab, AK
Weisberg, E
Sahin, I
Liu, F
Awwad, R
Azab, F
Liu, Q
Griffin, JD
Ghobrial, IM
AF Azab, A. K.
Weisberg, E.
Sahin, I.
Liu, F.
Awwad, R.
Azab, F.
Liu, Q.
Griffin, J. D.
Ghobrial, I. M.
TI The influence of hypoxia on CML trafficking through modulation of CXCR4
and E-cadherin expression
SO LEUKEMIA
LA English
DT Letter
ID CHRONIC MYELOID-LEUKEMIA; BONE-MARROW MICROENVIRONMENT; CHRONIC
MYELOGENOUS LEUKEMIA; BCR-ABL; MULTIPLE-MYELOMA; STEM-CELLS; INHIBITION;
IMATINIB; STROMA; PROGENITORS
C1 [Azab, A. K.; Azab, F.] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63130 USA.
[Weisberg, E.; Sahin, I.; Griffin, J. D.; Ghobrial, I. M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Liu, F.; Liu, Q.] Chinese Acad Sci, High Magnet Field Lab, Hefei, Peoples R China.
[Awwad, R.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
RP Azab, AK (reprint author), Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63130 USA.
EM aazab@radonc.wustl.edu
OI liu, qing song/0000-0002-7829-2547
NR 15
TC 8
Z9 9
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD APR
PY 2013
VL 27
IS 4
BP 961
EP 964
DI 10.1038/leu.2012.353
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA 124NT
UT WOS:000317472200029
PM 23212153
ER
PT J
AU Lane, AA
Odejide, O
Kopp, N
Kim, S
Yoda, A
Erlich, R
Wagle, N
Abel, GA
Rodig, SJ
Antin, JH
Weinstock, DM
AF Lane, A. A.
Odejide, O.
Kopp, N.
Kim, S.
Yoda, A.
Erlich, R.
Wagle, N.
Abel, G. A.
Rodig, S. J.
Antin, J. H.
Weinstock, D. M.
TI Low frequency clonal mutations recoverable by deep sequencing in
patients with aplastic anemia
SO LEUKEMIA
LA English
DT Letter
ID FOLLICULAR LYMPHOMA; BETA-2-MICROGLOBULIN; INDIVIDUALS; CELLS
C1 [Lane, A. A.; Odejide, O.; Kopp, N.; Kim, S.; Yoda, A.; Wagle, N.; Abel, G. A.; Antin, J. H.; Weinstock, D. M.] Dept Med Oncol, Boston, MA USA.
[Lane, A. A.; Wagle, N.; Abel, G. A.; Rodig, S. J.; Antin, J. H.; Weinstock, D. M.] Harvard Univ, Sch Med, Boston, MA USA.
[Erlich, R.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
[Rodig, S. J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Lane, AA (reprint author), Dept Med Oncol, Boston, MA USA.
EM dweinstock@partners.org
FU NCI NIH HHS [T32 CA009172]
NR 10
TC 19
Z9 21
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD APR
PY 2013
VL 27
IS 4
BP 968
EP 971
DI 10.1038/leu.2013.30
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA 124NT
UT WOS:000317472200031
PM 23370706
ER
PT J
AU Tomov, S
Lazarchick, J
Self, SE
Bruner, ET
Budisavljevic, MN
AF Tomov, S.
Lazarchick, J.
Self, S. E.
Bruner, E. T.
Budisavljevic, M. N.
TI Kidney-limited thrombotic microangiopathy in patients with SLE treated
with romiplostim
SO LUPUS
LA English
DT Article
DE Thrombotic microangiopathy; antiphospholipid syndrome; thrombotic
thrombocytopenic purpura; romiplostim; acute renal failure; systemic
lupus erythematosus; plasma exchange
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HEMOLYTIC-UREMIC SYNDROME;
THROMBOCYTOPENIC PURPURA; ANTIPHOSPHOLIPID SYNDROME; IMMUNE
THROMBOCYTOPENIA; VASCULAR-LESIONS; NEPHRITIS; ADAMTS13; THROMBOPOIETIN;
ANEMIA
AB We present the case of a 19 year-old Caucasian female with history of systemic lupus erythematosus (SLE) and normal baseline kidney function who developed severe acute renal failure following treatment of thrombocytopenia with the thrombopoietic agent romiplostim. Percutaneous kidney biopsy revealed thrombotic microangiopathy (TMA) without immune complex lupus glomerulonephritis. We discuss pathogenesis and differential diagnosis of TMA in patients with SLE and raise concerns regarding the use of thrombopoietic agents in such patients. Based on favorable long-term outcome in our case aggressive treatment and in particular prolonged use of plasma exchange in these patients are advocated. Lupus (2013) 22, 504-509.
C1 [Tomov, S.; Budisavljevic, M. N.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Lazarchick, J.; Self, S. E.; Bruner, E. T.] Pathol & Lab Med Med Univ South Carolina, Charleston, SC USA.
[Budisavljevic, M. N.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Budisavljevic, MN (reprint author), Med Univ S Carolina, Div Nephrol, 171 Ashley Ave, Charleston, SC 29425 USA.
EM budisamn@musc.edu
NR 37
TC 1
Z9 1
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0961-2033
J9 LUPUS
JI Lupus
PD APR
PY 2013
VL 22
IS 5
BP 504
EP 509
DI 10.1177/0961203313477900
PG 6
WC Rheumatology
SC Rheumatology
GA 122TV
UT WOS:000317341900014
PM 23554039
ER
PT J
AU de Villiers, TJ
Gass, MLS
Haines, CJ
Hall, JE
Lobo, RA
Pierroz, DD
Rees, M
AF de Villiers, T. J.
Gass, M. L. S.
Haines, C. J.
Hall, J. E.
Lobo, R. A.
Pierroz, D. D.
Rees, M.
TI Global Consensus Statement on menopausal hormone therapy
SO MATURITAS
LA English
DT Editorial Material
C1 [de Villiers, T. J.] MediClin Panorama, Cape Town, South Africa.
[de Villiers, T. J.] Univ Stellenbosch, Dept Obstet & Gynecol, Cape Town, South Africa.
[Gass, M. L. S.] Case Western Reserve Univ, Sch Med, Dept Surg, Cleveland Clin,Lerner Coll Med, Cleveland, OH 44106 USA.
[Haines, C. J.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynecol, Shatin, Hong Kong, Peoples R China.
[Hall, J. E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Hall, J. E.] Harvard Univ, Sch Med, Boston, MA USA.
[Lobo, R. A.] Columbia Univ, Dept Obstet & Gynecol, New York, NY USA.
[Pierroz, D. D.] Univ Geneva, CH-1211 Geneva 4, Switzerland.
[Rees, M.] Univ Oxford, Oxford OX1 2JD, England.
RP de Villiers, TJ (reprint author), MediClin Panorama, ZA-7500 Parow, South Africa.
OI Hall, Janet/0000-0003-4644-3061
NR 0
TC 37
Z9 38
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-5122
J9 MATURITAS
JI Maturitas
PD APR
PY 2013
VL 74
IS 4
BP 391
EP 392
DI 10.1016/j.maturitas.2013.02.001
PG 2
WC Geriatrics & Gerontology; Obstetrics & Gynecology
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA 124II
UT WOS:000317456600016
PM 23497918
ER
PT J
AU Shampo, MA
Kyle, RA
Steensma, DP
AF Shampo, Marc A.
Kyle, Robert A.
Steensma, David P.
TI Horace Magoun-Neuroanatomist and Neurophysiologist
SO MAYO CLINIC PROCEEDINGS
LA English
DT Biographical-Item
C1 [Shampo, Marc A.; Kyle, Robert A.] Mayo Clin, Rochester, MN 55905 USA.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Shampo, MA (reprint author), Mayo Clin, Rochester, MN 55905 USA.
OI Steensma, David/0000-0001-5130-9284
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD APR
PY 2013
VL 88
IS 4
BP E33
EP E33
DI 10.1016/j.mayocp.2012.01.027
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122QJ
UT WOS:000317332500001
PM 23541022
ER
PT J
AU Gat-Viks, I
Chevrier, N
Wilentzik, R
Eisenhaure, T
Raychowdhury, R
Steuerman, Y
Shalek, AK
Hacohen, N
Amit, I
Regev, A
AF Gat-Viks, Irit
Chevrier, Nicolas
Wilentzik, Roni
Eisenhaure, Thomas
Raychowdhury, Raktima
Steuerman, Yael
Shalek, Alex K.
Hacohen, Nir
Amit, Ido
Regev, Aviv
TI Deciphering molecular circuits from genetic variation underlying
transcriptional responsiveness to stimuli
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID QUANTITATIVE TRAIT LOCI; TOLL-LIKE RECEPTORS; INNATE IMMUNITY; RIG-I;
EXPRESSION; CELLS; RESPONSES; IDENTIFICATION; RECOGNITION; REGULATORS
AB Individual genetic variation affects gene responsiveness to stimuli, often by influencing complex molecular circuits. Here we combine genomic and intermediate-scale transcriptional profiling with computational methods to identify variants that affect the responsiveness of genes to stimuli (responsiveness quantitative trait loci or reQTLs) and to position these variants in molecular circuit diagrams. We apply this approach to study variation in transcriptional responsiveness to pathogen components in dendritic cells from recombinant inbred mouse strains. We identify reQTLs that correlate with particular stimuli and position them in known pathways. For example, in response to a virus-like stimulus, a trans-acting variant responds as an activator of the antiviral response; using RNA interference, we identify Rgs16 as the likely causal gene. Our approach charts an experimental and analytic path to decipher the mechanisms underlying genetic variation in circuits that control responses to stimuli.
C1 [Gat-Viks, Irit; Chevrier, Nicolas; Eisenhaure, Thomas; Raychowdhury, Raktima; Hacohen, Nir; Amit, Ido; Regev, Aviv] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Gat-Viks, Irit; Wilentzik, Roni; Steuerman, Yael] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.
[Chevrier, Nicolas] Harvard Univ, Sch Med, Div Med Sci, Grad Program Immunol, Boston, MA USA.
[Chevrier, Nicolas] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
[Eisenhaure, Thomas; Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA.
[Shalek, Alex K.] Harvard Univ, Dept Chem, Cambridge, MA 02138 USA.
[Shalek, Alex K.] Harvard Univ, Dept Biol Chem, Cambridge, MA 02138 USA.
[Shalek, Alex K.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.
[Hacohen, Nir] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Amit, Ido] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.
[Regev, Aviv] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA USA.
RP Gat-Viks, I (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
EM iritgv@post.tau.ac.il; ido.amit@weizmann.ac.il; aregev@broad.mit.edu
OI Shalek, Alex K./0000-0001-5670-8778
FU Human Frontiers Science Program postdoctoral fellowships; Howard Hughes
Medical Institute; US National Institutes of Health; Burroughs-Wellcome
Fund Career Award at the Scientific Interface; Center for Excellence in
Genome Science from the National Human Genome Research Institute
[5P50HG006193-02]; Klarman Cell Observatory at the Broad Institute; New
England Regional Center for Excellence/Biodefense and Emerging
Infectious Disease [U54 AI057159]; Israeli Centers of Research
Excellence (I-CORE) Gene Regulation in Complex Human Disease [41/11];
Human Frontiers Science Program Career Development Award; Israeli
Science Foundation Bikura Institutional Research Grant Program; Edmond
J. Safra Center for Bioinformatics at Tel-Aviv University
FX We thank C. (Jimmie) Ye, J. Pickerel, M. Daly and E. Lander for comments
and discussions. I.G.-V. and I.A. were supported by Human Frontiers
Science Program postdoctoral fellowships. Work was supported by Howard
Hughes Medical Institute, a US National Institutes of Health PIONEER
award, a Burroughs-Wellcome Fund Career Award at the Scientific
Interface (A.R.), a Center for Excellence in Genome Science grant
5P50HG006193-02 from the National Human Genome Research Institute (N.H.
and A.R.), the Klarman Cell Observatory at the Broad Institute (A.R.),
the New England Regional Center for Excellence/Biodefense and Emerging
Infectious Disease U54 AI057159 (N.H.), the Israeli Centers of Research
Excellence (I-CORE) Gene Regulation in Complex Human Disease, Center No.
41/11 (I.G.-V., R.W. and Y.S.), the Human Frontiers Science Program
Career Development Award and an Israeli Science Foundation Bikura
Institutional Research Grant Program (I.A.) and the Edmond J. Safra
Center for Bioinformatics at Tel-Aviv University (R.W. and Y.S.). A.R.
is a fellow of the Merkin Foundation for Stem Cell Research at the Broad
Institute. I.G.-V. is a Faculty Fellow of the Edmond J. Safra Center for
Bioinformatics at Tel Aviv University and an Alon Fellow.
NR 50
TC 19
Z9 19
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD APR
PY 2013
VL 31
IS 4
BP 342
EP +
DI 10.1038/nbt.2519
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 120TI
UT WOS:000317195500028
PM 23503680
ER
PT J
AU Huang, LF
Jin, JM
Deighan, P
Kiner, E
McReynolds, L
Lieberman, J
AF Huang, Linfeng
Jin, Jingmin
Deighan, Padraig
Kiner, Evgeny
McReynolds, Larry
Lieberman, Judy
TI Efficient and specific gene knockdown by small interfering RNAs produced
in bacteria
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID DOUBLE-STRANDED RNAS; SHORT HAIRPIN RNAS; CAENORHABDITIS-ELEGANS;
MAMMALIAN-CELLS; EXPRESSION; SIRNAS; PLANTS; INHIBITION; INVASION;
DUPLEXES
AB Synthetic small interfering RNAs (siRNAs) are an indispensable tool to investigate gene function in eukaryotic cells(1,2) and may be used for therapeutic purposes to knock down genes implicated in disease(3). Thus far, most synthetic siRNAs have been produced by chemical synthesis. Here we present a method to produce highly potent siRNAs in Escherichia coli. This method relies on ectopic expression of p19, an siRNA-binding protein found in a plant RNA virus(4,5). When expressed in E. coli, p19 stabilizes an similar to 21-nt siRNA-like species produced by bacterial RNase III. When mammalian cells are transfected by them, siRNAs that were generated in bacteria expressing p19 and a hairpin RNA encoding 200 or more nucleotides of a target gene reproducibly knock down target gene expression by similar to 90% without immunogenicity or off-target effects. Because bacterially produced siRNAs contain multiple sequences against a target gene, they may be especially useful for suppressing polymorphic cellular or viral genes.
C1 [Huang, Linfeng; Kiner, Evgeny; Lieberman, Judy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Huang, Linfeng; Kiner, Evgeny; Lieberman, Judy] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Jin, Jingmin; McReynolds, Larry] New England Biolabs Inc, Ipswich, MA USA.
[Deighan, Padraig] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Deighan, Padraig] Univ Cambridge Emmanuel Coll, Dept Biol, Boston, MA USA.
RP Lieberman, J (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
EM judy.lieberman@childrens.harvard.edu
RI Lieberman, Judy/A-2717-2015;
OI Huang, Linfeng/0000-0002-0322-4929
FU National Institutes of Health [AI087431]; GSK-IDI Alliance fellowship
FX The authors thank J. Carrington (Donald Danforth Plant Science Center)
for the p19 clone, C. Zhang and G. Ruvkun (Massachusetts General
Hospital) for L4440 plasmid and HT115(DE3) strain, S. Kushner
(University of Georgia) for SK7622 strain, D. Higgins (Harvard Medical
School) for pLIV-1 plasmid, and S. Ranjbar (Boston Children's Hospital)
for HIV strains and cell lines. We thank L.M. Mazzola, J.M. Bybee and
D.B. Munafo from New England Biolabs for assistance with RNA deep
sequencing and Z. Ansara for technical help. We thank A. Hochschild
(Harvard Medical School) for suggestions and critical reading of the
manuscript and Lieberman Lab members for technical assistance, helpful
discussions and comments on the manuscript. This work was supported by
National Institutes of Health grant AI087431 (J.L.) and a GSK-IDI
Alliance fellowship (L.H.).
NR 33
TC 16
Z9 16
U1 1
U2 44
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD APR
PY 2013
VL 31
IS 4
BP 350
EP +
DI 10.1038/nbt.2537
PG 9
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 120TI
UT WOS:000317195500029
PM 23475073
ER
PT J
AU DeKosky, ST
Blennow, K
Ikonomovic, MD
Gandy, S
AF DeKosky, Steven T.
Blennow, Kaj
Ikonomovic, Milos D.
Gandy, Sam
TI Acute and chronic traumatic encephalopathies: pathogenesis and
biomarkers
SO NATURE REVIEWS NEUROLOGY
LA English
DT Review
ID POSTTRAUMATIC-STRESS-DISORDER; AMYLOID-BETA ACCUMULATION; PITTSBURGH
COMPOUND-B; SEVERE BRAIN-INJURY; HEAD-INJURY; ALZHEIMERS-DISEASE;
CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; COGNITIVE DECLINE; PRECURSOR
PROTEIN
AB Over the past decade, public awareness of the long-term pathological consequences of traumatic brain injury (TBI) has increased. Such awareness has been stimulated mainly by reports of progressive neurological dysfunction in athletes exposed to repetitive concussions in high-impact sports such as boxing and American football, and by the rising number of TBIs in war veterans who are now more likely to survive explosive blasts owing to improved treatment. Moreover, the entity of chronic traumatic encephalopathy (CTE)-which is marked by prominent neuropsychiatric features including dementia, parkinsonism, depression, agitation, psychosis, and aggression-has become increasingly recognized as a potential late outcome of repetitive TBI. Annually, about 1% of the population in developed countries experiences a clinically relevant TBI. The goal of this Review is to provide an overview of the latest understanding of CTE pathophysiology, and to delineate the key issues that are challenging clinical and research communities, such as accurate quantification of the risk of CTE, and development of reliable biomarkers for single-incident TBI and CTE. DeKosky, S. T. et al. Nat. Rev. Neurol. 9, 192-200 (2013); doi:10.1038/nrneurol.2013.36
C1 [DeKosky, Steven T.] Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA.
[DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
[Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Clin Neurochem Lab, Inst Neurosci & Physiol,Sahlgrenska Univ Hosp, SE-43180 Molndal, Sweden.
[Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Gandy, Sam] James J Peters Med Ctr, Icahn Sch Med, Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Gandy, Sam] James J Peters Med Ctr, Icahn Sch Med, Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Gandy, Sam] James J Peters Med Ctr, Icahn Sch Med, Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.
RP DeKosky, ST (reprint author), Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA.
EM dekosky@virginia.edu
FU NIH [P01NS30318, P01AG14449, P50AG05133]; VA MERIT review grants
[1I01BX000348, 1I01RX000511]; Cure Alzheimer's Fund; US NIH [P50
AG05138]
FX The authors gratefully acknowledge the support of NIH grants P01NS30318,
P01AG14449 and P50AG05133 (S. T. DeKosky and M. D. Ikonomovic), and VA
MERIT review grants 1I01BX000348 (S. Gandy) and 1I01RX000511 (M. D.
Ikonomovic). S. Gandy also acknowledges the support of the Cure
Alzheimer's Fund and of US NIH P50 AG05138. The authors thank P. Davies
(North Shore-Hofstra) for helpful discussions.
NR 96
TC 77
Z9 79
U1 10
U2 66
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD APR
PY 2013
VL 9
IS 4
BP 192
EP 200
DI 10.1038/nrneurol.2013.36
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 121TV
UT WOS:000317268100007
PM 23558985
ER
PT J
AU McDougle, CJ
AF McDougle, Christopher J.
TI Recent progress in autism spectrum disorder FOREWORD
SO NEUROPSYCHIATRY
LA English
DT Editorial Material
C1 [McDougle, Christopher J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McDougle, Christopher J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[McDougle, Christopher J.] Lurie Ctr Autism, Lexington, MA 02421 USA.
RP McDougle, CJ (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM cmcdougle@partners.org
NR 12
TC 1
Z9 1
U1 1
U2 14
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD APR
PY 2013
VL 3
IS 2
BP 119
EP 122
DI 10.2217/NPY.13.17
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 126QM
UT WOS:000317636300001
ER
PT J
AU Mody, M
Manoach, DS
Guenther, FH
Kenet, T
Bruno, KA
McDougle, CJ
Stigler, KA
AF Mody, Maria
Manoach, Dara S.
Guenther, Frank H.
Kenet, Tal
Bruno, Katelyn A.
McDougle, Christopher J.
Stigler, Kimberly Ann
TI Speech and language in autism spectrum disorder: a view through the lens
of behavior and brain imaging
SO NEUROPSYCHIATRY
LA English
DT Review
ID HIGH-FUNCTIONING AUTISM; WHITE-MATTER; RIGHT-HEMISPHERE; SENTENCE
COMPREHENSION; CORTICAL ACTIVATION; AUDITORY LANGUAGE; EARLY
RECOGNITION; EARLY-CHILDHOOD; MISMATCH FIELD; COMPLEX SOUNDS
AB Numerous studies have examined the brain bases of autism; few, however, have specifically examined the neurobiology of speech and language impairments in children and adults on the spectrum, especially those characterized as low functioning or minimally verbal, due to compliance issues. With exciting new advances in the development of paradigms and tools, and the ability to image children at risk for autism as young as 6 months of age, functional neuroimaging (EEG, magnetoencephalography and functional MRI) holds tremendous promise. Findings of reduced activation and structural and functional connectivity in the language network, together with deficits in social reciprocity and motivation, and a preference for visual over verbal information, appear to be carving out a neurobiological profile for the impaired social communication brain in autism.
C1 [Mody, Maria] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA.
[Mody, Maria] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Mody, Maria] Lurie Ctr Autism, Charlestown, MA 02129 USA.
[Mody, Maria; Manoach, Dara S.; Kenet, Tal] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Manoach, Dara S.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
[Manoach, Dara S.; Kenet, Tal] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Guenther, Frank H.] Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA.
[Guenther, Frank H.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Kenet, Tal] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
[Bruno, Katelyn A.] Spaulding Rehabil Hosp, Lurie Ctr Autism, Lexington, MA 02421 USA.
[Bruno, Katelyn A.] Massachusetts Gen Hosp Children, Lexington, MA 02421 USA.
[McDougle, Christopher J.] Massachusetts Gen Hosp Children, Dept Psychiat, Lexington, MA 02421 USA.
[McDougle, Christopher J.] Massachusetts Gen Hosp Children, Dept Pediat, Lexington, MA 02421 USA.
[McDougle, Christopher J.] Massachusetts Gen Hosp Children, Lurie Ctr Autism, Lexington, MA 02421 USA.
[McDougle, Christopher J.] Massachusetts Gen Hosp, Lexington, MA 02421 USA.
[McDougle, Christopher J.] Harvard Univ, Sch Med, Lexington, MA 02421 USA.
[Stigler, Kimberly Ann] Indiana Univ Sch Med, James Whitcomb Riley Hosp Children, Dept Psychiat, Indianapolis, IN 46202 USA.
RP Mody, M (reprint author), Massachusetts Gen Hosp, Dept Radiol, 149 13th St,CNY 2301, Charlestown, MA 02129 USA.
EM maria@nmr.mgh.harvard.edu
FU Bristol-Myers Squibb Co.; Eli Lilly Co.; Forest Research Institute;
Janssen; Novartis; Seaside Therapeutics; SynapDx
FX KA Stigler receives research support from Bristol-Myers Squibb Co., Eli
Lilly & Co., Forest Research Institute, Janssen, Novartis, Seaside
Therapeutics and SynapDx. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
NR 126
TC 5
Z9 5
U1 6
U2 63
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD APR
PY 2013
VL 3
IS 2
BP 223
EP 232
DI 10.2217/NPY.13.19
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 126QM
UT WOS:000317636300015
ER
PT J
AU Vahabzadeh, A
Buxton, D
McDougle, CJ
Stigler, KA
AF Vahabzadeh, Arshya
Buxton, David
McDougle, Christopher J.
Stigler, Kimberly A.
TI Current state and future prospects of pharmacological interventions for
autism
SO NEUROPSYCHIATRY
LA English
DT Review
ID PERVASIVE DEVELOPMENTAL DISORDERS; OPEN-LABEL TRIAL; PLACEBO-CONTROLLED
TRIAL; DEFICIT HYPERACTIVITY DISORDER; PSYCHOTROPIC MEDICATION USE;
SELF-INJURIOUS-BEHAVIOR; SPECTRUM DISORDERS; DOUBLE-BLIND;
D-CYCLOSERINE; YOUNG-ADULTS
AB Autism spectrum disorder (ASD) is a group of heterogeneous developmental disorders manifesting in early childhood. They are associated with a range of core and associated symptoms, including repetitive behaviors, hyperactivity and irritability. This review will describe the current evidence for psychopharmacological management of individuals with ASD. Additionally, some of the future treatment prospects will be discussed. Safety issues, adverse effects and limitations of the current literature will also be highlighted.
C1 [Vahabzadeh, Arshya] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA.
[Buxton, David] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[McDougle, Christopher J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[McDougle, Christopher J.] Massachusetts Gen Hosp, Lurie Ctr Autism, Boston, MA 02114 USA.
[Stigler, Kimberly A.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN USA.
[Stigler, Kimberly A.] James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA.
RP Stigler, KA (reprint author), Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN USA.
EM kstigler@iupui.edu
FU Bristol-Myers Squibb Co.; Eli Lilly Co.; Forest Research Institute;
Janssen; Novartis; Seaside Therapeutics; SynapDx
FX KA Stigler receives research support from Bristol-Myers Squibb Co., Eli
Lilly & Co., Forest Research Institute, Janssen, Novartis, Seaside
Therapeutics and SynapDx. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
NR 94
TC 2
Z9 2
U1 2
U2 15
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD APR
PY 2013
VL 3
IS 2
BP 245
EP 259
DI 10.2217/NPY.13.22
PG 15
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 126QM
UT WOS:000317636300017
ER
PT J
AU Villar, CC
Lin, AL
Cao, Z
Zhao, XR
Wu, LA
Chen, S
Sun, Y
Yeh, CK
AF Villar, C. C.
Lin, A. L.
Cao, Z.
Zhao, X-R
Wu, L-A
Chen, S.
Sun, Y.
Yeh, C-K
TI Anticandidal activity and biocompatibility of a rechargeable antifungal
denture material
SO ORAL DISEASES
LA English
DT Article
DE anticandidal; rechargeable denture material; denture stomatitis; Candida
albicans; epithelial cells
ID ORAL EPITHELIAL-CELLS; SECRETED PROTEINASE GENES; CANDIDA-ALBICANS;
IN-VITRO; TISSUE CONDITIONERS; BIOFILM FORMATION; SILVER-ZEOLITE;
DRUG-RELEASE; MICONAZOLE; INFECTION
AB OBJECTIVES: Candida-associated denture stomatitis is a recurrent and debilitating oral mucosal disease. Development of anticandidal denture materials represents a promising strategy to manage this condition. We have previously shown that miconazole incorporated in methacrylic acid (MAA) copolymerized diurethane dimethacrylate (UDMA) denture materials has long-term anticandidal activity. In this study, we examined the ability of culture medium conditioned with drug-free-or miconazole-MAA-UDMA discs to prevent Candida infection in an in vitro oral epithelial cell/Candida albicans coculture system.
MATERIALS AND METHODS: Candida albicans (C. albicans)-induced OKF6/TERT-2 cell damage was quantified by the release of lactate dehydrogenase from epithelial cells, cytokine production was quantified using protein cytokine arrays, and the expression of C. albicans genes was measured by RT-qPCR.
RESULTS: Candida albicans had limited growth with altered expression levels of secreted aspartyl proteinase-2 and -5 in culture medium conditioned by miconazole-MAA-UDMA discs. Significantly, the ability of C. albicans to induce oral epithelial cell damage and trigger epithelial proinflammatory cytokine production was also inhibited by miconazole disc conditioned media.
CONCLUSION: Miconazole released from MAA-UDMA denture materials effectively prevents the development of candidal infection in an in vitro oral epithelial system. Further characterization of this drug-rechargeable denture material is warranted. Oral Diseases (2013) 19, 287--295
C1 [Villar, C. C.; Zhao, X-R] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
[Lin, A. L.; Yeh, C-K] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA.
[Cao, Z.; Sun, Y.] Univ S Dakota, Dept Biomed Engn Program, Sioux Falls, SD USA.
[Wu, L-A; Chen, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Dev Dent, San Antonio, TX 78229 USA.
[Yeh, C-K] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX 78229 USA.
RP Yeh, CK (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182, Audie L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM yeh@uthscsa.edu
RI Villar, Cristina/D-6353-2013
OI Villar, Cristina/0000-0002-5905-5079
FU NIDCR/NIH [R01 DE021084, R01DE019892]; NCRR/NIH [UL1RR025767]
FX We are grateful to Drs. Brian Wickes (Department of Microbiology,
UTHSCSA) and Spencer Redding (Comprehensive Dentistry, UTHSCSA) for
their support and useful discussion during this research. Cell line
OKF6/TERT-2 was a gift from Dr. Jim. Rhienwald (Brigham and Women's
Hospital, Harvard Medical. School, Boston, MA). We would also like to
thank Ms. Shuko Lee for her assistance in statistical analysis. This
research is support by NIDCR/NIH grants R01 DE021084 (Y. Sun and C-K.
Yeh), R01DE019892 (S. Chen), and NCRR/NIH grant UL1RR025767 (C.C.
Villar). Dr. Zhengbing Cao current address is Medetech Development
Corporation, 12527 MUKILTEO SPEEDWAY STE 103 LYNNWOOD, WA 98087-1532,
USA (zhengbing@medetech.com).
NR 52
TC 3
Z9 3
U1 2
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1354-523X
J9 ORAL DIS
JI Oral Dis.
PD APR
PY 2013
VL 19
IS 3
BP 287
EP 295
DI 10.1111/odi.12000
PG 9
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 124TP
UT WOS:000317490300008
PM 22957799
ER
PT J
AU Koolaee, RM
Schumacher, H
Shoemaker, MJ
Mooar, SK
Pullman-Mooar, S
AF Koolaee, R. M.
Schumacher, H., Jr.
Shoemaker, M. J.
Mooar, S. K.
Pullman-Mooar, S.
TI FACTORS PREDICTING THE EFFICACY OF VISCOSUPPLEMENTATION IN KNEE
OSTEOARTHRITIS
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Meeting Abstract
CT World Congress of the Osteoarthritis-Research-Society-International
(OARSI)
CY APR 18-21, 2013
CL Philadelphia, PA
SP OsteoArthritis Res Soc Int (OARSI)
C1 [Koolaee, R. M.; Schumacher, H., Jr.; Mooar, S. K.; Pullman-Mooar, S.] Univ Penn, Philadelphia, PA 19104 USA.
[Koolaee, R. M.; Schumacher, H., Jr.; Mooar, S. K.; Pullman-Mooar, S.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Shoemaker, M. J.] Grand Valley State Univ, Grand Rapids, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD APR
PY 2013
VL 21
SU S
BP S258
EP S258
PG 1
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 130TF
UT WOS:000317942300526
ER
PT J
AU Mootanah, R
Hillstrom, HJ
Gross, KD
Niu, J
Nevitt, MC
Lewis, CE
Torner, J
Hietpas, J
Felson, D
AF Mootanah, R.
Hillstrom, H. J.
Gross, K. D.
Niu, J.
Nevitt, M. C.
Lewis, C. E.
Torner, J.
Hietpas, J.
Felson, D.
TI STANCE AND SINGLE SUPPORT TIME ASYMMETRY IDENTIFY UNILATERAL KNEE OA AND
THE INVOLVED LIMB: THE MULTICENTER OSTEOARTHRITIS STUDY
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Meeting Abstract
CT World Congress of the Osteoarthritis-Research-Society-International
(OARSI)
CY APR 18-21, 2013
CL Philadelphia, PA
SP OsteoArthritis Res Soc Int (OARSI)
C1 [Mootanah, R.; Hillstrom, H. J.] Anglia Ruskin Univ, Chelmsford, Essex, England.
[Mootanah, R.; Hillstrom, H. J.] Hosp Special Surg, New York, NY 10021 USA.
[Gross, K. D.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA.
[Niu, J.; Felson, D.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Nevitt, M. C.; Hietpas, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Lewis, C. E.] Univ Alabama Hosp & Clin, Birmingham, AL USA.
[Torner, J.] Univ Iowa, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD APR
PY 2013
VL 21
SU S
BP S246
EP S247
PG 2
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 130TF
UT WOS:000317942300498
ER
PT J
AU Suri, P
Hunter, DJ
Rainville, J
Guermazi, A
Katz, JN
AF Suri, P.
Hunter, D. J.
Rainville, J.
Guermazi, A.
Katz, J. N.
TI ASSOCIATIONS BETWEEN SELF-REPORTED PHYSICAL ACTIVITY AND LUMBAR FACET
JOINT OSTEOARTHRITIS: THE FRAMINGHAM STUDY
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Meeting Abstract
CT World Congress of the Osteoarthritis-Research-Society-International
(OARSI)
CY APR 18-21, 2013
CL Philadelphia, PA
SP OsteoArthritis Res Soc Int (OARSI)
C1 [Suri, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Hunter, D. J.] Univ Sydney, Sydney, NSW 2006, Australia.
[Rainville, J.] New England Baptist Hosp, Boston, MA USA.
[Guermazi, A.] Boston Univ, Boston, MA 02215 USA.
[Katz, J. N.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD APR
PY 2013
VL 21
SU S
BP S279
EP S279
PG 1
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 130TF
UT WOS:000317942300576
ER
PT J
AU Dowben, JS
Grant, JS
Froelich, KD
Keltner, NL
AF Dowben, Jonathan S.
Grant, Joan S.
Froelich, Kimberly D.
Keltner, Norman L.
TI Biological Perspectives Hydroxyzine for Anxiety: Another Look at an Old
Drug
SO PERSPECTIVES IN PSYCHIATRIC CARE
LA English
DT Article
DE Hydroxyzine; anxiety
ID GENERALIZED ANXIETY; DISORDER; EFFICACY; PLACEBO
C1 [Dowben, Jonathan S.] Brooke Army Med Ctr, Pediat & Adolescent Behav Hlth Serv, San Antonio, TX USA.
[Grant, Joan S.; Keltner, Norman L.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Froelich, Kimberly D.] Birmingham VA Med Ctr, Patient Care Serv, Birmingham, AL USA.
RP Keltner, NL (reprint author), Univ Alabama Birmingham, Birmingham, AL 35294 USA.
EM nkeltner@uab.edu
OI Grant, Joan/0000-0001-6000-4060
NR 9
TC 4
Z9 4
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-5990
J9 PERSPECT PSYCHIATR C
JI Perspect. Psychiatr. Care
PD APR
PY 2013
VL 49
IS 2
BP 75
EP 77
DI 10.1111/ppc.12012
PG 3
WC Nursing; Psychiatry
SC Nursing; Psychiatry
GA 122DE
UT WOS:000317295600002
PM 23557449
ER
PT J
AU Yeh, H
Moore, DJ
Markmann, JF
Kim, JI
AF Yeh, Heidi
Moore, Daniel J.
Markmann, James F.
Kim, James I.
TI Mechanisms of regulatory T cell counter-regulation by innate immunity
SO TRANSPLANTATION REVIEWS
LA English
DT Article
ID INDUCED TNF RECEPTOR; IMMUNOLOGICAL SELF-TOLERANCE; TRANSCRIPTION FACTOR
FOXP3; TGF-BETA; CUTTING EDGE; DENDRITIC CELLS; ALLOGRAFT ACCEPTANCE;
IN-VIVO; TRANSPLANTATION TOLERANCE; COSTIMULATION BLOCKADE
AB One of the most significant advances in the field of immunology in the last decade is delineation of the pivotal role of regulatory T cells (Tregs) in the maintenance of self-tolerance. While Tregs are just now being applied therapeutically in early phase clinical trials, data gleaned from basic and translational studies to-date suggest enormous potential to intervene in human disease. Data from our work and the work of others suggest that the innate immune system plays an important role in the differentiation and function of Tregs, largely through the production of cytokines but also through expression of cell surface ligands. These molecules are expressed differentially depending on whether the stimulus includes trauma, ischemia/necrosis, and microbial infection, and have opposing effects on Tregs, in contrast to those associated with dendritic cell maturation and somatic cell apoptosis, which promote Treg differentiation and function. We refer to the former process as Treg counter-regulation. Since the transplantation procedure involves surgical trauma, organ ischemia, and exposure to environmental microbes, Treg counter-regulation represents a key area of intervention to improve strategies for promoting allograft tolerance. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Yeh, Heidi; Markmann, James F.; Kim, James I.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Moore, Daniel J.] Vanderbilt Childrens Hosp, Dept Pediat, Ian Burr Div Endocrinol & Diabet, Nashville, TN 37232 USA.
RP Kim, JI (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM jkim35@partners.org
RI Moore, Daniel/A-4924-2008
OI Moore, Daniel/0000-0002-6889-9345
FU NIH [2R56AI048820, 5R01AI048820, 1F32DK083161]; Vanderbilt Physician
Scientist Development Program
FX Supported in part by: NIH 2R56AI048820 (JFM), 5R01AI048820 (JFM),
1F32DK083161 (DJM) and the Vanderbilt Physician Scientist Development
Program (DJM).
NR 78
TC 2
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-470X
J9 TRANSPLANT REV-ORLAN
JI Transplant. Rev.
PD APR
PY 2013
VL 27
IS 2
BP 61
EP 64
DI 10.1016/j.trre.2013.02.001
PG 4
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 124CK
UT WOS:000317441200007
PM 23474287
ER
PT J
AU Lu, T
Zwicker, L
Kwena, Z
Bukusi, E
Mwaura-Muiru, E
Dworkin, SL
AF Lu, Tiffany
Zwicker, Lindsey
Kwena, Zachary
Bukusi, Elizabeth
Mwaura-Muiru, Esther
Dworkin, Shari L.
TI ASSESSING BARRIERS AND FACILITATORS OF IMPLEMENTING AN INTEGRATED HIV
PREVENTION AND PROPERTY RIGHTS PROGRAM IN WESTERN KENYA
SO AIDS EDUCATION AND PREVENTION
LA English
DT Article
ID WOMENS EMPOWERMENT; MICROFINANCE; IMPACT
AB Despite the recognized need for structural HIV prevention interventions, few scientific programs have integrated women's property and inheritance rights with HIV prevention and treatment. The current study focused on a community-led land and property rights intervention that was implemented in two rural areas of Western Kenya with high HIV prevalence rates (24-30%). The program was designed to respond to women's property rights violations in order to reduce HIV risk at the local level. Through in-depth interviews with twenty program leaders, we identified several facilitators to program implementation, including the leadership of home-based HIV caregivers and involvement of traditional leaders in mediating property rights disputes. We also identified the voluntary basis of the intervention and its lack of integration with the formal justice system as implementation barriers. Our findings can guide future research and design of structural HIV prevention strategies that integrate women's economic empowerment through property and inheritance rights.
C1 [Lu, Tiffany] Massachusetts Gen Hosp, Dept Med, Residency Training Program, Boston, MA 02114 USA.
[Zwicker, Lindsey] Univ Calif San Francisco, San Francisco Sch Med, Bixby Ctr Reprod Hlth, San Francisco, CA 94143 USA.
[Kwena, Zachary; Bukusi, Elizabeth] Kenya Govt Med Res Ctr, Ctr Microbiol Res, Nairobi, Kenya.
[Mwaura-Muiru, Esther] GROOTS Kenya, Nairobi, Kenya.
[Dworkin, Shari L.] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA.
RP Lu, T (reprint author), Massachusetts Gen Hosp, Dept Med, Residency Training Program, 15 Parkman St,WAC-615, Boston, MA 02114 USA.
EM TLu4@partners.org
FU NIAID NIH HHS [P30 AI027763]
NR 30
TC 5
Z9 5
U1 2
U2 7
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0899-9546
J9 AIDS EDUC PREV
JI Aids Educ. Prev.
PD APR
PY 2013
VL 25
IS 2
BP 151
EP 163
PG 13
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA 116ZO
UT WOS:000316922100006
PM 23514082
ER
PT J
AU Chakrabarti, AK
Feeney, K
Abueg, C
Brown, DA
Czyz, E
Tendera, M
Janosi, A
Giugliano, RP
Kloner, RA
Weaver, WD
Bode, C
Godlewski, J
Merkely, B
Gibson, CM
AF Chakrabarti, Anjan K.
Feeney, Kristin
Abueg, Cassandra
Brown, David A.
Czyz, Ewa
Tendera, Michal
Andras Janosi
Giugliano, Robert P.
Kloner, Robert A.
Weaver, W. Douglas
Bode, Christoph
Godlewski, Jacek
Bela Merkely
Gibson, C. Michael
TI Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized,
double-blind, placebo-controlled trial to evaluate the safety,
tolerability and efficacy of intravenous Bendavia on reperfusion injury
in patients treated with standard therapy including primary percutaneous
coronary intervention and stenting for ST-segment elevation myocardial
infarction
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID PREVENTS MITOCHONDRIAL DEPOLARIZATION; NO-REFLOW PHENOMENON; APOPTOSIS;
PEPTIDES; SALVAGE; IMPACT; TIME
AB Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion.
Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid-left anterior descending artery undergoing primary percutaneous coronary intervention (PCI) within 4 hours of symptom onset. Patients will be randomized to receive either Bendavia at 0.05 mg/kg per hour or an identically appearing placebo administered as an intravenous infusion at 60 mL/h. The primary end point is infarct size measured by the area under the creatine kinase-MB enzyme curve calculated from measurements from the central clinical chemistry laboratory obtained over the initial 72 hours after the primary PCI procedure, and the major secondary end point is infarct size calculated by the volume of infarcted myocardium (late contrast gadolinium enhancement) on the day 4 +/- 1 cardiac magnetic resonance imaging.
Summary EMBRACE-STEMI is testing the hypothesis that Bendavia, in conjunction with standard-of-care therapy, is superior to placebo for the reduction of myocardial infarction size among patients with first time, acute, anterior wall STEMI who undergo successful reperfusion with primary PCI and stenting. (Am Heart J 2013;165:509-514.e7.)
C1 [Chakrabarti, Anjan K.; Feeney, Kristin; Abueg, Cassandra; Gibson, C. Michael] Harvard Univ, Sch Med, Dept Med,PERFUSE Study Grp, Cardiovasc Div,Beth Israel Deaconess Med, Boston, MA USA.
[Brown, David A.] E Carolina Univ, Dept Physiol, Brody Sch Med, Greenville, NC USA.
[Czyz, Ewa] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Cardiol & Angiol, D-55122 Mainz, Germany.
[Tendera, Michal] Med Univ Silesia, Cardiol Div, Katowice, Poland.
[Andras Janosi] Gottsegen Gyorgy Natl Inst Cardiol, Budapest, Hungary.
[Giugliano, Robert P.] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp,Dept Med,Med Sch, Boston, MA 02115 USA.
[Kloner, Robert A.] Univ So Calif, Good Samaritan Hosp, Inst Heart, Los Angeles, CA USA.
[Kloner, Robert A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Weaver, W. Douglas] Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA.
[Bode, Christoph] Tech Univ Bergakad Freiberg, Ctr Heart, D-09596 Freiberg, Germany.
[Godlewski, Jacek] Jagiellonian Univ, Inst Cardiol, Sch Med, Krakow, Poland.
[Bela Merkely] Semmelweis Univ, Ctr Heart, H-1085 Budapest, Hungary.
RP Gibson, CM (reprint author), Beth Israel Deaconess Med Ctr, 185 Pilgrim Rd,Deaconess 319, Boston, MA 02215 USA.
EM mgibson@perfuse.org
FU Stealth Peptides Inc.
FX The EMBRACE-STEMI trial is supported by Stealth Peptides Inc. The
authors are solely responsible for all study analyses, the drafting and
editing of the manuscript, and its final contents.
NR 39
TC 40
Z9 42
U1 0
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD APR
PY 2013
VL 165
IS 4
BP 509
EP +
DI 10.1016/j.ahj.2012.12.008
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 120PV
UT WOS:000317184300011
PM 23537966
ER
PT J
AU Vedantham, S
Goldhaber, SZ
Kahn, SR
Julian, J
Magnuson, E
Jaff, MR
Murphy, TP
Cohen, DJ
Comerota, AJ
Gornik, HL
Razavi, MK
Lewis, L
Kearon, C
AF Vedantham, Suresh
Goldhaber, Samuel Z.
Kahn, Susan R.
Julian, Jim
Magnuson, Elizabeth
Jaff, Michael R.
Murphy, Timothy P.
Cohen, David J.
Comerota, Anthony J.
Gornik, Heather L.
Razavi, Mahmood K.
Lewis, Lawrence
Kearon, Clive
TI Rationale and design of the ATTRACT Study: A multicenter randomized
trial to evaluate pharmacomechanical catheter-directed thrombolysis for
the prevention of postthrombotic syndrome in patients with proximal deep
vein thrombosis
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID QUALITY-OF-LIFE; VENOUS THROMBOSIS; DETERMINANTS; SEVERITY; DISEASE;
HEPARIN; BURDEN; STREPTOKINASE; DEFINITION; VILLALTA
AB Background Current standard therapy for patients with acute proximal deep vein thrombosis (DVT) consists of anticoagulant therapy and graduated elastic compression stockings. Despite use of this strategy, the postthrombotic syndrome (PTS) develops frequently, causes substantial patient disability, and impairs quality of life. Pharmacomechanical catheter-directed thrombolysis (PCDT), which rapidly removes acute venous thrombus, may reduce the frequency of PTS. However, this hypothesis has not been tested in a large multicenter randomized trial.
Study design The ATTRACT Study is an ongoing National Institutes of Health-sponsored, Phase III, multicenter, randomized, open-label, assessor-blinded, parallel two-arm, controlled clinical trial. Approximately 692 patients with acute proximal DVT involving the femoral, common femoral, and/or iliac vein are being randomized to receive PCDT + standard therapy versus standard therapy alone. The primary study hypothesis is that PCDT will reduce the proportion of patients who develop PTS within 2 years by one-third, assessed using the Villalta Scale. Secondary outcomes include safety, general and venous disease-specific quality of life, relief of early pain and swelling, and cost-effectiveness.
Conclusion ATTRACT will determine if PCDT should be routinely used to prevent PTS in patients with symptomatic proximal DVT above the popliteal vein. (Am Heart J 2013;165:523-530.e3.)
C1 [Vedantham, Suresh] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63130 USA.
[Goldhaber, Samuel Z.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Kahn, Susan R.] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada.
[Julian, Jim; Kearon, Clive] McMaster Univ, Hamilton, ON, Canada.
[Magnuson, Elizabeth; Cohen, David J.] Univ Missouri Kansas City, St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Jaff, Michael R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Murphy, Timothy P.] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA.
[Comerota, Anthony J.] Univ Michigan, Toledo, OH USA.
[Gornik, Heather L.] Cleveland Clin, Inst Heart & Vasc, Cleveland, OH 44106 USA.
[Razavi, Mahmood K.] St Josephs Vasc Inst, Orange, CA USA.
[Lewis, Lawrence] Washington Univ, Sch Med, St Louis, MO USA.
RP Vedantham, S (reprint author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, 510 S Kingshighway Blvd,Box 8131, St Louis, MO 63130 USA.
EM vedanthams@mir.wustl.edu
FU National Heart, Lung, and Blood Institute (NIH) [U01-HL088476,
U01-HL088118]; Bayer Healthcare; BSN Medical; Covidien; Genentech
FX The ATTRACT Study is supported by awards U01-HL088476 and U01-HL088118
from the National Heart, Lung, and Blood Institute (NIH). The contents
of this article are solely the responsibility of the authors and do not
represent the official views of the National Heart, Lung, and Blood
Institute or NIH. Additional support for the study was provided by Bayer
Healthcare, BSN Medical, Covidien, and Genentech. The authors wish to
recognize the Society of Interventional Radiology Foundation, including
Drs Stephen Kee and John Rundback, for its support for the planning and
conduct of the ATTRACT Study.
NR 30
TC 50
Z9 53
U1 1
U2 10
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD APR
PY 2013
VL 165
IS 4
BP 523
EP +
DI 10.1016/j.ahj.2013.01.024
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 120PV
UT WOS:000317184300013
PM 23537968
ER
PT J
AU Bui, AL
Grau-Sepulveda, MV
Hernandez, AF
Peterson, ED
Yancy, CW
Bhatt, DL
Fonarow, GC
AF Bui, Anh L.
Grau-Sepulveda, Maria V.
Hernandez, Adrian F.
Peterson, Eric D.
Yancy, Clyde W.
Bhatt, Deepak L.
Fonarow, Gregg C.
TI Admission heart rate and in-hospital outcomes in patients hospitalized
for heart failure in sinus rhythm and in atrial fibrillation
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; GUIDELINES PROGRAM;
PREDICTIVE VALUE; RISK-FACTOR; MORTALITY; ASSOCIATION; TRIAL
AB Background Prior studies have suggested an association between higher heart rate and higher mortality, particularly in chronic heart failure (HF). Whether this relationship holds true in patients hospitalized with HF and differs between patients in sinus rhythm (SR) and atrial fibrillation (AF) has not been well studied.
Methods We examined 145,221 admissions for HF from 295 hospitals enrolled in Get With The Guidelines-Heart Failure from January 2005 through September 2011. The associations of admission heart rate with in-hospital outcomes were evaluated overall and by heart rhythm.
Results Patients presenting at higher heart rate tended to be younger and have less comorbidities. In-hospital mortality had a J-shaped relationship with heart rate, with the lowest mortality rate associated with heart rates between 70 and 75. However, the relationship differed between patients presenting in SR and AF: at heart rates above 100, the mortality curve for AF plateaued, whereas that for SR continued to rise. Higher heart rate was independently associated with higher mortality (SR adjusted OR 1.21, 95% CI 1.15-1.28 per 10 beat per minute increase in heart rate between 70-105; AF adjusted OR 1.20, 95% CI 1.14-1.27). Findings were similar when stratifying patients by ischemic etiology, diabetes, ejection fraction, blood pressure, and beta-blocker use.
Conclusions Higher admission heart rate is independently associated with worse outcomes in patients admitted for HF, including those in SR and AF. Whether early heart rate reduction improves outcomes in patients hospitalized with HF is worthy of investigation. (Am Heart J 2013;165:567-574.e6.)
C1 [Bui, Anh L.] Kaiser Permanente Med Ctr, Dept Cardiol, Los Angeles, CA 90034 USA.
[Grau-Sepulveda, Maria V.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Univ, Duke Clin Res Inst, Durham, NC USA.
[Yancy, Clyde W.] Northwestern Univ, Sch Med, Div Cardiol, Chicago, IL USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Fonarow, Gregg C.] Ahmanson UCLA Cardiomyopathy Ctr, UCLA Med Ctr, Los Angeles, CA 90095 USA.
RP Fonarow, GC (reprint author), Ahmanson UCLA Cardiomyopathy Ctr, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM gfonarow@mednet.ucla.edu
RI Hernandez, Adrian F./A-7818-2016
OI Hernandez, Adrian F./0000-0003-3387-9616
FU Medtronic; GlaxoSmithKline; Ortho-McNeil; American Heart Association
Pharmaceutical Roundtable
FX The GWTG-HF program is provided by the American Heart Association.
GWTG-HF has been funded in the past through support from Medtronic,
GlaxoSmithKline, Ortho-McNeil, and the American Heart Association
Pharmaceutical Roundtable.
NR 25
TC 13
Z9 15
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD APR
PY 2013
VL 165
IS 4
BP 567
EP +
DI 10.1016/j.ahj.2013.01.007
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 120PV
UT WOS:000317184300019
PM 23537974
ER
PT J
AU Soni, RK
Palevsky, PM
AF Soni, Ritu K.
Palevsky, Paul M.
TI THE SMARTPHONE IN NEPHROLOGY: PRELIMINARY SURVEY ON CURRENT TRENDS AND
PERCEIVED NEEDS
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Meeting Abstract
CT International Conference on Glomerular Diseases
CY APR 27, 2012
CL Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens, Great Neck, NY
SP N Shore LIJ Hlth Syst, Natl Kidney Fdn
HO Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens
C1 Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA.
VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD APR
PY 2013
VL 61
IS 4
MA 302
BP A91
EP A91
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 121WG
UT WOS:000317274900304
ER
PT J
AU Chang, TI
Li, SY
Chen, SC
Peralta, CA
Shlipak, MG
Fried, LF
Whaley-Connell, AT
McCullough, PA
Tamura, MK
AF Chang, Tara I.
Li, Suying
Chen, Shu-Cheng
Peralta, Carmen A.
Shlipak, Michael G.
Fried, Linda F.
Whaley-Connell, Adam T.
McCullough, Peter A.
Tamura, Manjula Kurella
CA KEEP Investigators
TI Risk Factors for ESRD in Individuals With Preserved Estimated GFR With
and Without Albuminuria: Results From the Kidney Early Evaluation
Program (KEEP)
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Albuminuria; blood pressure; chronic kidney disease; diabetes; dialysis
risk factors; end-stage renal disease; public health.
ID STAGE RENAL-DISEASE; BLOOD-PRESSURE CONTROL; GLOMERULAR-FILTRATION-RATE;
COMPETING RISK; PROGRESSION; PROTEINURIA; FAILURE; TRIAL; NEPHROPATHY;
POPULATION
AB Background: Given the increasing costs and poor outcomes of end-stage renal disease (ESRD), we sought to identify risk factors for ESRD in people with preserved estimated glomerular filtration rate (eGFR), with or without albuminuria, who were at high risk of ESRD.
Methods: This cohort study included participants in the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) with eGFR >= 60 mL/min/1.73 m(2) at baseline stratified by the presence or absence of albuminuria. The Chronic Kidney Disease Epidemiology Collaboration equation was used to calculate eGFR. Urine was tested for albuminuria by semiquantitative dipstick. The outcome was the development of treated chronic kidney failure, defined as initiation of maintenance dialysis therapy or kidney transplantation, determined by linkage to the US Renal Data System. We used a Cox model with the Fine-Gray method to assess risk factors for treated chronic kidney failure while accounting for the competing risk of death.
Results: During a median follow-up of 4.8 years, 126 of 13,923 participants with albuminuria (16/10,000 patient-years) and 56 of 109,135 participants without albuminuria (1.1/10,000 patient-years) developed treated chronic kidney failure. Diabetes was a strong risk factor for developing treated chronic kidney failure in participants with and without albuminuria (adjusted HRs of 9.3 [95% CI, 5.7-15.3] and 7.8 [95% CI, 4.1-14.8], respectively). Black race, lower eGFR, and higher systolic blood pressure also were associated with higher adjusted risks of developing treated chronic kidney failure.
Conclusions: In a diverse high-risk cohort of KEEP participants with preserved eGFR, we showed that diabetes, higher systolic blood pressure, lower eGFR, and black race were risk factors for developing treated chronic kidney failure irrespective of albuminuria status, although the absolute risk of kidney failure in participants without albuminuria was very low. Our findings support testing for kidney disease in high-risk populations, which often have otherwise unrecognized kidney disease. Am J Kidney Dis. 61(4)(S2): S4-S11. (C) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Chang, Tara I.; Tamura, Manjula Kurella] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Palo Alto, CA 94304 USA.
[Li, Suying; Chen, Shu-Cheng] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA.
[Peralta, Carmen A.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Whaley-Connell, Adam T.] Harry S Truman Mem Vet Hosp, Res Serv, Columbia, MO 65201 USA.
[Whaley-Connell, Adam T.] Univ Missouri, Columbia Sch Med, Div Nephrol & Hypertens, Columbia, MO USA.
[McCullough, Peter A.] St John Providence Hlth Syst, Providence Pk Heart Inst, Novi, MI USA.
RP Chang, TI (reprint author), Stanford Univ, Sch Med, Div Nephrol, 777 Welch Rd,Ste DE,Rm D100, Palo Alto, CA 94304 USA.
EM tichang@stanford.edu
RI Kurella Tamura, Manjula/C-8284-2014;
OI Kurella Tamura, Manjula/0000-0001-5227-2479; Whaley-Connell,
Adam/0000-0001-8955-5560
FU National Kidney Foundation Inc; Abbott; Amgen; LifeScan; Siemens;
Genentech; GMFoundation; Nephroceuticals; Pfizer; American Heart
Association National Scientist Development Grant [12SDG11670032]; T.
FranklinWilliams Scholarship Award [CDA-2 BB47, AG040638]; Atlantic
Philanthropies Inc; John A. Hartford Foundation; ASP; ASN; Novartis
Corp.
FX KEEP is a program of the National Kidney Foundation Inc and is supported
by Abbott, Amgen, LifeScan, Siemens, Genentech, GMFoundation,
Nephroceuticals, and Pfizer. Dr Chang is supported by an American Heart
Association National Scientist Development Grant (12SDG11670032).
Department of Veterans Affairs CDA-2 BB47, National Institutes of Health
AG040638, and the American Society of Nephrology- Association of
Specialty Professors (ASN-ASP) Development Grant in Geriatric Nephrology
to Dr Whaley-Connell are supported by a T. FranklinWilliams Scholarship
Award, funding provided by Atlantic Philanthropies Inc, the John A.
Hartford Foundation, the ASP, and the ASN. This research was also
supported by Novartis Corp.
NR 30
TC 17
Z9 17
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD APR
PY 2013
VL 61
IS 4
SU 2
BP S4
EP S11
DI 10.1053/j.ajkd.2012.12.016
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 121US
UT WOS:000317270600002
PM 23507268
ER
PT J
AU Birdsall, HH
AF Birdsall, Holly H.
TI Women as Leaders and Investigators in VA Research
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Birdsall, Holly H.] US Dept Vet Affairs, Washington, DC USA.
[Birdsall, Holly H.] Baylor Coll Med, Houston, TX 77030 USA.
RP Birdsall, HH (reprint author), US Dept Vet Affairs, Washington, DC USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD APR
PY 2013
VL 126
IS 4
BP E9
EP E9
DI 10.1016/j.amjmed.2012.08.022
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 115IR
UT WOS:000316806300004
PM 23507219
ER
PT J
AU McCarren, M
Goldman, S
AF McCarren, Madeline
Goldman, Steven
TI Women as Leaders and Investigators in VA Research Reply
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Letter
C1 [McCarren, Madeline] US Dept Vet Affairs, Pharm Benefits Management Serv 10P4P, Hines, IL USA.
[Goldman, Steven] US Dept Vet Affairs, Southern Arizona VA Healthcare Syst 111C, Tucson, AZ USA.
RP McCarren, M (reprint author), US Dept Vet Affairs, Pharm Benefits Management Serv 10P4P, Hines, IL USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD APR
PY 2013
VL 126
IS 4
BP E11
EP E11
DI 10.1016/j.amjmed.2012.09.007
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 115IR
UT WOS:000316806300005
PM 23507209
ER
PT J
AU Masuzawa, A
Black, KM
Pacak, CA
Ericsson, M
Barnett, RJ
Drumm, C
Seth, P
Bloch, DB
Levitsky, S
Cowan, DB
McCully, JD
AF Masuzawa, Akihiro
Black, Kendra M.
Pacak, Christina A.
Ericsson, Maria
Barnett, Reanne J.
Drumm, Ciara
Seth, Pankaj
Bloch, Donald B.
Levitsky, Sidney
Cowan, Douglas B.
McCully, James D.
TI Transplantation of autologously derived mitochondria protects the heart
from ischemia-reperfusion injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE cardioprotection; ischemia; mitochondria; myocardial infarction
ID PROTEOMIC ANALYSIS; STROMAL CELLS; RABBIT HEART; STEM-CELLS;
CARDIOPROTECTION; CARDIOPLEGIA; RESPIRATION; SKELETAL; MYOCARDIUM;
DYSTROPHIN
AB Masuzawa A, Black KM, Pacak CA, Ericsson M, Barnett RJ, Drumm C, Seth P, Bloch DB, Levitsky S, Cowan DB, McCully JD. Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 304: H966-H982, 2013. First published January 25, 2013; doi:10.1152/ajpheart.00883.2012.-Mitochondrial damage and dysfunction occur during ischemia and modulate cardiac function and cell survival significantly during reperfusion. We hypothesized that transplantation of autologously derived mitochondria immediately prior to reperfusion would ameliorate these effects. New Zealand White rabbits were used for regional ischemia (RI), which was achieved by temporarily snaring the left anterior descending artery for 30 min. Following 29 min of RI, autologously derived mitochondria (RI-mitochondria; 9.7 +/- 1.7 x 10(6)/ml) or vehicle alone (RI-vehicle) were injected directly into the RI zone, and the hearts were allowed to recover for 4 wk. Mitochondrial transplantation decreased (P < 0.05) creatine kinase MB, cardiac troponin-I, and apoptosis significantly in the RI zone. Infarct size following 4 wk of recovery was decreased significantly in RI-mitochondria (7.9 +/- 2.9%) compared with RI-vehicle (34.2 +/- 3.3%, P < 0.05). Serial echocardiograms showed that RI-mitochondria hearts returned to normal contraction within 10 min after reperfusion was started; however, RI-vehicle hearts showed persistent hypokinesia in the RI zone at 4 wk of recovery. Electrocardiogram and optical mapping studies showed that no arrhythmia was associated with autologously derived mitochondrial transplantation. In vivo and in vitro studies show that the transplanted mitochondria are evident in the interstitial spaces and are internalized by cardiomyocytes 2-8 h after transplantation. The transplanted mitochondria enhanced oxygen consumption, high-energy phosphate synthesis, and the induction of cytokine mediators and proteomic pathways that are important in preserving myocardial energetics, cell viability, and enhanced post-infarct cardiac function. Transplantation of autologously derived mitochondria provides a novel technique to protect the heart from ischemia-reperfusion injury.
C1 [Masuzawa, Akihiro; Black, Kendra M.; Barnett, Reanne J.; Drumm, Ciara; Levitsky, Sidney; McCully, James D.] Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, Dept Surg, Boston, MA 02215 USA.
[Masuzawa, Akihiro; Black, Kendra M.; Pacak, Christina A.; Barnett, Reanne J.; Drumm, Ciara; Seth, Pankaj; Bloch, Donald B.; Levitsky, Sidney; Cowan, Douglas B.; McCully, James D.] Harvard Univ, Sch Med, Boston, MA USA.
[Pacak, Christina A.; Cowan, Douglas B.] Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
[Ericsson, Maria] Harvard Univ, Sch Med, Electron Microscopy Facil, Dept Cell Biol, Boston, MA USA.
[Seth, Pankaj] Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, Dept Med, Boston, MA 02215 USA.
[Bloch, Donald B.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
[Bloch, Donald B.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
RP McCully, JD (reprint author), Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, 330 Brookline Ave,DA 0734, Boston, MA 02215 USA.
EM james_mccully@hms.harvard.edu
FU National Heart, Lung, and Blood Institute [HL-103642, HL-088206]
FX This study was supported by National Heart, Lung, and Blood Institute
Grants HL-103642 and HL-088206.
NR 42
TC 29
Z9 30
U1 1
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD APR
PY 2013
VL 304
IS 7
BP H966
EP H982
DI 10.1152/ajpheart.00883.2012
PG 17
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 118DH
UT WOS:000317002500007
PM 23355340
ER
PT J
AU Thompson, BT
Matthay, MA
AF Thompson, B. Taylor
Matthay, Michael A.
TI The Berlin Definition of ARDS versus Pathological Evidence of Diffuse
Alveolar Damage
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; END-EXPIRATORY
PRESSURE; CLINICAL-TRIAL; VENTILATION
C1 [Thompson, B. Taylor] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Matthay, Michael A.] Univ San Francisco, Cardiovasc Res Inst, San Francisco, CA 94117 USA.
RP Thompson, BT (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
FU NHLBI NIH HHS [R37 HL051856]
NR 15
TC 25
Z9 27
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD APR 1
PY 2013
VL 187
IS 7
BP 675
EP 677
DI 10.1164/rccm.201302-0385ED
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 122KE
UT WOS:000317316200006
PM 23540876
ER
PT J
AU Bogoch, II
Andrews, JR
Speich, B
Utzinger, J
Ame, SM
Ali, SM
Keiser, J
AF Bogoch, Isaac I.
Andrews, Jason R.
Speich, Benjamin
Utzinger, Juerg
Ame, Shaali M.
Ali, Said M.
Keiser, Jennifer
TI Short Report: Mobile Phone Microscopy for the Diagnosis of
Soil-Transmitted Helminth Infections: A Proof-of-Concept Study
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID NEGLECTED TROPICAL DISEASES; EFFICACY
AB We created a mobile phone microscope and assessed its accuracy for the diagnosis of soil-transmitted helminths compared with conventional microscopy. Mobile phone microscopy has a sensitivity of 69.4% for detecting any helminth egg and sensitivities of 81.0%, 54.4%, and 14.3% for the diagnosis of Ascaris lumbricoides, Trichuris trichiura and hookworm respectively.
C1 [Bogoch, Isaac I.] Toronto Gen Hosp, Div Internal Med, Toronto, ON M5G 2C4, Canada.
[Bogoch, Isaac I.] Toronto Gen Hosp, Div Infect Dis, Toronto, ON M5G 2C4, Canada.
[Andrews, Jason R.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Speich, Benjamin; Keiser, Jennifer] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, Basel, Switzerland.
[Speich, Benjamin; Utzinger, Juerg; Keiser, Jennifer] Univ Basel, Basel, Switzerland.
[Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland.
[Ame, Shaali M.; Ali, Said M.] Publ Hlth Lab, Pemba Isl, Zanzibar, Tanzania.
RP Bogoch, II (reprint author), Toronto Gen Hosp, 14EN-209,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
EM isaac.bogoch@uhn.ca; jandrews6@partners.org; benjamin.speich@unibas.ch;
juerg.utzinger@unibas.ch; shaaliame@yahoo.com; saidmali2003@yahoo.com;
jennifer.keiser@unibas.ch
FU Medicor Foundation; Swiss National Science Foundation (SNSF)
[PPOOA-114941, PPOOP3_135170]
FX This work was supported by The Medicor Foundation. J.K. is financially
supported by the Swiss National Science Foundation (SNSF; projects
PPOOA-114941 and PPOOP3_135170).
NR 19
TC 41
Z9 42
U1 0
U2 13
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD APR
PY 2013
VL 88
IS 4
BP 626
EP 629
DI 10.4269/ajtmh.12-0742
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 118KP
UT WOS:000317024700005
PM 23478580
ER
PT J
AU Leung, DT
Das, SK
Malek, MA
Ahmed, D
Khanam, F
Qadri, F
Faruque, ASG
Ryan, ET
AF Leung, Daniel T.
Das, Sumon K.
Malek, M. A.
Ahmed, Dilruba
Khanam, Farhana
Qadri, Firdausi
Faruque, A. S. G.
Ryan, Edward T.
TI Non-Typhoidal Salmonella Gastroenteritis at a Diarrheal Hospital in
Dhaka, Bangladesh, 1996-2011
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ANTIMICROBIAL RESISTANCE; CHILDHOOD DIARRHEA; ASIAN COUNTRIES;
INFECTIONS; CHILDREN; DISEASE; SURVEILLANCE; BACTEREMIA; AFRICA;
ENTEROPATHOGENS
AB Data on non-typhoidal Salmonella (NTS) infection in South Asia are limited. We used data gathered prospectively from 1996 to 2011 as part of a hospital surveillance system in Dhaka, Bangladesh, to identify diarrheal patients with NTS isolated from stool. NTS was isolated in 1.3% (468 of 37,439) of diarrheal patients; 47% of total cases of NTS were in children <5 years of age, although older adults (>= 60 years) had the highest isolation rates. NTS isolation peaked in the monsoon months of July and August. Over the study period, rates of multidrug resistance decreased, whereas rates of decreased susceptibility to ciprofloxacin increased. Compared with control patients, NTS patients were older and wealthier; however, no differences in type of housing or exposure to animals were found. NTS patients had increased inflammatory cells in stool and required more fluid resuscitation.
C1 [Leung, Daniel T.; Khanam, Farhana; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, Bangladesh ICDDR B, Dhaka 1000, Bangladesh.
[Das, Sumon K.; Malek, M. A.; Faruque, A. S. G.] Int Ctr Diarrhoeal Dis Res, Ctr Nutr & Food Secur, Bangladesh ICDDR B, Dhaka 1000, Bangladesh.
[Ahmed, Dilruba] Int Ctr Diarrhoeal Dis Res, Clin Microbiol Lab, Bangladesh ICDDR B, Dhaka 1000, Bangladesh.
[Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Leung, DT (reprint author), Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, Bangladesh ICDDR B, GPO Box 128, Dhaka 1000, Bangladesh.
EM dleung@icddrb.org; sumon@icddrb.org; mamalek@icddrli.org;
dahmed@icddrb.org; farhanak@icddrb.org; fqadri@icddrb.org;
gfaruque@icddrb.org; etryan@partners.org
OI leung, daniel/0000-0001-8401-0801
FU ICDDR,B; National Institutes of Health; National Institutes of Health,
National Institute of Allergy and Infectious Diseases [AI100923,
AI100023, AI077883]; National Institutes of Health, Fogarty
International Center [TW005572]; American Society of Tropical Medicine
and Hygiene/Burroughs Wellcome Fund
FX This work was supported by the ICDDR,B and its donors, which provide
Unrestricted support to ICDDR,B for its operations and research. Current
donors providing unrestricted support include the Australian Agency for
'International Development (AusAID), the Government of the People's
Republic of Bangladesh, the Canadian International Development Agency
(CIDA), the Swedish International Development Cooperation Agency (Sida),
and the Department for International Development, United Kingdom (DFID).
This study was also supported by grants from the National Institutes of
Health, including National Institute of Allergy and Infectious Diseases
Grants AI100923 (to D.T.L), AI100023 (to E.T.R.), and AI077883 (to
E.T.R.) and Fogarty International Center Grant TW005572 (to F.K., F.Q.,
and E.T.R.), and a Postdoctoral Fellowship in Tropical Infectious
Diseases from the American Society of Tropical Medicine and
Hygiene/Burroughs Wellcome Fund (to D.T.L.).
NR 39
TC 6
Z9 7
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD APR
PY 2013
VL 88
IS 4
BP 661
EP 669
DI 10.4269/ajtmh.12-0672
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 118KP
UT WOS:000317024700010
PM 23358644
ER
PT J
AU Cserti-Gazdewich, CM
Dhabangi, A
Musoke, C
Ssewanyana, I
Ddungu, H
Nakiboneka-Ssenabulya, D
Nabukeera-Barungi, N
Mpimbaza, A
Dzik, WH
AF Cserti-Gazdewich, Christine M.
Dhabangi, Aggrey
Musoke, Charles
Ssewanyana, Isaac
Ddungu, Henry
Nakiboneka-Ssenabulya, Deborah
Nabukeera-Barungi, Nicolette
Mpimbaza, Arthur
Dzik, Walter H.
TI Inter-Relationships of Cardinal Features and Outcomes of Symptomatic
Pediatric Plasmodium falciparum Malaria in 1,933 Children in Kampala,
Uganda
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID LIFE-THREATENING MALARIA; AFRICAN CHILDREN; CEREBRAL MALARIA; INFECTED
ERYTHROCYTES; CLINICAL-FEATURES; CHILDHOOD MALARIA; ENDOTHELIAL-CELLS;
GABONESE CHILDREN; PROGNOSTIC VALUE; LACTIC-ACIDOSIS
AB Malaria remains a challenging diagnosis with variable clinical presentation and a wide spectrum of disease severity. Using a structured case report form, we prospectively assessed 1,933 children at Mulago Hospital in Kampala, Uganda with acute Plasmodium falciparum malaria. Children with uncomplicated malaria significantly differed from those with severe disease for 17 features. Among 855 children with severe disease, the case-fatality rate increased as the number of severity features increased. Logistic regression identified five factors independently associated with death: cerebral malaria, hypoxia, severe thrombocytopenia, leukocytosis, and lactic acidosis. Cluster analysis identified two groups: one combining anemia, splenomegaly, and leukocytosis; and a second group centered on death, severe thrombocytopenia, and lactic acidosis, which included cerebral malaria, hypoxia, hypoglycemia, and hyper-parasitemia. Our report updates previous clinical descriptions of severe malaria, quantifies significant clinical and laboratory interrelationships, and will assist clinicians treating malaria and those planning or assessing future research (NCT00707200) (www.clinicaltrials.gov).
C1 Univ Toronto, Univ Hlth Network, Toronto, ON, Canada.
[Musoke, Charles; Nabukeera-Barungi, Nicolette] Makerere Univ, Coll Hlth Sci, Mulago Hosp, Dept Paediat & Child Hlth, Kampala, Uganda.
Joint Clin Res Ctr, Kampala, Uganda.
[Ddungu, Henry] Uganda Canc Inst, Kampala, Uganda.
[Ddungu, Henry] African Palliat Care Assoc, Kampala, Uganda.
[Dzik, Walter H.] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Blood Transfus Serv, Boston, MA 02114 USA.
[Cserti-Gazdewich, Christine M.] Toronto Gen Hosp, Univ Hlth Network, Dept Lab Hematol, Blood Transfus Med Lab, Toronto, ON, Canada.
[Cserti-Gazdewich, Christine M.] Toronto Gen Hosp, Univ Hlth Network, Dept Med & Hematol, Toronto, ON, Canada.
[Dhabangi, Aggrey] Child Hlth & Dev Ctr, Kampala, Uganda.
[Ssewanyana, Isaac] Cent Publ Hlth Labs, Kampala, Uganda.
[Nakiboneka-Ssenabulya, Deborah] London Sch Hyg & Trop Med, London WC1, England.
[Mpimbaza, Arthur] Makerere Univ, Coll Hlth Sci, Child Hlth & Dev Ctr, Mulago Hosp, Kampala, Uganda.
RP Dzik, WH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Blood Transfus Serv, J224,55 Fruit St, Boston, MA 02114 USA.
EM christine.cserti@uhn.ca; adhabangi@gmail.com; jxyug@yahoo.com;
sewyisaac@yahoo.co.uk; hddungu@gmail.com; debsenabulya@yahoo.com;
nicbarungi@yahoo.com; arthurwakg@yahoo.com; sdzik@partners.org
FU International Society of Blood Transfusion; National Blood Foundation;
University of Toronto Dean's Fund; Evelyn and Robert Luick Fund
FX This study was supported by the International Society of Blood
Transfusion, the National Blood Foundation, the University of Toronto
Dean's Fund, and the Evelyn and Robert Luick Fund.
NR 37
TC 9
Z9 9
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD APR
PY 2013
VL 88
IS 4
BP 747
EP 756
DI 10.4269/ajtmh.12-0668
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 118KP
UT WOS:000317024700025
PM 23358640
ER
PT J
AU Tsai, CL
Delclos, GL
Huang, JS
Hanania, NA
Camargo, CA
AF Tsai, Chu-Lin
Delclos, George L.
Huang, Jamie S.
Hanania, Nicola A.
Camargo, Carlos A., Jr.
TI Age-related differences in asthma outcomes in the United States,
1988-2006
SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
LA English
DT Article
ID SERUM 25-HYDROXYVITAMIN D; NUTRITION EXAMINATION SURVEY; 3RD
NATIONAL-HEALTH; OLDER US ADULTS; VITAMIN-D; NHANES-III; BRONCHODILATOR
RESPONSIVENESS; CANCER-MORTALITY; REFERENCE VALUES; LUNG-FUNCTION
AB Background: Relatively little is known about the effect of age on asthma outcomes in adults, particularly at a national level.
Objective: To investigate age-related differences in asthma outcomes in a nationally representative, longitudinal study.
Methods: We analyzed data from the Third National Health and Nutrition Examination Survey (1988-1994) with linked mortality files through 2006. Adults with physician-diagnosed asthma were identified and were divided into 2 age groups: younger adults (17-54 years of age) and older adults (55 years or older). The outcome measures were both cross-sectional (health care use, comorbidity, and lung function) and longitudinal (all-cause mortality).
Results: There were an estimated 9,566,000 adults with current asthma. Of these, 73% were younger adults and 27% older adults. Compared with younger adults, older adults had more hospitalizations in the past year, more comorbidities, and poorer lung function (eg, lower forced expiratory volume in 1 second) (P<.05 for all). During a median follow-up of 15 years, significant baseline predictors of higher all-cause mortality included older age (>= 55 vs <55 years old: adjusted hazard ratio [HR], 6.77; 95% confidence interval [CI], 3.15-14.54), poor health status (fair and poor vs excellent health status: adjusted HR, 10.07; 95% CI, 3.75-27.01), and vitamin D deficiency (vitamin D level <30 vs >= 50 nmol/L: adjusted HR,2.19; 95% CI, 1.05-4.58), whereas Mexican American ethnicity (adjusted HR, 0.31; 95% CI, 0.14-0.65) was associated with lower mortality. Controlling for age, asthma was not associated with increased all-cause mortality (adjusted HR, 1.28; 95% CI, 0.99-1.65).
Conclusion: Older adults with asthma have a substantial burden of morbidity and increased mortality. The ethnic differences in asthma mortality and the vitamin Demortality link merit further investigation. (C) 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
C1 [Tsai, Chu-Lin; Delclos, George L.; Huang, Jamie S.] Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
[Hanania, Nicola A.] Baylor Coll Med, Dept Med, Sect Pulm & Crit Care Med, Houston, TX 77030 USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Tsai, CL (reprint author), Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, 1200 Herman Pressler,Ste W610, Houston, TX 77030 USA.
EM cltsai@post.harvard.edu
OI TSAI, CHU-LIN/0000-0003-4639-1513
NR 45
TC 13
Z9 13
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1081-1206
J9 ANN ALLERG ASTHMA IM
JI Ann. Allergy Asthma Immunol.
PD APR
PY 2013
VL 110
IS 4
BP 240
EP +
DI 10.1016/j.anai.2013.01.002
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 121VY
UT WOS:000317274000006
PM 23535086
ER
PT J
AU Muniappan, A
Wain, JC
Wright, CD
Donahue, DM
Gaissert, H
Lanuti, M
Mathisen, DJ
AF Muniappan, Ashok
Wain, John C.
Wright, Cameron D.
Donahue, Dean M.
Gaissert, Henning
Lanuti, Michael
Mathisen, Douglas J.
TI Surgical Treatment of Nonmalignant Tracheoesophageal Fistula: A
Thirty-Five Year Experience
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID MANAGEMENT; REPAIR
AB Background. Acquired nonmalignant tracheoesophageal fistula in the adult patient develops in a variety of conditions. We have applied surgical closure with success for 35 years.
Methods. From 1975 to 1991, 38 patients underwent surgical repair of a tracheoesophageal fistula. A retrospective study of 36 additional patients undergoing surgical repair from 1992 to 2010 was conducted.
Results. The most common causes were postintubation injury (n = 17, 47%), trauma (n = 6, 17%), prior laryngectomy (n = 6,17%), and prior esophagectomy (n = 4,11%). Four patients presented after failing fistula control with an endoluminal stent. The tracheal defect was closed with resection and reconstruction (n = 17, 41%), laryngotracheal resection (n = 5, 12%), membranous tracheal repair (n = 17, 41%), or repair over a tracheal T tube (n = 2, 5%), while esophageal repair consisted of 2-layer closure (n. = 31, 78%), 1-layer closure (n = 6, 15%), esophagostomy (n = 1, 3%), end-to-end esophageal anastomosis (n = 1, 3%), or full thickness skin graft reconstruction (n = 1, 3%). The esophageal and tracheal repairs were buttressed by interposing pedicled muscle or omental flaps in all patients. There was 1 postoperative death (3%). Recurrence after repair developed only in fistulas arising after esophagectomy or laryngectomy (n = 4, 11%). Fistula closure was ultimately successful in 34 patients (94%). Twenty-nine patients (83%) resumed oral intake and 25 patients (71%) were breathing without a tracheal appliance.
Conclusions. Successful closure of benign tracheoesophageal fistula is achieved with several surgical techniques based on buttressed repair and restoration of normal breathing and swallowing. Closure of complex postsurgical fistula may fail. Endoluminal stenting was not found useful. (Ann Thorac Surg 2013;95:1141-6) (C) 2013 by The Society of Thoracic Surgeons
C1 [Muniappan, Ashok; Wain, John C.; Wright, Cameron D.; Donahue, Dean M.; Gaissert, Henning; Lanuti, Michael; Mathisen, Douglas J.] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA.
RP Muniappan, A (reprint author), Massachusetts Gen Hosp, Div Thorac Surg, Blake 1570,55 Fruit St, Boston, MA 02114 USA.
EM amuniappan@partners.org
NR 15
TC 18
Z9 18
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD APR
PY 2013
VL 95
IS 4
BP 1141
EP 1146
DI 10.1016/j.athoracsur.2012.07.041
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 120DI
UT WOS:000317150600001
PM 23000263
ER
PT J
AU Rankin, JS
He, X
O'Brien, SM
Jacobs, JP
Welke, KF
Filardo, G
Shahian, DM
AF Rankin, J. Scott
He, Xia
O'Brien, Sean M.
Jacobs, Jeffrey P.
Welke, Karl F.
Filardo, Giovanni
Shahian, David M.
TI The Society of Thoracic Surgeons Risk Model for Operative Mortality
After Multiple Valve Surgery
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID MITRAL-VALVE; ATRIAL-FIBRILLATION; CARDIAC DATABASE; REPAIR;
REPLACEMENT; REOPERATION; SURVIVAL; FAILURE; TRENDS
AB Background. This study was undertaken to develop The Society of Thoracic Surgeons (STS) mortality risk models for multiple valve procedures, which comprise 12% of total valve operations.
Methods. Data were obtained from the STS Adult Cardiac Surgery Database for 50,231 patients undergoing combinations of aortic (A), mitral (M), and tricuspid (T) surgery between January 1, 2004, and December 31, 2010, divided into developmental (2004 to 2009) and validation (2010) samples. Pulmonary valve operations, aortic root replacements, and dissection procedures were excluded, and insufficient AT procedures were available to model. Using stepwise logistic regression, the risk of operative mortality was estimated for each valve surgery type: AM, n = 27,035; MT, n = 18,686; and AMT, n = 4,510. Two separate models were estimated, one that included only patient characteristics and status at presentation, and thereby would be suitable for performance profiling; and another that added discretionary operative variables such as arrhythmia ablation or valve repair.
Results. Unadjusted operative mortality was 7.6% for MT, 9.4% for AM, and 13.1% for AMT procedures. Significant risk factors for mortality included emergency presentation, advanced age, renal failure, reoperation, endocarditis, diabetes mellitus, severe chronic lung disease, peripheral vascular disease, coronary artery disease, and female sex. In models containing intraoperative variables, performance of arrhythmia ablation and atrioventricular valve repair were protective for mortality. In the validation sample, the model exhibited acceptable discrimination in each of the three procedural subgroups (C = 0.711 to 0.727).
Conclusions. Risk models were developed to predict operative mortality for patients having multiple valve procedures. These models may be useful for outcome assessment, quality improvement, patient counseling, shared decision making, and research. (Ann Thorac Surg 2013;95:1484-90) (c) 2013 by The Society of Thoracic Surgeons
C1 Vanderbilt Univ, Centennial Med Ctr, Nashville, TN 37205 USA.
Duke Clin Res Inst, Durham, NC USA.
Univ S Florida, Congenital Heart Inst Florida, All Childrens Hosp, Tampa, FL USA.
Seattle Childrens Hosp, Seattle, WA USA.
Univ Washington, Sch Med, Seattle, WA USA.
Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, Dallas, TX USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Rankin, JS (reprint author), Vanderbilt Univ, 320 Lynnwood Blvd, Nashville, TN 37205 USA.
EM jsrankinmd@cs.com
RI O'Brien, Sean/H-6268-2013
NR 25
TC 16
Z9 17
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD APR
PY 2013
VL 95
IS 4
BP 1484
EP 1490
DI 10.1016/j.athoracsur.2012.11.077
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 120DI
UT WOS:000317150600062
PM 23522221
ER
PT J
AU Rosenberg, M
Noonan, S
DeGutis, J
Esterman, M
AF Rosenberg, Monica
Noonan, Sarah
DeGutis, Joseph
Esterman, Michael
TI Sustaining visual attention in the face of distraction: a novel
gradual-onset continuous performance task
SO ATTENTION PERCEPTION & PSYCHOPHYSICS
LA English
DT Article
DE Sustained attention; Attentional fluctuations; Inhibition; Vigilance
ID SELECTIVE ATTENTION; VIGILANCE DECREMENT; MINDFULNESS; VARIABILITY;
FAILURES; LAPSES; BRAIN; MINDLESSNESS; ADHD; MIND
AB Sustained attention is a fundamental aspect of human cognition and has been widely studied in applied and clinical contexts. Despite a growing understanding of how attention varies throughout task performance, moment-to-moment fluctuations are often difficult to assess. In order to better characterize fluctuations in sustained visual attention, in the present study we employed a novel continuous performance task (CPT), the gradual-onset CPT (gradCPT). In the gradCPT, a central face stimulus gradually transitions between individuals at a constant rate (1,200 ms), and participants are instructed to respond to each male face but not to a rare target female face. In the distractor-present version, the background distractors consist of scene images, and in the distractor-absent condition, of phase-scrambled scene images. The results confirmed that the gradCPT taxes sustained attention, as vigilance decrements were observed over the task's 12-min duration: Participants made more commission errors and showed increasingly variable response latencies (RTs) over time. Participants' attentional states also fluctuated from moment to moment, with periods of higher RT variability being associated with increased likelihood of errors and greater speed-accuracy trade-offs. In addition, task performance was related to self-reported mindfulness and the propensity for attention lapses in everyday life. The gradCPT is a useful tool for studying both low- and high-frequency fluctuations in sustained visual attention and is sensitive to individual differences in attentional ability.
C1 [Rosenberg, Monica; Noonan, Sarah; DeGutis, Joseph; Esterman, Michael] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Noonan, Sarah; Esterman, Michael] Boston Univ, Sch Med, Boston, MA 02118 USA.
[DeGutis, Joseph] Harvard Univ, Cambridge, MA 02138 USA.
RP Rosenberg, M (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave 182 JP, Boston, MA 02130 USA.
EM monica.rosenberg@yale.edu
OI Esterman, Michael/0000-0002-9000-3920
NR 73
TC 22
Z9 22
U1 2
U2 36
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1943-3921
J9 ATTEN PERCEPT PSYCHO
JI Atten. Percept. Psychophys.
PD APR
PY 2013
VL 75
IS 3
BP 426
EP 439
DI 10.3758/s13414-012-0413-x
PG 14
WC Psychology; Psychology, Experimental
SC Psychology
GA 122GQ
UT WOS:000317306800005
PM 23299180
ER
PT J
AU Schendan, HE
Tinaz, S
Maher, SM
Stern, CE
AF Schendan, Haline E.
Tinaz, Sule
Maher, Stephen M.
Stern, Chantal E.
TI Frontostriatal and Mediotemporal Lobe Contributions to Implicit
Higher-Order Spatial Sequence Learning Declines in Aging and Parkinson's
Disease
SO BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE Parkinson's disease; aging; implicit learning; medial temporal lobe;
striatum; prefrontal cortex
ID REACTION-TIME-TASK; MEDIAL TEMPORAL-LOBE; POSITRON-EMISSION-TOMOGRAPHY;
BASAL GANGLIA; OLDER-ADULTS; MOTOR-SEQUENCE; ASSOCIATIVE DEFICIT;
COGNITIVE DEFICITS; AGE-DIFFERENCES; MEMORY-SYSTEMS
AB Sequence learning depends on the striatal system, but recent findings also implicate the mediotemporal lobe (MTL) system. Schendan, Searl, Melrose, and Stern (2003) found higher-order associative, learning-related activation in the striatum, dorsolateral prefrontal cortex, and the MTL during the early acquisition phase of both implicit and explicit variants of a serial response time task. This functional MRI (fMRI) study capitalized on this task to determine how changes in MTL function observed in aging and compromised frontostriatal function characteristic of patients with Parkinson's disease (PD) impacts sequence learning and memory under implicit instructions. Brain activity was compared between "sequence" and "random" conditions in 12 nondemented patients with PD and education-and gender-matched healthy control participants of whom 12 were age matched (MC) and 14 were younger (YC). Behaviorally, sequence-specific learning of higher-order associations was reduced with aging and changed further with PD and resulted primarily in implicit knowledge in the older participants. fMRI revealed reduced intensity and extent of sequence learning-related activation in older relative to younger people in frontostriatal circuits and the MTL. This was because signal was greater for the sequence than random condition in younger people, whereas older people, especially those with PD, showed the opposite pattern. Both older groups also showed increased activation to the task itself relative to baseline fixation. In addition, right MTL showed hypoactivation and left MTL hyperactivation in PD relative to the MC group. The results suggest changes in frontostriatal and MTL activity occur during aging that affect task-related activity and the initial acquisition phase of implicit higher-order sequence learning. In addition, the results suggest that Parkinson's disease adversely affects processes in the MTL including sequence learning and memory.
C1 [Schendan, Haline E.] Univ Plymouth, Sch Psychol, Ctr Brain Cognit & Behav, Cognit Inst, Plymouth PL4 8AA, Devon, England.
[Schendan, Haline E.; Tinaz, Sule; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Tinaz, Sule; Stern, Chantal E.] Boston Univ, Ctr Memory & Brain, Boston, MA 02215 USA.
[Maher, Stephen M.] Tufts Univ, Dept Psychol, Medford, MA USA.
[Stern, Chantal E.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Stern, Chantal E.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Schendan, HE (reprint author), Univ Plymouth, Sch Psychol, Ctr Brain Cognit & Behav, Cognit Inst, Portland Sq A208, Plymouth PL4 8AA, Devon, England.
EM Haline.Schendan@plymouth.ac.uk
OI Schendan, Haline/0000-0001-8925-5605
FU NIMH [R21 MH066213]; Plymouth University; EU
[PCIG09-GA-2011-294144-COGNITSIMS]
FX Research was supported by NIMH Award R21 MH066213 to C.E.S. and H.E.S.
and an International Research, Networking and Collaboration grant from
Plymouth University and EU FP7 Marie Curie award
PCIG09-GA-2011-294144-COGNITSIMS to H.E.S. We acknowledge imaging
support from the Athinoula A. Martinos Center for Biomedical Imaging and
NCRR P41RR14075. We thank Kim C. Willment, PhD, for assisting with
analyzing the neuroimaging data and preparing earlier drafts of the
manuscript. We thank Alice Cronin-Golomb, PhD, for assistance with
participant recruitment and visual and cognitive clinical assessment and
Robert Ross, PhD, for his assistance with the study. We are also
extremely grateful for the generous time and cooperation of the PD
patients and the MC individuals who participated in this research.
NR 76
TC 11
Z9 11
U1 1
U2 14
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7044
J9 BEHAV NEUROSCI
JI Behav. Neurosci.
PD APR
PY 2013
VL 127
IS 2
BP 204
EP 221
DI 10.1037/a0032012
PG 18
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 119VY
UT WOS:000317128600008
PM 23565935
ER
PT J
AU Radhakrishnan, K
Bhatia, M
Geyer, MB
del Toro, G
Jin, ZZ
Baker, C
Harrison, L
Morris, E
Baxter-Lowe, LA
Cairo, MS
AF Radhakrishnan, Kavita
Bhatia, Monica
Geyer, Mark B.
del Toro, Gustavo
Jin, Zhezhen
Baker, Courtney
Harrison, Lauren
Morris, Erin
Baxter-Lowe, Lee Ann
Cairo, Mitchell S.
TI Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord
Blood Transplantation in Children with Sickle Cell Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Letter
ID RECIPIENTS; DONORS
C1 [Radhakrishnan, Kavita; Bhatia, Monica; Baker, Courtney] Columbia Univ, Dept Pediat, NewYork Presbyterian Morgan Stanley Childrens Hos, New York, NY 10027 USA.
[Jin, Zhezhen] Columbia Univ, Dept Biostat, NewYork Presbyterian Morgan Stanley Childrens Hos, New York, NY USA.
[Geyer, Mark B.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
[del Toro, Gustavo] Wyckoff Hts Med Ctr, Dept Pediat, New York, NY USA.
[Baxter-Lowe, Lee Ann] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Harrison, Lauren; Morris, Erin; Cairo, Mitchell S.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA.
[Cairo, Mitchell S.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
[Cairo, Mitchell S.] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA.
[Cairo, Mitchell S.] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.
[Cairo, Mitchell S.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.
RP Cairo, MS (reprint author), New York Med Coll, Dept Pediat, Room 110A, Valhalla, NY 10595 USA.
EM Mitchell_cairo@nymc.edu
OI Geyer, Mark/0000-0001-5248-9117
NR 10
TC 13
Z9 13
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD APR
PY 2013
VL 19
IS 4
BP 676
EP 677
DI 10.1016/j.bbmt.2013.02.002
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 120IH
UT WOS:000317163500026
PM 23403308
ER
PT J
AU Budde, LE
Zhang, MM
Shustov, AR
Pagel, JM
Gooley, TA
Oliveira, GR
Chen, TL
Knudsen, NL
Roden, JE
Kammerer, BE
Frayo, SL
Warr, TA
Boyd, TE
Press, OW
Gopal, AK
AF Budde, Lihua E.
Zhang, Michelle M.
Shustov, Andrei R.
Pagel, John M.
Gooley, Ted A.
Oliveira, George R.
Chen, Tara L.
Knudsen, Nancy L.
Roden, Jennifer E.
Kammerer, Britt E.
Frayo, Shani L.
Warr, Thomas A.
Boyd, Thomas E.
Press, Oliver W.
Gopal, Ajay K.
TI A phase I study of pulse high-dose vorinostat (V) plus rituximab (R),
ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed
lymphoma
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE 2 stage design; clinical trial; lymphoma; phase I; vorinostat
ID HISTONE DEACETYLASE INHIBITOR; B-CELL LYMPHOMA; SUBEROYLANILIDE
HYDROXAMIC ACID; HODGKINS-LYMPHOMA; FOLLICULAR LYMPHOMA; ADVANCED
CANCER; EXPRESSION; TRANSPLANTATION; ANGIOGENESIS; SURVIVAL
AB Given the poor outcomes of relapsed aggressive lymphomas and preclinical data suggesting that 2 center dot 5mol/l concentrations of vorinostat synergize with both etoposide and platinums, we hypothesized that pulse high-dose vorinostat could safely augment the anti-tumour activity of (R)ICE [(rituximab), ifosphamide, carboplatin, etoposide] chemotherapy. We conducted a phase I dose escalation study using a schedule with oral vorinostat ranging from 400mg/d to 700mg bid for 5d in combination with the standard (R)ICE regimen (days 3, 4 and 5). Twenty-nine patients [median age 56years, median 2 prior therapies, 14 chemoresistant (of 27 evaluable), 2 prior transplants] were enrolled and treated. The maximally tolerated vorinostat dose was defined as 500mg twice dailyx5d. Common dose limiting toxicities included infection (n=2), hypokalaemia (n=2), and transaminitis (n=2). Grade 3 related gastrointestinal toxicity was seen in 9 patients. The median vorinostat concentration on day 3 was 4 center dot 5mol/l (range 4 center dot 26 center dot 0mol/l) and in vitro data confirmed the augmented antitumour and histone acetylation activity at these levels. Responses were observed in 19 of 27 evaluable patients (70%) including 8 complete response/unconfirmed complete response. High-dose vorinostat can be delivered safely with (R)ICE, achieves potentially synergistic drug levels, and warrants further study, although adequate gastrointestinal prophylaxis is warranted.
C1 [Budde, Lihua E.; Shustov, Andrei R.; Pagel, John M.; Gooley, Ted A.; Knudsen, Nancy L.; Kammerer, Britt E.; Frayo, Shani L.; Press, Oliver W.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Budde, Lihua E.; Shustov, Andrei R.; Pagel, John M.; Gooley, Ted A.; Roden, Jennifer E.; Press, Oliver W.; Gopal, Ajay K.] Univ Washington, Dept Med, Seattle, WA 98109 USA.
[Zhang, Michelle M.] Valley Med Ctr, Renton, WA USA.
[Oliveira, George R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Chen, Tara L.] Univ Washington, Serv Pharm, Seattle, WA 98109 USA.
[Warr, Thomas A.] Great Falls Clin, Great Falls, MT USA.
[Boyd, Thomas E.] Yakima Reg Med & Cardiac Ctr, Yakima, WA USA.
[Budde, Lihua E.] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA.
RP Gopal, AK (reprint author), Univ Washington, Med Ctr, Dept Med, 825 Eastlake Ave E,G3-200, Seattle, WA 98109 USA.
EM agopal@u.washington.edu
FU Merck Sharp Dohme Corp USA; Washington State Life Sciences Discovery
Fund; NIH PO1 [CA44991]; Lymphoma Research Foundation Mantle Cell
Lymphoma Initiative, a SCOR [7040]; Leukemia and Lymphoma Society;
Wright Memorial Research Fund; Clinical Research of the Leukemia and
Lymphoma Society
FX This work was supported by Merck Sharp & Dohme Corp USA, the Washington
State Life Sciences Discovery Fund, an NIH PO1 grant (CA44991), a grant
from the Lymphoma Research Foundation Mantle Cell Lymphoma Initiative, a
SCOR grant (7040) from the Leukemia and Lymphoma Society, the Mary A.
Wright Memorial Research Fund, a donation from Frank and Betty
Vandermeer. L.E.B is a Special Fellow in Clinical Research of the
Leukemia and Lymphoma Society. A.K.G is a Scholar in Clinical Research
of the Leukemia and Lymphoma Society.
NR 28
TC 9
Z9 9
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD APR
PY 2013
VL 161
IS 2
BP 183
EP 191
DI 10.1111/bjh.12230
PG 9
WC Hematology
SC Hematology
GA 119UN
UT WOS:000317124200006
PM 23356514
ER
PT J
AU Hartmann, AS
Hilbert, A
AF Hartmann, A. S.
Hilbert, A.
TI Child and adolescent obesity, psychosocial consequences and treatment
strategies
SO BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ
LA German
DT Article
DE Obesity; Childhood and adolescence; Psychosocial factors; Therapeutic
strategies; Overweight
ID GERMAN HEALTH INTERVIEW; QUALITY-OF-LIFE; OVERWEIGHT CHILDREN; DUTCH
ADOLESCENTS; EATING-DISORDER; WEIGHT STATUS; PREVENTION; SAMPLE; KIGGS;
RISK
AB Being overweight and obese in childhood and adolescence is associated with various somatic and psychosocial sequelae. Psychosocial problems can negatively influence the future weight trajectory. Therefore, weight reduction or stabilization should be complemented by the treatment of significant psychosocial problems. This review provides an overview of the psychosocial problems associated with being overweight and obese in childhood and adolescence. Evidence on weight-related stigmatization and discrimination, eating disorder symptoms, general psychopathology, impaired quality of life, lowered self-esteem, social skill deficits, as well as academic problems is summarized. Furthermore, state-of-the-art diagnostic and therapeutic procedures for the psychosocial problems are summarized. Future research should focus on the development of interventions targeting the destigmatization of obesity, as experiences of stigmatization and discrimination likely aggravate the psychosocial sequelae of overweight and obesity.
C1 [Hartmann, A. S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Hartmann, A. S.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Hilbert, A.] Univ Med Leipzig, Integriertes Forsch & Behandlungszentrum Adiposit, Leipzig, Germany.
RP Hartmann, AS (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 185 Cambridge St,Suite 2200,Simches Res Bldg, Boston, MA 02114 USA.
EM andrea.sabrina.hartmann@gmail.com
NR 60
TC 0
Z9 0
U1 3
U2 39
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1436-9990
J9 BUNDESGESUNDHEITSBLA
JI Bundesgesundheitsblatt-Gesund.
PD APR
PY 2013
VL 56
IS 4
BP 532
EP 538
DI 10.1007/s00103-012-1637-6
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 114MH
UT WOS:000316744900009
PM 23529599
ER
PT J
AU Ahmed, N
AF Ahmed, Na'eem
TI Scientific publishing needs disruption
SO CLINICAL MEDICINE
LA English
DT Editorial Material
C1 [Ahmed, Na'eem] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ahmed, Na'eem] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Ahmed, Na'eem] Kings Coll Hosp, London, England.
RP Ahmed, N (reprint author), NHS Commissioning Board, 4-8 Maple St, London W1T 5HD, England.
EM naeem.ahmed@nhs.net
NR 3
TC 0
Z9 0
U1 0
U2 1
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
J9 CLIN MED
JI Clin. Med.
PD APR
PY 2013
VL 13
IS 2
BP 125
EP 125
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122JQ
UT WOS:000317314800002
PM 23681856
ER
PT J
AU Khoshbin, S
Herring, A
Holmes, GL
Schomer, D
Hoch, D
Dooling, EC
Vining, EPG
Holmes, LB
AF Khoshbin, Shahram
Herring, Amy
Holmes, Gregory L.
Schomer, Donald
Hoch, Daniel
Dooling, Elizabeth C.
Vining, Eileen P. G.
Holmes, Lewis B.
TI Inter-rater agreement for diagnoses of epilepsy in pregnant women
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Types of seizures; Adult and pediatric neurologists; Log-linear modeling
ID SEIZURES; CLASSIFICATION; RELIABILITY; CHILDHOOD; CHILDREN; SCALE
AB We report on inter-rater agreement in assessing the types of seizures exhibited by one hundred mothers ascertained in a study of the teratogenicity of maternal epilepsy and antiepileptic drugs. A summary of each woman's medical record and a one-page report of her responses to questions about her epilepsy were reviewed independently by six neurologists, three in pediatric neurology and three in adult neurology. Agreement was measured by the kappa statistic and log-linear modeling techniques. The adult neurologists agreed with each other 59% of the time, with the agreement higher when all three used information from the patients' records, such as an EEG, rather than when depending on the patients' responses to questions about their epilepsy. The pediatric neurologists agreed with each other 44% of the time and tended to rely more heavily on information in the patients' records, such as an EEG or a prior diagnosis, compared with the adult neurologists. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Khoshbin, Shahram] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Herring, Amy] Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA.
[Holmes, Gregory L.] Childrens Hosp, Dept Neurol, Boston, MA USA.
[Schomer, Donald] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA.
[Hoch, Daniel] Massachusetts Gen Hosp, Epilepsy Ctr, Boston, MA 02114 USA.
[Dooling, Elizabeth C.] Massachusetts Gen Hosp, Div Pediat Neurol, Dept Neurol, Boston, MA 02114 USA.
[Vining, Eileen P. G.] Johns Hopkins Med Inst, John M Freeman Pediat Epilepsy Ctr, Baltimore, MD USA.
[Holmes, Lewis B.] MassGen Hosp Children, Med Genet Unit, Boston, MA 02114 USA.
RP Holmes, LB (reprint author), MassGen Hosp Children, Med Genet Unit, 175 Cambridge St, Boston, MA 02114 USA.
EM holmes.lewis@mgh.harvard.edu
OI Hoch, Daniel/0000-0002-4294-024X
FU NCRR NIH HHS [M01 RR001066]; NICHD NIH HHS [R24 HD050924]
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD APR
PY 2013
VL 27
IS 1
BP 148
EP 153
DI 10.1016/j.yebeh.2012.12.030
PG 6
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 118MG
UT WOS:000317029000028
PM 23416992
ER
PT J
AU Sullivan, RJ
Flaherty, KT
AF Sullivan, Ryan J.
Flaherty, Keith T.
TI Resistance to BRAF-targeted therapy in melanoma
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Review
DE Melanoma; BRAF inhibitor resistance; Molecular targeted therapy
ID RANDOMIZED DISCONTINUATION TRIAL; INHIBITOR AZD6244 ARRY-142886; CHRONIC
MYELOID-LEUKEMIA; B-RAF; METASTATIC MELANOMA; PHASE-II; MULTIKINASE
INHIBITOR; MALIGNANT-MELANOMA; ADVANCED CANCERS; OPEN-LABEL
AB BRAF mutations are identified in 40-50% of patients with melanoma. Treatment of these patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor trametinib is associated with improved clinical benefit (response rate, progression free survival, and overall survival) compared with treatment with chemotherapy in three phase III trials. Unfortunately, most patients, including those who experience initial, profound tumour regression, have evidence of disease progression within 6-8 months after commencing therapy with one of these agents. The mechanisms of resistance are varied and include activation of alternative signalling pathways as well as reactivating the MAP kinase pathway through alternative means. This review describes relevant aspects of MAP kinase pathway signalling, summarises the clinical data with BRAF and MEK inhibitors, presents the known resistance mechanisms to BRAF inhibitor therapy, and provides some strategies for how resistance may be overcome. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Sullivan, Ryan J.; Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Ctr Melanoma, Boston, MA 02114 USA.
RP Flaherty, KT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Henri & Belinda Termeer Ctr Targeted Therapies, 55 Fruit St, Boston, MA 02114 USA.
EM kflaherty@partners.org
NR 64
TC 124
Z9 128
U1 2
U2 44
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD APR
PY 2013
VL 49
IS 6
BP 1297
EP 1304
DI 10.1016/j.ejca.2012.11.019
PG 8
WC Oncology
SC Oncology
GA 120RF
UT WOS:000317188600016
PM 23290787
ER
PT J
AU Konijeti, GG
Deshpande, V
Bunker, CJ
AF Konijeti, Gauree Gupta
Deshpande, Vikram
Bunker, Cheryl J.
TI An Unusual Case of Chronic Diarrhea Answer to the Clinical Challenges
and Images in GI Question: Image 3 (page 696): Lansoprazole-induced
Microscopic Colitis
SO GASTROENTEROLOGY
LA English
DT Editorial Material
C1 [Konijeti, Gauree Gupta; Bunker, Cheryl J.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Konijeti, GG (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
FU NIDDK NIH HHS [T32 DK007191, T32DK007191]
NR 0
TC 0
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2013
VL 144
IS 4
BP 696
EP +
DI 10.1053/j.gastro.2012.11.002
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 114JB
UT WOS:000316735800026
PM 23491834
ER
PT J
AU Peters, U
Jiao, S
Schumacher, FR
Hutter, CM
Aragaki, AK
Baron, JA
Berndt, SI
Bezieau, S
Brenner, H
Butterbach, K
Caan, BJ
Campbell, PT
Carlson, CS
Casey, G
Chan, AT
Chang-Claude, J
Chanock, SJ
Chen, LS
Coetzee, GA
Coetzee, SG
Conti, DV
Curtis, KR
Duggan, D
Edwards, T
Fuchs, CS
Gallinger, S
Giovannucci, EL
Gogarten, SM
Gruber, SB
Haile, RW
Harrison, TA
Hayes, RB
Henderson, BE
Hoffmeister, M
Hopper, JL
Hudson, TJ
Hunter, DJ
Jackson, RD
Jee, SH
Jenkins, MA
Jia, WH
Kolonel, LN
Kooperberg, C
Kuery, S
Lacroix, AZ
Laurie, CC
Laurie, CA
Le Marchand, L
Lemire, M
Levine, D
Lindor, NM
Liu, Y
Ma, J
Makar, KW
Matsuo, K
Newcomb, PA
Potter, JD
Prentice, RL
Qu, CH
Rohan, T
Rosse, SA
Schoen, RE
Seminara, D
Shrubsole, M
Shu, XO
Slattery, ML
Taverna, D
Thibodeau, SN
Ulrich, CM
White, E
Xiang, YB
Zanke, BW
Zeng, YX
Zhang, B
Zheng, W
Hsu, L
AF Peters, Ulrike
Jiao, Shuo
Schumacher, Fredrick R.
Hutter, Carolyn M.
Aragaki, Aaron K.
Baron, John A.
Berndt, Sonja I.
Bezieau, Stephane
Brenner, Hermann
Butterbach, Katja
Caan, Bette J.
Campbell, Peter T.
Carlson, Christopher S.
Casey, Graham
Chan, Andrew T.
Chang-Claude, Jenny
Chanock, Stephen J.
Chen, Lin S.
Coetzee, Gerhard A.
Coetzee, Simon G.
Conti, David V.
Curtis, Keith R.
Duggan, David
Edwards, Todd
Fuchs, Charles S.
Gallinger, Steven
Giovannucci, Edward L.
Gogarten, Stephanie M.
Gruber, Stephen B.
Haile, Robert W.
Harrison, Tabitha A.
Hayes, Richard B.
Henderson, Brian E.
Hoffmeister, Michael
Hopper, John L.
Hudson, Thomas J.
Hunter, David J.
Jackson, Rebecca D.
Jee, Sun Ha
Jenkins, Mark A.
Jia, Wei-Hua
Kolonel, Laurence N.
Kooperberg, Charles
Kuery, Sebastien
Lacroix, Andrea Z.
Laurie, Cathy C.
Laurie, Cecelia A.
Le Marchand, Loic
Lemire, Mathieu
Levine, David
Lindor, Noralane M.
Liu, Yan
Ma, Jing
Makar, Karen W.
Matsuo, Keitaro
Newcomb, Polly A.
Potter, John D.
Prentice, Ross L.
Qu, Conghui
Rohan, Thomas
Rosse, Stephanie A.
Schoen, Robert E.
Seminara, Daniela
Shrubsole, Martha
Shu, Xiao-Ou
Slattery, Martha L.
Taverna, Darin
Thibodeau, Stephen N.
Ulrich, Cornelia M.
White, Emily
Xiang, Yongbing
Zanke, Brent W.
Zeng, Yi-Xin
Zhang, Ben
Zheng, Wei
Hsu, Li
CA Colon Canc Family Registry
Genetics Epidemiology Colorectal
TI Identification of Genetic Susceptibility Loci for Colorectal Tumors in a
Genome-Wide Meta-analysis
SO GASTROENTEROLOGY
LA English
DT Article
DE Colon Cancer; Genetics; Risk Factors; SNP
ID STRANDED-DNA-BINDING; BASE-LINE CHARACTERISTICS; CANCER SCREENING TRIAL;
REPLICATION PROTEIN-A; ASSOCIATION SCAN; COLON-CANCER; WOMENS HEALTH;
EPITHELIAL-CELLS; RANDOMIZED-TRIAL; MEAT CONSUMPTION
AB BACKGROUND & AIMS: Heritable factors contribute to the development of colorectal cancer. Identifying the genetic loci associated with colorectal tumor formation could elucidate the mechanisms of pathogenesis. METHODS: We conducted a genome-wide association study that included 14 studies, 12,696 cases of colorectal tumors (11,870 cancer, 826 adenoma), and 15,113 controls of European descent. The 10 most statistically significant, previously unreported findings were followed up in 6 studies; these included 3056 colorectal tumor cases (2098 cancer, 958 adenoma) and 6658 controls of European and Asian descent. RESULTS: Based on the combined analysis, we identified a locus that reached the conventional genome-wide significance level at less than 5.0 X 10(-8): an intergenic region on chromosome 2q32.3, close to nucleic acid binding protein 1 (most significant single nucleotide polymorphism: rs11903757; odds ratio [OR], 1.15 per risk allele; P = 3.7 X 10(-8)). We also found evidence for 3 additional loci with P values less than 5.0 X 10(-7): a locus within the laminin gamma 1 gene on chromosome 1q25.3 (rs10911251; OR, 1.10 per risk allele; P = 9.5 X 10(-8)), a locus within the cyclin D2 gene on chromosome 12p13.32 (rs3217810 per risk allele; OR, 0.84; P = 5.9 X 10(-8)), and a locus in the T-box 3 gene on chromosome 12q24.21 (rs59336; OR, 0.91 per risk allele; P = 3.7 X 10(-7)). CONCLUSIONS: In a large genome-wide association study, we associated polymorphisms close to nucleic acid binding protein 1 (which encodes a DNA-binding protein involved in DNA repair) with colorectal tumor risk. We also provided evidence for an association between colorectal tumor risk and polymorphisms in laminin gamma 1 (this is the second gene in the laminin family to be associated with colorectal cancers), cyclin D2 (which encodes for cyclin D2), and T-box 3 (which encodes a T-box transcription factor and is a target of Wnt signaling to beta-catenin). The roles of these genes and their products in cancer pathogenesis warrant further investigation.
C1 [Peters, Ulrike; Hutter, Carolyn M.; Aragaki, Aaron K.; Carlson, Christopher S.; Curtis, Keith R.; Harrison, Tabitha A.; Kooperberg, Charles; Lacroix, Andrea Z.; Makar, Karen W.; Newcomb, Polly A.; Potter, John D.; Prentice, Ross L.; Qu, Conghui; Rosse, Stephanie A.; Ulrich, Cornelia M.; White, Emily; Hsu, Li] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98109 USA.
[Gogarten, Stephanie M.; Laurie, Cathy C.; Laurie, Cecelia A.; Levine, David] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Peters, Ulrike; Hutter, Carolyn M.; Carlson, Christopher S.; Newcomb, Polly A.; Rosse, Stephanie A.; Ulrich, Cornelia M.; White, Emily] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Schumacher, Fredrick R.; Casey, Graham; Coetzee, Gerhard A.; Coetzee, Simon G.; Conti, David V.; Gruber, Stephen B.; Haile, Robert W.; Henderson, Brian E.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Baron, John A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
[Berndt, Sonja I.; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Seminara, Daniela] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Bezieau, Stephane; Kuery, Sebastien] CHU Nantes, Serv Genet Med, F-44035 Nantes 01, France.
[Brenner, Hermann; Butterbach, Katja; Hoffmeister, Michael] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Caan, Bette J.] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA.
[Campbell, Peter T.] Amer Canc Soc, Atlanta, GA 30329 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Chan, Andrew T.; Fuchs, Charles S.; Giovannucci, Edward L.; Ma, Jing] Harvard Univ, Sch Med, Boston, MA USA.
[Chan, Andrew T.; Fuchs, Charles S.; Giovannucci, Edward L.; Ma, Jing] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Chen, Lin S.] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA.
[Duggan, David; Taverna, Darin] Translat Genom Res Inst, Phoenix, AZ USA.
[Edwards, Todd; Shrubsole, Martha; Shu, Xiao-Ou; Zhang, Ben] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
[Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Gallinger, Steven] Toronto Gen Hosp, Dept Surg, Toronto, ON, Canada.
[Giovannucci, Edward L.; Hunter, David J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Hayes, Richard B.] NYU, Sch Med, Div Epidemiol, New York, NY USA.
[Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Melborne Sch Populat Hlth, Melbourne, Vic, Australia.
[Hudson, Thomas J.; Lemire, Mathieu] Ontario Inst Canc Res, Toronto, ON, Canada.
[Hudson, Thomas J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
[Hudson, Thomas J.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Jackson, Rebecca D.] Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA.
[Jee, Sun Ha] Yonsei Univ, Inst Hlth Promot, Seoul 120749, South Korea.
[Jia, Wei-Hua; Zeng, Yi-Xin] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
[Kolonel, Laurence N.; Le Marchand, Loic] Univ Hawaii, Ctr Canc, Program Epidemiol, Honolulu, HI 96822 USA.
[Lindor, Noralane M.] Mayo Clin Scottsdale, Dept Hlth Sci Res, Scottsdale, AZ USA.
[Liu, Yan] Stephens & Associates, Carrollton, GA USA.
[Matsuo, Keitaro] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan.
[Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand.
[Rohan, Thomas] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Schoen, Robert E.] Univ Pittsburgh, Med Ctr, Dept Epidemiol, Pittsburgh, PA USA.
[Slattery, Martha L.] Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT USA.
[Thibodeau, Stephen N.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Thibodeau, Stephen N.] Mayo Clin, Dept Lab Genet, Rochester, MN USA.
[Ulrich, Cornelia M.] Natl Ctr Tumor Dis, Div Prevent Oncol, Heidelberg, Germany.
[Ulrich, Cornelia M.] German Canc Res Ctr, Heidelberg, Germany.
[Xiang, Yongbing] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China.
[Zanke, Brent W.] Univ Ottawa, Fac Med, Div Hematol, Ottawa, ON, Canada.
[Zheng, Wei] Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Epidemiol Ctr, Nashville, TN 37212 USA.
RP Peters, U (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North,M4-B402,POB 19024, Seattle, WA 98109 USA.
EM upeters@fhcrc.org; lih@fhcrc.org
RI Gallinger, Steven/E-4575-2013; Hoffmeister, Michael/B-5745-2012; KURY,
Sebastien/G-5971-2015; Shrubsole, Martha/K-5052-2015; Bezieau,
stephane/G-5621-2015; Jenkins, Mark/P-7803-2015; Brenner,
Hermann/B-4627-2017; Coetzee, Simon/C-1218-2014;
OI Gogarten, Stephanie/0000-0002-7231-9745; Hayes,
Richard/0000-0002-0918-661X; Matsuo, Keitaro/0000-0003-1761-6314;
Hoffmeister, Michael/0000-0002-8307-3197; KURY,
Sebastien/0000-0001-5497-0465; Shrubsole, Martha/0000-0002-5591-7575;
Bezieau, stephane/0000-0003-0095-1319; Jenkins,
Mark/0000-0002-8964-6160; Brenner, Hermann/0000-0002-6129-1572; Coetzee,
Simon/0000-0003-4267-5930; Potter, John/0000-0001-5439-1500
FU National Cancer Institute, National Institutes of Health; US Department
of Health and Human Services [U01 CA137088, R01 CA059045]; Japanese
Ministry of Education, Culture, Sports, Science and Technology
[17015018, 221S0001]; Hospital Clinical Research Program (PHRC);
Regional Council of Pays de la Loire; Groupement des Entreprises
Francaises dans la Lutte Contre le Cancer; Association Anne de Bretagne
Genetique; Ligue Regionale Contre le Cancer; National Institutes of
Health [U01 CA074783, R01 CA60987, RFA CA-95-011, R37CA070867,
R01CA082729, R01CA124558, R01CA148667, R01CA122364, P50CA95103,
R01CA121060, K05 CA154337]; Ontario Research Fund; Canadian Institutes
of Health Research; Cancer Risk Evaluation Program grant from the
Canadian Cancer Society Research Institute; Ontario Institute for Cancer
Research; National Cancer Institute, National Institutes of Health [U01
CA122839]; Vanderbilt University School of Medicine; Vanderbilt-Ingram
Cancer Center [P30 CA 68485]; National Heart, Lung, and Blood Institute,
National Institutes of Health, US Department of Health and Human
Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]
FX The Genetics and Epidemiology of Colorectal Cancer Consortium study was
supported by the National Cancer Institute, National Institutes of
Health, and the US Department of Health and Human Services (U01
CA137088; R01 CA059045). The Asian Consortium was supported by a
Grant-in-aid for Cancer Research, the Grant for the Third Term
Comprehensive Control Research for Cancer and Grants-in-Aid for
Scientific Research from the Japanese Ministry of Education, Culture,
Sports, Science and Technology (17015018 and 221S0001). The french
Association STudy Evaluating RISK for sporadic colorectal cancer was
supported by a Hospital Clinical Research Program (PHRC) and by the
Regional Council of Pays de la Loire, the Groupement des Entreprises
Francaises dans la Lutte Contre le Cancer, the Association Anne de
Bretagne Genetique, and the Ligue Regionale Contre le Cancer. The
Assessment of Risk in Colorectal Tumours in Canada study was supported
by the National Institutes of Health through funding allocated to the
Ontario Registry for Studies of Familial Colorectal Cancer (U01
CA074783; see the Colon Cancer Family Registry support section below);
and by a GL2 grant from the Ontario Research Fund, the Canadian
Institutes of Health Research, by a Cancer Risk Evaluation Program grant
from the Canadian Cancer Society Research Institute, and by Senior
Investigator Awards (T.J.H. and B.W.Z.) from the Ontario Institute for
Cancer Research, through generous support from the Ontario Ministry of
Economic Development and Innovation. The Hawaii Colorectal Cancer
Studies 2 and 3 studies were supported by the National Institutes of
Health (R01 CA60987). The Colon Cancer Family Registry was supported by
the National Institutes of Health (RFA CA-95-011) and through
cooperative agreements with members of the Colon Cancer Family Registry
and P.I.s. This genome-wide scan was supported by the National Cancer
Institute, National Institutes of Health (U01 CA122839). The content of
this manuscript does not necessarily reflect the views or policies of
the National Cancer Institute or any of the collaborating centers in the
cancer family registries, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government or the
cancer family registries. The following colon cancer family registries
centers contributed data to this article and were supported by National
Institutes of Health: the Australasian Colorectal Cancer Family Registry
(U01 CA097735), Seattle Colorectal Cancer Family Registry (U01
CA074794), and the Ontario Registry for Studies of Familial Colorectal
Cancer (U01 CA074783). The Darmkrebs: Chancen der Verhutung durch
Screening study was supported by the German Research Council (Deutsche
Forschungsgemeinschaft, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, and CH
117/1-1), and the German Federal Ministry of Education and Research
(01KH0404 and 01ER0814). The Diet, Activity, and Lifestyle Study was
supported by the National Institutes of Health (R01 CA48998 to M. L.
S.); Guangzhou-1 was supported by the National Key Scientific and
Technological Project (2011ZX09307-001-04) and the National Basic
Research Program (2011CB504303) was supported by the People's Republic
of China.; The Health Professionals Follow-up Study was supported by the
National Institutes of Health (P01 CA 055075, UM1 CA167552, R01 137178,
and P50 CA 127003), the Nurses' Health Study was supported by the
National Institutes of Health (R01 137178, P01 CA 087969, and P50 CA
127003), and the Physicians' Health Study was supported by the National
Institutes of Health (CA42182). The Korean Cancer Prevention Study-II
study was supported by the National R&D Program for cancer control
(1220180), and the Seoul R&D Program (10526, Republic of Korea). The
Multiethnic Cohort study was supported by the National Institutes of
Health (R37 CA54281, P01 CA033619, and R01 CA63464). The Prostate, Lung,
Colorectal Cancer, and Ovarian Cancer Screening Trial was supported by
the Intramural Research Program of the Division of Cancer Epidemiology
and Genetics, and supported by contracts from the Division of Cancer
Prevention, National Cancer Institute, National Institutes of Health,
Department of Health and Human Services. Control samples were genotyped
as part of the Cancer Genetic Markers of Susceptibility prostate cancer
scan, supported by the Intramural Research Program of the National
Cancer Institute. The data sets used in this analysis were accessed with
appropriate approval through the dbGaP online resource
(http://www.cgems.cancer.gov/data_acess.html) through dbGaP accession
number 000207v.1p1. Control samples also were genotyped as part of the
GWAS of Lung Cancer and Smoking (Yeager, M et al. Nat Genet
2008;124:161-170). Support for this work was provided through the
National Institutes of Health, Genes, Environment and Health Initiative
(Z01 CP 010200). The human subjects participating in the genome-wide
association study were derived from the Prostate, Lung, Colon, and
Ovarian Screening Trial and the study was supported by intramural
resources of the National Cancer Institute. Assistance with genotype
cleaning, as well as with general study coordination, was provided by
the Gene Environment Association Studies, Geneva Coordinating Center
(U01 HG004446). Assistance with data cleaning was provided by the
National Center for Biotechnology Information. Funding support for
genotyping, which was performed at the Johns Hopkins University Center
for Inherited Disease Research, was provided by the National Institutes
of Health, Genes, Environment and Health Initiative (U01 HG 004438). The
data sets used for the analyses described in this article were obtained
from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession
number phs000093 v2.p2. The Postmenopausal Hormone Study was supported
by the National Institutes of Health (R01 CA076366 to P.A.N.). The
Shanghai-1 and Shanghai-2 studies were supported by the National
Institutes of Health (R37CA070867, R01CA082729, R01CA124558,
R01CA148667, and R01CA122364), as well as an Ingram Professorship and
Research Reward funds from the Vanderbilt University School of Medicine.
The Tennessee Colorectal Polyp Study was supported by the National
Institutes of Health (P50CA95103 and R01CA121060) and was conducted by
the Survey and Biospecimen Shared Resource, which was supported in part
by the Vanderbilt-Ingram Cancer Center (P30 CA 68485). The VITamins And
Lifestyle study was supported by the National Institutes of Health (K05
CA154337).; The Women's Health Initiative program was funded by the
National Heart, Lung, and Blood Institute, National Institutes of
Health, US Department of Health and Human Services, through contracts
HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.
NR 106
TC 121
Z9 122
U1 4
U2 47
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2013
VL 144
IS 4
BP 799
EP +
DI 10.1053/j.gastro.2012.12.020
PG 33
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 114JB
UT WOS:000316735800039
PM 23266556
ER
PT J
AU Sia, D
Hoshida, Y
Villanueva, A
Roayaie, S
Ferrer, J
Tabak, B
Peix, J
Sole, M
Tovar, V
Alsinet, C
Cornella, H
Klotzle, B
Fan, JB
Cotsoglou, C
Thung, SN
Fuster, J
Waxman, S
Garcia-Valdecasas, JC
Bruix, J
Schwartz, ME
Beroukhim, R
Mazzaferro, V
Llovet, JM
AF Sia, Daniela
Hoshida, Yujin
Villanueva, Augusto
Roayaie, Sasan
Ferrer, Joana
Tabak, Barbara
Peix, Judit
Sole, Manel
Tovar, Victoria
Alsinet, Clara
Cornella, Helena
Klotzle, Brandy
Fan, Jian-Bing
Cotsoglou, Christian
Thung, Swan N.
Fuster, Josep
Waxman, Samuel
Carlos Garcia-Valdecasas, Juan
Bruix, Jordi
Schwartz, Myron E.
Beroukhim, Rameen
Mazzaferro, Vincenzo
Llovet, Josep M.
TI Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma
Reveals 2 Classes That Have Different Outcomes
SO GASTROENTEROLOGY
LA English
DT Article
DE Liver Cancer; Molecular Classification; Whole-Genome Profiling;
Prognosis
ID BILIARY-TRACT CANCER; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION;
PROMOTER METHYLATION; THERAPEUTIC TARGETS; LIVER; PATHWAY; CELLS;
CLASSIFICATION; IDENTIFICATION
AB BACKGROUND & AIMS: Cholangiocarcinoma, the second most common liver cancer, can be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma. We performed an integrative genomic analysis of ICC samples from a large series of patients. METHODS: We performed a gene expression profile, high-density single-nucleotide polymorphism array, and mutation analyses using formalin-fixed ICC samples from 149 patients. Associations with clinicopathologic traits and patient outcomes were examined for 119 cases. Class discovery was based on a non-negative matrix factorization algorithm and significant copy number variations were identified by Genomic Identification of Significant Targets in Cancer (GISTIC) analysis. Gene set enrichment analysis was used to identify signaling pathways activated in specific molecular classes of tumors, and to analyze their genomic overlap with hepatocellular carcinoma (HCC). RESULTS: We identified 2 main biological classes of ICC. The inflammation class (38% of ICCs) is characterized by activation of inflammatory signaling pathways, overexpression of cytokines, and STAT3 activation. The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC. Copy number variation-based clustering was able to refine these molecular groups further. We identified high-level amplifications in 5 regions, including 1p13 (9%) and 11q13.2 (4%), and several focal deletions, such as 9p21.3 (18%) and 14q22.1 (12% in coding regions for the SAV1 tumor suppressor). In a complementary approach, we identified a gene expression signature that was associated with reduced survival times of patients with ICC; this signature was enriched in the proliferation class (P < .001). CONCLUSIONS: We used an integrative genomic analysis to identify 2 classes of ICC. The proliferation class has specific copy number alterations, activation of oncogenic pathways, and is associated with worse outcome. Different classes of ICC, based on molecular features, therefore might require different treatment approaches.
C1 [Sia, Daniela; Villanueva, Augusto; Peix, Judit; Sole, Manel; Tovar, Victoria; Alsinet, Clara; Cornella, Helena; Fuster, Josep; Bruix, Jordi; Llovet, Josep M.] Univ Barcelona, Hosp Clin, Barcelona Clin Liver Canc Grp,Pathol Dept, HCC Translat Res Lab,Liver Unit,Inst Invest Biome, Barcelona, Catalonia, Spain.
[Sia, Daniela; Cotsoglou, Christian; Mazzaferro, Vincenzo] Natl Canc Inst, Dept Expt Oncol, Gastrointestinal Surg & Liver Transplantat Unit, I-20133 Milan, Italy.
[Hoshida, Yujin; Roayaie, Sasan; Thung, Swan N.; Waxman, Samuel; Schwartz, Myron E.; Llovet, Josep M.] Mt Sinai Sch Med, Recanati Miller Transplantat Inst, Dept Surg Oncol,Mt Sinai Liver Canc Program, Dept Pathol,Tisch Canc Inst,Dept Med,Div Liver Di, New York, NY USA.
[Villanueva, Augusto; Peix, Judit; Bruix, Jordi; Llovet, Josep M.] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
[Ferrer, Joana; Fuster, Josep; Carlos Garcia-Valdecasas, Juan] Hosp Clin Barcelona, Dept Surg, Barcelona, Catalonia, Spain.
[Tabak, Barbara; Beroukhim, Rameen] Broad Inst, Canc Program, Cambridge, MA USA.
[Klotzle, Brandy; Fan, Jian-Bing] Illumina Inc, San Diego, CA USA.
[Beroukhim, Rameen] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Div Canc Biol, Div Med Oncol, Boston, MA 02115 USA.
[Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain.
RP Llovet, JM (reprint author), Hosp Clin, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi & Sunyer, Barcelona Clin Liver Canc BCLC Grp,Liver Unit, Villarroel 170, Catalonia 08036, Spain.
EM jmllovet@clinic.cat
RI Augusto, Villanueva/F-9378-2012; Llovet, Josep M /D-4340-2014;
Mazzaferro, Vincenzo/C-2726-2017;
OI Augusto, Villanueva/0000-0003-3585-3727; Llovet, Josep M
/0000-0003-0547-2667; Mazzaferro, Vincenzo/0000-0002-4013-8085; Bruix,
Jordi/0000-0002-9826-0753
FU Asociacion Espanola Contra el Cancer; Instituto de Salud Carlos III
[ISCIII/FIS FI10/00143, ISCIII/FIS FI09/00605]; US National Cancer
Institute [K08CA122833, U54CA143798]; V Foundation Scholarship;
Instituto Carlos III [ISCIII/FIS PI 11/01830]; Italian Association for
Cancer Research; Oncology Research Project of the Italian Ministry of
Health; US National Institute of Diabetes and Digestive and Kidney
Diseases [1R01DK076986-01]; European Commission [259744]; Samuel Waxman
Cancer Research Foundation; Spanish National Health Institute
[SAF-2010-16055]
FX The study has been supported by a grant from the Asociacion Espanola
Contra el Cancer. Helena Cornella is supported by a fellowship from the
Instituto de Salud Carlos III (ISCIII/FIS FI10/00143); Clara Alsinet is
supported by a fellowship from Instituto de Salud Carlos III (ISCIII/FIS
FI09/00605); Rameen Beroukhim is supported by grants from the US
National Cancer Institute (K08CA122833 and U54CA143798) and a V
Foundation Scholarship; Jordi Bruix is supported by a grant from the
Instituto Carlos III (ISCIII/FIS PI 11/01830); Vincenzo Mazzaferro is
supported by grants from the Italian Association for Cancer Research and
the Oncology Research Project of the Italian Ministry of Health; Josep
Llovet is supported by grants from the Asociacion Espanola Contra el
Cancer, the US National Institute of Diabetes and Digestive and Kidney
Diseases (1R01DK076986-01), European Commission-FP7 Framework
(HEPTROMIC, proposal no. 259744), the Samuel Waxman Cancer Research
Foundation, and the Spanish National Health Institute (SAF-2010-16055).
NR 51
TC 101
Z9 105
U1 1
U2 17
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2013
VL 144
IS 4
BP 829
EP 840
DI 10.1053/j.gastro.2013.01.001
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 114JB
UT WOS:000316735800042
PM 23295441
ER
PT J
AU Townamchai, K
Berkowitz, R
Bhagwat, M
Damato, AL
Friesen, S
Lee, LJ
Matulonis, U
O'Farrell, D
Viswanathan, AN
AF Townamchai, Kanokpis
Berkowitz, Ross
Bhagwat, Mandar
Damato, Antonio L.
Friesen, Scott
Lee, Larissa J.
Matulonis, Ursula
O'Farrell, Desmond
Viswanathan, Akila N.
TI Vaginal brachytherapy for early stage uterine papillary serous and clear
cell endometrial cancer
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Vaginal brachytherapy; Uterine papillary serous cancer; High-dose-rate
brachytherapy
ID HIGH-DOSE-RATE; ADJUVANT RADIATION-THERAPY; CARBOPLATIN/PACLITAXEL
CHEMOTHERAPY; INTRAVAGINAL RADIATION; AMERICAN BRACHYTHERAPY; SURVIVAL
OUTCOMES; I PATIENTS; CARCINOMA; RADIOTHERAPY; MANAGEMENT
AB Objective. To report clinical outcomes following adjuvant high-dose-rate (HDR) vaginal brachytherapy (VB) for early-stage uterine papillary serous (UPSC) and clear cell (CC) endometrial cancer.
Methods. A retrospective study of Stage I and II papillary serous and clear cell endometrial cancer treated with post-operative HDR VB between October 2005 and May 2012 was performed. A total of 37 patients were identified, 26 with UPSC, 9 with CC and 2 with mixed UPSC/CC. After total hysterectomy and bilateral salpingo-oophorectomy, VB was administered without external-beam radiation with a dose of 24 Gy in 6 fractions prescribed to the vaginal surface. Chemotherapy was given to 30 patients (75%).
Results. The median follow up time was 24.8 months (range, 2.0 to 71.5 months). Four patients relapsed, 2 with UPSC and 2 with CC. The initial site of relapse was concurrent vagina, pelvic/para-aortic nodes and abdominal wall (1), pelvic/para-aortic nodes (1) and para-aortic nodes alone (2). The 2-year vaginal-control rate was 96.8%. The pelvic-control rate including vaginal and nodal relapse was 93.5%. The 2-year disease-free and overall survival rates were 893% and 100%, respectively.
Conclusion. HDR VB as the sole adjuvant treatment modality for early-stage UPSC/CC is associated with a low rate of vaginal relapse and excellent survival outcomes. This novel low-dose regimen for VB is safe and effective. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Townamchai, Kanokpis; Bhagwat, Mandar; Damato, Antonio L.; Friesen, Scott; Lee, Larissa J.; O'Farrell, Desmond; Viswanathan, Akila N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Berkowitz, Ross] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Gynecol Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Matulonis, Ursula] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Viswanathan, AN (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,ASB 1,L2, Boston, MA 02115 USA.
EM aviswanathan@lroc.harvard.edu
NR 28
TC 17
Z9 17
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD APR
PY 2013
VL 129
IS 1
BP 18
EP 21
DI 10.1016/j.ygyno.2012.12.026
PG 4
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 119IH
UT WOS:000317090500005
PM 23262378
ER
PT J
AU Rauh-Hain, JA
Nitschmann, CC
Worley, MJ
Bradford, LS
Berkowitz, RS
Schorge, JO
Campos, SM
del Carmen, MG
Horowitz, NS
AF Rauh-Hain, J. Alejandro
Nitschmann, Caroline C.
Worley, Micheal J., Jr.
Bradford, Leslie S.
Berkowitz, Ross S.
Schorge, John O.
Campos, Susana M.
del Carmen, Marcela G.
Horowitz, Neil S.
TI Platinum resistance after neoadjuvant chemotherapy compared to primary
surgery in patients with advanced epithelial ovarian carcinoma
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Ovarian cancer; Platinum resistance; Neoadjuvant chemotherapy
ID SURGICAL CYTOREDUCTION; CANCER; METAANALYSIS; SENSITIVITY; THERAPY
AB Objective. Primary debulking surgery (PDS) has historically been the standard treatment for advanced ovarian cancer. Recent data appear to support a paradigm shift toward neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) for a subset of women with advanced ovarian cancer. It remains unresolved whether NACT-IDS increases the risk of platinum resistance. We compared response to chemotherapy in patients that received NACT-IDS vs. PDS.
Methods. From our Cancer Registry database we identified patients with stages IIIC and IV epithelial ovarian cancer who underwent treatment from January, 2005 to December, 2010. Standard univariate analyses were performed, as were multivariable analysis with logistic regression. The Kaplan-Meier method was used to generate survival data.
Results. The study population consisted of 425 patients, 95 (22.3%) underwent NACT-IDS and 330 (77.6%) PDS. After the initial platinum-based chemotherapy, 42 (44.2%) women in the NACT-IDS group were considered to have platinum resistant disease, compared to 103 (31.2%) in the PDS group (P=0.01). When multivariate logistic regression was used to control for factors independently associated with platinum resistance, NACT-IDS was no longer associated with an initial increased risk. However, in women that had a recurrence and were retreated with platinum-based chemotherapy, 32 (88.8%) in the NACT-IDS group had developed a recurrence within six months and were considered platinum resistant, compared to 62 (55.3%) in the PDS (P<0.001).
Conclusion. In women with EOC that have a recurrence and are treated again with platinum-based chemotherapy, NACT-IDS appears to increase the risk of platinum resistance. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Rauh-Hain, J. Alejandro; Nitschmann, Caroline C.; Bradford, Leslie S.; Schorge, John O.; del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol,Vincent Obstet & Gynecol, Boston, MA USA.
[Nitschmann, Caroline C.; Worley, Micheal J., Jr.; Berkowitz, Ross S.; Campos, Susana M.; Horowitz, Neil S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gynecol Oncol, Boston, MA 02115 USA.
RP Horowitz, NS (reprint author), Brigham & Womens Hosp, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.
EM nhorowitz@partners.org
NR 23
TC 27
Z9 30
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD APR
PY 2013
VL 129
IS 1
BP 63
EP 68
DI 10.1016/j.ygyno.2013.01.009
PG 6
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 119IH
UT WOS:000317090500014
PM 23337490
ER
PT J
AU Worley, MJ
Guseh, SH
Rauh-Hain, JA
Williams, KA
Muto, MG
Feltmate, CM
Berkowitz, RS
Horowitz, NS
AF Worley, Michael J., Jr.
Guseh, Stephanie H.
Rauh-Hain, J. Alejandro
Williams, Kristina A.
Muto, Michael G.
Feltmate, Colleen M.
Berkowitz, Ross S.
Horowitz, Neil S.
TI Does neoadjuvant chemotherapy decrease the risk of hospital readmission
following debulking surgery?
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Neoadjuvant chemotherapy; Ovarian-cancer; Elderly; Readmission
ID EPITHELIAL OVARIAN-CANCER; CYTOREDUCTIVE SURGERY; ELDERLY-WOMEN; OLDER
PATIENTS; SURVIVAL; AGE; CARCINOMA; MORBIDITY; PATTERNS
AB Objective. To compare primary debulking surgery (PDS) vs. neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) among elderly patients with ovarian/fallopian tube/primary peritoneal carcinoma.
Methods. Medical records of patients >= 70 years old with epithelial ovarian/fallopian tube/primary peritoneal carcinoma between January 2000 and December 2010 were reviewed. Patients were separated by PDS or NACT-IDS. Preoperative characteristics, surgical procedures and postoperative and oncologic outcomes were compared. Surgical procedures were given a complexity score based on a previously published method.
Results. Of 165 patients, 125 (75.8%) underwent PDS and 40(24.2%) underwent NACT-IDS. Patients undergoing NACT-IDS were more likely to have a pleural effusion (without cytology) and stage 4 disease. Median CA-125 at diagnosis was greater for those undergoing NACT-IDS. The NACT-IDS group was associated with less intraoperative blood loss (250 vs. 400 mL, p = 0.001), a greater chance of achieving no residual disease (40% vs. 16%, p=0.005) and a shorter hospital length of stay (LOS) (5 vs. 7 days, p<0.001). PFS (17 vs. 15 months, p = 0.708) and OS (29 vs. 33 months, p = 0.827) were similar between the two groups. Readmission rates within 30 days of surgery were greater in those undergoing PDS (17.6% vs. 2.5%, p = 0.016). After readmission, the median hospital LOS was 6 days (range: 1-41).
Conclusions. Elderly patients undergoing PDS have similar oncologic outcomes when compared to patients undergoing NACT-IDS. The risk of readmission within 30 days of surgery is significantly greater among patients undergoing PDS. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Worley, Michael J., Jr.; Muto, Michael G.; Feltmate, Colleen M.; Berkowitz, Ross S.; Horowitz, Neil S.] Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02115 USA.
[Guseh, Stephanie H.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Rauh-Hain, J. Alejandro] Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
[Williams, Kristina A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Horowitz, NS (reprint author), Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.
EM nhorowitz@partners.org
NR 31
TC 9
Z9 9
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD APR
PY 2013
VL 129
IS 1
BP 69
EP 73
DI 10.1016/j.ygyno.2013.01.012
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 119IH
UT WOS:000317090500015
PM 23375727
ER
PT J
AU Armoundas, AA
Weiss, EH
Sayadi, O
Laferriere, S
Sajja, N
Mela, T
Singh, JP
Barrett, CD
Heist, EK
Merchant, FM
AF Armoundas, Antonis A.
Weiss, Eric H.
Sayadi, Omid
Laferriere, Shawna
Sajja, Naveen
Mela, Theofanie
Singh, Jagmeet P.
Barrett, Conor D.
Heist, E. Kevin
Merchant, Faisal M.
TI A novel pacing method to suppress repolarization alternans in vivo:
Implications for arrhythmia prevention
SO HEART RHYTHM
LA English
DT Article
DE Repolarization alternans; Ventricular tachycardia/ventricular
fibrillation; Cardiac pacing; Heart failure; Sudden cardiac death
ID T-WAVE ALTERNANS; CARDIAC CONTRACTILITY MODULATION; VENTRICULAR
TACHYARRHYTHMIAS; DISCORDANT ALTERNANS; HEART; FIBRILLATION;
ELECTROGRAMS; MECHANISMS; THERAPY; GENESIS
AB BACKGROUND Repolarization alternans (RA), a pattern of ventricular repolarization that repeats on an every other beat basis, has been closely linked with the substrate associated with ventricular tachycardia/ventricular fibrillation.
OBJECTIVE To evaluate a novel method to suppress RA.
METHODS We have developed a novel method to dynamically (on R-wave detection) trigger pacing pulses during the absolute refractory period. We have tested the ability of this method to control RA in a structurally normal swine heart in vivo.
RESULTS RA induced by triggered pacing can be measured from both intracardiac and body surface leads and the amplitude of R-wave triggered pacing-induced alternans can be locally modulated by varying the amplitude and width of the pacing pulse. We have estimated that to induce a 1 mu V change in alternans voltage on the body surface, coronary sinus, and left ventricle leads, a triggered pacing pulse delivered in the right ventricle of 0.04 +/- 0.02, 0.05 +/- 0.025, and 0.06 +/- 0.033 mu C, respectively, is required. Similarly, to induce a 1 unit change in K-score (ratio of alternans peak to noise), a pacing stimulus of 0.93 +/- 0.73, 0.32 +/- 0.29, and 0.33 +/- 0.37 mu C, respectively, is required. We have been able to demonstrate that RA can be suppressed by R-wave triggered pacing from a site that is within or across ventricles. lastly, we have demonstrated that the proposed method can be used to suppress spontaneously occurring alternans in the diseased heart.
CONCLUSION We have developed a novel method to suppress RA in vivo.
C1 [Armoundas, Antonis A.; Weiss, Eric H.] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Armoundas, Antonis A.; Sayadi, Omid; Laferriere, Shawna; Sajja, Naveen; Mela, Theofanie; Singh, Jagmeet P.; Barrett, Conor D.; Heist, E. Kevin; Merchant, Faisal M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Armoundas, AA (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.
EM aarmoundas@partners.org
FU American Heart Association [0635127N, 12POST9310001, 0815767D]; National
Institute of Aging [1R21AG035128]; National Institutes of Health
[1RO1HL103961]; Center for Integration of Medicine and Innovative
Technology (CIMIT); Deane Institute for Integrative Research in Atrial
Fibrillation and Stroke; Cardiovascular Research Society; St Jude
Medical; Medtronic; Boston Scientific; Biotronik; Guidant; Sorin
FX This work was supported by a Scientist Development Grant (#0635127N), by
a postdoctoral fellowship (#12POST9310001) and a predoctoral fellowship
(#0815767D) from the American Heart Association, by National Institute
of Aging grant 1R21AG035128 and National Institutes of Health grant
1RO1HL103961. This work was also supported by a fellowship and a science
award from the Center for Integration of Medicine and Innovative
Technology (CIMIT), the Deane Institute for Integrative Research in
Atrial Fibrillation and Stroke, and the Cardiovascular Research
Society.; Dr Mela has received honoraria from Medtronic, Biotronik, and
St Jude. Dr Singh has received research grants from St Jude Medical,
Medtronic, Boston Scientific, and Biotronik and honoraria/speaker fees
from Medtronic, Biotronik, Guidant, St Jude Medical, and Sorin; he is
the advisory board member/steering committee member/consultant at Boston
Scientific, Biotronik, St Jude Medical, Medtronic, CardioInsight,
Thoratec, Biosense Webster. Dr Heist has received honoraria from
Biotronik, Boston Scientific, Medtronic, Sorin, and St Jude Medical and
research grants from Biotronik, Boston Scientific, and St Jude Medical;
he is a consultant at Boston Scientific, Sanofi, Sorin, and St Jude
Medical.
NR 26
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD APR
PY 2013
VL 10
IS 4
BP 564
EP 572
DI 10.1016/j.hrthm.2012.12.026
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 121XE
UT WOS:000317277700023
PM 23274372
ER
PT J
AU Russo, AM
Stainback, RF
Bailey, SR
Epstein, AE
Heidenreich, PA
Jessup, M
Kapa, S
Kremers, MS
Lindsay, BD
Stevenson, LW
Bailey, SR
Russo, AM
Kapa, S
Alexander, MB
Bailey, SR
Birgersdotter-Green, U
Brown, AS
Grimm, RA
Hauptman, PJ
Hunt, SA
Lampert, R
Lindenfeld, J
Malenka, DJ
Mani, K
Marine, JE
Martin, ET
Page, RL
Rich, MW
Varosy, PD
Walsh, MN
Wolk, MJ
Bailey, SR
Doherty, JU
Douglas, PS
Hendel, RC
Kramer, CM
Min, JK
Patel, MR
Shaw, L
Stainback, RF
Allen, JM
AF Russo, Andrea M.
Stainback, Raymond F.
Bailey, Steven R.
Epstein, Andrew E.
Heidenreich, Paul A.
Jessup, Mariell
Kapa, Suraj
Kremers, Mark S.
Lindsay, Bruce D.
Stevenson, Lynne Warner
Bailey, Steven R.
Russo, Andrea M.
Kapa, Suraj
Alexander, Michael B.
Bailey, Steven R.
Birgersdotter-Green, Ulrika
Brown, Alan S.
Grimm, Richard A.
Hauptman, Paul J.
Hunt, Sharon A.
Lampert, Rachel
Lindenfeld, JoAnn
Malenka, David J.
Mani, Kartik
Marine, Joseph E.
Martin, Edward T.
Page, Richard L.
Rich, Michael W.
Varosy, Paul D.
Walsh, Mary Norine
Wolk, Michael J.
Bailey, Steven R.
Doherty, John U.
Douglas, Pamela S.
Hendel, Robert C.
Kramer, Christopher M.
Min, James K.
Patel, Manesh R.
Shaw, Leslee
Stainback, Raymond F.
Allen, Joseph M.
CA Amer Geriatrics Soc
TI ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate Use Criteria for
Implantable Cardioverter-Defibrillators and Cardiac Resynchronization
Therapy A Report of the American College of Cardiology Foundation
Appropriate Use Criteria Task Force, Heart Rhythm Society, American
Heart Association, American Society of Echocardiography, Heart Failure
Society of America, Society for Cardiovascular Angiography and
Interventions, Society of Cardiovascular Computed Tomography, and
Society for Cardiovascular Magnetic Resonance
SO HEART RHYTHM
LA English
DT Article
DE ACCF appropriate use criteria; CRT; electrophysiology; heart failure;
ICD; implantable defibrillator; sudden death
ID ACUTE MYOCARDIAL-INFARCTION; MONOMORPHIC VENTRICULAR-TACHYCARDIA;
DUAL-CHAMBER; QRS DURATION; TASK-FORCE; NUCLEAR CARDIOLOGY; PRIMARY
PREVENTION; UNIVERSAL DEFINITION; COMPLICATION RATES; THORACIC-SURGEONS
AB The American College of Cardiology Foundation in collaboration with the Heart Rhythm Society and key specialty and subspecialty societies conducted a review of common clinical scenarios where implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are frequently considered. The clinical scenarios covered in this document address secondary prevention, primary prevention, comorbidities, generator replacement at elective replacement indicator, dual-chamber ICD, and CRT.
The indications (clinical scenarios) were derived from common applications or anticipated uses, as well as from current clinical practice guidelines and results of studies examining device implantation. The 369 indications in this document were developed by a multidisciplinary writing group and scored by a separate independent technical panel on a scale of 1 to 9 to designate care that is Appropriate (median 7 to 9), May Be Appropriate (median 4 to 6), and Rarely Appropriate (median 1 to 3). The final ratings reflect the median score of the 17 technical panel members: 45% of the indications were rated as Appropriate, 33% were rated May Be Appropriate and 22% were rated Rarely Appropriate.
In general, Appropriate designations were assigned to scenarios for which clinical trial evidence and/or clinical experience was available that supported device implantation. By contrast, scenarios for which clinical trial evidence was limited or device implantation seemed reasonable for extenuating reasons were categorized as May Be Appropriate. Scenarios for which there were data showing harm, or no data were available, and medical judgment deemed device therapy ill-advised were categorized as Rarely Appropriate. For example, comorbidities including life expectancy and cognitive function impacted appropriateness ratings.
The Appropriate Use Criteria for ICD/CRT have the potential to enhance physician decision making, healthcare delivery, and reimbursement policy. Furthermore, recognition of clinical scenarios rated as May Be Appropriate facilitates the identification of areas that would benefit from future research.
C1 [Russo, Andrea M.; Russo, Andrea M.] UMDNJ, Robert Wood Johnson Med Sch, Piscataway, NJ USA.
[Russo, Andrea M.; Russo, Andrea M.] Cooper Univ Hosp, Cardiac Electrophysiol Serv, Camden, NJ USA.
[Russo, Andrea M.; Russo, Andrea M.] Cooper Univ Hosp, Arrhythmia Serv, Camden, NJ USA.
[Stainback, Raymond F.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA.
[Stainback, Raymond F.] Baylor Coll Med, Houston, TX 77030 USA.
[Bailey, Steven R.; Bailey, Steven R.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA.
[Bailey, Steven R.; Bailey, Steven R.] Univ Texas Hlth Sci Ctr San Antonio, Janey Briscoe Distinguished Chair, San Antonio, TX 78229 USA.
[Epstein, Andrew E.] Univ Penn, Electrophysiol Sect, Cardiovasc Div, Philadelphia, PA 19104 USA.
[Epstein, Andrew E.] Philadelphia VA Med Ctr, Cardiol Sect, Philadelphia, PA USA.
[Heidenreich, Paul A.] Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
[Jessup, Mariell] Univ Penn, Heart & Vasc Ctr, Philadelphia, PA 19104 USA.
[Kapa, Suraj; Kapa, Suraj] Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA.
[Kremers, Mark S.] Mid Carolina Cardiol, Charlotte, NC USA.
[Lindsay, Bruce D.] Cleveland Clin Fdn Cardiovasc Med, Cleveland, OH USA.
[Stevenson, Lynne Warner] Brigham & Womens Hosp, Cardiomyopathy & Heart Failure Program, Cardiovasc Div, Boston, MA 02115 USA.
[Alexander, Michael B.] Cigna HealthCare, Blue Bell, PA USA.
[Birgersdotter-Green, Ulrika] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
[Birgersdotter-Green, Ulrika] Univ Calif San Diego, Med Ctr, Pacemaker & ICD Clin, La Jolla, CA 92093 USA.
[Brown, Alan S.] Midwest Heart Dis Prevent Ctr, Naperville, IL USA.
[Brown, Alan S.] Loyola Univ, Stritch Sch Med, Naperville, IL USA.
[Grimm, Richard A.] Cleveland Clin, Sect Cardiovasc Imaging, Cardiovasc Med Heart & Vasc Inst, Cleveland, OH 44106 USA.
[Hauptman, Paul J.] St Louis Univ Hosp, Heart Failure & Transplant Program, St Louis, MO USA.
[Hauptman, Paul J.] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA.
[Hunt, Sharon A.] Stanford Univ, Dept Cardiovasc Med, Stanford, CA 94305 USA.
[Lampert, Rachel] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA.
[Lindenfeld, JoAnn] Univ Colorado, Hlth Sci Ctr, Cardiac Transplant Program, Aurora, CO USA.
[Malenka, David J.] Dartmouth Inst Hlth Policy & Clin Practice, Dartmouth Med Sch, Lebanon, NH USA.
[Mani, Kartik] Mercy Med Ctr, Roseburg, OR USA.
[Marine, Joseph E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Martin, Edward T.] Oklahoma Heart Inst, Cardiovasc MRI, Tulsa, OK USA.
[Martin, Edward T.] Univ Oklahoma, Tulsa, OK USA.
[Page, Richard L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Rich, Michael W.] Washington Univ, Sch Med, St Louis, MO USA.
[Varosy, Paul D.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA.
[Walsh, Mary Norine] St Vincent Heart Ctr Indiana, Indianapolis, IN USA.
Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
VA Med Ctr, Heart Failure Program, Minneapolis, MN USA.
Johns Hopkins Med Inst, Cardiac Elect Training Program, Baltimore, MD 21205 USA.
Ctr Med Technol Policy, Baltimore, MD USA.
Los Angeles Biomed Res Inst, Torrance, CA USA.
Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
Beth Israel Deaconess Med Ctr, Clin Electrophysiol Lab, Boston, MA 02215 USA.
Cardiac Arrhythmia Serv, Baltimore, MD USA.
Electrophysiol Lab, Baltimore, MD USA.
Johns Hopkins ARVD C Program, Baltimore, MD USA.
SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA.
RI Page, Richard/L-5501-2014
OI Page, Richard/0000-0001-5603-1330
NR 61
TC 46
Z9 47
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD APR
PY 2013
VL 10
IS 4
BP E11
EP E58
DI 10.1016/j.hrthm.2013.01.008
PG 48
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 121XE
UT WOS:000317277700001
PM 23473952
ER
PT J
AU Li, Y
Chang, XY
Zhou, WX
Xiao, Y
Nakatsuka, LN
Chen, J
Lauwers, GY
AF Li, Yuan
Chang, Xiaoyan
Zhou, Weixun
Xiao, Yu
Nakatsuka, Laura N.
Chen, Jie
Lauwers, Gregory Y.
TI Gastric intestinal metaplasia with basal gland atypia: a morphological
and biologic evaluation in a large Chinese cohort
SO HUMAN PATHOLOGY
LA English
DT Article
DE Stomach; Adenocarcinoma; Intestinal metaplasia; Basal gland atypia;
Dysplasia; Gastric pit dysplasia
ID BARRETTS-ESOPHAGUS; ULCERATIVE-COLITIS; DYSPLASIA; LESIONS; CANCER;
EXPRESSION; CLASSIFICATION; INDEFINITE; NEOPLASIA; MUCOSA
AB Gastric intestinal metaplasia can display cytoarchitectural atypia that falls short of qualifying for dysplasia but can be classified as indefinite for dysplasia. Yet few studies have evaluated the prevalence, the morphologic, and biologic characteristics of this variant. Out of a cohort of 554 biopsies with chronic atrophic gastritis and/or dysplasia, we categorized the cases as either (1) simple intestinal metaplasia; (2) intestinal metaplasia with hyperplasia; (3) intestinal metaplasia with basal gland atypia; and (4) gastric dysplasia. The relationship between the subtypes and various clinicopathologic features, mucin immunophenotypes, and biologic characteristics was evaluated. The final cohort consisted of 424 cases of simple intestinal metaplasia, 93 intestinal metaplasia with hyperplasia, 16 intestinal metaplasia with basal gland atypia, and 21 gastric dysplasia. Intestinal metaplasia with basal gland atypia had a prevalence of 2.8% and similar to gastric dysplasia, 3.7%. Both of these lesions were similar in body/fundus distribution (12.5%) and paucity of goblet cells (68.8%). Intestinal metaplasia with basal gland atypia and gastric dysplasia seem to share some biologic similarities but with a lower frequency of alpha-methylacyl-CoA racemase expression (25% versus 62%), p53 expression (6.3% versus 47.6%), and increased Ki-67 index on surface/pit and isthmus in intestinal metaplasia with basal gland atypia. Alternatively, simple intestinal metaplasia and intestinal metaplasia with hyperplasia did not differ statistically with regard to the various characteristics evaluated. We concluded that gastric intestinal metaplasia can be divided into 2 broad categories that are readily defined by cytoarchitectural and biologic characteristics. Based on the characteristics of intestinal metaplasia with basal gland atypia and in keeping with others, we confirm that this subtype could represent a preneoplastic lesion that needs further evaluation. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Li, Yuan; Chang, Xiaoyan; Zhou, Weixun; Xiao, Yu; Chen, Jie] Beijing Union Med Coll Hosp, Chinese Acad Med Sci, Peking Union Med Coll, Dept Pathol, Beijing 100730, Peoples R China.
[Li, Yuan; Nakatsuka, Laura N.; Lauwers, Gregory Y.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Lauwers, GY (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02144 USA.
EM xhblk@163.com; glauwers@partners.org
FU Scientific Research Special Projects of the Health Industry of China,
People's Republic of China [200802011]
FX Supported by a grant (200802011) from the Scientific Research Special
Projects of the Health Industry of China, People's Republic of China.
NR 35
TC 5
Z9 6
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD APR
PY 2013
VL 44
IS 4
BP 578
EP 590
DI 10.1016/j.humpath.2012.07.002
PG 13
WC Pathology
SC Pathology
GA 121LQ
UT WOS:000317246700015
PM 23079203
ER
PT J
AU Ting, JY
Remenschneider, A
Holbrook, EH
AF Ting, Jonathan Y.
Remenschneider, Aaron
Holbrook, Eric H.
TI Management of severe epistaxis after Young's procedure: a case report
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE nasal closure; modified Young's procedure; epistaxis; hereditary
hemorrhagic telangiectasia; Osler-Weber-Rendu disease
ID HEREDITARY HEMORRHAGIC TELANGIECTASIA; PULSED DYE-LASER; NOSTRIL
CLOSURE; THERAPY; BEVACIZUMAB; SECONDARY
AB Background Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder affecting multiple organ systems, with epistaxis being the most common manifestation. Multiple procedures have been used for the management of epistaxis in the setting of HHT, including closure of the anterior nares via a Young's procedure. While this procedure results in loss of smell and permanent nasal obstruction, proponents note significant improvement in patient symptomatology. Methods Case report. Results A 70-year-old female with a history of HHT presented to an outside hospital with bleeding into the nasopharynx 2 months after undergoing a modified Young's procedure at an unaffiliated institution. She was transfused with 2 units of packed red blood cells (PRBCs) and transferred to our facility. Due to persistent epistaxis and need for airway protection, the patient was intubated and her throat was packed. She also developed aspiration pneumonia and hypotensive shock requiring vasopressors. Twenty-four hours following bilateral internal maxillary and sphenopalatine artery embolization, she developed significant epistaxis requiring reversal of the Young's procedure on the left and placement of an anterior-posterior pack at the bedside. Upon packing removal several days later in the operating room, she was noted to have significant bleeding that necessitated reversal of the Young's procedure on the right side to obtain adequate exposure and hemostasis. Conclusion We report a case of significant, life-threatening epistaxis following a modified Young's procedure that requiring multiple transfusions, bilateral embolization, and ultimately reversal of the Young's procedure for control of epistaxis. Although recognized as a potential complication, to our knowledge this is the first report in the English literature of such a case. (C) 2013 ARS-AAOA, LLC.
C1 [Ting, Jonathan Y.; Remenschneider, Aaron; Holbrook, Eric H.] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA.
RP Ting, JY (reprint author), 243 Charles St, Boston, MA 02114 USA.
EM jonathan_ting@meei.harvard.edu
NR 34
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD APR
PY 2013
VL 3
IS 4
BP 334
EP 337
DI 10.1002/alr.21099
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 123BK
UT WOS:000317362900012
PM 23109496
ER
PT J
AU Garshick, E
AF Garshick, E.
TI EPIDEMIOLOGY OF CANCER AND DIESEL EXHAUST
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Meeting Abstract
C1 [Garshick, E.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Channing Div Network Med, Boston, MA 02115 USA.
[Garshick, E.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD APR
PY 2013
VL 26
IS 2
BP A7
EP A7
PG 1
WC Respiratory System
SC Respiratory System
GA 118QI
UT WOS:000317040000019
ER
PT J
AU Greenblatt, EE
Venegas, JG
AF Greenblatt, E. E.
Venegas, J. G.
TI ANALYSIS OF AEROSOL DEPOSITION USING ANATOMICALLY DERIVED REGIONS OF
INTEREST (ROIs): BEYOND BLACK AND WHITE
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Meeting Abstract
C1 [Greenblatt, E. E.] MIT, Boston, MA USA.
[Greenblatt, E. E.; Venegas, J. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Venegas, J. G.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD APR
PY 2013
VL 26
IS 2
BP A34
EP A35
PG 2
WC Respiratory System
SC Respiratory System
GA 118QI
UT WOS:000317040000094
ER
PT J
AU Greenblatt, EE
Harris, RS
Winkler, T
Kelly, VJ
Kone, M
Katz, I
Martin, A
Caillibotte, G
Venegas, JG
AF Greenblatt, E. E.
Harris, R. S.
Winkler, T.
Kelly, V. J.
Kone, M.
Katz, I.
Martin, A.
Caillibotte, G.
Venegas, J. G.
TI RELATIONSHIP BETWEEN REGIONAL VENTILATION AND AEROSOL DEPOSITION IN
BRONCHOCONSTRICTED SUBJECTS WITH ASTHMA
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Meeting Abstract
C1 [Greenblatt, E. E.] MIT, Boston, MA USA.
[Greenblatt, E. E.; Harris, R. S.; Winkler, T.; Kelly, V. J.; Kone, M.; Venegas, J. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Harris, R. S.; Winkler, T.; Kelly, V. J.; Kone, M.; Venegas, J. G.] Harvard Univ, Sch Med, Boston, MA USA.
[Katz, I.; Martin, A.; Caillibotte, G.] Air Liquide R&D, Jouy En Josas, France.
RI Winkler, Tilo/B-5337-2009
OI Winkler, Tilo/0000-0002-7276-5550
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD APR
PY 2013
VL 26
IS 2
BP A34
EP A34
PG 1
WC Respiratory System
SC Respiratory System
GA 118QI
UT WOS:000317040000092
ER
PT J
AU Hess, DR
AF Hess, D. R.
TI MODES OF NONINVASIVE POSITIVE PRESSURE VENTILATION AND MASK INTERFACES
EMPLOYED
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Meeting Abstract
C1 [Hess, D. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hess, D. R.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD APR
PY 2013
VL 26
IS 2
BP A3
EP A3
PG 1
WC Respiratory System
SC Respiratory System
GA 118QI
UT WOS:000317040000006
ER
PT J
AU Venegas, JG
Greenblatt, EE
Winkler, T
Kelly, VJ
Kone, M
Katz, I
Martin, A
Caillibotte, G
Harris, RS
AF Venegas, J. G.
Greenblatt, E. E.
Winkler, T.
Kelly, V. J.
Kone, M.
Katz, I.
Martin, A.
Caillibotte, G.
Harris, R. S.
TI EFFECT OF CARRIER GAS ON THE RELATIONSHIP BETWEEN REGIONAL VENTILATION
AND AEROSOL DEPOSITION IN BRONCHOCONSTRICTED SUBJECTS WITH ASTHMA
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Meeting Abstract
C1 [Venegas, J. G.; Greenblatt, E. E.; Winkler, T.; Kelly, V. J.; Kone, M.; Harris, R. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Greenblatt, E. E.] MIT, Boston, MA USA.
[Katz, I.; Martin, A.; Caillibotte, G.] Air Liquide R&D, Jouy En Josas, France.
RI Winkler, Tilo/B-5337-2009
OI Winkler, Tilo/0000-0002-7276-5550
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD APR
PY 2013
VL 26
IS 2
BP A34
EP A34
PG 1
WC Respiratory System
SC Respiratory System
GA 118QI
UT WOS:000317040000093
ER
PT J
AU Venegas, JG
Greenblatt, EE
Winkler, T
Kelly, VJ
Kone, M
Harris, RS
AF Venegas, J. G.
Greenblatt, E. E.
Winkler, T.
Kelly, V. J.
Kone, M.
Harris, R. S.
TI AEROSOL IMAGING WITH PET-CT: FROM DEPOSITION TO TISSUE DOSING
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Meeting Abstract
C1 [Venegas, J. G.; Greenblatt, E. E.; Winkler, T.; Kelly, V. J.; Kone, M.; Harris, R. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Venegas, J. G.; Winkler, T.; Kelly, V. J.; Kone, M.; Harris, R. S.] Harvard Univ, Sch Med, Boston, MA USA.
[Greenblatt, E. E.] MIT, Boston, MA USA.
RI Winkler, Tilo/B-5337-2009
OI Winkler, Tilo/0000-0002-7276-5550
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD APR
PY 2013
VL 26
IS 2
BP A15
EP A16
PG 2
WC Respiratory System
SC Respiratory System
GA 118QI
UT WOS:000317040000044
ER
PT J
AU Cattaneo, F
Recher, M
Masneri, S
Baxi, SN
Fiorini, C
Antonelli, F
Wysocki, CA
Calderon, JG
Eibel, H
Smith, AR
Bonilla, FA
Tsitsikov, E
Giliani, S
Notarangelo, LD
Pai, SY
AF Cattaneo, Federica
Recher, Mike
Masneri, Stefania
Baxi, Sachin N.
Fiorini, Claudia
Antonelli, Francesca
Wysocki, Christian A.
Calderon, Jose G.
Eibel, Hermann
Smith, Angela R.
Bonilla, Francisco A.
Tsitsikov, Erdyni
Giliani, Silvia
Notarangelo, Luigi D.
Pai, Sung-Yun
TI Hypomorphic Janus kinase 3 mutations result in a spectrum of immune
defects, including partial maternal T-cell engraftment
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Severe combined immunodeficiency; cytokine signaling; maternal
engraftment
ID SEVERE COMBINED-IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION;
RECEPTOR-GAMMA-CHAIN; IMMUNOLOGICAL MANIFESTATIONS; OMENN-SYNDROME;
LYMPHOCYTES; DEFICIENCY; DISEASE; JAK3; IDENTIFICATION
AB Background: Mutations in Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 defects can result in a milder clinical phenotype, with residual development and function of autologous T cells. Maternal T-cell engraftment is a common finding in infants with severe combined immunodeficiency but is not typically observed in patients with residual T-cell development.
Objective: We sought to study in detail the molecular, cellular, and humoral immune phenotype and function of 3 patients with hypomorphic JAK3 mutations. Methods: We analyzed the distribution and function of T and B lymphocytes in 3 patients and studied the in vitro and in vivo responses of maternal T lymphocytes in 1 patient with maternal T-cell engraftment and residual production of autologous T lymphocytes.
Results: B cells were present in normal numbers but with abnormal distribution of marginal zone-like and memory B cells. B-cell differentiation to plasmablasts in vitro in response to CD40 ligand and IL-21 was abolished. In 2 patients the T-cell repertoire was moderately restricted. Surprisingly, 1 patient showed coexistence of maternal and autologous T lymphocytes. By using an mAb recognizing the maternal noninherited HLA-A2 antigen, we found that autologous cells progressively accumulated in vivo but did not compete with maternal cells in vitro.
Conclusion: The study of 3 patients with hypomorphic JAK3 mutations suggests that terminal B-cell maturation/differentiation requires intact JAK3 function, even if partially functioning T lymphocytes are present. Maternal T-cell engraftment can occur in patients with JAK3 mutations despite the presence of autologous T cells. (J Allergy Clin Immunol 2013; 131:1136-45.)
C1 [Cattaneo, Federica; Fiorini, Claudia; Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Recher, Mike; Notarangelo, Luigi D.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA.
[Recher, Mike; Baxi, Sachin N.; Bonilla, Francisco A.; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA USA.
[Tsitsikov, Erdyni] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA.
[Masneri, Stefania; Antonelli, Francesca; Giliani, Silvia] Univ Brescia, A Nocivelli Inst Mol Med, Brescia, Italy.
[Masneri, Stefania; Antonelli, Francesca; Giliani, Silvia] Spedali Civil Brescia, Lab Genet Disorders Childhood, I-25125 Brescia, Italy.
[Wysocki, Christian A.; Calderon, Jose G.] Yale Univ, Sch Med, Yale New Haven Hosp, Sect Allergy & Clin Immunol, New Haven, CT USA.
[Eibel, Hermann] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiencies, Freiburg, Germany.
[Smith, Angela R.] Univ Minnesota, Div Pediat Blood & Marrow Transplantat, Minneapolis, MN USA.
[Notarangelo, Luigi D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
RP Pai, SY (reprint author), Boston Childrens Hosp, Karp Family Res Labs, 1 Blackfan Circle,Rm 08214, Boston, MA 02115 USA.
EM sung-yun.pai@childrens.harvard.edu
RI sebastianovitsch, stepan/G-8507-2013; Notarangelo, Luigi/F-9718-2016;
OI Notarangelo, Luigi/0000-0002-8335-0262; Fiorini,
Claudia/0000-0003-4878-2438
FU Translational Investigator Service at Boston Children's Hospital; Manton
Foundation; National Institutes of Health [U54AI082973];
FondazioneNocivelli; Swiss National Science Foundation (SNSF/SSMBS)
[PASMP3-127678]; National Institute of Allergy and Infectious Diseases
and from Translational Research Program at Boston Children's Hospital
FX Supported by the Translational Investigator Service at Boston Children's
Hospital (to S.-Y.P.), the Manton Foundation (to L.D.N.), the National
Institutes of Health (U54AI082973 to S.-Y.P. and L.D.N.), and
FondazioneNocivelli (to S. G). M. R. was supported by the Swiss National
Science Foundation (SNSF/SSMBS) grant PASMP3-127678.; Disclosure of
potential conflict of interest: M. Recher has been supported by one or
more grants from the Swiss National Science Foundation (SNSF/SSMBS; Nrz
PASMP3127678). C. A. Wysocki has been supported by one or more grants
from the National Institutes of Health. L. D. Notarangelo has received
one or more grants from the National Institutes of Health and from the
Manton Foundation, is a Board member for the Immune Disease Institute,
is employed by Boston Children's Hospital, has received one or more
grants from or has one or more grants pending with the Wiskott-Aldrich
Foundation and with the March of Dimes, and has received royalties from
UpToDate. S.-Y. Pai has been supported by one or more grants from the
National Institute of Allergy and Infectious Diseases and from
Translational Research Program at Boston Children's Hospital. The rest
of the authors declare that they have no relevant conflicts of interest.
NR 41
TC 8
Z9 9
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD APR
PY 2013
VL 131
IS 4
BP 1136
EP 1145
DI 10.1016/j.jaci.2012.12.667
PG 10
WC Allergy; Immunology
SC Allergy; Immunology
GA 120QT
UT WOS:000317187200024
PM 23384681
ER
PT J
AU Henderson, LA
Frugoni, F
Hopkins, G
Al-Herz, W
Weinacht, K
Comeau, AM
Bonilla, FA
Notarangelo, LD
Pai, SY
AF Henderson, Lauren A.
Frugoni, Francesco
Hopkins, Gregory
Al-Herz, Waleed
Weinacht, Katja
Comeau, Anne Marie
Bonilla, Francisco A.
Notarangelo, Luigi D.
Pai, Sung-Yun
TI First reported case of Omenn syndrome in a patient with reticular
dysgenesis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID SEVERE COMBINED IMMUNODEFICIENCY; ADENYLATE KINASE 2; SENSORINEURAL
DEAFNESS; ALEUKOCYTOSIS
C1 [Henderson, Lauren A.; Frugoni, Francesco; Bonilla, Francisco A.; Notarangelo, Luigi D.] Childrens Hosp Boston, Div Immunol, Boston, MA USA.
[Hopkins, Gregory; Weinacht, Katja; Pai, Sung-Yun] Childrens Hosp Boston, Div Hematol & Oncol, Boston, MA USA.
[Notarangelo, Luigi D.] Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA.
[Al-Herz, Waleed] Kuwait Univ, Dept Pediat, Fac Med, Allergy & Clin Immunol Unit, Kuwait, Kuwait.
[Weinacht, Katja; Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Comeau, Anne Marie] Univ Massachusetts, Sch Med, New England Newborn Screening Program, Worcester, MA USA.
RP Henderson, LA (reprint author), Childrens Hosp Boston, Div Immunol, Boston, MA USA.
EM Sung-Yun.Pai@childrens.harvard.edu
RI Notarangelo, Luigi/F-9718-2016;
OI Notarangelo, Luigi/0000-0002-8335-0262; Frugoni,
Francesco/0000-0002-1769-8121
FU NCEH CDC HHS [1U01EH00362, U01 EH000362]; NIAID NIH HHS [U54 AI082973,
U54AI082973]
NR 10
TC 10
Z9 10
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD APR
PY 2013
VL 131
IS 4
BP 1227
EP 1230
DI 10.1016/j.jaci.2012.07.045
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 120QT
UT WOS:000317187200034
PM 23014587
ER
PT J
AU Hamilos, DL
AF Hamilos, Daniel L.
TI Host-microbial interactions in patients with chronic rhinosinusitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
ID ENDOSCOPIC SINUS SURGERY; REFRACTORY CHRONIC RHINOSINUSITIS; TOLL-LIKE
RECEPTORS; BACTERIAL BIOFILMS; EPITHELIAL-CELLS; INNATE IMMUNITY;
STAPHYLOCOCCUS-AUREUS; NASAL POLYPOSIS; SINONASAL CAVITY;
BINDING-PROTEIN
C1 Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
RP Hamilos, DL (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.
EM dhamilos@partners.org
NR 63
TC 6
Z9 6
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD APR
PY 2013
VL 131
IS 4
BP 1263
EP +
DI 10.1016/j.jaci.2013.02.020
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 120QT
UT WOS:000317187200055
PM 23540620
ER
PT J
AU Carbo, C
Yuki, K
Demers, M
Wagner, DD
Shimaoka, M
AF Carbo, Carla
Yuki, Koichi
Demers, Melanie
Wagner, Denisa D.
Shimaoka, Motomu
TI Isoflurane inhibits neutrophil recruitment in the cutaneous Arthus
reaction model
SO JOURNAL OF ANESTHESIA
LA English
DT Article
DE beta 2 Integrin; Reverse passive Arthus reaction; Skin; Isoflurane;
Neutrophil recruitment
ID INTERCELLULAR-ADHESION MOLECULE-1; SELECTIN GLYCOPROTEIN LIGAND-1;
ANESTHETIC ACTION; INTEGRIN LFA-1; MICE; INFLAMMATION; MECHANISMS;
MIGRATION; MAC-1; SURGERY
AB Neutrophil recruitment to the inflammatory sites is regulated by a variety of adhesion molecules including beta 2 integrins. The dependency of neutrophil recruitment on beta 2 integrins is variable in different tissues, but has not yet been verified in the cutaneous passive reverse Arthus reaction. We examined this question and also evaluated the impact of isoflurane on neutrophil recruitment to the skin because we previously showed in vitro that isoflurane binds and inhibits beta 2 integrins.
The dependency on beta 2 integrins in neutrophil recruitment to the skin in the Arthus reaction was examined using alpha L, alpha M and beta 2 knockout mice. Then, we evaluated the effect of isoflurane on neutrophil recruitment to the skin. In addition, the effects of isoflurane on neutrophil binding to intercellular adhesion molecule-1 (ICAM-1), one of the beta 2 integrin ligands, were studied in vitro using cell adhesion assays.
Neutrophil recruitment to the skin in the Arthus reaction model was totally dependent on beta 2 integrins, as beta 2 knockout mice completely abolished it. However, the defect of only one of the beta 2 integrins was not sufficient to abolish neutrophil recruitment. Isoflurane reduced neutrophil recruitment to the skin by approximately 90 %. Also, isoflurane inhibited neutrophil adhesion to beta 2 integrin ligand ICAM-1.
We demonstrated that (1) neutrophil recruitment to the skin was totally dependent on beta 2 integrins, and (2) isoflurane significantly impaired neutrophil recruitment. Based on the previous studies on the contribution of other adhesion molecules in neutrophil recruitment, it is likely that isoflurane at least partially affects on beta 2 integrins in this model.
C1 [Carbo, Carla; Yuki, Koichi; Demers, Melanie; Wagner, Denisa D.; Shimaoka, Motomu] Immune Dis Inst, Boston, MA USA.
[Carbo, Carla; Demers, Melanie; Wagner, Denisa D.; Shimaoka, Motomu] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Carbo, Carla; Demers, Melanie; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Yuki, Koichi] Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
[Yuki, Koichi; Shimaoka, Motomu] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
[Shimaoka, Motomu] Mie Univ, Grad Sch Med, Dept Mol Pathobiol & Cell Adhes Biol, Tsu, Mie 5148507, Japan.
RP Yuki, K (reprint author), Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM yuki.koichi@gmail.com; shimaoka@doc.medic.mie-u.ac.jp
FU National Institute of Health (NIH) [HL041002, K08GM101345]; CHMC
Anesthesia Foundation
FX In part supported by National Institute of Health (NIH) grants HL041002
(D. W.), K08GM101345 (K.Y.) and CHMC Anesthesia Foundation (K.Y.).
Acknowledge Dr. Roderic G. Eckenhoff (University of Pennsylvania) for
valuable suggestions.
NR 46
TC 3
Z9 4
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
JAPAN
SN 0913-8668
J9 J ANESTH
JI J. Anesth.
PD APR
PY 2013
VL 27
IS 2
BP 261
EP 268
DI 10.1007/s00540-012-1508-1
PG 8
WC Anesthesiology
SC Anesthesiology
GA 123CR
UT WOS:000317366400016
PM 23096126
ER
PT J
AU Gurubhagavatula, I
Fields, BG
Morales, CR
Hurley, S
Pien, GW
Wick, LC
Staley, BA
Townsend, RR
Maislin, G
AF Gurubhagavatula, Indira
Fields, Barry G.
Morales, Christian R.
Hurley, Sharon
Pien, Grace W.
Wick, Lindsay C.
Staley, Bethany A.
Townsend, Raymond R.
Maislin, Greg
TI Screening for Severe Obstructive Sleep Apnea Syndrome in Hypertensive
Outpatients
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID POSITIVE AIRWAY PRESSURE; HIGH BLOOD-PRESSURE; DAYTIME SLEEPINESS;
DIAGNOSTIC SYSTEM; CONTROLLED-TRIAL; ASSOCIATION; POLYSOMNOGRAPHY;
PREVALENCE; MEN; POPULATION
AB The authors attempted to validate a 2-stage strategy to screen for severe obstructive sleep apnea syndrome (s-OSAS) among hypertensive outpatients, with polysomnography (PSG) as the gold standard. Using a prospective design, outpatients with hypertension were recruited from medical outpatient clinics. Interventions included (1) assessment of clinical data; (2) home sleep testing (HST); and (3) 12-channnel, in-laboratory PSG. The authors developed models using clinical or HST data alone (single-stage models) or clinical data in tandem with HST (2-stage models) to predict s-OSAS. For each model, area under receiver operating characteristic curves (AUCs), sensitivity, specificity, negative likelihood ratio, and negative post-test probability (NPTP) were computed. Models were then rank-ordered based on AUC values and NPTP. HST used alone had limited accuracy (AUC=0.727, NPTP=2.9%). However, models that used clinical data in tandem with HST were more accurate in identifying s-OSAS, with lower NPTP: (1) facial morphometrics (AUC=0.816, NPTP=0.6%); (2) neck circumference (AUC=0.803, NPTP=1.7%); and Multivariable Apnea Prediction Score (AUC=0.799, NPTP=1.5%) where sensitivity, specificity, and NPTP were evaluated at optimal thresholds. Therefore, HST combined with clinical data can be useful in identifying s-OSAS in hypertensive outpatients, without incurring greater cost and patient burden associated with in-laboratory PSG. These models were less useful in identifying obstructive sleep apnea syndrome of any severity.
C1 [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Pulm & Crit Care & Sleep Sect, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Gurubhagavatula, Indira; Fields, Barry G.; Morales, Christian R.; Hurley, Sharon; Pien, Grace W.; Wick, Lindsay C.; Staley, Bethany A.; Maislin, Greg] Univ Penn, Med Ctr, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA.
[Gurubhagavatula, Indira; Fields, Barry G.; Pien, Grace W.] Univ Penn, Med Ctr, Div Sleep Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA.
[Townsend, Raymond R.] Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
RP Fields, BG (reprint author), Ctr Sleep & Circadian Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA.
EM barry.fields@uphs.upenn.edu
FU National Institutes of Health [K23 RR16068, RO1-OH009149, T32 HL07713];
Veterans Integrated Services Network
FX This work was supported by National Institutes of Health grant K23
RR16068, RO1-OH009149, T32 HL07713, and by the Veterans Integrated
Services Network 4 Competitive Pilot Project Fund. ResMed, Inc provided
an unrestricted loan for use of portable diagnostic sleep study
equipment (AutoSet) and had no role in protocol development, data
collection, storage, analysis, or manuscript preparation.
NR 41
TC 8
Z9 9
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD APR
PY 2013
VL 15
IS 4
BP 279
EP 288
DI 10.1111/jch.12073
PG 10
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 119YK
UT WOS:000317135700010
PM 23551728
ER
PT J
AU Elmer, J
Wilcox, SR
Raja, AS
AF Elmer, Jonathan
Wilcox, Susan R.
Raja, Ali S.
TI MASSIVE TRANSFUSION IN TRAUMATIC SHOCK
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE hemorrhage; coagulopathy; massive transfusion; resuscitation; trauma
ID FRESH-FROZEN PLASMA; RED-BLOOD-CELL; LIFE-THREATENING COAGULOPATHY;
ACUTE LUNG INJURY; PROTHROMBIN COMPLEX CONCENTRATE; RANDOMIZED
CONTROLLED-TRIAL; DAMAGE CONTROL HEMATOLOGY; INDEPENDENT RISK-FACTOR;
LAST 60 YEARS; EXSANGUINATION PROTOCOL
AB Background: Hemorrhage after trauma is a common cause of death in the United States and globally. The primary goals when managing traumatic shock are the restoration of oxygen delivery to end organs, maintenance of circulatory volume, and prevention of ongoing bleeding through source control and correction of coagulopathy. Achieving these goals may require massive transfusion of blood products. Although use of blood products may be lifesaving, dose-related adverse effects are well described. Discussion: Complications of massive transfusion include interdependent derangements such as coagulopathy, hypothermia, acidosis, and electrolyte abnormalities, as well as infectious and immunomodulatory phenomena. This article explores the pathogenesis, implications, prevention, and treatment of these complications through the use of massive transfusion protocols. Particular attention is given to the optimal ratio of blood products transfused in large volume resuscitation and prevention of secondary coagulopathy. Conclusions: Observational data indicate that the development and use of a massive transfusion protocol may reduce the morbidity and mortality associated with large-volume resuscitation of patients with hemorrhagic shock. Such protocols should include a pre-defined ratio of packed red blood cells, fresh frozen plasma, and platelets transfused; most commonly, the ratio used is 1:1:1. Additionally, such protocols should monitor for and correct hypothermia, hypofibrinogenemia, and electrolyte disturbances such as hypocalcemia and hyperkalemia. (C) 2013 Published Elsevier Inc.
C1 [Elmer, Jonathan; Raja, Ali S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
[Elmer, Jonathan; Wilcox, Susan R.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Wilcox, Susan R.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Raja, AS (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.
OI Wilcox, Susan/0000-0001-7477-7531
NR 119
TC 19
Z9 21
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
J9 J EMERG MED
JI J. Emerg. Med.
PD APR
PY 2013
VL 44
IS 4
BP 829
EP 838
DI 10.1016/j.jemermed.2012.11.025
PG 10
WC Emergency Medicine
SC Emergency Medicine
GA 121YQ
UT WOS:000317282000026
PM 23375220
ER
PT J
AU Ring, D
AF Ring, David
TI Benchmarking Changes in Symptom Intensity and Magnitude of Disability
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD APR
PY 2013
VL 38A
IS 4
BP 650
EP 651
DI 10.1016/j.jhsa.2012.12.031
PG 2
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 121LK
UT WOS:000317246100002
PM 23537442
ER
PT J
AU Bolmers, A
Luiten, WE
Doornberg, JN
Brouwer, KM
Goslings, JC
Ring, D
Kloen, P
AF Bolmers, Annelies
Luiten, Willem E.
Doornberg, Job N.
Brouwer, Kim M.
Goslings, J. Carel
Ring, David
Kloen, Peter
TI A Comparison of the Long-Term Outcome of Partial Articular (AO Type B)
and Complete Articular (AO Type C) Distal Radius Fractures
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Trauma; distal radius fracture; outcome; wrist function
ID DISPLACED INTRAARTICULAR FRACTURES; YOUNG-ADULTS; INTERNAL-FIXATION;
OPEN REDUCTION; END
AB Purpose A short-term comparison of AO type B (shearing) and type C (compression) articular fractures of the distal radius found no significant differences in functional outcome, but long-term studies would provide important information. We tested the null hypothesis that there is no difference in arm-specific disability between patients with type B and C fractures in long-term follow-up.
Methods We evaluated 46 patients (17 with type B fractures and 29 patients with 31 type C fractures of the distal radius) with a mean age of 39 years at the time of injury at a mean of 20 years after operative treatment. We used the Disabilities of the Arm, Shoulder, and Hand questionnaire and 2 physician-based rating systems, the modified Mayo wrist score and the modified Gartland and Werley score. We performed bivariate and multivariable analyses to identify the factors that contributed most to the variation in these scores.
Results There were no significant differences between patients with type B and C fractures on the Disabilities of the Arm, Shoulder, and Hand, modified Mayo wrist, or Gartland and Werley scores, or with respect to range of motion, grip strength, and arthrosis. The only statistical difference was in volar tilt of the articular surface on lateral radiographs.
Conclusions On average, patients undergoing operative treatment of type B and type C articular fractures of the distal radius have similar impairment, symptoms, and disability in the long-term. (J Hand Surg 2013;38A:753-759. Copyright (C) 2013 by the American Society for Surgery of the Hand. All rights reserved.)
C1 Univ Amsterdam, Dept Surg, Orthotrauma Res Ctr Amsterdam, Orthopaed Residency Program,Trauma Unit, NL-1100 DD Amsterdam, Netherlands.
Univ Amsterdam, Acad Med Ctr, Dept Orthopaed Surg, NL-1105 AZ Amsterdam, Netherlands.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Upper Extrem Serv, Boston, MA USA.
RP Doornberg, JN (reprint author), Univ Amsterdam, Acad Med Ctr Amsterdam, Orthopaed Residency Program, Orthotrauma Res Ctr Amsterdam,Secretariaat Orthop, G4 Noord,Meibergdreef 9, NL-1100 DD Amsterdam, Netherlands.
EM jobdoombergortho@gmail.com
FU Keuning-Marti-Eckhardt Foundation
FX D.R. is a consultant for Biomet. J.N.D. received a Postdoctoral Research
Fellowship from the Keuning-Marti-Eckhardt Foundation. There was no
external finding source for the preparation of this manuscript.
NR 17
TC 6
Z9 6
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD APR
PY 2013
VL 38A
IS 4
BP 753
EP 759
DI 10.1016/j.jhsa.2012.12.027
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 121LK
UT WOS:000317246100018
PM 23453896
ER
PT J
AU Hartzell, TL
Kuo, P
Eberlin, KR
Winograd, JM
Day, CS
AF Hartzell, Tristan L.
Kuo, Phoebe
Eberlin, Kyle R.
Winograd, Jonathan M.
Day, Charles S.
TI The Overutilization of Resources in Patients With Acute Upper Extremity
Trauma and Infection
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Emergency; infection; transfer; trauma
ID AMERICAN-COLLEGE; FINANCIAL IMPACT; TRIAGE CRITERIA; MAJOR TRAUMA;
HEALTH-CARE; EMERGENCY; CENTERS; INJURY; BENEFIT; SYSTEM
AB Purpose To compare patients with acute upper extremity injuries and infections presenting initially to the emergency department with patients transferred from outside institutions, and to evaluate triage guidelines for the appropriate transfer of these patients.
Methods We reviewed the records of 1,172 consecutive patients with acute upper extremity injuries or infections presenting to 2 level 1 trauma centers over 3-month periods. We analyzed demographics, transfer details, injury characteristics, intervention received, follow-up, and complications. Triage guidelines were established by a board of academic upper extremity and emergency physicians and retrospectively applied to patient data.
Results Of 1,172 patients, 155 (13%) arrived via transfer from outside facilities. Transferred patients had more complex injuries by our guidelines, but many did not require level 1 emergent care. The receiving emergency department discharged 26% of the transferred patients without upper extremity specialist evaluation, and 24% of the transferred patients received no procedural intervention at any point. Only 10% went to the operating room emergently. Implementing our guidelines for appropriate triage, we found that 53% of transfers did not require emergent transfer to a level 1 facility. These nonemergent transfers spent an average of 15.2 hours from the time of initial evaluation at the outside facility to discharge from the level 1 emergency department, compared with 3.1 hours in patients who arrived primarily. Retrospectively, our triage guidelines had a 2% undertriage rate and a 3% overtriage rate.
Conclusions Over half of the patients transferred with upper extremity injuries and infections for specialized evaluation may be transferred unnecessarily. Guidelines for the care and transfer of patients with acute upper extremity injuries or infections may lead to better use of resources. (J Hand Surg 2013;38A:766-773. Copyright (C) 2013 by the American Society for Surgery of the Hand. All rights reserved.)
C1 Faith Reg Hlth Serv, Norfolk, NE 68701 USA.
Harvard Univ, Sch Med, Dept Orthoped Surg, Beth Israel Deaconess Hosp, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast Surg, Boston, MA USA.
RP Hartzell, TL (reprint author), Faith Reg Hlth Serv, Dept Surg, 301 N 27th St,Suite 8, Norfolk, NE 68701 USA.
EM tristanhartzell@gmail.com
NR 25
TC 13
Z9 13
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD APR
PY 2013
VL 38A
IS 4
BP 766
EP 773
DI 10.1016/j.jhsa.2012.12.016
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 121LK
UT WOS:000317246100020
PM 23395105
ER
PT J
AU Kumar, P
Upadhyay, GA
Cavaliere-Ogus, C
Heist, EK
Altman, RK
Chatterjee, NA
Parks, KA
Singh, JP
AF Kumar, Prabhat
Upadhyay, Gaurav A.
Cavaliere-Ogus, Christine
Heist, E. Kevin
Altman, Robert K.
Chatterjee, Neal A.
Parks, Kimberly A.
Singh, Jagmeet P.
TI Right ventricular lead adjustment in cardiac resynchronization therapy
and acute hemodynamic response: a pilot study
SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY
LA English
DT Article
DE Cardiac resynchronization therapy; Right ventricular lead position; Left
ventricular lead position; Left ventricular lead electrical delay;
Hemodynamic response
ID CORONARY VENOUS ANATOMY; CHRONIC HEART-FAILURE; LITHIUM DILUTION;
POSITION; SITE; RESYNCHRONISATION; ECHOCARDIOGRAPHY; OPTIMIZATION;
VARIABILITY; MORTALITY
AB Optimal left ventricular (LV) lead position has emerged as an important determinant of response after cardiac resynchronization therapy (CRT). Comparatively, strategy for right ventricular (RV) lead optimization remains uncertain.
Three variations of RV lead position (apex, mid-septal, and high septal) were tested in seven consecutive patients. At each location, intra-procedural measurement of LV lead electrical delay (LVLED) was obtained during intrinsic rhythm and RV pacing (RV-LVLED). Simultaneous cardiac output assessment was performed using the LiDCO (TM) (lithium chloride indicator dilution) system. Final RV lead location was selected based on best-measured cardiac output. Clinical and echocardiographic outcomes were assessed at baseline and 6 months.
Adjustment of RV lead position after securing a LV lead site led to an incremental change of 30 +/- 18 % (range, 7-52 %) in the cardiac index (CI). There was substantial variation in acute hemodynamic response (a dagger CI, 14 +/- 13 %; range, 3-41 %) seen with pacing from each patient's worst to best RV lead position; no single RV lead position emerged as optimal across all patients. Paced RV-LVLED was not correlated with percent change in CI (r = 0.18; p = NS). LV ejection fraction (LVEF) increased significantly (28 +/- 4 to 40 +/- 8 %, p = 0.006) at 6 months. LVLED measured during intrinsic rhythm, but not during RV pacing, correlated with percent change in LVEF (r = 0.88, p = 0.02).
RV lead position adjustment can be used to enhance acute hemodynamic response during CRT. Measurement of paced RV-LVLED, however, does not reliably predict change in cardiac output.
C1 [Kumar, Prabhat; Upadhyay, Gaurav A.; Cavaliere-Ogus, Christine; Heist, E. Kevin; Altman, Robert K.; Chatterjee, Neal A.; Parks, Kimberly A.; Singh, Jagmeet P.] Harvard Univ, Cardiac Arrhythmia Serv, Sch Med, Massachusetts Gen Hosp,Heart Ctr, Boston, MA 02412 USA.
[Singh, Jagmeet P.] Massachusetts Gen Hosp, Ctr Heart, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
RP Singh, JP (reprint author), Massachusetts Gen Hosp, Ctr Heart, Cardiac Arrhythmia Serv, GRB 109,55 Fruit St, Boston, MA 02114 USA.
EM jsingh@partners.org
OI Altman, Robert/0000-0002-1612-3561
FU Medtronic Inc.; Medtronic; Biotronik; St. Jude Medical; Boston
Scientific; Sorin Group; Boston Scientific Corp.; Guidant Corp
FX This study was supported in part by a research grant from Medtronic
Inc.; Christine Cavaliere is an employee of and receives salary support
from Medtronic. E. Kevin Heist receives honoraria from Biotronik, Boston
Scientific, Medtronic, St. Jude Medical, and Sorin group; receives
research grants from Biotronik, St. Jude Medical, and Boston Scientific;
and is consultant to Boston Scientific, St. Jude Medical, and Sorin
group (all modest). Kimberly A. Parks received honoraria from Sorin
Group and Research grants from Medtronic, St. Jude Medical, and Sorin
Group. Jagmeet P Singh has received research grants from St. Jude
Medical, Medtronic Inc., Boston Scientific Corp., and Biotronik; has
received honoraria/speaker fees from Medtronic Inc., Biotronik, Guidant
Corp, Sorin group, and St. Jude Medical; and has served on advisory
Board/Steering Committee and as consultant to Boston Scientific Corp.,
Biotronik, St. Jude Medical, Medtronic, Sorin Group, Cardioinsight, and
Thoratec Inc. All other authors have no potential conflicts of interest.
NR 34
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1383-875X
J9 J INTERV CARD ELECTR
JI J. Interv. Card. Electrophysiol.
PD APR
PY 2013
VL 36
IS 3
BP 223
EP 231
DI 10.1007/s10840-012-9759-1
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 123YX
UT WOS:000317430300004
PM 23263893
ER
PT J
AU Ptaszek, LM
Chalhoub, F
Perna, F
Beinart, R
Barrett, CD
Danik, SB
Heist, EK
Ruskin, JN
Mansour, M
AF Ptaszek, Leon M.
Chalhoub, Fadi
Perna, Francesco
Beinart, Roy
Barrett, Conor D.
Danik, Stephan B.
Heist, E. Kevin
Ruskin, Jeremy N.
Mansour, Moussa
TI Rapid acquisition of high-resolution electroanatomical maps using a
novel multielectrode mapping system
SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY
LA English
DT Article
DE Animal studies; Biomedical engineering; Electroanatomical mapping;
Catheter ablation
ID RIGHT-VENTRICULAR CARDIOMYOPATHY/DYSPLASIA; OUTFLOW TRACT TACHYCARDIA;
FOCAL ATRIAL TACHYCARDIA; CATHETER ABLATION; RADIOFREQUENCY ABLATION;
ENDOMYOCARDIAL BIOPSY; FIBRILLATION; SUBSTRATE; ACCURACY; TECHNOLOGY
AB Conventional electroanatomical mapping systems employ roving catheters with one or a small number of electrodes. Maps acquired using these systems usually contain a small number of points and take a long time to acquire. Use of a multielectrode catheter could facilitate rapid acquisition of higher-resolution maps through simultaneous collection of data from multiple points in space; however, a large multielectrode array could potentially limit catheter maneuverability. The purpose of this study was to test the feasibility of using a novel, multielectrode catheter to map the right atrium and the left ventricle.
Electroanatomical mapping of the right atrium and the left ventricle during both sinus and paced rhythm were performed in five swine using a conventional mapping catheter and a novel, multielectrode catheter.
Average map acquisition times for the multielectrode catheter (with continuous data collection) ranged from 5.2 to 9.5 min. These maps contained an average of 2,753 to 3,566 points. Manual data collection with the multielectrode catheter was less rapid (average map completion in 11.4 to 18.1 min with an average of 870 to 1,038 points per map), but the conventional catheter was slower still (average map completion in 28.6 to 32.2 min with an average 120 to 148 points per map).
Use of this multielectrode catheter is feasible for mapping the left ventricle as well as the right atrium. The multielectrode catheter facilitates acquisition of electroanatomical data more rapidly than a conventional mapping catheter. This results in shorter map acquisition times and higher-density electroanatomical maps in these chambers.
C1 [Ptaszek, Leon M.; Chalhoub, Fadi; Perna, Francesco; Beinart, Roy; Barrett, Conor D.; Danik, Stephan B.; Heist, E. Kevin; Ruskin, Jeremy N.; Mansour, Moussa] Massachusetts Gen Hosp, MGH Heart Ctr, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
RP Mansour, M (reprint author), Massachusetts Gen Hosp, MGH Heart Ctr, Cardiac Arrhythmia Serv, 55 Fruit St,GRB 109, Boston, MA 02114 USA.
EM mmansour@partners.org
OI Perna, Francesco/0000-0002-9019-9492
FU Deane Institute for Integrative Research Atrial Fibrillation and Stroke
at the Massachusetts General Hospital; Harvard Catalyst/The Harvard
Clinical and Translational Science Center (NIH) [UL1 RR 025758]; Harvard
University and its affiliated academic health care centers; Boston
Scientific; Biotronik; St. Jude Medical; Biosense Webster; Medtronic;
St. JudeMedical; MC 10; Voyage Medical; CardioFocus
FX L.M.P. received research support from the Deane Institute for
Integrative Research Atrial Fibrillation and Stroke at the Massachusetts
General Hospital. Statistical analyses were performed with support from
Harvard Catalyst/The Harvard Clinical and Translational Science Center
(NIH award No. UL1 RR 025758 and financial contributions from Harvard
University and its affiliated academic health care centers).; Leon M.
Ptaszek, M. D., Ph.D., Fadi Chalhoub, M. D., Francesco Perna, M. D., Roy
Beinart, M. D., Conor D. Barrett, M. D., and Stephan B. Danik, M. D.
have no financial disclosures to declare. E. Kevin Heist, M. D., Ph. D.
declares no financial support but with potential conflicts of interest
from the following: Boston Scientific (research grant and honoraria),
Biotronik (research grant and honoraria), Boston Scientific (research
grant, consultant, and honoraria), Medtronic (honoraria), Sanofi
(consultant), Sorin (consultant and honoraria), and St. Jude Medical
(research grant, consultant, and honoraria). Jeremy N. Ruskin, M. D.
declares no financial support but with potential conflicts of interest
from the following: Atricure (consultant), Biosense Webster (consultant
and fellowship support), Boston Scientific (fellowship support),
CardioFocus (Clinical Oversight Committee-no compensation),
CardioInsight (Scientific Advisory Board), CryoCath (Scientific Steering
Committee-no compensation), Medtronic (consultant and fellowship
support), St. JudeMedical (fellowship support), and Third Rock Ventures
(consultant). Moussa Mansour, M. D. declares the following disclosures:
Biosense Webster (consultant and research grant), Boston Scientific
(consultant and research grant), St. Jude Medical (consultant and
research grant), Medtronic (consultant), MC 10 (research grant), Voyage
Medical (research grant), Rhythmia Medical (research grant), and
CardioFocus (research grant).
NR 30
TC 5
Z9 5
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1383-875X
J9 J INTERV CARD ELECTR
JI J. Interv. Card. Electrophysiol.
PD APR
PY 2013
VL 36
IS 3
BP 233
EP 242
DI 10.1007/s10840-012-9733-y
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 123YX
UT WOS:000317430300005
PM 23179916
ER
PT J
AU Hayakawa, K
Miyamoto, N
Seo, JH
Pham, LDD
Kim, KW
Lo, EH
Arai, K
AF Hayakawa, Kazuhide
Miyamoto, Nobukazu
Seo, Ji Hae
Pham, Loc-Duyen D.
Kim, Kyu-Won
Lo, Eng H.
Arai, Ken
TI High-mobility group box 1 from reactive astrocytes enhances the
accumulation of endothelial progenitor cells in damaged white matter
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE endothelial progenitor cells (EPCs); high-mobility group box 1 (HMGB1);
neurovascular unit; reactive astrocytes; white matter injury; white
matter remodeling
ID GLYCATION END-PRODUCTS; OLIGODENDROCYTE PRECURSOR CELLS; TOLL-LIKE
RECEPTORS; EXPERIMENTAL STROKE; ISCHEMIC-STROKE; MOUSE MODEL; IN-VITRO;
NEUROVASCULAR UNIT; BRAIN; ACTIVATION
AB High-mobility group box 1 (HMGB1) was initially described as a damage-associated-molecular-pattern (DAMP) mediator that worsens acute brain injury after stroke. But, recent findings suggest that HMGB1 can play a surprisingly beneficial role during stroke recovery by promoting endothelial progenitor cell (EPC) function and vascular remodeling in cortical gray matter. Here, we ask whether HMGB1 may also influence EPC responses in white matter injury. The standard lysophosphatidylcholine (LPC) injection model was used to induce focal demyelination in the corpus callosum of mice. Immunostaining showed that within the focal white matter lesions, HMGB1 was up-regulated in GFAP-positive reactive astrocytes, along with the accumulation of Flk1/CD34-double-positive EPCs that expressed pro-recovery mediators such as brain-derived neurotrophic factor and basic fibroblast growth factor. AstrocyteEPC signaling required the HMGB1 receptor RAGE as treatment with RAGE-neutralizing antibody significantly decreased EPC accumulation. Moreover, suppression of HMGB1 with siRNA in vivo significantly decreased EPC numbers in damaged white matter as well as proliferated endothelial cell numbers. Finally, in vitro cell culture systems confirmed that HMGB1 directly affected EPC function such as migration and tube formation. Taken together, our findings suggest that HMGB1 from reactive astrocytes may attract EPCs to promote recovery after white matter injury.
C1 [Hayakawa, Kazuhide; Miyamoto, Nobukazu; Seo, Ji Hae; Pham, Loc-Duyen D.; Lo, Eng H.; Arai, Ken] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA USA.
[Hayakawa, Kazuhide; Miyamoto, Nobukazu; Seo, Ji Hae; Pham, Loc-Duyen D.; Lo, Eng H.; Arai, Ken] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, Charlestown, MA USA.
[Hayakawa, Kazuhide; Miyamoto, Nobukazu; Seo, Ji Hae; Pham, Loc-Duyen D.; Lo, Eng H.; Arai, Ken] Harvard Univ, Sch Med, Charlestown, MA USA.
[Seo, Ji Hae; Kim, Kyu-Won] Seoul Natl Univ, NeuroVasc Coordinat Res Ctr, Coll Pharm, Seoul, South Korea.
[Seo, Ji Hae; Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea.
[Kim, Kyu-Won] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul, South Korea.
RP Arai, K (reprint author), Neuroprotect Res Lab, MGH East 149-2401, Charlestown, MA 02129 USA.
EM lo@helix.mgh.harvard.edu; karai@partners.org
FU Deane Foundation; MGH ECOR Fund for Medical Discovery; American Heart
Association; National Institutes of Health; Research Abroad from the
Japan Society for the Promotion of Science; National Research Foundation
of Korea; World Class University Program; Global Research Laboratory
Program
FX Supported in part by the Deane Foundation, MGH ECOR Fund for Medical
Discovery, American Heart Association, National Institutes of Health,
Research Abroad from the Japan Society for the Promotion of Science,
National Research Foundation of Korea, the World Class University
Program, and the Global Research Laboratory Program.
NR 58
TC 15
Z9 15
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD APR
PY 2013
VL 125
IS 2
BP 273
EP 280
DI 10.1111/jnc.12120
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 122DV
UT WOS:000317297700011
PM 23227954
ER
PT J
AU Belland, L
Handel, D
Yadav, K
Heard, K
Rivera, L
Eisenberg, A
Noble, M
Mekala, S
Valley, M
Hwang, U
AF Belland, L.
Handel, D.
Yadav, K.
Heard, K.
Rivera, L.
Eisenberg, A.
Noble, M.
Mekala, S.
Valley, M.
Hwang, U.
TI Disparities in the quality of pain care for geriatric patients in the
Emergency Department (ED).
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Belland, L.; Rivera, L.; Hwang, U.] Mt Sinai Sch Med, New York, NY USA.
[Hwang, U.] James J Peters VAMC, GRECC, Bronx, NY USA.
[Heard, K.; Valley, M.] Univ Colorado, Sch Med, Denver, CO USA.
[Yadav, K.; Eisenberg, A.] George Washington Univ, Washington, DC USA.
[Handel, D.; Noble, M.; Mekala, S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S83
EP S83
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600238
ER
PT J
AU Bowling, B
Sharma, P
O'Hare, AM
Allman, RM
Muntner, P
AF Bowling, B.
Sharma, P.
O'Hare, A. M.
Allman, R. M.
Muntner, P.
TI Increasing Prevalence of Reduced Estimated Glomerular Filtration Rate
among the Oldest-Old US Adults from 1988-1994 through 2005-2010.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Bowling, B.; Allman, R. M.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Sharma, P.; Muntner, P.] UAB, Birmingham, AL USA.
[O'Hare, A. M.] VA Puget Sound, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S116
EP S116
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600330
ER
PT J
AU Brown, RT
Ahalt, C
Steinman, MA
Williams, BA
AF Brown, R. T.
Ahalt, C.
Steinman, M. A.
Williams, B. A.
TI Hands on the Hood, Grandpa: Assessing the Need for Geriatrics Health
Training among Police.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Brown, R. T.; Ahalt, C.; Steinman, M. A.; Williams, B. A.] Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S15
EP S15
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600041
ER
PT J
AU Carrejo, M
DeWitt, M
Tan, RS
AF Carrejo, M.
DeWitt, M.
Tan, R. S.
TI The Collaborative Model of Geriatrics & Mental Health Care for Older
Veterans in a Nursing Home.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Carrejo, M.; DeWitt, M.; Tan, R. S.] VA Med Ctr, Houston, TX USA.
[DeWitt, M.] Baylor Coll Med, Sect Geriatr, Houston, TX 77030 USA.
[Tan, R. S.] Univ Texas Houston, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S112
EP S113
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600320
ER
PT J
AU Fega, R
Motyckova, G
Sherman, A
DeAngelo, DJ
Abel, GA
Steensma, D
Wadleigh, M
Stone, RM
Driver, JA
AF Fega, R.
Motyckova, G.
Sherman, A.
DeAngelo, D. J.
Abel, G. A.
Steensma, D.
Wadleigh, M.
Stone, R. M.
Driver, J. A.
TI Geriatric Assessment Variables Add Prognostic Value to the International
Prognostic Scoring System for Myelodysplastic Syndrome.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Fega, R.] Univ Arizona, Coll Med Phoenix, Phoenix, AZ USA.
[Motyckova, G.; DeAngelo, D. J.; Abel, G. A.; Steensma, D.; Wadleigh, M.; Stone, R. M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sherman, A.] Univ Cincinnati, Cincinnati, OH USA.
[Driver, J. A.] VA Boston Med Ctr, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
[Driver, J. A.] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S121
EP S121
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600344
ER
PT J
AU Franco, E
Ramadan, F
AF Franco, E.
Ramadan, F.
TI "A MONSTER IN MY STOMACH": A CASE OF ABDOMINAL PAIN.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Franco, E.; Ramadan, F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S77
EP S78
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600221
ER
PT J
AU Fung, CH
Martin, J
Jouldjian, S
Dzierzewski, J
Josephson, K
Alessi, C
AF Fung, C. H.
Martin, J.
Jouldjian, S.
Dzierzewski, J.
Josephson, K.
Alessi, C.
TI Mental health and sleep characteristics among older veterans with
untreated obstructive sleep apnea and comorbid insomnia.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Fung, C. H.; Martin, J.; Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Fung, C. H.; Martin, J.; Jouldjian, S.; Dzierzewski, J.; Josephson, K.; Alessi, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S94
EP S94
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600266
ER
PT J
AU Ghidei, L
Simone, M
Salow, M
Zimmerman, K
Paquin, A
Skarf, LM
Kostas, T
Rudolph, JL
AF Ghidei, L.
Simone, M.
Salow, M.
Zimmerman, K.
Paquin, A.
Skarf, L. Michal
Kostas, T.
Rudolph, J. L.
TI Aging, Adherence, and Antiretroviral Therapy: A Systematic Review of
Adherence in Older HIV-Infected Individuals.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Ghidei, L.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Simone, M.; Kostas, T.; Rudolph, J. L.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA.
[Simone, M.; Skarf, L. Michal; Kostas, T.] Harvard Univ, Sch Med, Boston, MA USA.
[Salow, M.; Paquin, A.] VA Boston Healthcare Syst, Dept Pharm, Boston, MA USA.
[Salow, M.; Zimmerman, K.; Paquin, A.; Skarf, L. Michal; Rudolph, J. L.] VA Boston Healthcare Syst, Div Geriatr & Palliat Care, Boston, MA USA.
[Zimmerman, K.] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S111
EP S112
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600317
ER
PT J
AU Grigoryan, K
Javedan, H
Rudolph, J
AF Grigoryan, K.
Javedan, H.
Rudolph, J.
TI Ortho-Geriatric Models and Optimal Outcomes: A Systematic Review and
Meta-Analysis
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Grigoryan, K.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Javedan, H.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Rudolph, J.] VA Boston Healthcare Syst, GRECC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S8
EP S9
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600023
ER
PT J
AU Gruenewald, D
Virtue, J
Hartmann, T
Kopf, W
Nason, E
White, E
AF Gruenewald, D.
Virtue, J.
Hartmann, T.
Kopf, W.
Nason, E.
White, E.
TI Outcomes For Outpatient Veterans With Cancer Receiving Care
Coordination-Home Telehealth Services.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Gruenewald, D.; Virtue, J.; Hartmann, T.; Kopf, W.; Nason, E.; White, E.] VA Puget Sound Hlth Care Syst, Geriatr Extended Care, Seattle, WA USA.
[Gruenewald, D.] Univ Washington, Sch Med, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S56
EP S56
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600158
ER
PT J
AU Hanson, AJ
Hernandez, H
Bartholomew, LM
Gabriel, AK
Chapman, D
Craft, S
AF Hanson, A. J.
Hernandez, H.
Bartholomew, L. M.
Gabriel, A. K.
Chapman, D.
Craft, S.
TI APOE Genotype and Gender Influence Glucose Tolerance in Older Adults.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Hanson, A. J.; Hernandez, H.; Bartholomew, L. M.; Gabriel, A. K.; Chapman, D.; Craft, S.] Univ Washington, Seattle, WA 98195 USA.
[Hanson, A. J.] VA Puget Sound HCS, GRECC, Seattle, WA USA.
[Craft, S.] Wake Forest Univ, Sch Med, Sticht Ctr Aging, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S114
EP S114
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600324
ER
PT J
AU Hernandez, A
Ramadan, F
AF Hernandez, A.
Ramadan, F.
TI Is this Aspiration Pneumonia?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Hernandez, A.; Ramadan, F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S128
EP S128
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600364
ER
PT J
AU Hung, WW
Ross, JS
Siu, AL
AF Hung, W. W.
Ross, J. S.
Siu, A. L.
TI Predictors of adverse events during acute medical hospital admission
among older adults.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Hung, W. W.; Siu, A. L.] Mt Sinai Sch Med, New York, NY USA.
[Hung, W. W.; Siu, A. L.] James J Peters VA Med Ctr, Bronx, NY USA.
[Ross, J. S.] Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S171
EP S171
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600491
ER
PT J
AU Kelley, E
Nguyen, G
Anjum, S
Lee, S
Sanchez-Reilly, S
AF Kelley, E.
Nguyen, G.
Anjum, S.
Lee, S.
Sanchez-Reilly, S.
TI Is PTSD a Geriatric Condition? Caring for Vietnam Era Older Adults
Facing Terminal Illness.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Kelley, E.; Anjum, S.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Kelley, E.; Nguyen, G.; Anjum, S.; Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GRECC GEC, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S227
EP S227
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600654
ER
PT J
AU Kinosian, B
Mann, E
Hammond, J
Haggerty, M
Feinberg, A
Casarett, D
AF Kinosian, B.
Mann, E.
Hammond, J.
Haggerty, M.
Feinberg, A.
Casarett, D.
TI Hospital <@> Home as an Inter-agency Collaborative in the VA
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Kinosian, B.; Mann, E.; Casarett, D.] Univ Penn, Philadelphia, PA 19104 USA.
[Kinosian, B.; Hammond, J.; Haggerty, M.; Feinberg, A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S9
EP S9
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600024
ER
PT J
AU Kostas, TR
Simone, M
Zimmerman, K
Salow, M
Noto, N
Rudolph, JL
McMahon, GT
AF Kostas, T. R.
Simone, M.
Zimmerman, K.
Salow, M.
Noto, N.
Rudolph, J. L.
McMahon, G. T.
TI Improving Medication Management Competency Through an Interdisciplinary
Workshop.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Kostas, T. R.; Salow, M.; Noto, N.; Rudolph, J. L.] VA Boston Healthcare Syst, Boston, MA USA.
[Kostas, T. R.; Simone, M.; Rudolph, J. L.; McMahon, G. T.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Simone, M.; McMahon, G. T.] Harvard Univ, Sch Med, Boston, MA USA.
[Zimmerman, K.] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA.
RI McMahon, Graham/D-3740-2009
OI McMahon, Graham/0000-0003-4288-6535
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S153
EP S153
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600440
ER
PT J
AU LaMantia, MA
Jhanji, S
Maina, M
Nazir, A
Alder, C
Chodosh, J
Boustani, M
AF LaMantia, M. A.
Jhanji, S.
Maina, M.
Nazir, A.
Alder, C.
Chodosh, J.
Boustani, M.
TI Redesigning Acute Care for Cognitively Impaired Older Adults: Optimizing
Health Care Services for the 21st Century.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [LaMantia, M. A.; Jhanji, S.; Maina, M.; Boustani, M.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA.
[LaMantia, M. A.; Jhanji, S.; Maina, M.; Boustani, M.] Regenstrief Inst Inc, Indianapolis, IN USA.
[Nazir, A.] Indiana Univ, Geriatr Program, Indianapolis, IN 46204 USA.
[Alder, C.] Wishard Hlth Serv, Indianapolis, IN USA.
[Chodosh, J.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA.
[Chodosh, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S112
EP S112
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600319
ER
PT J
AU Levy, C
Edes, T
Whitfield, E
Kinosian, B
AF Levy, C.
Edes, T.
Whitfield, E.
Kinosian, B.
TI Medical Foster Homes - Is this new model of care an effective substitute
for nursing homes?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Levy, C.; Whitfield, E.] Denver VA Med Ctr, Denver, CO USA.
[Kinosian, B.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Edes, T.] Vet Affairs Cent Off, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S109
EP S110
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600311
ER
PT J
AU Matsuwaka, S
Jouldjian, S
Martin, J
Alessi, C
AF Matsuwaka, S.
Jouldjian, S.
Martin, J.
Alessi, C.
TI Insomnia in Older Veterans: Prevalence, Self-Rated Health, and Talking
to a Doctor about Sleep Problems.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Matsuwaka, S.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.
[Jouldjian, S.; Martin, J.; Alessi, C.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA.
[Martin, J.; Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S205
EP S205
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600590
ER
PT J
AU Methvin, BL
Lee, S
Sharp, C
Sanchez-Reilly, S
Ross, J
AF Methvin, B. L.
Lee, S.
Sharp, C.
Sanchez-Reilly, S.
Ross, J.
TI Caregiver Burden Among Family Caregivers Of Homebound Older Veterans.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Methvin, B. L.; Sanchez-Reilly, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Lee, S.; Sharp, C.; Sanchez-Reilly, S.; Ross, J.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S93
EP S93
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600264
ER
PT J
AU Methvin, BL
Lee, S
Ross, J
AF Methvin, B. L.
Lee, S.
Ross, J.
TI Analysis of YouTube Resources for Caregivers of Aging Individuals
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Methvin, B. L.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Lee, S.; Ross, J.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S7
EP S7
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600019
ER
PT J
AU Meziab, O
Yaffe, K
Brach, J
Simonsick, EM
Harris, TB
Barnes, DE
AF Meziab, O.
Yaffe, K.
Brach, J.
Simonsick, E. M.
Harris, T. B.
Barnes, D. E.
TI Changes in Physical Activity Before and After Development of
Pre-Clinical Cognitive Impairment.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Meziab, O.] Univ Arizona, Coll Med, Tucson, AZ USA.
[Yaffe, K.; Barnes, D. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Brach, J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Simonsick, E. M.; Harris, T. B.] NIA, Baltimore, MD 21224 USA.
[Yaffe, K.; Barnes, D. E.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S115
EP S115
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600327
ER
PT J
AU Moody, S
Newsom, EM
Covinsky, KE
AF Moody, S.
Newsom, E. M.
Covinsky, K. E.
TI Determinants Of Emotional Recovery And Perceived Change In Health
Following A Disaster
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Moody, S.; Covinsky, K. E.] Univ Calif San Francisco, Med Div Geriatr, San Francisco, CA 94143 USA.
[Moody, S.; Covinsky, K. E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Newsom, E. M.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA.
[Moody, S.] Kameda Med Ctr, Grad Med Educ, Kamogawa City, Chiba, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S102
EP S102
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600291
ER
PT J
AU Mori, T
Greendale, GA
Cauley, JA
Han, W
Huang, M
Karlamangla, AS
AF Mori, T.
Greendale, G. A.
Cauley, J. A.
Han, W.
Huang, M.
Karlamangla, A. S.
TI Dietary Phytoestrogens and Femoral Neck Strength: Findings from the
Study of Women's Health Across the Nation.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Mori, T.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA.
[Mori, T.; Greendale, G. A.; Han, W.; Huang, M.; Karlamangla, A. S.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Cauley, J. A.] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S87
EP S88
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600249
ER
PT J
AU Mulligan, EA
Moye, J
Schwartzenburg, M
Gosian, J
Herman, L
Naik, AD
AF Mulligan, E. A.
Moye, J.
Schwartzenburg, M.
Gosian, J.
Herman, L.
Naik, A. D.
TI Beyond Mortality and Treatment Effects: Cancer Impacts Older Survivors'
Social Roles, Emotional States and Relationships.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Mulligan, E. A.; Moye, J.; Gosian, J.] VA Boston Hlth Care Syst, Boston, MA USA.
[Mulligan, E. A.; Moye, J.] Harvard Univ, Sch Med, Boston, MA USA.
[Schwartzenburg, M.] Rice Univ, Houston, TX USA.
[Herman, L.; Naik, A. D.] Michael E DeBakey VAMC HSR&D CoE, Houston, TX USA.
[Herman, L.; Naik, A. D.] Baylor Coll Med, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S119
EP S119
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600339
ER
PT J
AU Nazir, A
Lamantia, M
Perkins, A
Hui, S
Campbell, N
Khan, B
Chodosh, J
Boustani, M
AF Nazir, A.
Lamantia, M.
Perkins, A.
Hui, S.
Campbell, N.
Khan, B.
Chodosh, J.
Boustani, M.
TI Impact of Cognitive Impairment on Rehospitalizations
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Nazir, A.] Indiana Univ, Geriatr Program, Indianapolis, IN 46204 USA.
[Lamantia, M.; Perkins, A.; Hui, S.; Campbell, N.; Khan, B.; Boustani, M.] Indiana Univ, Ctr Aging Res, Regenstrief Inst Inc, Indianapolis, IN 46204 USA.
[Chodosh, J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Chodosh, J.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S104
EP S104
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600296
ER
PT J
AU Northern, J
Beckjord, S
Rossi, MI
Thatcher, T
Kendjelic, E
AF Northern, J.
Beckjord, S.
Rossi, M. I.
Thatcher, T.
Kendjelic, E.
TI The Efficacy of a Neuropsychological Test Battery used in a VA Driving
Clinic on Assessing Driving Ability amongst Older Veterans.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Northern, J.; Rossi, M. I.; Thatcher, T.; Kendjelic, E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Beckjord, S.] Apex Psychol Care & Memory Ctr, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S64
EP S64
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600182
ER
PT J
AU O'Kula, S
Gottesman, E
Hung, W
Boockvar, K
AF O'Kula, S.
Gottesman, E.
Hung, W.
Boockvar, K.
TI The Spanish-English Language Barrier as a Factor in Veterans' Care
Transitions
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [O'Kula, S.; Hung, W.; Boockvar, K.] Mt Sinai Sch Med, New York, NY USA.
[Gottesman, E.; Hung, W.; Boockvar, K.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S219
EP S219
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600632
ER
PT J
AU Qiu, A
Ortiz, J
Cruz-Oliver, D
Sanchez-Reilly, S
AF Qiu, A.
Ortiz, J.
Cruz-Oliver, D.
Sanchez-Reilly, S.
TI Barriers to End of Life Care among Latino Elders: A Healthcare Provider
Perspective.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Qiu, A.; Ortiz, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA.
[Ortiz, J.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
[Cruz-Oliver, D.] St Louis Univ, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S211
EP S212
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600609
ER
PT J
AU Reed, ML
AF Reed, M. L.
TI A Case of Granuloma Annulare and Malignancy.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Reed, M. L.] VA Puget Sound, Geriatr, Tacoma, WA USA.
[Reed, M. L.] Madigan Healthcare Syst, Family Med, Tacoma, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S80
EP S80
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600228
ER
PT J
AU Rothrock, AG
Sawyer, P
Ford, CR
Brown, CJ
AF Rothrock, A. G.
Sawyer, P.
Ford, C. R.
Brown, C. J.
TI Can a Single Dose of Interprofessional Team Training Influence Medical
Student Attitudes Toward Healthcare Teams?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Rothrock, A. G.; Sawyer, P.; Ford, C. R.; Brown, C. J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Brown, C. J.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S145
EP S145
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600417
ER
PT J
AU Sherman, AE
Motyckova, G
Fega, K
DeAngelo, DJ
Abel, GA
Steensma, D
Wadleigh, M
Stone, RM
Driver, JA
AF Sherman, A. E.
Motyckova, G.
Fega, K.
DeAngelo, D. J.
Abel, G. A.
Steensma, D.
Wadleigh, M.
Stone, R. M.
Driver, J. A.
TI Geriatric Assessment in Older Patients with Acute Myeloid Leukemia: A
Prospective Study of Associated Treatment and Outcomes.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Sherman, A. E.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Motyckova, G.; DeAngelo, D. J.; Abel, G. A.; Steensma, D.; Wadleigh, M.; Stone, R. M.; Driver, J. A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fega, K.] Univ Arizona, Coll Med Phoenix, Phoenix, AZ USA.
[Driver, J. A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Aging,Dept Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S201
EP S201
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600580
ER
PT J
AU Siddiqui, A
Hwang, UY
AF Siddiqui, A.
Hwang, U. Y.
TI The Effects of Age on the Quality of ED Pain Care and Outcomes.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Siddiqui, A.; Hwang, U. Y.] Mt Sinai Sch Med, New York, NY USA.
[Hwang, U. Y.] James J Peters VAMC, GRECC, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S83
EP S83
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600237
ER
PT J
AU Smith, GM
Block, S
Schaefer, K
Bernacki, R
AF Smith, G. M.
Block, S.
Schaefer, K.
Bernacki, R.
TI Serious Illness Communication Checklist: Effects on Clinician Attitude
and Confidence.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Smith, G. M.; Block, S.; Schaefer, K.; Bernacki, R.] Harvard Univ, Sch Med, Boston, MA USA.
[Smith, G. M.; Block, S.; Schaefer, K.; Bernacki, R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S207
EP S208
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600597
ER
PT J
AU Su, C
McMahan, R
Sudore, R
AF Su, C.
McMahan, R.
Sudore, R.
TI Family Matters: Effects of Birth Order and Family Dynamics on Surrogate
Decision Making
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Su, C.] Mt Sinai Sch Med, New York, NY USA.
[McMahan, R.; Sudore, R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[McMahan, R.; Sudore, R.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S6
EP S6
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600017
ER
PT J
AU Win, AZ
Ceresa, C
Allison, TA
AF Win, A. Z.
Ceresa, C.
Allison, T. A.
TI The Prevalence of Malnutrition in Frail Older Veterans.
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-Geriatrics-Society
CY MAY 03-05, 2013
CL Grapevine, TX
SP Amer Geriatr Soc
C1 [Win, A. Z.; Ceresa, C.; Allison, T. A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Allison, T. A.] Univ San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94117 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD APR
PY 2013
VL 61
SU 1
SI SI
BP S159
EP S159
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 120QW
UT WOS:000317187600456
ER
PT J
AU Hall, RK
O'Hare, AM
Anderson, RA
Colon-Emeric, CS
AF Hall, Rasheeda K.
O'Hare, Ann M.
Anderson, Ruth A.
Colon-Emeric, Cathleen S.
TI End-Stage Renal Disease in Nursing Homes: A Systematic Review
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Review
DE Renal dialysis; skilled nursing facilities; aged
ID EXTENDED-CARE FACILITY; LONG-TERM-CARE; PERITONEAL-DIALYSIS; PATIENT
CHARACTERISTICS; STARTING DIALYSIS; HEMODIALYSIS; REHABILITATION;
MORTALITY; PREVALENCE; EXPERIENCE
AB Objectives/Introduction: Demand for nursing home (NH) care by patients with end-stage renal disease (ESRD) is likely to increase with growing numbers of older adults initiating chronic dialysis. We completed a systematic review to summarize the literature on NH residents with ESRD.
Methods: MEDLINE, CINAHL, EMBASE, and relevant conference proceedings were searched to identify articles using the following MESH terms or related key words in the title or abstract: "residential facilities", "renal dialysis", "renal replacement therapy", and "chronic kidney failure". We selected case control, cohort studies, and clinical trials that included older adults with ESRD (defined as those receiving chronic dialysis or those with stage 5 chronic kidney disease) living in residential care facilities. We abstracted information on study design, quality, and results.
Results: Of 198 unique citations identified by the search strategy, 14 articles met eligibility criteria. Most articles were multicenter studies that were conducted in the 1990s. One study focused on patients with stage 5 chronic kidney disease, and the remaining 13 studies focused on patients receiving chronic dialysis, of which eight studies included only those receiving peritoneal dialysis, four studies included patients receiving both peritoneal dialysis and hemodialysis, and one study included only patients receiving hemodialysis. All studies were observational, no clinical trials were identified, and study design limitations and heterogeneity within study populations were common. Summarizing results across these studies suggests that NH residents with ESRD have limited survival, particularly early after dialysis initiation. Functional impairment is highly prevalent in this population and independently associated with poor outcomes.
Conclusions: NH residents with ESRD appear to be a particularly vulnerable population, but current information on their prevalence, characteristics, and outcomes is limited. Further research is needed to provide a better understanding of modifiable predictors of survival and functional decline in this population. Copyright (C) 2013 -American Medical Directors Association, Inc.
C1 [Hall, Rasheeda K.] Duke Univ, Med Ctr, Dept Med, Div Nephrol, Durham, NC 27710 USA.
[O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA.
[O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA.
[O'Hare, Ann M.] VA Puget Sound Healthcare Syst, HSR&D Ctr Excellence, Seattle, WA USA.
[Anderson, Ruth A.] Duke Univ, Sch Nursing, Durham, NC 27710 USA.
[Anderson, Ruth A.; Colon-Emeric, Cathleen S.] Duke Univ, Ctr Study Aging & Human Dev, Durham, NC 27710 USA.
[Colon-Emeric, Cathleen S.] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA.
[Colon-Emeric, Cathleen S.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
RP Hall, RK (reprint author), Duke Univ, Med Ctr, Box DUMC 2747,2424 Erwin Rd,Suite 605, Durham, NC 27710 USA.
EM rasheeda.stephens@duke.edu
OI Anderson, Ruth/0000-0001-6640-644X
FU Claude D. Pepper Older Americans Independence Center [NIH P30 AG028716];
Agency for Healthcare Research and Quality [T32HS019490]
FX None of the authors report any potential conflicts of interest. This
material is the result of work supported with resources and the use of
facilities at the Durham VA Medical Center. This study is supported by
the Claude D. Pepper Older Americans Independence Center (NIH P30
AG028716) and the Agency for Healthcare Research and Quality
(T32HS019490). Some of the data reported here has been supplied by the
United States Renal Data System (USRDS). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the Department of Veterans Affairs, the National
Institutes of Health, or the United States government.
NR 32
TC 4
Z9 4
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD APR
PY 2013
VL 14
IS 4
BP 242
EP 247
DI 10.1016/j.jamda.2013.01.004
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 121YI
UT WOS:000317281200005
PM 23375523
ER
PT J
AU Pellikka, PA
Douglas, PS
Miller, JG
Abraham, TP
Baumann, R
Buxton, DB
Byrd, BF
Chen, P
Cook, NL
Gardin, JM
Hansen, G
Houle, HC
Husson, S
Kaul, S
Klein, AL
Lang, RM
Leong-Poi, H
Lopez, H
Mahmoud, TM
Maslak, S
McCulloch, ML
Metz, S
Nagueh, SF
Pearlman, AS
Pibarot, P
Picard, MH
Porter, TR
Prater, D
Rodriguez, R
Sarano, ME
Scherrer-Crosbie, M
Shirali, GS
Sinusas, A
Slosky, JJ
Sugeng, L
Tatpati, A
Villanueva, FS
von Ramm, OT
Weissman, NJ
Zamani, S
AF Pellikka, Patricia A.
Douglas, Pamela S.
Miller, James G.
Abraham, Theodore P.
Baumann, Rolf
Buxton, Denis B.
Byrd, Benjamin F., III
Chen, Peter
Cook, Nakela L.
Gardin, Julius M.
Hansen, Gunnar
Houle, Helene C.
Husson, Stefan
Kaul, Sanjiv
Klein, Allan L.
Lang, Roberto M.
Leong-Poi, Howard
Lopez, Hector
Mahmoud, Tamer M.
Maslak, Sam
McCulloch, Marti L.
Metz, Steve
Nagueh, Sherif F.
Pearlman, Alan S.
Pibarot, Philippe
Picard, Michael H.
Porter, Thomas R.
Prater, David
Rodriguez, Rudy
Sarano, Maurice E.
Scherrer-Crosbie, Marielle
Shirali, Girish S.
Sinusas, Albert
Slosky, Jack J.
Sugeng, Lissa
Tatpati, Anand
Villanueva, Flordeliza S.
von Ramm, Olaf T.
Weissman, Neil J.
Zamani, Shaun
TI American Society of Echocardiography Cardiovascular Technology and
Research Summit: A Roadmap for 2020
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Editorial Material
DE Echocardiography; Cardiac imaging; Cardiovascular imaging;
Cardiovascular technology; Cardiovascular technology development;
Research; Clinical Research; Myocardial deformation; Three-dimensional
imaging; Doppler; Contrast echocardiography; Valvular heart disease;
Therapeutic ultrasound; Research infrastructure; Research training
ID VALVULAR HEART-DISEASE; REGIONAL MYOCARDIAL-FUNCTION; 3-DIMENSIONAL
ECHOCARDIOGRAPHY; DIAGNOSTIC ULTRASOUND; IN-VIVO; EAE/ASE
RECOMMENDATIONS; MICROBUBBLES; STRAIN; QUANTIFICATION; INVESTIGATORS
C1 [Pellikka, Patricia A.; Sarano, Maurice E.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA.
[Douglas, Pamela S.; von Ramm, Olaf T.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
[Miller, James G.] Washington Univ, Dept Phys, St Louis, MO 63130 USA.
[Abraham, Theodore P.] Johns Hopkins Univ, Baltimore, MD USA.
[Baumann, Rolf] TomTec Imaging Syst GmbH, Munich, Germany.
[Buxton, Denis B.; Cook, Nakela L.] NHLBI, Bethesda, MD 20892 USA.
[Byrd, Benjamin F., III] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Chen, Peter] GE Healthcare Med Diagnost, Chicago, IL USA.
[Gardin, Julius M.] Hackensack Univ Med Ctr, Hackensack, NJ USA.
[Hansen, Gunnar] GE Healthcare, Horten, Norway.
[Houle, Helene C.] Siemens Med Solut USA Inc, Mountain View, CA USA.
[Husson, Stefan] GE Ultrasound, Milwaukee, WI USA.
[Kaul, Sanjiv] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Klein, Allan L.] Cleveland Clin, Cleveland, OH 44106 USA.
[Lang, Roberto M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Leong-Poi, Howard] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
[Lopez, Hector] Natl Inst Biomed Imaging & Bioengn, Bethesda, MD USA.
[Mahmoud, Tamer M.] Abbott Vasc Struct Heart, Menlo Pk, CA USA.
[McCulloch, Marti L.; Nagueh, Sherif F.] Methodist Hosp, Methodist DeBakey Heart & Vasc Ctr, Houston, TX 77030 USA.
[Metz, Steve] Philips Healthcare, Seattle, WA USA.
[Pearlman, Alan S.] Univ Washington, Seattle, WA 98195 USA.
[Pibarot, Philippe] Univ Laval, Quebec Heart Inst, Quebec City, PQ, Canada.
[Picard, Michael H.; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Picard, Michael H.; Scherrer-Crosbie, Marielle] Harvard Univ, Sch Med, Boston, MA USA.
[Porter, Thomas R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Prater, David] Philips Healthcare, Andover, MA USA.
[Rodriguez, Rudy; Zamani, Shaun] Edwards Lifesci, Irvine, CA USA.
[Shirali, Girish S.] Childrens Mercy Hosp, Kansas City, MO 64108 USA.
[Sinusas, Albert; Sugeng, Lissa] Yale Univ, New Haven, CT USA.
[Slosky, Jack J.] Lantheus Med Imaging, North Billerica, MA USA.
[Tatpati, Anand] Siemens Med Solut, San Francisco, CA USA.
[Villanueva, Flordeliza S.] Univ Pittsburgh, Pittsburgh, PA USA.
[Weissman, Neil J.] Washington Hosp Ctr, MedStar Res Inst, Washington, DC 20010 USA.
RP Pellikka, PA (reprint author), Amer Soc Echocardiog, 2100 Gateway Ctr Blvd,Suite 310, Morrisville, NC 27560 USA.
EM ase@asecho.org
OI Buxton, Denis/0000-0003-3077-6435; Picard, Michael/0000-0002-9264-3243
NR 37
TC 15
Z9 15
U1 0
U2 15
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD APR
PY 2013
VL 26
IS 4
BP 325
EP 338
DI 10.1016/j.echo.2013.02.003
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 122UM
UT WOS:000317343600001
PM 23537771
ER
PT J
AU Bhatia, RS
Kumar, V
Picard, MH
Weiner, RB
AF Bhatia, R. Sacha
Kumar, Vishesh
Picard, Michael H.
Weiner, Rory B.
TI Comparison of the 2008 and 2011 Appropriate Use Criteria for Stress
Echocardiography
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Article
DE Appropriate use criteria; Stress echocardiography
ID AMERICAN-HEART-ASSOCIATION; STATEMENT; CARDIOLOGY; MEDICARE; EXERCISE;
OUTCOMES; SOCIETY; DISEASE; KIDNEY
AB Background: The 2008 appropriate use criteria (AUC) for stress echocardiographic (SE) examinations were revised in 2011 to cover a wider range of scenarios of use. Data comparing the 2008 and 2011 AUC for SE are limited.
Methods: A retrospective chart review of SE studies performed at an academic medical center was conducted, and ordering of SE studies was assessed using the 2008 and 2011 AUC.
Results: A total of 252 consecutive SE studies performed in 2011 were reviewed. The 2008 AUC classified 126 SE studies (50%), and the 2011 AUC classified 221 SE studies (88%) (P < .001). Of all SE studies, 106 (42%) were performed as part of evaluations for noncardiac solid-organ transplantation. The majority of these studies (79%) were classified as inappropriate using the 2011 AUC and were not classifiable using the 2008 AUC. Of the 146 SE studies performed for other reasons, 69% were appropriate and 22% were inappropriate using the 2011 AUC. Inappropriate SE studies for both the general nontransplant and noncardiac solid-organ transplantation populations were nearly exclusively ordered for perioperative assessment with normal functional capacity. The SE studies that remained unclassified by the 2011 AUC were related to the assessment of specialized cardiac conditions, including hypertrophic cardiomyopathy and follow-up after heart transplantation.
Conclusions: The 2011 AUC classify a significantly greater proportion of SE studies compared with the 2008 AUC. Most of the reclassified SE studies using the 2011 AUC were inappropriate and were ordered for perioperative assessments in patients with normal functional capacity. (J Am Soc Echocardiogr 2013;26:339-43.)
C1 [Bhatia, R. Sacha; Kumar, Vishesh; Picard, Michael H.; Weiner, Rory B.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Bhatia, RS (reprint author), Massachusetts Gen Hosp, Div Cardiol, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA.
EM rsbhatia@partners.org
OI Picard, Michael/0000-0002-9264-3243
NR 19
TC 6
Z9 7
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD APR
PY 2013
VL 26
IS 4
BP 339
EP 343
DI 10.1016/j.echo.2012.12.001
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 122UM
UT WOS:000317343600002
PM 23313389
ER
PT J
AU Tecilazich, F
Dinh, T
Lyons, TE
Guest, J
Villafuerte, RA
Sampanis, C
Gnardellis, C
Zuo, CS
Veves, A
AF Tecilazich, Francesco
Thanh Dinh
Lyons, Thomas E.
Guest, Julie
Villafuerte, Rosemond A.
Sampanis, Christos
Gnardellis, Charalambos
Zuo, Chun S.
Veves, Aristidis
TI Postexercise phosphocreatine recovery, an index of mitochondrial
oxidative phosphorylation, is reduced in diabetic patients with lower
extremity complications
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID PERIPHERAL ARTERIAL-DISEASE; MAGNETIC-RESONANCE-SPECTROSCOPY; ENERGY
PHOSPHATE-METABOLISM; SKELETAL-MUSCLE; INSULIN-RESISTANCE; CALF MUSCLE;
SKIN MICROCIRCULATION; TASK-FORCE; NEUROPATHY; EXERCISE
AB Objective: To identify differences in postexercise phosphocreatine (PCr) recovery, an index of mitochondrial function, in diabetic patients with and without lower extremity complications.
Methods: We enrolled healthy control subjects and three groups of patients with type 2 diabetes mellitus: without complications, with peripheral neuropathy, and with both peripheral neuropathy and peripheral arterial disease. We used magnetic resonance spectroscopic measurements to perform continuous measurements of phosphorous metabolites (PCr and inorganic phosphate [Pi]) during a 3-minute graded exercise at the level of the posterior calf muscles (gastrocnemius and soleus muscles). Micro- and macrovascular reactivity measurements also were performed.
Results: The resting Pi/PCr ratio and PCr at baseline and the maximum reached during exercise were similar in all groups. The postexercise time required for recovery of Pi/PCr ratio and PCr levels to resting levels, an assessment of mitochondrial oxidative phosphorylation, was significantly higher in diabetic patients with neuropathy and those with both neuropathy and peripheral arterial disease (P < .01 for both measurements). These two groups also had higher levels of tumor necrosis factor-alpha (P < .01) and granulocyte colony-stimulating factor (P < .05). Multiple regression analysis showed that only granulocyte colony-stimulating factor, osteoprotegerin, and tumor necrosis factor-alpha were significant contributing factors in the variation of the Pi/PCr ratio recovery time. No associations were observed between micro- and macrovascular reactivity measurements and Pi/PCr ratio or PCr recovery time.
Conclusions: Mitochondrial oxidative phosphorylation is impaired only in type 2 diabetes mellitus patients with neuropathy whether or not peripheral arterial disease is present and is associated with the increased proinflammatory state observed in these groups. (J Vasc Surg 2013;57:997-1005.)
C1 [Tecilazich, Francesco; Thanh Dinh; Lyons, Thomas E.; Guest, Julie; Sampanis, Christos; Veves, Aristidis] Joslin Beth Israel Deaconess Foot Ctr, Boston, MA USA.
[Tecilazich, Francesco; Thanh Dinh; Lyons, Thomas E.; Guest, Julie; Sampanis, Christos; Veves, Aristidis] Beth Israel Deaconess Med Ctr, Microcirculat Lab, Boston, MA 02215 USA.
[Tecilazich, Francesco; Thanh Dinh; Lyons, Thomas E.; Guest, Julie; Sampanis, Christos; Veves, Aristidis] Harvard Univ, Sch Med, Boston, MA USA.
[Villafuerte, Rosemond A.; Zuo, Chun S.] McLean Hosp, MR Imaging Ctr, Belmont, MA 02178 USA.
[Villafuerte, Rosemond A.; Zuo, Chun S.] Harvard Univ, Sch Med, Belmont, MA 02178 USA.
[Gnardellis, Charalambos] Technol Educ Inst Messolonghi, Mesolongion, Greece.
RP Veves, A (reprint author), Beth Israel Deaconess Med Ctr, 1 Deaconess Rd,PA 321A, Boston, MA 02215 USA.
EM aveves@bidmc.harvard.edu
FU NIH [1R21DK082987, R21MH081076]; Clinical Translational Science Award
[UL1RR025758]; Beth Israel Deaconess Medical Center from the National
Center for Research Resources
FX This work is funded in part by NIH Grant 1R21DK082987 (A. V.) and NIH
Grant R21MH081076 (C.S.Z.). The project described was supported by the
Clinical Translational Science Award UL1RR025758 to Harvard University
and Beth Israel Deaconess Medical Center from the National Center for
Research Resources. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Center for Research Resources or the National Institutes of
Health.
NR 37
TC 6
Z9 6
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD APR
PY 2013
VL 57
IS 4
BP 997
EP 1005
DI 10.1016/j.jvs.2012.10.011
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 120QZ
UT WOS:000317187900014
PM 23465172
ER
PT J
AU Draca, N
Lazic, R
Simic, P
Dumic-Cule, I
Luetic, AT
Gabric, N
AF Draca, Natasa
Lazic, Ratimir
Simic, Petra
Dumic-Cule, Ivo
Luetic, Ana Tikvica
Gabric, Nikica
TI Potential beneficial role of sevelamer hydrochloride in diabetic
retinopathy
SO MEDICAL HYPOTHESES
LA English
DT Article
ID C-REACTIVE PROTEIN; CORONARY-ARTERY CALCIFICATION; CHRONIC
KIDNEY-DISEASE; RETINAL VASCULAR CALIBER; MAINTENANCE
HEMODIALYSIS-PATIENTS; URINARY ALBUMIN EXCRETION; CELL-ADHESION
MOLECULE-1; STAGE RENAL-DISEASE; ATHEROSCLEROSIS RISK; ENDOTHELIAL
DYSFUNCTION
AB Patients with chronic kidney disease (CKD) experience co-morbid illnesses, including cardiovascular disease and retinopathy. Sevelamer hydrochloride (Renagel (R)); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD. Since retinopathy is proven to be associated with increased coronary calcification, shared pathophysiological processes may contribute to both microvascular and macrovascular disease. We here suggest three different mechanisms of possible sevelamer's influence on the retinopathy: (1) by direct effect on the microvasculature through lowering CRP and LDL, involved in endothelial dysfunction and atherogenesis, (2) indirectly by attenuation of vascular calcification of aorta and carotid internal artery, it reduces ischaemia and improves circulation in the opthalmic artery and hence postponing retinopathy, (3) through hypertension by reducing atherosclerosis and calcification of carotid arteries, sevelamer decreases stiffness and intima-media wall thickness, therefore lowering blood pressure, which is well known to increase progression of diabetic retinopathy. So far no studies have yet been published on the direct influence of sevelamer on the retinopathy which we believe has good theoretical background. With its combined macrovascular and microvascular effect, sevelamer could potentially postpone and/or decrease retinopathy in diabetic patients with hypertension, and that are on hemodialysis or even predialysis patients. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Draca, Natasa; Lazic, Ratimir; Gabric, Nikica] Univ Rijeka, Eye Specialty Hosp Svjetlost, Sch Med, Zagreb 10000, Croatia.
[Simic, Petra] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA.
[Dumic-Cule, Ivo] Univ Zagreb, Sch Med, Zagreb 41000, Croatia.
[Luetic, Ana Tikvica] Univ Zagreb, Dept Obstet & Gynecol, Clin Hosp Sveti Duh, Sch Med, Zagreb 41000, Croatia.
RP Draca, N (reprint author), Univ Rijeka, Eye Specialty Hosp Svjetlost, Sch Med, Heinzelova 39, Zagreb 10000, Croatia.
EM natasha.draca@gmail.com
NR 78
TC 2
Z9 2
U1 0
U2 37
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PD APR
PY 2013
VL 80
IS 4
BP 431
EP 435
DI 10.1016/j.mehy.2012.12.035
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 120IR
UT WOS:000317164500021
PM 23357670
ER
PT J
AU Tanabe, KK
Chiocca, EA
AF Tanabe, Kenneth K.
Chiocca, E. Antonio
TI "Infectious" Optimism for Treatment of Hepatocellular Carcinoma
SO MOLECULAR THERAPY
LA English
DT Editorial Material
ID CANCER
C1 [Tanabe, Kenneth K.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
[Chiocca, E. Antonio] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
RP Tanabe, KK (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7-924, Boston, MA 02114 USA.
EM ktanabe@partners.org
NR 10
TC 2
Z9 2
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD APR
PY 2013
VL 21
IS 4
BP 721
EP 724
DI 10.1038/mt.2013.47
PG 4
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 119PR
UT WOS:000317110300003
PM 23542566
ER
PT J
AU Montgomery, EB
AF Montgomery, Erwin B., Jr.
TI Predictors of Parkinson's disease-not quite sound
SO MOVEMENT DISORDERS
LA English
DT Editorial Material
C1 [Montgomery, Erwin B., Jr.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Montgomery, Erwin B., Jr.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Montgomery, EB (reprint author), Univ Alabama Birmingham, Dept Neurol, 1720 7th Ave South, Birmingham, AL 35294 USA.
EM emontgom@uab.edu
NR 5
TC 3
Z9 3
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR
PY 2013
VL 28
IS 4
BP 413
EP 415
DI 10.1002/mds.25432
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 123CO
UT WOS:000317366100002
PM 23483647
ER
PT J
AU Fisher, MB
Mauck, RL
AF Fisher, Matthew B.
Mauck, Robert L.
TI Starting with form, emerging with function: nanofibrous scaffolds for
tissue engineering of orthopedic tissuesalternatives
SO NANOMEDICINE
LA English
DT Editorial Material
DE function; nanofibrous scaffold; orthopedics; structure; tissue
engineering
ID LIGAMENT
AB "This is an exciting time for the tissue engineering and regenerative medicine field as the complexity and usefulness of scaffolds, including nanofibrous scaffolds, continues to increase."
C1 [Fisher, Matthew B.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthoped Surg, McKay Orthoped Res Lab, Philadelphia, PA 19104 USA.
[Fisher, Matthew B.; Mauck, Robert L.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Mauck, Robert L.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA.
RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthoped Surg, McKay Orthoped Res Lab, 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM lemauck@mail.med.upenn.edu
RI Fisher, Matthew/M-5809-2016
OI Fisher, Matthew/0000-0002-3212-0870
FU NIAMS NIH HHS [P30AR050950, R01AR056624]; NIBIB NIH HHS [R01EB02425]
NR 21
TC 4
Z9 4
U1 0
U2 11
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD APR
PY 2013
VL 8
IS 4
SI SI
BP 505
EP 508
DI 10.2217/NNM.13.18
PG 4
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
Topics
GA 120NU
UT WOS:000317178200002
PM 23560399
ER
PT J
AU Bellot, G
McClintock, MA
Chou, JJ
Shih, WM
AF Bellot, Gaetan
McClintock, Mark A.
Chou, James J.
Shih, William M.
TI DNA nanotubes for NMR structure determination of membrane proteins
SO NATURE PROTOCOLS
LA English
DT Article
ID LIQUID-CRYSTALLINE MEDIUM; RESIDUAL DIPOLAR COUPLINGS; MOLECULAR
ALIGNMENT; BIOLOGICAL MACROMOLECULES; POLYACRYLAMIDE-GELS; DETERGENT
MICELLES; NANOSCALE SHAPES; WEAK ALIGNMENT; PROTON CHANNEL; FOLDING DNA
AB Finding a way to determine the structures of integral membrane proteins using solution nuclear magnetic resonance (NMR) spectroscopy has proved to be challenging. A residual-dipolar-coupling-based refinement approach can be used to resolve the structure of membrane proteins up to 40 kDa in size, but to do this you need a weak-alignment medium that is detergent-resistant and it has thus far been difficult to obtain such a medium suitable for weak alignment of membrane proteins. We describe here a protocol for robust, large-scale synthesis of detergent-resistant DNA nanotubes that can be assembled into dilute liquid crystals for application as weak-alignment media in solution NMR structure determination of membrane proteins in detergent micelles. The DNA nanotubes are heterodimers of 400-nm-long six-helix bundles, each self-assembled from a M13-based p7308 scaffold strand and >170 short oligonucleotide staple strands. Compatibility with proteins bearing considerable positive charge as well as modulation of molecular alignment, toward collection of linearly independent restraints, can be introduced by reducing the negative charge of DNA nanotubes using counter ions and small DNA-binding molecules. This detergent-resistant liquid-crystal medium offers a number of properties conducive for membrane protein alignment, including high-yield production, thermal stability, buffer compatibility and structural programmability. Production of sufficient nanotubes for four or five NMR experiments can be completed in 1 week by a single individual.
C1 [Bellot, Gaetan; Chou, James J.; Shih, William M.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Bellot, Gaetan; Shih, William M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Bellot, Gaetan; Shih, William M.] Wyss Inst Biol Inspired Engn Harvard, Boston, MA USA.
[McClintock, Mark A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
RP Shih, WM (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM william_shih@dfci.harvard.edu
RI Chou, James/N-9840-2013
FU US National Institutes of Health (NIH) [1U54GM094608, 1DP20D004641]
FX We thank I. Ayala and J. Boisbouvier (CNRS, Institut de Biologie
Structurale) for the gift of the ubiquitin vector and R. Sounier
(Harvard Medical School) for helpful discussions. This work was
supported by the US National Institutes of Health (NIH) grants
1U54GM094608 to J.J.C., and 1DP20D004641 and 1U54GM094608 to W.M.S.
NR 52
TC 18
Z9 18
U1 3
U2 66
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
J9 NAT PROTOC
JI Nat. Protoc.
PD APR
PY 2013
VL 8
IS 4
BP 755
EP 770
DI 10.1038/nprot.2013.037
PG 16
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 119PY
UT WOS:000317111000010
PM 23518667
ER
PT J
AU DeCaprio, JA
Garcea, RL
AF DeCaprio, James A.
Garcea, Robert L.
TI A cornucopia of human polyomaviruses
SO NATURE REVIEWS MICROBIOLOGY
LA English
DT Review
ID MERKEL-CELL POLYOMAVIRUS; LARGE T-ANTIGEN; PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATHY; AFRICAN-GREEN MONKEY; INDUCED DEMYELINATING
DISEASE; GLUTATHIONE-S-TRANSFERASE; CAPSID PROTEIN VP1; JC VIRUS;
RESPIRATORY-DISEASE; WU POLYOMAVIRUS
AB During the past 6 years, focused virus hunting has led to the discovery of nine new human polyomaviruses, including Merkel cell polyomavirus, which has been linked to Merkel cell carcinoma, a lethal skin cell cancer. The discovery of so many new and highly divergent human polyomaviruses raises key questions regarding their evolution, tropism, latency, reactivation, immune evasion and contribution to disease. This Review describes the similarities and differences among the new human polyomaviruses and discusses how these viruses might interact with their human host.
C1 [DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[DeCaprio, James A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[DeCaprio, James A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
[Garcea, Robert L.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.
[Garcea, Robert L.] Univ Colorado, Biofrontiers Inst, Boulder, CO 80309 USA.
RP DeCaprio, JA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Mayer 440, Boston, MA 02115 USA.
EM james_decaprio@dfci.harvard.edu; robert.garcea@colorado.edu
FU US Public Health Service [P01CA050661, RO1 CA93804, R01CA63113,
RO1CA37667]
FX This work was supported in part by US Public Health Service grants
P01CA050661, RO1 CA93804 and R01CA63113 to J.A.D. and RO1CA37667 to
R.L.G. The authors thank D. McDonald for assistance with the
bioinformatics
NR 163
TC 101
Z9 105
U1 1
U2 39
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1740-1526
J9 NAT REV MICROBIOL
JI Nat. Rev. Microbiol.
PD APR
PY 2013
VL 11
IS 4
BP 264
EP 276
DI 10.1038/nrmicro2992
PG 13
WC Microbiology
SC Microbiology
GA 114YD
UT WOS:000316778000014
PM 23474680
ER
PT J
AU Walker, DA
Liu, JF
Kieran, M
Jabado, N
Picton, S
Packer, R
St Rose, C
AF Walker, David A.
Liu, JoFen
Kieran, Mark
Jabado, Nada
Picton, Susan
Packer, Roger
St Rose, Christian
CA CPN Paris 2011 Conference
TI A multi-disciplinary consensus statement concerning surgical approaches
to low-grade, high-grade astrocytomas and diffuse intrinsic pontine
gliomas in childhood (CPN Paris 2011) using the Delphi method
SO NEURO-ONCOLOGY
LA English
DT Article
DE low-grade astrocytoma
ID OPTIC PATHWAY GLIOMAS; CHILDREN; TUMORS
AB A multidisciplinary consensus conference on pediatric neurosurgery was held in February 2011, where 92 invited participants reviewed evidence for clinical management of hypothalamic chiasmatic glioma (HCLGG), diffuse intrinsic pontine glioma (DIPG), and high-grade glioma (HGG). Twenty-seven statements were drafted and subjected to online Delphi consensus voting by participants, seeking 70 agreement from 60 of respondents; where 70 consensus occurred, the statement was modified and resubmitted for voting.
Twenty-seven statements meeting consensus criteria are reported. For HCLGG, statements describing overall therapeutic purposeand indications for biopsy, observation, or treatment aimed at limiting the risk of visual damage and the need for on-going clinical trials were made. Primary surgical resection was not recommended. For DIPG, biopsy was recommended to ascertain biological characteristics to enhance understanding and targeting of treatments, especially in clinical trials. For HGG, biopsy is essential, the World Health Organization classification was recommended; selection of surgical strategy to achieve gross total resection in a single or multistep process should be discussed with the PNMDT and integrated with trials based drug strategies for adjuvant therapies.
C1 [Walker, David A.; Liu, JoFen] Univ Nottingham, Childrens Brain Tumour Res Ctr, Queens Med Ctr, Nottingham NG7 2UH, England.
[Liu, JoFen; Kieran, Mark] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jabado, Nada] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Res Inst, Montreal, PQ, Canada.
[Picton, Susan] St James Univ Hosp, Reg Paediat Oncol Unit, Leeds, W Yorkshire, England.
[Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[St Rose, Christian] Hop Necker Enfants Malad, Serv Neurochirurg, Paris, France.
RP Walker, DA (reprint author), Univ Nottingham, Childrens Brain Tumour Res Ctr, Queens Med Ctr, Nottingham NG7 2UH, England.
EM david.walker@nottingham.ac.uk
RI Hargrave, Darren/H-1066-2014;
OI Hargrave, Darren/0000-0001-8219-9807; Depreitere,
Bart/0000-0002-7458-0648; Ternier, Jessica/0000-0003-4673-802X;
FRASSANITO, PAOLO/0000-0003-0071-3126; Kieran, Mark/0000-0003-2184-7692;
Dorfer, Christian/0000-0002-1843-7732; Van Vuurden,
Dannis/0000-0002-1364-9007
NR 9
TC 23
Z9 23
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
IS 4
BP 462
EP 468
DI 10.1093/neuonc/nos330
PG 7
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 117PM
UT WOS:000316965600008
PM 23502427
ER
PT J
AU Peereboom, DM
Ahluwalia, MS
Ye, XB
Supko, JG
Hilderbrand, SL
Phuphanich, S
Nabors, LB
Rosenfeld, MR
Mikkelsen, T
Grossman, SA
AF Peereboom, David M.
Ahluwalia, Manmeet S.
Ye, Xiaobu
Supko, Jeffrey G.
Hilderbrand, Sarah L.
Phuphanich, Surasak
Nabors, L. Burt
Rosenfeld, Myrna R.
Mikkelsen, Tom
Grossman, Stuart A.
CA New Approaches Brain Tumor Therapy
TI NABTT 0502: a phase II and pharmacokinetic study of erlotinib and
sorafenib for patients with progressive or recurrent glioblastoma
multiforme
SO NEURO-ONCOLOGY
LA English
DT Article
DE EGFR; erlotinib; pharmacokinetics; glioblastoma; Ras signaling;
sorafenib; targeted therapy
ID GROWTH-FACTOR-RECEPTOR; REFRACTORY SOLID TUMORS; TYROSINE KINASE
INHIBITOR; CELL LUNG-CANCER; HIGH-GRADE GLIOMAS; DAYS ON/7 DAYS;
MALIGNANT GLIOMA; RAF KINASE; CLINICAL PHARMACOKINETICS; POSTRADIATION
THERAPY
AB The signal transduction pathways of epidermal growth factor receptor and Ras are both important in the growth of glioblastoma multiforme (GBM). We hypothesized that inhibition of both pathways would improve the survival time of patients with recurrent GBM.
Patients with recurrent/progressive GBM with 02 prior chemotherapy regimens received erlotinib 150 mg once daily and sorafenib 400 mg twice daily until progression. The primary endpoint was overall survival. Pharmacokinetic sampling was performed during cycle 1.
The median overall survival was 5.7 months. Progression-free survival at 6 months was 14. Toxicity was manageable. Clearance of erlotinib was markedly enhanced by sorafenib.
The study did not meet its objective of a 30 increase in overall survival time compared with historical controls. Erlotinib and sorafenib have significant pharmacokinetic interactions that may negatively impact the efficacy of the combination regimen.
C1 [Peereboom, David M.; Ahluwalia, Manmeet S.] Cleveland Clin, Cleveland, OH 44195 USA.
[Ye, Xiaobu; Grossman, Stuart A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Supko, Jeffrey G.; Hilderbrand, Sarah L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Phuphanich, Surasak] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Nabors, L. Burt] Univ Alabama Birmingham, Birmingham, AL USA.
[Rosenfeld, Myrna R.] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain.
[Mikkelsen, Tom] Henry Ford Hosp, Detroit, MI 48202 USA.
RP Peereboom, DM (reprint author), Cleveland Clin, Burkhardt Brain Tumor & Neurooncol Ctr, Neurol Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM peerebd@ccf.org
OI Rosenfeld, Myrna/0000-0001-5095-2534
FU National Cancer Institute [CA-62475]
FX This work was supported by the National Cancer Institute (grant no.
CA-62475).
NR 53
TC 27
Z9 28
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD APR
PY 2013
VL 15
IS 4
BP 490
EP 496
DI 10.1093/neuonc/nos322
PG 7
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 117PM
UT WOS:000316965600011
PM 23328813
ER
PT J
AU Beloiartsev, A
Baron, DM
Yu, BL
Bloch, KD
Zapol, WM
AF Beloiartsev, Arkadi
Baron, David M.
Yu, Binglan
Bloch, Kenneth D.
Zapol, Warren M.
TI Hemoglobin infusion does not alter murine pulmonary vascular tone
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Hemoglobin; Endothelium; Hypoxia; Vasoconstriction; Nitric oxide
ID CELL-FREE HEMOGLOBIN; NITRIC-OXIDE SYNTHASE; STROMA-FREE HEMOGLOBIN;
ENDOTHELIAL DYSFUNCTION; RELAXING FACTOR; OXYGEN CARRIER; RAT LUNGS;
VASOCONSTRICTION; BLOOD; HYPERTENSION
AB Plasma hemoglobin (Hb) scavenges endothelium-derived nitric oxide (NO), producing systemic and pulmonary vasoconstriction in many species. We hypothesized that i.v. administration of murine cell-free Hb would produce pulmonary vasoconstriction and enhance hypoxic pulmonary vasoconstriction (HPV) in mice.
To assess the impact of plasma Hb on basal pulmonary vascular tone in anesthetized mice we measured left lung pulmonary vascular resistance (LPVRI) before and after infusion of Hb at thoracotomy. To confirm the findings obtained at thoracotomy, measurements of right ventricular systolic pressure (RVSP) and systemic arterial pressure (SAP) were obtained in closed-chest wild-type mice. To elucidate whether pretreatment with Hb augments HPV we assessed the increase in LPVRI before and during regional lung hypoxia produced by left mainstem bronchial occlusion (LMBO) in wild-type mice pretreated with Hb.
Infusion of Hb increased SAP but did not change pulmonary arterial pressure (PAP), left lung pulmonary arterial flow (Q(LPA)) or LPVRI in either wild-type or diabetic mice with endothelial dysfunction. Scavenging of NO by plasma Hb did not alter HPV in wild-type mice. Inhibition of NO synthase with L-NAME did not change the basal LPVRI, but augmented HPV during LMBO.
Our data suggest that scavenging of NO by plasma Hb does not alter pulmonary vascular tone in mice. Therefore, generation of NO in the pulmonary circulation is unlikely to be responsible for the low basal pulmonary vascular tone of mice. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Beloiartsev, Arkadi; Baron, David M.; Yu, Binglan; Bloch, Kenneth D.; Zapol, Warren M.] Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Beloiartsev, Arkadi; Baron, David M.; Yu, Binglan; Bloch, Kenneth D.; Zapol, Warren M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Zapol, WM (reprint author), Anesthesia Ctr Crit Care Res, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,Thier 503, Boston, MA 02114 USA.
EM wzapol@partners.org
FU Department of Anesthesia, Critical Care, and Pain Medicine,
Massachusetts General Hospital, Boston, Massachusetts; National
Institute of Health, Bethesda, Maryland [HL074352]
FX This study was supported by funds of the Department of Anesthesia,
Critical Care, and Pain Medicine, Massachusetts General Hospital,
Boston, Massachusetts. Dr. Kenneth D. Bloch was supported by a National
Institute of Health R01 grant (HL074352), Bethesda, Maryland.
NR 54
TC 1
Z9 1
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD APR 1
PY 2013
VL 30
BP 1
EP 8
DI 10.1016/j.niox.2012.12.007
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 122LV
UT WOS:000317320500001
PM 23313572
ER
PT J
AU Loh, AR
Joseph, D
Keenan, JD
Lietman, TM
Naseri, A
AF Loh, Allison R.
Joseph, Damien
Keenan, Jeremy D.
Lietman, Thomas M.
Naseri, Ayman
TI Predictors of Matching in an Ophthalmology Residency Program
SO OPHTHALMOLOGY
LA English
DT Article
ID SELECTION; DIRECTORS; SCORES
AB Purpose: To examine the characteristics of US medical students applying for ophthalmology residency and to determine the predictors of matching.
Design: A retrospective case series.
Participants: A total of 3435 medical students from the United States who applied to an ophthalmology residency program from 2003 to 2008 were included.
Methods: Matched and unmatched applicants were compared and stratified by predictor variables, including United States Medical Licensing Examination (USMLE) Step 1 score, Alpha Omega Alpha (AOA) status, medical school reputation, and medical school geographic region. Differences in proportions were analyzed using the Fisher exact test. Logistic regression was used to determine the predictors of successful matching.
Main Outcome Measures: Successful matching to an ophthalmology program.
Results: The majority of applicants (72%, 2486/3435) matched in ophthalmology. In multivariate analysis, AOA membership (odds ratio [OR], 2.6, P < 0.0001), USMLE score (OR, 1.6; P < 0.0001), presence of an ophthalmology residency at medical school (OR, 1.4; P = 0.01), top 25 medical school (OR, 1.4; P < 0.03), top 10 medical school (OR, 1.6; P < 0.02), and allopathic degree (OR, 4.0; P < 0.0001) were statistically significant predictors of matching. Approximately 60% (1442/2486) of applicants matched to the same geographic region as their medical school. Applicants were more likely to match at a program in the same geographic region as their medical school than would be predicted by chance alone (P < 0.0001). In multivariate analysis, higher USMLE score (OR, 0.9; P < 0.0001) and top 10 medical school (OR, 0.7; P = 0.027) were statistically significant predictors of matching to outside the geographic region as one's medical school.
Conclusions: The majority of applicants applying for an ophthalmology residency position match successfully. Higher performance on quantitative metrics seems to confer an advantage for matching. The majority of applicants match at a residency program within the same geographic region as one's medical school.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:865-870 (C) 2013 by the American Academy of Ophthalmology.
C1 [Loh, Allison R.; Keenan, Jeremy D.; Lietman, Thomas M.; Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94121 USA.
[Joseph, Damien] San Francisco Match Program, San Francisco, CA USA.
[Keenan, Jeremy D.; Lietman, Thomas M.; Naseri, Ayman] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94121 USA.
[Naseri, Ayman] San Francisco Vet Adm Med Ctr, Dept Ophthalmol, San Francisco, CA USA.
RP Naseri, A (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94121 USA.
EM Ayman.Naseri@va.gov
NR 19
TC 5
Z9 5
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2013
VL 120
IS 4
BP 865
EP 870
DI 10.1016/j.ophtha.2012.09.028
PG 6
WC Ophthalmology
SC Ophthalmology
GA 122UL
UT WOS:000317343500033
PM 23260256
ER
PT J
AU Bassetto, F
Turra, G
Salmaso, R
Lancerotto, L
Del Vecchio, DA
AF Bassetto, Franco
Turra, Giovanni
Salmaso, Roberto
Lancerotto, Luca
Del Vecchio, Daniel A.
TI Autologous Injectable Dermis: A Clinical and Histological Study
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID PROSTHETIC BREAST RECONSTRUCTION; COCKTAIL INJECTION MICROGRAFT;
COMPLETE SUBMUSCULAR COVERAGE; MINIGRAFT MIXTURE; FAT; OUTCOMES;
ADJUNCTION; SURVIVAL; FASCIA
AB Background: No perfect solution yet exists for dermal fillers. The authors hypothesized that autologous dermis can be processed in an operator-friendly manner and adopted in selected patients as a filler, following the principle of replacing "like with like."
Methods: The authors designed a prototype "cutting chamber" to morsel dermis into an injectable form. Autologous injectable dermis grafting was performed in 16 patients who underwent lip or labionasal fold correction concomitant with abdominoplasty or cesarean scar correction; patient dermis was used for the donor graft. Furthermore, injectable dermis grafting was performed in the subcutaneous tissue of three patients undergoing multistage reconstructive procedures for obesity. The grafts were harvested and examined histologically at 3, 7, and 12 months.
Results: Dermis processing and injection proved feasible with limited effort. All 16 patients presented good volume maintenance by 12 months. Two reported transient palpable firmness for the first 6 months, which subsequently resolved. Histological examination of processed and injected dermis showed volume maintenance over time, effective revascularization of the mass, and structural reorganization with collagen bundles and nested fibroblasts reminiscent of reticular dermis. A transient inflammatory reaction was observed, consistent with the expected healing events.
Conclusions: Use of autologous dermis as a filler substance for both aesthetic and reconstructive procedures appears to be a feasible option. It could be advised for patients requiring filler correction who undergo concomitant procedures involving excision of potential donor dermis. (Plast. Reconstr. Surg. 131: 589e, 2013.)
C1 Univ Padua, Inst Plast Surg, I-35100 Padua, Italy.
Univ Hosp Padova, Dept Pathol, Padua, Italy.
Brigham & Womens Hosp, Div Plast Surg, Boston, MA 02115 USA.
[Del Vecchio, Daniel A.] Back Bay Plast Surg, Boston, MA 02116 USA.
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
RP Del Vecchio, DA (reprint author), Back Bay Plast Surg, 38 Newbury St, Boston, MA 02116 USA.
EM dandelvecchio@aol.com
NR 14
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD APR
PY 2013
VL 131
IS 4
BP 589E
EP 596E
DI 10.1097/PRS.0b013e318282770c
PG 8
WC Surgery
SC Surgery
GA 121YW
UT WOS:000317282800013
PM 23542277
ER
PT J
AU Hazani, R
Rao, A
Ford, R
Yaremchuk, MJ
Wilhelmi, BJ
AF Hazani, Ron
Rao, Arun
Ford, Rachel
Yaremchuk, Michael J.
Wilhelmi, Bradon J.
TI The Safe Zone for Placement of Chin Implants
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID INFERIOR ALVEOLAR NERVE; LOWER LIP POSITION; ESSENTIAL COMPONENT;
MENTALIS MUSCLE; AUGMENTATION
AB Background: Alloplastic chin augmentation requires the surgeon to predict the location of the mental foramen and the origin of the mentalis muscle to avoid the postoperative sequelae lower lip parasthesia, lower lip incompetence, or chin ptosis. The authors define a safe zone of dissection along the inferior border of the mandible for placement of alloplastic chin implants.
Methods: Fourteen fresh cadaveric hemifaces were dissected with the aid of loupe magnification. Previously described anatomic landmarks were used to identify the origin of the mentalis muscle and the location of the mental foramen along the alveolar ridge of the mandible. Vertical distances were then measured from the mandibular border to the inferior aspect of the mentalis muscle origin and the lower edge of the mental foramen to construct the zone of safe dissection.
Results: The mentalis was identified as a fan-shaped muscle originating from the alveolar process below the incisors roots and inserting into the chin just below the labiomental sulcus. The mental foramen was located most commonly below the roots of the first and second premolars or in the space between the roots. The mentalis origin and the mental foramen were 1.8 +/- 0.3 cm and 1.5 +/- 0.2 cm cephalad to the inferior edge of the mandible, respectively. These distances define the borders of a safe zone above the mandibular border.
Conclusions: A safe zone of dissection for alloplastic chin augmentation is identified. This study is applicable to implant placement through a submental or an intraoral incision. This safe zone is also useful for reconstructive or orthognathic mandible procedures. (Plast. Reconstr. Surg. 131: 869, 2013.)
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Louisville, Sch Med, Louisville, KY 40292 USA.
Loma Linda Univ, Sch Med, Loma Linda, CA 92350 USA.
RP Hazani, R (reprint author), Harvard Univ, Sch Med, Div Plast & Reconstruct Surg, Massachusetts Gen Hosp, 15 Parkman St,WACC 435, Boston, MA 02114 USA.
EM ronmdsurg@hotmail.com
NR 16
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD APR
PY 2013
VL 131
IS 4
BP 869
EP 872
DI 10.1097/PRS.0b013e3182818e6c
PG 4
WC Surgery
SC Surgery
GA 121YW
UT WOS:000317282800068
PM 23542258
ER
PT J
AU Eriksson, E
Rohrich, RJ
Sachs, DH
Pomahac, B
Delmonico, FL
Caterson, EJ
Goldwyn, RM
AF Eriksson, Elof
Rohrich, Rod J.
Sachs, David H.
Pomahac, Bohdan
Delmonico, Francis L.
Caterson, E. J.
Goldwyn, Robert M.
TI The Nobler Angels of Our Nature: A Tribute to Joseph E. Murray, MD, 1919
to 2012
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Biographical-Item
C1 [Eriksson, Elof] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cambridge, MA 02138 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Texas Southwestern Med Ctr, Dept Plast Surg, Dallas, TX USA.
RP Eriksson, E (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD APR
PY 2013
VL 131
IS 4
BP 912
EP 913
DI 10.1097/PRS.0b013e31828aaf23
PG 2
WC Surgery
SC Surgery
GA 121YW
UT WOS:000317282800074
PM 23542265
ER
PT J
AU Meyer, F
Zhang, BH
Gao, X
Prigerson, HG
AF Meyer, Fremonta
Zhang, Baohui
Gao, Xin
Prigerson, Holly G.
TI Associations between cognitive impairment in advanced cancer patients
and psychiatric disorders in their caregivers
SO PSYCHO-ONCOLOGY
LA English
DT Article
DE cancer; oncology; caregiver; cognitive impairment; depression;
psychiatric disorder
ID MENTAL STATUS QUESTIONNAIRE; GENERALIZED ANXIETY; OF-LIFE; DEMENTIA;
DELIRIUM; HEALTH
AB Objective This study examined whether cognitive impairment in advanced cancer patients is associated with a heightened frequency of psychiatric disorders in their primary caregivers. Methods Three hundred fifty-six patient-caregiver dyads were interviewed and administered the Short Portable Mental Status Questionnaire and the Structured Clinical Interview of the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition approximately 3.4months before the patient's death. The Structured Clinical Interview of the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition was administered to caregivers again approximately 6months after the patient's death. Results Forty-six (12.9%) patients displayed signs of mild cognitive impairment at the baseline interview. After adjustment for relevant confounders, patient cognitive impairment was significantly associated with caregiver pre-loss major depressive disorder [OR 6.88 (95% CI 1.3235.92); p=0.02], without associated increases in suicidality. There were no significant associations between patient cognitive impairment and caregiver pre-loss generalized anxiety disorder, posttraumatic stress disorder, panic disorder, or grief. Likewise, there were no significant associations between patient cognitive impairment and caregiver post-loss psychiatric disorders, but caregivers of cognitively impaired patients appeared to be less satisfied with the patient's manner of death (p=0.01). Conclusions Caregivers of cognitively impaired advanced cancer patients appear at heightened risk of major depression that resolves after the patient's death. Further study with a larger sample and more sensitive longitudinal cognitive measures is indicated. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Meyer, Fremonta; Zhang, Baohui; Gao, Xin; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA.
[Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Meyer, Fremonta; Prigerson, Holly G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
RP Meyer, F (reprint author), 450 Brookline Ave,SW411, Boston, MA 02115 USA.
EM flmeyer@partners.org
FU National Institute of Mental Health [MH63892]; National Cancer Institute
[CA 106370, CA 156732]; Center for Psycho-Oncology and Palliative Care
Research, Dana-Farber Cancer Institute
FX This research was supported in part by the following grants to Dr
Prigerson: MH63892 from the National Institute of Mental Health and CA
106370 and CA 156732 from the National Cancer Institute; and the Center
for Psycho-Oncology and Palliative Care Research, Dana-Farber Cancer
Institute.
NR 14
TC 4
Z9 4
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD APR
PY 2013
VL 22
IS 4
BP 952
EP 955
DI 10.1002/pon.3076
PG 4
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 122IQ
UT WOS:000317312200031
PM 22451155
ER
PT J
AU Saladin, ME
Gray, KM
McRae-Clark, AL
LaRowe, SD
Yeatts, SD
Baker, NL
Hartwell, KJ
Brady, KT
AF Saladin, Michael E.
Gray, Kevin M.
McRae-Clark, Aimee L.
LaRowe, Steven D.
Yeatts, Sharon D.
Baker, Nathaniel L.
Hartwell, Karen J.
Brady, Kathleen T.
TI A double blind, placebo-controlled study of the effects of
post-retrieval propranolol on reconsolidation of memory for craving and
cue reactivity in cocaine dependent humans
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Reconsolidation; Retrieval; Craving; Cocaine dependence; Cue exposure;
Human subjects
ID BETA-ADRENERGIC-BLOCKADE; NORADRENERGIC BLOCKADE; RECEPTOR BLOCKADE;
ERASING FEAR; DAILY-LIFE; EXTINCTION; CONSOLIDATION; ADDICTION;
PREFERENCE; DISRUPTION
AB This study examined the effects of propranolol vs. placebo, administered immediately after a "retrieval" session of cocaine cue exposure (CCE), on craving and physiological responses occurring 24 h later during a subsequent "test" session of CCE. It was hypothesized that compared to placebo-treated cocaine-dependent (CD) individuals, propranolol-treated CD individuals would evidence attenuated craving and physiological reactivity during the test session. Secondarily, it was expected that group differences identified in the test session would be evident at a 1-week follow-up CCE session. Exploratory analyses of treatment effects on cocaine use were also performed at follow-up.
CD participants received either 40 mg propranolol or placebo immediately following a "retrieval" CCE session. The next day, participants received a "test" session of CCE that was identical to the "retrieval" session except no medication was administered. Participants underwent a "follow-up" CCE session 1 week later. Craving and other reactivity measures were obtained at multiple time points during the CCE sessions.
Propranolol- vs. placebo-treated participants evidenced significantly greater attenuation of craving and cardiovascular reactivity during the test session. Analysis of the follow-up CCE session data did not reveal any group differences. Although there was no evidence of treatment effects on cocaine use during follow-up, this study was insufficiently powered to rigorously evaluate differential cocaine use.
This double-blind, placebo-controlled laboratory study provides the first evidence that propranolol administration following CCE may modulate memories for learning processes that subserve cocaine craving/cue reactivity in CD humans. Alternative interpretations of the findings were considered, and implications of the results for treatment were noted.
C1 [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Saladin, Michael E.; Gray, Kevin M.; McRae-Clark, Aimee L.; LaRowe, Steven D.; Yeatts, Sharon D.; Baker, Nathaniel L.; Hartwell, Karen J.; Brady, Kathleen T.] Med Univ S Carolina, Clin Neurosci Div, Charleston, SC 29425 USA.
[Gray, Kevin M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Youth Div, Charleston, SC 29425 USA.
[Yeatts, Sharon D.; Baker, Nathaniel L.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Subst Abuse Treatment Ctr, Charleston, SC USA.
[Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA.
RP Saladin, ME (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Room 224,MSC700, Charleston, SC 29425 USA.
EM saladinm@musc.edu
RI McRae-Clark, Aimee/I-3341-2013
OI McRae-Clark, Aimee/0000-0002-9774-318X
FU NIDA grant [R21DA025155]; South Carolina Clinical & Translational
Research (SCTR) Institute; NIH [UL1 RR029882, UL1 TR000062]
FX This research was supported by NIDA grant R21DA025155 (Saladin, PI) and
by the South Carolina Clinical & Translational Research (SCTR)
Institute, with an academic home at the Medical University of South
Carolina, through NIH Grant Numbers UL1 RR029882 and UL1 TR000062. The
authors report no conflicts of interest pertaining to this study.
NR 91
TC 24
Z9 25
U1 3
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD APR
PY 2013
VL 226
IS 4
BP 721
EP 737
DI 10.1007/s00213-013-3039-3
PG 17
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 122GL
UT WOS:000317306200009
PM 23460266
ER
PT J
AU Levitt, JJ
Rosow, LK
Nestor, PG
Pelavin, PE
Swisher, TM
McCarley, RW
Shenton, ME
AF Levitt, James J.
Rosow, Laura K.
Nestor, Paul G.
Pelavin, Paula E.
Swisher, Talis M.
McCarley, Robert W.
Shenton, Martha E.
TI A volumetric MRI study of limbic, associative and sensorimotor striatal
subregions in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Magnetic Resonance Imaging; Striatum; Ventral striatum;
Dorsal striatum; Prefrontal cortex
ID POSITRON-EMISSION-TOMOGRAPHY; SCHIZOTYPAL PERSONALITY-DISORDER;
MESOLIMBIC DOPAMINE TRANSMISSION; FRONTAL-SUBCORTICAL CIRCUITS; CAUDATE
NUCLEI VOLUMES; BASAL GANGLIA VOLUMES; NEUROLEPTIC-NAIVE; PREMORBID
ADJUSTMENT; ANTIPSYCHOTIC-DRUGS; PREFRONTAL CORTEX
AB Introduction: Cognitive and emotional functioning is mediated by frontal-subcortical feedback loops. The striatum, a component of this circuitry, thus is a possible neural substrate of schizophrenia. Striatum volume, however, is believed to be differentially influenced by neuroleptic treatment due to an anterior-posterior D2 receptor density gradient. We thus rigorously parcellated it into subregions in order to assess whether neuroleptic effect on group differences is regionally specific.
Methods: 29 chronic, male, schizophrenia patients and 28 male, normal controls (NCs), group-matched for handedness, age, and parental SES, underwent structural brain imaging on a 1.5 Tesla GE system. We manually measured the volume, normalized for intracranial contents, of the striatum parcellated into anatomic subregions and their corresponding limbic, associative and sensorimotor functional subregions and performed clinical correlations.
Results: First, we found a localized bilateral enlargement of the posterior putamen in medicated chronic schizophrenia. Second, we showed associative striatal subregion volumes correlated with executive function in schizophrenia subjects and, to a lesser extent, in NCs. Third, we showed associative striatal subregions inversely correlated with negative symptoms but conversely, the ventral/limbic striatum did not correlate with positive or negative clinical symptoms.
Discussion: Our novel parcellation strategy, based on rigorous delineation of the ventral striatum, allowed for the demonstration of localized volumetric differences between schizophrenia and NCs. Furthermore, by parcellating the striatum into functional subregions we demonstrated significant positive correlations between the volume of the associative striatum and executive functioning in schizophrenia, adding further support to the importance of its role in the pathophysiology of schizophrenia. Published by Elsevier B.V.
C1 [Levitt, James J.; Nestor, Paul G.; McCarley, Robert W.; Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Dept Psychiat, Clin Neurosci Div,Lab Neurosci, Brockton, MA 02301 USA.
[Levitt, James J.; Nestor, Paul G.; McCarley, Robert W.; Shenton, Martha E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Levitt, James J.; Rosow, Laura K.; Pelavin, Paula E.; Swisher, Talis M.; Shenton, Martha E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02215 USA.
[Shenton, Martha E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Surg Planning Lab,MRI Div,Dept Radiol, Boston, MA 02215 USA.
RP Levitt, JJ (reprint author), Harvard Univ, VA Boston Healthcare Syst, Dept Psychiat 116A, Sch Med, 940 Belmont St, Brockton, MA 02301 USA.
EM james_levitt@hms.harvard.edu
RI McCarley, Robert/N-5562-2014
OI McCarley, Robert/0000-0001-5705-7495
FU Department of Veteran Affairs; VA Schizophrenia Center; Department of
Veterans Affairs; National Institutes of Health [K05 MH 700047, R01 MH
50747, R01 MH 40799]
FX This work was supported in part by the Department of Veteran Affairs
Awards (Merits, JJL, MES, RWM; Research Enhancement Award Program, RWM,
MES), by a VA Schizophrenia Center grant (RWM, MES), by a Middleton
Award (RWM) from the Department of Veterans Affairs, and by grants from
the National Institutes of Health (K05 MH 700047 and R01 MH 50747 to
MES, R01 MH 40799 to RWM). Our sponsors served no role in the study
design; in the collection, analysis and interpretation of data; in the
writing of the report; or in the decision to submit the paper for
publication.
NR 74
TC 9
Z9 9
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD APR
PY 2013
VL 145
IS 1-3
BP 11
EP 19
DI 10.1016/j.schres.2012.08.032
PG 9
WC Psychiatry
SC Psychiatry
GA 122RS
UT WOS:000317336200002
PM 23380548
ER
PT J
AU Matos, FM
Raemer, DB
AF Matos, Francisco M.
Raemer, Daniel B.
TI Mixed-Realism Simulation of Adverse Event Disclosure An Educational
Methodology and Assessment Instrument
SO SIMULATION IN HEALTHCARE-JOURNAL OF THE SOCIETY FOR SIMULATION IN
HEALTHCARE
LA English
DT Article
DE Patient simulation; Adverse events; Disclosure
ID MEDICAL ERRORS; RESIDENTS; AGREEMENT; ATTITUDES; SKILLS
AB Introduction: Physicians have an ethical duty to disclose adverse events to patients or families. Various strategies have been reported for teaching disclosure, but no instruments have been shown to be reliable for assessing them.
The aims of this study were to report a structured method for teaching adverse event disclosure using mixed-realism simulation, develop and begin to validate an instrument for assessing performance, and describe the disclosure practice of anesthesiology trainees.
Methods: Forty-two anesthesiology trainees participated in a 2-part exercise with mixed-realism simulation. The first part took place using a mannequin patient in a simulated operating room where trainees became enmeshed in a clinical episode that led to an adverse event and the second part in a simulated postoperative care unit where the learner is asked to disclose to a standardized patient who systematically moves through epochs of grief response. Two raters scored subjects using an assessment instrument we developed that combines a 4-element behaviorally anchored rating scale (BARS) and a 5-stage objective rating scale.
Results: The performance scores for elements within the BARS and the 5-stage instrument showed excellent interrater reliability (Cohen's kappa = 0.7), appropriate range (mean range for BARS, 4.20Y4.47; mean range for 5-stage instrument, 3.73-4.46), and high internal consistency (P < 0.05).
Conclusions: We have demonstrated a comprehensive methodology using a mixed-realism simulation that engages learners in an adverse event and allows them to practice disclosure to a structured range of patient responses. We have developed a reliable 2-part instrument with strong psychometric properties for assessing disclosure performance. (Sim Healthcare 8:84-90, 2013)
C1 [Matos, Francisco M.; Raemer, Daniel B.] Ctr Med Simulat, Charlestown, MA 02129 USA.
[Raemer, Daniel B.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Raemer, Daniel B.] Harvard Univ, Sch Med, Boston, MA USA.
[Matos, Francisco M.] Coimbra Univ Hosp, Dept Anesthesia Crit Care & Pain Med, Coimbra, Portugal.
[Matos, Francisco M.] Univ Beira Interior, CICS UBI Hlth Sci Res Ctr, Covilha, Portugal.
RP Raemer, DB (reprint author), Ctr Med Simulat, 100 1st Ave,Suite 400, Charlestown, MA 02129 USA.
EM draemer@partners.org
NR 31
TC 5
Z9 5
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-2332
J9 SIMUL HEALTHC
JI Simul. Healthc.
PD APR
PY 2013
VL 8
IS 2
BP 84
EP 90
DI 10.1097/SIH.0b013e31827cbb27
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 118QE
UT WOS:000317039600004
PM 23334365
ER
PT J
AU Neofytos, D
Kobayashi, K
Alonso, CD
Cady-Reh, J
Lepley, D
Harris, M
Desai, N
Kraus, E
Subramanian, A
Treadway, S
Ostrander, D
Thompson, C
Marr, K
AF Neofytos, D.
Kobayashi, K.
Alonso, C. D.
Cady-Reh, J.
Lepley, D.
Harris, M.
Desai, N.
Kraus, E.
Subramanian, A.
Treadway, S.
Ostrander, D.
Thompson, C.
Marr, K.
TI Epidemiology, risk factors, and outcomes of Clostridium difficile
infection in kidney transplant recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Clostridium difficile; kidney transplant
ID CARE FACILITIES; DIARRHEA; COLITIS; TOXIN; COLONIZATION; VANCOMYCIN;
MORTALITY; OUTBREAK; ANTIBODY; DISEASE
AB Background We sought to describe the epidemiology and risk factors for Clostridium difficile infection (CDI) among kidney transplant recipients (KTR) between 1 January 2008 and 31 December 2010. Methods A single-institution retrospective study was conducted among all adult KTR with CDI, defined as a positive test for C.difficile by a cell cytotoxic assay for C.difficile toxin A or B or polymerase chain reaction test for toxigenic C.difficile. Results Among 603 kidney transplants performed between 1 January 2008 and 31 December 2010, 37 (6.1%) patients developed CDI: 12 (of 128; 9.4%) high-risk (blood group incompatible and/or anti-human leukocyte antigen donor-specific antibodies) vs. 25 (of 475; 5.3%, P=0.08) standard-risk patients. The overall rate of CDI increased from 3.7% in 2008 to 9.4% in 2010 (P=0.05). The median time to CDI diagnosis was 9days, with 27 (73.0%) patients developing CDI within the first 30days after their transplant, and 14 (51.8%) developing CDI within 7days. A casecontrol analysis of 37 CDI cases and 74 matched controls demonstrated the following predictors for CDI among KTR: vancomycin-resistant Enterococcus colonization before transplant (odds ratio [OR]: 3.6, P=0.03), receipt of an organ from Centers for Disease Control high-risk donor (OR: 5.9, P=0.006), and administration of high-risk antibiotics within 30days post transplant (OR: 6.6, P=0.001). Conclusions CDI remains a common early complication in KTR, with rates steadily increasing during the study period. Host and transplant-related factors and exposure to antibiotics appeared to significantly impact the risk for CDI among KTR.
C1 [Neofytos, D.; Kobayashi, K.; Alonso, C. D.; Harris, M.; Kraus, E.; Subramanian, A.; Treadway, S.; Ostrander, D.; Marr, K.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Kobayashi, K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Alonso, C. D.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Cady-Reh, J.; Lepley, D.] Johns Hopkins Univ, Qual Improvement Dept, Baltimore, MD USA.
[Desai, N.] Johns Hopkins Univ, Dept Surg, Baltimore, MD USA.
[Thompson, C.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Biostat, Baltimore, MD USA.
[Marr, K.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA.
RP Neofytos, D (reprint author), Johns Hopkins Sch Med, Transplant & Oncol Infect Dis Program, Div Infect Dis, 1830 E Monument St,Suite 421, Baltimore, MD 21205 USA.
EM dneofyt1@jhmi.edu
FU NIH [K24 AI085118]; National Center for Advancing Translational Sciences
(NCATS) of the National Institutes of Health [101872]; Pfizer; Astellas;
Merck
FX The study was in part supported by a grant from the NIH: K24 AI085118.
Statistical analysis was, in part, supported by a National Center for
Research Resources and the National Center for Advancing Translational
Sciences (NCATS) of the National Institutes of Health Grant (101872).;
D.N. has received research grants from Pfizer. K.M. has received grant
support from Astellas, Merck, and Pfizer, and has served on advisory
boards or as consultant for Astellas, Merck, Optimer, and Pfizer. All
other authors: No conflicts of interest.
NR 32
TC 14
Z9 14
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD APR
PY 2013
VL 15
IS 2
BP 134
EP 141
DI 10.1111/tid.12030
PG 8
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 122AT
UT WOS:000317287900011
PM 23173772
ER
PT J
AU Welty, LJ
Carter, RE
Finkelstein, DM
Harrell, FE
Lindsell, CJ
Macaluso, M
Mazumdar, M
Nietert, PJ
Oster, RA
Pollock, BH
Roberson, PK
Ware, JH
AF Welty, Leah J.
Carter, Rickey E.
Finkelstein, Dianne M.
Harrell, Frank E., Jr.
Lindsell, Christopher J.
Macaluso, Maurizio
Mazumdar, Madhu
Nietert, Paul J.
Oster, Robert A.
Pollock, Brad H.
Roberson, Paula K.
Ware, James H.
CA Clinical Translational Sci Award C
TI Strategies for Developing Biostatistics Resources in an Academic Health
Center
SO ACADEMIC MEDICINE
LA English
DT Article
ID MEDICAL-RESEARCH
AB Biostatistics-the application of statistics to understanding health and biology-provides powerful tools for developing research questions, designing studies, refining measurements, analyzing data, and interpreting findings. Biostatistics plays an important role in health-related research, yet biostatistics resources are often fragmented, ad hoc, or oversubscribed within academic health centers (AHCs). Given the increasing complexity and quantity of health-related data, the emphasis on accelerating clinical and translational science, and the importance of conducting reproducible research, the need for the thoughtful development of biostatistics resources within AHCs is growing.
In this article, the authors identify strategies for developing biostatistics resources in three areas: (1) recruiting and retaining biostatisticians, (2) efficiently using biostatistics resources, and (3) improving biostatistical contributions to science. AHCs should consider these three domains in building strong biostatistics resources, which they can leverage to support a broad spectrum of research. For each of the three domains, the authors describe the advantages and disadvantages of AHCs creating centralized biostatistics units rather than dispersing such resources across clinical departments or other research units. They also address the challenges that biostatisticians face in contributing to research without sacrificing their individual professional growth or the trajectory of their research teams. The authors ultimately recommend that AHCs create centralized biostatistics units because this approach offers distinct advantages both to investigators who collaborate with biostatisticians as well as to the biostatisticians themselves, and it is better suited to accomplish the research and education missions of AHCs.
C1 [Welty, Leah J.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Carter, Rickey E.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Carter, Rickey E.] Mayo Clin, Ctr Translat Sci Awards, Rochester, MN USA.
[Finkelstein, Dianne M.] Harvard Univ, Sch Med, Boston, MA USA.
[Finkelstein, Dianne M.; Ware, James H.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Finkelstein, Dianne M.] Massachusetts Gen Hosp, Biostat Unit, Boston, MA 02114 USA.
[Harrell, Frank E., Jr.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
[Harrell, Frank E., Jr.] Vanderbilt Inst Clin & Translat Res, Design Biostat & Res Eth Program, Nashville, TN USA.
[Lindsell, Christopher J.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA.
[Lindsell, Christopher J.; Macaluso, Maurizio] Univ Cincinnati, Ctr Clin & Translat Sci & Training, Cincinnati, OH USA.
[Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA.
[Mazumdar, Madhu] Cornell Univ, Weill Cornell Med Coll, Div Biostat & Epidemiol, Dept Publ Hlth, New York, NY 10021 USA.
[Mazumdar, Madhu] Cornell Univ, Weill Cornell Med Coll, Res Design & Biostat Core, Clin & Translat Sci Ctr, New York, NY 10021 USA.
[Nietert, Paul J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Nietert, Paul J.] South Carolina Clin & Translat Sci Inst, Biostat Epidemiol & Res Design Program, Charleston, SC USA.
[Oster, Robert A.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Prevent Med, Birmingham, AL USA.
[Oster, Robert A.] Univ Alabama Birmingham, Sch Med, Ctr Clin & Translat Sci, Biostat Epidemiol & Res Design Program, Birmingham, AL USA.
[Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Biostat Epidemiol & Res Design Core, Inst Integrat Med & Sci, San Antonio, TX 78229 USA.
[Roberson, Paula K.] Univ Arkansas Med Sci, Coll Med, Dept Biostat, Little Rock, AR 72205 USA.
[Roberson, Paula K.] Univ Arkansas Med Sci, Coll Med, Biostat & Res Design Component Translat Res Inst, Little Rock, AR 72205 USA.
[Ware, James H.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Welty, LJ (reprint author), Dept Prevent Med, Suite 1400,680 N Lake Shore Dr, Chicago, IL 60611 USA.
EM lwelty@northwestern.edu
RI Macaluso, Maurizio/J-2076-2015;
OI Macaluso, Maurizio/0000-0002-2977-9690; Lindsell,
Christopher/0000-0002-3297-2811; Nietert, Paul/0000-0002-3933-4986
FU National Center for Research Resources; NCATS, National Institutes of
Health (NIH), through the CTSA Program; NIH CTSA [UL1 TR000135, UL1
RR025741, UL1 RR024150, UL1 TR000170, UL1 RR025758, UL1 TR000445, UL1
RR024975]; NIH CTSA. [UL1 TR000077, UL1 RR026314, UL1 TR000457, UL1
RR024996, UL1 TR000062, UL1 RR029882, UL1 TR000165, UL1 RR025777, UL1
TR000149, UL1 RR025767, UL1 TR000039, UL1 RR029884, UL1 TR000150]
FX This project was funded in whole or in part with federal funds from the
National Center for Research Resources and NCATS, National Institutes of
Health (NIH), through the CTSA Program, which is part of the Roadmap
Initiative, Re-Engineering the Clinical Research Enterprise (award
numbers listed below in order of NCATS, NCRR). This article was approved
by the CTSA Consortium Publications Committee.; The NIH CTSA funding was
awarded to Northwestern University Feinberg School of Medicine (UL1
TR000150, UL1 RR025741), Mayo Clinic (UL1 TR000135, UL1 RR024150),
Harvard University School of Medicine (UL1 TR000170, UL1 RR025758),
Vanderbilt University (UL1 TR000445, UL1 RR024975), University of
Cincinnati (UL1 TR000077, UL1 RR026314), Weill Cornell Medical College
(UL1 TR000457, UL1 RR024996), Medical University of South Carolina (UL1
TR000062, UL1 RR029882), University of Alabama at Birmingham (UL1
TR000165, UL1 RR025777), University of Texas Health Science Center at
San Antonio (UL1 TR000149, UL1 RR025767), and University of Arkansas for
Medical Sciences (UL1 TR000039, UL1 RR029884).
NR 16
TC 8
Z9 8
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD APR
PY 2013
VL 88
IS 4
BP 454
EP 460
DI 10.1097/ACM.0b013e31828578ed
PG 7
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 116AD
UT WOS:000316853100012
PM 23425984
ER
PT J
AU Theobald, CN
Stover, DG
Choma, NN
Hathaway, J
Green, JK
Peterson, NB
Sponsler, KC
Vasilevskis, EE
Kripalani, S
Sergent, J
Brown, NJ
Denny, JC
AF Theobald, Cecelia N.
Stover, Daniel G.
Choma, Neesha N.
Hathaway, Jacob
Green, Jennifer K.
Peterson, Neeraja B.
Sponsler, Kelly C.
Vasilevskis, Eduard E.
Kripalani, Sunil
Sergent, John
Brown, Nancy J.
Denny, Joshua C.
TI The Effect of Reducing Maximum Shift Lengths to 16 Hours on Internal
Medicine Interns' Educational Opportunities
SO ACADEMIC MEDICINE
LA English
DT Article
ID SURGICAL RESIDENT EDUCATION; PATIENT-CARE; ACCREDITATION-COUNCIL; SCHOOL
CURRICULUM; 80-HOUR WORKWEEK; DUTY HOURS; IMPACT; EXPERIENCE; PROGRAM;
RESTRICTIONS
AB Purpose
To evaluate educational experiences of internal medicine interns before and after maximum shift lengths were decreased from 30 hours to 16 hours.
Method
The authors compared educational experiences of internal medicine interns at Vanderbilt University Medical Center before (2010; 47 interns) and after (2011; 50 interns) duty hours restrictions were implemented in July 2011. The authors compared number of inpatient encounters, breadth of concepts in notes, exposure to five common presenting problems, procedural experience, and attendance at teaching conferences.
Results
Following the duty hours restrictions, interns cared for more unique patients (mean 118 versus 140 patients per intern, P = .005) and wrote more history and physicals (mean 73 versus 88, P = .005). Documentation included more total concepts after the 16-hour maximum shift implementation, with a 14% increase for history and physicals (338 versus 387, P < .001) and a 10% increase for progress notes (316 versus 349, P < .001). There was no difference in the median number of selected procedures performed (6 versus 6, P = 0.94). Attendance was higher at the weekly chief resident conference (60% versus 68% of expected attendees, P < .001) but unchanged at morning report conferences (79% versus 78%, P = .49).
Conclusions
Intern clinical exposure did not decrease after implementation of the 16-hour shift length restriction. In fact, interns saw more patients, produced more detailed notes, and attended more conferences following duty hours restrictions.
C1 [Theobald, Cecelia N.; Choma, Neesha N.; Hathaway, Jacob; Green, Jennifer K.; Peterson, Neeraja B.; Sponsler, Kelly C.; Vasilevskis, Eduard E.; Kripalani, Sunil; Sergent, John; Brown, Nancy J.; Denny, Joshua C.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
[Theobald, Cecelia N.] VA Tennessee Valley Healthcare Syst, VA Qual Scholars, Nashville, TN 37212 USA.
[Stover, Daniel G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Stover, Daniel G.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Hathaway, Jacob] VA Tennessee Valley Healthcare Syst, Primary Care Serv, Nashville, TN 37212 USA.
[Green, Jennifer K.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA.
[Peterson, Neeraja B.; Sergent, John] Vanderbilt Univ, Sch Med, Internal Med Residency Program, Nashville, TN 37212 USA.
[Sponsler, Kelly C.] VA Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.
[Denny, Joshua C.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA.
RP Theobald, CN (reprint author), VA Tennessee Valley Healthcare Syst, GRECC, 1310 24th Ave S, Nashville, TN 37212 USA.
EM cecelia.theobald@vanderbilt.edu
OI Vasilevskis, Eduard/0000-0001-8165-5321; Stover,
Daniel/0000-0001-9003-8165
FU Office of Academic Affiliations, Department of Veterans Affairs, VA
National Quality Scholars Program; National Institutes of Health
[K23AG040157]; VA Tennessee Valley Geriatric Research, Education, and
Clinical Center
FX This material is based on work supported by the Office of Academic
Affiliations, Department of Veterans Affairs, VA National Quality
Scholars Program, and was made possible by the use of the facilities at
VA Tennessee Valley Healthcare System, Nashville, Tennessee.; Funding
for Dr. Vasilevskis was provided by the National Institutes of Health
(K23AG040157) and the VA Tennessee Valley Geriatric Research, Education,
and Clinical Center.
NR 39
TC 12
Z9 12
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD APR
PY 2013
VL 88
IS 4
BP 512
EP 518
DI 10.1097/ACM.0b013e318285800f
PG 7
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 116AD
UT WOS:000316853100023
PM 23425987
ER
PT J
AU Sarwar, A
Ding, A
Slanetz, PJ
AF Sarwar, Ammar
Ding, Alexander
Slanetz, Priscilla J.
TI Getting Involved in Organized Medicine-A Remedy for the Current Health
Care Crisis?
SO ACADEMIC RADIOLOGY
LA English
DT Letter
C1 [Sarwar, Ammar; Slanetz, Priscilla J.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02115 USA.
[Ding, Alexander] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Sarwar, Ammar; Ding, Alexander; Slanetz, Priscilla J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sarwar, A (reprint author), Beth Israel Deaconess Med Ctr, Dept Radiol, 330 Brookline Ave, Boston, MA 02115 USA.
OI Slanetz, Priscilla/0000-0003-1248-5116
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1076-6332
J9 ACAD RADIOL
JI Acad. Radiol.
PD APR
PY 2013
VL 20
IS 4
BP 519
EP 520
DI 10.1016/j.acra.2012.10.001
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 118MF
UT WOS:000317028900020
PM 23498996
ER
PT J
AU Cubeddu, RJ
Palacios, IF
Blankenship, JC
Horvath, SA
Xu, K
Kovacic, JC
Dangas, GD
Witzenbichler, B
Guagliumi, G
Kornowski, R
Dudek, D
Stone, GW
Mehran, R
AF Cubeddu, Roberto J.
Palacios, Igor F.
Blankenship, James C.
Horvath, Sofia A.
Xu, Ke
Kovacic, Jason C.
Dangas, George D.
Witzenbichler, Bernhard
Guagliumi, Giulio
Kornowski, Ran
Dudek, Dariusz
Stone, Gregg W.
Mehran, Roxana
TI Outcome of Patients With ST-Segment Elevation Myocardial Infarction
Undergoing Primary Percutaneous Coronary Intervention. During On- Versus
Off-hours (A Harmonizing Outcomes With RevasculariZatiON and Stents in
Acute Myocardial Infarction [HORIZONS-AMI] Trial Substudy)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID PRIMARY ANGIOPLASTY; HOSPITAL MORTALITY; REPERFUSION; TIME; DELAY;
IMPACT
AB Patients with ST-segment elevation myocardial infarction (STEMI) admitted during nonregular working hours (off-hours) have been reported to have greater mortality than those admitted during regular working hours (on-hours), perhaps because of the lower availability of catheterization laboratory services and longer door-to-balloon times. This might not be the case, however, for hospital centers in which primary percutaneous coronary intervention (PCI) is invariably performed. We conducted a substudy using the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction study data to determine whether the STEMI arrival time was associated with differing clinical outcomes. We identified all patients with STEMI admitted to a PCI-capable hospital who underwent primary PCI. Patients presenting during on-hours were compared to those presenting during off-hours. The primary outcome of death, major adverse cardiovascular events, and net adverse clinical events was examined. We identified 2,440 patients (1,205 [49%] on-hours and 1,235 [51%] off-hours). Similar baseline characteristics were observed. The off-hour patients had a significantly longer door-to-balloon time (92 vs 75 minutes; p < 0.0001) and total ischemic time (209 vs 194 minutes; p < 0.0001). Despite these differences, the risk-adjusted all-cause mortality, major adverse cardiovascular events, and net adverse clinical events rates were similar for both groups during the in-hospital, 1-year, and 3-year follow-up. In conclusion, patients with STEMI presenting to primary PCI hospitals during off-hours might have slightly longer delays to revascularization; however, they experienced similar short- and long-term survival and clinical outcomes as those arriving during on-hours. 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:946-954)
C1 [Cubeddu, Roberto J.; Horvath, Sofia A.] Aventura Hosp Med Ctr, Miami, FL USA.
[Palacios, Igor F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Blankenship, James C.] Geisinger Med Ctr, Danville, PA 17822 USA.
[Xu, Ke; Dangas, George D.; Stone, Gregg W.; Mehran, Roxana] Cardiovasc Res Fdn, New York, NY USA.
[Kovacic, Jason C.; Dangas, George D.; Mehran, Roxana] Mt Sinai Sch Med, New York, NY USA.
[Witzenbichler, Bernhard] Charite Campus Benjamin Franklin, Berlin, Germany.
[Guagliumi, Giulio] Osped Riuniti Bergamo, I-24100 Bergamo, Italy.
[Kornowski, Ran] Rabin Med Ctr, Petah Tiqwa, Israel.
[Kornowski, Ran] Tel Aviv Univ, IL-69978 Tel Aviv, Israel.
[Dudek, Dariusz] Jagiellonian Univ, Krakow, Poland.
[Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA.
RP Mehran, R (reprint author), Cardiovasc Res Fdn, New York, NY USA.
EM roxana.mehran@mountsinai.org
FU National Institutes of Health (Bethesda, Maryland) [1K08HL111330-01];
Medicines Company (Parsippany, New Jersey); Bristol-Myers Squibb/Sanofi
(New York, New York); Bristol-Myers Squibb/Sanofi (Paris, France); Eli
Lilly and Company/Daiichi Sankyo Co. (Indianapolis, Indiana); Eli Lilly
and Company/Daiichi Sankyo Co. (Tokyo, Japan); Boston Scientific
(Natick, Massachusetts); Medicines Company; Abbott Vascular; Medtronic
(Minneapolis, Minnesota); LightLab Imaging (Westford, Massachusetts);
Boston Scientific; St. Jude Medical; Volcano Corporation; BMS/Sanofi;
Lilly/Daiichi Sankyo; Cardiovascular Research Foundation
FX Dr. Kovacic is supported by National Institutes of Health grant
1K08HL111330-01 (Bethesda, Maryland); Dr. Dangas has received research
grants (institutional) from The Medicines Company (Parsippany, New
Jersey), Bristol-Myers Squibb/Sanofi (New York, New York and Paris,
France), and Eli Lilly and Company/Daiichi Sankyo Co. (Indianapolis,
Indiana and Tokyo, Japan), and is a consultant to Abbott Vascular (Santa
Clara, California), AstraZeneca (Wilmington, Delaware), Janssen
Pharmaceuticals (Titusville, New Jersey), Regado Biosciences (Basking
Ridge, New Jersey), The Medicines Company, Merck & Co. (Whitehouse
Station, New Jersey), and BMS/Sanofi; Dr. Witzenbichler has received
lecture fees (modest) from Boston Scientific (Natick, Massachusetts) and
The Medicines Company; Dr. Guagliumi is a consultant to Boston
Scientific, St. Jude Medical (St. Paul, Minnesota), Volcano Corporation
(San Diego, California), and Cordis (Bridgewater Township, New Jersey)
and has received research grants from Abbott Vascular, Medtronic
(Minneapolis, Minnesota), Boston Scientific (Natick, Massachusetts), and
LightLab Imaging (Westford, Massachusetts); Dr. Dudek has received grant
support from Boston Scientific, St. Jude Medical, and Volcano
Corporation and is a consultant for Boston Scientific and St. Jude
Medical; Dr. Stone is a consultant to Boston Scientific; Dr. Mehran has
received research grants (institutional) from The Medicines Company
(Parsippany, New Jersey), BMS/Sanofi, and Lilly/Daiichi Sankyo, and is a
consultant to Abbott Vascular, AstraZeneca, Janssen Pharmaceuticals,
Regado Biosciences, The Medicines Company, Merck, and BMS/Sanofi;; The
HORIZONS-AMI trial was sponsored by the Cardiovascular Research
Foundation with research grant support from Boston Scientific (Natick,
Massachusetts) and The Medicines Company (Parsippany, New Jersey).
NR 26
TC 11
Z9 11
U1 0
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD APR 1
PY 2013
VL 111
IS 7
BP 946
EP 954
DI 10.1016/j.amjcard.2012.11.062
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 117AE
UT WOS:000316923700005
PM 23340031
ER
PT J
AU Schiros, CG
Ahmed, MI
Sanagala, T
Zha, W
McGiffin, DC
Bamman, MM
Gupta, H
Lloyd, SG
Denney, TS
Dell'Italia, LJ
AF Schiros, Chun G.
Ahmed, Mustafa I.
Sanagala, Thriveni
Zha, Wei
McGiffin, David C.
Bamman, Marcas M.
Gupta, Himanshu
Lloyd, Steven G.
Denney, Thomas S., Jr.
Dell'Italia, Louis J.
TI Importance of Three-Dimensional Geometric Analysis in the Assessment of
the Athlete's Heart
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ISOLATED MITRAL REGURGITATION; LEFT-VENTRICULAR TORSION; BETA-BLOCKADE;
EXERCISE; VOLUME
AB How the left ventricle remodels in response to a high-volume stimulus is important in evaluating the endurance athlete's heart. Marathoners and patients with isolated, moderate chronic compensated mitral regurgitation (MR) represent physiologic and pathologic forms of eccentric left ventricular (LV) remodeling in response to intermittent and chronic volume overload, respectively. Thus, in this study, magnetic resonance imaging with tissue tagging and 3-dimensional data analysis at rest were performed in 19 marathoners (mean age 39 +/- 10 years, 47% women), 17 patients with isolated MR without coronary artery disease or medical therapy (mean age 46 +/- 5 years, 53% women), and 24 controls (mean age 45 +/- 8 years, 50% women). Marathoners and patients with MR had approximately 35% greater LV end-diastolic volume indexes, approximately 50% greater end-systolic volume indexes, and approximately 34% greater LV stroke volume indexes (p < 0.0001) compared to controls. However, marathoners' hearts had increased long-axis length, while those of patients with MR did not differ from the hearts of controls. The hearts of patients with MR had greater LV global and apex sphericity compared to those of marathoners and controls (p < 0.0001). Marathoners had normal LV mass/volume ratios and wall thicknesses, whereas these were significantly decreased in the MR group. In marathoners, the baseline LV work rate was similar to that in controls and higher in patients with MR compared to controls. In conclusion, marathoners' hearts achieve elevated stroke volume at rest with adherence to an elliptical shape defined by 3-dimensional geometry and mass/volume ratio. Thus, a comprehensive evaluation of LV geometry and mass/volume ratio may be important in the evaluation of the athlete's heart. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:1067-1072)
C1 [Schiros, Chun G.; Ahmed, Mustafa I.; McGiffin, David C.; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Ctr Heart Failure Res, Birmingham, AL 35233 USA.
[Bamman, Marcas M.] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL USA.
[Sanagala, Thriveni] Loyola Univ Chicago, Div Cardiol, Dept Med, Stritch Sch Med, Maywood, IL USA.
[Zha, Wei; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Samuel Ginn Coll Engn, Auburn, AL 36849 USA.
[Bamman, Marcas M.; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Dell'Italia, LJ (reprint author), Univ Alabama Birmingham, Dept Med, Ctr Heart Failure Res, Birmingham, AL 35233 USA.
EM dell'italia@physiology.uab.edu
FU National Heart, Lung, and Blood Institute Specialized Center for
Clinically Oriented Research in Cardiac Dysfunction, Bethesda, Maryland
[P50HL077100]
FX This study was funded by Grant P50HL077100 from the National Heart,
Lung, and Blood Institute Specialized Center for Clinically Oriented
Research in Cardiac Dysfunction, Bethesda, Maryland.
NR 22
TC 6
Z9 6
U1 0
U2 6
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD APR 1
PY 2013
VL 111
IS 7
BP 1067
EP 1072
DI 10.1016/j.amjcard.2012.12.027
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 117AE
UT WOS:000316923700024
PM 23332597
ER
PT J
AU Salinardi, TC
Batra, P
Roberts, SB
Urban, LE
Robinson, LM
Pittas, AG
Lichtenstein, AH
Deckersbach, T
Saltzman, E
Das, SK
AF Salinardi, Taylor C.
Batra, Payal
Roberts, Susan B.
Urban, Lorien E.
Robinson, Lisa M.
Pittas, Anastassios G.
Lichtenstein, Alice H.
Deckersbach, Thilo
Saltzman, Edward
Das, Sai Krupa
TI Lifestyle intervention reduces body weight and improves cardiometabolic
risk factors in worksites
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; LOW-GLYCEMIC LOAD; DIABETES-PREVENTION;
PHYSICAL-ACTIVITY; OBESITY; PROGRAM; DIET; OVERWEIGHT; EMPLOYEES;
EPIDEMIC
AB Background: Worksites are potentially effective locations for obesity control because they provide opportunities for group intervention and social support. Studies are needed to identify effective interventions in these settings.
Objective: We examined the effects of a multicomponent lifestyle intervention on weight loss and prevention of regain in 4 worksites (2 intervention and 2 control sites).
Design: Overweight and obese employees (n = 133) enrolled in this pilot worksite-randomized controlled trial with a 0-6-mo weight-loss phase and a 6-12-mo structured weight-maintenance phase. The intervention combined recommendations to consume a reduced-energy, low-glycemic load, high-fiber diet with behavioral change education. Outcome measurements included changes in body weight and cardiometabolic risk factors.
Results: The mean +/- SEM weight loss was substantial in intervention participants, whereas control subjects gained weight (-8.0 +/- 0.7 compared with +0.9 +/- 0.5 kg, respectively; P < 0.001), and 89% of participants completed the weight-loss phase. Intervention effects were not significant at the 0.05 level but would have been at the 0.10 level (P = 0.08) in a mixed model in which the worksite nested within group was a random factor. There were also significant improvements in cardiometabolic risk factors in intervention compared with control subjects regarding fasting total cholesterol, glucose, systolic blood pressure, and diastolic blood pressure (P <= 0.02 for each). No significant weight regain was observed in participants who enrolled in the structured weight-maintenance program (0.5 +/- 0.7 kg; P = 0.65), and overweight and obese employees in intervention worksites who were not enrolled in the weight-loss program lost weight compared with subjects in control worksites (-1.3 +/- 0.5 compared with +0.7 +/- 0.2 kg, respectively; P = 0.02).
Conclusion: Worksites can be effective for achieving clinically important reductions in body weight and improved cardiometabolic risk factors. This trial was registered at clinicaltrials.gov as NCT01470222. Am J Clin Nutr 2013;97:667-76.
C1 [Salinardi, Taylor C.; Batra, Payal; Roberts, Susan B.; Urban, Lorien E.; Robinson, Lisa M.; Lichtenstein, Alice H.; Saltzman, Edward; Das, Sai Krupa] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
[Pittas, Anastassios G.] Tufts Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA USA.
[Deckersbach, Thilo] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Das, SK (reprint author), Jean Mayer USDA Human Nutr Res Ctr Aging, Energy Metab Lab, 711 Washington St, Boston, MA 02111 USA.
EM sai.das@tufts.edu
FU USDA [58-1950-0-0014]; Tufts University; Jean Mayer USDA Human Nutrition
Research Center on Aging, Tufts University [H15001-DAX023]; National
Heart, Lung and Blood Institute [T32 HL 069772]
FX Supported by the USDA (agreement 58-1950-0-0014 with Tufts University);
the Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts
University (pilot grant H15001-DAX023); and the National Heart, Lung and
Blood Institute (grant T32 HL 069772; to TCS).
NR 40
TC 16
Z9 17
U1 2
U2 40
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD APR
PY 2013
VL 97
IS 4
BP 667
EP 676
DI 10.3945/ajcn.112.046995
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 113CQ
UT WOS:000316644200003
PM 23426035
ER
PT J
AU Kong, FM
Lally, BE
Chang, JY
Chetty, IJ
Decker, RH
Ginsburg, ME
Kestin, LL
Langer, CJ
Movsas, B
Videtic, GMM
Willers, H
Rosenzweig, KE
AF Kong, Feng-Ming (Spring)
Lally, Brian E.
Chang, Joe Yujiao
Chetty, Indrin J.
Decker, Roy H.
Ginsburg, Mark E.
Kestin, Larry L.
Langer, Corey J.
Movsas, Benjamin
Videtic, Gregory M. M.
Willers, Henning
Rosenzweig, Kenneth E.
CA Expert Panel Radiation
TI ACR Appropriateness Criterias (R) Radiation Therapy for Small-Cell Lung
Cancer
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Review
DE small cell lung cancer; radiation therapy; appropriateness criteria
ID PROPHYLACTIC CRANIAL IRRADIATION; COMBINED-MODALITY TREATMENT;
RANDOMIZED CLINICAL-TRIAL; LEUKEMIA GROUP-B; PHASE-III TRIAL; COUNCIL
COMPARATIVE TRIAL; CISPLATIN PLUS ETOPOSIDE; THORACIC RADIOTHERAPY;
COMPLETE REMISSION; COMBINATION CHEMOTHERAPY
AB The current standard of care for small cell lung cancer is combined-modality therapy, including the use of chemotherapy, surgery (in selected cases of limited stage of disease), and radiation therapy. This review will focus on the role, dose fractionation, technology and timing of thoracic radiation, and the role and dose regimen of prophylactic cranial irradiation for both limited and extensive stage of diseases. Consensus recommendation from experts is summarized in the tables for 2 typical case scenarios. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
C1 [Kong, Feng-Ming (Spring)] Univ Michigan, Ann Arbor Veteran Affairs Med Ctr, Ann Arbor, MI 48109 USA.
[Chetty, Indrin J.; Movsas, Benjamin] Henry Ford Hlth Syst, Detroit, MI USA.
[Kestin, Larry L.] 21st Century Oncol Michigan, Farmington Hills, MI USA.
[Lally, Brian E.] Univ Miami, Dept Radiat Oncol, Miami, FL USA.
[Chang, Joe Yujiao] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Decker, Roy H.] Yale Univ, Sch Med, New Haven, CT USA.
[Ginsburg, Mark E.] Columbia Univ, Soc Thorac Surg, New York, NY USA.
[Rosenzweig, Kenneth E.] Mt Sinai Sch Med, New York, NY USA.
[Langer, Corey J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Videtic, Gregory M. M.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Willers, Henning] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kong, FM (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA.
EM fengkong@med.umich.edu
FU Henry Ford Health System Radiation Oncology Department from Varian Inc.;
Philips Inc.; Resonant Inc.
FX B.M. provides research support to Henry Ford Health System Radiation
Oncology Department from Varian Inc.; Philips Inc.; and Resonant Inc.
NR 63
TC 6
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3732
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD APR
PY 2013
VL 36
IS 2
BP 206
EP 213
DI 10.1097/COC.0b013e31827e5523
PG 8
WC Oncology
SC Oncology
GA 114KP
UT WOS:000316740100018
PM 23511336
ER
PT J
AU Tse, JY
Pawlak, AC
Boussahmain, C
Routhier, CA
Dias-Santagata, D
Kalomiris, D
Hoang, MP
AF Tse, Julie Y.
Pawlak, Amanda C.
Boussahmain, Chakib
Routhier, Caitlin Ann
Dias-Santagata, Dora
Kalomiris, Dimitrios
Hoang, Mai P.
TI Basal Cell Carcinoma With Osteosarcomatous Component
SO AMERICAN JOURNAL OF DERMATOPATHOLOGY
LA English
DT Article
DE basal cell carcinoma; osteosarcomatous carcinoma; TP53; carcinosarcoma
ID PRIMARY CUTANEOUS CARCINOSARCOMA; ANALYSIS SHOWS; GIANT-CELLS; SKIN;
TUMORS; BREAST
AB Sarcomatoid carcinoma or carcinosarcomas of the skin are rare. Basal cell carcinoma (BCC) with osteosarcomatous differentiation is the second most common sarcomatoid carcinoma of the skin, following squamous cell carcinoma with heterologous mesenchymal differentiation. There are only 11 cases of BCC with osteosarcomatous component reported in the literature, with limited documented molecular analyses. The authors report the clinical and histological features of 2 cases with molecular analyses for recurrent mutations in 17 cancer genes. In both cases, the epithelial or BCC component was positive for BerEP4 and high-molecular weight cytokeratin, whereas the sarcomatous component was negative for both markers. Mutational analyses revealed TP53 mutation in 1 case with p53 expression noted in both components. The other case was negative for both p53 expression and TP53 mutation.
C1 [Tse, Julie Y.; Pawlak, Amanda C.; Boussahmain, Chakib; Routhier, Caitlin Ann; Dias-Santagata, Dora; Hoang, Mai P.] Harvard Univ, Sch Med, Boston, MA USA.
[Tse, Julie Y.; Pawlak, Amanda C.; Boussahmain, Chakib; Routhier, Caitlin Ann; Dias-Santagata, Dora; Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Kalomiris, Dimitrios] Adv Dermatol, Dermatopathol, Delray Beach, FL USA.
RP Hoang, MP (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA.
EM mhoang@partners.org
NR 26
TC 5
Z9 5
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0193-1091
J9 AM J DERMATOPATH
JI Am. J. Dermatopathol.
PD APR
PY 2013
VL 35
IS 2
BP 261
EP 265
DI 10.1097/DAD.0b013e31826b352b
PG 5
WC Dermatology
SC Dermatology
GA 117GJ
UT WOS:000316941200024
PM 23221485
ER
PT J
AU Pham, CM
Syed, AA
Siddiqui, HA
Keller, RA
Kowalewski, C
AF Pham, Catherine M.
Syed, Almas A.
Siddiqui, Huma A.
Keller, Richard A.
Kowalewski, Catherine
TI Case of Metastatic Basal Cell Carcinoma to Bone Marrow, Resulting in
Myelophthisic Anemia
SO AMERICAN JOURNAL OF DERMATOPATHOLOGY
LA English
DT Article
DE metastatic; non-melanoma skin cancer; basal cell carcinoma
ID CYTOTOXIC THERAPY; SKIN
AB Background: While basal cell carcinoma (BCC) remains the most common skin cancer, the incidence of metastasis is rare. Most cases of metastatic BCC have been to regional lymph nodes. Metastasis to bone marrow with myelophthisic anemia is especially rare. To our knowledge, there have been only 5 reported cases in literature. We report a sixth case.
Observations: A 46-year-old male patient presented with an 8 x 7-cm ulcerated plaque on his chest, found to be morpheaform basal cell on pathology. Laboratory findings were notable for normocytic anemia, thrombocytopenia, and elevated LDH. Further work up with bone marrow biopsy revealed tumor cells staining positive for CK AE1/AE3, BerEP4, CK7, CD56, and PIN-4. This confirmed the diagnosis of metastatic BCC (MBCC) to bone marrow.
Conclusions: Although the rate of metastasis for BCC is rare, once it occurs, prognosis is poor. MBCC remains a challenge to treat. Therefore, it is critical to resolve the primary BCC and obtain vigilant follow-up, especially in patients with multiple risk factors for MBCC.
C1 [Pham, Catherine M.; Syed, Almas A.] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA.
[Siddiqui, Huma A.] Audie L Murphy Mem Vet Adm Med Ctr, Dept Pathol, San Antonio, TX 78229 USA.
[Keller, Richard A.; Kowalewski, Catherine] Audie L Murphy Mem Vet Adm Med Ctr, Div Dermatol, San Antonio, TX 78229 USA.
RP Kowalewski, C (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care Serv, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
NR 19
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0193-1091
J9 AM J DERMATOPATH
JI Am. J. Dermatopathol.
PD APR
PY 2013
VL 35
IS 2
BP E34
EP E36
DI 10.1097/DAD.0b013e3182761362
PG 3
WC Dermatology
SC Dermatology
GA 117GJ
UT WOS:000316941200004
PM 23147353
ER
PT J
AU Schulman, S
Awad, MM
Kuter, DJ
AF Schulman, Sol
Awad, Mark M.
Kuter, David J.
TI Neutrophil-erythrocyte rosettes in autoimmune hemolytic anemia
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Editorial Material
ID RED-CELLS; MONOCYTES; BINDING
C1 [Schulman, Sol; Kuter, David J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Schulman, Sol; Awad, Mark M.; Kuter, David J.] Massachusetts Gen Hosp, Dept Hematol, Boston, MA 02114 USA.
[Awad, Mark M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Schulman, S (reprint author), Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02115 USA.
EM sol.schulman@gmail.com
OI schulman, sol/0000-0002-5229-3592
NR 7
TC 1
Z9 1
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD APR
PY 2013
VL 88
IS 4
BP 333
EP 334
DI 10.1002/ajh.23277
PG 2
WC Hematology
SC Hematology
GA 115JQ
UT WOS:000316808800016
PM 22886729
ER
PT J
AU Brierley, CK
Morgan, EA
Sprague, JR
Odejide, OO
DeAngelo, DJ
Steensma, DP
AF Brierley, Charlotte K.
Morgan, Elizabeth A.
Sprague, Julian R.
Odejide, Oreofe O.
DeAngelo, Daniel J.
Steensma, David P.
TI An extreme example of focal bone marrow involvement in acute myeloid
leukemia
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Editorial Material
ID HODGKINS-LYMPHOMA; SPECIMENS; DYSPLASIA
C1 [Brierley, Charlotte K.] Univ Oxford, Christ Church, Oxford, England.
[Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Sprague, Julian R.] Univ Vermont, Vermont Canc Ctr, Fletcher Allen Hlth Care, Burlington, VT USA.
[Odejide, Oreofe O.; DeAngelo, Daniel J.; Steensma, David P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Steensma, DP (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Suite D1B30 Mayer 1B21, Boston, MA 02215 USA.
EM david_steensma@dfci.harvard.edu
OI Steensma, David/0000-0001-5130-9284; Morgan,
Elizabeth/0000-0001-5880-9337
NR 16
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD APR
PY 2013
VL 88
IS 4
BP 335
EP 336
DI 10.1002/ajh.23350
PG 2
WC Hematology
SC Hematology
GA 115JQ
UT WOS:000316808800017
PM 23115117
ER
PT J
AU Dietz, PM
Kuklina, EV
Bateman, BT
Callaghan, WM
AF Dietz, Patricia M.
Kuklina, Elena V.
Bateman, Brian T.
Callaghan, William M.
TI Assessing Cardiovascular Disease Risk among Young Women with a History
of Delivering a Low-Birth-Weight Infant
SO AMERICAN JOURNAL OF PERINATOLOGY
LA English
DT Article
DE low birth weight; fetal growth; cardiovascular disease; preterm
ID FETAL-GROWTH RESTRICTION; ISCHEMIC-HEART-DISEASE; PREGNANCY
COMPLICATIONS; RETROSPECTIVE COHORT; PRETERM DELIVERY; SERUM COTININE;
UNITED-STATES; MORTALITY; MOTHERS; PREECLAMPSIA
AB Objective To assess the prevalence and risk factors of cardiovascular disease (CVD) among younger women by pregnancy history.
Methods Cross-sectional study using 1999 to 2006 National Health and Nutrition Examination Survey including women aged 20 to 64 years who had delivered at least one infant (n = 4820). Women self-reported pregnancy history and a clinician diagnosed CVD; CVD risk factors included hypertension (mean systolic blood pressure [BP] >= 140 mm Hg or mean diastolic BP >= 90 mm Hg, or currently treated), high cholesterol (total cholesterol >= 240 mg/dL or currently treated), diabetes (self-report or hemoglobin A1c >= 6.5), and smoking (self-report or cotinine-verified). Multivariable logistic regression was used to assess the association between pregnancy history and CVD.
Results Of the women we studied, 4.6% had CVD; 3.1% had delivered a term low-birth-weight infant (TLBWI). Women with a history of TLBWI had an adjusted odds ratio (AOR) of 2.07 (95% confidence intervals [CI] 1.08 to 3.99) for CVD compared with women without a history of LBWI. Adjustment for hypertension and high cholesterol mildly attenuated the association (AOR 1.85, 95% CI 0.89 to 3.83). Among women without CVD (n = 4555), 23.11 with a history of TLBWI had two risk factors compared with 14.0% of those without a history of LBWI (p = 0.0016).
Conclusion Women with a history of TLBWI should be informed of a possible increased risk of CVD and encouraged to receive screenings as recommended.
C1 [Dietz, Patricia M.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
RP Dietz, PM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Hwy NE,MS K-23, Atlanta, GA 30341 USA.
EM PDietz@cdc.gov
NR 37
TC 4
Z9 4
U1 1
U2 9
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0735-1631
J9 AM J PERINAT
JI Am. J. Perinatol.
PD APR
PY 2013
VL 30
IS 4
BP 267
EP 273
DI 10.1055/s-0032-1323589
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 115SF
UT WOS:000316831500003
PM 22875656
ER
PT J
AU Ahmad, FS
Tsang, T
AF Ahmad, Faraz S.
Tsang, Thomas
TI Diabetes Prevention, Health Information Technology, and Meaningful Use
Challenges and Opportunities
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID PHYSICIAN ORDER ENTRY; RANDOMIZED CONTROLLED-TRIAL; CLINICAL
DECISION-SUPPORT; CENTERED MEDICAL HOME; OF-THE-LITERATURE;
HEART-FAILURE; RECORD USE; CARE; MANAGEMENT; QUALITY
AB The U.S. health system has historically been poorly equipped to confront the growing impact of diabetes on the nation's health. The Affordable Care Act legislates a number of new strategies-such as innovative payment and delivery models and increased public health funding-intended to improve diabetes prevention and care quality. Health information technology (IT) is often cited as a critical part of these strategies. Through the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, the federal government has been supporting the rapid adoption of health IT, and more specifically of electronic health records (EHRs) through the Centers for Medicare and Medicaid Services (CMS) EHR Incentive Program. Health IT has the potential to contribute to diabetes prevention and improved quality of care, but the evidence supporting its benefits is mixed. This article provides a brief overview of the CMS EHR Incentive Program and meaningful-use criteria. Then it examines health IT strategies for diabetes prevention in the context of current evidence and identifies areas of needed research and innovation. (Am J Prev Med 2013;44(4S4):S357-S363) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Ahmad, Faraz S.] Univ Penn, Perelman Sch Med, Ctr Therapeut Effectiveness Res, Ctr Healthcare Improvement & Patient Safety, Philadelphia, PA 19104 USA.
[Ahmad, Faraz S.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Tsang, Thomas] Dupont Merck Pharmaceut Co, Strategy & Business Dev, Boston, MA USA.
RP Ahmad, FS (reprint author), Hosp Univ Penn, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA.
EM faraz.ahmad@uphs.upenn.edu
FU Joslin Diabetes Center; Novo Nordisk
FX Publication of this supplement was supported by Joslin Diabetes Center
and Novo Nordisk.
NR 61
TC 8
Z9 8
U1 5
U2 39
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD APR
PY 2013
VL 44
IS 4
SU 4
BP S357
EP S363
DI 10.1016/j.amepre.2012.12.020
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 113NH
UT WOS:000316674200011
PM 23498299
ER
PT J
AU Beaser, RS
Brown, JA
AF Beaser, Richard S.
Brown, Julie A.
TI Preventive Intervention in Diabetes A New Model for Continuing Medical
Education
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID BLOOD-GLUCOSE CONTROL; LIFE-STYLE INTERVENTION; SELF-ASSESSMENT;
CLINICAL-PRACTICE; GLYCEMIC CONTROL; US ADULTS; TYPE-2; PROGRAM;
MELLITUS; PERFORMANCE
AB Competence and skills in overcoming clinical inertia for diabetes treatment, and actually supporting and assisting the patient through adherence and compliance (as opposed to just reiterating what they "should" be doing and then assigning them the blame if they fail) is a key component to success in addressing diabetes, and to date it is a component that has received little formal attention. To improve and systematize diabetes care, it is critical to move beyond the "traditional" continuing medical education (CME) model of imparting knowledge as the entirety of the educational effort, and move toward a focus on Performance Improvement CME. This new approach does not just teach new information but also provides support for improvements where needed most within practice systems based on targeted data-based on self-assessments for the entire system of care. Joslin data conclude that this new approach will benefit support, clinical, and office teams as well as the specialist. In short, the Performance Improvement CME structure reflects the needed components of the successful practice today, particularly for chronic conditions such as diabetes, including the focus on interdisciplinary team care and on quality improvement, which is becoming more and more aligned with reimbursement schemes, public and private, in the U.S. (Am J Prev Med 2013;44(4S4):S394-S399) (C) 2013 American Journal of Preventive Medicine
C1 [Beaser, Richard S.; Brown, Julie A.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Brown, Julie A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Beaser, RS (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM Richard.beaser@joslin.harvard.edu
FU Joslin Diabetes Center; Novo Nordisk
FX Publication of this supplement was supported by Joslin Diabetes Center
and Novo Nordisk.
NR 48
TC 2
Z9 2
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD APR
PY 2013
VL 44
IS 4
SU 4
BP S394
EP S399
DI 10.1016/j.amepre.2013.01.003
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 113NH
UT WOS:000316674200017
PM 23498305
ER
PT J
AU Brooks, JL
AF Brooks, John L., III
TI Diabetes Prevention The Joslin Diabetes Center
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Editorial Material
C1 Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Brooks, JL (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM john.brooks@joslin.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD APR
PY 2013
VL 44
IS 4
SU 4
BP S299
EP S300
DI 10.1016/j.amepre.2013.01.005
PG 2
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 113NH
UT WOS:000316674200002
PM 23498290
ER
PT J
AU Miller, SC
Baktash, SH
Webb, TS
Whitehead, CR
Maynard, C
Wells, TS
Otte, CN
Gore, RK
AF Miller, Shannon C.
Baktash, Suzanne H.
Webb, Timothy S.
Whitehead, Casserly R.
Maynard, Charles
Wells, Timothy S.
Otte, Clifford N.
Gore, Russel K.
TI Risk for Addiction-Related Disorders Following Mild Traumatic Brain
Injury in a Large Cohort of Active-Duty US Airmen
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID ALCOHOL-USE; SUBSTANCE-ABUSE; HEAD-INJURY; DRUG-USE; AFGHANISTAN;
DEPRESSION; IRAQ; POPULATION; PATTERNS; CARE
AB Objective: Military personnel are at increased risk for traumatic brain injury (TBI) from combat and noncombat exposures. The sequelae of moderate to severe TBI are well described, but little is known regarding long-term performance decrements associated with mild TBI. Furthermore, while alcohol and drug use are well known to increase risk for TBI, little is known regarding the reverse pattern. The authors sought to assess possible associations between mild TBI and addiction-related disorders in active-duty U.S. military personnel.
Method: A historical prospective study was conducted using electronically recorded demographic, medical, and military data for more than a half million active-duty U.S. Air Force service members. Cases were identified by ICD-9-CM codes considered by an expert panel to be indicative of mild TBI. Outcomes included ICD-9-CM diagnoses of selected addiction-related disorders. Cox proportional hazards modeling was used to calculate hazard ratios while controlling for varying lengths of follow-up and potential confounding variables.
Results: Airmen with mild TBI were at increased risk for certain addiction-related disorders compared with a similarly injured non-mild TBI comparison group. Hazards for alcohol dependence, nicotine dependence, and nondependent abuse of drugs or alcohol were significantly elevated, with a consistent decrease over time.
Conclusions: A novel finding of this study was the initial increased risk for addiction-related disorders that decreased with time, thus eroding war fighter performance in a military population. Moreover, these results suggest that mild TBI is distinguished from moderate to severe TBI in terms of timing of the risk, indicating that there is a need for screening and prevention of addiction-related disorders in mild TBI. Screening may be warranted in military troops as well as civilians at both short- and long-term milestones following mild TBI. (Am J Psychiatry 2013; 170:383-390)
C1 [Whitehead, Casserly R.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA.
Univ Cincinnati, Dept Psychiat & Behav Neurosci, Ctr Treatment Res & Educ Addict Disorders, Cincinnati, OH USA.
Univ Tennessee, Dept Elect Engn & Comp Sci, Knoxville, TN USA.
USAF, Res Lab, Vulnerabil Anal Branch, AFMC Human Performance Wing 711, Wright Patterson AFB, OH 45433 USA.
Infoscitex Corp, Waltham, MA USA.
VA Puget Sound, Epidemiol Res & Informat Ctr, Seattle, WA USA.
Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
RP Whitehead, CR (reprint author), Vet Affairs Med Ctr, Cincinnati, OH 45267 USA.
EM casserly.whitehead.ctr@wpafb.af.mil
RI Maynard, Charles/N-3906-2015; Gore, Russell/N-8988-2016
OI Maynard, Charles/0000-0002-1644-7814; Gore, Russell/0000-0002-8012-1579
NR 37
TC 15
Z9 17
U1 1
U2 19
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD APR
PY 2013
VL 170
IS 4
BP 383
EP 390
DI 10.1176/appi.ajp.2012.12010126
PG 8
WC Psychiatry
SC Psychiatry
GA 117AW
UT WOS:000316925500008
PM 23429886
ER
PT J
AU Melcher, ML
Blosser, CD
Baxter-Lowe, LA
Delmonico, FL
Gentry, SE
Leishman, R
Knoll, GA
Leffell, MS
Leichtman, AB
Mast, DA
Nickerson, PW
Reed, EF
Rees, MA
Rodrigue, JR
Segev, DL
Serur, D
Tullius, SG
Zavala, EY
Feng, S
AF Melcher, M. L.
Blosser, C. D.
Baxter-Lowe, L. A.
Delmonico, F. L.
Gentry, S. E.
Leishman, R.
Knoll, G. A.
Leffell, M. S.
Leichtman, A. B.
Mast, D. A.
Nickerson, P. W.
Reed, E. F.
Rees, M. A.
Rodrigue, J. R.
Segev, D. L.
Serur, D.
Tullius, S. G.
Zavala, E. Y.
Feng, S.
TI Dynamic Challenges Inhibiting Optimal Adoption of Kidney Paired
Donation: Findings of a Consensus Conference
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Allocation; donor evaluation; finances; histocompatibility testing;
kidney paired donation; nondirected donors; paired kidney exchange;
transport
ID CLINICAL-RELEVANCE; EXCHANGE PROGRAMS; CROSS-MATCHES; DONOR KIDNEYS;
TRANSPLANTATION; CHAIN; PARTICIPATION; EXPERIENCE; TRANSPORT; OUTCOMES
AB While kidney paired donation (KPD) enables the utilization of living donor kidneys from healthy and willing donors incompatible with their intended recipients, the strategy poses complex challenges that have limited its adoption in United States and Canada. A consensus conference was convened March 2930, 2012 to address the dynamic challenges and complexities of KPD that inhibit optimal implementation. Stakeholders considered donor evaluation and care, histocompatibility testing, allocation algorithms, financing, geographic challenges and implementation strategies with the goal to safely maximize KPD at every transplant center. Best practices, knowledge gaps and research goals were identified and summarized in this document.
C1 [Melcher, M. L.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA.
[Blosser, C. D.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
[Baxter-Lowe, L. A.; Feng, S.] UCSF, Dept Surg, San Francisco, CA USA.
[Delmonico, F. L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Delmonico, F. L.] New England Organ Bank Inc, Boston, MA USA.
[Gentry, S. E.] USN Acad, Dept Math, Annapolis, MD 21402 USA.
[Leishman, R.] United Network Organ Sharing, Richmond, VA USA.
[Knoll, G. A.] Ottawa Hosp, Dept Med, Ottawa, ON, Canada.
[Leffell, M. S.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Leichtman, A. B.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Mast, D. A.] Stanford Hosp & Clin, Palo Alto, CA USA.
[Nickerson, P. W.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada.
[Reed, E. F.] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA.
[Rees, M. A.] Univ Toledo, Med Ctr, Dept Urol & Pathol, Toledo, OH 43606 USA.
[Rodrigue, J. R.] Beth Israel Deaconess Med Sch, Transplant Inst, Boston, MA USA.
[Segev, D. L.] Johns Hopkins Univ, Dept Surg, Baltimore, MD USA.
[Serur, D.] Cornell Univ, Dept Surg, New York, NY 10021 USA.
[Tullius, S. G.] Harvard Univ, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Zavala, E. Y.] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA.
RP Feng, S (reprint author), UCSF, Dept Surg, San Francisco, CA USA.
EM sandy.feng@ucsfmedctr.org
OI Nickerson, Peter/0000-0002-7393-7799; Melcher, Marc/0000-0002-7185-4383
FU AHRQ HHS [R18 HS020610]
NR 37
TC 19
Z9 19
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
IS 4
BP 851
EP 860
DI 10.1111/ajt.12140
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 116VT
UT WOS:000316911900008
PM 23398969
ER
PT J
AU Malinoski, DJ
Patel, MS
Ahmed, O
Daly, MC
Mooney, S
Graybill, CO
Foster, CE
Salim, A
AF Malinoski, D. J.
Patel, M. S.
Ahmed, O.
Daly, M. C.
Mooney, S.
Graybill, C. O.
Foster, C. E.
Salim, A.
CA United Network Organ Sharing UNOS
TI The Impact of Meeting Donor Management Goals on the Development of
Delayed Graft Function in Kidney Transplant Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Catastrophic brain injury guidelines; critical care; delayed graft
function
ID DECEASED ORGAN DONORS; RENAL-FUNCTION; RISK-FACTORS; SURVIVAL;
RESUSCITATION; DONATION; NUMBER
AB Many organ procurement organizations (OPOs) utilize preset critical care endpoints as donor management goals (DMGs) in order to standardize care and improve outcomes. The objective of this study was to determine the impact of meeting DMGs on delayed graft function (DGF) in renal transplant recipients. All eight OPOs of the United Network for Organ Sharing Region 5 prospectively implemented nine DMGs in every donor after neurologic determination of death (DNDD). DMGs met was defined a priori as achieving any seven of the nine DMGs and this was recorded at the time of consent for donation to reflect donor hospital ICU management, 1218 h later, and prior to organ recovery. Multivariable analyses were performed to identify independent predictors of DGF (dialysis in the first week after transplantation) with a p < 0.05. A total of 722 transplanted kidneys from 492 DNDDs were included. A total of 28% developed DGF. DMGs were met at consent in 14%, 1218 h in 32% and prior to recovery in 38%. DGF was less common when DMGs were met at consent (17% vs. 30%, p = 0.007). Independent predictors of DGF were age, Cr and cold ischemia time, while meeting DMGs at consent was significantly protective. The management of potential organ donors prior to consent affects outcomes and should remain a priority in the intensive care unit.
C1 [Malinoski, D. J.] Portland VA Med Ctr, Surg Crit Care Sect, Portland, OR USA.
[Patel, M. S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Ahmed, O.; Daly, M. C.; Mooney, S.; Foster, C. E.] Univ Calif Irvine, Div Transplantat Surg, Orange, CA 92668 USA.
[Graybill, C. O.] United Network Organ Sharing, Richmond, VA USA.
[Salim, A.] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA.
RP Malinoski, DJ (reprint author), Portland VA Med Ctr, Surg Crit Care Sect, Portland, OR USA.
EM malinosk@ohsu.edu
FU Health Resources and Services Administration [234-2005-37011C]
FX Additionally, this work was supported in part by Health Resources and
Services Administration contract 234-2005-37011C. The content is the
responsibility of the authors alone and does not necessarily reflect the
views or policies of the Department of Health and Human Services, nor
does mention of trade names, commercial products, or organizations imply
endorsement by the US Government.
NR 26
TC 16
Z9 18
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
IS 4
BP 993
EP 1000
DI 10.1111/ajt.12090
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 116VT
UT WOS:000316911900023
PM 23406284
ER
PT J
AU Chung, RT
Gordon, FD
Curry, MP
Schiano, TD
Emre, S
Corey, K
Markmann, JF
Hertl, M
Pomposelli, JJ
Pomfret, EA
Florman, S
Schilsky, M
Broering, TJ
Finberg, RW
Szabo, G
Zamore, PD
Khettry, U
Babcock, GJ
Ambrosino, DM
Leav, B
Leney, M
Smith, HL
Molrine, DC
AF Chung, R. T.
Gordon, F. D.
Curry, M. P.
Schiano, T. D.
Emre, S.
Corey, K.
Markmann, J. F.
Hertl, M.
Pomposelli, J. J.
Pomfret, E. A.
Florman, S.
Schilsky, M.
Broering, T. J.
Finberg, R. W.
Szabo, G.
Zamore, P. D.
Khettry, U.
Babcock, G. J.
Ambrosino, D. M.
Leav, B.
Leney, M.
Smith, H. L.
Molrine, D. C.
TI Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following
Liver Transplantation: A Randomized Controlled Study
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE HCV RNA titer; hepatitis C virus; liver transplantation; monoclonal
antibody
ID HEPATITIS-C VIRUS; IMMUNE GLOBULIN; NEUTRALIZING ANTIBODIES;
GAMMA-GLOBULIN; OPEN-LABEL; PROPHYLAXIS; RECURRENCE; PREVENTION;
KINETICS; IMMUNOGLOBULINS
AB Rapid allograft infection complicates liver transplantation (LT) in patients with hepatitis C virus (HCV). Pegylated interferon- and ribavirin therapy after LT has significant toxicity and limited efficacy. The effect of a human monoclonal antibody targeting the HCV E2 glycoprotein (MBL-HCV1) on viral clearance was examined in a randomized, double-blind, placebo-controlled pilot study in patients infected with HCV genotype 1a undergoing LT. Subjects received 11 infusions of 50 mg/kg MBL-HCV1 (n = 6) or placebo (n = 5) intravenously with three infusions on day of transplant, a single infusion on days 1 through 7 and one infusion on day 14 after LT. MBL-HCV1 was well-tolerated and reduced viral load for a period ranging from 7 to 28 days. Median change in viral load (log10 IU/mL) from baseline was significantly greater (p = 0.02) for the antibody-treated group (range 3.07 to 3.34) compared to placebo group (range 0.331 to 1.01) on days 3 through 6 posttransplant. MBL-HCV1 treatment significantly delayed median time to viral rebound compared to placebo treatment (18.7 days vs. 2.4 days, p < 0.001). As with other HCV monotherapies, antibody-treated subjects had resistance-associated variants at the time of viral rebound. A combination study of MBL-HCV1 with a direct-acting antiviral is underway.
C1 [Chung, R. T.; Corey, K.; Markmann, J. F.; Hertl, M.] Massachusetts Gen Hosp, Dept Transplant Surg, Boston, MA 02114 USA.
[Gordon, F. D.; Pomposelli, J. J.; Pomfret, E. A.; Khettry, U.] Lahey Clin Med Ctr, Dept Transplantat, Burlington, MA 01803 USA.
[Curry, M. P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Schiano, T. D.; Florman, S.] Mt Sinai Med Ctr, Dept Surg, New York, NY 10029 USA.
[Emre, S.; Schilsky, M.] Yale New Haven Med Ctr, Dept Med, New Haven, CT 06504 USA.
[Broering, T. J.; Babcock, G. J.; Ambrosino, D. M.; Leav, B.; Leney, M.; Smith, H. L.; Molrine, D. C.] Univ Massachusetts, Sch Med, MassBiol, Boston, MA 02125 USA.
[Finberg, R. W.; Szabo, G.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Zamore, P. D.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.
[Zamore, P. D.] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA USA.
RP Molrine, DC (reprint author), Univ Massachusetts, Sch Med, MassBiol, Harbor Campus, Boston, MA 02125 USA.
EM deborah.molrine@umassmed.edu
RI sebastianovitsch, stepan/G-8507-2013
FU MassBiologics, University of Massachusetts, Boston, MA; CTSA grant
[UL1TR000067]; NIH [DK078772]; MassBiologics; Merck; Gilead; Pfizer;
Romark
FX This study was funded by MassBiologics, University of Massachusetts,
Boston, MA. CTSA grant (UL1TR000067) awarded to Mt. Sinai School of
Medicine for CRC research support. RTC was supported in part by NIH
DK078772.; The authors of this manuscript have conflicts of interest to
disclose as described by the American Journal of Transplantation. DMA,
TJB and GJB are co-inventors on relevant patents with all rights and
royalties assigned to MassBiologics; GJB, TJB, DMA, BL ML, HLS, DCM are
current or former employees of MassBiologics; RTC, FDG, MPC, TDS, SE
received research support from MassBiologics; RTC (Grant: Merck, Gilead,
Pfizer, Romark); FDG (Consulting: Merck, Vertex; Grant: Merck; Speaking
and Teaching: Merck); TDS (Advisory Committees or Review Panels: Vertex,
Salix, Merck, Gilead); DMA spouse is stockholder, Merck.
NR 30
TC 35
Z9 36
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
IS 4
BP 1047
EP 1054
DI 10.1111/ajt.12083
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 116VT
UT WOS:000316911900030
PM 23356386
ER
PT J
AU Vagefi, PA
Kelsey, PB
Hochberg, EP
Kotton, CN
AF Vagefi, Parsia A.
Kelsey, Peter B.
Hochberg, Ephraim P.
Kotton, Camille N.
TI Jaundice Six Months Following Liver Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Editorial Material
C1 [Vagefi, Parsia A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg, Boston, MA 02115 USA.
[Kelsey, Peter B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol, Boston, MA USA.
[Hochberg, Ephraim P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol, Boston, MA USA.
[Kotton, Camille N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA.
RP Vagefi, PA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg, Boston, MA 02115 USA.
EM pvagefi@partners.org
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
IS 4
BP 1106
EP 1108
DI 10.1111/ajt.12052
PG 3
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 116VT
UT WOS:000316911900040
PM 23551633
ER
PT J
AU Berry, JD
Miller, R
Moore, DH
Cudkowicz, ME
Van den Berg, LH
Kerr, DA
Dong, YW
Ingersoll, EW
Archibald, D
AF Berry, James D.
Miller, Robert
Moore, Dan H.
Cudkowicz, Merit E.
Van den Berg, Leonard H.
Kerr, Douglas A.
Dong, Yingwen
Ingersoll, Evan W.
Archibald, Donald
TI The Combined Assessment of Function and Survival (CAFS): A new endpoint
for ALS clinical trials
SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
LA English
DT Article
DE Amyotrophic lateral sclerosis; clinical trials; study design; ALS
survival; ALS function; primary endpoint
ID AMYOTROPHIC-LATERAL-SCLEROSIS; COMPOSITE OUTCOMES; JOINT ANALYSIS;
MORTALITY; TIME
AB Our objective was to describe a new endpoint for amyotrophic lateral sclerosis (ALS), the Combined Assessment of Function and Survival (CAFS). CAFS ranks patients' clinical outcomes based on survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Each patient's outcome is compared to every other patient's outcome, assigned a score, and the summed scores are ranked. The mean rank score for each treatment group can then be calculated. A higher mean CAFS score indicates a better group outcome. Historically, ALS clinical trials have assessed survival and function as independent endpoints. Combined endpoints have been used in other diseases to decrease the confounding effect of mortality on analysis of functional outcomes. We explored the application of a similar approach in ALS, the CAFS endpoint, which was used as a pre-specified secondary analysis in a phase II study of dexpramipexole. Those results and some hypothetical examples based on modeling exercises are presented here. CAFS is the primary endpoint of a dexpramipexole phase III study in ALS. In conclusion, the CAFS is a robust statistical tool for ALS clinical trials and appropriately accounts for and weights mortality in the analysis of function.
C1 [Berry, James D.; Cudkowicz, Merit E.] Massachusetts Gen Hosp, Neurol Clin Res Inst, Boston, MA 02114 USA.
[Miller, Robert; Moore, Dan H.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Van den Berg, Leonard H.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Kerr, Douglas A.; Dong, Yingwen] Biogen Idec Inc, Cambridge, MA USA.
[Ingersoll, Evan W.; Archibald, Donald] Knopp Biosci, Pittsburgh, PA USA.
RP Berry, JD (reprint author), Massachusetts Gen Hosp, Neurol Clin Res Inst, Bigelow 1256, Boston, MA 02114 USA.
EM jdberry@partners.org
FU Biogen Idec, Inc.; Muscular Dystrophy Association; ALS Therapy Alliance;
Baxter
FX Medical writing assistance was provided by Aruna Seth of UBC Scientific
Solutions and funded by Biogen Idec, Inc.; J. D. Berry has served as a
consultant to Biogen Idec, Inc. and as a paid speaker for Oakstone
Publishing. He is a site co-investigator for the EMPOWER study. He
receives research support from the Muscular Dystrophy Association and
the ALS Therapy Alliance. R. Miller served on a Biogen Idec advisory
board. M. E. Cudkowicz is the principal investigator of the ongoing
EMPOWER study and receives a grant from Biogen Idec, Inc. for this role.
In the past 2 years, she has served as a consultant for Teva
Pharmaceuticals, Millenium, and Trophos (Data and Safety Monitoring
Board) and has served on an advisory board for Biogen Idec, Inc. L. H.
van den Berg has served on a Biogen Idec, Inc. advisory board and has
received travel grants from Baxter. D. A. Kerr and Y. Dong are employees
of Biogen Idec, Inc. E. Ingersoll and D. Archibald are employees of
Knopp Biosciences LLC.
NR 25
TC 19
Z9 19
U1 1
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 2167-8421
J9 AMYOTROPH LAT SCL FR
JI Amyotroph. Lateral Scher. Frontotemp. Degenerat.
PD APR
PY 2013
VL 14
IS 3
BP 162
EP 168
DI 10.3109/21678421.2012.762930
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 117KT
UT WOS:000316952900002
PM 23323713
ER
PT J
AU Cotten, JF
AF Cotten, Joseph F.
TI TASK-1 (KCNK3) and TASK-3 (KCNK9) Tandem Pore Potassium Channel
Antagonists Stimulate Breathing in Isoflurane-Anesthetized Rats
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID UPPER ABDOMINAL-SURGERY; BACKGROUND K+ CHANNEL; CAROTID-BODY;
CHEMORECEPTOR CELLS; RESPIRATORY NEURONS; DOXAPRAM; ANESTHESIA; PH;
CONTRIBUTE; CURRENTS
AB BACKGROUND: TASK-1 and TASK-3 tandem pore potassium channel subunits provide a constitutive acidic pH- and hypoxia-inhibited potassium conductance. TASK channels are expressed in a number of tissues involved in regulation of breathing, and the TASK-1/TASK-3 heterodimer provides the predominant hypoxia-sensitive potassium conductance in carotid body type 1 glomus chemosensing cells. The carotid bodies have an important role in regulation of breathing. Doxapram is a potent TASK-1 and TASK-3 potassium channel antagonist and a carotid body and breathing stimulant. PK-THPP and A1899 are potent and selective TASK-1 and TASK-3 antagonists. I hypothesized PK-THPP and A1899 are, like doxapram, breathing stimulants.
METHODS: I studied rat TASK-3 potassium channel function by Ussing chamber using Fischer rat thyroid monolayers. To quantify breathing effects, I studied male Sprague Dawley rats spontaneously breathing 1.5% isoflurane in room air by noninvasive plethysmography and by arterial blood gas analysis.
RESULTS: PK-THPP, A1899, and doxapram inhibit rat TASK-3 potassium channel function with IC(50)s of 42 nM (33-52), 1.6 mu M (0.8-3.3), and 22 mu M (18-28) (n = 4-6; 95% confidence limits). IV PK-THPP, A1899, and doxapram stimulated breathing by plethysmography with a peak change in minute ventilation relative to baseline of 84% +/- 19% and 226% +/- 56% (for PK-THPP at 0.5 and 5 mg/kg; mean +/- SEM; n = 3-4; P < 0.05 and P < 0.001, respectively, relative to vehicle); 46% +/- 2% and 236% +/- 48% (for A1899 at 5 and 25 mg/kg; n = 3-4; P > 0.05 and P < 0.001, respectively); 103% +/- 20% (for doxapram at 25 mg/kg; n = 4), and 33% +/- 9% (for dimethylsulfoxide vehicle at 1 mL/kg; n = 4). PK-THPP and A1899, unlike doxapram, induced a profound and lasting respiratory alkalosis by arterial blood gas analysis. Thirty minutes after IV drug administration, I observed an arterial pH and carbon dioxide partial pressure of 7.62 +/- 0.02 and 23 +/- 0.8 mm Hg (for PK-THPP after 5 mg/kg; n = 4; P < 0.001 for both relative to vehicle), 7.49 +/- 0.02 and 31 +/- 2 mm Hg (for A1899 at 25 mg/kg; n = 6; P < 0.05 and 0.001, respectively), 7.43 +/- 0.03 and 39 +/- 4 mm Hg (for doxapram after 25 mg/kg; n = 4; P > 0.05 for both), and 7.38 +/- 0.03 and 48 +/- 4 mm Hg (for dimethylsulfoxide vehicle after 1 mL/kg; n = 3).
CONCLUSIONS: PK-THPP and A1899 are potent rat TASK-3 antagonists and effective breathing stimulants. PK-THPP and A1899 effects on breathing were of greater magnitude and/or duration relative to that of doxapram. PK-THPP and A1899 or related compounds may have therapeutic potential for treating breathing disorders..(Anesth Analg 2013;116:810-6)
C1 Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Cotten, JF (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, GRB 444,55 Fruit St, Boston, MA 02114 USA.
EM jcotten@partners.org
FU NIH/NIGMS [GM083216]; Massachusetts General Hospital Department of
Anesthesia, Critical Care, and Pain Medicine
FX This work was supported by NIH/NIGMS GM083216 and Massachusetts General
Hospital Department of Anesthesia, Critical Care, and Pain Medicine.
NR 44
TC 11
Z9 11
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD APR
PY 2013
VL 116
IS 4
BP 810
EP 816
DI 10.1213/ANE.0b013e318284469d
PG 7
WC Anesthesiology
SC Anesthesiology
GA 113EA
UT WOS:000316648100011
PM 23460565
ER
PT J
AU Forman, SA
AF Forman, Stuart A.
TI The Expanding Genetic Toolkit for Exploring Mechanisms of General
Anesthesia
SO ANESTHESIOLOGY
LA English
DT Editorial Material
ID RECEPTOR BETA-3 SUBUNIT; A RECEPTOR; KNOCKOUT MICE; ETOMIDATE
C1 [Forman, Stuart A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Forman, Stuart A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Forman, SA (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM saforman@partners.org
FU NIGMS NIH HHS [P01 GM058448, GM089745, R01 GM089745, GM58448]
NR 14
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD APR
PY 2013
VL 118
IS 4
BP 769
EP 771
DI 10.1097/ALN.0b013e318287b7e4
PG 3
WC Anesthesiology
SC Anesthesiology
GA 109GR
UT WOS:000316355000002
PM 23364596
ER
PT J
AU Sasaki, N
Meyer, MJ
Eikermann, M
AF Sasaki, Nobuo
Meyer, Matthew J.
Eikermann, Matthias
TI Postoperative Respiratory Muscle Dysfunction Pathophysiology and
Preventive Strategies
SO ANESTHESIOLOGY
LA English
DT Review
ID OBSTRUCTIVE SLEEP-APNEA; INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS;
RESIDUAL NEUROMUSCULAR BLOCKADE; UPPER AIRWAY COLLAPSIBILITY; UPPER
ABDOMINAL-SURGERY; TUMOR-NECROSIS-FACTOR; INDUCED DIAPHRAGMATIC
DYSFUNCTION; POSITIVE-PRESSURE VENTILATION; NEGATIVE PHARYNGEAL PRESSURE
AB Postoperative pulmonary complications are responsible for significant increases in hospital cost as well as patient morbidity and mortality; respiratory muscle dysfunction represents a contributing factor. Upper airway dilator muscles functionally resist the upper airway collapsing forces created by the respiratory pump muscles. Standard perioperative medications (anesthetics, sedatives, opioids, and neuromuscular blocking agents), interventions (patient positioning, mechanical ventilation, and surgical trauma), and diseases (lung hyperinflation, obesity, and obstructive sleep apnea) have differential effects on the respiratory muscle subgroups. These effects on the upper airway dilators and respiratory pump muscles impair their coordination and function and can result in respiratory failure. Perioperative management strategies can help decrease the incidence of postoperative respiratory muscle dysfunction. Such strategies include minimally invasive procedures rather than open surgery, early and optimal mobilizing of respiratory muscles while on mechanical ventilation, judicious use of respiratory depressant anesthetics and neuromuscular blocking agents, and noninvasive ventilation when possible.
C1 [Sasaki, Nobuo; Meyer, Matthew J.; Eikermann, Matthias] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Eikermann, M (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Gray Bigelow 444,55 Fruit St, Boston, MA 02114 USA.
EM meikermann@partners.org
NR 235
TC 23
Z9 24
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD APR
PY 2013
VL 118
IS 4
BP 961
EP 978
DI 10.1097/ALN.0b013e318288834f
PG 18
WC Anesthesiology
SC Anesthesiology
GA 109GR
UT WOS:000316355000028
PM 23429163
ER
PT J
AU Forman, SA
AF Forman, Stuart A.
TI A Paradigm Shift from Biophysical to Neurobiological: The Fading
Influence of Claude Bernard's Ideas about General Anesthesia
SO ANESTHESIOLOGY
LA English
DT Letter
ID CONSCIOUSNESS
C1 [Forman, Stuart A.] Harvard Univ, Sch Med, Boston, MA 02163 USA.
[Forman, Stuart A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Forman, SA (reprint author), Harvard Univ, Sch Med, Boston, MA 02163 USA.
EM saforman@partners.org
FU NIGMS NIH HHS [P01 GM058448, R01 GM089745]
NR 12
TC 2
Z9 2
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD APR
PY 2013
VL 118
IS 4
BP 984
EP 985
DI 10.1097/ALN.0b013e3182860777
PG 2
WC Anesthesiology
SC Anesthesiology
GA 109GR
UT WOS:000316355000032
PM 23511525
ER
PT J
AU Scemama, PH
Hull, JW
AF Scemama, Pascal H.
Hull, Jeffrey W.
TI Case Scenario Consistent with Lack of Knowledge and Psychological Bias
Reply
SO ANESTHESIOLOGY
LA English
DT Letter
C1 [Scemama, Pascal H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Scemama, PH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM pscemamadegialluly@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD APR
PY 2013
VL 118
IS 4
BP 991
EP 991
DI 10.1097/ALN.0b013e3182862f4a
PG 1
WC Anesthesiology
SC Anesthesiology
GA 109GR
UT WOS:000316355000039
PM 23511532
ER
PT J
AU Shindoh, J
Andreou, A
Aloia, TA
Zimmitti, G
Lauwers, GY
Laurent, A
Nagorney, DM
Belghiti, J
Cherqui, D
Poon, RTP
Kokudo, N
Vauthey, JN
AF Shindoh, Junichi
Andreou, Andreas
Aloia, Thomas A.
Zimmitti, Giuseppe
Lauwers, Gregory Y.
Laurent, Alexis
Nagorney, David M.
Belghiti, Jacques
Cherqui, Daniel
Poon, Ronnie Tung-Ping
Kokudo, Norihiro
Vauthey, Jean-Nicolas
TI Microvascular Invasion Does Not Predict Long-Term Survival in
Hepatocellular Carcinoma up to 2 cm: Reappraisal of the Staging System
for Solitary Tumors
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID AMERICAN-JOINT-COMMITTEE; LIVER-TRANSPLANTATION; CIRRHOSIS; RESECTION;
CLASSIFICATION; PROGRESSION; VALIDATION; PATHOLOGY; JAPAN
AB Excellent long-term outcomes have been reported recently for patients with small (a parts per thousand currency sign2 cm) hepatocellular carcinoma (HCC). However, the significance of microvascular invasion (MVI) in small HCC remains unclear. The purpose of this study was to determine the impact of MVI in small HCC up to 2 cm.
In 1,109 patients with solitary HCC from six major international hepatobiliary centers, the impact of MVI on long-term survival in patients with small HCC (a parts per thousand currency sign2 cm) and patients with tumors larger than 2 cm was analyzed.
In patients with small HCC, long-term survival was not affected by MVI (p = 0.8), whereas in patients with larger HCC, significantly worse survival was observed in patients with MVI (p < 0.0001). In multivariate analysis, MVI (hazard ratio [HR] 1.59; 95 % confidence interval (CI) 1.27-1.99; p < 0.001), elevated alpha-fetoprotein (HR 1.41; 95 % CI 1.11-1.8; p = 0.005), and higher histologic grade (HR 1.29; 95 % CI 1.01-1.64; p = 0.04) were significant predictors of worse survival in patients with HCC larger than 2 cm but were not correlated with long-term survival in small HCC. When the cohort was divided into three groups-HCC a parts per thousand currency sign2, > 2 cm without MVI, and HCC > 2 cm with MVI-significant between-group survival difference was observed (p < 0.0001).
Small HCC is associated with an excellent prognosis that is not affected by the presence of MVI. The discriminatory power of the 7th edition of the AJCC classification for solitary HCC could be further improved by subdividing tumors according to size (a parts per thousand currency sign2 vs. > 2 cm).
C1 [Shindoh, Junichi; Andreou, Andreas; Aloia, Thomas A.; Zimmitti, Giuseppe; Vauthey, Jean-Nicolas] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Int Cooperat Study Grp Hepatocellular Carcinoma, Houston, TX 77030 USA.
[Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Laurent, Alexis; Cherqui, Daniel] Hop Henri Mondor, Dept Digest & Hepatobiliary Surg & Liver Transpla, F-94010 Creteil, France.
[Nagorney, David M.] Mayo Clin, Dept Gastroenterol & Gen Surg, Rochester, MI USA.
[Belghiti, Jacques] Beaujon Hosp, AP HP, Dept Hepatopancreatobiliary & Transplantat Surg, Clichy, France.
[Poon, Ronnie Tung-Ping] Univ Hong Kong, Dept Surg, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
[Kokudo, Norihiro] Univ Tokyo, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan.
RP Shindoh, J (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Int Cooperat Study Grp Hepatocellular Carcinoma, Houston, TX 77030 USA.
EM jvauthey@mdanderson.org
FU National Institutes of Health through Cancer Center Support Grant
[CA016672]
FX The authors thank Ms. Stephanie Deming and Ms. Ruth Haynes for their
contribution to our manuscript. The University of Texas MD Anderson
Cancer Center is supported in part by the National Institutes of Health
through Cancer Center Support Grant CA016672.
NR 35
TC 16
Z9 18
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
IS 4
BP 1223
EP 1229
DI 10.1245/s10434-012-2739-y
PG 7
WC Oncology; Surgery
SC Oncology; Surgery
GA 109TV
UT WOS:000316392600025
PM 23179993
ER
PT J
AU Coopey, SB
Specht, MC
Warren, L
Smith, BL
Winograd, JM
Fleischmann, K
AF Coopey, Suzanne B.
Specht, Michelle C.
Warren, Lisa
Smith, Barbara L.
Winograd, Jonathan M.
Fleischmann, Katharine
TI Use of Preoperative Paravertebral Block Decreases Length of Stay in
Patients Undergoing Mastectomy Plus Immediate Reconstruction
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID BREAST-CANCER SURGERY; 20-YEAR FOLLOW-UP; GENERAL-ANESTHESIA;
RADICAL-MASTECTOMY; UNITED-STATES; CARCINOMA
AB A prior study in patients undergoing breast surgery with and without the use of paravertebral blocks (PVB) found no significant difference in patient length of stay (LOS). However, patients undergoing bilateral procedures and those undergoing immediate reconstructions were excluded. We sought to determine if the use of PVB in patients undergoing unilateral or bilateral mastectomy plus immediate reconstruction decreases patient LOS.
We undertook a retrospective review of patients who had mastectomies with immediate reconstructions with and without the use of preoperative PVB. Outcomes including LOS, postoperative nausea and vomiting, and time to oral narcotics were compared between groups.
Mean LOS for the PVB group was 42 h. This was significantly less than the mean LOS of 47 h for the nonblock group (p = .0015). The significantly lower LOS for the PVB group was true for patients undergoing bilateral procedures (p = .045), unilateral procedures (p = .0031), tissue expander placement (p = .0114), and immediate implant placement (p = .037). Mean time to conversion to oral narcotics was significantly shorter in the PVB group (15 h) compared with the nonblock group (20 h) (p < .001). The incidence of postoperative nausea in the PVB group (42.8 %) was also significantly less than in the nonblock group (54.7 %) (p = .031).
The routine use of preoperative PVB in patients undergoing mastectomy plus immediate reconstruction significantly decreased patient LOS. In addition to improved pain control from the block itself, quicker conversion to oral narcotics because of less postoperative nausea likely contributed to a decreased LOS.
C1 [Coopey, Suzanne B.; Specht, Michelle C.; Warren, Lisa; Smith, Barbara L.; Winograd, Jonathan M.; Fleischmann, Katharine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Coopey, SB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM scoopey@partners.org
NR 19
TC 12
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
IS 4
BP 1282
EP 1286
DI 10.1245/s10434-012-2678-7
PG 5
WC Oncology; Surgery
SC Oncology; Surgery
GA 109TV
UT WOS:000316392600033
PM 23064793
ER
PT J
AU Santamaria-Barria, JA
Boland, GM
Yeap, BY
Nardi, V
Dias-Santagata, D
Cusack, JC
AF Santamaria-Barria, Juan A.
Boland, Genevieve M.
Yeap, Beow Y.
Nardi, Valentina
Dias-Santagata, Dora
Cusack, James C., Jr.
TI Merkel Cell Carcinoma: 30-Year Experience from a Single Institution
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID SENTINEL LYMPH-NODE; TRABECULAR CARCINOMA; RADIATION-THERAPY; CASE
SERIES; SYNCHRONOUS CARBOPLATIN/ETOPOSIDE; MULTIMODALITY MANAGEMENT;
ADJUVANT RADIOTHERAPY; CYTOKERATIN 20; SKIN; POLYOMAVIRUS
AB Merkel cell carcinoma (MCC) is a rare cutaneous malignancy. Few single-institution series have been reported.
Review of MCC patients treated at our institution between 1980 and 2010. Patient, tumor, and treatment variables were analyzed to determine MCC-specific outcomes.
We identified 161 patients with MCC. There was a 2.5-fold increase in cases over the last decade. Median length of follow-up was 36 months. Stage at diagnosis was I in 35 %, II in 21 %, IIIa in 12 %, IIIb in 23 %, and IV in 9 %. The 5-year MCC-specific survival rates were 87, 63, 42, and 0 % for stages I, II, III, and IV, respectively. Death from the disease occurred in 10 % of patients with T1 and in 50 % with larger lesions. One-third of patients presented with nodal disease. Sentinel lymph node biopsy (SLNB) identified micrometastases in 9 out of 27 (33 %) early-stage patients. Recurrence developed in 56 % of SLNB-positive and 39 % of SLNB-negative patients. Half of patients recurred after a median time of 9 months. Proportions of first recurrence location were distant (52 %), nodal (27 %), and local (21 %). Adjuvant treatments did not improve recurrence or survival rates. One-third of patients died of the disease.
SLNB identifies micrometastasis in one-third of early-stage patients. Negative SLNB may predict for improved but not necessarily favorable outcome. Initial tumor size and clinical nodal disease predict for poor outcome. High recurrence rates warrant the development of more effective adjuvant therapies, and better markers of recurrence and treatment response for MCC are needed.
C1 [Santamaria-Barria, Juan A.; Boland, Genevieve M.; Cusack, James C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
[Yeap, Beow Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
[Nardi, Valentina; Dias-Santagata, Dora] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
RP Santamaria-Barria, JA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
EM jcusack@partners.org
NR 63
TC 24
Z9 24
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2013
VL 20
IS 4
BP 1365
EP 1373
DI 10.1245/s10434-012-2779-3
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA 109TV
UT WOS:000316392600046
PM 23208132
ER
PT J
AU Lima, XT
Alora-Palli, MB
Kimball, AB
Kay, J
AF Lima, Xinaida Taligare
Alora-Palli, Maria Beatrice
Kimball, Alexandra Boer
Kay, Jonathan
TI Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID CONTRAST AGENT; RENAL-FAILURE; GADOLINIUM; DERMOPATHY; ASSOCIATION;
DEPOSITION; SKIN
AB Objective To develop and pilot test a screening tool to identify cases of nephrogenic systemic fibrosis (NSF) among patients exposed to gadolinium-containing contrast agents. Methods Sixty English-speaking subjects were enrolled: 10 subjects diagnosed as having NSF, 10 subjects with other fibrosing skin diseases, 20 subjects with nonfibrosing skin diseases, and 20 subjects without a skin disease. Subjects answered a questionnaire with 8 closed-ended (yes/no) questions focusing on cutaneous and musculoskeletal manifestations of NSF. The subjects were evaluated by a dermatologist for the presence of clinical signs of NSF. We compared the number of affirmative responses in the NSF group to those in the other groups, and the optimal cutoff that would differentiate groups was calculated. Discrimination, positive and negative predictive values, and internal consistency were also assessed. Results Subjects in the NSF group tended to provide more affirmative answers. Using a cutoff of 3 affirmative responses yields a sensitivity of 90% and a specificity of 70%, with an area under the curve of 0.85, indicating good discrimination. Sensitivity analysis using modified control group or weighted scores exhibited only slightly better discriminatory power. The positive predictive value of the questionnaire ranged from 0.3% to 39.7%, and its negative predictive values ranged from 97% to >99% with the different proposed prevalence estimates. The instrument had high internal consistency. Conclusion This pilot study demonstrates that this questionnaire has both high internal consistency and good discriminatory ability. Thus, it may be used to screen populations for NSF.
C1 [Lima, Xinaida Taligare; Alora-Palli, Maria Beatrice; Kimball, Alexandra Boer] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kay, Jonathan] UMass Mem Med Ctr, Worcester, MA 01605 USA.
[Kay, Jonathan] Univ Massachusetts, Sch Med, Worcester, MA USA.
RP Kay, J (reprint author), UMass Mem Med Ctr, Rheumatol Ctr, 119 Belmont St, Worcester, MA 01605 USA.
EM jonathan.kay@umassmemorial.org
OI Kay, Jonathan/0000-0002-8970-4260
NR 26
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD APR
PY 2013
VL 65
IS 4
BP 637
EP 642
DI 10.1002/acr.21877
PG 6
WC Rheumatology
SC Rheumatology
GA 116UI
UT WOS:000316908100020
PM 23097320
ER
PT J
AU Conway, KL
Kuballa, P
Khor, B
Zhang, M
Shi, HN
Virgin, HW
Xavier, RJ
AF Conway, Kara L.
Kuballa, Petric
Khor, Bernard
Zhang, Mei
Shi, Hai Ning
Virgin, Herbert W.
Xavier, Ramnik J.
TI ATG5 regulates plasma cell differentiation
SO AUTOPHAGY
LA English
DT Article
DE ATG5; B lymphocytes; antibody secretion; immunity; plasma cell
differentiation
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; UNFOLDED PROTEIN RESPONSE; INTESTINAL
PANETH CELLS; AUTOPHAGY GENE ATG5; TRANSCRIPTION FACTOR; CROHN-DISEASE;
B-CELLS; INFLAMMATION; EXPRESSION; BLIMP-1
AB Autophagy is a conserved homeostatic process in which cytoplasmic contents are degraded and recycled. Two ubiquitin-like conjugation pathways are required for the generation of autophagosomes, and ATG5 is necessary for both of these processes. Studies of mice deficient in ATG5 reveal a key role for autophagy in T lymphocyte function, as well as in B cell development and B-1a B cell maintenance. However, the role of autophagy genes in B cell function and antibody production has not been described. Using mice in which Atg5 is conditionally deleted in B lymphocytes, we showed here that this autophagy gene is essential for plasma cell homeostasis. In the absence of B cell ATG5 expression, antibody responses were significantly diminished during antigen-specific immunization, parasitic infection and mucosal inflammation. Atg5-deficient B cells maintained the ability to produce immunoglobulin and undergo class-switch recombination, yet had impaired SDC1 expression, significantly decreased antibody secretion in response to toll-like receptor ligands, and an inability to upregulate plasma cell transcription factors. These results build upon previous data demonstrating a role for ATG5 in early B cell development, illustrating its importance in late B cell activation and subsequent plasma cell differentiation.
C1 [Conway, Kara L.; Kuballa, Petric; Khor, Bernard; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02115 USA.
[Conway, Kara L.; Kuballa, Petric; Khor, Bernard; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA.
[Conway, Kara L.; Kuballa, Petric; Khor, Bernard; Xavier, Ramnik J.] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA.
[Conway, Kara L.; Kuballa, Petric; Khor, Bernard; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA.
[Khor, Bernard] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Serv, Boston, MA USA.
[Zhang, Mei; Shi, Hai Ning] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA USA.
[Zhang, Mei; Shi, Hai Ning] Harvard Univ, Sch Med, Charlestown, MA USA.
[Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Virgin, Herbert W.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
[Virgin, Herbert W.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
RP Xavier, RJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02115 USA.
EM xavier@molbio.mgh.harvard.edu
OI Khor, Bernard/0000-0003-4689-5092
FU National Institutes of Health [DK043351, DK083756, DK086502, DK060049];
CCFA Genetics Initiative Grant
FX We acknowledge Noboru Mizushima (Tokyo Medical and Dental University,
Tokyo, Japan) for providing Atg5flox/flox mice and WT and
atg5-/- MEFs. We also acknowledge Natalia Nedelsky for review
of the manuscript and helpful discussions. This work was supported by
the National Institutes of Health Grants DK043351, DK083756, DK086502
and DK060049 (to R.J.X.), and CCFA Genetics Initiative Grant (to
R.J.X./H.W.V.).
NR 47
TC 44
Z9 45
U1 3
U2 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD APR
PY 2013
VL 9
IS 4
BP 528
EP 537
DI 10.4161/auto.23484
PG 10
WC Cell Biology
SC Cell Biology
GA 114HR
UT WOS:000316732200007
PM 23327930
ER
PT J
AU Nunes, P
Ernandez, T
Roth, I
Qiao, XM
Strebel, D
Bouley, R
Charollais, A
Ramadori, P
Foti, M
Meda, P
Feraille, E
Brown, D
Hasler, U
AF Nunes, Paula
Ernandez, Thomas
Roth, Isabelle
Qiao, Xiaomu
Strebel, Deborah
Bouley, Richard
Charollais, Anne
Ramadori, Pierluigi
Foti, Michelangelo
Meda, Paolo
Feraille, Eric
Brown, Dennis
Hasler, Udo
TI Hypertonic stress promotes autophagy and microtubule-dependent
autophagosomal clusters
SO AUTOPHAGY
LA English
DT Article
DE ATG12; Golgi apparatus; MAP1LC3/LC3; MAPRE1/EB1; MTOC; SQSTM1/p62;
apoptosis; autophagy; dynein; lysosome; microtubule; osmotic stress;
proteasome; rapamycin; tubulin; ubiquitin
ID DUCT PRINCIPAL CELLS; COATED PIT FORMATION; PROTEIN AGGREGATION;
ENDOPLASMIC-RETICULUM; POTASSIUM-DEPLETION; SELECTIVE AUTOPHAGY;
MAMMALIAN AUTOPHAGY; ACTIN CYTOSKELETON; EPITHELIAL-CELLS;
GOLGI-APPARATUS
AB Osmotic homeostasis is fundamental for most cells, which face recurrent alterations of environmental osmolality that challenge cell viability. Protein damage is a consequence of hypertonic stress, but whether autophagy contributes to the osmoprotective response is unknown. Here, we investigated the possible implications of autophagy and microtubule organization on the response to hypertonic stress. We show that hypertonicity rapidly induced long-lived protein degradation, LC3-II generation and Ptdlns3K-dependent formation of LC3- and ATG12-positive puncta. Lysosomotropic agents chloroquine and bafilomycin A 1, but not nutrient deprivation or rapamycin treatment, further increased LC3-II generation, as well as ATG12-positive puncta, indicating that hypertonic stress increases autophagic flux. Autophagy induction upon hypertonic stress enhanced cell survival since cell death was increased by ATG12 siRNA-mediated knockdown and reduced by rapamycin. We additionally showed that hypertonicity induces fast reorganization of microtubule networks, which is associated with strong reorganization of microtubules at centrosomes and fragmentation of Golgi ribbons. Microtubule remodeling was associated with pericentrosomal clustering of ATG12-positive autolysosomes that colocalized with SQSTM1/p62 and ubiquitin, indicating that autophagy induced by hypertonic stress is at least partly selective. Efficient autophagy by hypertonic stress required microtubule remodeling and was DYNC/dynein-dependent as autophagosome clustering was enhanced by paclitaxel-induced microtubule stabilization and was reduced by nocodazole- induced tubulin depolymerization as well as chemical (EHNA) or genetic [DCTN2/dynactin 2 (p50) overexpression] interference of DYNC activity. The data document a general and hitherto overlooked mechanism, where autophagy and microtubule remodeling play prominent roles in the osmoprotective response.
C1 [Nunes, Paula; Ernandez, Thomas; Roth, Isabelle; Qiao, Xiaomu; Strebel, Deborah; Charollais, Anne; Ramadori, Pierluigi; Foti, Michelangelo; Meda, Paolo; Feraille, Eric; Hasler, Udo] Univ Geneva, Dept Cellular Physiol & Metab, Geneva, Switzerland.
[Ernandez, Thomas; Roth, Isabelle; Qiao, Xiaomu; Strebel, Deborah; Feraille, Eric; Hasler, Udo] Univ Geneva, Dept Med Specialties, Serv Nephrol, Geneva, Switzerland.
[Nunes, Paula; Bouley, Richard; Brown, Dennis; Hasler, Udo] Massachusetts Gen Hosp, Program Membrane Biol, Ctr Syst Biol, Boston, MA 02114 USA.
[Nunes, Paula; Bouley, Richard; Brown, Dennis; Hasler, Udo] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
RP Hasler, U (reprint author), Univ Geneva, Dept Cellular Physiol & Metab, Geneva, Switzerland.
EM Udo.Hasler@unige.ch
RI Nunes-Hasler, Paula/N-4337-2015
OI Nunes-Hasler, Paula/0000-0002-4598-685X
FU Swiss National Science Foundation [3100A0_122559/1, 31003A_138408/1,
IZ73ZO-127935, 310030_141162, CR3213_129987, 310000-120280/1];
Foundation Novartis pour la Recherche en Sciences Medico-Biologique;
Fondation Ernest Boninchi; Fondation Schmidheiny; Amgen; Juvenile
Diabetes Research Foundation [40-2011-11, 5-2012281]; European Union
[BETAIMAGE 222980, BETATRAIN 289932, IMIDIA C2008-T7]; Fondation
Schmidheiny grant; National Institutes of Health Grant [DK38452]; Boston
Area Diabetes and Endocrinology Research Center [DK57521]; Center for
the Study of Inflammatory Bowel Disease [DK43351]
FX This work was supported by a Swiss National Science Foundation Grants
3100A0_122559/1 and 31003A_138408/1 and grants from the Foundation
Novartis pour la Recherche en Sciences Medico-Biologique, Fondation
Ernest Boninchi, Fondation Schmidheiny and Amgen to U.H.; Swiss National
Science Foundation Grants IZ73ZO-127935, 310030_141162, CR3213_129987,
grants from the Juvenile Diabetes Research Foundation (40-2011-11,
5-2012281) and grants from the European Union (BETAIMAGE 222980,
BETATRAIN 289932 and IMIDIA C2008-T7) to P.M.; a Swiss National Science
Foundation Grant 310000-120280/1 to M.F.; a Fondation Schmidheiny grant
to T.E. and a National Institutes of Health Grant DK38452 to R.B. and
D.B. The microscopy core facility of the MGH Program in Membrane Biology
receives additional support from the Boston Area Diabetes and
Endocrinology Research Center (DK57521) and the Center for the Study of
Inflammatory Bowel Disease (DK43351).
NR 94
TC 16
Z9 18
U1 3
U2 28
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD APR
PY 2013
VL 9
IS 4
BP 550
EP 567
DI 10.4161/auto.23662
PG 18
WC Cell Biology
SC Cell Biology
GA 114HR
UT WOS:000316732200009
PM 23380587
ER
PT J
AU Steele, JW
Gandy, S
AF Steele, John W.
Gandy, Sam
TI Latrepirdine (Dimebon (R)), a potential Alzheimer therapeutic, regulates
autophagy and neuropathology in an Alzheimer mouse model
SO AUTOPHAGY
LA English
DT Editorial Material
DE Alzheimer; therapeutics; latrepirdine; dimebon; synuclein;
macroautophagy; amyloid; lysosome; presenilin; neurodegeneration
AB Alzheimer disease (AD) is a form of neurodegeneration that develops over the course of multiple decades and as a result of the accumulation of the pathogenic amyloid-beta (A beta) peptide, also known as A4. In late-stage AD, failure of autophagic clearance results in neuronal cell bodies that are almost entirely consumed by autophagic vacuoles (AVs). Previously, we have shown that the potential AD drug latrepirdine (aka Dimebon (R)), a Russian antihistamine that has shown mixed results in phase II clinical trials in AD, regulates metabolism of the amyloid-beta/A4 precursor protein (APP). In two Molecular Psychiatry papers in 2012, we sought to determine the mechanism through which latrepirdine regulates APP metabolism and to determine, using an Alzheimer mouse model, whether latrepirdine provides protection from the toxicity associated with the accumulation of A beta. In cultured cells, we provided evidence that latrepirdine stimulates MTOR- and ATG5-dependent autophagy, leading to the reduction of intracellular levels of APP metabolites, including A beta. Consistent with this finding, we found that chronic latrepirdine administration resulted in increased levels of the biomarkers thought to correlate with autophagy activation in the brains of TgCRND8 (APP K670M, N671L, V717F) or wild-type mice, and that treatment was associated with abrogation of behavioral deficit, reduction in A beta neuropathology, and prevention of autophagic failure among TgCRND8 mice.
C1 [Steele, John W.] Rockefeller Univ, Elizabeth & Zachary Fisher Ctr Alzheimers Dis Res, New York, NY 10021 USA.
[Steele, John W.] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA.
[Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, Ctr Cognit Hlth, New York, NY USA.
[Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, Ctr Cognit Hlth, New York, NY USA.
[Gandy, Sam] Icahn Sch Med Mt Sinai, Mt Sinai Alzheimers Dis Res Ctr, New York, NY USA.
[Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY USA.
RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, Ctr Cognit Hlth, New York, NY USA.
EM samuel.gandy@mssm.edu
NR 0
TC 39
Z9 42
U1 1
U2 8
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD APR
PY 2013
VL 9
IS 4
BP 617
EP 618
DI 10.4161/auto.23487
PG 2
WC Cell Biology
SC Cell Biology
GA 114HR
UT WOS:000316732200018
PM 23380933
ER
PT J
AU Purcell, SM
AF Purcell, Shaun M.
TI Antidepressant Response and Polygenes
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
C1 [Purcell, Shaun M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Purcell, Shaun M.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Purcell, Shaun M.] Broad Inst, Cambridge, MA USA.
RP Purcell, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
EM shaun.purcell@mssm.edu
NR 6
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD APR 1
PY 2013
VL 73
IS 7
BP 600
EP 601
DI 10.1016/j.biopsych.2013.01.023
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 113RL
UT WOS:000316685400004
PM 23497743
ER
PT J
AU Hek, K
Demirkan, A
Lahti, J
Terracciano, A
Teumer, A
Cornelis, MC
Amin, N
Bakshis, E
Baumert, J
Ding, JZ
Liu, YM
Marciante, K
Meirelles, O
Nalls, MA
Sun, YV
Vogelzangs, N
Yu, L
Bandinelli, S
Benjamin, EJ
Bennett, DA
Boomsma, D
Cannas, A
Coker, LH
de Geus, E
De Jager, PL
Diez-Roux, AV
Purcell, S
Hu, FB
Rimm, EB
Hunter, DJ
Jensen, MK
Curhan, G
Rice, K
Penman, AD
Rotter, JI
Sotoodehnia, N
Emeny, R
Eriksson, JG
Evans, DA
Ferrucci, L
Fornage, M
Gudnason, V
Hofman, A
Illig, T
Kardia, S
Kelly-Hayes, M
Koenen, K
Kraft, P
Kuningas, M
Massaro, JM
Melzer, D
Mulas, A
Mulder, CL
Murray, A
Oostra, BA
Palotie, A
Penninx, B
Petersmann, A
Pilling, LC
Psaty, B
Rawal, R
Reiman, EM
Schulz, A
Shulman, JM
Singleton, AB
Smith, AV
Sutin, AR
Uitterlinden, AG
Volzke, H
Widen, E
Yaffe, K
Zonderman, AB
Cucca, F
Harris, T
Ladwig, KH
Llewellyn, DJ
Raikkonen, K
Tanaka, T
van Duijn, CM
Grabe, HJ
Launer, LJ
Lunetta, KL
Mosley, TH
Newman, AB
Tiemeier, H
Murabito, J
AF Hek, Karin
Demirkan, Ayse
Lahti, Jari
Terracciano, Antonio
Teumer, Alexander
Cornelis, Marilyn C.
Amin, Najaf
Bakshis, Erin
Baumert, Jens
Ding, Jingzhong
Liu, Yongmei
Marciante, Kristin
Meirelles, Osorio
Nalls, Michael A.
Sun, Yan V.
Vogelzangs, Nicole
Yu, Lei
Bandinelli, Stefania
Benjamin, Emelia J.
Bennett, David A.
Boomsma, Dorret
Cannas, Alessandra
Coker, Laura H.
de Geus, Eco
De Jager, Philip L.
Diez-Roux, Ana V.
Purcell, Shaun
Hu, Frank B.
Rimm, Eric B.
Hunter, David J.
Jensen, Majken K.
Curhan, Gary
Rice, Kenneth
Penman, Alan D.
Rotter, Jerome I.
Sotoodehnia, Nona
Emeny, Rebecca
Eriksson, Johan G.
Evans, Denis A.
Ferrucci, Luigi
Fornage, Myriam
Gudnason, Vilmundur
Hofman, Albert
Illig, Thomas
Kardia, Sharon
Kelly-Hayes, Margaret
Koenen, Karestan
Kraft, Peter
Kuningas, Maris
Massaro, Joseph M.
Melzer, David
Mulas, Antonella
Mulder, Cornelis L.
Murray, Anna
Oostra, Ben A.
Palotie, Aarno
Penninx, Brenda
Petersmann, Astrid
Pilling, Luke C.
Psaty, Bruce
Rawal, Rajesh
Reiman, Eric M.
Schulz, Andrea
Shulman, Joshua M.
Singleton, Andrew B.
Smith, Albert V.
Sutin, Angelina R.
Uitterlinden, Andre G.
Voelzke, Henry
Widen, Elisabeth
Yaffe, Kristine
Zonderman, Alan B.
Cucca, Francesco
Harris, Tamara
Ladwig, Karl-Heinz
Llewellyn, David J.
Raikkonen, Katri
Tanaka, Toshiko
van Duijn, Cornelia M.
Grabe, Hans J.
Launer, Lenore J.
Lunetta, Kathryn L.
Mosley, Thomas H., Jr.
Newman, Anne B.
Tiemeier, Henning
Murabito, Joanne
TI A Genome-Wide Association Study of Depressive Symptoms
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Center for Epidemiologic Studies Depression Scale; CHARGE consortium;
depression; depressive symptoms; genetics; genome-wide association
study; meta-analysis
ID MAJOR DEPRESSION; CES-D; ATHEROSCLEROSIS RISK; VITAL EXHAUSTION; LIFE
EVENTS; POPULATION; DISORDER; GENE; METAANALYSIS; LINKAGE
AB Background: Depression is a heritable trait that exists on a continuum of varying severity and duration. Yet, the search for genetic variants associated with depression has had few successes. We exploit the entire continuum of depression to find common variants for depressive symptoms.
Methods: In this genome-wide association study, we combined the results of 17 population-based studies assessing depressive symptoms with the Center for Epidemiological Studies Depression Scale. Replication of the independent top hits (p < 1 x 10(-5)) was performed in five studies assessing depressive symptoms with other instruments. In addition, we performed a combined meta-analysis of all 22 discovery and replication studies.
Results: The discovery sample comprised 34,549 individuals (mean age of 66.5) and no loci reached genome-wide significance (lowest p = 1.05 x 10(-7)). Seven independent single nucleotide polymorphisms were considered for replication. In the replication set (n = 16,709), we found suggestive association of one single nucleotide polymorphism with depressive symptoms (rs161645, 5q21, p = 9.19 x 10(-3)). This 5q21 region reached genome-wide significance (p = 4.78 x 10(-8)) in the overall meta-analysis combining discovery and replication studies (n = 51,258).
Conclusions: The results suggest that only a large sample comprising more than 50,000 subjects may be sufficiently powered to detect genes for depressive symptoms.
C1 [Hek, Karin; Mulder, Cornelis L.; Tiemeier, Henning] Erasmus MC, Res Ctr O3, Dept Psychiat, NL-3000 CA Rotterdam, Netherlands.
[Hek, Karin; Hofman, Albert; Kuningas, Maris; Uitterlinden, Andre G.; Tiemeier, Henning] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
[Lahti, Jari; Raikkonen, Katri] Univ Helsinki, Inst Behav Sci, Helsinki, Finland.
[Tanaka, Toshiko] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Teumer, Alexander] Univ Med Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany.
[Cornelis, Marilyn C.; Hu, Frank B.; Rimm, Eric B.; Jensen, Majken K.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Bakshis, Erin; Diez-Roux, Ana V.; Kardia, Sharon] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Baumert, Jens; Emeny, Rebecca; Ladwig, Karl-Heinz] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 2, Neuherberg, Germany.
[Ding, Jingzhong] Wake Forest Univ, Dept Internal Med, Div Geriatr, Winston Salem, NC 27109 USA.
[Liu, Yongmei] Wake Forest Univ, Dept Epidemiol & Prevent, Div Publ Hlth Sci, Winston Salem, NC 27109 USA.
[Marciante, Kristin] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Terracciano, Antonio; Meirelles, Osorio; Sutin, Angelina R.] NIA, NIH, Dept Hlth & Human Serv, Baltimore, MD 21224 USA.
[Nalls, Michael A.; Singleton, Andrew B.] NIA, Neurogenet Lab, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Sun, Yan V.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
[Vogelzangs, Nicole; Penninx, Brenda] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
[Vogelzangs, Nicole; Penninx, Brenda] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
[Yu, Lei; Bennett, David A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA.
[Yu, Lei; Bennett, David A.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Bandinelli, Stefania] Geriatr Unit Azienda Sanitaria Firenze, Florence, Italy.
[Benjamin, Emelia J.; Kelly-Hayes, Margaret; Massaro, Joseph M.; Lunetta, Kathryn L.; Murabito, Joanne] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med & Publ Hlth, Sect Cardiol & Prevent Med, Dept Med, Boston, MA 02215 USA.
[Boomsma, Dorret; de Geus, Eco] Vrije Univ Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands.
[Cannas, Alessandra; Mulas, Antonella] CNR, Ist Ric Genet & Biomed, Cagliari, Italy.
[Coker, Laura H.] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA.
[De Jager, Philip L.] Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp,Program Translat NeuroPsych, Boston, MA 02115 USA.
[Purcell, Shaun] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Broad Inst, Cambridge, MA USA.
[Hu, Frank B.; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Rice, Kenneth] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Penman, Alan D.] Univ Mississippi, Med Ctr, Ctr Biostat, Jackson, MS 39216 USA.
[Penman, Alan D.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
[Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Sotoodehnia, Nona] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Sotoodehnia, Nona] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Eriksson, Johan G.] Univ Helsinki, Natl Inst Hlth & Welf, Helsinki, Finland.
[Eriksson, Johan G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland.
[Eriksson, Johan G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland.
[Eriksson, Johan G.] Folkhalsan Res Ctr, Helsinki, Finland.
[Eriksson, Johan G.] Vasa Cent Hosp, Vaasa, Finland.
[Evans, Denis A.] Rush Univ, Med Ctr, Rush Inst Hlth Aging, Dept Internal Med, Chicago, IL 60612 USA.
[Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Clin Res Branch, NIH, Baltimore, MD 21224 USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX USA.
[Hofman, Albert; Uitterlinden, Andre G.; van Duijn, Cornelia M.; Tiemeier, Henning] Netherlands Consortium Hlth Aging, Netherlands Genom Initiat, Leiden, Netherlands.
[Illig, Thomas] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Mol Epidemiol, Neuherberg, Germany.
[Kelly-Hayes, Margaret] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Koenen, Karestan] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Massaro, Joseph M.] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA USA.
[Melzer, David; Pilling, Luke C.; Llewellyn, David J.] Univ Exeter, Peninsula Coll Med & Dent, Exeter, Devon, England.
[van Duijn, Cornelia M.] Ctr Med Syst Biol, Leiden, Netherlands.
[Murray, Anna] Univ Exeter, Peninsula Coll Med & Dent, Inst Biomed & Clin Sci, Exeter, Devon, England.
[Mulder, Cornelis L.] Erasmus MC, Mental Hlth Ctr BavoEuropoort, NL-3000 CA Rotterdam, Netherlands.
[Oostra, Ben A.] Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands.
[Palotie, Aarno] Wellcome Trust Genome Campus, Wellcome Trust Sanger Inst, Cambridge, England.
[Palotie, Aarno; Widen, Elisabeth] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland.
[Palotie, Aarno] Univ Helsinki, Dept Med Genet, Helsinki, Finland.
Univ Cent Hosp, Helsinki, Finland.
[Palotie, Aarno] Broad Inst Massachusetts Inst Technol & Harvard, Program Med & Populat Genet & Genet Anal Platform, Cambridge, MA USA.
[Penninx, Brenda] Leiden Univ, Med Ctr, Dept Psychiat, Leiden, Netherlands.
[Penninx, Brenda] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9713 AV Groningen, Netherlands.
[Petersmann, Astrid] Univ Med Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany.
[Psaty, Bruce] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Rawal, Rajesh] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Genet Epidemiol, Neuherberg, Germany.
[Reiman, Eric M.] Translat Genom Res Inst, Neurogenom Div, Phoenix, AZ USA.
[Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA.
[Schulz, Andrea; Grabe, Hans J.] Univ Med Greifswald, Helios Hosp, Dept Psychiat & Psychotherapy, Stralsund, Germany.
[Zonderman, Alan B.] NIA, Lab Behav Neurosci, Baltimore, MD 21224 USA.
[Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands.
[Voelzke, Henry] Univ Med Greifswald, Inst Community Med, Greifswald, Germany.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Gudnason, Vilmundur; Smith, Albert V.] Iceland Heart Assoc, Kopavogur, Iceland.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Harris, Tamara; Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Lunetta, Kathryn L.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Mosley, Thomas H., Jr.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
[Murabito, Joanne] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Hunter, David J.; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[Curhan, Gary] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Gudnason, Vilmundur; Smith, Albert V.] Univ Iceland, Dept Med, Reykjavik, Iceland.
[Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany.
[Terracciano, Antonio; Sutin, Angelina R.] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA.
[Demirkan, Ayse; Amin, Najaf; Oostra, Ben A.; van Duijn, Cornelia M.] Erasmus MC, Genet Epidemiol Unit, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
[Demirkan, Ayse; Amin, Najaf; Oostra, Ben A.; van Duijn, Cornelia M.] Erasmus MC, Genet Epidemiol Unit, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands.
[Shulman, Joshua M.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Shulman, Joshua M.] Baylor Coll Med, Dept Human Genet, Houston, TX 77030 USA.
RP Tiemeier, H (reprint author), Erasmus MC, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM h.tiemeier@erasmusmc.nl
RI Smith, Albert/K-5150-2015; Pilling, Luke/E-4917-2013; terracciano,
antonio/B-1884-2008; Singleton, Andrew/C-3010-2009; Ladwig,
Karl-Heinz/B-5351-2014; Newman, Anne/C-6408-2013; Emeny,
Rebecca/I-1100-2014; Gudnason, Vilmundur/K-6885-2015; de Geus,
Eco/M-9318-2015;
OI Zonderman, Alan B/0000-0002-6523-4778; Ware, Erin/0000-0003-4731-8158;
Lahti, Jari/0000-0002-4310-5297; Raikkonen, Katri/0000-0003-3124-3470;
Murray, Anna/0000-0002-2351-2522; Melzer, David/0000-0002-0170-3838;
Tiemeier, Henning/0000-0002-4395-1397; Benjamin,
Emelia/0000-0003-4076-2336; Eriksson, Johan/0000-0002-2516-2060; Smith,
Albert/0000-0003-1942-5845; Murabito, Joanne/0000-0002-0192-7516;
Massaro, Joseph/0000-0002-2682-4812; Lunetta,
Kathryn/0000-0002-9268-810X; Pilling, Luke/0000-0002-3332-8454; Ladwig,
Karl-Heinz/0000-0003-0710-1720; Newman, Anne/0000-0002-0106-1150; Emeny,
Rebecca/0000-0002-8780-5439; Gudnason, Vilmundur/0000-0001-5696-0084; de
Geus, Eco/0000-0001-6022-2666; Mulas, Antonella/0000-0002-6856-1483
FU Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium; National Institutes of Health (NIH) [N01-AG-12100,
HHSN268200625226C, UL1RR025005, HHSN268200782096C, R01 MH086498,
CA65725, CA87969, CA49449, CA67262, CA50385, 5UO1CA098233]; NIA;
Hjartavernd (the Icelandic Heart Association); Althingi (the Icelandic
Parliament); National Heart, Lung, and Blood Institute [N01-HC-55015,
N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021,
N01-HC-55022, R01-HL087641, R01-HL093029, R01-HL70825]; National Human
Genome Research Institute [U01-HG004402]; NIH Roadmap for Medical
Research; NIH, National Institute on Aging [NO1-AG-1-2109]; NHLBI
[N01-HC-85239, N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103,
N01 HC-55222, N01-HC-75150, N01-HC-45133, HL080295, HL075366, HL087652,
HL105756, N01-HC-25195, N02-HL-6-4278, N01-HC-65226]; NIA [AG-023629,
AG-15928, AG-20098, AG-027058, N01AG62101, N01AG62103, N01AG62106,
1R01AG032098-01A1, R01AG15819, R01AG17917, K08AG34290, P30AG10161,
R01AG30146]; Clinical and Translational Science Institute [UL1RR033176];
National Institute of Diabetes and Digestive and Kidney Diseases
[DK063491]; European Community; European Network for Genetic and Genomic
Epidemiology Consortium [HEALTHF-4-2007- 201413]; European Special
Populations Research Network; European Commission [018947,
LSHG-CT-2006-01947]; Netherlands Organisation for Scientific Research,
Erasmus MC; Centre for Medical Systems Biology; Netherlands Brain
Foundation (HersenStichting Nederland); Robert Dawson Evans Endowment of
the Department of Medicine at Boston University School of Medicine;
Boston Medical Center; Academy of Finland; Finnish Diabetes Research
Society; Folkhalsan Research Foundation; Novo Nordisk Foundation; Finska
Lakaresallskapet; Signe and Ane Gyllenberg Foundation; University of
Helsinki; European Science Foundation (EUROSTRESS); Ministry of
Education; Ahokas Foundation; Emil Aaltonen Foundation; Juho Vainio
Foundation; Wellcome Trust [WT098051]; Italian Ministry of Health [ICS
110.1RS97.71]; U.S. National Institute on Aging [N01]AG]916413,
N01]AG]821336, 263 MD 9164 13, 263 MD 821336]; Helmholtz Zentrum
Munchen; German Research Center for Environmental Health, Neuherberg,
Germany; German Federal Ministry of Education and Research; Munich
Center of Health Sciences as part of Ludwig-Maximilians-University;
Netherlands Organisation of Scientific Research Investments
[175.010.2005.011, 911-03-012]; Research Institute for Diseases in the
Elderly [014-93-015]; Netherlands Genomics Initiative/Netherlands
Organisation for Scientific Research [050-060-810]; Erasmus MC; Erasmus
University, Rotterdam; Netherlands Organization for the Health Research
and Development; Ministry of Education, Culture and Science; Ministry
for Health, Welfare and Sports; European Commission (Directorate-General
XII); Municipality of Rotterdam; Vidi Grant of Netherlands Organization
for the Health Research and Development [2009-017.106.370];
BavoEuropoort; German Bundesministerium fur Forschung und Technology [01
AK 803 A-H, 01 IG 07015 G]; Translational Genomics Research Institute;
Burroughs Wellcome Fund; Federal Ministry of Education and Research
[01ZZ9603, 01ZZ0103, 01ZZ0403, 03ZIK012]; Ministry of Cultural Affairs;
Social Ministry of the Federal State of Mecklenburg-West Pomerania;
Siemens Healthcare, Erlangen, Germany; Federal State of Mecklenburg-West
Pomerania; German Research Foundation (DFG) [GR 1912/5-1]; Federal
Ministry of Education and Research Germany; Humboldt Foundation; German
Research Foundation; Lundbeck; Janssen-Cilag; Eli Lilly; Novartis;
AstraZeneca; SALUS-Institute for Trend-Research and Therapy Evaluation
in Mental Health; Sanofi-Aventis; Biotronik; [R01-AG29451];
[N01-HC-95159]; [N01-HC-95169]; [UL1-RR-024156]; [R01 HL101161]
FX We acknowledge the essential role of the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium in development and
support of this manuscript. Cohorts for Heart and Aging Research in
Genomic Epidemiology Consortium members include the Netherland's
Rotterdam Study, the National Heart, Lung, and Blood Institute's (NHLBI)
Framingham Heart Study, Cardiovascular Health Study, the NHLBI's
Atherosclerosis Risk in Communities Study, and the National Institute on
Aging's (NIA) Iceland Age, Gene/Environment Susceptibility Study.; The
Age, Gene/Environment Susceptibility Reykjavik Study has been funded by
National Institutes of Health (NIH) contract N01-AG-12100, the NIA
Intramural Research Program, Hjartavernd (the Icelandic Heart
Association), and the Althingi (the Icelandic Parliament).; The
Atherosclerosis Risk in Communities Study research is carried out as a
collaborative study supported by National Heart, Lung, and Blood
Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018,
N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022 and Grants
R01-HL087641, R01-HL093029, and R01-HL70825; National Human Genome
Research Institute contract U01-HG004402; and National Institutes of
Health contract HHSN268200625226C. We thank the staff and participants
of the Atherosclerosis Risk in Communities Study for their important
contributions. Infrastructure was partly supported by Grant Number
UL1RR025005, a component of the National Institutes of Health and NIH
Roadmap for Medical Research.; The Baltimore Longitudinal Study of Aging
research was supported entirely by the Intramural Research Program of
the NIH, National Institute on Aging.; This Cardiovascular Health Study
research was supported by NHLBI contracts N01-HC-85239, N01-HC-85079
through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222,
N01-HC-75150, N01-HC-45133 and NHLBI Grants HL080295, HL075366,
HL087652, and HL105756 with additional contribution from National
Institute of Neurological Disorders and Stroke. Additional support was
provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the
NIA. See also http://www.chs-nhlbi.org/pi.htm. DNA handling and
genotyping was supported, in part, by Clinical and Translational Science
Institute Grant UL1RR033176 to the Cedars-Sinai General Clinical
Research Center Genotyping core, National Institute of Diabetes and
Digestive and Kidney Diseases Grant DK063491 to the Southern California
Diabetes Endocrinology Research Center, and the Governors' Chair in
Medical Genetics (JIR).; The Erasmus Rucphen Family (ERF) research was
supported through funds from The European Community's Seventh Framework
Programme (FP7/2007-2013), European Network for Genetic and Genomic
Epidemiology Consortium, Grant agreement HEALTHF-4-2007- 201413.; The
genotyping for the ERF study was supported by European Special
Populations Research Network and the European Commission FP6 STRP Grant
(018947; LSHG-CT-2006-01947). The ERF study was further supported by
Grants from the Netherlands Organisation for Scientific Research,
Erasmus MC, the Centre for Medical Systems Biology, and the Netherlands
Brain Foundation (HersenStichting Nederland). We are grateful to all
participating individuals and their relatives, general practitioners,
and neurologists for their contributions and to P. Veraart for her help
in genealogy, Jeannette Vergeer for the supervision of the laboratory
work, and P. Snijders for his help in data collection.; Framingham Heart
Study: The phenotype-genotype association analyses were supported by
R01-AG29451. "This research was conducted in part using data and
resources from the Framingham Heart Study of the National Heart Lung and
Blood Institute of the National Institutes of Health and Boston
University School of Medicine. The analyses reflect intellectual input
and resource development from the Framingham Heart Study investigators
participating in the SNP Health Association Resource project. This work
was partially supported by the National Heart, Lung and Blood
Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its
contract with Affymetrix, Inc for genotyping services (Contract No.
N02-HL-6-4278). A portion of this research utilized the Linux Cluster
for Genetic Analysis funded by the Robert Dawson Evans Endowment of the
Department of Medicine at Boston University School of Medicine and
Boston Medical Center.''; Helsinki Birth Cohort Study has been supported
by Grants from the Academy of Finland, the Finnish Diabetes Research
Society, Folkhalsan Research Foundation, Novo Nordisk Foundation, Finska
Lakaresallskapet, Signe and Ane Gyllenberg Foundation, University of
Helsinki, European Science Foundation (EUROSTRESS), Ministry of
Education, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio
Foundation, and Wellcome Trust (Grant number WT098051). We thank all
study participants, as well as everybody involved in the Helsinki Birth
Cohort Study.; The Health, Aging and Body Composition research was
supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The
genome-wide association study was funded by NIA Grant 1R01AG032098-01A1
to Wake Forest University Health Sciences and genotyping services were
provided by the Center for Inherited Disease Research. Center for
Inherited Disease Research is fully funded through a federal contract
from the National Institutes of Health to The Johns Hopkins University,
contract number HHSN268200782096C. This research was supported, in part,
by the Intramural Research Program of the NIH, National Institute on
Aging. Dr. Yaffe is supported by NIH Grant R01 MH086498.; The
Invechhiare in Chianti Study was supported as a targeted project (ICS
110.1RS97.71) by the Italian Ministry of Health, by the U.S. National
Institute on Aging (Contracts N01]AG]916413, N01] AG] 821336, 263 MD
9164 13, and 263 MD 821336), and, in part, by the Intramural Research
Program, National Institute on Aging, National Institutes of Health.;
The Multi-Ethnic Study of Atherosclerosis (MESA) SNP Health Association
Resource project is conducted and supported by the NHLBI in
collaboration with MESA investigators. Support for MESA is provided by
contracts N01-HC-95159 through N01-HC-95169 and UL1-RR-024156. Funding
for genotyping was provided by NHLBI Contract N02-HL-6-4278 and
N01-HC-65226. Funding for this project was also provided by #R01
HL101161.; The Monitoring of Trends and Determinants of Cardiovascular
Disease/Cooperative Health Research in the Region of Augsburg studies
were financed by the Helmholtz Zentrum Munchen, German Research Center
for Environmental Health, Neuherberg, Germany, and supported by Grants
from the German Federal Ministry of Education and Research. Furthermore,
the research was supported within the Munich Center of Health Sciences
as part of Ludwig-Maximilians-University.; The Nurses' Health Studies
are supported by NIH Grants CA 65725, CA87969 (National Cancer
Institute), CA49449, CA67262, CA50385, and 5UO1CA098233.; The generation
and management of genome-wide association study genotype data for the
Rotterdam Study is supported by the Netherlands Organisation of
Scientific Research Investments (number 175.010.2005.011, 911-03-012).
This study is funded by the Research Institute for Diseases in the
Elderly (014-93-015), the Netherlands Genomics Initiative/Netherlands
Organisation for Scientific Research project number 050-060-810. The
Rotterdam Study is funded by Erasmus MC and Erasmus University,
Rotterdam, Netherlands Organization for the Health Research and
Development, the Ministry of Education, Culture and Science, the
Ministry for Health, Welfare and Sports, the European Commission
(Directorate-General XII), and the Municipality of Rotterdam. Henning
Tiemeier was supported by the Vidi Grant of Netherlands Organization for
the Health Research and Development (2009-017.106.370). Karin Hek was
supported by a Grant from BavoEuropoort. We are grateful to the study
participants, the staff from the Rotterdam Study, and the participating
general practitioners and pharmacists. We thank Pascal Arp, Mila Jhamai,
Marijn Verkerk, Lizbeth Herrera, and Marjolein Peters for their help in
creating the genome-wide association study database, and Dr. Karol
Estrada and Maksim V. Struchalin for their support in creation and
analysis of imputed data. We thank Dr. Karol Estrada, Dr. Fernando
Rivadeneira, Dr. Tobias A. Knoch, Anis Abuseiris, Luc V. de Zeeuw, and
Rob de Graaf (Erasmus MC Rotterdam, The Netherlands) for their help in
creating GRIMP and BigGRID, MediGRID, and Services@MediGRID/D-Grid
(funded by the German Bundesministerium fur Forschung und Technology;
Grants 01 AK 803 A-H, 01 IG 07015 G) for access to their grid computing
resources.; The Rush Memory and Aging Project is supported by NIA Grants
R01AG15819, R01AG17917, and K08AG34290 and the Translational Genomics
Research Institute. The Rush Religious Orders Study is supported by NIA
Grants P30AG10161, R01AG15819, R01AG30146, and K08AG34290 and the
Translational Genomics Research Institute. We thank the study
participants and the staff of the Rush Alzheimer's Disease Center.
Joshua Shulman was additionally supported by a Career Award for Medical
Scientists from Burroughs Wellcome Fund.; The SardiNIA research was
supported, in part, by the Intramural Research Program of the NIH,
National Institute on Aging. Funding was also provided through contract
NO1-AG-1-2109 from the NIA-NIH.; Study of Health in Pomerania is part of
the Community Medicine Research net of the University of Greifswald,
Germany, which is funded by the Federal Ministry of Education and
Research (Grant no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of
Cultural Affairs, and the Social Ministry of the Federal State of
Mecklenburg-West Pomerania. Genome-wide data have been supported by the
Federal Ministry of Education and Research (Grant no. 03ZIK012) and a
joint Grant from Siemens Healthcare, Erlangen, Germany, and the Federal
State of Mecklenburg-West Pomerania. The University of Greifswald is a
member of the Center of Knowledge Interchange program of the Siemens AG.
This work was also funded by the German Research Foundation (DFG: GR
1912/5-1), Federal Ministry of Education and Research Germany, the
Humboldt Foundation, and the German Research Foundation.; Study of
Health in Pomerania: To HJG German Research Foundation; Federal Ministry
of Education and Research Germany; speakers honoraria from Bristol-Myers
Squibb, Eli Lilly, Novartis, Eisai, Wyeth, Pfizer, Boehringer Ingelheim,
and Servier; and travel funds from Lundbeck, Janssen-Cilag, Eli Lilly,
Novartis, AstraZeneca, and SALUS-Institute for Trend-Research and
Therapy Evaluation in Mental Health. To HV research grants by
Sanofi-Aventis, Biotronik, the Humboldt Foundation, the Federal Ministry
of Education and Research (Germany), and the German Research Foundation.
All other authors reported no biomedical financial interests or
potential conflicts of interest.
NR 75
TC 60
Z9 61
U1 1
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD APR 1
PY 2013
VL 73
IS 7
BP 667
EP 678
DI 10.1016/j.biopsych.2012.09.033
PG 12
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 113RL
UT WOS:000316685400013
PM 23290196
ER
PT J
AU Leussis, MP
Berry-Scott, EM
Saito, M
Jhuang, H
de Haan, G
Alkan, O
Luce, CJ
Madison, JM
Sklar, P
Serre, T
Root, DE
Petryshen, TL
AF Leussis, Melanie P.
Berry-Scott, Erin M.
Saito, Mai
Jhuang, Hueihan
de Haan, Georgius
Alkan, Ozan
Luce, Catherine J.
Madison, Jon M.
Sklar, Pamela
Serre, Thomas
Root, David E.
Petryshen, Tracey L.
TI The ANK3 Bipolar Disorder Gene Regulates Psychiatric-Related Behaviors
That Are Modulated by Lithium and Stress
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Ankyrin G; dentate gyrus; GWAS; mouse; RNA interference; schizophrenia
ID DENTATE GYRUS; SYNAPTIC PLASTICITY; ANXIETY; ABNORMALITIES; HIPPOCAMPAL;
ANKYRIN(G); DEPRESSION; SEGMENTS; CHANNELS; CACNA1C
AB Background: Ankyrin 3 (ANK3) has been strongly implicated as a risk gene for bipolar disorder (BD) by recent genome-wide association studies of patient populations. However, the genetic variants of ANK3 contributing to BD risk and their pathological function are unknown.
Methods: To gain insight into the potential disease relevance of ANK3, we examined the function of mouse Ank3 in the regulation of psychiatric-related behaviors using genetic, neurobiological, pharmacological, and gene-environment interaction (G x E) approaches. Ank3 expression was reduced in mouse brain either by viral-mediated RNA interference or through disruption of brain-specific Ank3 in a heterozygous knockout mouse.
Results: RNA interference of Ank3 in hippocampus dentate gyrus induced a highly specific and consistent phenotype marked by decreased anxiety-related behaviors and increased activity during the light phase, which were attenuated by chronic treatment with the mood stabilizer lithium. Similar behavioral alterations of reduced anxiety and increased motivation for reward were also exhibited by Ank3+/- heterozygous mice compared with wild-type Ank3+/+ mice. Remarkably, the behavioral traits of Ank3+/- mice transitioned to depression-related features after chronic stress, a trigger of mood episodes in BD. Ank3+/- mice also exhibited elevated serum corticosterone, suggesting that reduced Ank3 expression is associated with elevated stress reactivity.
Conclusions: This study defines a new role for Ank3 in the regulation of psychiatric-related behaviors and stress reactivity that lends support for its involvement in BD and establishes a general framework for determining the disease relevance of genes implicated by patient genome-wide association studies.
C1 [Leussis, Melanie P.; Berry-Scott, Erin M.; Saito, Mai; de Haan, Georgius; Madison, Jon M.; Petryshen, Tracey L.] Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Leussis, Melanie P.; Petryshen, Tracey L.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Leussis, Melanie P.; Petryshen, Tracey L.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Leussis, Melanie P.; Berry-Scott, Erin M.; Saito, Mai; de Haan, Georgius; Luce, Catherine J.; Madison, Jon M.; Petryshen, Tracey L.] Broad Inst Harvard & Massachusetts Inst Technol, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Jhuang, Hueihan] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Alkan, Ozan; Root, David E.] Broad Inst Harvard & Massachusetts Inst Technol, RNA Interference Platform, Cambridge, MA USA.
[Sklar, Pamela] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Sklar, Pamela] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA.
[Sklar, Pamela] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
[Serre, Thomas] Brown Univ, Dept Cognit Linguist & Psychol Sci, Providence, RI 02912 USA.
RP Petryshen, TL (reprint author), Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, 185 Cambridge St, Boston, MA 02114 USA.
EM petryshen@chgr.mgh.harvard.edu
FU Stanley Medical Research Institute; RNAi Consortium; Massachusetts
General Hospital Executive Committee on Research; McGovern Institute
Neurotechnology Program; Robert J. and Nancy D. Carney Fund for
Scientific Innovation; Bristol Myers Squibb; Pfizer
FX Funding was provided by the Stanley Medical Research Institute (to JM,
PS, TLP), The RNAi Consortium (to DER), the Massachusetts General
Hospital Executive Committee on Research (to MPL), the McGovern
Institute Neurotechnology Program (to TS), and the Robert J. and Nancy
D. Carney Fund for Scientific Innovation (to TS).; Dr. Serre reports
receiving research funding from Bristol Myers Squibb. Dr. Sklar reports
having received a consultant fee from Pfizer and reports a patent on
brain-derived neurotrophic factor and bipolar disorder. The other
authors report no biomedical financial interests or potential conflicts
of interest.
NR 44
TC 26
Z9 27
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD APR 1
PY 2013
VL 73
IS 7
BP 683
EP 690
DI 10.1016/j.biopsych.2012.10.016
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 113RL
UT WOS:000316685400015
PM 23237312
ER
PT J
AU Lee, IS
Spector, M
AF Lee, In-Seop
Spector, Myron
TI Biomedical materials and 2013
SO BIOMEDICAL MATERIALS
LA English
DT Editorial Material
C1 [Lee, In-Seop] Yonsei Univ, Seoul 120749, South Korea.
[Spector, Myron] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
RP Lee, IS (reprint author), Yonsei Univ, Seoul 120749, South Korea.
NR 3
TC 0
Z9 0
U1 1
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748-6041
J9 BIOMED MATER
JI Biomed. Mater.
PD APR
PY 2013
VL 8
IS 2
AR 020201
DI 10.1088/1748-6041/8/2/020201
PG 1
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 114MS
UT WOS:000316746100001
ER
PT J
AU Wang, TY
Halaney, D
Ho, D
Feldman, MD
Milner, TE
AF Wang, Tianyi
Halaney, David
Ho, Derek
Feldman, Marc D.
Milner, Thomas E.
TI Two-photon luminescence properties of gold nanorods
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID EXCITATION CROSS-SECTIONS; ASPECT RATIO; METAL NANOPARTICLES; CORONARY
PLAQUE; IN-VITRO; PHOTOLUMINESCENCE; ABSORPTION; FIELD; ENHANCEMENT;
SIMULATION
AB Gold nanorods can be internalized by macrophages (an important early cellular marker in atherosclerosis and cancer) and used as an imaging contrast agent for macrophage targeting. Objective of this study is to compare two-photon luminescence (TPL) properties of four aspect ratios of gold nanorods with surface plasmon resonance at 700, 756, 844 and 1060 nm respectively. TPL from single nanorods and Rhodamine 6G particles was measured using a laser-scanning TPL microscope. Nanorod TPL emission spectrum was recorded by a spectrometer. Quadratic dependence of luminescence intensity on excitation power (confirming a TPL process) was observed below a threshold (e. g., <1.6 mW), followed by photobleaching at higher power levels. Dependence of nanorod TPL intensity on excitation wavelength indicated that the two-photon action cross section (TPACS) is plasmon-enhanced. Largest TPACS of a single nanorod (12271 GM) was substantially larger than a single Rhodamine 6G particle (25 GM) at 760 nm excitation. Characteristics of nanorod TPL emission spectrum can be explained by plasmon-enhanced interband transition of gold. Comparison results of TPL brightness, TPACS and emission spectrum of nanorods can guide selection of optimal contrast agent for selected imaging applications. (C) 2013 Optical Society of America
C1 [Wang, Tianyi; Ho, Derek; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
[Halaney, David; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA.
[Halaney, David; Feldman, Marc D.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Wang, TY (reprint author), Univ Texas Austin, Dept Biomed Engn, 1 Univ Stn C0800, Austin, TX 78712 USA.
EM Tianyi.Wang@utexas.edu
OI Halaney, David/0000-0003-4437-0516
FU VA Merit grant; Clayton Foundation for Biomedical Research; Janey and
Dolph Briscoe Center for Cardiovascular Research; Cigarrora Endowed
Professorship; Marion E. Forsman Professorship in Engineering; American
Society for Laser Medicine and Surgery
FX The authors would like to acknowledge the technical support from
Nanopartz, Inc, Mr. John Alford from Andor Technology, PLC, and kind
supply of the objective patent and model by Drs. Fabian F. Voigt and
Fritjof Helmchen from University of Zurich. This work is supported by a
VA Merit grant, the Clayton Foundation for Biomedical Research, Janey
and Dolph Briscoe Center for Cardiovascular Research, a Cigarrora
Endowed Professorship (M. D. F.), a Marion E. Forsman Professorship in
Engineering (T. E. M.), and a travel grant from the American Society for
Laser Medicine and Surgery (T. W.).
NR 53
TC 23
Z9 25
U1 4
U2 94
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD APR 1
PY 2013
VL 4
IS 4
BP 584
EP 595
PG 12
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 117GW
UT WOS:000316942500011
PM 23577293
ER
PT J
AU Chung, A
Bachmann, A
Sancha, FG
Collins, E
Tabatabaei, S
Muir, G
Woo, H
AF Chung, A.
Bachmann, A.
Gomez Sancha, F.
Collins, E.
Tabatabaei, S.
Muir, G.
Woo, H.
TI Photoselective vaporisation of the prostate using the 180 W lithium
triborate laser in the treatment of benign prostatic obstruction: an
international multicenter experience
SO BJU INTERNATIONAL
LA English
DT Meeting Abstract
CT 66th Annual Scientific Meeting of the
Urological-Society-of-Australia-and-New Zealand
CY APR 13-16, 2013
CL Melbourne, AUSTRALIA
SP Urol Soc Australia & New Zealand
DE Prostatic hyperplasia; lasers; prostatectomy; transurethral resection of
prostate; lower urinary tract symptoms
C1 [Chung, A.; Woo, H.] Univ Sydney, Sydney Adventist Hosp Clin Sch, Sydney, NSW 2006, Australia.
[Bachmann, A.] Univ Basel Hosp, Dept Urol, CH-4031 Basel, Switzerland.
[Gomez Sancha, F.] ICUA Clin CEMTRO, Dept Urol, Madrid, Spain.
[Collins, E.] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA.
[Tabatabaei, S.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Muir, G.] Kings Coll Hosp, Dept Urol, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
J9 BJU INT
JI BJU Int.
PD APR
PY 2013
VL 111
SU 1
SI SI
MA 4
BP 14
EP 15
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 116XQ
UT WOS:000316917000004
ER
PT J
AU Wong, S
Miller, K
Smith, MR
Dearnaley, D
Dogliott, L
Egerdie, B
Fizazi, K
Kueppers, F
De Oca, LM
Morote, J
Pavlik, I
Sieber, P
Tammel, TJ
Van Poppel, H
Wirth, M
Ye, Z
Braun, A
AF Wong, S.
Miller, K.
Smith, M. R.
Dearnaley, D.
Dogliott, L.
Egerdie, B.
Fizazi, K.
Kueppers, F.
Montes De Oca, L.
Morote, J.
Pavlik, I.
Sieber, P.
Tammel, T. J.
Van Poppel, H.
Wirth, M.
Ye, Z.
Braun, A.
TI Denosumab in men with non-metastatic castration-resistant prostate
cancer (CRPC) and PSA doubling time (PSADT) <= 6 months - a post-hoc
analysis of a randomised trial
SO BJU INTERNATIONAL
LA English
DT Meeting Abstract
CT 66th Annual Scientific Meeting of the
Urological-Society-of-Australia-and-New Zealand
CY APR 13-16, 2013
CL Melbourne, AUSTRALIA
SP Urol Soc Australia & New Zealand
C1 [Wong, S.] Western Hosp, Footscray, Vic, Australia.
[Miller, K.] Charite, Berlin, Germany.
[Smith, M. R.] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
[Dearnaley, D.] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
[Dogliott, L.] Osped San Luigi Gonzaga, Orbassano, TO, Italy.
[Egerdie, B.] Urol Associates, Urol Med Res, Kitchener, ON, Canada.
[Fizazi, K.] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
[Kueppers, F.] Canterbury Urol Res Trust, Christchurch, New Zealand.
[Montes De Oca, L.] Ctr Diagnost Urol, Buenos Aires, DF, Argentina.
[Morote, J.] Hosp Valle De Hebron, Barcelona, Spain.
[Pavlik, I.] Gen Teaching Hosp, Urol Clin, Prague, Czech Republic.
[Pavlik, I.] Fac Med 1, Prague, Czech Republic.
[Sieber, P.] Urol Associates Lancaster, Lancaster, PA USA.
[Tammel, T. J.] Tampere Univ Hosp, Tampere, Finland.
[Van Poppel, H.] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium.
[Wirth, M.] Univ Klinikum Carl Gustav Carus, Dresden, Germany.
[Ye, Z.; Braun, A.] Amgen Inc, Thousand Oaks, CA 91320 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
J9 BJU INT
JI BJU Int.
PD APR
PY 2013
VL 111
SU 1
SI SI
MA 51
BP 37
EP 38
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 116XQ
UT WOS:000316917000047
ER
PT J
AU Saad, F
Patrick, DJ
Smith, M
Cleeland, C
Fallowfield, L
Tombal, B
Oudard, S
Shore, N
Marx, G
Coleman, R
Gomez-Veiga, F
Damiao, R
Zhou, Y
Arellano, J
Braun, A
Qian, Y
AF Saad, F.
Patrick, D. J.
Smith, M.
Cleeland, C.
Fallowfield, L.
Tombal, B.
Oudard, S.
Shore, N.
Marx, G.
Coleman, R.
Gomez-Veiga, F.
Damiao, R.
Zhou, Y.
Arellano, J.
Braun, A.
Qian, Y.
TI The impact of bone metastases on pain: post-hoc analysis of a phase III
study of denosumab in men with non-metastatic Castration-Resistant
Prostate Cancer (CRPC)
SO BJU INTERNATIONAL
LA English
DT Meeting Abstract
CT 66th Annual Scientific Meeting of the
Urological-Society-of-Australia-and-New Zealand
CY APR 13-16, 2013
CL Melbourne, AUSTRALIA
SP Urol Soc Australia & New Zealand
C1 [Saad, F.] Univ Montreal Hosp Ctr, CRCHUM, Montreal, PQ, Canada.
[Patrick, D. J.] Univ Washington, Seattle, WA 98195 USA.
[Smith, M.] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
[Cleeland, C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Tombal, B.] Univ Sussex, SHORE C, Brighton, E Sussex, England.
[Tombal, B.] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium.
[Oudard, S.] Georges Pompidou Hosp, Paris, France.
[Shore, N.] Carolina Urol Res Ctr, Myrtle Beach, SC USA.
[Marx, G.] Sydney Adventist Hosp, Wahroonga, NSW, Australia.
[Marx, G.] Univ Sydney, Sydney, NSW 2006, Australia.
[Coleman, R.] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England.
[Gomez-Veiga, F.] Hosp Juan Canalejo, La Coruna, Spain.
[Damiao, R.] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil.
[Zhou, Y.; Arellano, J.; Braun, A.; Qian, Y.] Amgen Inc, Thousand Oaks, CA 91320 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
J9 BJU INT
JI BJU Int.
PD APR
PY 2013
VL 111
SU 1
SI SI
MA 52
BP 38
EP 38
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 116XQ
UT WOS:000316917000048
ER
PT J
AU Glotzbecker, B
Ho, VT
Aldridge, J
Kim, HT
Horowitz, G
Ritz, J
Soiffer, R
Avigan, D
Rosenblatt, J
AF Glotzbecker, B.
Ho, V. T.
Aldridge, J.
Kim, H. T.
Horowitz, G.
Ritz, J.
Soiffer, R.
Avigan, D.
Rosenblatt, J.
TI Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT
correlate with the development of chronic GVHD
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE Vitamin D; GVHD; hematopoietic SCT
ID BONE-MINERAL DENSITY; VITAMIN-D STATUS; VERSUS-HOST-DISEASE; LONG-TERM
SURVIVORS; 1,25-DIHYDROXYVITAMIN D-3; DENDRITIC CELLS;
MULTIPLE-SCLEROSIS; D DEFICIENCY; MARROW TRANSPLANTATION;
LIVER-TRANSPLANTATION
AB Vitamin D, a hormone involved in bone and calcium homeostasis, has been shown to have potent immunomodulatory effects. We performed a retrospective cohort analysis to evaluate whether monohydroxyvitamin D levels before allogeneic hematopoietic SCT (HSCT) correlate with the risk of GVHD. Fifty-three patients who underwent myeloablative HSCT were studied. Vitamin D levels were measured in serum samples obtained before HSCT. The median 25-hydroxyvitamin vitamin D level was 21.9 ng/mL (7.8-45.7). The cumulative incidence (CI) of grades II-IV acute GVHD at 100 days was 53.1% in patients with vitamin D<25, versus 33.3% in patients with vitamin D >= 25 ng/mL (P=0.13). The CI of chronic GVHD (cGVHD) at 2 years in patients with vitamin D<25 was 63.8%, compared with 23.8% in patients with vitamin D >= 25 ng/mL (P=0.009). Similarly, the 2 year CI of extensive cGVHD was significantly greater in patients with vitamin D<25 compared with those with vitamin D >= 25 ng/mL (54.5% versus 14.3%, P=0.005). In a multivariable competing risk model, low pre-transplant vitamin D levels remained a significant factor associated with cGVHD (hazard ratio=5.26, P=0.02). Our results demonstrate that vitamin D deficiency before HSCT is associated with an increased risk of cGVHD. Bone Marrow Transplantation (2013) 48, 593-597; doi: 10.1038/bmt.2012.177; published online 24 September 2012
C1 [Glotzbecker, B.; Ho, V. T.; Aldridge, J.; Kim, H. T.; Ritz, J.; Soiffer, R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Horowitz, G.] Beth Israel Deaconess Med Ctr, Dept Clin Chem, Boston, MA 02215 USA.
[Avigan, D.; Rosenblatt, J.] Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA 02215 USA.
RP Glotzbecker, B (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.
EM brett_glotzbecker@dfci.harvard.edu
OI Ritz, Jerome/0000-0001-5526-4669
FU Pasquarello Tissue Bank; NIH [CA142106, AI29530]
FX This work was supported in part by the Pasquarello Tissue Bank and NIH
grants CA142106 and AI29530.
NR 50
TC 8
Z9 9
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2013
VL 48
IS 4
BP 593
EP 597
DI 10.1038/bmt.2012.177
PG 5
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 118NP
UT WOS:000317032500019
PM 23000654
ER
PT J
AU Chen, YB
McDonough, S
Chen, H
Kennedy, J
Illiano, C
Attar, EC
Ballen, KK
Dey, BR
McAfee, SL
Jagasia, M
Soiffer, R
Spitzer, TR
Ritz, J
AF Chen, Y-B
McDonough, S.
Chen, H.
Kennedy, J.
Illiano, C.
Attar, E. C.
Ballen, K. K.
Dey, B. R.
McAfee, S. L.
Jagasia, M.
Soiffer, R.
Spitzer, T. R.
Ritz, J.
TI Expression of alpha 4 beta 7 integrin on memory CD8(+) T cells at the
presentation of acute intestinal GVHD
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE intestinal GVHD; alpha 4 beta 7 integrin; lymphocyte trafficking
ID VERSUS-HOST-DISEASE; L-SELECTIN; PEYERS PATCH; NATALIZUMAB; MIGRATION;
THERAPY; COLITIS; NAIVE; SITE
AB Acute intestinal GVHD remains a major source of morbidity after allogeneic hematopoietic cell transplantation (HCT). alpha 4 beta 7 integrin is a cell surface molecule that mediates lymphocyte trafficking to intestinal tissue. In this analysis, peripheral blood was collected at the time of presentation of symptoms of acute GVHD and before any treatment. In all, 45 samples were collected and divided into three groups on the basis of subsequent evaluation: intestinal GVHD (n = 15), skin GVHD (n = 20) and no GVHD (n = 10). Two patients developed intestinal GVHD after DLI. The no-GVHD group comprised 10 patients who presented with suspicious symptoms, but evaluation yielded other etiologies. Analysis by flow cytometry showed that intestinal GVHD patients had a significantly higher percentage of alpha 4 beta 7 integrin-expressing memory CD8(+) T cells (median 7.69%; lower and upper quartiles, 1.06% and 11.64%, respectively) compared with patients with skin GVHD (1.26%; 0.57% and 2.49%) and no GVHD (0.96%; 0.44% and 1.85%), P = 0.03. No differences were found in alpha 4 beta 7 expression in any CD4(+) T-cell subsets or naive CD8(+) T cells. This study adds to the evidence that alpha 4 beta 7 integrin is involved in lymphocyte trafficking in acute intestinal GVHD. Bone Marrow Transplantation (2013) 48, 598-603; doi: 10.1038/bmt.2012.191; published online 8 October 2012
C1 [Chen, Y-B; Kennedy, J.; Illiano, C.; Attar, E. C.; Ballen, K. K.; Dey, B. R.; McAfee, S. L.; Spitzer, T. R.; Ritz, J.] Massachusetts Gen Hosp, Dept Hematol & Oncol, Div Bone Marrow Transplantat, Boston, MA 02114 USA.
[McDonough, S.; Soiffer, R.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA.
[Chen, H.; Jagasia, M.] Vanderbilt Univ, Dept Biostat, Nashville, TN USA.
RP Chen, YB (reprint author), Massachusetts Gen Hosp, Dept Hematol & Oncol, Div Bone Marrow Transplantat, Cox 106,55 Fruit St, Boston, MA 02114 USA.
EM ychen6@partners.org
FU NIH [AI29530, HL070149]; Ted and Ellen Pasquarello Research Fund;
Wernick Family Fund for Cancer Care; Rogers Family Foundation; Leukemia
& Lymphoma Society; Millennium Pharmaceuticals, Inc.
FX This research was supported in part by NIH grants AI29530 and HL070149,
the Ted and Ellen Pasquarello Research Fund, the Wernick Family Fund for
Cancer Care, the Rogers Family Foundation and the Leukemia & Lymphoma
Society. This research was presented in abstract form at the American
Society for Bone Marrow Transplantation (ASBMT) Tandem Meetings in San
Diego, CA from 1 to 5 February 2012.; Dr Chen receives funding to
conduct clinical research from Millennium Pharmaceuticals, Inc. The
other authors declare no conflict of interest.
NR 25
TC 3
Z9 3
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2013
VL 48
IS 4
BP 598
EP 603
DI 10.1038/bmt.2012.191
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 118NP
UT WOS:000317032500020
PM 23042495
ER
PT J
AU Park, ER
Gareen, IF
Jain, A
Ostroff, JS
Duan, FH
Sicks, JD
Rakowski, W
Diefenbach, M
Rigotti, NA
AF Park, Elyse R.
Gareen, Ilana F.
Jain, Amanda
Ostroff, Jamie S.
Duan, Fenghai
Sicks, JoRean D.
Rakowski, William
Diefenbach, Michael
Rigotti, Nancy A.
TI Examining whether lung screening changes risk perceptions: National Lung
Screening Trial participants at 1-year follow-up
SO CANCER
LA English
DT Article
DE cancer; lung screening; risk perception; smoking
ID COMPUTED-TOMOGRAPHY; SMOKING-CESSATION; UNITED-STATES;
CIGARETTE-SMOKING; TEACHABLE MOMENT; CANCER-PATIENTS; PERCEIVED RISK;
BEHAVIOR; SMOKERS; BLAME
AB BACKGROUND: The National Lung Screening Trial (NLST) research team reported reduced lung cancer mortality among current and former smokers with a minimum 30 pack-year history who were screened with spiral computed tomography scans compared with chest x-rays. The objectives of the current study were to examine, at 1-year follow-up: 1) risk perceptions of lung cancer and smoking-related diseases and behavior change determinants, 2) whether changes in risk perceptions differed by baseline screening result; and 3) whether changes in risk perceptions affected smoking behavior. METHODS: A 25-item risk perception questionnaire was administered to a subset of participants at 8 American College of Radiology Imaging Network/NLST sites before initial and 1-year follow-up screens. Items assessed risk perceptions of lung cancer and smoking-related diseases, cognitive and emotional determinants of behavior change, and knowledge of smoking risks. RESULTS: Among 430 NLST participants (mean age, 61.0 years; 55.6% men; 91.9% white), half were current smokers at baseline. Overall, risk perceptions and associated cognitive and emotional determinants of behavior change did not change significantly from prescreen trial enrollment to 1-year follow-up and did not differ significantly by screening test result. Changes in risk perceptions were not associated with changes in smoking status (9.7% of participants quit, and 6.6% relapsed) at 1-year follow-up. CONCLUSIONS: Lung screening did not change participants' risk perceptions of lung cancer or smoking-related disease. A negative screening test, which was the most common screening result, did not appear to decrease risk perceptions nor provide false reassurance to smokers. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Park, Elyse R.; Rigotti, Nancy A.] Harvard Univ, Sch Med, Mongan Inst Hlth Policy, Boston, MA USA.
[Park, Elyse R.; Rigotti, Nancy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Tobacco Res & Treatment Ctr,Dept Med, Boston, MA USA.
[Park, Elyse R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Gareen, Ilana F.; Jain, Amanda; Duan, Fenghai; Sicks, JoRean D.] Brown Univ, Sch Med, Ctr Stat Sci, Providence, RI 02912 USA.
[Ostroff, Jamie S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Rakowski, William] Brown Univ, Dept Behav & Social Sci, Publ Hlth Program, Providence, RI 02912 USA.
[Diefenbach, Michael] Mt Sinai Sch Med, Dept Urol, New York, NY USA.
[Diefenbach, Michael] Mt Sinai Sch Med, Div Internal Med, New York, NY USA.
RP Park, ER (reprint author), Mongan Inst Hlth Policy, 50 Staniford St,Room 907, Boston, MA 02114 USA.
EM epark@partners.org
RI Gareen, Ilana/I-2816-2014; Duan, Fenghai/J-3709-2014;
OI Gareen, Ilana/0000-0002-0457-5595; Duan, Fenghai/0000-0002-5084-0070;
Ostroff, Jamie/0000-0003-2671-5680
FU American Cancer Society's Mentored Research Scholar Award
[MRSG-005-05-CPPB]; ACRIN/NLST Trial [U01 CA79778 S2]; NHLBI Midcareer
Investigator Award in Patient-Oriented Research [K24-HL04440]; Nabi
Biopharmaceuticals
FX This project was funded by a grant from the American Cancer Society's
Mentored Research Scholar Award (MRSG-005-05-CPPB), the ACRIN/NLST Trial
(U01 CA79778 S2), and a NHLBI Midcareer Investigator Award in
Patient-Oriented Research (#K24-HL04440).; Dr. Rigotti works as an
unpaid consultant for Pfizer and Alere Wellbeing. She previously
received funding from Nabi Biopharmaceuticals and royalties from work
published in UptoDate.
NR 35
TC 7
Z9 7
U1 0
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD APR 1
PY 2013
VL 119
IS 7
BP 1306
EP 1313
DI 10.1002/cncr.27925
PG 8
WC Oncology
SC Oncology
GA 115KU
UT WOS:000316811900004
PM 23280348
ER
PT J
AU Merkow, RP
Kmiecik, TE
Bentrem, DJ
Winchester, DP
Stewart, AK
Ko, CY
Bilimoria, KY
AF Merkow, Ryan P.
Kmiecik, Thomas E.
Bentrem, David J.
Winchester, David P.
Stewart, Andrew K.
Ko, Clifford Y.
Bilimoria, Karl Y.
TI Effect of including cancer-specific variables on models examining
short-term outcomes
SO CANCER
LA English
DT Article
DE colorectal cancer; outcomes; risk-adjustment; outcomes; American College
of Surgeons National Surgical Quality Improvement Program; National
Cancer Data Base; cancer stage; neoadjuvant therapy
ID SURGICAL QUALITY IMPROVEMENT; RISK PREDICTION MODELS; RECTAL-CANCER;
ABDOMINOPERINEAL RESECTION; PREOPERATIVE RADIOTHERAPY; SURGERY; SAFETY;
CARE; COMPLICATIONS; PROGRAM
AB BACKGROUND: The American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) generally has not collected cancer-specific variables. Because increasing numbers of studies are using ACS NSQIP data to study cancer surgery, the objectives of the current study were 1) to examine differences between existing ACS NSQIP variables and cancer registry variables, and 2) to determine whether the addition of cancer-specific variables improves modeling of short-term outcomes. METHODS: Data from patients in the ACS NSQIP and National Cancer Data Base (NCDB) who underwent colorectal resection for cancer were linked (2006-2008). By using regression methods, the relative importance of cancer staging and neoadjuvant therapy variables were assessed along with their effects on morbidity, serious morbidity, and mortality. RESULTS: From 146 hospitals, 11,405 patients were identified who underwent surgery for colorectal cancer (colon, 85%; rectum, 15%). The NCDB metastatic cancer variable and the ACS NSQIP disseminated cancer variables agreed marginally (Cohen kappa coefficient, 0.454). For mortality, only the ACS NSQIP disseminated cancer variable and the NCDB stage IV variable were identified as important predictors; whereas the variables stage I through III, tumor (T)-classification, and lymph node (N)-classification were not selected. Cancer stage variables were inconsistently important for serious morbidity (stage IV, T-classification), superficial surgical site infection (N-classification), venous thromboembolism (metastatic cancer), and pneumonia (T-classification). With respect to neoadjuvant therapy, ACS NSQIP and NCDB variables agreed moderately (kappa, 0.570) and predicted superficial surgical site infection, serious morbidity, and organ space surgical site infection. The model fit was similar regardless of the inclusion of stage and neoadjuvant therapy variables. CONCLUSIONS: Although advanced disease stage and neoadjuvant therapy variables were predictors of short-term outcomes, their inclusion did not improve the models. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Merkow, Ryan P.; Winchester, David P.; Stewart, Andrew K.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Merkow, Ryan P.; Kmiecik, Thomas E.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA.
[Merkow, Ryan P.; Kmiecik, Thomas E.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Northwestern Inst Comparat Effectiveness Res Onco, Chicago, IL 60611 USA.
[Merkow, Ryan P.] Univ Colorado Denver, Dept Surg, Aurora, CO USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 North St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM kbilimoria@facs.org
FU American Cancer Society; Agency for Healthcare Research and Quality;
Northwestern Institute for Comparative Effectiveness Research in
Oncology
FX This study was supported by the American Cancer Society, the Agency for
Healthcare Research and Quality, and the Northwestern Institute for
Comparative Effectiveness Research in Oncology.
NR 36
TC 14
Z9 14
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD APR 1
PY 2013
VL 119
IS 7
BP 1412
EP 1419
DI 10.1002/cncr.27891
PG 8
WC Oncology
SC Oncology
GA 115KU
UT WOS:000316811900018
PM 23184472
ER
PT J
AU Armstrong, EJ
Kwa, AT
Yeo, KK
Mahmud, E
Javed, U
Patel, M
Shunk, KA
MacGregor, JS
Low, RI
Rogers, JH
AF Armstrong, Ehrin J.
Kwa, Andrew T.
Yeo, Khung Keong
Mahmud, Ehtisham
Javed, Usman
Patel, Mitul
Shunk, Kendrick A.
MacGregor, John S.
Low, Reginald I.
Rogers, Jason H.
TI Angiographically confirmed stent thrombosis in contemporary practice:
Insights from intravascular ultrasound
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE stent thrombosis; intravascular ultrasound; acute coronary syndrome
(ACS); intravascular ultrasound (IVUS); thrombosis (THRM)
ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION;
DRUG-ELUTING STENTS; IMPLANTATION; PREDICTORS; MALAPPOSITION; FRACTURE;
IMPACT; DEPLOYMENT; OUTCOMES
AB Objective: We hypothesized that patients presenting with stent thrombosis (ST) have a high prevalence of stent underexpansion and malapposition when assessed by intravascular ultrasound (IVUS). Background: IVUS can provide mechanistic insight into mechanical factors, including stent underexpansion, malapposition, and fracture that may predispose to ST. Methods: All consecutive cases of angiographically confirmed ST from a multicenter registry (from 2005 to 2010) were reviewed. All IVUS images were reviewed off-line for the presence of stent underexpansion, malapposition, and fracture. KaplanMeier analysis was used to determine whether use of IVUS at the time of ST was associated with long-term mortality and major adverse cardiovascular events. Results: IVUS was performed in 32 of 173 subjects with ST (18%). Stent underexpansion was present in 82% of cases and in all cases of early ST, with a mean stent expansion of 0.7 +/- 0.23 by MUSIC criteria. Stent malapposition was most frequently observed in very late ST (40%). In-hospital mortality was similar between subjects who had IVUS performed at the time of ST when compared with the non-IVUS group (3.2% vs. 4.3%, P = 0.8). Subjects who had IVUS performed at the time of ST had lower rates of mortality (HR 0.4, 95% CI 0.1-1.6, P =0.2) and major adverse cardiovascular events (HR 0.5, 95% CI 0.21.4, P =0.2) at follow-up, but these values were not statistically significant. Conclusions: There is a high prevalence of stent underexpansion in early ST, while the prevalence of malapposition is higher in very late ST. Use of IVUS during treatment for ST may identify mechanisms underlying the development of ST. (c) 2012 Wiley Periodicals, Inc.
C1 [Armstrong, Ehrin J.; Kwa, Andrew T.; Yeo, Khung Keong; Javed, Usman; Low, Reginald I.; Rogers, Jason H.] Calif State Univ Sacramento, Davis Med Ctr, Sacramento, CA 95819 USA.
[Mahmud, Ehtisham; Patel, Mitul] Univ Calif San Diego, San Diego Med Ctr, San Diego, CA 92103 USA.
[Shunk, Kendrick A.] Univ Calif San Francisco, San Francisco Med Ctr, San Francisco, CA 94143 USA.
[Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[MacGregor, John S.] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
RP Rogers, JH (reprint author), 4860 Y St,Suite 2820, Sacramento, CA 95817 USA.
EM jason.rogers@ucdmc.ucdavis.edu
FU Boston Scientific; Abbott Vascular; Sanofi Aventis
FX Drs. Armstrong, Kwa, Javed, Patel, Shunk, and MacGregor have no
disclosures. Dr Low is on the advisory board of Abbott Vascular and
Boston Scientific. Dr Rogers is a consultant for Volcano, Medtronic,
Cordis, and Boston Scientific. Dr Mahmud is on the Speakers Bureau for
Medtronic and Eli Lilly; is a consultant for Eli Lilly; and has research
support from Boston Scientific, Abbott Vascular and Sanofi Aventis.
NR 31
TC 9
Z9 9
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD APR
PY 2013
VL 81
IS 5
BP 782
EP 790
DI 10.1002/ccd.24460
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 113TL
UT WOS:000316691300010
PM 22511567
ER
PT J
AU Chen, BB
Mallampalli, RK
AF Chen, Bill B.
Mallampalli, Rama K.
TI F-box protein substrate recognition A new insight
SO CELL CYCLE
LA English
DT Editorial Material
ID IDENTIFICATION; DEGRADATION; ARREST; FBXL2
C1 [Chen, Bill B.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Chen, BB (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.
EM chenb@upmc.edu; mallampallirk@upmc.edu
FU BLRD VA [I01 BX002200]; NHLBI NIH HHS [R01 HL098174, R01 HL116472, R01
HL096376]
NR 10
TC 5
Z9 5
U1 1
U2 5
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD APR 1
PY 2013
VL 12
IS 7
BP 1009
EP 1010
DI 10.4161/cc.23071
PG 2
WC Cell Biology
SC Cell Biology
GA 117HJ
UT WOS:000316943900001
PM 23255120
ER
PT J
AU Ghosh, SK
Pantazopoulos, P
Medarova, Z
Moore, A
AF Ghosh, Subrata K.
Pantazopoulos, Pamela
Medarova, Zdravka
Moore, Anna
TI Expression of Underglycosylated MUC1 Antigen in Cancerous and Adjacent
Normal Breast Tissues
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Cancer biomarker; Glucosylation; Malignant transformation; Sialation;
Tumor grade
ID GENE-EXPRESSION; CELL-LINES; TUMOR CHARACTERISTICS; CARCINOMA CELLS;
SERIAL ANALYSIS; EPISIALIN MUC1; OVARIAN-CANCER; LUNG-CANCER; THERAPY;
ADHESION
AB Underglycosylated mucin 1 antigen (uMUC1) is aberrantly expressed in breast cancer. Using tissue microarray (TMA) and fresh-frozen breast cancer tissues, we analyzed its expression and found changes associated with higher tumor grade. We also observed changes in tissues adjacent to tumor but identified as normal on pathology reports. These findings suggest that uMUC1 can indeed serve as an early diagnostic marker.
Introduction: Mucin 1 antigen (MUC1) is a high-molecular-weight transmembrane glycoprotein with an aberrant expression profile in various malignancies, including breast cancer. Its increased overexpression and underglycosylation in breast cancer is associated with tumor invasiveness and metastatic potential. In this study, we took the next step toward establishing MUC1 as a potential diagnostic, prognostic, and therapeutic target by investigating its expression and posttranslational modification (glycosylation/sialylation). Patients and Methods: In these studies we used a breast cancer tissue microarray (TMA) and fresh-frozen multistage breast cancer tissues. We analyzed in detail the expression of normal and underglycosylated/sialated MUC1 by immunohistochemical techniques, real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and various analytic techniques. Results: We found that changes in cellular localization as well as in upregulation and/or underglycosylation of MUC1 were associated with higher tumor grade. A key finding in this study was that underglycosylated MUC1 (uMUC1) overexpression and sialation were observed in tissues adjacent to tumor but identified as normal on pathology reports. Conclusions: These findings suggest that uMUC1 can indeed be used as an early diagnostic marker and provide additional insights into breast cancer management. Clinical Breast Cancer, Vol. 13, No. 2, 109-18 (C) 2013 Elsevier Inc. All rights reserved.
C1 [Ghosh, Subrata K.; Pantazopoulos, Pamela; Medarova, Zdravka; Moore, Anna] Harvard Univ, Sch Med, Dept Radiol,Massachusetts Gen Hosp, Mol Imaging Lab,MGH HST Athinoula A Martinos Ctr, Boston, MA 02115 USA.
RP Moore, A (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Imaging Lab,MGH MIT HMS Athinoula A Martinos, Bldg 75, Charlestown, MA 02129 USA.
EM zmedarova@partners.org; amoore@helix.mgh.harvard.edu
FU NIH [1RO1CA135650]
FX This study was supported in part by the NIH grant award 1RO1CA135650 to
A.M and Z.M.
NR 61
TC 13
Z9 15
U1 0
U2 12
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD APR
PY 2013
VL 13
IS 2
BP 109
EP 118
DI 10.1016/j.clbc.2012.09.016
PG 10
WC Oncology
SC Oncology
GA 115RK
UT WOS:000316829400005
PM 23122537
ER
PT J
AU Oxnard, GR
Janne, PA
AF Oxnard, Geoffrey R.
Jaenne, Pasi A.
TI Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor
Genotypes
SO CLINICAL CANCER RESEARCH
LA English
DT Editorial Material
ID CELL LUNG-CANCER; MUTATIONS; EGFR; GEFITINIB
AB Widespread tumor genotyping has increased the complexity of lung cancer care, often identifying mutations of uncertain clinical significance. In the accompanying article, the authors carried out a meta-analysis of the published literature on EGF receptor (EGFR) genotype and erlotinib/gefitinib sensitivity to develop a publicly accessible database to inform patient care. Clin Cancer Res; 19(7); 1634-6. (C) 2013 AACR.
C1 [Oxnard, Geoffrey R.; Jaenne, Pasi A.] Lowe Ctr Thorac Oncol, Boston, MA USA.
[Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA.
[Oxnard, Geoffrey R.; Jaenne, Pasi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Janne, PA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,HIM 223, Boston, MA 02215 USA.
EM pjanne@partners.org
FU NCI NIH HHS [P50 CA090578, P50CA090578, R01 CA114465, R01CA114465]
NR 12
TC 4
Z9 4
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2013
VL 19
IS 7
BP 1634
EP 1636
DI 10.1158/1078-0432.CCR-13-0169
PG 3
WC Oncology
SC Oncology
GA 118BH
UT WOS:000316996900002
PM 23403632
ER
PT J
AU Tothova, Z
Steensma, DP
Ebert, BL
AF Tothova, Zuzana
Steensma, David P.
Ebert, Benjamin L.
TI New Strategies in Myelodysplastic Syndromes: Application of Molecular
Diagnostics to Clinical Practice
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PROGNOSTIC SCORING SYSTEM; ACUTE MYELOID-LEUKEMIA; FLOW-CYTOMETRY;
WORKING CONFERENCE; EPIGENETIC CHANGES; POINT MUTATIONS; TET2 MUTATIONS;
GENE; FREQUENT; IMPACT
AB An increasingly complete compendium of recurrently mutated genes in myelodysplastic syndromes (MDS) has been defined, and the application of massively parallel sequencing to identify mutations in clinical practice now promises to improve the care of patients with this disease. More than 25 recurrent MDS-associated somatic mutations have been identified, involving biologic pathways as diverse as chromatin remodeling and pre-mRNA splicing. Several of these mutations have been shown to have prognostic implications that are independent of existing risk stratification systems based on clinical and pathologic parameters. Application of these recent discoveries to diagnosis, prognosis, risk stratification, and treatment selection for patients with MDS has the potential to improve patient outcomes. Here, we review recent advances in MDS and discuss potential applications of these discoveries to clinical practice. Clin Cancer Res; 19(7); 1637-43. (C) 2013 AACR.
C1 [Tothova, Zuzana; Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
[Tothova, Zuzana; Steensma, David P.; Ebert, Benjamin L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Ebert, BL (reprint author), Karp Family Res Labs, 5-211,1 Blackfan Circle, Boston, MA 02115 USA.
EM Benjamin_Ebert@dfci.harvard.edu
OI Steensma, David/0000-0001-5130-9284
FU NIH [R01 HL082945, P01 CA108631]; Leukemia and Lymphoma Society;
Burroughs-Wellcome Fund
FX This work was funded by the NIH (grants R01 HL082945 and P01 CA108631),
the Leukemia and Lymphoma Society, and the Burroughs-Wellcome Fund.
NR 49
TC 9
Z9 13
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2013
VL 19
IS 7
BP 1637
EP 1643
DI 10.1158/1078-0432.CCR-12-1251
PG 7
WC Oncology
SC Oncology
GA 118BH
UT WOS:000316996900003
PM 23329810
ER
PT J
AU Pinto, EM
Morton, C
Rodriguez-Galindo, C
McGregor, L
Davidoff, AM
Mercer, K
Debelenko, LV
Billups, C
Ribeiro, RC
Zambetti, GP
AF Pinto, Emilia M.
Morton, Christopher
Rodriguez-Galindo, Carlos
McGregor, Lisa
Davidoff, Andrew M.
Mercer, Kimberly
Debelenko, Larisa V.
Billups, Catherine
Ribeiro, Raul C.
Zambetti, Gerard P.
TI Establishment and Characterization of the First Pediatric Adrenocortical
Carcinoma Xenograft Model Identifies Topotecan as a Potential
Chemotherapeutic Agent
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PHASE-II; CANCER-PATIENTS; HIGH-RISK; ETOPOSIDE; CISPLATIN; TUMORS;
DOXORUBICIN; CHILDREN; MITOTANE; P53
AB Purpose: Pediatric adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy. Conventional chemotherapeutic agents have shown limited utility and are largely ineffective in treating children with advanced ACC. The lack of cell lines and animal models of pediatric ACC has hampered the development of new therapies. Here we report the establishment of the first pediatric ACC xenograft model and the characterization of its sensitivity to selected chemotherapeutic agents.
Experimental Design: A tumor from an 11-year-old boy with previously untreated ACC was established as a subcutaneous xenograft in immunocompromised CB17 scid(-/-) mice. The patient harbored a germline TP53 G245C mutation, and the primary tumor showed loss of heterozygosity with retention of the mutated TP53 allele. Histopathology, DNA fingerprinting, gene expression profiling, and biochemical analyses of the xenograft were conducted and compared with the primary tumor and normal adrenal cortex. The second endpoint was to assess the preliminary antitumor activity of selected chemotherapeutic agents.
Results: The xenograft maintained the histopathologic and molecular features of the primary tumor. Screening the xenograft for drug responsiveness showed that cisplatin had a potent antitumor effect. However, etoposide, doxorubicin, and a panel of other common cancer drugs had little or no antitumor activity, with the exception of topotecan, which was found to significantly inhibit tumor growth. Consistent with these preclinical findings, topotecan as a single agent in a child with relapsed ACC resulted in disease stabilization.
Conclusion: Our study established a novel TP53-associated pediatric ACC xenograft and identified topotecan as a potentially effective agent for treating children with this disease. Clin Cancer Res; 19(7); 1740-7. (C)2013 AACR.
C1 [Pinto, Emilia M.; Ribeiro, Raul C.] St Jude Childrens Res Hosp, Int Outreach Program, Memphis, TN 38105 USA.
[Pinto, Emilia M.; Zambetti, Gerard P.] St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA.
[Morton, Christopher; Davidoff, Andrew M.; Mercer, Kimberly] St Jude Childrens Res Hosp, Dept Surg, Memphis, TN 38105 USA.
[McGregor, Lisa; Ribeiro, Raul C.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
[Debelenko, Larisa V.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA.
[Billups, Catherine] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA.
[Rodriguez-Galindo, Carlos] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
RP Zambetti, GP (reprint author), St Jude Childrens Res Hosp, Dept Biochem, 262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM gerard.zambetti@stjude.org
FU National Institutes of Health/National Cancer Institute [CA021765,
CA023099]; Johnson & Johnson Pharmaceutical Research and Development;
American Lebanese Syrian Associated Charities (ALSAC)
FX National Institutes of Health/National Cancer Institute (CA021765,
CA023099), Johnson & Johnson Pharmaceutical Research and Development,
and the American Lebanese Syrian Associated Charities (ALSAC).
NR 32
TC 7
Z9 7
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2013
VL 19
IS 7
BP 1740
EP 1747
DI 10.1158/1078-0432.CCR-12-3354
PG 8
WC Oncology
SC Oncology
GA 118BH
UT WOS:000316996900013
PM 23406775
ER
PT J
AU Holkova, B
Supko, JG
Ames, MM
Reid, JM
Shapiro, GI
Perkins, EB
Ramakrishnan, V
Tombes, MB
Honeycutt, C
McGovern, RM
Kmieciak, M
Shrader, E
Wellons, MD
Sankala, H
Doyle, A
Wright, J
Roberts, JD
Grant, S
AF Holkova, Beata
Supko, Jeffrey G.
Ames, Matthew M.
Reid, Joel M.
Shapiro, Geoffrey I.
Perkins, Edward Brent
Ramakrishnan, Viswanathan
Tombes, Mary Beth
Honeycutt, Connie
McGovern, Renee M.
Kmieciak, Maciej
Shrader, Ellen
Wellons, Martha D.
Sankala, Heidi
Doyle, Austin
Wright, John
Roberts, John D.
Grant, Steven
TI A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed,
Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with
Excess Blasts-2
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; DEPENDENT KINASE INHIBITOR; CHRONIC
LYMPHOCYTIC-LEUKEMIA; FLAVOPIRIDOL INDUCES APOPTOSIS; BREAST-CARCINOMA
CELLS; ACUTE MYELOID-LEUKEMIA; HYDROXAMIC ACID SAHA; DOWN-REGULATION;
TRANSCRIPTIONAL REPRESSION; MYELODYSPLASTIC SYNDROMES
AB Purpose: This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Secondary objectives included investigating the pharmacokinetic and pharmacodynamic effects of the combination.
Experimental Design: Patients received vorinostat (200mgorally, three times a day, for 14 days) on a 21-day cycle, combined with 2 different alvocidib administration schedules: a 1-hour intravenous infusion, daily x 5; or a 30-minute loading infusion followed by a 4-hour maintenance infusion, weekly x 2. The alvocidib dose was escalated using a standard 3+3 design.
Results: Twenty-eight patients were enrolled and treated. The alvocidib MTD was 20 mg/m(2) (30-minute loading infusion) followed by 20 mg/m(2) (4-hour maintenance infusion) on days one and eight, in combination with vorinostat. The most frequently encountered toxicities were cytopenias, fatigue, hyperglycemia, hypokalemia, hypophosphatemia, and QT prolongation. Dose-limiting toxicities (DLT) were cardiac arrhythmia-atrial fibrillation and QT prolongation. No objective responses were achieved although 13 of 26 evaluable patients exhibited stable disease. Alvocidib seemed to alter vorinostat pharmacokinetics, whereas alvocidib pharmacokinetics were unaffected by vorinostat. Ex vivo exposure of leukemia cells to plasma obtained from patients after alvocidib treatment blocked vorinostat-mediated p21(CIP1) induction and downregulated Mcl-1 and p-RNA Pol II for some specimens, although parallel in vivo bone marrow responses were infrequent.
Conclusions: Alvocidib combined with vorinostat is well tolerated. Although disease stabilization occurred in some heavily pretreated patients, objective responses were not obtained with these schedules. Clin Cancer Res; 19(7); 1873-83. (C)2013 AACR.
C1 [Holkova, Beata; Perkins, Edward Brent; Ramakrishnan, Viswanathan; Tombes, Mary Beth; Honeycutt, Connie; Kmieciak, Maciej; Shrader, Ellen; Wellons, Martha D.; Sankala, Heidi; Roberts, John D.; Grant, Steven] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA.
[Holkova, Beata; Perkins, Edward Brent; Roberts, John D.; Grant, Steven] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA.
[Ramakrishnan, Viswanathan] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA.
[Grant, Steven] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA.
[Grant, Steven] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA 23298 USA.
[Grant, Steven] Virginia Commonwealth Univ, Inst Mol Med, Richmond, VA 23298 USA.
[Supko, Jeffrey G.; Shapiro, Geoffrey I.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Ames, Matthew M.; Reid, Joel M.; McGovern, Renee M.] Mayo Clin, Ctr Comprehens Canc, Rochester, MN USA.
[Doyle, Austin; Wright, John] NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA.
RP Grant, S (reprint author), Virginia Commonwealth Univ, POB 980035,401 Coll St, Richmond, VA 23298 USA.
EM bholkova@mcvh-vcu.edu; stgrant@vcu.edu
FU NIH [R21 CA115260, R01 CA93738, P30 CA016059, M01RR00065, U01 CA69912,
23XS026, P30 CA15083, P30 CA60516]
FX This study was supported by NIH grants R21 CA115260, R01 CA93738, P30
CA016059, M01RR00065, U01 CA69912, 23XS026, P30 CA15083, and P30
CA60516.
NR 50
TC 12
Z9 13
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2013
VL 19
IS 7
BP 1873
EP 1883
DI 10.1158/1078-0432.CCR-12-2926
PG 11
WC Oncology
SC Oncology
GA 118BH
UT WOS:000316996900025
PM 23515411
ER
PT J
AU Rhee, CM
Alexander, EK
Bhan, I
Brunelli, SM
AF Rhee, Connie M.
Alexander, Erik K.
Bhan, Ishir
Brunelli, Steven M.
TI Hypothyroidism and Mortality among Dialysis Patients
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID SUBCLINICAL THYROID-DISEASE; CHRONIC KIDNEY-DISEASE; STAGE
RENAL-DISEASE; CORONARY-HEART-DISEASE; HEMODIALYSIS-PATIENTS; LOW
TRIIODOTHYRONINE; PERITONEAL-DIALYSIS; HORMONE METABOLISM; ARTERIAL
STIFFNESS; PREVALENCE
AB Background and objectives Hypothyroidism is highly prevalent among ESRD patients, but its clinical significance and the benefits of thyroid hormone replacement in this context remain unclear.
Design, setting, participants, & measurements This study examined the association between hypothyroidism and all-cause mortality among 2715 adult dialysis patients with baseline thyrotropin levels measured between April. of 2005 and April of 2011. Mortality was ascertained from Social Security Death Master Index and local registration systems. The association between hypothyroidism (thyrotropin greater than assay upper limit normal) and mortality was estimated using Cox proportional hazards models. To reduce the risk of observing reverse-causal associations, models included a 30-day lag between thyrotropin measurement and at-risk time.
Results Among 350 (12.9%) hypothyroid and 2365 (87.1%) euthyroid (assay within referent range) patients, 917 deaths were observed during 5352 patient-years of at-risk time. Hypothyroidism was associated with higher mortality. Compared with thyrotropin in the low-normal range (0.4-2.9 mIU/L), subclinical hypothyroidism (thyrotropin >upper limit normal and <= 10.0 mIU/L) was associated with higher mortality; high-normal thyrotropin (>= 3.0 mIU/L and <= upper limit normal) and overt hypothyroidism (thyrotropin >10.0 mIU/L) were associated with numerically greater risk, but estimates were not statistically significant. Compared with spontaneously euthyroid controls, patients who were euthyroid while on exogenous thyroid replacement were not at higher mortality risk, whereas patients who were hypothyroid were at higher mortality risk. Sensitivity analyses indicated that effects on cardiovascular risk factors may mediate the observed association between hypothyroidism and death.
Conclusions These data suggest that hypothyroidism is associated with higher mortality in dialysis patients, which may be ameliorated by thyroid hormone replacement therapy. Clin J Am Soc Nephrol 8: 593-601, 2013. doi: 10.2215/CJN.06920712
C1 [Rhee, Connie M.; Brunelli, Steven M.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA.
[Alexander, Erik K.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA.
[Brunelli, Steven M.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02115 USA.
[Rhee, Connie M.; Alexander, Erik K.; Bhan, Ishir; Brunelli, Steven M.] Harvard Univ, Sch Med, Boston, MA USA.
[Bhan, Ishir] Massachusetts Gen Hosp, Dept Med, Div Renal, Boston, MA 02114 USA.
RP Brunelli, SM (reprint author), Brigham & Womens Hosp, 75 Francis St,MRB 4, Boston, MA 02115 USA.
EM sbrunelli@partners.org
FU National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases Grants [DK007527-26, DK093201, DK079056];
Veracyte, Inc.; Asuragen, Inc
FX This work was supported by National Institutes of Health/National
Institute of Diabetes and Digestive and Kidney Diseases Grants
DK007527-26 (to C.M.R.), DK093201 (to C.M.R.), and DK079056 (to
S.M.B.).; E.K.A. receives research support from Veracyte, Inc. and
Asuragen, Inc. Since completing work on this study, S.M.B. has become a
full-time employee of DaVita Clinical Research. None of the other
authors declare any relevant conflicts of interest.
NR 49
TC 17
Z9 20
U1 0
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD APR
PY 2013
VL 8
IS 4
BP 593
EP 601
DI 10.2215/CJN.06920712
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 118KB
UT WOS:000317023300014
PM 23258793
ER
PT J
AU Palevsky, PM
AF Palevsky, Paul M.
TI Introduction: Perspectives on Integrated Nephrology Care
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
C1 [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA.
RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Mail Stop 111 F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD APR
PY 2013
VL 8
IS 4
BP 681
EP 681
DI 10.2215/CJN.00230113
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 118KB
UT WOS:000317023300024
PM 23564886
ER
PT J
AU Ginat, DT
Kelly, HR
Schaefer, PW
Davidson, CJ
Curry, W
AF Ginat, Daniel T.
Kelly, Hillary R.
Schaefer, Pamela W.
Davidson, Christian J.
Curry, William
TI Recurrent scalp metastasis from glioblastoma following resection
SO CLINICAL NEUROLOGY AND NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Metastasis; Recurrence; Scalp; MRI
ID MULTIFORME
C1 [Ginat, Daniel T.; Kelly, Hillary R.; Schaefer, Pamela W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Davidson, Christian J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Curry, William] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Ginat, DT (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM ginatd01@gmail.com
NR 5
TC 5
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0303-8467
J9 CLIN NEUROL NEUROSUR
JI Clin. Neurol. Neurosurg.
PD APR
PY 2013
VL 115
IS 4
BP 461
EP 463
DI 10.1016/j.clineuro.2012.05.038
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 117TN
UT WOS:000316976100015
PM 22727368
ER
PT J
AU Benes, CH
AF Benes, C. H.
TI Functionalizing Genomic Data for Personalization of Medicine
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID ANAPLASTIC LYMPHOMA KINASE; DRUG-SENSITIVITY; CANCER
AB The wealth of genomic information currently available to researchers and clinicians has dramatically changed the way some diseases are defined. However, leveraging this information is a major challenge, in part because previously established concepts and tools used for research and development are largely inadequate. Using the example of cancer genomics, this article focuses on systems-biology approaches to inform the development of personalized medicine.
C1 Massachusetts Gen Hosp, Ctr Canc, Ctr Mol Therapeut, Charlestown, MA USA.
RP Benes, CH (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Mol Therapeut, Charlestown, MA USA.
EM cbenes@partners.org
FU Wellcome Trust [086357]; National Institutes of Health [1U54
HG006097-01]
FX This study was supported by Wellcome Trust grant 086357 and National
Institutes of Health grant 1U54 HG006097-01.
NR 5
TC 3
Z9 3
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD APR
PY 2013
VL 93
IS 4
BP 309
EP 311
DI 10.1038/clpt.2012.219
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 115YI
UT WOS:000316847400009
PM 23321554
ER
PT J
AU Horner, MD
Mintzer, JE
Turner, TH
Edmiston, KR
Brawman-Mintzer, O
AF Horner, Michael David
Mintzer, Jacobo E.
Turner, Travis H.
Edmiston, Keith R.
Brawman-Mintzer, Olga
TI Attentional functioning in patients with posttraumatic stress disorder:
a preliminary study
SO CNS SPECTRUMS
LA English
DT Article
DE PTSD; neuropsychology; attention; cognition
ID INTIMATE PARTNER VIOLENCE; COMBAT VETERANS; MEMORY FUNCTION; PTSD;
SYMPTOMS; SURVIVORS; DEFICITS; WAR
AB Objective. To compare patients with posttraumatic stress disorder (PTSD) to patients without psychiatric or cognitive disorders on neuropsychological measures of attention.
Methods. The sample included 19 patients with PTSD and 22 participants with no cognitive or psychiatric diagnosis. All had been referred for clinical neuropsychological evaluation at a VA Medical Center. None were diagnosed with dementia, delirium, or current substance dependence except nicotine or caffeine, and none had a history of stroke or of traumatic brain injury with loss of consciousness. Patients were excluded if they failed to exert adequate effort on testing.
Results. PTSD patients performed significantly more poorly than patients without psychiatric diagnoses on Digit Span.
Conclusion. PTSD patients were impaired relative to participants without psychiatric diagnoses on a measure of focused attention. Several factors, including the small sample size, suggest that the results should be considered preliminary.
C1 [Horner, Michael David; Mintzer, Jacobo E.; Turner, Travis H.; Brawman-Mintzer, Olga] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
[Horner, Michael David; Mintzer, Jacobo E.; Turner, Travis H.; Brawman-Mintzer, Olga] Med Univ S Carolina, Charleston, SC 29425 USA.
[Edmiston, Keith R.] Coll Charleston, Charleston, SC 29401 USA.
RP Horner, MD (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM hornermd@musc.edu
RI Kilic, Cengiz/I-9145-2013
FU Department of Veterans Affairs; Pfizer; NIH/NIA; Genentech; University
of San Diego; Novartis, Inc.; Janssen; Wyeth, Inc.; Lilly Research Labs;
Eli Lilly Company; CSP [545]; Elan Pharmaceuticals; BioPharma Connex;
Takeda; Shire; Novartis
FX This study was supported in part by the Department of Veterans Affairs.;
Jacobo Mintzer has the following disclosures: Pfizer: research support
(grant); NIH/NIA: research support (grant); Genentech: research support
(grant); University of San Diego: research support (grant); Novartis,
Inc.: research support (grant); Janssen: research support (grant);
Wyeth, Inc.: research support (grant); Lilly Research Labs: research
support (grant); Eli Lilly & Company: research support (grant); CSP
#545: research support (grant); Elan Pharmaceuticals: research support
(grant); BioPharma Connex: founder and chair (salary); NeuroQuest:
consultant. Olga Brawman-Mintzer has the following disclosures: Takeda:
research support (grant); Shire: research support (grant); Novartis:
research support (grant). The remaining authors have nothing to
disclose.
NR 30
TC 4
Z9 4
U1 0
U2 14
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1092-8529
J9 CNS SPECTRUMS
JI CNS Spectr.
PD APR
PY 2013
VL 18
IS 2
BP 90
EP 94
DI 10.1017/S1092852912000909
PG 5
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 119WO
UT WOS:000317130200006
PM 23298713
ER
PT J
AU Delahanty, DL
Gabert-Quillen, C
Ostrowski, SA
Nugent, NR
Fischer, B
Morris, A
Pitman, RK
Bon, J
Fallon, W
AF Delahanty, Douglas L.
Gabert-Quillen, Crystal
Ostrowski, Sarah A.
Nugent, Nicole R.
Fischer, Beth
Morris, Adam
Pitman, Roger K.
Bon, John
Fallon, William, Jr.
TI The efficacy of initial hydrocortisone administration at preventing
posttraumatic distress in adult trauma patients: a randomized trial
SO CNS SPECTRUMS
LA English
DT Article
ID QUALITY-OF-LIFE; GLUCOCORTICOID-INDUCED IMPAIRMENT; MOTOR-VEHICLE
ACCIDENTS; STRESS-DISORDER; DECLARATIVE MEMORY; PERITRAUMATIC
DISSOCIATION; MAJOR DEPRESSION; SEPTIC SHOCK; PTSD; VICTIMS
AB Objective/Introduction. Secondary pharmacological interventions have shown promise at reducing the development of posttraumatic stress disorder symptoms (PTSS) in preclinical studies. The present study examined the preliminary efficacy of a 10-day low-dose (20 mg bid) course of hydrocortisone at preventing PTSS in traumatic injury victims.
Methods. Sixty-four traumatic injury patients (34% female) were randomly assigned in a double-blind protocol to receive either a 10-day course of hydrocortisone or placebo initiated within 12 hours of the trauma. One-month and 3-months posttrauma participants completed an interview to assess PTSS and self-report measures of depression and health-related quality of life.
Results. Hydrocortisone recipients reported fewer PTSD and depression symptoms, and had greater improvements in health-related quality of life during the first 3 months posttrauma than did placebo recipients. Hydrocortisone recipients who had never received prior mental health treatment had the lowest PTSD scores.
Conclusion. Low-dose hydrocortisone may be a promising approach to the prevention of PTSD in acutely injured trauma patients, and may be particularly efficacious in acutely injured trauma victims without a history of significant psychopathology.
C1 [Delahanty, Douglas L.; Gabert-Quillen, Crystal; Morris, Adam] Kent State Univ, Dept Psychol, Kent, OH 44242 USA.
[Ostrowski, Sarah A.] Akron Childrens Hosp, NeuroDev Sci Ctr, Akron, OH USA.
[Nugent, Nicole R.] RIH Bradley Hasbro Childrens Res Ctr, Alpert Brown Med Sch, Providence, RI USA.
[Fischer, Beth] Ctr Family Safety & Healing, Columbus, OH USA.
[Pitman, Roger K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Bon, John] Summa Hlth Syst, Dept Pharm, Akron, OH USA.
[Delahanty, Douglas L.; Fallon, William, Jr.] Dept Trauma Serv, Akron, OH USA.
RP Delahanty, DL (reprint author), Kent State Univ, Dept Psychol, 144 Kent Hall, Kent, OH 44242 USA.
EM ddelahan@kent.edu
FU National Institute of Mental Health [R34 MH73014]; Ohio Board of Regents
FX Funding for this study was provided by the National Institute of Mental
Health (R34 MH73014) and the Ohio Board of Regents.
NR 55
TC 28
Z9 29
U1 5
U2 15
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1092-8529
EI 2165-6509
J9 CNS SPECTRUMS
JI CNS Spectr.
PD APR
PY 2013
VL 18
IS 2
BP 103
EP 111
DI 10.1017/S1092852913000096
PG 9
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 119WO
UT WOS:000317130200008
PM 23557627
ER
PT J
AU Mayaud, L
Lai, PS
Clifford, GD
Tarassenko, L
Celi, LA
Annane, D
AF Mayaud, Louis
Lai, Peggy S.
Clifford, Gari D.
Tarassenko, Lionel
Celi, Leo Anthony
Annane, Djillali
TI Dynamic Data During Hypotensive Episode Improves Mortality Predictions
Among Patients With Sepsis and Hypotension
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE data mining; hospital mortality; physiologic reserve; sepsis; Severity
of Illness Index
ID INTENSIVE-CARE-UNIT; SEPTIC SHOCK; HOSPITAL MORTALITY; CRITICALLY-ILL;
PROGNOSTIC MODEL; SCORING SYSTEMS; ROC CURVE; THERAPY; INDEX; ICU
AB Objectives: To determine if a prediction rule for hospital mortality using dynamic variables in response to treatment of hypotension in patients with sepsis performs better than current models.
Design: Retrospective cohort study.
Setting: All ICUs at a tertiary care hospital.
Patients: Adult patients admitted to ICUs between 2001 and 2007 of whom 2,113 met inclusion criteria and had sufficient data.
Interventions: None.
Measurements and Main Results: We developed a prediction algorithm for hospital mortality in patients with sepsis and hypotension requiring medical intervention using data from the Multiparameter Intelligent Monitoring in Intensive Care II. We extracted 189 candidate variables, including treatments, physiologic variables and laboratory values collected before, during, and after a hypotensive episode. Thirty predictors were identified using a genetic algorithm on a training set (n = 1500) and validated with a logistic regression model on an independent validation set (n = 613). The final prediction algorithm used included dynamic information and had good discrimination (area under the receiver operating curve = 82.0%) and calibration (Hosmer-Lemeshow C statistic = 10.43, p = 0.06). This model was compared with Acute Physiology and Chronic Health Evaluation IV using reclassification indices and was found to be superior with an Net Reclassification Improvement of 0.19 (p < 0.001) and an Integrated Discrimination Improvement of 0.09 (p < 0.001).
Conclusions: Hospital mortality predictions based on dynamic variables surrounding a hypotensive event is a new approach to predicting prognosis. A model using these variables has good discrimination and calibration and offers additional predictive prognostic information beyond established ones. (Crit Care Med 2013; 41: 954-962)
C1 [Mayaud, Louis; Clifford, Gari D.; Tarassenko, Lionel] Univ Oxford, Inst Biomed Engn, Oxford OX3 7DQ, England.
[Mayaud, Louis] Ctr Invest Clin & Innovat Technol, INSERM, Garches, France.
[Mayaud, Louis] Univ Versailles St Quentin, Hop Raymond Poincare, APHP, Intens Care Unit, Garches, France.
[Mayaud, Louis] Univ Versailles St Quentin, Versailles, France.
[Annane, Djillali] Paris Hosp Trust, Raymond Poincare Hosp, APHP, Intens Care Unit, Paris, France.
[Lai, Peggy S.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Celi, Leo Anthony] Harvard Massachusetts Inst Technol, Lab Computat Physiol Hlth Sci & Technol, Cambridge, MA USA.
[Celi, Leo Anthony] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA.
RP Mayaud, L (reprint author), Univ Oxford, Dept Engn Sci, Inst Biomed Engn IBME, ORCRB,Roosevelt Dr, Oxford OX3 7DQ, England.
EM louis.mayaud@eng.ox.ac.uk
FU RCUK Digital Economy Programme (Centre for Doctoral Training in
Healthcare Innovation) [EP/G036861/1]; National Institute of Health
(NIH); National Institute of Biomedical Imaging and Bioengineering
(NIBIB) [2R01 EB001659]
FX Supported, in part, by the RCUK Digital Economy Programme (Centre for
Doctoral Training in Healthcare Innovation) grant (EP/G036861/1) to L.
M. The National Institute of Health (NIH) and its National Institute of
Biomedical Imaging and Bioengineering (NIBIB) under grant (2R01
EB001659) funded the MIMIC II database.
NR 49
TC 9
Z9 10
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD APR
PY 2013
VL 41
IS 4
BP 954
EP 962
DI 10.1097/CCM.0b013e3182772adb
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA 114HN
UT WOS:000316731800013
PM 23385106
ER
PT J
AU Melo, MFV
Bates, JHT
AF Melo, Marcos F. Vidal
Bates, Jason H. T.
TI Pleural Effusion in Acute Respiratory Distress Syndrome: Water, Water,
Everywhere, Nor Any Drop to Drain
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
DE acute lung injury; acute respiratory distress syndrome; computed
tomography; lung imaging; pleural effusion; respiratory physiology
ID END-EXPIRATORY PRESSURE; MECHANICS; DOGS
C1 [Melo, Marcos F. Vidal] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Bates, Jason H. T.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
[Bates, Jason H. T.] Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA.
RP Melo, MFV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
NR 8
TC 0
Z9 0
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD APR
PY 2013
VL 41
IS 4
BP 1133
EP 1134
DI 10.1097/CCM.0b013e31827c02cb
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 114HN
UT WOS:000316731800031
PM 23528756
ER
PT J
AU Higgins, MJ
Liedke, PER
Goss, PE
AF Higgins, Michaela J.
Liedke, Pedro E. R.
Goss, Paul E.
TI Extended adjuvant endocrine therapy in hormone dependent breast cancer:
The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Review
DE Extended adjuvant endocrine therapy; MA.17
ID CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; 2-GENE EXPRESSION
RATIO; MOLECULAR GRADE INDEX; TO-TREAT ANALYSIS; QUALITY-OF-LIFE;
POSTMENOPAUSAL WOMEN; TAMOXIFEN THERAPY; RANDOMIZED-TRIAL;
COST-EFFECTIVENESS
AB Early hormone-receptor-positive breast cancer is a chronic relapsing disease that can remain clinically silent for many years. The NCIC-CTG MA.17/BIG 1-97 trial randomized disease-free early breast cancer patients who had received five years of adjuvant tamoxifen to either letrozole or placebo and was the first to demonstrate a benefit with extended endocrine therapy. MA.17/BIG 1-97 was stopped at the first interim analysis because disease free survival was strongly prolonged in the letrozole arm. Subsequent subset analyses and longer follow up have shown that this therapy improved survival across all groups, particularly among women with node-positive disease and those that were pre-menopausal at time of study enrolment. The MA.17/BIG 1-97 study should be considered a paradigm for extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Higgins, Michaela J.; Liedke, Pedro E. R.; Goss, Paul E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA.
[Liedke, Pedro E. R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
RP Goss, PE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,Lawrence House 302, Boston, MA 02114 USA.
EM pgoss@partners.org
NR 58
TC 13
Z9 13
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD APR
PY 2013
VL 86
IS 1
BP 23
EP 32
DI 10.1016/j.critrevonc.2012.09.013
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA 118MD
UT WOS:000317028700003
PM 23116626
ER
PT J
AU Krmpotich, TD
Tregellas, JR
Thompson, LL
Banich, MT
Klenk, AM
Tanabe, JL
AF Krmpotich, Theodore D.
Tregellas, Jason R.
Thompson, Laetitia L.
Banich, Marie T.
Klenk, Amanda M.
Tanabe, Jody L.
TI Resting-state activity in the left executive control network is
associated with behavioral approach and is increased in substance
dependence
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Substance dependence; Approach; Avoidance; Resting-state; Executive
control network; Laterality
ID INTRINSIC CONNECTIVITY NETWORKS; DEFAULT-MODE; FUNCTIONAL CONNECTIVITY;
ACTIVATION SYSTEMS; INHIBITION SYSTEM; HEALTHY-SUBJECTS;
DECISION-MAKING; USE DISORDERS; ADDICTION; REWARD
AB Background: Individuals with drug addictions report increased willingness to approach rewards. Approach behaviors are thought to involve executive control processes and are more strongly represented in the left compared to right prefrontal cortex. A direct link between approach tendencies and left hemisphere activity has not been shown in the resting brain. We hypothesized that compared to controls, substance dependent individuals (SDI) would have greater left hemisphere activity in the left executive control network (ECN) at rest.
Methods: Twenty-five SDI and 25 controls completed a Behavioral Inhibition System/Behavioral Activation System (BIS/BAS) questionnaire and underwent a resting-state fMRI scan. Group independent component analysis was performed. We used template matching to identify the left and right ECN separately and compared the corresponding components across groups. Across group, BAS scores were correlated with signal fluctuations in the left ECN and BIS scores with right ECN.
Results: BAS scores were higher in SDI compared to controls (p < .003) and correlated with signal fluctuation in the left ECN. SDI showed significantly more activity than controls in the left prefrontal cortex of the left ECN. Conversely, SDI showed less activity than controls in the right prefrontal cortex of the right ECN.
Conclusions: Results from this study suggest that approach tendencies are related to the left ECN, even during rest. Higher resting-state signal in the left ECN may play a role in heightened approach tendencies that contribute to drug-seeking behavior. Published by Elsevier Ireland Ltd.
C1 [Krmpotich, Theodore D.; Klenk, Amanda M.; Tanabe, Jody L.] Univ Colorado Denver, Dept Radiol, Denver, CO USA.
[Tregellas, Jason R.; Thompson, Laetitia L.; Banich, Marie T.; Tanabe, Jody L.] Univ Colorado Denver, Dept Psychiat, Denver, CO USA.
[Banich, Marie T.] Univ Colorado Boulder, Inst Cognit Sci, Boulder, CO USA.
[Tregellas, Jason R.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO USA.
RP Tanabe, JL (reprint author), 12700 E 17th Ave,C278, Aurora, CO 80045 USA.
EM Jody.Tanabe@ucdenver.edu
RI Tregellas, Jason/J-3637-2015
FU NIDA [R01 DA024104, DA027748]
FX Funding for this study was provided by NIDA grants R01 DA024104 and
DA027748; NIDA had no further role in study design; in the collection,
analysis and interpretation of data; in the writing of the report; or in
the decision to submit the paper for publication.
NR 45
TC 15
Z9 16
U1 0
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2013
VL 129
IS 1-2
BP 1
EP 7
DI 10.1016/j.drugalcdep.2013.01.021
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 115QS
UT WOS:000316827600001
PM 23428318
ER
PT J
AU Shen, XYY
Kosten, TA
Lopez, AY
Kinsey, BM
Kosten, TR
Orson, FM
AF Shen, Xiaoyun Y.
Kosten, Therese A.
Lopez, Angel Y.
Kinsey, Berma M.
Kosten, Thomas R.
Orson, Frank M.
TI A vaccine against methamphetamine attenuates its behavioral effects in
mice
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Conjugate vaccine; Keyhole limpet hemocyanin; Monophosphoryl lipid A;
Serum antibody titers; Locomotor activity; Conditioned place preference
ID CONDITIONED PLACE PREFERENCE; ACTIVE IMMUNIZATION;
MONOCLONAL-ANTIBODIES; COCAINE; RATS; AMPHETAMINE; (+)-METHAMPHETAMINE;
NICOTINE; IMMUNOGENICITY; NEUROTOXICITY
AB Background: Vaccines have treatment potential for methamphetamine (MA) addiction. We tested whether a conjugate vaccine against MA (succinyl-methamphetamine-keyhole limpet hemocyanin carrier protein; SMA-KLH) would generate MA antibodies and alter MA-induced behaviors.
Methods: Mice were injected with SMA-KLH and received booster administrations 3 and 20 weeks later. Serum antibody titers reached peak levels by 4-6 weeks, remained at a modest level through 18 weeks, peaked again at 22 weeks after the second boost, and were still elevated at 35 weeks. At 7 weeks, groups of vaccinated and non-vaccinated mice were administered one of three MA doses (1, 2 or 3 mg/kg) to assess locomotor activity.
Results: Non-vaccinated mice showed dose-dependent effects of MA with hypolocomotion at the lowest dose and elevated activity levels at the highest dose. Both dose effects were reduced in SMA-KLH groups, particularly low dose-induced hypolocomotion at later times post MA administration. Separate groups of vaccinated and non-vaccinated mice were trained in MA place conditioning at 30 weeks with either 0 (vehicle) or 0.5 mg/kg MA. Although times spent in the MA-paired side did not differ between groups on test vs. baseline sessions, SMA-KLH mice conditioned with MA showed reduced conditioned approach behaviors and decreased conditioned activity levels compared to control groups.
Conclusion: These data suggest SMA-KLH attenuates the ability of MA to support place conditioning and reduces or delays its locomotor effects. Overall, results support SMA-KLH as a candidate MA vaccine. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Shen, Xiaoyun Y.; Lopez, Angel Y.; Kinsey, Berma M.; Orson, Frank M.] Michael E Debakey Vet Med Affairs Ctr, Dept Med, Houston, TX 77030 USA.
[Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Michael E Debakey Vet Med Affairs Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Kosten, TA (reprint author), Michael E Debakey VAMC, Res Serv Line 151, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM tkosten@bcm.edu
FU National Institute on Drug Abuse (NIDA) [DP1DA033502, U01023898]; NIH;
Department of Veterans Affairs
FX This research was supported by grants DP1DA033502 and U01023898 from The
National Institute on Drug Abuse (NIDA). NIDA had no further role in
study design; in the collection, analysis and interpretation of data; in
the writing of the report; or in the decision to submit the paper for
publication. Drs. T.A. Kosten, T.R. Kosten, and Orson have received
funding from the NIH and the Department of Veterans Affairs.
NR 41
TC 17
Z9 17
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2013
VL 129
IS 1-2
BP 41
EP 48
DI 10.1016/j.drugalcdep.2012.09.007
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 115QS
UT WOS:000316827600006
PM 23022610
ER
PT J
AU Kelly, JF
Stout, RL
Slaymaker, V
AF Kelly, John F.
Stout, Robert L.
Slaymaker, Valerie
TI Emerging adults' treatment outcomes in relation to 12-step mutual-help
attendance and active involvement
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcoholics Anonymous; Narcotics Anonymous; 12-Step; Young adults;
Emerging adults; Addiction treatment
ID LEEDS-DEPENDENCE-QUESTIONNAIRE; UNTREATED INDIVIDUALS; GROUP
PARTICIPATION; SUBSTANCE-ABUSE; BEHAVIOR-CHANGE; USE DISORDERS; ALCOHOL;
MECHANISMS; ASSOCIATION; ADOLESCENTS
AB Background: Participation in Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) during and following treatment has been found to confer recovery-related benefit among adults and adolescents, but little is known about emerging adults (18-24years). This transitional life-stage is distinctive for greater distress, higher density of psychopathology, and poorer treatment and continuing care compliance. Greater knowledge would inform the utility of treatment referrals to 12-step organizations for this age-group.
Methods: Emerging adults (N=303; 18-24years; 26% female; 95% White; 51% comorbid [SCID-derived] axis I disorders) enrolled in a naturalistic study of residential treatment effectiveness assessed at intake, 3,6, and 12 months on 12-step attendance and involvement and treatment outcomes (percent days abstinent [PDA]; percent days heavy drinking [PDHD]). Lagged hierarchical linear models (HLMs) tested whether attendance and involvement conferred recovery benefits, controlling for a variety of confounds.
Results: The percentage attending 12-step meetings prior to treatment (36%) rose sharply at 3 months (89%), was maintained at 6 months (82%), but declined at 12 months (76%). Average attendance peaked at about 3 times per week at 3 months dropping to just over once per week at 12 months. Initially high, but similarly diminishing, levels of active 12-step involvement were also observed. Lagged HLMs found beneficial effects for attendance, but stronger effects, which increased overtime, for active involvement. Several active 12-step involvement indices were associated individually with outcome benefits.
Conclusions: Ubiquitous 12-step organizations may provide a supportive recovery context for this high-risk population at a developmental stage where non-using/sober peers are at a premium. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Kelly, John F.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA.
[Kelly, John F.] Harvard Univ, Sch Med, Boston, MA USA.
[Stout, Robert L.] Decis Sci Inst Providence, Providence, RI USA.
[Slaymaker, Valerie] Hazelden Fdn, Ctr City, MN USA.
RP Kelly, JF (reprint author), MGH Ctr Addict Med, 60 Staniford St, Boston, MA 02114 USA.
EM jkelly11@partners.org
OI Stout, Robert/0000-0003-2596-241X
FU National Institute of Alcohol Abuse and Alcoholism [NIAAA
R21AA018185-01A2]
FX This research was supported by a grant from the National Institute of
Alcohol Abuse and Alcoholism (NIAAA R21AA018185-01A2; Mechanisms and
Moderators of Behavior Change among young adults treated for Alcohol use
disorder). NIAAA had no further role in study design; in the collection,
analysis and interpretation of data; in the writing of the report; or in
the decision to submit the paper for publication.
NR 62
TC 19
Z9 19
U1 3
U2 40
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2013
VL 129
IS 1-2
BP 151
EP 157
DI 10.1016/j.drugalcdep.2012.10.005
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 115QS
UT WOS:000316827600020
PM 23122600
ER
PT J
AU Mentz, RJ
Hernandez, AF
Stebbins, A
Ezekowitz, JA
Felker, GM
Heizer, GM
Atar, D
Teerlink, JR
Califf, RM
Massie, BM
Hasselblad, V
Starling, RC
O'Connor, CM
Ponikowski, P
AF Mentz, Robert J.
Hernandez, Adrian F.
Stebbins, Amanda
Ezekowitz, Justin A.
Felker, G. Michael
Heizer, Gretchen M.
Atar, Dan
Teerlink, John R.
Califf, Robert M.
Massie, Barry M.
Hasselblad, Vic
Starling, Randall C.
O'Connor, Christopher M.
Ponikowski, Piotr
TI Predictors of early dyspnoea relief in acute heart failure and the
association with 30-day outcomes: findings from ASCEND-HF
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Acute heart failure; Dyspnoea relief; Prognosis; Outcomes
ID EUROPEAN-SOCIETY; NESIRITIDE; NITROGLYCERIN; REGISTRY; PROTECT; UPDATE;
TRIAL
AB To examine the characteristics associated with early dyspnoea relief during acute heart failure (HF) hospitalization, and its association with 30-day outcomes.
ASCEND-HF was a randomized trial of nesiritide vs. placebo in 7141 patients hospitalized with acute HF in which dyspnoea relief at 6 h was measured on a 7-point Likert scale. Patients were classified as having early dyspnoea relief if they experienced moderate or marked dyspnoea improvement at 6 h. We analysed the clinical characteristics, geographical variation, and outcomes (mortality, mortality/HF hospitalization, and mortality/hospitalization at 30 days) associated with early dyspnoea relief. Early dyspnoea relief occurred in 2984 patients (43). In multivariable analyses, predictors of dyspnoea relief included older age and oedema on chest radiograph; higher systolic blood pressure, respiratory rate, and natriuretic peptide level; and lower serum blood urea nitrogen (BUN), sodium, and haemoglobin (model mean C index 0.590). Dyspnoea relief varied markedly across countries, with patients enrolled from Central Europe having the lowest risk-adjusted likelihood of improvement. Early dyspnoea relief was associated with lower risk-adjusted 30-day mortality/HF hospitalization [hazard ratio (HR) 0.81; 95 confidence interval (CI) 0.680.96] and mortality/hospitalization (HR 0.85; 95 CI 0.740.99), but similar mortality.
Clinical characteristics such as respiratory rate, pulmonary oedema, renal function, and natriuretic peptide levels are associated with early dyspnoea relief, and moderate or marked improvement in dyspnoea was associated with a lower risk for 30-day outcomes.
C1 [Mentz, Robert J.; Hernandez, Adrian F.; Felker, G. Michael; Califf, Robert M.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA.
[Hernandez, Adrian F.; Stebbins, Amanda; Felker, G. Michael; Heizer, Gretchen M.; Califf, Robert M.; Hasselblad, Vic; O'Connor, Christopher M.] Duke Clin Res Inst, Durham, NC 27715 USA.
[Ezekowitz, Justin A.] Univ Alberta, Edmonton, AB, Canada.
[Atar, Dan] Oslo Univ Hosp, Oslo, Norway.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Starling, Randall C.; Ponikowski, Piotr] Cleveland Clin, Cleveland, OH 44106 USA.
[Starling, Randall C.; Ponikowski, Piotr] Kardiol Klin, Wroclaw, Poland.
RP Hernandez, AF (reprint author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.
EM adrian.hernandez@duke.edu
RI Ezekowitz, Justin/C-4579-2013; Ponikowski, Piotr/O-6454-2015; Hernandez,
Adrian F./A-7818-2016
OI Ezekowitz, Justin/0000-0002-2724-4086; Ponikowski,
Piotr/0000-0002-3391-7064; Hernandez, Adrian F./0000-0003-3387-9616
FU Johnson and Johnson; Scios Inc.; Amgen; Bayer; Corthera; Cytokinetics;
Novartis; Trevena; Johnson Johnson; DCRI; Otsuka; Roche Diagnostics;
Merck; BG Medicine; NIH
FX Johnson and Johnson provided funding for the overall ASCEND-HF trial.;
J.R.T. has received research grants for his role as a Steering committee
member in ASCEND-HF from Scios Inc., the sponsor of this trial. He
received research support and/or consultation fees from Amgen, Bayer,
Corthera, Cytokinetics, Novartis, and Trevena. R. C. has received
research grants and consulting fees from Johnson & Johnson. All other
industry relations are publicly displayed at www.dcri.org/about-us. J.E.
is currently conducting research sponsored by Johnson & Johnson. B. M.
has received consulting fees/honoraria from DCRI. G. M. F. has received
consulting fees from Amgen, Trevena, Otsuka, Roche Diagnostics,
Novartis, Merck, and BG Medicine, and research funding from NIH, Amgen,
Otsuka, and Roche Diagnostics. P. P. has received fees in respect of
consultancy and speaker's bureau from Scios Inc., Corthera, Novartis,
Johnson & Johnson, and Bayer. All other authors declare no conflict of
interest.
NR 24
TC 18
Z9 18
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD APR
PY 2013
VL 15
IS 4
BP 456
EP 464
DI 10.1093/eurjhf/hfs188
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 117LR
UT WOS:000316955400014
PM 23159547
ER
PT J
AU Lauritzen, HPMM
AF Lauritzen, Hans P. M. M.
TI Insulin- and Contraction-Induced Glucose Transporter 4 Traffic in
Muscle: Insights From a Novel Imaging Approach
SO EXERCISE AND SPORT SCIENCES REVIEWS
LA English
DT Review
DE living mice; intravital; in vivo; PI3 kinase; AMP kinase; LKB1
ID RAT SKELETAL-MUSCLE; STIMULATED GLUCOSE-TRANSPORT; GLUT4 TRANSLOCATION;
LIVING MICE; TRANSVERSE TUBULES; T-TUBULES; IN-VIVO; PROTEIN; FIBERS;
AS160
AB LAURITZEN, H. P. M. M. Insulin- and contraction-induced glucose transporter 4 traffic in muscle: insights from a novel imaging approach. Exerc. Sport Sci. Rev., Vol. 41, No. 2, pp. 77-86, 2013. Insulin- and contraction-mediated glucose transporter 4 (GLUT4) trafficking have different kinetics in mature skeletal muscle. Intravital imaging indicates that insulin-stimulated GLUT4 trafficking differs between t-tubules and sarcolemma. In contrast, contraction-induced GLUT4 trafficking does not differ between membrane surfaces. This distinction likely is caused by differences in the underlying signaling pathways regulating GLUT4 vesicle depletion, GLUT4 membrane fusion, and GLUT4 reinternalization.
C1 Harvard Univ, Sch Med, Sect Integrat Physiol & Metab, Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Lauritzen, HPMM (reprint author), Harvard Univ, Sch Med, Sect Integrat Physiol & Metab, Joslin Diabet Ctr, Room 525, Boston, MA 02215 USA.
EM Hans.Lauritzen@joslin.harvard.edu
FU Weimann Foundation; DERC (Diabetes and Endocrinology Research Center) at
the Joslin Diabetes Center [P30DK036836]
FX This project was supported by funding from the Weimann Foundation and
the DERC (Diabetes and Endocrinology Research Center) P30DK036836 at the
Joslin Diabetes Center.
NR 40
TC 3
Z9 3
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0091-6331
J9 EXERC SPORT SCI REV
JI Exerc. Sport Sci. Rev.
PD APR
PY 2013
VL 41
IS 2
BP 77
EP 86
DI 10.1097/JES.0b013e318275574c
PG 10
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 114IA
UT WOS:000316733100003
PM 23072821
ER
PT J
AU Pistilli, EE
Quinn, LS
AF Pistilli, Emidio E.
Quinn, LeBris S.
TI From Anabolic to Oxidative: Reconsidering the Roles of IL-15 and IL-15R
alpha in Skeletal Muscle
SO EXERCISE AND SPORT SCIENCES REVIEWS
LA English
DT Review
DE cytokines; myokines; fatigue; oxidative muscle; atrophy; hypertrophy
ID TUMOR-BEARING RATS; INTERLEUKIN-15 RECEPTOR; CARBOHYDRATE INGESTION;
CYTOKINE; EXERCISE; PROTEIN; ALPHA; DIFFERENTIATION; EXPRESSION;
ELEVATION
AB PISTILLI, E. E. and L. S. QUINN. From anabolic to oxidative: reconsidering the roles of IL-15 and IL-15R alpha in skeletal muscle. Exerc. Sport Sci. Rev., Vol. 41, No. 2, pp. 100-106, 2013. Interleukin 15 (IL-15) and its receptor IL-15 receptor-alpha (IL-15R alpha) are suggested to function in the determination of skeletal muscle phenotypes, with IL-15 originally proposed as an anabolic cytokine. This review will focus on recent work demonstrating that manipulation of IL-15 and IL-15R alpha in vivo promotes changes in exercise capacity, muscle fatigue, and gene expression indicative of a more oxidative skeletal muscle phenotype.
C1 [Pistilli, Emidio E.] W Virginia Univ, Div Exercise Physiol, Sch Med, Morgantown, WV 26506 USA.
[Pistilli, Emidio E.] W Virginia Univ, Ctr Cardiovasc & Resp Sci, Sch Med, Morgantown, WV 26506 USA.
[Quinn, LeBris S.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Quinn, LeBris S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Pistilli, EE (reprint author), W Virginia Univ, Div Exercise Physiol, Sch Med, Morgantown, WV 26506 USA.
EM epistilli2@hsc.wvu.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[5T32AR053461]; Department of Veterans Affairs [BX001026]
FX This work was supported by a Ruth L. Kirschstein National Research
Service Award (5T32AR053461) from the National Institute of Arthritis
and Musculoskeletal and Skin Diseases (to E. E. Pistilli) and Merit
Review BX001026 from the Department of Veterans Affairs (to L. S.
Quinn), with resources from the VA Puget Sound Health Care System.
NR 35
TC 8
Z9 8
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0091-6331
J9 EXERC SPORT SCI REV
JI Exerc. Sport Sci. Rev.
PD APR
PY 2013
VL 41
IS 2
BP 100
EP 106
DI 10.1097/JES.0b013e318275d230
PG 7
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 114IA
UT WOS:000316733100006
PM 23072822
ER
PT J
AU Hartmann, M
Furrer, S
Herzog, MH
Merfeld, DM
Mast, FW
AF Hartmann, Matthias
Furrer, Sarah
Herzog, Michael H.
Merfeld, Daniel M.
Mast, Fred W.
TI Self-motion perception training: thresholds improve in the light but not
in the dark
SO EXPERIMENTAL BRAIN RESEARCH
LA English
DT Article
DE Self-motion thresholds; Whole-body motion; Perceptual learning;
Vestibular thresholds; Vestibular learning
ID QUALITATIVELY DIFFERENT MECHANISMS; HUMAN VESTIBULAR CORTEX;
EARTH-VERTICAL AXIS; WHOLE-BODY; VESTIBULOOCULAR REFLEX; CONTRAST
DISCRIMINATION; VELOCITY STORAGE; VISUAL-SYSTEM; ORIENTATION; ROTATION
AB We investigated perceptual learning in self-motion perception. Blindfolded participants were displaced leftward or rightward by means of a motion platform and asked to indicate the direction of motion. A total of eleven participants underwent 3,360 practice trials, distributed over twelve (Experiment 1) or 6 days (Experiment 2). We found no improvement in motion discrimination in both experiments. These results are surprising since perceptual learning has been demonstrated for visual, auditory, and somatosensory discrimination. Improvements in the same task were found when visual input was provided (Experiment 3). The multisensory nature of vestibular information is discussed as a possible explanation of the absence of perceptual learning in darkness.
C1 [Hartmann, Matthias; Furrer, Sarah; Mast, Fred W.] Univ Bern, Dept Psychol, CH-3000 Bern, Switzerland.
[Hartmann, Matthias; Mast, Fred W.] Univ Bern, Ctr Cognit Learning & Memory, CH-3000 Bern, Switzerland.
[Herzog, Michael H.] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Psychophys, Lausanne, Switzerland.
[Merfeld, Daniel M.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA.
[Merfeld, Daniel M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Hartmann, M (reprint author), Univ Bern, Dept Psychol, Muesmattstr 45, CH-3000 Bern, Switzerland.
EM matthias.hartmann@psy.unibe.ch
RI Hartmann, Matthias/D-8586-2014;
OI Herzog, Michael/0000-0001-5433-1030
FU Swiss National Science Foundation [PDFMP1_127238, CRSII1-125135/1]
FX This study was funded by the Swiss National Science Foundation (Pro*Doc
grant PDFMP1_127238 and Sinergia grant CRSII1-125135/1). We thank Cora
Bobst, Wilhelm Klatt, and Antje Stahnke for assistance in data
collection.
NR 79
TC 7
Z9 7
U1 2
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0014-4819
J9 EXP BRAIN RES
JI Exp. Brain Res.
PD APR
PY 2013
VL 226
IS 2
BP 231
EP 240
DI 10.1007/s00221-013-3428-1
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 115QA
UT WOS:000316825800008
PM 23392475
ER
PT J
AU Deepa, SS
Pulliam, D
Hill, S
Shi, Y
Walsh, ME
Salmon, A
Sloane, L
Zhang, N
Zeviani, M
Viscomi, C
Musi, N
Van Remmen, H
AF Deepa, Sathyaseelan S.
Pulliam, Daniel
Hill, Shauna
Shi, Yun
Walsh, Michael E.
Salmon, Adam
Sloane, Lauren
Zhang, Ning
Zeviani, Massimo
Viscomi, Carlo
Musi, Nicolas
Van Remmen, Holly
TI Improved insulin sensitivity associated with reduced mitochondrial
complex IV assembly and activity
SO FASEB JOURNAL
LA English
DT Article
DE fatty acid oxidation; PGC-1 alpha; longevity; Surf1
ID CYTOCHROME-C-OXIDASE; ACTIVATED RECEPTOR-ALPHA; FATTY-ACID OXIDATION;
ADIPOSE-TISSUE; LIFE-SPAN; GLUCOSE-METABOLISM; SKELETAL-MUSCLE;
GROWTH-HORMONE; KNOCKOUT MICE; UP-REGULATION
AB Mice lacking Surf1, a complex IV assembly protein, have similar to 50-70% reduction in cytochrome c oxidase activity in all tissues yet a paradoxical increase in lifespan. Here we report that Surf1(-/-) mice have lower body (15%) and fat (20%) mass, in association with reduced lipid storage, smaller adipocytes, and elevated indicators of fatty acid oxidation in white adipose tissue (WAT) compared with control mice. The respiratory quotient in the Surf1(-/-) mice was significantly lower than in the control animals (0.83-0.93 vs. 0.90-0.98), consistent with enhanced fat utilization in Surf1(-/-) mice. Elevated fat utilization was associated with increased insulin sensitivity measured as insulin-stimulated glucose uptake, as well as an increase in insulin receptor levels (similar to 2-fold) and glucose transporter type 4 (GLUT4; similar to 1.3-fold) levels in WAT in the Surf1(-/-) mice. The expression of peroxisome proliferator-activated receptor gamma-coactivator 1-alpha (PGC-1 alpha) mRNA and protein was up-regulated by 2.5- and 1.9-fold, respectively, in WAT from Surf1(-/-) mice, and the expression of PGC-1 alpha target genes and markers of mitochondrial biogenesis was elevated. Together, these findings point to a novel and unexpected link between reduced mitochondrial complex IV activity, enhanced insulin sensitivity, and increased mitochondrial biogenesis that may contribute to the increased longevity in the Surf1(-/-) mice.-Deepa, S. S., Pulliam, D., Hill, S., Shi, Y., Walsh, M. E., Salmon, A., Sloane, L., Zhang, N., Zeviani, M., Viscomi, C., Musi, N., Van Remmen, H. Improved insulin sensitivity associated with reduced mitochondrial complex IV assembly and activity. FASEB J. 27, 1371-1380 (2013). www.fasebj.org
C1 [Deepa, Sathyaseelan S.; Pulliam, Daniel; Hill, Shauna; Shi, Yun; Walsh, Michael E.; Salmon, Adam; Sloane, Lauren; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Deepa, Sathyaseelan S.; Pulliam, Daniel; Hill, Shauna; Walsh, Michael E.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Zhang, Ning; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78245 USA.
[Salmon, Adam; Musi, Nicolas; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Zeviani, Massimo; Viscomi, Carlo] Ist Ricovero & Cura Carattere Sci, Fdn Ist Neurol Carlo Besta, Unit Mol Neurogenet, Milan, Italy.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr,Mail Code 5566, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
RI Zeviani, Massimo/K-2891-2014; Viscomi, Carlo/R-1940-2016
FU Ellison Medical Foundation; Telethon grant [GPP10005]; Italian Ministry
of Health [GR2010-2306756]
FX The authors thank Yuhong Liu, Li Yan, Marian Sabia, Amanda Jernigan, and
Barbara Hunter for technical support. This work was supported by an
Ellison Medical Foundation Senior Scholar award to H. V. R. Telethon
grant GPP10005 to M.Z. and Italian Ministry of Health grant
GR2010-2306756 to C.V. are also acknowledged. The authors report no
conflicts of interest.
NR 47
TC 14
Z9 14
U1 0
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
IS 4
BP 1371
EP 1380
DI 10.1096/fj.12-221879
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 117GF
UT WOS:000316940800010
PM 23241310
ER
PT J
AU Oh, HC
Brugge, WR
AF Oh, Hyoung-Chul
Brugge, William R.
TI EUS-guided pancreatic cyst ablation: a critical review
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Review
ID SIMPLE RENAL CYSTS; HEPATIC CYSTS; ETHANOL INJECTION; PERCUTANEOUS
ASPIRATION; ALCOHOL SCLEROTHERAPY; SINGLE INSTITUTION; PORCINE PANCREAS;
THYROID CYSTS; FOLLOW-UP; LESIONS
C1 [Oh, Hyoung-Chul] Chung Ang Univ, Coll Med, Div Gastroenterol, Seoul 156756, South Korea.
[Brugge, William R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
RP Brugge, WR (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Blake 452C,55 Fruit St, Boston, MA 02114 USA.
FU ASGE Cook Medical Don Wilson Award
FX The authors disclosed no financial relationships relevant to this
publication. Dr Oh was supported by the 2012 ASGE Cook Medical Don
Wilson Award.
NR 47
TC 16
Z9 18
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
EI 1097-6779
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD APR
PY 2013
VL 77
IS 4
BP 526
EP 533
DI 10.1016/j.gie.2012.10.033
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 115CP
UT WOS:000316790300002
PM 23321339
ER
PT J
AU Shao, DD
Tsherniak, A
Gopal, S
Weir, BA
Tamayo, P
Stransky, N
Schumacher, SE
Zack, TI
Beroukhim, R
Garraway, LA
Margolin, AA
Root, DE
Hahn, WC
Mesirov, JP
AF Shao, Diane D.
Tsherniak, Aviad
Gopal, Shuba
Weir, Barbara A.
Tamayo, Pablo
Stransky, Nicolas
Schumacher, Steven E.
Zack, Travis I.
Beroukhim, Rameen
Garraway, Levi A.
Margolin, Adam A.
Root, David E.
Hahn, William C.
Mesirov, Jill P.
TI ATARiS: Computational quantification of gene suppression phenotypes from
multisample RNAi screens
SO GENOME RESEARCH
LA English
DT Article
ID CANCER-CELL LINES; HEPATOCYTE NUCLEAR FACTOR-1-BETA; GENOME-WIDE
ASSOCIATION; OVARIAN-CANCER; BREAST-CANCER; HIT SELECTION; TARGET GENE;
COPY-NUMBER; INTERFERENCE; IDENTIFICATION
AB Genome-scale RNAi libraries enable the systematic interrogation of gene function. However, the interpretation of RNAi screens is complicated by the observation that RNAi reagents designed to suppress the mRNA transcripts of the same gene often produce a spectrum of phenotypic outcomes due to differential on-target gene suppression or perturbation of off-target transcripts. Here we present a computational method, Analytic Technique for Assessment of RNAi by Similarity (ATARiS), that takes advantage of patterns in RNAi data across multiple samples in order to enrich for RNAi reagents whose phenotypic effects relate to suppression of their intended targets. By summarizing only such reagent effects for each gene, ATARiS produces quantitative, gene-level phenotype values, which provide an intuitive measure of the effect of gene suppression in each sample. This method is robust for data sets that contain as few as 10 samples and can be used to analyze screens of any number of targeted genes. We used this analytic approach to interrogate RNAi data derived from screening more than 100 human cancer cell lines and identified HNF1B as a transforming oncogene required for the survival of cancer cells that harbor HNF1B amplifications. ATARiS is publicly available at http://broadinstitute.org/ataris.
C1 [Shao, Diane D.; Tsherniak, Aviad; Gopal, Shuba; Weir, Barbara A.; Tamayo, Pablo; Stransky, Nicolas; Schumacher, Steven E.; Zack, Travis I.; Beroukhim, Rameen; Garraway, Levi A.; Margolin, Adam A.; Root, David E.; Hahn, William C.; Mesirov, Jill P.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Shao, Diane D.; Beroukhim, Rameen; Garraway, Levi A.; Hahn, William C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Schumacher, Steven E.; Zack, Travis I.; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Zack, Travis I.] Harvard Univ, Program Biophys, Boston, MA 02115 USA.
[Beroukhim, Rameen; Garraway, Levi A.; Hahn, William C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Beroukhim, Rameen; Garraway, Levi A.; Hahn, William C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Hahn, WC (reprint author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
EM William_Hahn@dfci.harvard.edu; mesirov@broad.mit.edu
RI Schumacher, Steven/E-9821-2013
OI Schumacher, Steven/0000-0002-6819-5647
FU NIH/NCI [RC2 CA148268, P01 CA050661, U54 CA112962, R01 CA109467]; H.L.
Snyder Medical Foundation; Ivy Research Foundation
FX We thank the Broad Institute Project Achilles investigators for the data
from RNAi pooled screening, and the Broad-Novartis Cancer Cell Line
Encyclopedia investigators for providing cell lines for validation. We
thank D. Nijhawan, J. Rosenbluh, D. Barbie, and F. Verdeguer for helpful
discussions. We thank L. Solomon and L. Gaffney for assistance with
figure design. This work was supported by grants from the NIH/NCI (RC2
CA148268, P01 CA050661, U54 CA112962, R01 CA109467), the H.L. Snyder
Medical Foundation, and the Ivy Research Foundation.
NR 58
TC 39
Z9 40
U1 0
U2 15
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD APR
PY 2013
VL 23
IS 4
BP 665
EP 678
DI 10.1101/gr.143586.112
PG 14
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
GA 116YY
UT WOS:000316920500008
PM 23269662
ER
PT J
AU Kutner, N
Zhang, R
Johansen, K
Bliwise, D
AF Kutner, Nancy
Zhang, Rebecca
Johansen, Kirsten
Bliwise, Donald
TI Associations among nocturnal sleep, daytime intradialytic sleep, and
mortality risk in patients on daytime conventional hemodialysis: US
Renal Data System special study data
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Article
DE Sleep; sleep quality; sleepiness; hemodialysis; mortality risk
ID QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; NAP HABITS; LONG-SLEEP;
DIALYSIS; DURATION; SIESTA; POPULATION; HEALTH; DEPRESSION
AB Fragmented nocturnal sleep is commonly reported by patients undergoing daytime conventional hemodialysis (CHD) and may be associated with higher mortality risk. Subjective sleepiness during CHD is also frequently observed. We examined the association of reported sleep fragmentation and nocturnal and daytime (intradialytic) sleep durations with survival in a national cohort of 1440 CHD patients who were interviewed in 20052007 in a phone survey conducted by the US Renal Data System. Patient survival was followed through September 30, 2010 in the US Renal Data System. A total of 76% of patients reported that they typically dozed off or slept during their treatment, and intradialytic dozing was especially common among patients whose treatment shift started before 1000 hours. There was a trend for patients who reported dozing during CHD to report nocturnal sleep fragmentation (60.4% vs. 55.1%; P=0.07). With adjustment for intradialytic sleep and other covariates, nocturnal sleep fragmentation was not associated with survival. Mortality risk was higher for patients who reported sleeping 9 or more hours/night compared with the referent category of nocturnal sleep equal to 67 hours (hazard ratio: 1.50 [95% confidence interval: 1.042.17]; P=0.03). Continued investigation of the association of timing and duration of sleep with hemodialysis patient outcomes is warranted.
C1 [Kutner, Nancy; Zhang, Rebecca; Johansen, Kirsten; Bliwise, Donald] Emory Univ, US Renal Data Syst, Rehabil Qual Life Special Studies Ctr, Atlanta, GA 30322 USA.
[Bliwise, Donald] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA.
[Johansen, Kirsten] Univ Calif San Francisco, Nephrol Sect, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Johansen, Kirsten] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
RP Kutner, N (reprint author), Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA.
EM nkutner@emory.edu
FU National Institutes of Health [HHSN267200715004C]; ADB [N01-DK-7-5004]
FX This study was supported by National Institutes of Health contract
HHSN267200715004C, ADB No. N01-DK-7-5004 (Dr. Kutner). The
interpretation and reporting of the data presented here are the
responsibility of the authors and in no way should be seen as an
official policy or interpretation of the US government.
NR 28
TC 5
Z9 5
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1492-7535
J9 HEMODIAL INT
JI Hemodial. Int.
PD APR
PY 2013
VL 17
IS 2
BP 223
EP 229
DI 10.1111/hdi.12005
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 117PX
UT WOS:000316966700004
PM 23216956
ER
PT J
AU Race, E
Keane, MM
Verfaellie, M
AF Race, Elizabeth
Keane, Margaret M.
Verfaellie, Mieke
TI Losing sight of the future: Impaired semantic prospection following
medial temporal lobe lesions
SO HIPPOCAMPUS
LA English
DT Article
DE semantic memory; episodic memory; hippocampus; amnesia; imagination
ID MENTAL TIME-TRAVEL; CONSTRUCTIVE EPISODIC SIMULATION; AUTOBIOGRAPHICAL
MEMORY; RELATIONAL MEMORY; RETRIEVAL; THINKING; EVENTS; HIPPOCAMPUS;
AMNESIA; BRAIN
AB The ability to imagine the future (prospection) relies on many of the same brain regions that support memory for the past. To date, scientific research has primarily focused on the neural substrates of episodic forms of prospection (mental simulation of spatiotemporally specific future events); however, little is known about the neural substrates of semantic prospection (mental simulation of future nonpersonal facts). Of particular interest is the role of the medial temporal lobes (MTLs), and specifically the hippocampus. Although the hippocampus has been proposed to play a key role in episodic prospection, recent evidence suggests that it may not play a similar role in semantic prospection. To examine this possibility, amnesic patients with MTL lesions were asked to imagine future issues occurring in the public domain. The results showed that patients could list general semantic facts about the future, but when probed to elaborate, patients produced impoverished descriptions that lacked semantic detail. This impairment occurred despite intact performance on standard neuropsychological tests of semantic processing and did not simply reflect deficits in narrative construction. The performance of a patient with damage limited to the hippocampus was similar to that of the remaining patients with MTL lesions and amnesic patients' impaired elaboration of the semantic future correlated with their impaired elaboration of the semantic past. Together, these results provide novel evidence from MTL amnesia that memory and prospection are linked in the semantic domain and reveal that the MTLs play a critical role in the construction of detailed, multi-element semantic simulations. (c) 2012 Wiley Periodicals, Inc.
C1 [Race, Elizabeth; Keane, Margaret M.; Verfaellie, Mieke] Boston Univ, VA Boston Healthcare Syst, Memory Disorders Res Ctr, Sch Med, Boston, MA 02130 USA.
[Keane, Margaret M.] Wellesley Coll, Dept Psychol, Wellesley, MA 02181 USA.
RP Race, E (reprint author), VA Boston Healthcare Syst, Memory Disorders Res Ctr, 150 S Huntington Ave 151-A, Boston, MA 02130 USA.
EM race@bu.edu
OI Verfaellie, Mieke/0000-0001-5535-4584
FU NIH (NIMH and NINDS) [R01MH093431, F32NS073212]; Clinical Science
Research and Development Service, Department of Veterans Affairs
FX Grant sponsor: NIH (NIMH and NINDS); Grant numbers: R01MH093431,
F32NS073212; Grant sponsor: Clinical Science Research and Development
Service, Department of Veterans Affairs.
NR 65
TC 32
Z9 33
U1 0
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1050-9631
J9 HIPPOCAMPUS
JI Hippocampus
PD APR
PY 2013
VL 23
IS 4
BP 268
EP 277
DI 10.1002/hipo.22084
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 113PF
UT WOS:000316679300004
PM 23197413
ER
PT J
AU Ferrone, S
AF Ferrone, Soldano
TI A tribute to Edgardo Carosella on the occasion of the 6th International
Conference on HLA-G held in Paris, France, July 9-11, 2012
SO HUMAN IMMUNOLOGY
LA English
DT Editorial Material
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
RP Ferrone, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
EM SFerrone@Partners.org
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD APR
PY 2013
VL 74
IS 4
SI SI
BP 405
EP 405
DI 10.1016/j.humimm.2012.11.029
PG 1
WC Immunology
SC Immunology
GA 118KT
UT WOS:000317025100003
PM 23232062
ER
PT J
AU Wong, KFK
Gong, JJ
Cotten, JF
Solt, K
Brown, EN
AF Wong, Kin Foon Kevin
Gong, Jen J.
Cotten, Joseph F.
Solt, Ken
Brown, Emery N.
TI Assessing the Effects of Pharmacological Agents on Respiratory Dynamics
Using Time-Series Modeling
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Bootstrap; general anesthesia; respiratory rate; serial correlation
ID FUNCTIONAL MRI; DEPRESSION; NALOXONE; VARIABILITY; ANTAGONISM;
ANESTHESIA; THERAPY; CAT
AB Developing quantitative descriptions of how stimulant and depressant drugs affect the respiratory system is an important focus in medical research. Respiratory variables-respiratory rate, tidal volume, and end tidal carbon dioxide-have prominent temporal dynamics that make it inappropriate to use standard hypothesis-testing methods that assume independent observations to assess the effects of these pharmacological agents. We present a polynomial signal plus autoregressive noise model for analysis of continuously recorded respiratory variables. We use a cyclic descent algorithm to maximize the conditional log likelihood of the parameters and the corrected Akaike's information criterion to choose simultaneously the orders of the polynomial and the autoregressive models. In an analysis of respiratory rates recorded from anesthetized rats before and after administration of the respiratory stimulant methylphenidate, we use the model to construct within-animal z-tests of the drug effect that take account of the time-varying nature of the mean respiratory rate and the serial dependence in rate measurements. We correct for the effect of model lack-of-fit on our inferences by also computing bootstrap confidence intervals for the average difference in respiratory rate pre- and postmethylphenidate treatment. Our time-series modeling quantifies within each animal the substantial increase in mean respiratory rate and respiratory dynamics following methylphenidate administration. This paradigm can be readily adapted to analyze the dynamics of other respiratory variables before and after pharmacologic treatments.
C1 [Wong, Kin Foon Kevin; Solt, Ken] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02129 USA.
[Gong, Jen J.] MIT, Cambridge, MA 02129 USA.
[Gong, Jen J.; Cotten, Joseph F.; Brown, Emery N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Cotten, Joseph F.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02129 USA.
[Solt, Ken; Brown, Emery N.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
[Solt, Ken; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
RP Brown, EN (reprint author), Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
EM kfwong@partners.org; jengong@mit.edu; jcotten@partners.org;
KSOLT@partners.org; enb@neurostat.mit.edu
RI Wong, Kin Foon Kevin/C-7896-2014;
OI Solt, Ken/0000-0001-5328-2062
FU National Institutes of Health [DP1-OD003646, K08-GM094394, K08-GM083216]
FX This research was supported by National Institutes of Health Grant
DP1-OD003646, Grant K08-GM094394, and Grant K08-GM083216. Asterisk
indicates corresponding author.
NR 28
TC 0
Z9 0
U1 0
U2 7
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD APR
PY 2013
VL 60
IS 4
BP 1118
EP 1125
DI 10.1109/TBME.2012.2225834
PG 8
WC Engineering, Biomedical
SC Engineering
GA 115KX
UT WOS:000316812200029
PM 23193230
ER
PT J
AU Tu, GW
Hwabejire, JO
Ju, MJ
Yang, YF
Zhang, GJ
Xu, JW
Xue, ZG
Jiang, C
Luo, Z
AF Tu, Guo-Wei
Hwabejire, J. O.
Ju, Min-Jie
Yang, Yuan-Feng
Zhang, Guang-Jian
Xu, Jian-Wei
Xue, Zhang-Gang
Jiang, C.
Luo, Z.
TI Multidisciplinary intensive care in extensive necrotizing fasciitis
SO INFECTION
LA English
DT Article
DE Necrotizing fasciitis; Soft tissue infection; Klebsiella pneumoniae
ID SOFT-TISSUE INFECTIONS; MANAGEMENT; MORTALITY; DETERMINANTS; DIAGNOSIS
AB This is a case report of extensive necrotizing fasciitis (NF). A 65-year-old man presented with high fever, pain, swelling, and redness of the perineum, scrotum, and right lower limb. Based on the clinical symptoms and an imaging examination, a diagnosis of NF was made. The patient underwent an extensive exploration followed by daily bedside debridement. A diversion colostomy and six additional debridement procedures on the right thigh and perineum were subsequently performed. Although the patient had an eventful course, he recovered well under a multidisciplinary treatment regimen. The treatment and hospital course of the patient are described.
C1 [Tu, Guo-Wei; Ju, Min-Jie; Xue, Zhang-Gang; Luo, Z.] Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, Shanghai 200032, Peoples R China.
[Tu, Guo-Wei; Ju, Min-Jie; Xue, Zhang-Gang; Luo, Z.] Fudan Univ, Zhongshan Hosp, Surg Intens Care Unit, Shanghai 200032, Peoples R China.
[Hwabejire, J. O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care,Dept S, Boston, MA USA.
[Yang, Yuan-Feng] Fudan Univ, Dept Urol, Zhongshan Hosp, Shanghai 200433, Peoples R China.
[Zhang, Guang-Jian; Jiang, C.] Fudan Univ, Dept Orthoped, Zhongshan Hosp, Shanghai 200433, Peoples R China.
[Xu, Jian-Wei] Fudan Univ, Dept Plast & Reconstruct Surg, Zhongshan Hosp, Shanghai 200433, Peoples R China.
RP Luo, Z (reprint author), Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM jcyh01@sina.com; luo-zhe@zshospital.sh.cn
NR 17
TC 6
Z9 6
U1 0
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
J9 INFECTION
JI Infection
PD APR
PY 2013
VL 41
IS 2
BP 583
EP 587
DI 10.1007/s15010-012-0346-2
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 113BO
UT WOS:000316641000040
PM 23104255
ER
PT J
AU Okike, K
Lee, OC
Makanji, H
Harris, MB
Vrahas, MS
AF Okike, Kanu
Lee, Olivia C.
Makanji, Heeren
Harris, Mitchel B.
Vrahas, Mark S.
TI Factors associated with the decision for operative versus non-operative
treatment of displaced proximal humerus fractures in the elderly
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Proximal humerus fractures; Orthopaedics; Trauma; Surgical
decision-making; Surgery
ID RANDOMIZED CONTROLLED-TRIAL; LOCKING-PLATE FIXATION; INTERNAL-FIXATION;
SURGICAL-TREATMENT; OPEN REDUCTION; PHILOS PLATE; CONSERVATIVE
TREATMENT; EARLY COMPLICATIONS; LOCKED PLATE; EPIDEMIOLOGY
AB Background: In the management of displaced proximal humerus fractures in the elderly, wide variation has been documented. However, no prior study has investigated the factors that currently lead surgeons to treat patients with surgical fixation, arthroplasty or non-operative management. The purpose of this study was to identify the factors associated with treatment selection in the management of displaced proximal humerus fractures in individuals over the age of 60 years. To this end, we conducted a retrospective review of all such injuries that presented to our two level-I trauma centres between 2006 and 2009.
Patients and methods: From our prospectively collected trauma database, we identified 229 displaced proximal humerus fractures that met all inclusion and exclusion criteria. Data were collected on patient-, fracture-and surgeon-related characteristics that were plausibly related to the decision for treatment. The choice of management was recorded, and logistic regression was used to identify factors associated with the decision for treatment.
Results: In the multivariate analysis, the predictors of operative intervention as opposed to non-operative treatment were younger patient age (p = 0.038), associated orthopaedic injuries requiring surgery (p = 0.012), higher Arbeitsgemeinschaft fur Osteosynthesefragen (AO) classification (p = 0.012), translation-type displacement (p = 0.0012) and associated glenohumeral dislocation (p = 0.0006). In addition, shoulder and upper extremity specialists were found to choose operative intervention significantly more frequently than orthopaedic trauma specialists (49.1% vs. 26.1%, adjusted relative risk (RR) 1.96, p = 0.012). Factors associated with the decision for arthroplasty as opposed to fixation were higher Charlson score (p = 0.045), higher Neer classification (p = 0.012), and higher AO classification (p = 0.0097).
Conclusions: In this study of displaced proximal humerus fractures in the elderly, the decision for surgery was influenced by the patient's age, the presence of associated orthopaedic injuries, the severity of the fracture and the presence of an associated glenohumeral dislocation. In addition, treatment by a shoulder or upper extremity specialist (as opposed to an orthopaedic trauma specialist) was associated with a higher likelihood of operative intervention. Further investigation into the resultant clinical outcomes is required to determine whether the use of these characteristics to select operative candidates is appropriate and beneficial for patients. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Okike, Kanu; Harris, Mitchel B.] Brigham & Womens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
[Okike, Kanu; Vrahas, Mark S.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Lee, Olivia C.] Hosp Special Surg, Dept Orthopaed Surg, New York, NY 10021 USA.
[Makanji, Heeren] Harvard Univ, Sch Med, Boston, MA USA.
RP Okike, K (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA.
EM okike@post.harvard.edu
OI Okike, Kanu/0000-0001-9310-9969
FU Orthopaedic Research and Education Foundation; Depuy Orthopaedics; AO
Foundation; OREF/DePuy Orthopaedic Resident Educational Grant;
Massachusetts General Hospital Academic Enrichment Fund
FX Dr. Okike reports grant support from the Orthopaedic Research and
Education Foundation and Depuy Orthopaedics. Dr. Vrahas reports grant
support from the AO Foundation, and serving as a consultant for Pioneer
Medical. Drs. Lee, Makanji and Harris did not receive any financial
payments or other benefits from any commercial entity related to the
subject of this article.; This research was supported by an OREF/DePuy
Orthopaedic Resident Educational Grant, as well as a grant from the
Massachusetts General Hospital Academic Enrichment Fund. Neither entity
was involved in the study design; collection, analysis and
interpretation of data; the writing of the manuscript; or the decision
to submit the manuscript for publication.
NR 46
TC 12
Z9 12
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD APR
PY 2013
VL 44
IS 4
BP 448
EP 455
DI 10.1016/j.injury.2012.09.002
PG 8
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 114GO
UT WOS:000316729300010
PM 23022082
ER
PT J
AU Villar, J
Perez-Mendez, L
Blanco, J
Anon, JM
Blanch, L
Belda, J
Santos-Bouza, A
Fernandez, RL
Kacmarek, RM
AF Villar, Jesus
Perez-Mendez, Lina
Blanco, Jesus
Manuel Anon, Jose
Blanch, Lluis
Belda, Javier
Santos-Bouza, Antonio
Lidia Fernandez, Rosa
Kacmarek, Robert M.
CA Spanish Initiative Epidemiology
TI A universal definition of ARDS: the PaO2/FiO(2) ratio under a standard
ventilatory setting-a prospective, multicenter validation study
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Acute respiratory distress syndrome; Protective mechanical ventilation;
Standard ventilatory settings; Lung injury severity; Phenotype
classification; Definition; Prognosis
ID ACUTE RESPIRATORY-DISTRESS; ACUTE LUNG INJURY; RANDOMIZED
CONTROLLED-TRIAL; END-EXPIRATORY PRESSURE; CLINICAL-TRIAL; GAS-EXCHANGE;
STRATEGY; FAILURE; ADULTS
AB The PaO2/FiO(2) is an integral part of the assessment of patients with acute respiratory distress syndrome (ARDS). The American-European Consensus Conference definition does not mandate any standardization procedure. We hypothesized that the use of PaO2/FiO(2) calculated under a standard ventilatory setting within 24 h of ARDS diagnosis allows a more clinically relevant ARDS classification.
We studied 452 ARDS patients enrolled prospectively in two independent, multicenter cohorts treated with protective mechanical ventilation. At the time of ARDS diagnosis, patients had a PaO2/FiO(2) a parts per thousand currency sign 200. In the derivation cohort (n = 170), we measured PaO2/FiO(2) with two levels of positive end-expiratory pressure (PEEP) (a parts per thousand yen5 and a parts per thousand yen10 cmH(2)O) and two levels of FiO(2) (a parts per thousand yen0.5 and 1.0) at ARDS onset and 24 h later. Dependent upon PaO2 response, patients were reclassified into three groups: mild (PaO2/FiO(2) > 200), moderate (PaO2/FiO(2) 101-200), and severe (PaO2/FiO(2) a parts per thousand currency sign 100) ARDS. The primary outcome measure was ICU mortality. The standard ventilatory setting that reached the highest significance difference in mortality among these categories was tested in a separate cohort (n = 282).
The only standard ventilatory setting that identified the three PaO2/FiO(2) risk categories in the derivation cohort was PEEP a parts per thousand yen 10 cmH(2)O and FiO(2) a parts per thousand yen 0.5 at 24 h after ARDS onset (p = 0.0001). Using this ventilatory setting, patients in the validation cohort were reclassified as having mild ARDS (n = 47, mortality 17 %), moderate ARDS (n = 149, mortality 40.9 %), and severe ARDS (n = 86, mortality 58.1 %) (p = 0.00001).
Our method for assessing PaO2/FiO(2) greatly improved risk stratification of ARDS and could be used for enrolling appropriate ARDS patients into therapeutic clinical trials.
C1 [Villar, Jesus; Perez-Mendez, Lina; Blanco, Jesus; Blanch, Lluis; Lidia Fernandez, Rosa] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
[Villar, Jesus; Lidia Fernandez, Rosa] Hosp Univ Dr Negrin, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Res Unit, Las Palmas Gran Canaria, Spain.
[Perez-Mendez, Lina] Hosp Univ NS Candelaria, Res Unit, Tenerife, Spain.
[Blanco, Jesus] Hosp Univ Rio Hortega, Intens Care Unit, Valladolid, Spain.
[Manuel Anon, Jose] Hosp Virgen La Luz, Intens Care Unit, Cuenca, Spain.
[Blanch, Lluis] Corp Sanitaria & Univ, Crit Care Ctr, Sabadell, Spain.
[Belda, Javier] Hosp Clin Valencia, Dept Anesthesia, Valencia, Spain.
[Santos-Bouza, Antonio] Complejo Hosp Univ Santiago, Intens Care Unit, Santiago De Compostela, Spain.
[Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 01460 USA.
[Kacmarek, Robert M.] Harvard Univ, Dept Anesthesia, Boston, MA 02115 USA.
[Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Las Palmas Gran Canaria 35010, Spain.
RP Kacmarek, RM (reprint author), Massachusetts Gen Hosp, Dept Resp Care, 55 Fruit St, Boston, MA 01460 USA.
EM jesus.villar54@gmail.com; rkacmarek@partners.org
FU Instituto de Salud Carlos III [PI 07/0113, PI 10/0393]; Asociacion
Cientifica Pulmon y Ventilacion Mecanica; Hamilton; Maquet
FX This work was supported by the Instituto de Salud Carlos III (PI
07/0113, PI 10/0393) and by the Asociacion Cientifica Pulmon y
Ventilacion Mecanica. The funders had no role in the study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.; We have the following competing interests: RMK has received
research grants from Hamilton, honorarium for lecturing from Maquet and
Hamilton, and is a consultant for Newport, KCL, and Bayer. JV has
received research grants from Maquet. The rest of the authors declared
that no competing interests exist in relation to the content of this
study and manuscript.
NR 30
TC 55
Z9 62
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD APR
PY 2013
VL 39
IS 4
BP 583
EP 592
DI 10.1007/s00134-012-2803-x
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA 114RI
UT WOS:000316759500007
PM 23370826
ER
PT J
AU Sulemanji, DS
Marchese, A
Wysocki, M
Kacmarek, RM
AF Sulemanji, Demet S.
Marchese, Andrew
Wysocki, Marc
Kacmarek, Robert M.
TI Adaptive support ventilation with and without end-tidal CO2 closed loop
control versus conventional ventilation
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Mechanical ventilation; Adaptive support ventilation; Closed loop
control; ARDS; COPD; Brain injury
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; MECHANICAL
VENTILATION; PERMISSIVE HYPERCAPNIA; BREATHING PATTERN; GAS-EXCHANGE;
FAILURE; MORTALITY; STRATEGY; VOLUMES
AB Our aim was to compare adaptive support ventilation with and without closed loop control by end tidal CO2 (ASVCO(2), ASV) with pressure (PC) and volume control ventilation (VC) during simulated clinical scenarios [normal lungs (N), COPD, ARDS, brain injury (BI)].
A lung model was used to simulate representative compliance (mL/cmH(2)O): resistance (cmH(2)O/L/s) combinations, 45:5 for N and BI, 60:7.7 for COPD, 15:7.7 and 35:7.7 for ARDS. Two levels of PEEP (cmH(2)O) were used for each scenario, 12/16 for ARDS, and 5/10 for others. The CO2 productions of 2, 3, 4 and 5 mL/kg predicted body weight/min were simulated. Tidal volume was set to 6 mL/kg during VC and PC. Outcomes of interest were end tidal CO2 (etCO(2)) and plateau pressure (P (Plat)).
EtCO2 levels in N and BI and COPD were similar for all modes. In ARDS, etCO(2) was higher in ASVCO(2) than in other modes (p < 0.001). Under all mechanical conditions ASVCO(2) revealed a narrower range of etCO(2). P (Plat) was similar for all modes in all scenarios but ARDS where P (Plat) in ASV and ASVCO(2) were lower than in VC (p = 0.001). When P (Plat) was a parts per thousand yen28 cmH(2)O, P (plat) in ASV and ASVCO(2) were lower than in VC and PC (p = 0.024).
All modes performed similarly in most cases. Minor differences observed were in favor of the closed loop modes. Overall, ASVCO(2) maintained tighter CO2 control. The ASVCO(2) had the greatest impact during ARDS allowing etCO(2) to increase and protecting against hypocapnia evident with other modes while ensuring lower P (plat) and tidal volumes.
C1 [Sulemanji, Demet S.; Kacmarek, Robert M.] Harvard Univ, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Sulemanji, Demet S.; Marchese, Andrew; Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
[Wysocki, Marc] Hamilton Med, Bonaduz, Switzerland.
RP Kacmarek, RM (reprint author), Massachusetts Gen Hosp, Dept Resp Care, 55 Fruit St Warren 1225, Boston, MA 02114 USA.
EM dsulemanji@partners.org; rkacmarek@partners.org
FU Hamilton Medical; Covidien
FX Funding in part for this study was provided by Hamilton Medical.; Dr.
Kacmarek has received research grants from Covidien and Hamilton
Medical, an honorarium for lecturing from Maquet and Hamilton, and is a
consultant for Newport Medical, KCI and Bayer. Dr. Wysocki is a full
time employee of Hamilton Medical.
NR 23
TC 4
Z9 5
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD APR
PY 2013
VL 39
IS 4
BP 703
EP 710
DI 10.1007/s00134-012-2742-6
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 114RI
UT WOS:000316759500020
PM 23151992
ER
PT J
AU Ranieri, VM
Rubenfeld, GD
Thompson, BT
AF Ranieri, V. Marco
Rubenfeld, Gordon D.
Thompson, B. Taylor
TI Defining ARDS: do we need a mandatory waiting period?
SO INTENSIVE CARE MEDICINE
LA English
DT Editorial Material
ID RESPIRATORY-DISTRESS-SYNDROME; EUROPEAN CONSENSUS CONFERENCE; ACUTE LUNG
INJURY; CLINICAL-TRIAL COORDINATION; BERLIN DEFINITION; SUPPORTIVE
THERAPY; DESIGN STRATEGIES; RELEVANT OUTCOMES; PART 2; ISSUES
C1 [Ranieri, V. Marco] Univ Turin, Dipartimento Anestesia & Med Stati Critici, Azienda Osped S Giovanni Battista Molinette, I-10126 Turin, Italy.
[Rubenfeld, Gordon D.] Univ Toronto, Program Trauma Emergency & Crit Care, Interdept Div Crit Care Med, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
[Thompson, B. Taylor] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm Crit Care Unit,Dept Med, Boston, MA USA.
RP Ranieri, VM (reprint author), Univ Turin, Dipartimento Anestesia & Med Stati Critici, Azienda Osped S Giovanni Battista Molinette, Corso Dogliotti 14, I-10126 Turin, Italy.
EM marco.ranieri@unito.it
NR 25
TC 1
Z9 2
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD APR
PY 2013
VL 39
IS 4
BP 775
EP 778
DI 10.1007/s00134-013-2834-y
PG 4
WC Critical Care Medicine
SC General & Internal Medicine
GA 114RI
UT WOS:000316759500032
PM 23370830
ER
PT J
AU Williams, AB
Wang, HH
Burgess, J
Li, XH
Danvers, K
AF Williams, Ann B.
Wang, Honghong
Burgess, Jane
Li, Xianhong
Danvers, Karina
TI Cultural adaptation of an evidence-based nursing intervention to improve
medication adherence among people living with HIV/AIDS (PLWHA) in China
SO INTERNATIONAL JOURNAL OF NURSING STUDIES
LA English
DT Article
DE Cultural adaptation; Nursing intervention; Medication adherence;
HIV/AIDS; China
ID ACTIVE ANTIRETROVIRAL THERAPY; SELF-REPORTED ADHERENCE; HOME VISITS;
HIV; DISSEMINATION; CHALLENGES; ISSUES
AB Background: Adapting nursing interventions to suit the needs and culture of a new population (cultural adaptation) is an important early step in the process of implementation and dissemination. While the need for cultural adaptation is widely accepted, research-based strategies for doing so are not well articulated. Non-adherence to medications for chronic disease is a global problem and cultural adaptation of existing evidence-based interventions could be useful.
Objectives: This paper aims to describe the cultural adaptation of an evidence-based nursing intervention to improve medication adherence among people living with HIV/AIDS and to offer recommendations for adaptation of interventions across cultures and borders.
Site: The intervention, which demonstrated efficacy in a randomized controlled trial in North America, was adapted for the cultural and social context of Hunan Province, in south central China.
Sources of data: The adaptation process was undertaken by intervention stakeholders including the original intervention study team, the proposed adaptation team, and members of a Community Advisory Board, including people living with HIV/AIDS, family members, and health care workers at the target clinical sites.
Procedures: The adaptation process was driven by quantitative and qualitative data describing the new population and context and was guided by principles for cultural adaptation drawn from prevention science research.
Results: The primary adaptation to the intervention was the inclusion of family members in intervention activities, in response to the cultural and social importance of the family in rural China. In a pilot test of the adapted intervention, self-reported medication adherence improved significantly in the group receiving the intervention compared to the control group (p = 0.01). Recommendations for cultural adaptation of nursing interventions include (1) involve stakeholders from the beginning; (2) assess the population, need, and context; (3) evaluate the intervention to be adapted with attention to details of the original studies that demonstrated efficacy; (4) compare important elements of the original intervention with those of the proposed new population and context to identify primary points for adaptation; (5) explicitly identify sources of tension between intervention fidelity and cultural adaptive needs; (6) document the process of adaptation, pilot the adapted intervention, and evaluate its effectiveness before moving to dissemination and implementation on a large scale. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Williams, Ann B.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Wang, Honghong; Li, Xianhong] Cent S Univ, Sch Nursing, Changsha, Hunan, Peoples R China.
[Burgess, Jane] VA Greater Los Angeles Healthcare Syst, QUERI HIV Hepatitis, Los Angeles, CA 90024 USA.
[Danvers, Karina] Yale Univ, Connecticut AIDS Educ & Training Ctr, Sch Nursing, New Haven, CT 06610 USA.
RP Williams, AB (reprint author), Univ Calif Los Angeles, Sch Nursing, 10880 Wilshire Blvd,Suite 550, Los Angeles, CA 90024 USA.
EM awilliams@sonnet.ucla.edu; Honghong_wang@tom.com; Jane.Burgess@VA.gov;
Xianhong_li228@hotmail.com; Karina.Danvers@yale.edu
FU National Institute of Mental Health, USA
FX Partial funding provided by the National Institute of Mental Health,
USA, which had no role in the conduct of the work.
NR 26
TC 3
Z9 5
U1 4
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7489
J9 INT J NURS STUD
JI Int. J. Nurs. Stud.
PD APR
PY 2013
VL 50
IS 4
SI SI
BP 487
EP 494
DI 10.1015/j.ijnurstu.2012.08.018
PG 8
WC Nursing
SC Nursing
GA 117UC
UT WOS:000316977600006
PM 22981372
ER
PT J
AU Poorvu, PD
Sadow, CA
Townamchai, K
Damato, AL
Viswanathan, AN
AF Poorvu, Philip D.
Sadow, Cheryl A.
Townamchai, Kanokpis
Damato, Antonio L.
Viswanathan, Akila N.
TI Duodenal and Other Gastrointestinal Toxicity in Cervical and Endometrial
Cancer Treated With Extended-Field Intensity Modulated Radiation Therapy
to Paraaortic Lymph Nodes
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID GYNECOLOGIC-ONCOLOGY-GROUP; CISPLATIN CHEMOTHERAPY; SMALL-BOWEL; GUIDED
IMRT; CARCINOMA; RADIOTHERAPY; IRRADIATION; GUIDELINES; VOLUME;
BRACHYTHERAPY
AB Purpose: To characterize the rates of acute and late duodenal and other gastrointestinal (GI) toxicities among patients treated for cervical and endometrial cancers with extended-field intensity modulated radiation therapy (EF-IMRT) to the paraaortic nodes and to analyze dose-volume relationships of GI toxicities.
Methods and Materials: Fifty-three patients with endometrial or cervical cancer underwent EF-IMRT to the paraaortic nodes, of whom 46 met the inclusion criteria for GI toxicity and 45 for duodenal toxicity analysis. The median prescribed dose to the paraaortic nodes was 54 Gy (range, 41.4-65 Gy). The 4 duodenal segments, whole duodenum, small bowel loops, peritoneum, and peritoneum plus retroperitoneal segments of colon were contoured retrospectively, and dosimetric analysis was performed to identify dose-volume relationships to grade >= 3 acute (< 90 day) and late (>= 90 day) GI toxicity.
Results: Only 3/46 patients (6.5%) experienced acute grade >= 3 GI toxicity and 3/46 patients (6.5%) experienced late grade >= 3 GI toxicity. The median dose administered to these 6 patients was 50.4 Gy. One of 12 patients who received 63 to 65 Gy at the level of the renal hilum experienced grade 3 GI toxicity. Dosimetric analysis of patients with and without toxicity revealed no differences between the mean absolute or fractional volumes at any 5-Gy interval between 5 Gy and the maximum dose. None of the patients experienced duodenal toxicity.
Conclusions: Treatment of paraaortic nodes with IMRT is associated with low rates of GI toxicities and no duodenal-specific toxicity, including patients treated with concurrent chemotherapy. This technique may allow sufficient dose sparing of the bowel to enable safe dose escalation to at least 65 Gy. (C) 2013 Elsevier Inc.
C1 [Poorvu, Philip D.; Townamchai, Kanokpis; Damato, Antonio L.; Viswanathan, Akila N.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Poorvu, Philip D.; Townamchai, Kanokpis; Damato, Antonio L.; Viswanathan, Akila N.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sadow, Cheryl A.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Sadow, Cheryl A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Viswanathan, AN (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,ASB1 L-2, Boston, MA 02115 USA.
EM aviswanathan@lroc.harvard.edu
OI Viswanathan, Akila/0000-0002-2003-0392
NR 20
TC 20
Z9 23
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD APR 1
PY 2013
VL 85
IS 5
BP 1262
EP 1268
DI 10.1016/j.ijrobp.2012.10.004
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 115CR
UT WOS:000316790500032
PM 23182395
ER
PT J
AU Nanda, A
Chen, MH
Moran, BJ
Braccioforte, MH
D'Amico, AV
AF Nanda, Akash
Chen, Ming-Hui
Moran, Brian J.
Braccioforte, Michelle H.
D'Amico, Anthony V.
TI Cardiovascular Comorbidity and Mortality in Men With Prostate Cancer
Treated With Brachytherapy-Based Radiation With or Without Hormonal
Therapy
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID STATISTICS
AB Purpose: To assess the impact of coronary artery disease (CAD) risk factors and sequelae on the risk of all-cause mortality (ACM) in men treated for prostate cancer (PC).
Methods and Materials: The study cohort comprised 5077 men with PC consecutively treated with curative intent between 1997 and 2006 at the Chicago Prostate Cancer Center. Cox and Fine and Gray's competing risks regression multivariable analyses were performed, assessing whether cardiovascular comorbidity impacted the risk of ACM and PC-specific mortality, respectively, adjusting for CAD risk factors (diabetes mellitus, hypercholesterolemia, or hypertension) and sequelae (congestive heart failure or myocardial infarction), age, year and type of treatment, and known PC prognostic factors.
Results: When compared with men with no comorbidity there was a significantly increased risk of ACM in men with congestive heart failure or myocardial infarction (adjusted hazard ratio [AHR] 1.96, P <. 001) and in men with diabetes mellitus (AHR 1.60, P = .03) and hypertension (AHR 1.25, P = .04). In contrast, men with hypercholesterolemia had a similar risk of ACM (AHR 0.68, P = .17) when compared with men with no comorbidity. Other factors associated with a significantly increased risk of ACM included age (AHR 1.09, P < .001), prostate-specific antigen level (AHR 1.25, P = .008), and Gleason score 8-10 disease (AHR 1.71, P = .003). Cardiovascular comorbidity did not impact the risk of PC-specific mortality.
Conclusions: In addition to age and unfavorable PC prognostic factors, select CAD risk factors and sequelae are associated with an increased risk of ACM in men treated for PC. These comorbidity prognostic factors predict time courses of mortality from competing causes, which may be factored into the decision-making process when considering management options for PC in a given individual. (C) 2013 Elsevier Inc.
C1 [Nanda, Akash] MD Anderson Canc Ctr Orlando, Dept Radiat Oncol, Orlando, FL USA.
[Chen, Ming-Hui] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA.
[Moran, Brian J.; Braccioforte, Michelle H.] Prostate Canc Fdn Chicago, Westmont, IL USA.
[D'Amico, Anthony V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Nanda, A (reprint author), Anderson Canc Ctr Orlando, Dept Radiat Oncol, 1400 S Orange Ave,MP 760, Orlando, FL 32806 USA.
EM akash.nanda@orlandohealth.com
NR 20
TC 7
Z9 7
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD APR 1
PY 2013
VL 85
IS 5
BP E209
EP E215
DI 10.1016/j.ijrobp.2012.11.039
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 115CR
UT WOS:000316790500002
PM 23332383
ER
PT J
AU Oreskovic, NM
Goodman, E
AF Oreskovic, Nicolas M.
Goodman, Elizabeth
TI Association of Optimism With Cardiometabolic Risk in Adolescents
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Article
DE Optimism; Biomarkers; Cardiometabolic risk; Adolescents; Disparities
ID CORONARY-HEART-DISEASE; LIFE ORIENTATION TEST; DISPOSITIONAL OPTIMISM;
CARDIOVASCULAR HEALTH; SOCIOECONOMIC-STATUS; NATIONAL-HEALTH;
SOCIAL-STATUS; SELF-ESTEEM; INFLAMMATION; BIOMARKERS
AB Purpose: Dispositional optimism is a psychological trait associated with cardiovascular disease outcomes in adults. However, it is not known whether these associations are present in adolescents. We attempted to determine whether an association exits between optimism and 9 biomarkers of cardiometabolic risk during adolescence. Because cardiometabolic risk differs by race and ethnicity, we also explored whether race and ethnicity moderated the optimism-cardiometabolic risk relationship.
Methods: This was a cross-sectional study of 529 non-Hispanic white and 421 non-Hispanic black seventh through 12th graders living in greater Cincinnati in 2001-2002. We measured dispositional optimism with the Life-Orientation Test-Revised as a single continuum and as separate optimism and pessimism dimensions. Multivariable regression analyses tested for associations between optimism and nine biomarkers of risk (interleukin-6, tumor necrosis factor-alpha, lipids, insulin, glucose, and fibrinogen), adjusting for age, gender, parent education, body mass index, smoking, and pubertal stage.
Results: Dispositional optimism with the Life-Orientation Test-Revised as a single continuum was inversely associated with two risks (interleukin-6, beta = -.03, p = .02; insulin, beta = -.02, p = .01), but only among blacks. Optimism and pessimism were inversely related (R = -.27, p < .001) and both were higher in blacks than whites (p < .001). Optimism was directly associated with high-density lipoprotein among all subjects (beta = .42, p = .03), and among blacks (beta = .74, p = .02) but not whites. Among blacks, optimism was also inversely associated with interleukin-6 (beta = - .07, p = .001) and triglycerides (beta = -.02, p = .04). Pessimism was inversely associated with glucose, but only in whites (beta = -.38, p = .03).
Conclusions: Associations between dispositional optimism and cardiometabolic risks are present in adolescence and vary by race and ethnicity. A better understanding of the natural history of these associations over the lifespan may help decrease disparities and prevent cardiometabolic disease. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved.
C1 [Oreskovic, Nicolas M.; Goodman, Elizabeth] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02114 USA.
[Oreskovic, Nicolas M.; Goodman, Elizabeth] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Oreskovic, NM (reprint author), Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM noreskovic@partners.org
OI Goodman, Elizabeth/0000-0002-9640-9884; Oreskovic,
Nicolas/0000-0001-8702-8636
FU National Institutes of Health [R01HD041527, R01DK59183, K23HL103841]
FX This research was supported by National Institutes of Health Grants
R01HD041527, R01DK59183, and K23HL103841.
NR 36
TC 4
Z9 5
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD APR
PY 2013
VL 52
IS 4
BP 407
EP 412
DI 10.1016/j.jadohealth.2012.09.011
PG 6
WC Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA 114HE
UT WOS:000316730900005
PM 23298981
ER
PT J
AU Feruglio, PF
Vinegoni, C
Fexon, L
Thurber, G
Sbarbati, A
Weissleder, R
AF Feruglio, Paolo Fumene
Vinegoni, Claudio
Fexon, Lioubov
Thurber, Greg
Sbarbati, Andrea
Weissleder, Ralph
TI Noise suppressed, multifocus image fusion for enhanced intraoperative
navigation
SO JOURNAL OF BIOPHOTONICS
LA English
DT Article
DE intraoperative imaging; image processing; fluorescence microscopy;
intravital microscopy
ID CANCER; A33
AB Current intraoperative imaging systems are typically not able to provide sharp' images over entire large areas or entire organs. Distinct structures such as tissue margins or groups of malignant cells are therefore often difficult to detect, especially under low signal-to-noise-ratio conditions. In this report, we introduce a noise suppressed multifocus image fusion algorithm, that provides detailed reconstructions even when images are acquired under sub-optimal conditions, such is the case for real time fluorescence intraoperative surgery. The algorithm makes use of the Anscombe transform combined with a multi-level stationary wavelet transform with individual threshold-based shrinkage. While the imaging system is integrated with a respiratory monitor triggering system, it can be easily adapted to any commercial imaging system. The developed algorithm is made available as a plugin for Osirix. ((c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim)
C1 [Feruglio, Paolo Fumene; Vinegoni, Claudio; Fexon, Lioubov; Thurber, Greg; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Feruglio, Paolo Fumene; Vinegoni, Claudio; Fexon, Lioubov; Thurber, Greg; Weissleder, Ralph] Harvard Univ, Sch Med, Richard B Simches Res Ctr, Boston, MA 02114 USA.
[Feruglio, Paolo Fumene; Sbarbati, Andrea] Univ Verona, Dept Neurol Neuropsychol Morphol & Movement Sci, I-37134 Verona, Italy.
RP Vinegoni, C (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM cvinegoni@mgh.harvard.edu
OI Thurber, Greg/0000-0001-7570-2080
FU [T32CA79443-11]; [2P50CA086355-12]; [2RO1EB006432]; [2U24CA092782]
FX This project was funded in part by funds from grants Nr. T32CA79443-11,
2P50CA086355-12, 2RO1EB006432, 2U24CA092782.
NR 24
TC 2
Z9 2
U1 0
U2 16
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1864-063X
J9 J BIOPHOTONICS
JI J. Biophotonics
PD APR
PY 2013
VL 6
IS 4
BP 363
EP 370
DI 10.1002/jbio.201200086
PG 8
WC Biochemical Research Methods; Biophysics; Optics
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA 117ND
UT WOS:000316959300012
PM 22887724
ER
PT J
AU Spatz, JM
Ellman, R
Cloutier, AM
Louis, L
van Vliet, M
Suva, LJ
Dwyer, D
Stolina, M
Ke, HZ
Bouxsein, ML
AF Spatz, Jordan M.
Ellman, Rachel
Cloutier, Alison M.
Louis, Leeann
van Vliet, Miranda
Suva, Larry J.
Dwyer, Denise
Stolina, Marina
Ke, Hua Zhu
Bouxsein, Mary L.
TI Sclerostin antibody inhibits skeletal deterioration due to reduced
mechanical loading
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE LOSS; HINDLIMB UNLOADING; SCLEROSTIN ANTIBODY; BONE; MOUSE; BONE
DENSITY
ID INCREASES BONE-FORMATION; ADIPOCYTE DIFFERENTIATION; RAT MODEL; MASS;
ADIPOGENESIS; MICE; WNT; IMMOBILIZATION; EXPRESSION; STRENGTH
AB Sclerostin, a product of the SOST gene produced mainly by osteocytes, is a potent negative regulator of bone formation that appears to be responsive to mechanical loading, with SOST expression increasing following mechanical unloading. We tested the ability of a murine sclerostin antibody (SclAbII) to prevent bone loss in adult mice subjected to hindlimb unloading (HLU) via tail suspension for 21 days. Mice (n=1117/group) were assigned to control (CON, normal weight bearing) or HLU and injected with either SclAbII (subcutaneously, 25mg/kg) or vehicle (VEH) twice weekly. SclAbII completely inhibited the bone deterioration due to disuse, and induced bone formation such that bone properties in HLU-SclAbII were at or above values of CON-VEH mice. For example, hindlimb bone mineral density (BMD) decreased 9.2%+/- 1.0% in HLU-VEH, whereas it increased 4.2%+/- 0.7%, 13.1%+/- 1.0%, and 30.6%+/- 3.0% in CON-VEH, HLU-SclAbII, and CON-SclAbII, respectively (p<0.0001). Trabecular bone volume, assessed by microcomputed tomography (mu CT) imaging of the distal femur, was lower in HLU-VEH versus CON-VEH (p<0.05), and was 2- to 3-fold higher in SclAbII groups versus VEH (p<0.001). Midshaft femoral strength, assessed by three-point bending, and distal femoral strength, assessed by microfinite element analysis (mu FEA), were significantly higher in SclAbII versus VEH-groups in both loading conditions. Serum sclerostin was higher in HLU-VEH (134 +/- 5pg/mL) compared to CON-VEH (116 +/- 6pg/mL, p<0.05). Serum osteocalcin was decreased by hindlimb suspension and increased by SclAbII treatment. Interestingly, the anabolic effects of sclerostin inhibition on some bone outcomes appeared to be enhanced by normal mechanical loading. Altogether, these results confirm the ability of SclAbII to abrogate disuse-induced bone loss and demonstrate that sclerostin antibody treatment increases bone mass by increasing bone formation in both normally loaded and underloaded environments. (c) 2013 American Society for Bone and Mineral Research.
C1 [Spatz, Jordan M.; Ellman, Rachel] Harvard Massachusetts Inst Technol MIT Div Hlth S, Bioastronaut Program, Cambridge, MA USA.
[Spatz, Jordan M.; Ellman, Rachel; Cloutier, Alison M.; Louis, Leeann; van Vliet, Miranda; Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Boston, MA 02215 USA.
[Spatz, Jordan M.; Bouxsein, Mary L.] Massachusetts Gen Hosp, Div Endocrine, Boston, MA 02114 USA.
[Suva, Larry J.] Univ Arkansas, Dept Orthoped Surg, Ctr Orthopaed Res, Sch Med, Little Rock, AR 72204 USA.
[Dwyer, Denise; Stolina, Marina; Ke, Hua Zhu] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Bouxsein, Mary L.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Cambridge, MA 02138 USA.
RP Bouxsein, ML (reprint author), Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, 330 Brookline Ave, Boston, MA 02215 USA.
EM mbouxsei@bidmc.harvard.edu
FU NIH [R21 AR057522]; NASA [NNX10AE39G]; National Space Biomedical
Research Institute through NASA [NCC 9-58]; Amgen; NASA; Northrop
Grumman Aerospace Systems PhD Training Fellowship
FX This work was funded by NIH R21 AR057522, NASA NNX10AE39G, the National
Space Biomedical Research Institute through NASA NCC 9-58, and a
research grant from Amgen. RE was supported by a NASA-Jenkins
predoctoral fellowship. JMS was supported by a Northrop Grumman
Aerospace Systems PhD Training Fellowship.
NR 31
TC 50
Z9 51
U1 2
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2013
VL 28
IS 4
BP 865
EP 874
DI 10.1002/jbmr.1807
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 112EB
UT WOS:000316573900018
PM 23109229
ER
PT J
AU Ellman, R
Spatz, J
Cloutier, A
Palme, R
Christiansen, BA
Bouxsein, ML
AF Ellman, Rachel
Spatz, Jordan
Cloutier, Alison
Palme, Rupert
Christiansen, Blaine A.
Bouxsein, Mary L.
TI Partial reductions in mechanical loading yield proportional changes in
bone density, bone architecture, and muscle mass
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE MECHANICAL LOADING; DISUSE; MECHANOSTAT; FUNCTIONAL ADAPTATION; WEIGHT
BEARING
ID STRAIN MAGNITUDE; MURINE MODEL; MICE; RATS; IMMOBILIZATION;
CORTICOSTERONE; MECHANOSTAT
AB Although the musculoskeletal system is known to be sensitive to changes in its mechanical environment, the relationship between functional adaptation and below-normal mechanical stimuli is not well defined. We investigated bone and muscle adaptation to a range of reduced loading using the partial weight suspension (PWS) system, in which a two-point harness is used to offload a tunable amount of body weight while maintaining quadrupedal locomotion. Skeletally mature female C57Bl/6 mice were exposed to partial weight bearing at 20%, 40%, 70%, or 100% of body weight for 21 days. A hindlimb unloaded (HLU) group was included for comparison in addition to age-matched controls in normal housing. Gait kinematics was measured across the full range of weight bearing, and some minor alterations in gait from PWS were identified. With PWS, bone and muscle changes were generally proportional to the degree of unloading. Specifically, total body and hindlimb bone mineral density, calf muscle mass, trabecular bone volume of the distal femur, and cortical area of the femur midshaft were all linearly related to the degree of unloading. Even a load reduction to 70% of normal weight bearing was associated with significant bone deterioration and muscle atrophy. Weight bearing at 20% did not lead to better bone outcomes than HLU despite less muscle atrophy and presumably greater mechanical stimulus, requiring further investigation. These data confirm that the PWS model is highly effective in applying controllable, reduced, long-term loading that produces predictable, discrete adaptive changes in muscle and bone of the hindlimb. (c) 2012 American Society for Bone and Mineral Research (c) 2013 American Society for Bone and Mineral Research
C1 [Ellman, Rachel; Spatz, Jordan] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Ellman, Rachel; Spatz, Jordan; Cloutier, Alison; Christiansen, Blaine A.; Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Boston, MA 02215 USA.
[Ellman, Rachel; Spatz, Jordan; Cloutier, Alison; Christiansen, Blaine A.; Bouxsein, Mary L.] Harvard Univ, Sch Med, Boston, MA USA.
[Spatz, Jordan; Bouxsein, Mary L.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Palme, Rupert] Univ Vet Med, Dept Biomed Sci Biochem, Vienna, Austria.
[Christiansen, Blaine A.] Univ Calif Davis, Med Ctr, Dept Orthopaed Surg, Sacramento, CA 95817 USA.
RP Ellman, R (reprint author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,RN115, Boston, MA 02215 USA.
EM rellman@bidmc.harvard.edu
RI Palme, Rupert/A-3499-2008; Christiansen, Blaine/F-9021-2010
OI Palme, Rupert/0000-0001-9466-3662;
FU NIH [R21 AR057522]; NASA [NNX10AE39G]; National Space Biomedical
Research Institute through NASA [NCC 9-58]; NASA; Northrop Grumman
Aerospace Systems Ph.D. Training Fellowship
FX This work was supported by NIH R21 AR057522, NASA NNX10AE39G, and the
National Space Biomedical Research Institute through NASA NCC 9-58. RE
was supported by a NASA-Jenkins predoctoral fellowship. JMS was
supported by a Northrop Grumman Aerospace Systems Ph.D. Training
Fellowship. We thank Erika Wagner for consultation on the use of the PWS
system. We thank Timothy O'Shea for his assistance with the processing
of fecal samples.
NR 29
TC 23
Z9 23
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2013
VL 28
IS 4
BP 875
EP 885
DI 10.1002/jbmr.1814
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 112EB
UT WOS:000316573900019
PM 23165526
ER
PT J
AU Copin, JC
da Silva, RF
Fraga-Silva, RA
Capettini, L
Quintao, S
Lenglet, S
Pelli, G
Galan, K
Burger, F
Braunersreuther, V
Schaller, K
Deruaz, M
Proudfoot, AE
Dallegri, F
Stergiopulos, N
Santos, RAS
Gasche, Y
Mach, F
Montecucco, F
AF Copin, Jean-Christophe
da Silva, Rafaela F.
Fraga-Silva, Rodrigo A.
Capettini, Luciano
Quintao, Silvia
Lenglet, Sebastien
Pelli, Graziano
Galan, Katia
Burger, Fabienne
Braunersreuther, Vincent
Schaller, Karl
Deruaz, Maud
Proudfoot, Amanda E.
Dallegri, Franco
Stergiopulos, Nikolaos
Santos, Robson A. S.
Gasche, Yvan
Mach, Francois
Montecucco, Fabrizio
TI Treatment with Evasin-3 reduces atherosclerotic vulnerability for
ischemic stroke, but not brain injury in mice
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE acute stroke; atherosclerosis; brain ischemia; carotid artery;
inflammation
ID CEREBRAL-ARTERY OCCLUSION; SHEAR-STRESS; MODEL; HYPERCHOLESTEROLEMIA;
CHEMOKINES; MEDIATORS; DISEASE; SINGLE; RATS; DIET
AB Neutrophilic inflammation might have a pathophysiological role in both carotid plaque rupture and ischemic stroke injury. Here, we investigated the potential benefits of the CXC chemokine-binding protein Evasin-3, which potently inhibits chemokine bioactivity and related neutrophilic inflammation in two mouse models of carotid atherosclerosis and ischemic stroke, respectively. In the first model, the chronic treatment with Evasin-3 as compared with Vehicle (phosphate-buffered saline (PBS)) was investigated in apolipoprotein E-deficient mice implanted of a 'cast' carotid device. In the second model, acute Evasin-3 treatment (5 minutes after cerebral ischemia onset) was assessed in mice subjected to transient left middle cerebral artery occlusion. Although CXCL1 and CXCL2 were upregulated in both atherosclerotic plaques and infarcted brain, only CXCL1 was detectable in serum. In carotid atherosclerosis, treatment with Evasin-3 was associated with reduction in intraplaque neutrophil and matrix metalloproteinase-9 content and weak increase in collagen as compared with Vehicle. In ischemic stroke, treatment with Evasin-3 was associated with reduction in ischemic brain neutrophil infiltration and protective oxidants. No other effects in clinical and histological outcomes were observed. We concluded that Evasin-3 treatment was associated with reduction in neutrophilic inflammation in both mouse models. However, Evasin-3 administration after cerebral ischemia onset failed to improve poststroke outcomes. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 490-498; doi:10.1038/jcbfm.2012.198; published online 19 December 2012
C1 [Copin, Jean-Christophe] Univ Hosp Geneva, Div Neurosurg, Geneva, Switzerland.
[Copin, Jean-Christophe; Schaller, Karl; Gasche, Yvan] Univ Geneva, Geneva Neurosci Ctr, CH-1211 Geneva, Switzerland.
[da Silva, Rafaela F.; Fraga-Silva, Rodrigo A.; Capettini, Luciano; Quintao, Silvia; Stergiopulos, Nikolaos] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland.
[da Silva, Rafaela F.; Fraga-Silva, Rodrigo A.; Capettini, Luciano; Quintao, Silvia; Santos, Robson A. S.] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil.
[Lenglet, Sebastien; Pelli, Graziano; Galan, Katia; Burger, Fabienne; Braunersreuther, Vincent; Mach, Francois; Montecucco, Fabrizio] Univ Geneva, Fdn Med Res, Div Cardiol, CH-1211 Geneva, Switzerland.
[Deruaz, Maud] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Proudfoot, Amanda E.] Merck Serono Geneva Res Ctr, Geneva, Switzerland.
[Dallegri, Franco; Montecucco, Fabrizio] Univ Genoa, Dept Internal Med, Sch Med, Clin Internal Med 1, I-16126 Genoa, Italy.
[Gasche, Yvan] Univ Hosp Geneva, Div Intens Care Med, Geneva, Switzerland.
RP Montecucco, F (reprint author), Univ Geneva, Dept Internal Med, Div Cardiol, Fdn Med Res, 64 Ave Roseraie, CH-1211 Geneva, Switzerland.
EM fabrizio.montecucco@unige.ch
RI Nbiofar, Inct/J-9539-2013; LENGLET, Sebastien/N-8923-2013; Santos,
Robson/C-9336-2011; Montecucco, Fabrizio/K-8543-2016;
OI LENGLET, Sebastien/0000-0002-4853-8163; Santos,
Robson/0000-0001-8738-5852; Montecucco, Fabrizio/0000-0003-0823-8729;
DALLEGRI, FRANCO/0000-0001-9537-4547; Capettini,
Luciano/0000-0002-6487-9558
FU Brazilian Swiss Joint Research Program (BSJRP); EU [201668]; Swiss
National Science Foundation [310030-118245, 32003B-134963/1]; Novartis
Foundation
FX This research was funded by the Brazilian Swiss Joint Research Program
(BSJRP) to Dr F Mach, Dr N Stergiopulos, and AS Robson. This research
was funded by EU FP7, Grant number 201668, AtheroRemo to Dr F Mach. This
work was also supported by the Swiss National Science Foundation Grants
to Dr F Mach (#310030-118245) and Dr F Montecucco (#32003B-134963/1).
This work was also supported by a Grant from Novartis Foundation to Dr F
Montecucco.
NR 35
TC 25
Z9 25
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD APR
PY 2013
VL 33
IS 4
BP 490
EP 498
DI 10.1038/jcbfm.2012.198
PG 9
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 117CR
UT WOS:000316930200004
PM 23250107
ER
PT J
AU Yun, X
Maximov, VD
Yu, J
Zhu, H
Vertegel, AA
Kindy, MS
AF Yun, Xiang
Maximov, Victor D.
Yu, Jin
Zhu, Hong
Vertegel, Alexey A.
Kindy, Mark S.
TI Nanoparticles for targeted delivery of antioxidant enzymes to the brain
after cerebral ischemia and reperfusion injury
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE anti-oxidants; antibody; cerebral ischemia; nanoparticles; superoxide
dismutase
ID CONJUGATED SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; OXYGEN RADICALS;
LIPID-PEROXIDATION; FOREBRAIN ISCHEMIA; EDEMA FORMATION; FOCAL ISCHEMIA;
IN-VIVO; RATS; BARRIER
AB Stroke is one of the major causes of death and disability in the United States. After cerebral ischemia and reperfusion injury, the generation of reactive oxygen species (ROS) and reactive nitrogen species may contribute to the disease process through alterations in the structure of DNA, RNA, proteins, and lipids. We generated various nanoparticles (liposomes, polybutylcyanoacrylate (PBCA), or poly(lactide-co-glycolide) (PLGA)) that contained active superoxide dismutase (SOD) enzyme (4,000 to 20,000 U/kg) in the mouse model of cerebral ischemia and reperfusion injury to determine the impact of these molecules. In addition, the nanoparticles were untagged or tagged with nonselective antibodies or antibodies directed against the N-methyl-D-aspartate (NMDA) receptor 1. The nanoparticles containing SOD protected primary neurons in vitro from oxygen-glucose deprivation (OGD) and limited the extent of apoptosis. The nanoparticles showed protection against ischemia and reperfusion injury when applied after injury with a 50% to 60% reduction in infarct volume, reduced inflammatory markers, and improved behavior in vivo. The targeted nanoparticles not only showed enhanced protection but also showed localization to the CA regions of the hippocampus. Nanoparticles alone were not effective in reducing infarct volume. These studies show that targeted nanoparticles containing protective factors may be viable candidates for the treatment of stroke. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 583-592; doi:10.1038/jcbfm.2012.209; published online 6 February 2013
C1 [Yun, Xiang; Maximov, Victor D.; Vertegel, Alexey A.; Kindy, Mark S.] Clemson Univ, Dept Bioengn, Clemson, SC USA.
[Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Kindy, Mark S.] CU MUSC Bioengn Res Program, Charleston, SC USA.
RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM kindyms@musc.edu
RI Maximov, Victor/G-2991-2013
FU National Institutes of Health [R01 ES016774-01, 5 P20 RR016461,
8P20GM103444-04, 5P20RR021949-03]; VA Merit Award; National Science
Foundation [IIP-917987]
FX This work was partially supported by grants from the National Institutes
of Health (R01 ES016774-01, 5 P20 RR016461, 8P20GM103444-04, and
5P20RR021949-03), VA Merit Award, and a grant from the National Science
Foundation (IIP-917987). Dr Kindy is a Research Career Scientist in the
VA.
NR 49
TC 31
Z9 32
U1 5
U2 41
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD APR
PY 2013
VL 33
IS 4
BP 583
EP 592
DI 10.1038/jcbfm.2012.209
PG 10
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 117CR
UT WOS:000316930200015
PM 23385198
ER
PT J
AU Roccaro, AM
Sacco, A
Maiso, P
Azab, AK
Tai, YT
Reagan, M
Azab, F
Flores, LM
Campigotto, F
Weller, E
Anderson, KC
Scadden, DT
Ghobrial, IM
AF Roccaro, Aldo M.
Sacco, Antonio
Maiso, Patricia
Azab, Abdel-Kareem
Tai, Yu-Tzu
Reagan, Michaela
Azab, Feda
Flores, Ludmila M.
Campigotto, Federico
Weller, Edie
Anderson, Kenneth C.
Scadden, David T.
Ghobrial, Irene M.
TI BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma
progression
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID PROMOTE TUMOR-GROWTH; IN-VITRO; PROTEOMIC ANALYSIS; MICROARRAY DATA;
KAPPA-B; EXPRESSION; VIVO; MICRORNAS; VESICLES; MICROVESICLES
AB BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this disease. Cell-cell communication is mediated by exosomes. In this study, we showed that MM BM-MSCs release exosomes that are transferred to MM cells, thereby resulting in modulation of tumor growth in vivo. Exosomal microRNA (miR) content differed between MM and normal BM-MSCs, with a lower content of the tumor suppressor miR-15a. In addition, MM BM-MSC-derived exosomes had higher levels of oncogenic proteins, cytokines, and adhesion molecules compared with exosomes from the cells of origin. Importantly, whereas MM BM-MSC-derived exosomes promoted MM tumor growth, normal BM-MSC exosomes inhibited the growth of MM cells. In summary, these in vitro and in vivo studies demonstrated that exosome transfer from BM-MSCs to clonal plasma cells represents a previously undescribed and unique mechanism that highlights the contribution of BM-MSCs to MM disease progression.
C1 [Roccaro, Aldo M.; Sacco, Antonio; Maiso, Patricia; Azab, Abdel-Kareem; Tai, Yu-Tzu; Reagan, Michaela; Azab, Feda; Flores, Ludmila M.; Anderson, Kenneth C.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Campigotto, Federico; Weller, Edie] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Scadden, David T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Mayer 225, Boston, MA 02215 USA.
EM irene_ghobrial@dfci.harvard.edu
RI Sacco, Antonio/K-4681-2016; Reagan, Michaela/E-3549-2017;
OI Sacco, Antonio/0000-0003-2945-9416; Roccaro, Aldo/0000-0002-1872-5128;
Maiso, Patricia/0000-0003-3745-1924; Reagan,
Michaela/0000-0003-2884-6481
FU Noxxon; Bristol-Myers Squibb; GlaxoSmithKline; NIH [R01CA154648,
R01CA133799, R01CA125690]; Accademia Nazionale dei Lincei (Rome, Italy)
FX Irene M. Ghobrial serves on advisory boards for Bristol-Myers Squibb,
Millennium, Novartis, and Noxxon and receives research support from
Noxxon and Bristol-Myers Squibb. Kenneth C. Anderson serves on the board
of directors and/or advisory committees for Celgene, Millennium,
Bristol-Myers Squibb, and Onyx and is a scientific founder of Acetylon
and Oncopep. David T. Scadden is a stock owner and consultant for Fate
Therapeutics, serves as a consultant for GlaxoSmithKline and Bone
Therapeutics, and receives research support from GlaxoSmithKline.; The
authors thank Lisa Cameron (Confocal and Light Microscopy Core Facility,
Dana-Farber Cancer Institute) and Maria Ericcson (Electron Microscopy
Facility, Harvard Medical School) for technical help; Riccardo
Dalla-Favera for providing C57BL/6 miR-15a/16-1-/- mice; and
Siobhan Glavey for editing the manuscript. This work was supported by
NIH grants R01CA154648, R01CA133799, and R01CA125690 and by Accademia
Nazionale dei Lincei (Rome, Italy).
NR 54
TC 184
Z9 191
U1 13
U2 66
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2013
VL 123
IS 4
BP 1542
EP 1555
DI 10.1172/JCI66517
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 118JM
UT WOS:000317021800017
PM 23454749
ER
PT J
AU Wang, C
Yi, T
Qin, LF
Maldonado, RA
von Andrian, UH
Kulkarni, S
Tellides, G
Pober, JS
AF Wang, Chen
Yi, Tai
Qin, Lingfeng
Maldonado, Roberto A.
von Andrian, Ulrich H.
Kulkarni, Sanjay
Tellides, George
Pober, Jordan S.
TI Rapamycin-treated human endothelial cells preferentially activate
allogeneic regulatory T cells
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID RESPONSES IN-VIVO; DENDRITIC CELLS; ALLOGRAFT-REJECTION; TRANSPLANTATION
TOLERANCE; TRANSENDOTHELIAL MIGRATION; CORNEAL ALLOGRAFTS; IMMUNE
PRIVILEGE; GRAFT-REJECTION; EFFECTOR-CELLS; CUTTING EDGE
AB Human graft endothelial cells (ECs) can act as antigen-presenting cells to initiate allograft rejection by host memory T cells. Rapamycin, an mTOR inhibitor used clinically to suppress T cell responses, also acts on DCs, rendering them tolerogenic. Here, we report the effects of rapamycin on EC alloiummunogenicity. Compared with mock-treated cells, rapamycin-pretreated human ECs (rapa-ECs) stimulated less proliferation and cytokine secretion from allogeneic CD4(+) memory cells, an effect mimicked by shRNA knockdown of mTOR or raptor in ECs. The effects of rapamycin persisted for several days and were linked to upregulation of the inhibitory molecules PD-L1 and PD-L2 on rapa-ECs. Additionally, rapa-ECs produced lower levels of the inflammatory cytokine IL-6. CD4(+) memory cells activated by allogeneic rapa-ECs became hyporesponsive to restimulation in an alloantigen-specific manner and contained higher percentages of suppressive CD4(+)CD25(hi)CD127(lo)FoxP3(+) cells that did not produce effector cytokines. In a human-mouse chimeric model of allograft rejection, rapamycin pretreatment of human arterial allografts increased graft EC expression of PD-L1 and PD-L2 and reduced subsequent infiltration of allogeneic effector T cells into the artery intima and intimal expansion. Preoperative conditioning of allograft ECs with rapamycin could potentially reduce immune-mediated rejection.
C1 [Wang, Chen; Yi, Tai; Pober, Jordan S.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.
[Qin, Lingfeng; Kulkarni, Sanjay; Tellides, George] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA.
[Maldonado, Roberto A.; von Andrian, Ulrich H.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
RP Pober, JS (reprint author), Yale Univ, Sch Med, 10 Amistad St,Room 401D, New Haven, CT 06520 USA.
EM jordan.pober@yale.edu
FU NIH [P01-HL070295, R01-HL109455, AI06925, AI095261]; NIH Medical
Scientist Training Program grant [T32-GM007205]; NIH National Research
Service Award (NRSA) predoctoral fellowship [F30HL114253]
FX We thank L. Benson and G. Davis for expert assistance in EC culture and
animal care. This work is supported by NIH grants P01-HL070295 to J.S.
Pober and G. Tellides, R01-HL109455 to J.S. Pober, and AI06925 and
AI095261 to U.H. von Andrian. C. Wang was supported by an NIH Medical
Scientist Training Program grant (T32-GM007205) and is currently
supported by an NIH National Research Service Award (NRSA) predoctoral
fellowship (F30HL114253).
NR 85
TC 27
Z9 27
U1 0
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2013
VL 123
IS 4
BP 1677
EP 1693
DI 10.1172/JCI66204
PG 17
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 118JM
UT WOS:000317021800028
PM 23478407
ER
PT J
AU Roth, AJ
Ooi, JD
Hess, JJ
van Timmeren, MM
Berg, EA
Poulton, CE
McGregor, J
Burkart, M
Hogan, SL
Hu, YC
Winnik, W
Nachman, PH
Stegeman, CA
Niles, J
Heeringa, P
Kitching, AR
Holdsworth, S
Jennette, JC
Preston, GA
Falk, RJ
AF Roth, Aleeza J.
Ooi, Joshua D.
Hess, Jacob J.
van Timmeren, Mirjan M.
Berg, Elisabeth A.
Poulton, Caroline E.
McGregor, JulieAnne
Burkart, Madelyn
Hogan, Susan L.
Hu, Yichun
Winnik, Witold
Nachman, Patrick H.
Stegeman, Coen A.
Niles, John
Heeringa, Peter
Kitching, A. Richard
Holdsworth, Stephen
Jennette, J. Charles
Preston, Gloria A.
Falk, Ronald J.
TI Epitope specificity determines pathogenicity and detectability in
ANCA-associated vasculitis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; SMALL-VESSEL VASCULITIS;
MPO-ANCA; MICROSCOPIC POLYANGIITIS; WEGENERS-GRANULOMATOSIS; NATURAL
AUTOANTIBODIES; BASEMENT-MEMBRANE; MYELOPEROXIDASE; GLOMERULONEPHRITIS;
CERULOPLASMIN
AB Anti-neutrophil cytoplasmic antibody-associated (ANCA-associated) small vessel necrotizing vasculitis is caused by immune-mediated inflammation of the vessel wall and is diagnosed in some cases by the presence of myeloperoxidase-specific antibodies (MPO-ANCA). This multicenter study sought to determine whether differences in ANCA epitope specificity explain why, in some cases, conventional serologic assays do not correlate with disease activity, why naturally occurring anti-MPO autoantibodies can exist in disease-free individuals, and why ANCA are undetected in patients with ANCA-negative disease. Autoantibodies from human and murine samples were epitope mapped using a highly sensitive epitope excision/mass spectrometry approach. Data indicated that MPO autoantibodies from healthy individuals had epitope specificities different from those present in ANCA disease. Importantly, this methodology led to the discovery of MPO-ANCA in ANCA-negative disease that reacted against a sole linear sequence. Autoantibodies against this epitope had pathogenic properties, as demonstrated by their capacity to activate neutrophils in vitro and to induce nephritis in mice. The confounder for serological detection of these autoantibodies was the presence of a fragment of ceruloplasmin in serum, which was eliminated in purified IgG, allowing detection. These findings implicate immunodominant epitopes in the pathology of ANCA-associated vasculitis and suggest that autoantibody diversity may be common to other autoimmune diseases.
C1 [Roth, Aleeza J.; Hess, Jacob J.; Berg, Elisabeth A.; Poulton, Caroline E.; McGregor, JulieAnne; Burkart, Madelyn; Hogan, Susan L.; Hu, Yichun; Nachman, Patrick H.; Jennette, J. Charles; Preston, Gloria A.; Falk, Ronald J.] Univ N Carolina, Dept Med, Div Nephrol & Hypertens, UNC Kidney Ctr, Chapel Hill, NC USA.
[Ooi, Joshua D.; Kitching, A. Richard; Holdsworth, Stephen] Monash Univ, Dept Med, Clayton, Vic, Australia.
[van Timmeren, Mirjan M.; Stegeman, Coen A.; Heeringa, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands.
[Winnik, Witold] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA.
[Niles, John] Massachusetts Gen Hosp, Renal Div, Boston, MA 02114 USA.
RP Falk, RJ (reprint author), UNC Kidney Ctr, CB 7155,5009 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.
EM Ronald_Falk@med.unc.edu
RI Heeringa, Peter/A-6008-2009;
OI Heeringa, Peter/0000-0001-8684-763X; Kitching, Arthur
Richard/0000-0002-2713-2391; Ooi, Joshua/0000-0003-3328-2561
FU NIH/NIDDK [P01 DK058335-06]; NHMRC Australia [1008849]
FX This work as supported by federal grant P01 DK058335-06 (NIH/NIDDK) and
the NHMRC Australia Project Grant 1008849. The authors acknowledge the
UNC Michael Hooker Proteomic Center for training and access to the 4800
MALDI-TOF/TOF mass spectrometer under the expert guidance of Nely
Dicheva. We would like to thank Gary Hess for his programming assistance
of the compilation of epitope profiles. Anna Fisher and Gary Hatch, U.S.
Environmental Protection Agency, are acknowledged for their excellent
internal review of the manuscript. The research described in this
article has been reviewed by the National Health and Environmental
Effects Research Laboratory, U.S. Environmental Protection Agency, and
approved for publication. Approval does not signify that the contents
necessarily reflect the views and the policies of the Agency nor does
mention of trade names or commercial products constitute endorsement or
recommendation for use.
NR 31
TC 65
Z9 70
U1 1
U2 12
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2013
VL 123
IS 4
BP 1773
EP 1783
DI 10.1172/JCI65292
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 118JM
UT WOS:000317021800036
PM 23549081
ER
PT J
AU Westover, MB
Bianchi, MT
Shafi, M
Hoch, DB
Cole, AJ
Chiappa, K
Cash, SS
AF Westover, M. Brandon
Bianchi, Matt T.
Shafi, Mouhsin
Hoch, Daniel B.
Cole, Andrew J.
Chiappa, Keith
Cash, Sydney S.
TI Inferring Seizure Frequency From Brief EEG Recordings
SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE Bayes rule; Seizure frequency; Statistical inference; EEG
AB Routine EEGs remain a cornerstone test in caring for people with epilepsy. Although rare, a self-limited seizure (clinical or electrographic only) may be observed during such brief EEGs. The implications of observing a seizure in this situation, especially with respect to inferring the underlying seizure frequency, are unclear. The issue is complicated by the inaccuracy of patient-reported estimations of seizure frequency. The treating clinician is often left to wonder whether the single seizure indicates very frequent seizures, or if it is of lesser significance. We applied standard concepts of probabilistic inference to a simple model of seizure incidence to provide some guidance for clinicians facing this situation. Our analysis establishes upper and lower bounds on the seizure rate implied by observing a single seizure during routine EEG. Not surprisingly, with additional information regarding the expected seizure rate, these bounds can be further constrained. This framework should aid the clinician in applying a more principled approach toward decision making in the setting of a single seizure on a routine EEG.
C1 [Westover, M. Brandon; Shafi, Mouhsin; Hoch, Daniel B.; Cole, Andrew J.; Cash, Sydney S.] Massachusetts Gen Hosp, MGH Epilepsy Serv, Boston, MA 02114 USA.
[Westover, M. Brandon; Bianchi, Matt T.; Shafi, Mouhsin; Hoch, Daniel B.; Cole, Andrew J.; Cash, Sydney S.] Harvard Univ, Sch Med, Boston, MA USA.
[Bianchi, Matt T.] Massachusetts Gen Hosp, Sleep Div, Dept Neurol, Boston, MA 02114 USA.
[Chiappa, Keith] King Edward VII Mem Hosp, Paget, Bermuda.
[Chiappa, Keith] Dept Internal Med, Paget, Bermuda.
RP Westover, MB (reprint author), Massachusetts Gen Hosp, 55 Fruit St,WACC 827, Boston, MA 02114 USA.
EM mwestover@partners.org
OI Hoch, Daniel/0000-0002-4294-024X
FU National Institute of Neurological Disorders and Stroke (NINDS)
[NS062092]
FX S. S. Cash, A. J. Cole, D. B. Hoch, and M. B. Westover receive support
from National Institute of Neurological Disorders and Stroke (NINDS)
(NS062092).
NR 9
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0736-0258
J9 J CLIN NEUROPHYSIOL
JI J. Clin. Neurophysiol.
PD APR
PY 2013
VL 30
IS 2
BP 174
EP 177
DI 10.1097/WNP.0b013e3182767c35
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 117HE
UT WOS:000316943400010
PM 23545768
ER
PT J
AU Stone, RM
AF Stone, Richard M.
TI Acute Myeloid Leukemia in First Remission: To Choose Transplantation or
Not?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; POSTREMISSION
THERAPY; INTENSIVE CHEMOTHERAPY; METAANALYSIS; MUTATIONS; ADULTS
AB A42-year-oldwomanpresented with bruising and fatigue. HerWBCcount was 10,370/mu L, with a differential showing 5% polys, 5% monos, 10% lymphocytes, and 80% myeloid-appearing blasts, some of which contained Auer rods (Fig 1). Bonemarrow examination revealed90% infiltration with myeloid-appearing blasts, and flow cytometry analysis confirmed the diagnosis of acute myeloid leukemia (AML) with expression of CD33, CD13, and CD117. Cytogenetics revealed a normal female karyotype; molecular testing for NPM1, FLT3-ITD, and CEBP alpha mutations revealed wild-type status for each gene. The patient received induction therapy with daunorubicin 90 mg/m(2) per day for 3 days and continuous-infusion cytarabine 100 mg/m(2) per day for 7 days. After an induction course complicated by Gram-negative bacterial sepsis, her counts recovered by day 32, and bone marrow examination 6 weeks after diagnosis showed a complete remission. One week later she feels well and has normal physical and laboratory examinations. She is an only child (but has a common HLA type) and presents for discussion of postremission therapy options.
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Stone, RM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
NR 14
TC 12
Z9 13
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 1
PY 2013
VL 31
IS 10
BP 1262
EP 1266
DI 10.1200/JCO.2012.43.4258
PG 5
WC Oncology
SC Oncology
GA 118DP
UT WOS:000317003300011
PM 23439752
ER
PT J
AU Domchek, SM
Bradbury, A
Garber, JE
Offit, K
Robson, ME
AF Domchek, Susan M.
Bradbury, Angela
Garber, Judy E.
Offit, Kenneth
Robson, Mark E.
TI Multiplex Genetic Testing for Cancer Susceptibility: Out on the High
Wire Without a Net?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID AMINO-ACID SUBSTITUTIONS; POLICY STATEMENT UPDATE; LI-FRAUMENI SYNDROME;
AMERICAN-SOCIETY; MUTATION CARRIERS; BRCA2 MUTATION; OVARIAN-CANCER;
BREAST-CANCER; RISK; ONCOLOGY
C1 [Domchek, Susan M.; Bradbury, Angela] Univ Penn, Philadelphia, PA 19104 USA.
[Garber, Judy E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Offit, Kenneth; Robson, Mark E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Offit, Kenneth; Robson, Mark E.] Weill Cornell Med Coll, New York, NY USA.
RP Domchek, SM (reprint author), Univ Penn, Philadelphia, PA 19104 USA.
OI Robson, Mark/0000-0002-3109-1692
NR 26
TC 88
Z9 88
U1 0
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 1
PY 2013
VL 31
IS 10
BP 1267
EP 1270
DI 10.1200/JCO.2012.46.9403
PG 4
WC Oncology
SC Oncology
GA 118DP
UT WOS:000317003300012
PM 23460708
ER
PT J
AU Schiffer, CA
Mangu, PB
Wade, JC
Camp-Sorrell, D
Cope, DG
El-Rayes, BF
Gorman, M
Ligibel, J
Mansfield, P
Levine, M
AF Schiffer, Charles A.
Mangu, Pamela B.
Wade, James C.
Camp-Sorrell, Dawn
Cope, Diane G.
El-Rayes, Bassel F.
Gorman, Mark
Ligibel, Jennifer
Mansfield, Paul
Levine, Mark
TI Central Venous Catheter Care for the Patient With Cancer: American
Society of Clinical Oncology Clinical Practice Guideline
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BLOOD-STREAM INFECTION; PROSPECTIVE RANDOMIZED-TRIAL; DOUBLE-BLIND
TRIAL; LOW-DOSE WARFARIN; SUBCLAVIAN-VEIN CATHETERIZATION; ACCESS
DEVICES; NEUTROPENIC PATIENTS; HEMATOLOGICAL MALIGNANCIES; THROMBOTIC
COMPLICATIONS; HICKMAN CATHETERS
AB Purpose
To develop an evidence-based guideline on central venous catheter (CVC) care for patients with cancer that addresses catheter type, insertion site, and placement as well as prophylaxis and management of both catheter-related infection and thrombosis.
Methods
A systematic search of MEDLINE and the Cochrane Library (1980 to July 2012) identified relevant articles published in English. Results The overall quality of the randomized controlled trial evidence was rated as good. There is consistency among meta-analyses and guidelines compiled by other groups as well.
Recommendations
There is insufficient evidence to recommend one CVC type or insertion site; femoral catheterization should be avoided. CVC should be placed by well-trained providers, and the use of a CVC clinical care bundle is recommended. The use of antimicrobial/antiseptic-impregnated and/or heparin-impregnated CVCs is recommended to decrease the risk of catheter-related infections for short-term CVCs, particularly in high-risk groups; more research is needed. The prophylactic use of systemic antibiotics is not recommended before insertion. Data are not sufficient to recommend for or against routine use of antibiotic flush/lock therapy; more research is needed. Before starting antibiotic therapy, cultures should be obtained. Some life-threatening infections require immediate catheter removal, but most can be treated with antimicrobial therapy while the CVC remains in place. Routine flushing with saline is recommended. Prophylactic use of warfarin or low-molecular weight heparin is not recommended, although a tissue plasminogen activator (t-PA) is recommended to restore patency to occluded catheters. CVC removal is recommended when the catheter is no longer needed or if there is a radiologically confirmed thrombosis that worsens despite anticoagulation therapy. J Clin Oncol 31:1357-1370. (C) 2013 by American Society of Clinical Oncology
C1 [Schiffer, Charles A.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI USA.
[Schiffer, Charles A.; Mangu, Pamela B.] Amer Soc Clin Oncol, Alexandria, VA 22314 USA.
[Wade, James C.] Geisinger Canc Inst, Danville, PA USA.
[Camp-Sorrell, Dawn] Univ Alabama Birmingham, Birmingham, AL USA.
[Cope, Diane G.] Florida Canc Specialists & Res Inst, Ft Myers, FL USA.
[El-Rayes, Bassel F.] Emory Univ, Atlanta, GA 30322 USA.
[Ligibel, Jennifer] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mansfield, Paul] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Levine, Mark] Henderson Hosp, Hamilton, ON, Canada.
RP Schiffer, CA (reprint author), Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA.
EM guidelines@asco.org
NR 145
TC 63
Z9 65
U1 1
U2 16
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 1
PY 2013
VL 31
IS 10
BP 1357
EP 1370
DI 10.1200/JCO.2012.45.5733
PG 14
WC Oncology
SC Oncology
GA 118DP
UT WOS:000317003300025
PM 23460705
ER
PT J
AU Lepage, KQ
Ching, SN
Kramer, MA
AF Lepage, Kyle Q.
Ching, ShiNung
Kramer, Mark A.
TI Inferring evoked brain connectivity through adaptive perturbation
SO JOURNAL OF COMPUTATIONAL NEUROSCIENCE
LA English
DT Article
DE Perturbative; Network; Estimation; Functional connectivity; Adaptive
ID PULSE ELECTRICAL-STIMULATION; FUNCTIONAL CONNECTIVITY; LANGUAGE SYSTEM;
EPILEPSY; SEIZURES; NETWORK; PRINCIPLES; PATTERNS; ONSET
AB Inference of functional networks-representing the statistical associations between time series recorded from multiple sensors-has found important applications in neuroscience. However, networksexhibiting time-locked activity between physically independent elements can bias functional connectivity estimates employing passive measurements. Here, a perturbative and adaptive method of inferring network connectivity based on measurement and stimulation-so called "evoked network connectivity" is introduced. This procedure, employing a recursive Bayesian update scheme, allows principled network stimulation given a current network estimate inferred from all previous stimulations and recordings. The method decouples stimulus and detector design from network inference and can be suitably applied to a wide range of clinical and basic neuroscience related problems. The proposed method demonstrates improved accuracy compared to network inference based on passive observation of node dynamics and an increased rate of convergence relative to network estimation employing a na < ve stimulation strategy.
C1 [Lepage, Kyle Q.; Kramer, Mark A.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Ching, ShiNung] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Lepage, KQ (reprint author), Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
EM lepage@math.bu.edu; shinung@neurostat.mit.edu; mak@bu.edu
RI Kramer, Mark/A-1291-2014
FU Cognitive Rhythms Collaborative, NSF [DMS-1042134]; NIH [DP1-OD003646];
Burroughs Wellcome Fund
FX K.Q.L. acknowledges support for this research from the Cognitive Rhythms
Collaborative, NSF grant DMS-1042134 S.C. acknowledges support from NIH
DP1-OD003646. S.C. holds a Career Award at the Scientific Interface from
the Burroughs Wellcome Fund. M.A.K. holds a Career Award at the
Scientific Interface from the Burroughs Wellcome Fund.
NR 44
TC 5
Z9 5
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5313
J9 J COMPUT NEUROSCI
JI J. Comput. Neurosci.
PD APR
PY 2013
VL 34
IS 2
BP 303
EP 318
DI 10.1007/s10827-012-0422-8
PG 16
WC Mathematical & Computational Biology; Neurosciences
SC Mathematical & Computational Biology; Neurosciences & Neurology
GA 113SS
UT WOS:000316689300008
PM 22990598
ER
PT J
AU Ironson, G
O'Cleirigh, C
Leserman, J
Stuetzle, R
Fordiani, J
Fletcher, M
Schneiderman, N
AF Ironson, Gail
O'Cleirigh, Conall
Leserman, Jane
Stuetzle, Rick
Fordiani, Joanne
Fletcher, MaryAnn
Schneiderman, Neil
TI Gender-Specific Effects of an Augmented Written Emotional Disclosure
Intervention on Posttraumatic, Depressive, and HIV-Disease-Related
Outcomes: A Randomized, Controlled Trial
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE expressive writing; emotional disclosure; HIV; trauma; PTSD
ID COGNITIVE-PROCESSING THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDHOOD
SEXUAL-ABUSE; STRESS-DISORDER; GAY MEN; RHEUMATOID-ARTHRITIS;
HEALTH-STATUS; SEROPOSITIVE WOMEN; INFECTED PATIENTS; IMMUNE FUNCTION
AB Objective: Trauma histories and symptoms of PTSD occur at very high rates in people with HIV and are associated with poor disease management and accelerated disease progression. The authors of this study examined the efficacy of a brief written trauma disclosure intervention on posttraumatic stress, depression, HIV-related physical symptoms, and biological markers of HIV disease progression. Method: HIV-infected men and women were randomized to four 30-min expressive writing sessions in either a treatment (trauma writing) or an attention control (daily events writing) condition. The disclosure intervention augmented the traditional emotional disclosure paradigm with probes to increase processing by focusing on trauma appraisals, self-worth, and problem solving. Outcomes were assessed at baseline, 1-, 6-, and 12-month follow-up. Results: Hierarchical linear modeling (N = 244, intent-to-treat analyses) revealed no significant treatment effects for the group as a whole. Gender by treatment group interactions were significant such that women in the trauma-writing group had significantly reduced posttraumatic stress disorder (PTSD) symptoms (p = .017), depression (p = .009), and HIV-related symptoms (p = .022) compared with their controls. In contrast, men in the trauma-treatment condition did not improve more than controls on any outcome variables. Unexpectedly, men in the daily-event-writing control group had significantly greater reductions in depression then men in the trauma-writing group. Treatment effects were magnified in women when the analysis was restricted to those with elevated PTSD symptoms at baseline. Conclusions: A brief (4-session) guided written emotional disclosure intervention resulted in significant and meaningful reductions in PTSD, depression, and physical symptoms for women with HIV, but not for men.
C1 [Ironson, Gail; Stuetzle, Rick; Fletcher, MaryAnn; Schneiderman, Neil] Univ Miami, Dept Psychol, Coral Gables, FL 33146 USA.
[O'Cleirigh, Conall] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA.
[Leserman, Jane] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA.
[Fordiani, Joanne] VA Boston Healthcare Syst, Boston, MA USA.
[Fordiani, Joanne] Boston VA Res Inst, Boston, MA USA.
RP Ironson, G (reprint author), Univ Miami, Dept Psychol, 412 Flipse Bldg,5665 Ponce de Leon Blvd, Coral Gables, FL 33146 USA.
EM gironson@aol.com
FU NCCIH NIH HHS [R01 AT002035]; NIMH NIH HHS [T32 MH018917]
NR 89
TC 15
Z9 15
U1 3
U2 22
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD APR
PY 2013
VL 81
IS 2
SI SI
BP 284
EP 298
DI 10.1037/a0030814
PG 15
WC Psychology, Clinical
SC Psychology
GA 116UM
UT WOS:000316908500009
PM 23244367
ER
PT J
AU Mondolfi, AEP
Cressey, BD
Ahmad, A
Tapia-Centola, B
Cohen, LM
Mahmoodi, M
AF Paniz Mondolfi, A. E.
Cressey, B. D.
Ahmad, A.
Tapia-Centola, B.
Cohen, L. M.
Mahmoodi, M.
TI Granulomatous Alopecia: A Variant of Alopecia Areata?
SO JOURNAL OF CUTANEOUS PATHOLOGY
LA English
DT Article
DE alopecia; alopecia areata; granulomatous alopecia; non-scarring
ID PRIVILEGE
C1 [Paniz Mondolfi, A. E.; Cressey, B. D.; Tapia-Centola, B.; Mahmoodi, M.] Tufts Med Ctr, Miraca Life Sci Res Inst, Dept Dermatol, Boston, MA 02111 USA.
[Paniz Mondolfi, A. E.; Tapia-Centola, B.] MSDS UCV IVSS, Inst Biomed, Caracas, Venezuela.
[Ahmad, A.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Cohen, L. M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Cohen, L. M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Mondolfi, AEP (reprint author), Tufts Med Ctr, Miraca Life Sci Res Inst, Dept Dermatol, 800 Washington St,Box 114, Boston, MA 02111 USA.
EM Alberto.PanizMondolfi@bcm.edu
NR 10
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-6987
J9 J CUTAN PATHOL
JI J. Cutan. Pathol.
PD APR
PY 2013
VL 40
IS 4
BP 358
EP 360
DI 10.1111/cup.12126
PG 3
WC Dermatology; Pathology
SC Dermatology; Pathology
GA 115KS
UT WOS:000316811700002
ER
PT J
AU Smits, MM
Ioannou, GN
Boyko, EJ
Utzschneider, KM
AF Smits, Mark M.
Ioannou, George N.
Boyko, Edward J.
Utzschneider, Kristina M.
TI Non-alcoholic fatty liver disease as an independent manifestation of the
metabolic syndrome: Results of a US national survey in three ethnic
groups
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE factor analysis; insulin resistance; NAFLD; obesity
ID INSULIN-RESISTANCE ATHEROSCLEROSIS; CONFIRMATORY FACTOR-ANALYSIS;
NUTRITION EXAMINATION SURVEY; HEPATIC STEATOSIS; POPULATION; PREVALENCE;
HEALTH; RISK; PATHOPHYSIOLOGY; STEATOHEPATITIS
AB Background and Aim The metabolic syndrome (MetS) and each of its components are strongly associated with non-alcoholic fatty liver disease (NAFLD). This has led many investigators to suggest that NAFLD is an independent component of the MetS. We formally tested this hypothesis using confirmatory factor analysis, which allows comparison of different models, with or without including NAFLD as a component of the MetS. Methods We analyzed data from 3846 subjects of the Third National Health and Nutrition Examination Survey (19881994). NAFLD was defined by increased liver fat measured by ultrasonography. Results MetS by Adult Treatment Panel III criteria was present in 20.5%, and 30.2% had NAFLD, defined as mild, moderate, or severe ultrasonographic steatosis. Using confirmatory factor analysis, a basic model representing the MetS using its currently accepted components (glucose, waist, triglyceride/high-density lipoprotein ratio, and mean arterial pressure) showed excellent goodness-of-fit statistics. Addition of NAFLD to the model as a fifth independent variable decreased model fit, suggesting that NAFLD is not an additional independent component of the MetS. Analysis by ethnicity showed that addition of NAFLD decreased model fit in Whites but resulted in minor improvements in non-Hispanic Blacks and Mexican Americans. Conclusions The MetS is strongly associated with NAFLD. However, we found no evidence that NAFLD is an independent component or manifestation of the MetS. Interestingly, ethnic differences might be important in this relationship and require further study.
C1 [Smits, Mark M.; Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Ioannou, George N.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.
[Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA.
[Smits, Mark M.] Vrije Univ Amsterdam, Med Ctr, Ctr Diabet, Dept Internal Med, Amsterdam, Netherlands.
RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM kutzschn@u.washington.edu
RI Smits, Mark/E-6573-2014
OI Smits, Mark/0000-0001-8236-8842
FU Department of Veterans Affairs
FX The Department of Veterans Affairs provided support in part for the
involvement of Drs Utzschneider, Ioannou, and Boyko in this research.
NR 41
TC 42
Z9 42
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD APR
PY 2013
VL 28
IS 4
BP 664
EP 670
DI 10.1111/jgh.12106
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 115MV
UT WOS:000316817300013
PM 23286209
ER
PT J
AU Deng, M
Soltesz, E
Hsich, E
Naka, Y
Mancini, D
Esmailian, F
Kobashigawa, J
Camacho, M
Baran, D
Madsen, J
LePrince, P
Ardehali, A
AF Deng, M.
Soltesz, E.
Hsich, E.
Naka, Y.
Mancini, D.
Esmailian, F.
Kobashigawa, J.
Camacho, M.
Baran, D.
Madsen, J.
LePrince, P.
Ardehali, A.
TI Is Lactate Level during Warm Perfusion a Predictor for Post Transplant
Outcomes?
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Ardehali, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Cardiothorac Surg, Los Angeles, CA 90095 USA.
[Deng, M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA.
[Soltesz, E.] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44106 USA.
[Hsich, E.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Naka, Y.; Mancini, D.] New York Presbyterian Hosp, Columbia Med Ctr, Dept Surg, New York, NY USA.
[Esmailian, F.; Kobashigawa, J.] Cedars Sinai Med Ctr, Cedars Sinai Heart Inst, Los Angeles, CA 90048 USA.
[Camacho, M.] Newark Beth Isreal Med Ctr, Barnabas Hlth Heart Ctr, Dept Cardiothorac Surg, Newark, NJ USA.
[Baran, D.] Newark Beth Isreal Med Ctr, Barnabas Hlth Heart Ctr, Dept Heart Failure & Transplant, Newark, NJ USA.
[Madsen, J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
Grp Hosp Pitie Salpetriere, Dept Surg, F-75634 Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 411
BP S156
EP S157
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100408
ER
PT J
AU Deng, M
Soltesz, E
Hsich, E
Naka, Y
Mancini, D
Esmailian, F
Kobashigawa, J
Camacho, M
Baran, D
Madsen, J
LePrince, P
Ardehali, A
AF Deng, M.
Soltesz, E.
Hsich, E.
Naka, Y.
Mancini, D.
Esmailian, F.
Kobashigawa, J.
Camacho, M.
Baran, D.
Madsen, J.
LePrince, P.
Ardehali, A.
TI Ex-Vivo Perfusion of Human Donor Hearts Reduces Cold Ischemia Time
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Ardehali, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Cardiothorac Surg, Los Angeles, CA 90095 USA.
[Deng, M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA.
[Soltesz, E.] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44106 USA.
[Hsich, E.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Naka, Y.; Mancini, D.] New York Presbyterian Hosp, Columbia Med Ctr, Dept Surg, New York, NY USA.
[Esmailian, F.; Kobashigawa, J.] Cedars Sinai Med Ctr, Cedars Sinai Heart Inst, Los Angeles, CA 90048 USA.
[Camacho, M.] Newark Beth Isreal Med Ctr, Barnabas Hlth Heart Ctr, Dept Cardiothorac Surg, Newark, NJ USA.
[Baran, D.] Newark Beth Isreal Med Ctr, Barnabas Hlth Heart Ctr, Dept Heart Failure & Transplant, Newark, NJ USA.
[Madsen, J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[LePrince, P.] Grp Hosp Pitie Salpetriere, Dept Surg, F-75634 Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 410
BP S156
EP S156
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100407
ER
PT J
AU Esmailian, F
Kobashigawa, JA
Naka, Y
Mancini, D
Soltesz, E
Hsich, E
Camacho, M
Baran, D
Madsen, J
LePrince, P
Deng, M
Ardehali, A
AF Esmailian, F.
Kobashigawa, J. A.
Naka, Y.
Mancini, D.
Soltesz, E.
Hsich, E.
Camacho, M.
Baran, D.
Madsen, J.
LePrince, P.
Deng, M.
Ardehali, A.
TI The PROCEED II International Heart Transplant Trial with the Organ Care
System Technology (OCS)
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Esmailian, F.; Kobashigawa, J. A.] Cedars Sinai Med Ctr, Cedars Sinai Heart Inst, Los Angeles, CA 90048 USA.
[Naka, Y.; Mancini, D.] Columbia Univ, New York Presbyterian Hosp, Med Ctr, Dept Surg, New York, NY USA.
[Soltesz, E.] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44106 USA.
[Hsich, E.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Camacho, M.] Beth Israel Deaconess Med Ctr, Barnabas Hlth Heart Ctr Newark, Dept Cardiothorac Surg, Newark, NJ USA.
[Baran, D.] Beth Israel Deaconess Med Ctr, Barnabas Hlth Heart Ctr Newark, Dept Heart Failure & Transplant, Newark, NJ USA.
[Madsen, J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[LePrince, P.] Grp Hosp Pitie Salpetriere, Dept Surg, F-75634 Paris, France.
[Deng, M.] UCLA Med Ctr, David Geffen Sch Med, Dept Cardiothorac Med, Los Angeles, CA USA.
[Ardehali, A.] UCLA Med, David Geffen Sch Med, Div Cardiothor Surg, Dept Surg, Los Angeles, CA USA.
NR 0
TC 5
Z9 5
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 238
BP S95
EP S96
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100238
ER
PT J
AU Gilpin, SE
Guyette, JP
Ren, X
Gonzalez, G
Xiong, L
Song, JJ
Vacanti, J
Ott, HC
AF Gilpin, S. E.
Guyette, J. P.
Ren, X.
Gonzalez, G.
Xiong, L.
Song, J. J.
Vacanti, J.
Ott, H. C.
TI Up-Scaling Decellularization and Whole Organ Culture for Human Lung
Regeneration
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Gilpin, S. E.; Guyette, J. P.; Ren, X.; Gonzalez, G.; Xiong, L.; Song, J. J.; Vacanti, J.; Ott, H. C.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
NR 0
TC 2
Z9 2
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 169
BP S69
EP S70
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100170
ER
PT J
AU Guyette, JP
Song, JJ
Chuang, W
Ng, R
Charest, JM
Gaudette, GR
Vacanti, JP
Ott, HC
AF Guyette, J. P.
Song, J. J.
Chuang, W.
Ng, R.
Charest, J. M.
Gaudette, G. R.
Vacanti, J. P.
Ott, H. C.
TI Decellularizing Human Hearts: Characterizing Native Cardiac Matrix for
Clinical Translation
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Guyette, J. P.; Song, J. J.; Chuang, W.; Ng, R.; Charest, J. M.; Vacanti, J. P.; Ott, H. C.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Gaudette, G. R.] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA.
NR 0
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 100
BP S45
EP S45
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100101
ER
PT J
AU Madariaga, MLL
Sihag, S
Gottschall, JD
Farkash, EA
Haas, MS
Carroll, MC
Allan, JS
AF Madariaga, M. L. L.
Sihag, S.
Gottschall, J. D.
Farkash, E. A.
Haas, M. S.
Carroll, M. C.
Allan, J. S.
TI Mitigating Lung Ischemia-Reperfusion Injury in Miniature Swine
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Madariaga, M. L. L.; Sihag, S.; Gottschall, J. D.; Allan, J. S.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Cardiothorac Transplantat Lab, Boston, MA 02114 USA.
[Madariaga, M. L. L.; Sihag, S.; Gottschall, J. D.; Farkash, E. A.; Allan, J. S.] Harvard Univ, Sch Med, Boston, MA USA.
[Farkash, E. A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Carroll, M. C.] Harvard Univ, Sch Med, Dept Immunol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 832
BP S298
EP S298
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100827
ER
PT J
AU Michel, SG
Madariaga, MLL
Tasaki, M
Villani, V
LaMuraglia, GM
Farkash, EA
Allan, JS
Sachs, DH
Yamada, K
Madsen, JC
AF Michel, S. G.
Madariaga, M. L. L.
Tasaki, M.
Villani, V.
LaMuraglia, G. M., II
Farkash, E. A.
Allan, J. S.
Sachs, D. H.
Yamada, K.
Madsen, J. C.
TI Kidney-Induced Cardiac Allograft Tolerance across a Full MHC-Barrier in
Miniature Swine
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Michel, S. G.; Madariaga, M. L. L.; Tasaki, M.; Villani, V.; LaMuraglia, G. M., II; Allan, J. S.; Sachs, D. H.; Yamada, K.; Madsen, J. C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA.
[Farkash, E. A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 164
BP S68
EP S68
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100165
ER
PT J
AU Morell, E
Wolfe, J
Ziniel, S
Thiagarajan, R
Lang, P
Cheng, H
Kulik, T
Smoot, L
Blume, ED
AF Morell, E.
Wolfe, J.
Ziniel, S.
Thiagarajan, R.
Lang, P.
Cheng, H.
Kulik, T.
Smoot, L.
Blume, E. D.
TI Physician and Parent Perceptions of End-of-Life Experience in Children
with Advanced Heart Disease
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Morell, E.] Harvard Univ, Sch Med, Boston, MA USA.
[Wolfe, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ziniel, S.; Thiagarajan, R.; Lang, P.; Cheng, H.; Kulik, T.; Smoot, L.; Blume, E. D.] Boston Childrens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 1
BP S10
EP S10
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100002
ER
PT J
AU Wang, L
Gidea, CG
Baran, DA
Pieretti, J
Guerrero-Miranda, CY
Weiss, JA
Camacho, M
Chen, C
Martin, T
Zucker, MJ
AF Wang, L.
Gidea, C. G.
Baran, D. A.
Pieretti, J.
Guerrero-Miranda, C. Y.
Weiss, J. A.
Camacho, M.
Chen, C.
Martin, T.
Zucker, M. J.
TI Pre-Operative Velocity Vector Imaging To Predict the Need for Right
Ventricular Support in Patients Undergoing Left Ventricular Assist
Device Implantation
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting and Scientific Sessions of the
International-Society-for-Heart-and-Lung-Transplantation
CY APR 24-27, 2013
CL Montreal, CANADA
SP Int Soc Heart & Lung Transplantat
C1 [Wang, L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Gidea, C. G.; Baran, D. A.; Pieretti, J.; Guerrero-Miranda, C. Y.; Weiss, J. A.; Camacho, M.; Martin, T.; Zucker, M. J.] Newark Beth Israel Med Ctr, Heart Failure & Transplant Program, Newark, NJ USA.
[Chen, C.] Newark Beth Israel Med Ctr, Div Cardiol, Newark, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2013
VL 32
IS 4
SU S
MA 760
BP S273
EP S274
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA 114AM
UT WOS:000316712100755
ER
PT J
AU Fitzgerald, DC
Fonseca-Kelly, Z
Cullimore, ML
Safabakhsh, P
Saris, CJM
Zhang, GX
Rostami, A
AF Fitzgerald, Denise C.
Fonseca-Kelly, Zoe
Cullimore, Melissa L.
Safabakhsh, Pegah
Saris, Christiaan J. M.
Zhang, Guang-Xian
Rostami, Abdolmohamad
TI Independent and Interdependent Immunoregulatory Effects of IL-27,
IFN-beta, and IL-10 in the Suppression of Human Th17 Cells and Murine
Experimental Autoimmune Encephalomyelitis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CD4(+) T-CELLS; CENTRAL-NERVOUS-SYSTEM; HUMAN DENDRITIC CELLS;
INTERFERON-BETA; MULTIPLE-SCLEROSIS; KEY REGULATOR; CYTOKINE;
INTERLEUKIN-27; INFLAMMATION; WSX-1
AB IFN-beta, IL-27, and IL-10 have been shown to exert a range of similar immunoregulatory effects in murine and human experimental systems, particularly in Th1- and Th17-mediated models of autoimmune inflammatory disease. In this study we sought to translate some of our previous findings in murine systems to human in vitro models and delineate the interdependence of these different cytokines in their immunoregulatory effects. We demonstrate that human IL-27 upregulates IL-10 in T cell-activated PBMC cultures and that IFN-beta drives IL-27 production in activated monocytes. IFN-beta-driven IL-27 is responsible for the upregulation of IL-10, but not IL-17 suppression, by IFN-beta in human PBMCs. Surprisingly, IL-10 is not required for the suppression of IL-17 by either IL-27 or IFN-beta in this model or in de novo differentiating Th17 cells, nor is IL-27 signaling required for the suppression of experimental autoimmune encephalomyelitis (EAE) by IFN-beta in vivo. Furthermore, and even more surprisingly, IL-10 is not required for the suppression of Th17-biased EAE by IL-27, in sharp contrast to Th1-biased EAE. In conclusion, IFN-beta and IL-27 both induce human IL-10, both suppress human Th17 responses, and both suppress murine EAE. However, IL-27 signaling is not required for the therapeutic effect of IFN-beta in EAE. Suppression of Th17-biased EAE by IL-27 is IL-10-independent, in contrast to its mechanism of action in Th1-biased EAE. Taken together, these findings delineate a complex set of interdependent and independent immunoregulatory mechanisms of IFN-beta, IL-27, and IL-10 in human experimental models and in murine Th1- and Th17-driven autoimmunity. The Journal of Immunology, 2013, 190: 3225-3234.
C1 [Fitzgerald, Denise C.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT9 7AE, Antrim, North Ireland.
[Fonseca-Kelly, Zoe] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Cullimore, Melissa L.; Safabakhsh, Pegah; Zhang, Guang-Xian; Rostami, Abdolmohamad] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
[Saris, Christiaan J. M.] Amgen Inc, Dept Inflammat Res, Thousand Oaks, CA 91320 USA.
RP Fitzgerald, DC (reprint author), Queens Univ Belfast, Hlth Sci Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM d.fitzgerald@qub.ac.uk; a.m.rostami@jefferson.edu
OI Fonseca-Kelly, Zoe/0000-0002-3960-7796
FU National Institutes of Health [1U19A1082726, 2R01NS046782]; Department
of Employment and Learning (Northern Ireland)
FX This work was funded by National Institutes of Health Grants
1U19A1082726 and 2R01NS046782 and by the Department of Employment and
Learning (Northern Ireland).
NR 44
TC 18
Z9 22
U1 0
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2013
VL 190
IS 7
BP 3225
EP 3234
DI 10.4049/jimmunol.1200141
PG 10
WC Immunology
SC Immunology
GA 112RO
UT WOS:000316610700024
PM 23455508
ER
PT J
AU Chen, YZ
Liu, WC
Sun, T
Huang, Y
Wang, YL
Deb, DK
Yoon, D
Kong, J
Thadhani, R
Li, YC
AF Chen, Yunzi
Liu, Weicheng
Sun, Tao
Huang, Yong
Wang, Youli
Deb, Dilip K.
Yoon, Dosuk
Kong, Juan
Thadhani, Ravi
Li, Yan Chun
TI 1,25-Dihydroxyvitamin D Promotes Negative Feedback Regulation of TLR
Signaling via Targeting MicroRNA-155-SOCS1 in Macrophages
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID VITAMIN-D-RECEPTOR; INFLAMMATORY-BOWEL-DISEASE; KAPPA-B ACTIVATION;
T-CELLS; IMMUNE-SYSTEM; LETHAL INFLAMMATION; DENDRITIC CELLS; MICRORNAS;
D-3; INHIBITION
AB The negative feedback mechanism is essential to maintain effective immunity and tissue homeostasis. 1,25-dihydroxyvitamin D (1,25[OH](2)D-3) modulates innate immune response, but the mechanism remains poorly understood. In this article, we report that vitamin D receptor signaling attenuates TLR-mediated inflammation by enhancing the negative feedback inhibition. Vitamin D receptor inactivation leads to hyperinflammatory response in mice and macrophage cultures when challenged with LPS, because of microRNA-155 (miR-155) overproduction that excessively suppresses suppressor of cytokine signaling 1, a key regulator that enhances the negative feedback loop. Deletion of miR-155 attenuates vitamin D suppression of LPS-induced inflammation, confirming that 1,25(OH)(2)D-3 stimulates suppressor of cytokine signaling 1 by downregulating miR-155. 1,25(OH)(2)D-3 downregulates bic transcription by inhibiting NF-kappa B activation, which is mediated by a kappa B cis-DNA element located within the first intron of the bic gene. Together, these data identify a novel regulatory mechanism for vitamin D to control innate immunity. The Journal of Immunology, 2013, 190: 3687-3695.
C1 [Chen, Yunzi; Liu, Weicheng; Sun, Tao; Huang, Yong; Wang, Youli; Deb, Dilip K.; Yoon, Dosuk; Kong, Juan; Li, Yan Chun] Univ Chicago, Dept Med, Div Biol Sci, Chicago, IL 60637 USA.
[Chen, Yunzi; Kong, Juan; Li, Yan Chun] China Med Univ, Lab Metab Dis Res & Drug Dev, Shenyang 110000, Peoples R China.
[Thadhani, Ravi] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02115 USA.
[Li, Yan Chun] Univ Chicago, Comm Mol Metab & Nutr, Div Biol Sci, Chicago, IL 60637 USA.
RP Li, YC (reprint author), China Med Univ, Lab Metab Dis Res & Drug Dev, Shenyang 110000, Peoples R China.
EM cyan@medicine.bsd.uchicago.edu
FU National Institutes of Health [R01HL085793, R01DK092143]; Clinical and
Translational Science Award from National Center for Research Resources
[UL1 RR024999]
FX This work was supported by National Institutes of Health Grants
R01HL085793 and R01DK092143 and Clinical and Translational Science Award
Grant UL1 RR024999 from National Center for Research Resources.
NR 58
TC 63
Z9 69
U1 2
U2 21
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2013
VL 190
IS 7
BP 3687
EP 3695
DI 10.4049/jimmunol.1203273
PG 9
WC Immunology
SC Immunology
GA 112RO
UT WOS:000316610700072
PM 23436936
ER
PT J
AU Liew, C
Liew, C
Windmueller, R
Hollister-Lock, J
Weir, G
Kulkarni, RN
Ho, J
Qi, J
Park, PJ
Maas, R
Chick, J
Gygi, S
AF Liew, C.
Liew, C.
Windmueller, R.
Hollister-Lock, J.
Weir, G.
Kulkarni, R. N.
Ho, J.
Qi, J.
Park, P. J.
Maas, R.
Chick, J.
Gygi, S.
TI COMPUTATIONALLY INFORMED IDENTIFICATION OF PANCREATIC ISLET MATURATION
PATHWAYS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Combined Annual Meeting of the
Central-Society-for-Clinical-and-Translational-Research (CSCTR) and
Midwestern-Section-American-Federation-for-Medical-Research (MWAFMR)
CY APR 25-26, 2013
CL Chicago, IL
SP Cent Soc Clinl & Translat Res (CSCTR), Midwestern Sect Amer Federat Med Res (MWAFMR)
C1 [Liew, C.] Univ IL Chicago, Chicago, IL USA.
[Liew, C.; Windmueller, R.; Hollister-Lock, J.; Weir, G.; Kulkarni, R. N.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Ho, J.; Qi, J.; Park, P. J.; Maas, R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chick, J.; Gygi, S.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD APR
PY 2013
VL 61
IS 4
BP 768
EP 768
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 114FB
UT WOS:000316725300019
ER
PT J
AU Zhang, W
O-Sullivan, I
Unterman, T
Bu, S
Mashek, M
Mashek, D
Kahn, C
AF Zhang, W.
O-Sullivan, I.
Unterman, T.
Bu, S.
Mashek, M.
Mashek, D.
Kahn, C.
TI ADIPOSE TRIACYGLYCEROL LIPASE (ATGL) AND G0S2 MEDIATE EFFECTS OF FOXO1
ON HEPATIC TRIACYLGLYCEROL TURNOVER, LIPOGENIC GENE EXPRESSION AND VLDL
SECRETION
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Combined Annual Meeting of the
Central-Society-for-Clinical-and-Translational-Research (CSCTR) and
Midwestern-Section-American-Federation-for-Medical-Research (MWAFMR)
CY APR 25-26, 2013
CL Chicago, IL
SP Cent Soc Clinl & Translat Res (CSCTR), Midwestern Sect Amer Federat Med Res (MWAFMR)
C1 [Zhang, W.; O-Sullivan, I.; Unterman, T.] Univ IL, Chicago, IL USA.
[Zhang, W.; O-Sullivan, I.; Unterman, T.] JBVAMC, Chicago, IL USA.
[Bu, S.; Mashek, M.; Mashek, D.] Univ Minnesota, St Paul, MN 55108 USA.
[Kahn, C.] Joslin Diabet Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD APR
PY 2013
VL 61
IS 4
BP 768
EP 769
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 114FB
UT WOS:000316725300020
ER
PT J
AU Liew, C
Liew, C
Assmann, A
Hu, J
Goldfine, A
Kulkarni, RN
Lipson, KL
Urano, F
Sindhu, R
Philipson, L
Lindberg, I
Templin, AT
Mirmira, RG
Sonenberg, N
Urano, F
AF Liew, C.
Liew, C.
Assmann, A.
Hu, J.
Goldfine, A.
Kulkarni, R. N.
Lipson, K. L.
Urano, F.
Sindhu, R.
Philipson, L.
Lindberg, I.
Templin, A. T.
Mirmira, R. G.
Sonenberg, N.
Urano, F.
TI INSULIN SIGNALING MODULATES PROINSULIN PROCESSING BY REGULATING
TRANSLATION INITIATION IN PANCREATIC beta-CELLS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Combined Annual Meeting of the
Central-Society-for-Clinical-and-Translational-Research (CSCTR) and
Midwestern-Section-American-Federation-for-Medical-Research (MWAFMR)
CY APR 25-26, 2013
CL Chicago, IL
SP Cent Soc Clinl & Translat Res (CSCTR), Midwestern Sect Amer Federat Med Res (MWAFMR)
C1 [Liew, C.] Univ IL Chicago, Chicago, IL USA.
[Liew, C.; Assmann, A.; Hu, J.; Goldfine, A.; Kulkarni, R. N.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Lipson, K. L.; Urano, F.] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Sindhu, R.; Philipson, L.] Univ Chicago, Chicago, IL 60637 USA.
[Lindberg, I.] Univ Maryland, Baltimore, MD 21201 USA.
[Templin, A. T.; Mirmira, R. G.] Indiana Univ Sch Med, Indianapolis, IN USA.
[Sonenberg, N.] McGill Univ, Montreal, PQ, Canada.
[Urano, F.] Washington Univ, Sch Med, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD APR
PY 2013
VL 61
IS 4
BP 787
EP 787
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 114FB
UT WOS:000316725300080
ER
PT J
AU O-Sullivan, I
Zhang, W
Unterman, T
Beer-Stolz, D
Kahn, C
AF O-Sullivan, I.
Zhang, W.
Unterman, T.
Beer-Stolz, D.
Kahn, C.
TI FOXO1 IMPAIRS GLUCOSE TOLERANCE AND PROMOTES INSULIN RESISTANCE IN
LIVER-SPECIFIC INSULIN RECEPTOR KNOCKOUT (LIRKO) MICE
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Combined Annual Meeting of the
Central-Society-for-Clinical-and-Translational-Research (CSCTR) and
Midwestern-Section-American-Federation-for-Medical-Research (MWAFMR)
CY APR 25-26, 2013
CL Chicago, IL
SP Cent Soc Clinl & Translat Res (CSCTR), Midwestern Sect Amer Federat Med Res (MWAFMR)
C1 [O-Sullivan, I.; Zhang, W.; Unterman, T.] Univ Illinois, Chicago, IL USA.
[O-Sullivan, I.; Zhang, W.; Unterman, T.] Jesse Brown VA Med Ctr, Chicago, IL USA.
[Beer-Stolz, D.] Univ Pittsburgh, Pittsburgh, PA USA.
[Kahn, C.] Joslin Diabet Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD APR
PY 2013
VL 61
IS 4
BP 789
EP 789
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 114FB
UT WOS:000316725300085
ER
PT J
AU Keil, B
Wald, LL
AF Keil, Boris
Wald, Lawrence L.
TI Massively parallel MRI detector arrays
SO JOURNAL OF MAGNETIC RESONANCE
LA English
DT Article
DE Magnetic Resonance Imaging; RF coil; Phased-array; Parallel imaging;
Signal-to-noise ratio
ID TO-NOISE RATIO; TRANSMISSION-LINE ARRAY; RECEIVER-COIL ARRAY; NMR
PHASED-ARRAY; SURFACE COILS; HUMAN BRAIN; HEAD COIL; 3 TESLA;
IMAGE-RECONSTRUCTION; MULTIPLE DETECTORS
AB Originally proposed as a method to increase sensitivity by extending the locally high-sensitivity of small surface coil elements to larger areas via reception, the term parallel imaging now includes the use of array coils to perform image encoding. This methodology has impacted clinical imaging to the point where many examinations are performed with an array comprising multiple smaller surface coil elements as the detector of the MR signal. This article reviews the theoretical and experimental basis for the trend towards higher channel counts relying on insights gained from modeling and experimental studies as well as the theoretical analysis of the so-called "ultimate" SNR and g-factor. We also review the methods for optimally combining array data and changes in RF methodology needed to construct massively parallel MRI detector arrays and show some examples of state-of-the-art for highly accelerated imaging with the resulting highly parallel arrays. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Keil, Boris] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Keil, Boris; Wald, Lawrence L.] Harvard Univ, Sch Med, Boston, MA USA.
[Wald, Lawrence L.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA.
RP Keil, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, AA Martinos Ctr Biomed Imaging,Dept Radiol, 149 13th St, Charlestown, MA 02129 USA.
EM keil@nmr.mgh.harvard.edu
RI Keil, Boris/P-1411-2014; Wald, Lawrence/D-4151-2009
FU NIH [P41RR014075]; NIH Blueprint Initiative; the Human Connectome
Project [U01MH093765]
FX We would like to thank Andreas Potthast of Siemens AG Healthcare Sector
and Graham C. Wiggins, now of NYU, for their contribution to forming our
understanding of massively parallel arrays and receiver configurations
and Florian Wiesinger of ETH for results modeling brain arrays and the
ultimate SNR. We would like to acknowledge support from NIH, Grant
P41RR014075, and the NIH Blueprint Initiative; the Human Connectome
Project U01MH093765.
NR 105
TC 31
Z9 31
U1 2
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1090-7807
J9 J MAGN RESON
JI J. Magn. Reson.
PD APR
PY 2013
VL 229
BP 75
EP 89
DI 10.1016/j.jmr.2013.02.001
PG 15
WC Biochemical Research Methods; Physics, Atomic, Molecular & Chemical;
Spectroscopy
SC Biochemistry & Molecular Biology; Physics; Spectroscopy
GA 115VT
UT WOS:000316840700009
PM 23453758
ER
PT J
AU Feinberg, DA
Setsompop, K
AF Feinberg, David A.
Setsompop, Kawin
TI Ultra-fast MRI of the human brain with simultaneous multi-slice imaging
SO JOURNAL OF MAGNETIC RESONANCE
LA English
DT Article
DE Echo planar; MRI; EPI; GRASE; Simultaneous multi-slice; Multiband; MB;
EVI; GRAPPA; Functional connectivity; Connectome; fMRI; Diffusion; Fiber
tractography; Fast imaging; Parallel imaging; fMRI; BOLD;
Multiplexed-EPI; Simultaneous Multi-Slice EPI; Blipped-CAIPI
ID WHOLE-BRAIN; 7 T; ECHO; FMRI; TIME; EPI; SENSITIVITY; RESOLUTION; SENSE;
RECONSTRUCTION
AB The recent advancement of simultaneous multi-slice imaging using multiband excitation has dramatically. reduced the scan time of the brain. The evolution of this parallel imaging technique began over a decade ago and through recent sequence improvements has reduced the acquisition time of multi-slice EPI by over ten fold. This technique has recently become extremely useful for (i) functional MRI studies improving the statistical definition of neuronal networks, and (ii) diffusion based fiber tractography to visualize structural connections in the human brain. Several applications and evaluations are underway which show promise for this family of fast imaging sequences. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Feinberg, David A.] Univ Calif Berkeley, Helen Wills Inst Neurosci, Berkeley, CA 94720 USA.
[Feinberg, David A.] Adv MRI Technol, Sebastopol, CA USA.
[Feinberg, David A.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
[Setsompop, Kawin] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Setsompop, Kawin] Harvard Univ, Sch Med, Boston, MA USA.
RP Feinberg, DA (reprint author), Univ Calif Berkeley, Helen Wills Inst Neurosci, Berkeley, CA 94720 USA.
EM david.feinberg@berkeley.edu
RI Setsompop, Kawin/P-1464-2014
OI Setsompop, Kawin/0000-0003-0455-7634
FU NIH NIBIB [R00EB012107]; NINDS [R44NS073417]; NIH Blueprint for 788
Neuroscience Research [U01MH093765]
FX The work was supported by grants NIH NIBIB R00EB012107, NINDS
R44NS073417, the NIH Blueprint for 788 Neuroscience Research U01MH093765
the Human Connectome project. The authors thank Nikolaus Weiskopf for
helpful comments on the manuscript. The authors wish to thank all their
collaborators on these pulse sequences.
NR 67
TC 82
Z9 82
U1 3
U2 50
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1090-7807
EI 1096-0856
J9 J MAGN RESON
JI J. Magn. Reson.
PD APR
PY 2013
VL 229
BP 90
EP 100
DI 10.1016/j.jmr.2013.02.002
PG 11
WC Biochemical Research Methods; Physics, Atomic, Molecular & Chemical;
Spectroscopy
SC Biochemistry & Molecular Biology; Physics; Spectroscopy
GA 115VT
UT WOS:000316840700010
PM 23473893
ER
PT J
AU Jeon, HJ
Park, JH
Shim, EJ
AF Jeon, Hong Jin
Park, Jae-Hyun
Shim, Eun-Jung
TI Permissive Attitude Toward Suicide and Future Intent in Individuals With
and Without Depression Results From a Nationwide Survey in Korea
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Suicide; permissive attitude; Korea; depression
ID MENTAL-HEALTH SURVEYS; RISK-FACTORS; DSM-IV; PSYCHOLOGICAL AUTOPSY;
PSYCHIATRIC-DISORDERS; 12-MONTH PREVALENCE; LIFETIME PREVALENCE;
IDEATION; COMORBIDITY; POPULATION
AB Many previous studies have revealed that individuals with depression have higher thought of suicide, although not always exhibiting intent. We investigated the associated factors with respect to intent for suicide in the future. A total of 1584 adults were selected through a nationwide multistage probability sampling, randomly one person per household, and through face-to-face interviews (response rate was 63.4%) using the suicidality module of the Mini-International Neuropsychiatric Interview and the Patient Health Questionnaire-9. The group with depression (n = 152) revealed a significantly higher level of future suicide intent (t = 4.65, p <0.0001) and permissive attitude (t = 4.32, p <0.0001) than did the group without depression, which regarded suicide as free from life suffering, a personal right, and a solution to a difficult situation. After adjusting for all variables in the multiple logistic regression models, permissive attitude (adjusted odds ratio, 3.69; 95% confidence interval, 1.97-6.89) was the only factor significantly associated with future suicide intent, whereas age; sex; education years; monthly income; financial, job, and family stress; physical illness; lifetime suicide attempt; and depression showed no statistical significance. The group with depression showed significantly higher levels of future suicide intent than did the group without depression in those who had a higher permissive attitude (t = 4.18, p <0.0001) but not in those who had lower permissive attitudes (t = 1.98, p = 0.067). Permissive attitude toward suicide was associated with intent for suicide in the future in individuals with depression. Permissive attitude could be evaluated and corrected to prevent suicide.
C1 [Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, Seoul, South Korea.
[Jeon, Hong Jin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Park, Jae-Hyun; Shim, Eun-Jung] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Social & Prevent Med, Suwon 440746, Gyeonggi Do, South Korea.
[Shim, Eun-Jung] Catholic Univ Daegu, Dept Psychol, Gyeongbuk, South Korea.
RP Park, JH (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Social & Prevent Med, 300 Cheoncheon Dong, Suwon 440746, Gyeonggi Do, South Korea.
EM pjaehyun@skku.edu
FU Samsung Social Mental Health Institute [SMHI 2010-04]; National Research
Foundation of Korea (NRF); Ministry of Education, Science and Technology
[2011-0013064]
FX Funding for this study was provided by the Samsung Social Mental Health
Institute (SMHI 2010-04) and the Basic Science Research Program through
the National Research Foundation of Korea (NRF) funded by the Ministry
of Education, Science and Technology (2011-0013064).
NR 38
TC 6
Z9 6
U1 5
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD APR
PY 2013
VL 201
IS 4
BP 286
EP 291
DI 10.1097/NMD.0b013e318288d2c7
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 117HV
UT WOS:000316945100005
PM 23538973
ER
PT J
AU Hahl, P
Davis, T
Washburn, C
Rogers, JT
Smith, A
AF Hahl, Peter
Davis, Taron
Washburn, Cecilia
Rogers, Jack T.
Smith, Ann
TI Mechanisms of neuroprotection by hemopexin: modeling the control of heme
and iron homeostasis in brain neurons in inflammatory states
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE APP; heme; hemopexin; iron; neuroprotection; stroke
ID AMYLOID PRECURSOR PROTEIN; HUMAN-SERUM-ALBUMIN; ALZHEIMERS-DISEASE;
HYDROGEN-PEROXIDE; OXIDATIVE STRESS; 5'-UNTRANSLATED REGION;
HYPOCHLOROUS ACID; BINDING PROTEINS; OXYGENASE-1; HEMOGLOBIN
AB Hemopexin provides neuroprotection in mouse models of stroke and intracerebral hemorrhage and protects neurons in vitro against heme or reactive oxygen species (ROS) toxicity via heme oxygenase-1 (HO1) activity. To model human brain neurons experiencing hemorrhages and inflammation, we used human neuroblastoma cells, hemehemopexin complexes, and physiologically relevant ROS, for example, H2O2 and HOCl, to provide novel insights into the underlying mechanism whereby hemopexin safely maintains heme and iron homeostasis. Human amyloid precursor protein (hAPP), needed for iron export from neurons, is induced similar to twofold after hemehemopexin endocytosis by iron from heme catabolism via the iron-regulatory element of hAPP mRNA. Hemehemopexin is relatively resistant to damage by ROS and retains its ability to induce the cytoprotective HO1 after exposure to tert-butylhydroperoxide, although induction is impaired, but not eliminated, by exposure to high concentrations of H2O2 in vitro. Apo-hemopexin, which predominates in non-hemolytic states, resists damage by H2O2 and HOCl, except for the highest concentrations likely in vivo. Hemealbumin and albumin are preferential targets for ROS; thus, albumin protects hemopexin in biological fluids like CSF and plasma where it is abundant. These observations provide strong evidence that hemopexin will be neuroprotective after traumatic brain injury, with heme release in the CNS, and during the ensuing inflammation. Hemopexin sequesters heme, thus preventing unregulated heme uptake that leads to toxicity; it safely delivers heme to neuronal cells; and it activates the induction of proteins including HO1 and hAPP that keep heme and iron at safe levels in neurons.
C1 [Hahl, Peter; Davis, Taron; Smith, Ann] Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA.
[Washburn, Cecilia; Rogers, Jack T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp East, Neurochem Lab,Dept Psychiat Neurosci, Charlestown, MA USA.
RP Smith, A (reprint author), Univ Missouri KC, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd, Kansas City, MO 64110 USA.
EM smithan@umkc.edu
FU National Institute of Health [NIH R21DK64363]; University of Missouri
Research Board; University of Missouri Kansas City RIF; Alzheimer's
Association Zenith Award
FX The authors state that there is no conflict of interest. We wish to
thank Dr. Clare Hawkins (Heart Research Institute, Newtown, Australia)
and Dr. John Dawson (Univ. of South Carolina) for helpful discussions,
and Mr. Lee Likins and Dr. S. Simons (UMKC) for their advice with the
statistical analyses used. Vinusha Tummala (Department of
Psychiatry-Neuroscience, Massachusetts General Hospital) is thanked for
her technical help in the initial stages of the APP-IRE regulation
studies. The illustration for the "in this issue" is by Joe Moran
(UMKC-School of Medicine) and the neuron image is courtesy of the
National Institute on Aging/National Institutes of Health. This work was
partially supported by the National Institute of Health Grant NIH
R21DK64363, the University of Missouri Research Board, and University of
Missouri Kansas City RIF (all to A.S.) and an Alzheimer's Association
Zenith Award (J.T.R.).
NR 73
TC 16
Z9 17
U1 0
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD APR
PY 2013
VL 125
IS 1
BP 89
EP 101
DI 10.1111/jnc.12165
PG 13
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 112YR
UT WOS:000316631900010
PM 23350672
ER
PT J
AU Ramos-Rodriguez, JJ
Pacheco-Herrero, M
Thyssen, D
Murillo-Carretero, MI
Berrocoso, E
Spires-Jones, TL
Bacskai, BJ
Garcia-Alloza, M
AF Jose Ramos-Rodriguez, Juan
Pacheco-Herrero, Mar
Thyssen, Diana
Isabel Murillo-Carretero, Maria
Berrocoso, Esther
Spires-Jones, Tara L.
Bacskai, Brian J.
Garcia-Alloza, Monica
TI Rapid beta-Amyloid Deposition and Cognitive Impairment After Cholinergic
Denervation in APP/PS1 Mice
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE beta-amyloid; Alzheimer disease; Basal forebrain; Cholinergic system;
Murine p75(NTR) saporin; Senile plaques
ID PRECURSOR PROTEIN-METABOLISM; ALZHEIMERS-DISEASE; TRANSGENIC MICE;
A-BETA; MOUSE MODEL; IN-VIVO; MULTIPHOTON MICROSCOPY; NEUROTROPHIN
RECEPTOR; NUCLEUS BASALIS; NEURONS
AB Although extensive evidence supports the role of beta-amyloid (A beta) in Alzheimer disease (AD), the neurotoxic mechanisms underlying AD pathogenesis are not understood. On the other hand, neuronal loss is the pathologic feature that best correlates with cognitive impairment. We hypothesized that cholinergic neurodegeneration may lead to A beta deposition and tested this by inducing selective cholinergic lesions in APPswe/PS1dE9 mice with murine p75(NTR) saporin (mu p75-SAP). Intracerebroventricular lesions that removed approximately 50% of cholinergic innervation to the cortex and hippocampus were induced in animals with incipient (similar to 3 months) and marked (similar to 7 months of age) A beta deposition. Cranial windows were implanted, and A beta deposition was monitored in vivo using multiphoton microscopy. Deposition of A beta was increased as soon as 7 days after the lesion, and this effect was maintained up to 3 months later. Postmortem studies using immunohistochemistry with an anti-A beta antibody corroborated these findings in both cerebral cortex and hippocampus. Tau phosphorylation was also significantly increased after the lesions. Cholinergic denervation resulted in early memory impairment at 3 months of age that worsened with age (similar to 7 months); there was a synergistic effect between cholinergic denervation and the presence of APP/PS1 transgenes. Altogether, our data suggest that cholinergic denervation may trigger A beta deposition and synergistically contribute to cognitive impairment in AD patients.
C1 [Jose Ramos-Rodriguez, Juan; Pacheco-Herrero, Mar; Isabel Murillo-Carretero, Maria; Garcia-Alloza, Monica] Univ Cadiz, Sch Med, Div Physiol, Cadiz 11003, Spain.
[Thyssen, Diana; Spires-Jones, Tara L.; Bacskai, Brian J.] Harvard Univ, Dept Neurol, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA.
[Berrocoso, Esther] Univ Cadiz, Sch Med, Dept Neurosci, Cadiz 11003, Spain.
[Berrocoso, Esther] Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain.
RP Garcia-Alloza, M (reprint author), Univ Cadiz, Sch Med, Div Physiol, Plaza Fragela 9,4 Piso,410, Cadiz 11003, Spain.
EM monica.garcia@uca.es
OI Murillo-Carretero, Maria Isabel/0000-0003-4782-937X
FU ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion
[PS09/00969]; Junta de Andalucia, Proyectos de Excelencia
[P11-CTS-7847]; Instituto de Salud Carlos III; FEDER (European Union);
Fondo Europeo de Desarrollo Regional "Una manera de hacer Europa"
[PI12/00675]; NIH [R01 EB000768, R00 AG033670]; [RYC-2008-02333]
FX This study was supported by RYC-2008-02333, ISCIII-Subdireccion General
de Evaluacion y Fomento de la Investigacion (PS09/00969), Junta de
Andalucia, Proyectos de Excelencia (P11-CTS-7847), Instituto de Salud
Carlos III and FEDER (European Union), cofinanced by Fondo Europeo de
Desarrollo Regional "Una manera de hacer Europa" PI12/00675 (Monica
Garcia-Alloza), NIH R01 EB000768 (Brian J. Bacskai), and NIH R00
AG033670 (Tara L. Spires-Jones).
NR 51
TC 22
Z9 23
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD APR
PY 2013
VL 72
IS 4
BP 272
EP 285
DI 10.1097/NEN.0b013e318288a8dd
PG 14
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 117HM
UT WOS:000316944200001
PM 23481704
ER
PT J
AU Lee, SW
Eddington, DK
Fried, SI
AF Lee, Seung Woo
Eddington, Donald K.
Fried, Shelley I.
TI Responses to pulsatile subretinal electric stimulation: effects of
amplitude and duration
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
DE electrical stimulation; patch-clamp cell recordings; ganglion cells;
subretinal implant; retinal prosthesis
ID RETINAL GANGLION-CELLS; ISOLATED CHICKEN RETINA; BIPOLAR CELLS;
MAMMALIAN RETINA; AMACRINE CELLS; RABBIT RETINA; ACTIVATION; THRESHOLDS;
MICROELECTRODE; DEGENERATION
AB Lee SW, Eddington DK, Fried SI. Responses to pulsatile subretinal electric stimulation: effects of amplitude and duration. J Neurophysiol 109: 1954-1968, 2013. First published January 23, 2013; doi:10.1152/jn.00293.2012.-In working to improve the quality of visual percepts elicited by retinal prosthetics, considerable effort has been made to understand how retinal neurons respond to electric stimulation. Whereas responses arising from direct activation of retinal ganglion cells have been well studied, responses arising through indirect activation (e. g., secondary to activation of bipolar cells) are not as well understood. Here, we used cell-attached, patch-clamp recordings to measure the responses of rabbit ganglion cells in vitro to a wide range of stimulus-pulse parameters (amplitudes: 0-100 mu A; durations: 0.1-50 ms), applied to a 400-mu m-diameter, subretinal-stimulating electrode. The indirect responses generally consisted of multiple action potentials that were clustered into bursts, although the latency and number of spikes within a burst were highly variable. When different parameter pairs representing identical charge levels were compared, the shortest pulse durations generally elicited the most spikes. In addition, latencies were shortest, and jitter was lowest for short pulses. These findings suggest that short pulses are optimum for activation of presynaptic neurons, and therefore, short pulses are more effective for both direct as well as indirect activation.
C1 [Lee, Seung Woo; Fried, Shelley I.] Vet Affairs Boston Healthcare Syst, Ctr Innovat Visual Rehabil, Boston, MA USA.
[Lee, Seung Woo; Fried, Shelley I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA.
[Eddington, Donald K.] Massachusetts Eye & Ear Infirm, Cochlear Implant Res Lab, Boston, MA 02114 USA.
[Eddington, Donald K.] Harvard Univ, Dept Otol & Laryngol, Sch Med, Boston, MA 02114 USA.
RP Fried, SI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg,Simches Res Ctr, Rm 3824,185 Cambridge St, Boston, MA 02114 USA.
EM Fried.Shelley@mgh.harvard.edu
FU Veterans Administration [MR1I01RX000350-01A1]; National Eye Institute
[R01-EY019967]
FX Support for this work was provided by the Veterans Administration
(MR1I01RX000350-01A1) and by the National Eye Institute (R01-EY019967).
NR 46
TC 12
Z9 12
U1 1
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD APR
PY 2013
VL 109
IS 7
BP 1954
EP 1968
DI 10.1152/jn.00293.2012
PG 15
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 118AQ
UT WOS:000316995200024
PM 23343891
ER
PT J
AU Walcott, BP
Kwon, CS
Sheth, SA
Fehnel, CR
Koffie, RM
Asaad, WF
Nahed, BV
Coumans, JV
AF Walcott, Brian P.
Kwon, Churl-Su
Sheth, Sameer A.
Fehnel, Corey R.
Koffie, Robert M.
Asaad, Wael F.
Nahed, Brian V.
Coumans, Jean-Valery
TI Predictors of cranioplasty complications in stroke and trauma patients
Clinical article
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE cranioplasty; trauma; infection; complication; stroke; decompressive;
craniectomy; traumatic brain injury; vascular disorders
ID RESISTANT STAPHYLOCOCCUS-AUREUS; CEREBRAL-ARTERY INFARCTION;
INTENSIVE-CARE UNITS; DECOMPRESSIVE CRANIECTOMY; RISK-FACTORS;
WOUND-INFECTION; ISCHEMIC-STROKE; BRAIN-INJURY; CONTROLLED-TRIAL;
CARDIAC-SURGERY
AB Object. Decompressive craniectomy mandates subsequent cranioplasty. Complications of cranioplasty may be independent of the initial craniectomy, or they may be contingent upon the craniectomy. Authors of this study aimed to identify surgery- and patient-specific risk factors related to the development of surgical site infection and other complications following cranioplasty.
Methods. A consecutive cohort of patients of all ages and both sexes who had undergone cranioplasty following craniectomy for stroke or trauma at a single institution in the period from May 2004 to May 2012 was retrospectively established. Patients who had undergone craniectomy for infectious lesions or neoplasia were excluded. A logistic regression analysis was performed to model and predict determinants related to infection following cranioplasty.
Results. Two hundred thirty-nine patients met the study criteria. The overall rate of complication following cranioplasty was 23.85% (57 patients). Complications included, predominantly, surgical site infection, hydrocephalus, and new-onset seizures. Logistic regression analysis identified previous reoperation (OR 3.25, 95% CI 1.30-8.11, p = 0.01) and therapeutic indication for stroke (OR 2.45, 95% CI 1.11-5.39, p = 0.03) as significantly associated with the development of cranioplasty infection. Patient age, location of cranioplasty, presence of an intracranial device, bone flap preservation method, cranioplasty material, booking method, and time interval > 90 days between initial craniectomy and cranioplasty were not predictive of the development of cranioplasty infection.
Conclusions. Cranioplasty complications are common. Cranioplasty infection rates are, predicted by reoperation following craniectomy and therapeutic indication (stroke). These variables may be associated with patient-centered risk factors that increase cranioplasty infection risk. (http://thejns.org/doi/abs/10.3171/2013.1.JNS121626)
C1 [Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Koffie, Robert M.; Nahed, Brian V.; Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Koffie, Robert M.; Nahed, Brian V.; Coumans, Jean-Valery] Harvard Univ, Sch Med, Boston, MA USA.
[Fehnel, Corey R.] Brown Univ, Dept Neurol, Alpert Med Sch, Providence, RI 02912 USA.
[Fehnel, Corey R.] Rhode Isl Hosp, Providence, RI USA.
[Asaad, Wael F.] Dept Neurosurg, Providence, RI USA.
[Asaad, Wael F.] Brown Inst Brain Sci, Providence, RI USA.
RP Walcott, BP (reprint author), Massachusetts Gen Hosp, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.
EM walcott.brian@mgh.harvard.edu
RI Asaad, Wael/I-8485-2012
OI Asaad, Wael/0000-0003-4406-9096
NR 51
TC 37
Z9 40
U1 1
U2 5
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD APR
PY 2013
VL 118
IS 4
BP 757
EP 762
DI 10.3171/2013.1.JNS121626
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 114BT
UT WOS:000316715700012
PM 23394335
ER
PT J
AU Ngwenya, LB
Chiocca, EA
AF Ngwenya, Laura B.
Chiocca, E. Antonio
TI Postoperative ischemia
SO JOURNAL OF NEUROSURGERY
LA English
DT Editorial Material
ID GLIOMA; RESECTION
C1 [Ngwenya, Laura B.] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
[Chiocca, E. Antonio] Brigham & Womens Faulkner Hosp, Dept Neurosurg, Boston, MA USA.
[Chiocca, E. Antonio] Brigham & Womens Faulkner Hosp, Inst Neurosci, Boston, MA USA.
[Chiocca, E. Antonio] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA.
RP Ngwenya, LB (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
NR 6
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD APR
PY 2013
VL 118
IS 4
BP 799
EP 800
DI 10.3171/2012.8.JNS121410
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 114BT
UT WOS:000316715700019
PM 23373805
ER
PT J
AU Boucher, J
Roper, K
Underhill, M
Berry, D
AF Boucher, Jean
Roper, Kristin
Underhill, Meghan
Berry, Donna
TI Science and Practice Aligned Within Nursing Structure and Process for
Evidence-Based Practice
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Article
ID PARIHS FRAMEWORK; IMPLEMENTATION; EXCELLENCE; HOSPITALS; OUTCOMES;
INQUIRY
AB Science and Practice Aligned Within Nursing (SPAWN) is an innovative method developed to guide the implementation of evidence-based practice (EBP) by oncology nurses in direct patient care settings. Science and Practice Aligned Within Nursing actualizes and addresses the important and essential practice component of EBP in oncology nursing. This article describes the development of SPAWN infrastructure, phases of the process, implementation, outcome evaluation, key insights, and lessons learned.
C1 [Boucher, Jean; Roper, Kristin; Underhill, Meghan; Berry, Donna] Phyllis F Cantor Ctr Res Nursing & Patient Care S, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Boucher, J (reprint author), Phyllis F Cantor Ctr Res Nursing & Patient Care S, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM jean_boucher@dfci.harvard.edu
NR 30
TC 2
Z9 3
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-0443
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD APR
PY 2013
VL 43
IS 4
BP 229
EP 234
DI 10.1097/NNA.0b013e3182895a5b
PG 6
WC Nursing
SC Nursing
GA 116WJ
UT WOS:000316913700010
PM 23528689
ER
PT J
AU Almog, DM
Padberg, FT
Carmel, G
Friedlander, AH
AF Almog, Dov M.
Padberg, Frank T., Jr.
Carmel, Gwendolyhn
Friedlander, Arthur H.
TI Previously Unappreciated Carotid Artery Stenosis Diagnosed by Cone Beam
Computerized Tomography
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID PANORAMIC RADIOGRAPHS; HEART-DISEASE; ENDARTERECTOMY; ASSOCIATION;
SOCIETY; TRIAL
AB Stroke is the third leading cause of death in the western world. Calcification noted on cone beam computerized tomography, frequently used to evaluate the maxillofacial structures for extent of tumor, trauma, and implant placement, may indicate atherosclerotic disease in the carotid artery. Internal carotid artery stenosis is a recognized risk factor for stroke; multiple, large randomized controlled trials have demonstrated a decreased risk of stroke after repair of the stenotic artery. Recognition of calcified carotid artery plaque, on cone beam computerized tomography during the course of surgical care may offer the opportunity for stroke risk reduction. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 71:702-705, 2013
C1 [Almog, Dov M.] Univ Med & Dent New Jersey, New Jersey Med Sch, Vet Affairs New Jersey Healthcare Syst, Dent Serv, Newark, NJ 07103 USA.
[Padberg, Frank T., Jr.] Vet Affairs New Jersey Healthcare Syst, Newark, NJ USA.
[Padberg, Frank T., Jr.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Vasc Surg, Newark, NJ 07103 USA.
[Carmel, Gwendolyhn] Vet Affairs New Jersey Healthcare Syst, Dept Surg, Vasc Lab, E Orange, NJ USA.
[Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Friedlander, Arthur H.] Hosp Dent Serv Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@va.gov
NR 20
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD APR
PY 2013
VL 71
IS 4
BP 702
EP 705
DI 10.1016/j.joms.2012.09.021
PG 4
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 114MP
UT WOS:000316745800018
PM 23245518
ER
PT J
AU Goldwaser, BR
Magill, J
Papadaki, ME
Byl, M
Kromann, R
Yates, B
Morency, J
Kaban, LB
Troulis, MJ
AF Goldwaser, Batya R.
Magill, John
Papadaki, Maria E.
Byl, Martyn
Kromann, Roger
Yates, Brent
Morency, Joe
Kaban, Leonard B.
Troulis, Maria J.
TI Continuous Mandibular Distraction Osteogenesis: Novel Device and
Preliminary Results in Minipigs
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID GRADUAL DISTRACTION; BONE DISTRACTION
AB Purpose: To develop and test a novel, hydraulic, continuous, automated distraction device capable of 3D movements for treatment of mandibular deformities.
Materials and Methods: We used 2 cadaveric and 5 live female Yucatan minipigs to test the distractor. The 3 components (miniature buried distractor, external power and control box, and user interface on handheld computer) operate on a closed loop in which the hydraulic pulse strength correlates with the resistance of the bone and soft tissue. The system auto-adjusts to correct any discrepancy between the actual and desired position of mandibular fragments. The distraction protocol included 0-day latency, 1 mm (divided into 94 increments) per day, and 24 days' fixation. Clinical examination was performed and lateral and anteroposterior cephalometric radiographs were obtained preoperatively and postoperatively, at mid distraction osteogenesis (DO), end DO, and end fixation. Position information was obtained through the user interface.
Results: Both cadaveric trials resulted in the desired distraction gap (11 to 12 mm), with all components functioning as designed. In 4 of the 5 live animals, distraction averaged 7.29 mm (range, 5 to 11 mm) over 12 days of activation. In 3 of the 5 live animals, the osteotomy gap filled in with bone by 24 days of fixation. Two animals were sacrificed prematurely (1 at mid DO and 1 at end DO) because vital components malfunctioned.
Conclusions: The device is capable of automated, continuous, hydraulically powered DO at a rate of 1 mm/d. Future work will be directed at fortifying the device components and testing it in larger numbers of animals at varying distraction rates. (C) 2013 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 71:e168-e177, 2013
C1 [Goldwaser, Batya R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Magill, John; Byl, Martyn; Morency, Joe] Phys Sci Inc, Andover, MA 01810 USA.
[Papadaki, Maria E.; Kaban, Leonard B.; Troulis, Maria J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Papadaki, Maria E.; Kaban, Leonard B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Kromann, Roger; Yates, Brent] Embedded Syst Design, Atlanta, GA USA.
[Troulis, Maria J.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Residency Training Program, Boston, MA 02114 USA.
RP Troulis, MJ (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St, Boston, MA 02114 USA.
EM mtroulis@partners.org
FU Hanson Foundation (Boston, MA); Massachusetts General Hospital OMFS
Education and Research Fund; National Institutes of Health Small
Business Innovation Research Grant [5R44 DE 014803-03]; Harvard Medical
School Office of Enrichment Programs
FX Supported in part by the Hanson Foundation (Boston, MA), the
Massachusetts General Hospital OMFS Education and Research Fund, a
National Institutes of Health Small Business Innovation Research Grant
(5R44 DE 014803-03), and Harvard Medical School Office of Enrichment
Programs.
NR 28
TC 7
Z9 7
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD APR
PY 2013
VL 71
IS 4
BP E168
EP E177
DI 10.1016/j.joms.2012.09.012
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 114MP
UT WOS:000316745800003
PM 23507324
ER
PT J
AU Ullrich, C
Morrison, RS
AF Ullrich, Christina
Morrison, R. Sean
TI Pediatric Palliative Care Research Comes of Age: What We Stand To Learn
from Children with Life-Threatening Illness
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Editorial Material
ID YOUNG-ADULTS
C1 [Ullrich, Christina] Boston Childrens Hosp, Dept Med, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Ullrich, Christina] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
[Ullrich, Christina] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA.
RP Ullrich, C (reprint author), Boston Childrens Hosp, Dept Med, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
FU NHLBI NIH HHS [5K23HL107452-02]; NIA NIH HHS [5K24AG022345-10]
NR 8
TC 6
Z9 6
U1 0
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD APR
PY 2013
VL 16
IS 4
BP 334
EP 336
DI 10.1089/jpm.2013.9518
PG 3
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 116BJ
UT WOS:000316857000002
PM 23461300
ER
PT J
AU Leigh, AE
Burgio, KL
Williams, BR
Kvale, E
Bailey, FA
AF Leigh, Alexandra E.
Burgio, Kathryn L.
Williams, Beverly R.
Kvale, Elizabeth
Bailey, F. Amos
TI Hospice Emergency Kit for Veterans: A Pilot Study
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID MEDICATION MANAGEMENT; HOME; CAREGIVERS; DIE
AB Background: Although the provision of hospice emergency kits (HEKs) by home hospice agencies is thought to be widespread, little is known about their use, safety, and impact.
Objective: This study evaluated HEK medication utilization, safety, diversion, and perceived impact.
Design: Evaluation consisted of a retrospective patient chart abstraction and an anonymous questionnaire for home hospice nurses.
Setting/subjects: Chart abstraction examined the computerized records of deceased veterans discharged to home hospice in 2009 (N = 76). The questionnaire was completed by 78 home hospice nurses from 16 agencies.
Measurements: Chart abstraction examined HEK medication utilization, symptoms addressed, and safety / diversion concerns. The hospice nurse questionnaire assessed their perceptions of HEK utilization, safety, and impact, including efficacy for preventing emergency department (ED) visits and hospitalizations.
Results: Of patients who received an HEK, its use was documented in 50% of cases. The most used items were morphine concentrate and antibiotics. Nurses estimated that the HEK was utilized in 66.3% of cases, with the most frequently used medications being morphine, lorazepam, promethazine, and haloperidol. Fifty-nine percent of nurses felt HEKs were helpful 100% of the time (mean = 84.2%; median = 100% of the time) and 93% felt that an emergency department (ED) visit or hospitalization was avoided by having the kit in the home. Eighteen percent believed that medications in the kit are used by someone other than the patient.
Conclusions: HEKs have value as a means to alleviate many symptoms that emerge predictably in home hospice patients and may avoid unwanted hospitalizations and ED visits.
C1 [Leigh, Alexandra E.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
[Burgio, Kathryn L.; Williams, Beverly R.; Kvale, Elizabeth; Bailey, F. Amos] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL 35233 USA.
[Burgio, Kathryn L.; Williams, Beverly R.; Kvale, Elizabeth; Bailey, F. Amos] Univ Alabama Birmingham, Birmingham, AL USA.
RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 11G 700 South 19th St, Birmingham, AL 35233 USA.
EM kburgio@uabmc.edu
FU Birmingham/Atlanta Geriatric Research, Education, and Clinical Center
(GRECC)
FX This researh was supported by the Birmingham/Atlanta Geriatric Research,
Education, and Clinical Center (GRECC). The authors thank Donna Hix, RN,
the Hospice and Palliative Care Coordinator for the BVAMC, and Shanette
Granstaff, MPH, for analytic support.
NR 18
TC 2
Z9 2
U1 1
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD APR
PY 2013
VL 16
IS 4
BP 356
EP 361
DI 10.1089/jpm.2012.0304
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 116BJ
UT WOS:000316857000009
PM 23445251
ER
PT J
AU Winter, L
AF Winter, Laraine
TI Patient Values and Preferences for End-of-Life Treatments: Are Values
Better Predictors Than a Living Will?
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID ADVANCE DIRECTIVES; OLDER-ADULTS; DECISION-MAKING; CARE; VALIDATION;
QUALITY; HISTORY; BURDEN; HEALTH
AB Background: Advance care planning is widely considered important for good treatment decision making. Patient values have been proposed as superior to standard living wills as guides to end-of-life (EOL) care decisions on behalf of decisionally incapacitated patients. Little research has examined whether values outperform living wills as predictors of treatment preferences.
Objective: The study aimed to test whether patient values are associated with treatment preferences, compare values and preferences to responses from a standard living will, and determine whether some values are better predictors than others.
Design: Community-dwelling elderly men and women (n = 304) were interviewed in their homes by telephone. The interview consisted of an eight-item EOL values scale, a standard living will question, preferences for four life-prolonging treatments in each of six scenarios, and sociodemographic questions.
Results: Principal components analysis of the EOL values revealed two factors: (1) dignity, pain management, and reluctance to burden others; and (2) religiosity and desire for longevity and following family wishes. In regression analyses, stronger preferences for life-prolonging treatments were correlated with higher scores on factor 1 and lower scores on factor 2. But when living will responses were also entered into the regression model, only religiosity, longevity, and following family wishes predicted treatment preferences independently of the living will responses.
Conclusions: Providing better guidance than a living will in determining a patient's EOL treatment preferences are (1) knowledge about a patient's religiosity, (2) patient's wishes for longevity, and (3) patient's wishes for following family preferences. Wishes for dignity and pain management and reluctance to burden others do not offer better guidance than a living will.
C1 Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Winter, L (reprint author), Philadelphia VA Med Ctr, 3800 Woodland Ave, Philadelphia, PA 19104 USA.
EM Laraine.winter@gmail.com
NR 34
TC 3
Z9 3
U1 5
U2 29
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD APR
PY 2013
VL 16
IS 4
BP 362
EP 368
DI 10.1089/jpm.2012.0303
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 116BJ
UT WOS:000316857000010
PM 23442042
ER
PT J
AU Yoong, J
Traeger, LN
Gallagher, ER
Pirl, WF
Greer, JA
Temel, JS
AF Yoong, Jaclyn
Traeger, Lara N.
Gallagher, Emily R.
Pirl, William F.
Greer, Joseph A.
Temel, Jennifer S.
TI A Pilot Study To Investigate Adherence to Long-Acting Opioids among
Patients with Advanced Lung Cancer
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID HIV PROTEASE INHIBITORS; SELF-REPORTED ADHERENCE; QUALITY-OF-CARE; PAIN
MANAGEMENT; MEDICATION ADHERENCE; DEPRESSION; BARRIERS; VALIDITY;
QUESTIONNAIRES; OUTPATIENTS
AB Background: Uncontrolled pain remains prevalent in patients with advanced cancer and has been associated with worse quality of life and greater health care utilization. Poor adherence to analgesics may represent a modifiable barrier to pain management.
Objective: This pilot study aimed to establish feasibility/utility of evaluating self-reported adherence to long-acting (LA) opioids in patients with advanced lung cancer, and to explore rates and correlates of adherence.
Methods: Consecutive patients attending an ambulatory thoracic oncology clinic with a diagnosis of advanced lung cancer and a current LA opioid regimen were approached to complete a brief questionnaire during their clinic visit. Participants reported LA opioid adherence during the past 4 weeks (0%-100%) and knowledge of their LA opioid regimen, and completed the Patient Health Questionnaire-2 (PHQ-2) depression screen. Demographic and clinical information were confirmed via electronic health record review.
Results: Fifty-four eligible patients were approached to reach our target sample (n = 50; enrollment = 92.6%). Self-reported adherence to LA opioids was 85.4% (standard deviation [SD] = 21.0). Twenty-eight percent reported a frequency of medication use that did not match the prescribed daily frequency. Lower adherence was associated with inaccurate frequency (p = 0.004), positive depression screen (p = 0.005), and older age (p = 0.04).
Conclusions: Our results demonstrate the feasibility of integrating self-report assessments of LA opioid adherence into a thoracic oncology clinic. Patients reported high adherence, but more than one-quarter did not accurately report the prescribed frequency of daily doses. Understanding of LA opioid regimens may be a critical indicator of adherence in patients with advanced cancer.
C1 [Yoong, Jaclyn] St Vincents Hosp Melbourne, Caritas Christi Hosp, Melbourne, Vic, Australia.
[Traeger, Lara N.; Gallagher, Emily R.; Pirl, William F.; Greer, Joseph A.; Temel, Jennifer S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Yoong, J (reprint author), Caritas Christi Hosp, St Vincents Hosp, 104 Studley Pk Rd, Kew, Vic 3101, Australia.
EM jackieyoong@hotmail.com
FU Massachusetts General Hospital Thoracic Oncology Quality of Life Fund
FX This study was supported by the Massachusetts General Hospital Thoracic
Oncology Quality of Life Fund.
NR 56
TC 7
Z9 7
U1 2
U2 10
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD APR
PY 2013
VL 16
IS 4
BP 391
EP 396
DI 10.1089/jpm.2012.0400
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 116BJ
UT WOS:000316857000014
PM 23445248
ER
PT J
AU ter Horst, EN
van der Laan, AM
Begieneman, MPV
Hirsch, A
Krijnen, PAJ
Nahrendorf, M
Horrevoets, AJ
Niessen, HWM
Piek, JJ
AF ter Horst, E. N.
van der Laan, A. M.
Begieneman, M. P. V.
Hirsch, A.
Krijnen, P. A. J.
Nahrendorf, M.
Horrevoets, A. J.
Niessen, H. W. M.
Piek, J. J.
TI Monocyte Subset Accumulation in the Human Heart Following Acute
Myocardial Infarction and the Role of the Spleen as Monocyte Reservoir
SO JOURNAL OF PATHOLOGY
LA English
DT Meeting Abstract
CT 203rd Winter Joint Meeting of the
Pathological-Society-of-Great-Britain-and-Ireland and the
Dutch-Pathological-Society (NVVP)
CY JAN 08-09, 2013
CL Univ Med Ctr, Dept Pathol, Utrecht, NETHERLANDS
SP Pathol Soc Great Britain & Ireland, Dutch Pathol Soc (NVVP)
HO Univ Med Ctr, Dept Pathol
C1 [ter Horst, E. N.; van der Laan, A. M.; Hirsch, A.; Piek, J. J.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
[Begieneman, M. P. V.; Krijnen, P. A. J.; Horrevoets, A. J.; Niessen, H. W. M.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
[Nahrendorf, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PD APR
PY 2013
VL 229
SU 1
BP S11
EP S11
PG 1
WC Oncology; Pathology
SC Oncology; Pathology
GA 113VG
UT WOS:000316696800035
ER
PT J
AU Maneta, EK
Cohen, S
Schulz, MS
Waldinger, RJ
AF Maneta, E. K.
Cohen, S.
Schulz, M. S.
Waldinger, R. J.
TI TWO TO TANGO: A DYADIC ANALYSIS OF LINKS BETWEEN BORDERLINE PERSONALITY
TRAITS AND INTIMATE PARTNER VIOLENCE
SO JOURNAL OF PERSONALITY DISORDERS
LA English
DT Article
ID CONFLICT-TACTICS-SCALES; DIMENSIONAL MODEL; PHYSICAL ABUSE;
RISK-FACTORS; DISORDER; ORGANIZATION; EXPERIENCES; AGGRESSION; COUPLES;
STRESS
AB Although research has shown links between borderline personality and intimate partner violence (IPV), few studies have examined how each partner's personality traits may influence the other's behavior (Hines, 2008). This study incorporated dimensional assessments of borderline personality organization (BPO) in both partners into a dyadic model that examined associations with IPV. In a community sample of 109 couples, an Actor-Partner Interdependence Model was used to examine links between BPO traits in each partner and victimization and perpetration of IPV. Men's level of BPO traits was associated with more IPV toward and more victimization by their partners. Women's level of BPO traits was associated with their victimization only. This study is unique in examining links between BPO and IPV in couples using analyses that account for the interdependence of these variables in dyads.
C1 [Maneta, E. K.] Harvard Univ, Sch Med, Childrens Hosp Boston, Cambridge, MA 02138 USA.
[Cohen, S.; Waldinger, R. J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Schulz, M. S.] Bryn Mawr Coll, Bryn Mawr, PA 19010 USA.
RP Maneta, EK (reprint author), 151 Merrimac St,2nd Floor, Boston, MA 02114 USA.
EM manetael@gmail.com
FU NIMH NIH HHS [K08 MH01555]
NR 41
TC 8
Z9 8
U1 2
U2 24
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0885-579X
J9 J PERS DISORD
JI J. Pers. Disord.
PD APR
PY 2013
VL 27
IS 2
BP 233
EP 243
PG 11
WC Psychiatry
SC Psychiatry
GA 115RL
UT WOS:000316829500008
PM 23514186
ER
PT J
AU Maas, MB
Singhal, AB
AF Maas, Matthew B.
Singhal, Aneesh B.
TI Unwitnessed Stroke: Impact of Different Onset Times on Eligibility into
Stroke Trials
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Enrollment; onset; stroke; time; trials
ID ACUTE ISCHEMIC-STROKE
AB Background: Patients with unwitnessed stroke represent >25% of all strokes. Clinical trials enrolling patients with unwitnessed stroke onset have conservatively used last known normal (LKN) as the time of stroke onset. We explored the impact of alternative methods of selecting onset time in unwitnessed strokes on eligibility into an acute stroke therapeutic trial using a representative sample of acute stroke subjects. Methods: We analyzed data on 641 consecutive patients with suspected stroke presenting to our hospital between January 2007 and July 2008. Time of onset was calculated by 3 methods: (1) LKN, (2) first known abnormal (FKA), and (3) midpoint between LKN and FKA. Subjects with incomplete data or a final diagnosis of non-ischemic stroke were excluded. Rates of trial eligibility based on different onset times were compared for several inclusion time windows. Results: Onset time was known in 440 subjects (69%). Of the remaining 201 patients with unwitnessed onset, 114 (57%) were "wake-up" strokes. Among unwitnessed stroke subjects, eligibility increased from 18% using LKN to 57% using FKA at 4.5 hours and 42% to 81% at 9 hours (P < .001), respectively. Overall enrollment eligibility for the full cohort increased from 36% to 48% at 4.5 hours and 61% to 73% at 9 hours (P < .001), respectively. Conclusion: Given potential advantages in safety evaluation and the historical inadequate enrollment rates in acute stroke trials, alternative onset time definitions, perhaps in combination with advanced neuroimaging methods (e. g., fluid-attenuated inversion recovery-diffusion-weighted imaging mismatch), should be considered for early-phase trials.
C1 [Maas, Matthew B.] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Singhal, Aneesh B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
RP Maas, MB (reprint author), Northwestern Univ, Dept Neurol, 710 N Lake Shore Dr 11th Fl, Chicago, IL 60611 USA.
EM mbmaas@northwestern.edu
FU National Institutes of Health [P50NS051343, 5R01NS051412]
FX Supported by National Institutes of Health grants P50NS051343 and
5R01NS051412.
NR 9
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD APR
PY 2013
VL 22
IS 3
BP 241
EP 243
DI 10.1016/j.jstrokecerebrovasdis.2011.08.004
PG 3
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 114GE
UT WOS:000316728300009
PM 21917477
ER
PT J
AU Bhan, I
Thadhani, R
AF Bhan, Ishir
Thadhani, Ravi
TI Fibroblast Growth Factor-23 and Outcomes: New Answers, New Questions
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS; PHOSPHATE-METABOLISM;
MORTALITY; FGF23; HEMODIALYSIS
C1 [Bhan, Ishir; Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
RP Bhan, I (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
EM ibhan@partners.org
FU NIDDK NIH HHS [K24 DK094872]
NR 12
TC 0
Z9 0
U1 0
U2 30
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD APR
PY 2013
VL 24
IS 4
BP 523
EP 525
DI 10.1681/ASN.2013020169
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 116ZK
UT WOS:000316921700003
PM 23520207
ER
PT J
AU Dominguez, JR
Shlipak, MG
Whooley, MA
Ix, JH
AF Dominguez, Julie R.
Shlipak, Michael G.
Whooley, Mary A.
Ix, Joachim H.
TI Fractional Excretion of Phosphorus Modifies the Association between
Fibroblast Growth Factor-23 and Outcomes
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; GELATINASE-ASSOCIATED LIPOCALIN; INJURY
MOLECULE-1 KIM-1; CORONARY-HEART-DISEASE; CARDIOVASCULAR EVENTS;
CYSTATIN-C; ATHEROSCLEROSIS; COMMUNITY; KLOTHO; HEALTH
AB Fibroblast growth factor-23 (FGF23) induces phosphaturia through its effects on renal tubules. Higher levels of FGF23 associate with cardiovascular disease (CVD) events and all-cause mortality, but it is unknown whether these associations differ by the degree of phosphaturia. Here, we measured serum FGF23 and 24-hour urine fractional excretion of phosphorus (FePi) in 872 outpatients with stable CVD and a mean estimated G FR of 71 ml/nnin per 1.73 m(2). During an average 7.5 years of follow-up, there were 337 deaths and 199 CVD events. Urinary Fe Pi significantly modified the association of FGF23 with each outcome (P interaction<0.001 for all-cause mortality and P P interaction<0.05 for CVD events). In models adjusted for CVD risk factors, kidney function, and PTH, those patients who had FGF23 above the median (>= 42.3 relative units [RU]/ml) but FePi below the median (<15.7%) had the highest risks of both all-cause mortality (HR=1.98, 95% CI=1.42-2.77) and CVD events (HR=1.92, 95% CI=1.25-2.94) compared with those patients who had low concentrations of FGF23 and low FePi. In summary, associations of FGF23 with mortality and CVD events are stronger in persons with lower FePi independent of PTH and kidney function. In such individuals, the renal tubular response to FGF23 may be suboptimal. J Am Soc Nephrol 24: 647-654, 2013. doi: 10.1681/ASN.2012090894
C1 [Dominguez, Julie R.; Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA.
[Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA.
[Dominguez, Julie R.; Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA.
[Shlipak, Michael G.; Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA.
[Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA.
EM joeix@ucsd.edu
FU National Heart, Lung, and Blood Institute Training Grant [T32 HL007261];
National Heart, Lung, and Blood Institute [R01HL096851]; Department of
Veterans Epidemiology Merit Review Program; Department of Veterans
Affairs Health Services Research and Development Service, National
Heart, Lung, and Blood Institute [R01 HL079235]; National Heart, Lung,
and Blood Institute; American Federation for Aging Research (Paul Beeson
Scholars Program); Robert Wood Johnson Foundation (Generalist Physician
Faculty Scholars Program); Ischemia Research and Education Foundation;
American Heart Association; Sandra A. Daugherty Foundation; Veterans
Affairs San Diego Healthcare System
FX J.R.D. was supported by National Heart, Lung, and Blood Institute
Training Grant T32 HL007261. J.H.I. was supported by National Heart,
Lung, and Blood Institute Grant R01HL096851. The Heart and Soul Study
was supported by the Department of Veterans Epidemiology Merit Review
Program, the Department of Veterans Affairs Health Services Research and
Development Service, National Heart, Lung, and Blood Institute Grant R01
HL079235, the American Federation for Aging Research (Paul Beeson
Scholars Program), the Robert Wood Johnson Foundation (Generalist
Physician Faculty Scholars Program), and the Ischemia Research and
Education Foundation. This ancillary study was supported by the American
Heart Association and the National Heart, Lung, and Blood Institute.
Fibroblast growth factor-23 and urine measurements were supported by
grants from the American Heart Association and the Sandra A. Daugherty
Foundation. This material is the result of work supported with resources
of the Veterans Affairs San Diego Healthcare System.
NR 31
TC 39
Z9 39
U1 0
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD APR
PY 2013
VL 24
IS 4
BP 647
EP 654
DI 10.1681/ASN.2012090894
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 116ZK
UT WOS:000316921700016
PM 23520205
ER
PT J
AU Rusch, V
Baldini, EH
Bueno, R
De Perrot, M
Flores, R
Hasegawa, S
Klepetko, W
Krug, L
Lang-Lazdunski, L
Pass, H
Weder, W
Sugarbaker, DJ
AF Rusch, Valerie
Baldini, Elizabeth H.
Bueno, Raphael
De Perrot, Marc
Flores, Raja
Hasegawa, Seiki
Klepetko, Walter
Krug, Lee
Lang-Lazdunski, Loic
Pass, Harvey
Weder, Walter
Sugarbaker, David J.
CA Participants Int Mesothelioma Inte
TI The role of surgical cytoreduction in the treatment of malignant pleural
mesothelioma: Meeting summary of the International Mesothelioma Interest
Group Congress, September 11-14, 2012, Boston, Mass
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Editorial Material
ID FEASIBILITY
C1 [Rusch, Valerie] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, New York, NY 10021 USA.
[Baldini, Elizabeth H.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Bueno, Raphael; Sugarbaker, David J.] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA.
[De Perrot, Marc] Toronto Gen Hosp, Div Thorac Surg, Toronto, ON, Canada.
[De Perrot, Marc] Univ Hlth Network, Princess Margaret Hosp, Toronto, ON, Canada.
[Flores, Raja] Mt Sinai Med Ctr, Div Thorac Surg, New York, NY 10029 USA.
[Hasegawa, Seiki] Hyogo Coll Med, Dept Surg, Nishinomiya, Hyogo 6638501, Japan.
[Klepetko, Walter] Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Div Thorac Surg, Vienna, Austria.
[Krug, Lee] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Krug, Lee] Weill Cornell Med Coll, New York, NY USA.
[Lang-Lazdunski, Loic] Guys Hosp, Dept Thorac Surg, London SE1 9RT, England.
[Pass, Harvey] NYU, Langone Med Ctr, Dept Cardiothorac Surg, New York, NY USA.
[Weder, Walter] Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland.
RP Sugarbaker, DJ (reprint author), Brigham & Womens Hosp, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA.
EM dsugarbaker@partners.org
NR 11
TC 33
Z9 33
U1 2
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD APR
PY 2013
VL 145
IS 4
BP 909
EP 910
DI 10.1016/j.jtcvs.2013.01.039
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 114PA
UT WOS:000316753100005
PM 23415687
ER
PT J
AU Sugarbaker, DJ
Gill, RR
Yeap, BY
Wolf, AS
DaSilva, MC
Baldini, EH
Bueno, R
Richards, WG
AF Sugarbaker, David J.
Gill, Ritu R.
Yeap, Beow Y.
Wolf, Andrea S.
DaSilva, Marcelo C.
Baldini, Elizabeth H.
Bueno, Raphael
Richards, William G.
TI Hyperthermic intraoperative pleural cisplatin chemotherapy extends
interval to recurrence and survival among low-risk patients with
malignant pleural mesothelioma undergoing surgical macroscopic complete
resection
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT International Mesothelioma Interest Group Congress
CY SEP 11-14, 2012
CL Boston, MA
ID EXTRAPLEURAL PNEUMONECTOMY; PHASE-II; INTRAPLEURAL CISPLATIN;
MULTIMODALITY THERAPY; TRIMODALITY THERAPY; CYTOPROTECTION
AB Objective: Local recurrence limits long-term survival in patients with malignant pleural mesothelioma. We investigated whether hyperthermic intraoperative cisplatin chemotherapy lavage affects the interval to recurrence and overall survival among patients with favorable prognostic factors.
Methods: Using a preoperative risk assessment algorithm we had previously developed and validated, we retrospectively identified a cohort of patients treated with cytoreductive surgery from 2001 to 2009. The patients had epithelial histologic findings on biopsy and were characterized as having a low risk of early recurrence and death (ie, tumor volume <= 500 cm(3) and were either men with a hemoglobin level of >= 13 g/dL or were women). Those patients who had received hyperthermic intraoperative cisplatin chemotherapy were compared with a comparison group of those who had not. Fisher's exact test was used to determine the balance of prognostic factors. The Kaplan-Meier method and log-rank tests were used to estimate and compare the interval to recurrence and overall survival. Cox proportional hazards regression was used for multivariate analysis.
Results: The cohort criteria identified 103 patients: 72 who received hyperthermic intraoperative cisplatin chemotherapy and 31 who did not. The groups were balanced for prognostic factors, except for the use of neoadjuvant chemotherapy (more common in the comparison group). The hyperthermic intraoperative cisplatin chemotherapy group exhibited a significantly longer interval to recurrence (27.1 vs 12.8 months) and overall survival (35.3 vs 22.8 months) than the comparison group. The improved interval to recurrence and overall survival for the hyperthermic intraoperative cisplatin chemotherapy group were particularly evident among the subgroups of patients who had not received hemithoracic radiotherapy and who had pathologic stage N1 or N2 lymph node metastases.
Conclusions: A favorable outcome and minimal incremental morbidity support the incorporation of hyperthermic intraoperative cisplatin chemotherapy into multimodality treatment strategies for patients with low-risk epithelial malignant pleural mesothelioma. (J Thorac Cardiovasc Surg 2013;145:955-63)
C1 [Sugarbaker, David J.; Wolf, Andrea S.; DaSilva, Marcelo C.; Bueno, Raphael; Richards, William G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA.
[Gill, Ritu R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Yeap, Beow Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Baldini, Elizabeth H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02115 USA.
RP Sugarbaker, DJ (reprint author), Brigham & Womens Hosp, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA.
EM dsugarbaker@partners.org
NR 26
TC 29
Z9 30
U1 0
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD APR
PY 2013
VL 145
IS 4
BP 955
EP 963
DI 10.1016/j.jtcvs.2012.12.037
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 114PA
UT WOS:000316753100012
PM 23434448
ER
EF